WO2001000206A1 - Vla-4 inhibitor compounds - Google Patents

Vla-4 inhibitor compounds Download PDF

Info

Publication number
WO2001000206A1
WO2001000206A1 PCT/US2000/018079 US0018079W WO0100206A1 WO 2001000206 A1 WO2001000206 A1 WO 2001000206A1 US 0018079 W US0018079 W US 0018079W WO 0100206 A1 WO0100206 A1 WO 0100206A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
chosen
mmol
mixture
substituted
Prior art date
Application number
PCT/US2000/018079
Other languages
French (fr)
Inventor
John J. Baldwin
Edward Mcdonald
Kevin Joseph Moriarty
Christopher Ronald Sarko
Nobuo Machinaga
Atsushi Nakayama
Jun Chiba
Shin Iimura
Yoshiyuki Yoneda
Original Assignee
Daiichi Pharmaceutical Co., Ltd.
Pharmacopeia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00945035A priority Critical patent/EP1189612A4/en
Application filed by Daiichi Pharmaceutical Co., Ltd., Pharmacopeia, Inc. filed Critical Daiichi Pharmaceutical Co., Ltd.
Priority to IL14628800A priority patent/IL146288A0/en
Priority to JP2001505915A priority patent/JP2003503350A/en
Priority to BR0012068-5A priority patent/BR0012068A/en
Priority to MXPA01013406A priority patent/MXPA01013406A/en
Priority to AU59031/00A priority patent/AU781438B2/en
Priority to CA002369308A priority patent/CA2369308A1/en
Publication of WO2001000206A1 publication Critical patent/WO2001000206A1/en
Priority to NO20016319A priority patent/NO324892B1/en
Priority to US10/034,585 priority patent/US6756378B2/en
Priority to HK02105102.2A priority patent/HK1043318A1/en
Priority to US10/787,905 priority patent/US7179819B2/en
Priority to US11/594,432 priority patent/US20070054909A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/48Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Definitions

  • the present invention relates to compounds that selectively inhibit the binding of ligands to the adhesion receptor, 4 ⁇ j integrin, also known as VLA-4.
  • Compounds of the present invention are useful in the treatment and prevention of pathologies associated with VLA-4 mediated cell adhesion, such as inflammatory and autoimmune diseases, and tumor metastasis.
  • a primary feature of such pathologies as inflammation and autoimmune diseases is the accumulation of activated leukocytes in affected tissues.
  • the process by which leukocytes transmigrate from the circulation at a site of inflammation involves a cascade of interactions that can be divided into four major steps: tethering and rolling, activation, firm adhesion, and transmigration (Springer, T., Ann. Rev. Physiol.. 57:827 (1995)).
  • leukocytes are lightly tethered to the endothelium and roll along its surface. This is followed by cell activation, mediated by soluble chemotactic stimuli, which initiates the development of a firmer bond between individual leukocytes and endothelial cells.
  • the firm bond then results in the successful adhesion and transmigration of the leukocytes through endothelial cell junctions.
  • the steps occur in series and each is essential for transmigration to occur. This also means that transmigration can be modulated at each step, thus providing a number of potential targets for pharmacological inhibition.
  • the receptors involved in leukocyte migration have, to a large extent, been characterized as belonging to particular cell adhesion molecule families (Carlos and Harlan, Blood, 84:2068 (1994)).
  • the initial attachment and rolling step is mediated by a family of adhesion receptors referred to as selectins.
  • Firm adhesion is mediated by interaction of leukocyte surface integrins with molecules of the immunoglobulin superfamily expressed on the surface of the endothelium. Both integrins and the immunoglobulin-type adhesion molecules are also primarily involved in leukocyte transmigration. After transmigration, the leukocytes rely on integrins to traverse through the extracellular matrix and remain at the site of inflammation.
  • Integrins are a large family of heterodimeric glycoproteins composed of two noncovalently associated subunits, ⁇ and ⁇ (Hynes, R., Cell, 69: 11 (1992)). There are at least 16 different ⁇ subunits ( ⁇ - ⁇ 9 , ⁇ L , ⁇ M , ⁇ D , ⁇ x ⁇ E , ⁇ , ⁇ ,,) and at least 9 different ⁇ ( ⁇ - ⁇ 9 ) subunits. Integrins are divided into sub-families, based upon the ⁇ subunit.
  • Leukocytes express a number of different integrins, including ⁇ 4 ⁇ b ⁇ 5 ⁇ ⁇ 6 ⁇ ,, ⁇ 4 ⁇ 7 , ⁇ L ⁇ 2 , ⁇ x ⁇ 2> and ⁇ v ⁇ 3 .
  • ⁇ 4 ⁇ , integrin also known as very late antigen-4 (VLA-4) or CD49d/CD29, is expressed on monocytes, lymphocytes, eosinophils, and basophils, all of which are key effector cells in various inflammatory disorders (Helmer, M., Ann. Rev. Immunol.. 8:365 (1990)).
  • ⁇ 4 ⁇ , integrin serves as a receptor for vascular cell adhesion molecule-1 (VCAM-1), as well as to the extracellular protein fibronectin (FN) (Elices et al. , Cell. 60:577 (1990)).
  • Anti-inflammatory effects and delayed disease progression have been demonstrated after in vivo monoclonal antibody blockade of the ⁇ 4 ⁇ ,/VCAM-l pathway (Lobb et ⁇ /.. J. Clin. Invest. 94:1722-28 (1994)).
  • anti- ⁇ 4 inhibited both antigen-induced bronchial hyperreactivity and leukocyte recruitment in bronchoalveolar lavage fluid (Pretolani et al, J. Exp. Med., 180:795 (1994)).
  • Antibodies to ⁇ 4 or VCAM-1 prevented antigen-induced eosinophil infiltration of the mouse trachea (Nakajima et al, J. Exp.
  • ⁇ 4 or VCAM- 1 monoclonal antibody treatment also delayed or prevented cutaneous delayed hypersensitivity response in mice and monkeys (Chisholm et al. , Eur. J. Immunol. 23:682 (1993); Silber et al. , I Clin. Invest.. 93:1554 (1993); cardiac allograft rejection in mice, accompanied by specific immunosuppression (Isobe et al, J. Immunol.. 153:5810 (1994); graft-versus-host disease in mice after bone marrow transfer (Yang et al. , Proc. Natl. Acad. Sci. USA.
  • Rational drug design studies have produced soluble VCAM-Ig fusion protein containing the two N-terminal domains of human VCAM-1 fused to a human IgGl constant region.
  • In vivo administration of the fusion protein significantly delays the onset of adoptively transferred autoimmune diabetes in nonobese diabetic mice (Jakubowski et al, J. Immunol., 155:938 (1995)).
  • Another approach has used three-dimensional crystallographic structures of VCAM-1 fragments to synthesize cyclic peptide antagonists that closely mimicked the 4 integrin binding loop in domain 1 of VCAM-1.
  • VCAM-1 peptide CQIDSPC was able to inhibit the adhesion of VLA-4- expressing cells to purified VCAM-1 (Wang et al, Proc. Natl. Acad. Sci. USA, 92:5714 (1995)).
  • the compounds of the present invention selectively inhibit the binding of ligands to ⁇ 4 ⁇ , and therefore, are useful for inhibition, prevention and suppression of VLA-4-mediated cell adhesion and the pathologies associated with that adhesion, such as, for example, inflammation, asthma, arthritis, diabetes, autoimmune responses, multiple sclerosis, psoriasis, transplantation rejection, and tumor metastasis.
  • the present invention provides a compound represented by Formula I, or a salt thereof,
  • W is chosen from aryl group, substituted aryl group, heteroaryl group and substituted heteroaryl group
  • W 1 is chosen from arylene group, substituted arylene group, heteroarylene group and substituted heteroarylene group
  • R is chosen from a direct bond, alkyenylene group and -(CH 2 ) n -, wherein n is chosen from 1 and 2,
  • X is chosen from -C(O)-, -CH 2 - and S(0) 2 ,
  • R 1 , R 2 and R 3 are independently chosen from -H, -OH,-NH 2 , halogen atom, alkyl group, substituted alkyl group, aryl group, substituted aryl group, alkoxy group, substituted alkoxy group, monoalkylammo group, substituted monoalkyla ⁇ uno group, dialkylamino group, substituted dialkyla ⁇ uno group, cycloalkylammo group, substituted cycloalkylamino group, alkylsulfbnylamino group, substituted alkylsulfonylamino group, arylsulfonylamino group, substituted arylsulfonylamino group, aryloxy group, substituted aryloxy group, heteroaryloxy group, substituted heteroaryloxy group, benzyloxy group
  • Y is a direct bond or a divalent radical chosen from -C(O)-, -C(0)NH-, alkenylene group, alkynylene group and -(CH 2 ) k Y 2 , wherein k is chosen from 1, 2 and 3, and Y 2 is a direct bond or a divalent radical chosen from -0-, -S-,
  • Z is chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group and substituted cycloalkylene group
  • a 1 is a direct bond or a divalent radical chosen from alkenylene group, alkynylene group, -(CH 2 ) t - and -O CH ⁇ wherein t is chosen from 1, 2 and 3, and v is chosen from 0, 1, 2, and 3, and
  • R is chosen from -OH, lower alkoxy group, -N(H)OH, N N and
  • R 6 and R 7 are independently chosen from -H, -OH, halogen atom, alkyl group and alkoxy group
  • Y 1 is a divalent radical chosen from -0-, -S-, -S(O)-, -S(0) 2 - and -NY 4 -, wherein Y 4 is chosen from -H and lower alkyl group
  • Z 1 is a divalent radical chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group and substituted cycloalkylene group,
  • a 2 is a direct bond or a divalent radical chosen from alkenylene group, alkynylene group and -(CH 2 ) e wherein e is chosen from 1, 2 and 3, and
  • H H R is chosen from -OH, lower alkoxy group, -N(H)OH, N ⁇ N and
  • N f is a divalent 4-, 5-, 6- or 7-membered heterocychc moiety, optionally substituted with from 1 to 3 substitutents chosen independently from alkyl group, alkoxy group, hydroxyalkyl group, -OH, benzyloxy group, -NH 2 , halogen atom, aryl group and heteroaryl group, said moiety may be fused to 1 or 2 additional carbocyclic or heterocychc residues optionally substituted with from 1 to 3 substitutents chosen independently from alkyl group, aryloxy group, alkoxy group, hydroxyalkyl group, -OH, benzyloxy group, -NH 2 , , halogen atom, aryl group and heteroaryl group, m and q are independently chosen from 0, 1, 2 and 3,
  • R 9 is chosen from -H and lower alkyl group
  • R is chosen from -COOH, lower alkoxycarbonyl group
  • Z 2 is chosen from -H, COOH and lower alkoxycarbonyl group
  • R is chosen from --o0--, a m nd ⁇ -N ra R ⁇
  • R 12 is chosen from -H, alkyl group, substituted alkyl group, cycloalkyl group, substituted cycloalkyl group, aryl group, substituted aryl group, benzyl group, substituted benzyl group, lower alkenyl group, substituted lower alkenyl group and lower alkynyl group the left hand bond is the point of attachment to -X- and the right hand bond is the point of attachment to -Z 3 ;
  • Z 3 is chosen from a direct bond, a divalent aliphatic hydrocarbon moiety having 1 to 12 carbon atoms, wherein one or more carbon atoms may be replaced with -O- or -NR 13 -
  • R 13 is chosen from -H and lower alkyl group, and one or more hydrogen atoms attached to an aliphatic carbon atom may be replaced with lower alkyl group;
  • R 14 is chosen from -H, -OH and halogen atom
  • R u is -NR 12 , wherein l-z 4 wherein
  • R 14a is chosen from -H, -OH, lower alkyl group and halogen atom
  • Q -.2 is a divalent radical chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group, substituted cycloalkylene group,
  • R 15 and R 16 are independently chosen
  • R 1 and R 18 are independently chosen
  • L 1 is chosen from -COOH and -COOR 19 wherein R 19 is a lower alkyl group.
  • R 19 is a lower alkyl group.
  • M is In this
  • Preferred compounds of this embodiment are those wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof
  • W 1 is preferably unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-
  • M is In another preferred embodiment of Formula I, M is In
  • Preferred compounds of this embodiment are those wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof
  • W 1 is preferably unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-
  • M is In this
  • L is preferably chosen from
  • L is chosen from
  • L is chosen from
  • W 1 is preferably unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-.
  • Still another preferred embodiment of Formula I includes compounds wherein M is _ R 11_ Z 3_ Q 2_ L 1
  • W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof.
  • W 1 is preferably unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-.
  • preferred compounds are those wherein R 11 i os A. or -NR 12 , more preferably NR 12 , wherein
  • R 12 is chosen from -H, lower alkyl group and substituted lower alkyl group, most preferably dihydroxy lower alkyl group.
  • Preferred choices for Z is a divalent aliphatic hydrocarbon moiety having 4, 5 or 6 carbon atoms.
  • a preferred choice for W 1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-.
  • R examples include -H. -OH and -F
  • W 1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-.
  • Q 2 is ⁇ R 17R 8 and Z 3 is Y ° CH
  • R 11 is preferably
  • W 1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-
  • R 11 is preferably
  • R 12 is preferably lower alkyl group
  • Preferred compounds of this embodiment also include those wherein at least one of R 17 and R 18 is lower alkyl group or substituted lower alkyl group
  • R 11 is preferably
  • -NH- and R 1 and R 1 are each preferably -H
  • a preferred choice for W 1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-
  • Z 3 ,Z 3 is preferably a divalent aliphatic hydrocarbon moiety
  • Yet another embodiment of the invention is a compound represented by Formula ⁇ ,
  • R ,20 is preferably chosen from -H and lower alkyl, CH,
  • Still another embodiment of the invention is a compound represented by Formula HI,
  • the principles of the present invention also provide a method for inhibiting cell adhesion, and in particular, VLA-4 mediated cell adhesion at ⁇ 4 ⁇ l receptor sites in a mammal, wherein the method comprises administering an effective amount of a compound represented by Formula I.
  • inhibiting cell adhesion is intended to include inhibiting, suppressing and preventing VLA-4 mediated cell adhesion-associated conditions, including but not limited to, inflammation and cell adhesion-associated immune or autoimmune responses.
  • the principles of the present invention therefore also provide a method of treating a condition associated with VLA-4 mediated cell adhesion, wherein the method comprises administering to a mammal in need of such treatment, an effective amount of a compound represented by Formula I.
  • Such conditions include for example, but are not limited to, inflammatory and autoimmune responses, diabetes, asthma, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, transplantation rejection, and tumor metastasis.
  • treatment of a mammal is intended to include prophylaxis as well.
  • the compounds of the present invention may be administered as a monotherapy, or in combination with antiinflammatory or immunosuppressive agents.
  • combination therapies can involve the administration of the various pharmaceuticals as a single dosage form or as multiple dosage forms administered at the same time or at different times.
  • Suitable routes of administration may be employed for providing a patient with an effective amount of a compound of the present invention.
  • Suitable routes of administration may include, for example, oral, rectal, nasal, buccal, parenteral (such as, intravenous, intrathecal, subcutaneous, intramuscular, intrasternal, intrahepatic, intralesional, intracranial, intra-articular, and intra-synovial), transdermal (such as, for example, patches), and the like.
  • parenteral such as, intravenous, intrathecal, subcutaneous, intramuscular, intrasternal, intrahepatic, intralesional, intracranial, intra-articular, and intra-synovial
  • transdermal such as, for example, patches
  • oral dosage forms such as, for example, tablets, troches, dispersions, suspensions, solutions, capsules, soft gelatin capsules, and the like, may be preferred.
  • Administration may also be by controlled or sustained release means and delivery devices. Methods for the preparation of such dosage forms are well known in
  • compositions incorporating compounds of the present invention may include excipients, a pharmaceutically acceptable carrier, in addition to other therapeutic ingredients.
  • Excipients such as starches, sugars, microcrystalline cellulose, diluents, lubricants, binders, coloring agents, flavoring agents, granulating agents, disintegrating agents, and the like may be appropriate depending upon the route of administration. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.
  • the compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorgamc or organic bases.
  • suitable pharmaceutically acceptable base addition salts include, but are not limited to, ammonium salts, alkali metal salts, metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, organic salts made from chloroprocaine, choline, N.N'-dibenzylethylenediamine, dicyclohexylamine, diethanolamine, ethylenediamine, lysine, meglumine (N-methylglucamine) and procaine, as well as salts with amino acids, such as arginine, lysine, and so forth.
  • the compounds of the invention may be used in the form of pharmaceutically acceptable non-toxic organic or inorganic acids.
  • Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfomc, methanesulfomc, fuma ⁇ c, glucomc, glutamic, hydrobromic, hydrochlonc, lactic, maleic, malic, mandehc, nitnc, pamoic, pantothemc, phosphonc, succinic, sulfunc, tartanc, p- toluenesulfomc acids, and the like Particularly prefened are citnc, hydrochlonc, maleic, fumanc, phosphonc, sulfunc, tartanc and -toluenesulfonic acids
  • Compounds of the invention may also be in the form of hydrates
  • H HEEKK cceellllss 293E human embryonic kidney cells
  • Ac acetyl ant ⁇ - ⁇ 4-PE conjugated monoclonal antibody against integnn ⁇ 4 subumt
  • phycoerythnn conjugated anti- ⁇ l-FITC conjugated monoclonal antibody against integrin ⁇ l subumt
  • HOBt 1 -hydroxybenzotriazole human IgGl human immunoglobulin Gl ICAM intracellular adhesion molecule
  • LiHMDS lithium 1,1,1,3,3,3 -hexamethyldisilazane
  • VCAM-1 (D1D7) vascular cell adhesion molecule containing one to seven immuloglobulin domains
  • VCAM-IgG fusion protein a VCAM IgG fusion protein containing the one to seven immunoglobulin domains of human VCAM-1 (D1D7) attached above the hinge region of an IgGl molecule
  • Alkyl group is intended to include linear or branched hydrocarbon radicals and combinations thereof of 1 to 20 carbons.
  • “Lower alkyl group” means alkyl groups of from 1 to about 10, preferably from 1 to about 8, and more preferably, from 1 to about 6 carbon atoms. Examples of such radicals include methyl, ethyl, «-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, wo-amyl, hexyl, octyl groups and the like.
  • Alkylene group means a divalent radical formed by removing a hydrogen atom from an
  • Aryl group means a radical formed from an aromatic hydrocarbon ring of 4 to about 16 carbon atoms, preferably of 6 to about 12 carbon atoms, and more preferably of 6 to about 10 carbon atoms.
  • the rings may optionally be substituted with 1-3 substituents selected from alkyl, halogen, hydroxy, alkoxy, aryloxy, haloalkyl, phenyl and heteroaryl.
  • substituents selected from alkyl, halogen, hydroxy, alkoxy, aryloxy, haloalkyl, phenyl and heteroaryl. Examples of aryl groups are phenyl, biphenyl, 3,4-dichlorophenyl and naphthyl.
  • Allene group means a divalent radical formed by removing a hydrogen atom from an “aryl group.”
  • Arylalkyl group denotes a structure comprising an alkyl attached to an aryl ring. Examples include benzyl, phenethyl, 4-chlorobenzyl, and the like.
  • Cycloalkyl group refers to a saturated hydrocarbon ring radical of from 3 to 12 carbon atoms, and preferably from 3 to 8 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, adamantyl, myrtanyl groups and the like. “Lower cycloalkyl group” refers to cycloalkyl of 3 to 6 carbons.
  • Cycloalkylene group means a divalent radical formed by removing a hydrogen atom from a “cycloalkyl group.”
  • “Divalent C t to C 20 aliphatic hydrocarbon moiety” includes alkylene, cycloalkylene, alkenylene, alkynylene groups and combinations thereof. Examples include ethylene, propylene, propynylene, 2,4-heptadienylene groups and the like.
  • Heterocyclyl group refers to a cyclic radical having from 1 to 6 carbon atoms, preferably 3 to 6 carbon atoms, and from 1 to 4 heteroatoms chosen from O, N and S. Examples include: pyrrolyl, pyridinyl, pyrazolyl, triazolyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, imidazolyl, indolyl, thienyl, furyl, azetidiyl, tetrazolyl, 2-pyrrolinyl, 3-pynolinyl, pynolindinyl, 1,3-dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3 -triazolyl, 1,3,4
  • Heterocyclylene group means a radical formed by removing a hydrogen atom from a “heterocyclyl group.”
  • Heteroaryl group refers to an aromatic cyclic radical having from 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms, and from 1 to 4 heteroatoms chosen from O, N and S; or a bicyclic 9- or 10-membered heteroaromatic ring system containing 1-4 heteroatoms selected from O, N and S.
  • the methine H atoms of a heterocyclyl or heteroaryl structure may be optionally substituted with alkyl, alkoxy or halogen.
  • Examples include: imidazolyl, pyridyl, indolyl, thienyl, benzopyranyl, thiazolyl, furyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, pyrimidinyl, pyrazinyl, tetrazolyl, pyrazolyl groups and the like.
  • Heteroarylene group means a divalent radical formed by removing a hydrogen atom from a “heteroaryl group.”
  • Alkoxy group means a straight, branched or cyclic hydrocarbon configuration and combinations thereof, including from 1 to 20 carbon atoms, preferably from 1 to 8 carbon atoms, more preferably from 1 to 4 carbon atoms, and an oxygen atom at the point of attachment.
  • Suitable alkoxy groups include methoxy, ethoxy, w-propoxy, isopropoxy, n-butoxy, / ' so-butoxy, sec- butoxy, te -butoxy, cyclopropoxy, cyclohexyloxy groups and the like.
  • “Lower alkoxy group” refers to alkoxy groups having from 1 to 4 carbon atoms.
  • Alkenyl group refers to an unsaturated acyclic hydrocarbon radical in so much as it contains at least one double bond.
  • “Lower alkenyl group” refers to such radicals containing from 2 to 10 carbon atoms, preferably from 2 to 8 carbon atoms and more preferably from 2 to 6 carbon atoms.
  • alkenyl radicals examples include propenyl, buten-1-yl, isobutenyl, penten-1-yl, 2-methylbuten-l-yl, 3-methylbuten-l-yl, hexen-1-yl, hepten-1-yl, and octen-1-yl groups and the like.
  • Alkenylene group means a divalent radical formed by removing a hydrogen atom from an “alkenyl group.”
  • Alkynyl group refers to an unsaturated acyclic hydrocarbon radical containing at least one triple bond. Examples include ethynyl, propynyl groups, and the like.
  • Alkynylene group means a divalent radical formed by removing a hydrogen atom from an alkynyl group.”
  • Substituted alkyl group means a linear or branched alkyl group wherein at least one hydrogen atom attached to an aliphatic carbon is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
  • substituent groups include methyl, isopropyl, methoxy, ethoxy, propoxy, amino, methylamino, phenyl, naphthyl groups, chlorine, fluorine and the like.
  • Substituted alkylene group means a linear or branched alkylene group wherein at least one hydrogen atom attached to an aliphatic carbon is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
  • a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkyl
  • Substituted cycloalkyl group means a cycloalkyl group wherein at least one hydrogen atom attached to a ring carbon atom is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
  • a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, al
  • Substituted cycloalkyene group means a cycloalkylene group wherein at least one hydrogen atom attached to a ring carbon is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
  • a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alky
  • Substituted aryl group means an aryl group wherein at least one methine hydrogen atom attached to an aromatic carbon is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
  • a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkyl
  • Substituted arylene group means an arylene group wherein at least one hydrogen atom attached to an aromatic carbon is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
  • a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulf
  • Substituted heteroaryl group or “substituted heterocyclyl group” means a heteroaryl or heterocyclyl group wherein at least one hydrogen atom attached to a ring thereof is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
  • a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalky
  • Substituted heteroarylene group or “substituted heterocyclylene group” means a heteroarylene or heterocyclylene group wherein at least one hydrogen atom attached to a ring thereof is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
  • a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalky
  • Substituted arylalkyl group means an arylalkyl having one or more substituents such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, haloalkyl, alkoxycarbonylalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
  • substituents such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsul
  • Halogen is intended to include for example, F, Cl, Br and I.
  • prodrug refers to a chemical compound that is converted to an active agent by metabolic processes in vivo. [See, e.g., N. Boder and J.J. Kaminski, Ann. Rep. Med. Chem. 22:303 (1987) and H. Bundgand, Adv. Drug Delivery Rev., 3:39 (1989)].
  • prodrug precursors of compounds of the present invention in any of the methods described herein is contemplated and is intended to be within the scope of the invention.
  • a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable.
  • the protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or “deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere.
  • the functionalities that must be protected are amines. Suitable groups for that purpose are discussed in standard textbooks in the field of chemistry, such as Protective Groups in Organic Synthesis by T.W.Greene [John Wiley & Sons, New York, 1991], which is incorporated herein by reference. Particular attention is drawn to the chapter entitled "Protection for the Amino Group” (pages 309-405). Prefened protecting groups include BOC and Fmoc. Exemplary methods for protecting and deprotecting with these groups are found in Greene and Wuts on pages 318 and 327.
  • the materials upon which the syntheses described herein are performed are refened to as solid supports, beads, and resins. These terms are intended to include: (a) beads, pellets, disks, fibers, gels, or particles such as cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol, poly- acrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N.N'-bis- acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, etc., i.e., material having a rigid or semi-rigid surface; and (b) soluble supports such as polyethylene glycol or low molecular weight, non-cross-linked polystyrene.
  • the solid supports may, and usually do, have functional groups such as amino, hydroxy, carboxy, or halo groups; where amino groups are the most common.
  • TentagelTM NH 2 (Rapp Polymere, Tubingen, Germany) is a prefened amine functionalized polyethylene glycol- grafted polystyrene resin.
  • Tentagel IM -S-PHB resin has a para- hydroxy benzyl linker which can be cleaved by the use of 90% trifluoroacetic acid in dichloromethane. Techniques for fiinctionalizing the surface of solid phases are well known in the art.
  • Optical Isomers - Diastereomers - Geometric Isomers Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisometric forms which may be defined in terms of absolute stereochemistry as (R)- or (S)- , or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible diastereomers as well as their racemic and optically pure forms.
  • Optically active (R)- and (S)-, or (D)- and (Z,)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
  • the compounds of the present invention have demonstrated utility as selective inhibitors at VLA-4 receptors.
  • the inhibitory concentration (IC 50 ) and the VLA-4 selectivity of test compounds for an ⁇ 4 ⁇ 1 receptor using in vitro assays are determined in direct binding assays and competitive assays with other integrin receptors such as ⁇ 2 (LFA-1 and Mac-1), ⁇ 3 (GPIIb/IIIa and ⁇ v ⁇ 3) and ⁇ l ( ⁇ 4 ⁇ 7).
  • Compounds of the present invention have K, values ⁇ 1 ⁇ M.
  • Prefened compounds of the invention are those having K, values ⁇ 300 nM, more preferably ⁇ lOOnM, even more preferably ⁇ 50 nM, and most preferably, ⁇ 12nM.
  • prefened compounds having a K, value ⁇ 50 nM are shown below. These examples are provided by way of illustration only, and are not intended to limit the invention thereto.
  • VLA-4-expressing cells were seeded in a 96-well microtiter plate. The cells were allowed to grow for 2 days until confluent. Various concentrations of the test compound were added together with 2 nM of the europium-labeled, VCAM-IgG fusion protein. The cells were allowed to incubate at room temperature in the microwells for at least 30 minutes. Following incubation, the microwells were emptied and washed. The amount of europium-labeled VCAM- IgG fusion protein bound was determined by time-resolved fluorescence measurement. Inhibition of binding was determined by quantifying the fluorescence bound to the plate for each of the various concentrations of test compound, as well as for controls containing no test compound.
  • the VLA-4-expressing cells used in this assay was a CHO cell line stably transfected with the cDNA of the human ⁇ 4 and ⁇ l subunits. Construction and maintenance of the cell line are described in the assay procedures.
  • a VCAM IgG fusion protein containing the one to seven immunoglobulin domains of human VCAM-1 (D1D7) attached above the hinge region of an IgGl molecule was labeled with europium chelates. The preparation and labeling of the fusion protein are described in the assay procedures.
  • the cell adhesion inhibitory activity of the test compound was determined by blocking the Jurkat cell attachment to the D1D7-VCAM IgG fusion protein.
  • Jurkat cell is a human lymphocytic cell line expressing VLA-4 on cell surface.
  • each of the 96-well microtiter wells was coated with 75 ng of the VCAM IgG fusion protein. The wells were then blocked by the addition of 1% bovine serum albumin to remove nonspecific adhesive sites. Varying concentrations of the test compound were added together with the calcein-labeled Jurkat cells. The cells were allowed to adhere to the VCAM coated wells at room temperature for 1 hour in the dark.
  • the plate was washed by immersing face down into a container filled with phosphate buffered saline. The wells were blotted dry on paper towel. Quantitation of the adhered cell was determined by fluorescence measurement. Decreased fluorescence indicated inhibition of cell adhesion by the test compound.
  • LFA-1 binds to ICAM-1 and mediates the emigration of leukocytes into inflammatory sites.
  • Mac-1 binds to a number of ligands, including ICAM-1 and fibrinogen, and plays an important role in neutrophil phagocytosis and oxygen free radical generation.
  • GPIIb/IIIa on platelet surface binds to fibrinogen in plasma and induces platelet aggregation.
  • ⁇ v ⁇ 3 binds to a number of extracellular matrix proteins, including vitronectin and mediates cell migration and prevents cell apoptosis.
  • ⁇ 4 ⁇ 7 shares the same ligands as VLA-4 (VCAM-1, MAdCAM-l.and fibronectin), but with different preference. This receptor is expressed on lymphoid cells and is involved in lymphocyte migration to mucosal tissues.
  • Assays of LFA-1, Mac-1, GPIIb/IIIa and ⁇ v ⁇ 3 involved coating the purified receptor on a 96-well microtiter plate. The specific ligands for these receptors were labeled with europium chelates.
  • an ICAM-1 IgG fusion protein containing the one to five immunoglobulin domains of human ICAM-1 (D1D5) attached above the hinge region of an IgGl molecule was used.
  • In the assays of GPIIb/IIIa and ⁇ v ⁇ 3 europium-labeled fibrinogen and vitronectin, respectively, was used.
  • the purified receptors were allowed to incubate in the wells with various concentrations of test compound, in the presence of europium-labeled ligands. Following incubation, the wells are emptied and washed. The amount of europium-labeled ligand bound was determined by time-resolved fluorescence measurement.
  • Assay of ⁇ 4 ⁇ 7 is similar to the adhesion inhibition assay of VLA-4 described above, and uses the ⁇ 4 ⁇ 7-expressing cell, RPMI-8886.
  • a MAdCAM-1 IgG fusion protein containing the one and two immunoglobulin domains of human MAdCAM-1 and mucin-like repeat domain, is used as the corresponding ligand for ⁇ 4 ⁇ 7.
  • Eu + - VCAM-1 IgG binding to CHO/VLA-4 cells may be determined as follows. 4B4 cells
  • CHO VLA-4 cells are distributed into each well of a 96-well microtiter plate at 3 x 10 /well. The plate is incubated at 37 °C, 5% C0 2 for 48 hours and then washed twice with washing buffer, then blot dried. 50 ⁇ l of the inhibitor solution diluted with assay buffer (2% DMSO final) is added to each well, followed by 50 ⁇ l of Eu 3+ -VCAM-1 IgG diluted with assay buffer at 2 nM. The plate is incubated at room temperature for at least 30 min. Each well is then washed four times with washing buffer and blot dried. 100 ⁇ l of DELFIA Enhancement solution is added to each well, followed by agitation of the plate at room temperature for 5 min.
  • the washing buffer comprises 25 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 ,and 4 mM MnCl 2 ;
  • the assay buffer comprises 25 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 4 mM MnCl 2 , 1% BSA, and 20 ⁇ M DTPA.
  • the VLA-4 inhibitors may be further characterized in in vivo assays.
  • One such assay examines the inhibition of eosinophil infiltration into the bronchoalveolar lavage fluid in the mouse (murine) model.
  • the animals are treated with cyclophosphamide on day 0.
  • the animals are immunized intraperitoneally with Ascaris suum extract.
  • the animals are treated with various doses of the VLA-4 inhibitor.
  • the animals are challenged t Ascaris suum extract by instillation into the trachea. Bronchoalveolar lavage of the animal is performed by instilling saline into the lung, 48 hours later. Total cell and eosinophil counts in the lavage are determined.
  • the compounds of the present invention may also be further characterized in other in vivo assays, such as the eosioophil accumulation model tested in the rat.
  • Fifty ⁇ g of Compound 48/80 was injected into the pleural cavities of male Sprague Dawley rats. After 24 hrs, each cavity was washed twice with Hank's Balanced Salt Solution containing 0.2% EDTA. Total cell and eosinophil counts were determined.
  • Test compounds were given intraveneously, orally or subcutaneously, b.i.d. at 0 and 8 hours. The dosage, route of administration and inhibitory effect for the test compounds are shown in Table 6.
  • mice Female Balb/c mice (7-9 weeks old) were given the compound orally. Blood samples were collected from the postcaval vein of the anesthetized mice after fifteen minutes. Serum was prepared and stored at -20 °C. Serum concentration of the compound was determined from inhibitory activities of the diluted serum by a direct binding assay using VLA-4-expressing cells and VCAM-IgG fusion protein. Serum concentration determined by this method correlated well with the concentration determined by LC/MS/MS methodologies. The dosage, route of administration and resulting inhibitory effect for the test compounds are shown in Table 7.
  • VCAM-1 Binding assay of VCAM-1 to VLA-4 expressing cells
  • VCAM IgG fusion protein A VCAM IgG fusion protein containing the one to seven immunoglobulin domains of
  • VCAM-1 (D1D7) ligated to the hinge (H), CH2 and CH3 regions of human IgGl was used in the binding assay.
  • D1D7 VCAM IgG fusion protein Purification of D1D7 VCAM IgG fusion protein The cells were cultured in DMEM with 10% fetal calf serum for 2 days, then changed to
  • the D1D7-VCAM IgG fusion protein was dialyzed against 50 mM NaHC0 3 , 0.9% NaCl, pH 8.5.
  • the fusion protein was added to one vial of europium-labeling reagent (DELFIA labeling kit from Wallac, Gaithersberg, MD; catalog no. 1244-302) and incubated at room temperature in the dark overnight.
  • the labeled protein was purified using a Sepharose G10 column and assayed for the europium content and protein concentration. The protein was stored at minus 80°C until used.
  • a CHO cell line stably transfected with the cDNA of ⁇ 4 and ⁇ l was used in the binding assay.
  • the gene for human 4 was obtained from the American Type Culture Collection and recloned between the Xhol and Xba sites of the mammalian expression vector pCI-neo (Promega, Madison, WI).
  • the ⁇ 1 gene was amplified by PCR from human peripheral leukocyte cDNA and engineered such that the start codon was placed in the context of a consensus Kozak sequence. The gene was recloned into pCI-neo downstream of the CMV promoter and chimeric intron.
  • CHO-K1 cells were stably co-transfected with plasmids encoding the ⁇ 4 and ⁇ l genes, and single cells expressing high levels of VLA-4 were selected by fluorescence cell sorting (FACS).
  • the antibodies used in FACS analysis were: anti- ⁇ 4-PE conjugated (PharMingen, San Diego, CA) and anti- ⁇ l-FITC conjugated (Biosource, Camarillo, CA).
  • a cell line 4B4 which expresses 400,000 and 300,000 sites/cell of the ⁇ x4 and ⁇ l subunit, respectively, was used in the binding assay.
  • the subunit numbers were determined by FACS analysis, using Quantum Simply Cellular microbeads (Flow Cytometiy Standards Corporation, Puerto Rico) as standards.
  • the cells were maintained in F12 medium, containing 10% fetal bovine serum, 10 mM HEPES, pH 7.5, 0.5 mg/mL G418, using a 1:48 passage/week.
  • Binding Assay The CHO/VLA-4 cells were seeded in a 96-well microtiter plate at 30,000 cells/well and incubated at 37°C, 5% C0 2 for 48 hours until confluent. On the day of assay, the wells were emptied and washed twice with 350 ⁇ l of a washing buffer containing 25 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM MgCl 2, 1 mM CaCl 2 2 mM MnCl 2 . The plate was then drained and blotted dry on paper towels to remove buffer.
  • test compound was serially diluted in assay buffer (washing buffer together with 0.1% bovine serum albumin, 20 ⁇ M DTPA and 1% dimethysulfoxide), in the presence of 2 nM of europium-labeled D1D7-VCAM IgG fusion protein. Final concentrations used ranged from 0.1 nM-10 ⁇ M. 50 ⁇ l aliquot of the test compound mixture was added to duplicate wells in the plate. Control wells for total binding received no test compound. Non-specific binding wells contained an anti- ⁇ 4 monoclonal antibody (L25.3, Becton Dickinson, Bedford, MA).
  • the cells were allowed to incubate with the test compound mixture, in the presence of europium-labeled D1D7-VCAM IgG fusion protein at room temperature for at least 30 minutes. The cells were then washed three times with 350 ⁇ l of washing buffer, using a Skatron plate washer and blot dry. An 100 ⁇ l aliquot of DELFIA Enhancement solution was added to each well, followed by gentle agitation at room temperature for 10 minutes. The amount of europium-labeled VCAM-IgG fusion protein bound was determined by time-resolved fluorescence measurement (Model: VictorTM, Wallac Inc., Gaithersberg, MD).
  • Percent binding was calculated as: [(F T -F NS ) - (F,-F NS )] / (F T -F NS ) x 100 wherein F ⁇ and F NS is the fluorescence signal of the europium labeled D1D7-VCAM IgG fusion protein bound to cells, in the absence of test compound and containing an anti- ⁇ 4 monoclonal antibody, respectively. F, is the fluorescence in wells containing a test compound.
  • the IC 50 concentration of the inhibitor to inhibit 50% binding of VACM to CHO/VLA-4 cell was determined by a curve fitting routine, PRIZM (GraphPad Software, Inc., San Diego, CA).
  • Adhesion of VLA-4 expressing cell to VCAM-1 This secondary functional assay was used to determine the potency of a test compound in inhibiting VLA-4 mediated cell adhesion.
  • a 50 ⁇ l aliquot of the D1D7-VCAM IgG fusion protein (1.5 ⁇ g/mL in phosphate buffered saline, PBS) was added to each well of a 96-well Costar flat bottom plate (Costar, Franklin Lakes, NJ, catalog no. 2580). The plate was then incubated overnight at 4°C. On the day of assay, the wells were emptied and washed twice with 350 ⁇ l of PBS. The plate was then blocked with 100 ⁇ l of 1% bovine serum albumin (BSA, Sigma, cat# A9418) in PBS at room temperature for at least a hour.
  • BSA bovine serum albumin
  • Jurkat cell (clone E6-1) was obtained from American Type Cultured Collection and was maintained in RPMI medium, 10 mM HEPES, pH 7.5, 1 mM sodium pyruvate, 10% FCS, using a 1 :64 passage/week. Just prior to running the assay, Jurkat cells were labeled with 5 ⁇ M of calcein- AM (Molecular Probe, Eugene, OR, catalog no. C1430) in RPMI medium, at room temperature for 30 min in the dark. Following labeling, cells were washed twice with RPMI medium and resupended at 1 x 10 6 cells/mL.
  • calcein- AM Molecular Probe, Eugene, OR, catalog no. C1430
  • the BSA solution was emptied from the VCAM-coated plate. The plate was then washed twice with RPMI medium. A 100 ⁇ l aliquot of the labeled Jurkat cells was added to each well, followed by the addition of 50 ⁇ l of the inhibitor solutions. Final inhibitor concentrations range from 1 nM to 10 ⁇ M and each concentration was tested in triplicates. The inhibitor and cells were allowed to incubate at room temp for 1 hr in the dark. Following the incubation, the plate was immersed gently into a container filled with PBS, then inverted face down under PBS. The wells were drained and blotted dry on a layer of paper towel.
  • the solution was cooled to room temp, made basic with 150 mL of an aqueous solution of 40% sodium hydroxide, extracted with 3 x 125 mL CH 2 C1 2 , and the combined organic layers were washed with a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, and the solvent was removed under educed pressure to give 15.0 g (63.0 mmol, 86%) of 2-(2- bromobenzyl)-l-pyrolline.
  • the alkene ester (1.32 g, 4.1 mmol) was then subjected to hydrogenation.
  • the alkene was placed in a Parr hydrogenation bottle, EtOAc (10 mL) and 10% Pd C (100 mg) was added under inert atmosphere.
  • the bottle was then pressurized with hydrogen at 45 psi and shaken for 4 hr at room temp.
  • the solution was then filtered through celite and concentrated in vacuo to afford 1.29 g of the alkane ester.
  • the alkane ester (1.29 g, 4.0 mmol) was dissolved in THF (30 mL), MeOH (20mL), and water (10 mL) and saponified with LiOH (200 mg, 8.0 mmol). The reaction was stirred at room temp for 3 hr and then poured into 1 N HCl (50 mL). This solution was then extracted 3x with EtOAc, dried over MgS0 4 , and then concentrated in vacuo to afford 1.02 g of the alkane acid as a yellow solid.
  • the alkane acid (1.02 g, 3.3 mmol) was then deprotected by the addition of a 25% TFA CH 2 C1 2 solution and stirred for 2 hr at room temp.
  • the resulting mixture was then concentrated in vacuo and immediately protected by dissolving the deprotected acid in 50% dioxane/water, adding K 2 C0 3 (1.2 g), and Fmoc-Cl (1.08 g, 4.0 mmol). This mixture was stirred at room temp for 14 hr and then poured in 1 N HCl (100 mL). The solution was then extracted 3x with EtOAc, dried over MgS0 4 , and then concentrated in vacuo to afford 495 mg 1 as a white crystalline solid.
  • the dried resin (500 mg, 0.14 mmol) was placed into a small shaker vessel. The vessel was then charged with 9 mL of DMF (2 mg, 0.42 mmol), DIC (102 mg, 0.84 mmol), and DMAP (17 mg, 0.14 mmol). The vessel was subsequently shaken for 16 hr at room temp. The contents were drained and the resin was washed 3x with DMF, MeOH, and CH 2 C1 2 . The Fmoc group was then removed by the addition of 10 mL of 50% piperidine/DMF to the shaker vessel and shaking for 2 hr at room temp. The resulting amine resin was washed 3x with DMF, MeOH, and CH 2 C1 2 .
  • a solution of dicyclohexylborane was generated by the addition of borane-THF (12.0 mL, 12 mmol), at 0°C to a solution of cyclohexene (2.3 mL) in 6 mL of anhydrous THF. This solution was stirred for an additional 1 hr at 0°C The acetylene (2) (2.0 g, 5.84 mmol) was then added dropwise over 15 min at 0°C and then allowed to warm to room temp over 1 hr. The reaction mixture was then diluted with MeOH (20 mL) and then recooled to 0°C A solution of 2 N NaOH (6 mL) and 30% H 2 0 2 (3.5 mL) was then added dropwise.
  • the reaction mixture was then stirred at 0°C for 1 hr and then warmed to 40°C for 2.5 hr. The mixture was then cooled to room temp and an additional 6 mL of 2 N NaOH was added. The organics were removed in vacuo and the remaining aqueous solution was extracted 3x Et 2 0 and the organics were discarded. The aqueous extracts were then acidified with 1 N HCl and extracted with EtOAc dried over MgS0 4 , and then concentrated in vacuo to afford 1.7 g of the phenylacetic acid as a tan crystalline solid.
  • the acid (1.7 g, 5.6 mmol) was then deprotected by the addition of a 25% TFA/CH 2 C1 2 solution and stirred for 2 hr at room temp.
  • the resulting mixture was then concentrated in vacuo and immediately protected by dissolving the deprotected acid in 50% dioxane/water, adding K 2 C0 3 (15g), and Fmoc-Cl (1.4 g, 5.5 mmol).
  • This mixture was stirred at room temp for 14 hr and then poured in 1 N HCl (100 mL).
  • the solution was then extracted 3x with EtOAc, dried over MgS0 4 , and then concentrated in vacuo to afford 1.7 g 3 as a white crystalline solid.
  • the dried resin (500 mg, 0.14 mmol) was placed into a small shaker vessel. The vessel was then charged with 9 mL of DMF, 3 (180 mg, 0.42 mmol), DIC (102 mg, 0.84 mmol), and DMAP (17 mg, 0.14 mmol). The vessel was subsequently shaken for 16 hr at room temp. The contents were drained and the resin was washed 3x with DMF, MeOH, and CH 2 C1 2 . The Fmoc group was then removed by the addition of 10 mL of 50% piperidine/DMF to the shaker vessel and shaking for 2 hr at room temp. The resulting amine resin was washed 3x with DMF, MeOH, and CH 2 C1 2 .
  • the alkane acid (0.71 g ) was then deprotected by the addition of a 25% TFA/CH 2 C1 2 solution and stirred for 2 hr at room temp.
  • the resulting mixture was then concentrated in vacuo and immediately protected by dissolving the deprotected acid in 50% dioxane/water, adding K 2 C0 3 (15 g), and Fmoc-Cl (1.29 g, 4.9 mmol). This mixture was stirred at room temp for 14 hr and then poured in 1 N HCl (100 mlL).
  • the solution was then extracted 3x with EtOAc, dried over MgS0 4 , and then concentrated in vacuo to afford 4 as a brown oil.
  • the oil was then chromatographed with 5% MeOH/ dichloromethane to afford 110 mg of the desired compound.
  • the dried resin (500 mg, 0.14 mmol) was placed into a small shaker vessel. The vessel was then charged with 9 mL of DMF, 4 (184 mg, 0.42 mmol), DIC (102 mg, 0.84 mmol), and DMAP (17 mg, 0.14 mmol). The vessel was subsequently shaken for 16 hr at room temp. The contents were drained and the resin was washed 3x with DMF, MeOH, and CH 2 C1 2 . The Fmoc group was then removed by the addition of 10 mL of 50% piperidine/DMF to the shaker vessel and shaking for 2 hr at room temp. The resulting amine resin was washed 3x with DMF, MeOH, and CH 2 C1 2 .
  • the iodide (A) (0.5 g, 1.3 mmol) was placed into THF (20 mL) and cooled to minus
  • the benzoic acid (0.32 g, 1.68 mmol) was then deprotected by the addition of a 25% TFA/CH 2 C1 2 solution and stirred for 2 hr at room temp. The resulting mixture was then concentrated in vacuo and immediately protected by dissolving the deprotected acid in 50% dioxane/water, adding K 2 C0 3 (15 g), and Fmoc-Cl (0.44 g, 1.67 mmol). This mixture was stirred at room temp for 14 hr and then poured in 1 N HCl (100 mL). The solution was then extracted 3x with EtOAc, dried over MgS0 4 , and then concentrated in vacuo to afford 0.38 g 5 as a white crystalline solid. The dried resin (500 mg, 0.14 mmol) was placed into a small shaker vessel. The vessel was then charged with 9 mL of DMF, 5 (173 mg, 0.42 mmol), DIC (102 mg, 0.84 mmol), and
  • the resin was washed with DMF (x3), MeOH (x3), CH 2 C1 2 (x3).
  • 2-chlorophenyl isocyanate (0.050 mL, 0.41 mmol) was added to a suspension of resin in THF (1 mL) and CH 2 C1 2 (1 mL). The mixture was shaken for 20 hr and drained.
  • the resin was washed with DMF (x3), MeOH (x3), CH 2 C1 2 (x3).
  • To the resin was added a solution of TFA in CH 2 C1 2 (25 % v/v, 2 mL) and the mixture was shaken for 1.5 hr. The mixture was filtered and the filtrate was concentrated in vacuo.
  • Pr 2 NH (10 mL). The mixture was stirred for 1 hr under N 2 and a solution of l-(tert- butoxycarbonyl)-2-ethynylpyrrolidine (488 mg, 2.5 mmol) in /-Pr 2 NH (10 mL) was added to the mixture. After stirring for 2 hr, the mixture was poured into H 2 0 and extracted with EtOAc. The extract was washed with brine, dried over MgS0 4 , and evaporated.
  • N-tert-butoxycarbonyl-2-methylproline methyl ester (3.20g, 0.013 lmol) in THF (20mL) was added IN NaOH (15.7mL) at room temp. After the resulting mixture was stirred for 24 hr, the mixture was diluted with water and washed with EtOAc. The separated aqueous layer was acidified by the addition of IN HCl, and extracted with EtOAc. The extract was dried over Na 2 S0 4 and evaporated in vacuo to afford 1.71g(57%) N-tert- butoxycarbonyl-2-methylproline as a yellow syrup.
  • 'H-NMR (CDC1 3 ) ⁇ 1.42 (s, 9H), 1.48 (s, 3H), 1.88-2.31 (m, 4H), 3.34-3.57 (m, 2H), 9.35 (br s, IH)
  • Methyl 4-[l-(4-benzyloxycarbonylaminophenylacetyl)-(4S)-fluoro-(2S)-pyrrolidinylmethoxy] benzoate (300 mg, 0.576 mmol) was tsdded EtOH-THF (5: 1, 30 ml) and the solution was hydrogenated over 5% Pd/C (300 ml) for 12 h while stirring. The mixture was filtered to remove the catalyst. The filtrate was concentrated under a reduced pressure.

Abstract

Compounds that selectively inhibit the binding of ligands to α4β1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by formula (I). As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion.

Description

VLA-4 INHIBITOR COMPOUNDS
FIELD OF THE INVENTION
The present invention relates to compounds that selectively inhibit the binding of ligands to the adhesion receptor, 4βj integrin, also known as VLA-4. Compounds of the present invention are useful in the treatment and prevention of pathologies associated with VLA-4 mediated cell adhesion, such as inflammatory and autoimmune diseases, and tumor metastasis.
BACKGROUND OF THE INVENTION A primary feature of such pathologies as inflammation and autoimmune diseases is the accumulation of activated leukocytes in affected tissues. The process by which leukocytes transmigrate from the circulation at a site of inflammation involves a cascade of interactions that can be divided into four major steps: tethering and rolling, activation, firm adhesion, and transmigration (Springer, T., Ann. Rev. Physiol.. 57:827 (1995)). Initially, leukocytes are lightly tethered to the endothelium and roll along its surface. This is followed by cell activation, mediated by soluble chemotactic stimuli, which initiates the development of a firmer bond between individual leukocytes and endothelial cells. The firm bond then results in the successful adhesion and transmigration of the leukocytes through endothelial cell junctions. The steps occur in series and each is essential for transmigration to occur. This also means that transmigration can be modulated at each step, thus providing a number of potential targets for pharmacological inhibition.
The receptors involved in leukocyte migration have, to a large extent, been characterized as belonging to particular cell adhesion molecule families (Carlos and Harlan, Blood, 84:2068 (1994)). The initial attachment and rolling step is mediated by a family of adhesion receptors referred to as selectins. Firm adhesion is mediated by interaction of leukocyte surface integrins with molecules of the immunoglobulin superfamily expressed on the surface of the endothelium. Both integrins and the immunoglobulin-type adhesion molecules are also primarily involved in leukocyte transmigration. After transmigration, the leukocytes rely on integrins to traverse through the extracellular matrix and remain at the site of inflammation.
Integrins are a large family of heterodimeric glycoproteins composed of two noncovalently associated subunits, α and β (Hynes, R., Cell, 69: 11 (1992)). There are at least 16 different α subunits (αι-α9, αL, αM, αD, αx αE, α^, α,,) and at least 9 different β (βι-β9) subunits. Integrins are divided into sub-families, based upon the β subunit. Leukocytes express a number of different integrins, including α4βb α5β α6β ,, α4β7, αLβ 2, αxβ2> and αvβ3.
α4β, integrin, also known as very late antigen-4 (VLA-4) or CD49d/CD29, is expressed on monocytes, lymphocytes, eosinophils, and basophils, all of which are key effector cells in various inflammatory disorders (Helmer, M., Ann. Rev. Immunol.. 8:365 (1990)). α4β, integrin serves as a receptor for vascular cell adhesion molecule-1 (VCAM-1), as well as to the extracellular protein fibronectin (FN) (Elices et al. , Cell. 60:577 (1990)). Anti-inflammatory effects and delayed disease progression have been demonstrated after in vivo monoclonal antibody blockade of the α4β,/VCAM-l pathway (Lobb et α/.. J. Clin. Invest. 94:1722-28 (1994)). In a guinea pig model of pulmonary inflammation, anti-α4 inhibited both antigen-induced bronchial hyperreactivity and leukocyte recruitment in bronchoalveolar lavage fluid (Pretolani et al, J. Exp. Med., 180:795 (1994)). Antibodies to α4 or VCAM-1, prevented antigen-induced eosinophil infiltration of the mouse trachea (Nakajima et al, J. Exp. Med., 179: 1145 (1994)). α4 or VCAM- 1 monoclonal antibody treatment also delayed or prevented cutaneous delayed hypersensitivity response in mice and monkeys (Chisholm et al. , Eur. J. Immunol. 23:682 (1993); Silber et al. , I Clin. Invest.. 93:1554 (1993); cardiac allograft rejection in mice, accompanied by specific immunosuppression (Isobe et al, J. Immunol.. 153:5810 (1994); graft-versus-host disease in mice after bone marrow transfer (Yang et al. , Proc. Natl. Acad. Sci. USA. 90: 10494, (1993); and experimental autoimmune encephalomyelitis in rats and mice (Yednock et al, Nature. 356:63 (1992); Baron et al, J. Exp. Med.. 177:57 (1993)).
Rational drug design studies have produced soluble VCAM-Ig fusion protein containing the two N-terminal domains of human VCAM-1 fused to a human IgGl constant region. In vivo administration of the fusion protein significantly delays the onset of adoptively transferred autoimmune diabetes in nonobese diabetic mice (Jakubowski et al, J. Immunol., 155:938 (1995)). Another approach has used three-dimensional crystallographic structures of VCAM-1 fragments to synthesize cyclic peptide antagonists that closely mimicked the 4 integrin binding loop in domain 1 of VCAM-1. Synthetic VCAM-1 peptide CQIDSPC, was able to inhibit the adhesion of VLA-4- expressing cells to purified VCAM-1 (Wang et al, Proc. Natl. Acad. Sci. USA, 92:5714 (1995)).
An additional strategy is to block the binding of α4βι to its other counter receptor, that is, an alternatively spliced region of fibronectin containing the connecting segment-1 (CS-1) motif (E.A. Wayner, J. Cell. Biol, 116:489 (1992)). A synthetic CS-1 tetrapeptide (phenylacetic acid- Leu- Asp-Phe-d-Pro-amide) inhibited VLA-4-mediated lymphocyte adherence in vitro and reduced accelerated coronary arteriopathy in rabbit cardiac allografts (Molossi et al , J. Clin. Invest. 95:2601 (1995)). Each of these studies provide evidence that selective inhibition of α4β,/VCAM-l mediated adhesion is a proven strategy in the treatment of autoimmune and allergic inflammatory diseases.
Moreover, while United States Patent 5,821,231 and PCT Applications WO 96/22966, WO 97/03094, WO 98/04247 and WO 98/04913 describe compounds exhibiting VLA-4 inhibitory activity in in vitro binding assays, none of the described compounds have exhibited efficacy in oral administration.
Accordingly, despite these advances, there remains a need for small, non-peptidic, specific inhibitors of VLA-4 dependent cell adhesion that are orally bioavailable and that are suitable for the long-term treatment of chronic inflammatory diseases and other pathologies associated with leukocyte migration and adhesion.
SUMMARY OF THE INVENTION
The compounds of the present invention selectively inhibit the binding of ligands to α4β, and therefore, are useful for inhibition, prevention and suppression of VLA-4-mediated cell adhesion and the pathologies associated with that adhesion, such as, for example, inflammation, asthma, arthritis, diabetes, autoimmune responses, multiple sclerosis, psoriasis, transplantation rejection, and tumor metastasis.
In one embodiment, the present invention provides a compound represented by Formula I, or a salt thereof,
Figure imgf000004_0001
wherein W is chosen from aryl group, substituted aryl group, heteroaryl group and substituted heteroaryl group; W1 is chosen from arylene group, substituted arylene group, heteroarylene group and substituted heteroarylene group; A is chosen from =0, =S and =NH; R is chosen from a direct bond, alkyenylene group and -(CH2)n-, wherein n is chosen from 1 and 2,
X is chosen from -C(O)-, -CH2- and S(0)2,
M is chosen from
Figure imgf000005_0001
wherein
Figure imgf000005_0002
is a divalent 4-, 5-, 6- or 7-membered heterocychc moiety, wherein the nitrogen atom is the point of attachment to X, R1, R2 and R3 are independently chosen from -H, -OH,-NH2, halogen atom, alkyl group, substituted alkyl group, aryl group, substituted aryl group, alkoxy group, substituted alkoxy group, monoalkylammo group, substituted monoalkylaπuno group, dialkylamino group, substituted dialkylaπuno group, cycloalkylammo group, substituted cycloalkylamino group, alkylsulfbnylamino group, substituted alkylsulfonylamino group, arylsulfonylamino group, substituted arylsulfonylamino group, aryloxy group, substituted aryloxy group, heteroaryloxy group, substituted heteroaryloxy group, benzyloxy group and substituted benzyloxy group, or two of R1, R2 and R3 taken together may form a 3-, 4-, 5-, 6-, or 7-membered carbocychc or heterocychc residues optionally substituted with from 1 to 3 substituents chosen independently from -OH, halogen atom, -NH2, alkyl group, alkoxy group, aryl group, aryloxy group, alkylamino group, benzyloxy group and heteroaryl group, R4 is chosen from -H and lower alkyl group,
Y is a direct bond or a divalent radical chosen from -C(O)-, -C(0)NH-, alkenylene group, alkynylene group and -(CH2)kY2, wherein k is chosen from 1, 2 and 3, and Y2 is a direct bond or a divalent radical chosen from -0-, -S-,
-S(O), -S(0)2- and -NY3-, wherein Y is chosen from -H and lower alkyl group,
Z is chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group and substituted cycloalkylene group, A1 is a direct bond or a divalent radical chosen from alkenylene group, alkynylene group, -(CH2)t- and -O CH^ wherein t is chosen from 1, 2 and 3, and v is chosen from 0, 1, 2, and 3, and
R is chosen from -OH, lower alkoxy group, -N(H)OH, N N and
H
Figure imgf000006_0001
wherein
Figure imgf000006_0002
is a divalent 4-, 5-, 6- or 7-membered heterocychc moiety, wherein the nitrogen atom is the point of attachment to X,
R6 and R7 are independently chosen from -H, -OH, halogen atom, alkyl group and alkoxy group, Y1 is a divalent radical chosen from -0-, -S-, -S(O)-, -S(0)2- and -NY4-, wherein Y4 is chosen from -H and lower alkyl group, Z1 is a divalent radical chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group and substituted cycloalkylene group,
A2 is a direct bond or a divalent radical chosen from alkenylene group, alkynylene group and -(CH2)e wherein e is chosen from 1, 2 and 3, and
H H R is chosen from -OH, lower alkoxy group, -N(H)OH, N~~N and
H H i 1 N-tf
Figure imgf000007_0001
wherein
Figure imgf000007_0002
wherein
N f is a divalent 4-, 5-, 6- or 7-membered heterocychc moiety, optionally substituted with from 1 to 3 substitutents chosen independently from alkyl group, alkoxy group, hydroxyalkyl group, -OH, benzyloxy group, -NH2, halogen atom, aryl group and heteroaryl group, said moiety may be fused to 1 or 2 additional carbocyclic or heterocychc residues optionally substituted with from 1 to 3 substitutents chosen independently from alkyl group, aryloxy group, alkoxy group, hydroxyalkyl group, -OH, benzyloxy group, -NH2, , halogen atom, aryl group and heteroaryl group, m and q are independently chosen from 0, 1, 2 and 3,
X1 is chosen from -CH= and -N=,
R9 is chosen from -H and lower alkyl group,
R is chosen from -COOH, lower alkoxycarbonyl group,
Figure imgf000007_0003
Figure imgf000007_0004
Z2 is chosen from -H, COOH and lower alkoxycarbonyl group; and
Figure imgf000008_0001
wherein
R is chosen from --o0--,
Figure imgf000008_0002
a mndΛ -Nra
wherein
R12 is chosen from -H, alkyl group, substituted alkyl group, cycloalkyl group, substituted cycloalkyl group, aryl group, substituted aryl group, benzyl group, substituted benzyl group, lower alkenyl group, substituted lower alkenyl group and lower alkynyl group the left hand bond is the point of attachment to -X- and the right hand bond is the point of attachment to -Z3; Z3 is chosen from a direct bond, a divalent aliphatic hydrocarbon moiety having 1 to 12 carbon atoms, wherein one or more carbon atoms may be replaced with -O- or -NR13-
wherein R13 is chosen from -H and lower alkyl group, and one or more hydrogen atoms attached to an aliphatic carbon atom may be replaced with lower alkyl group; and
D14 ^ yf
wherein x is chosen from 0 and 1; y is chosen from 1, 2, and 3; and
R14 is chosen from -H, -OH and halogen atom,
Figure imgf000008_0003
Ru is -NR12, wherein l-z4 wherein
Z is chosen from
Figure imgf000009_0001
wherein R14a is chosen from -H, -OH, lower alkyl group and halogen atom;
^ - and ^ ^^ , wherein the left hand bond is the point of attachment to R11 and the right hand bond is the point of attachment to Q2;
Q -.2 is a divalent radical chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group, substituted cycloalkylene group,
Figure imgf000009_0002
wherein R 15 and R 16 are independently chosen
from -H, halogen atom and lower alkyl group; and
Figure imgf000009_0003
wherein R1 and R18 are independently chosen
from -H, lower alkyl group, substituted lower alkyl group and lower alkenyl group; and
L1 is chosen from -COOH and -COOR19 wherein R19 is a lower alkyl group. In a preferred embodiment of Formula I, M is
Figure imgf000010_0001
In this
embodiment, more preferred compounds are those wherein A is =0, R is -(CH2)n- and X is -C(O)-
Y { iiss pprreeffeerraabbllyy cchhoosseenn ffrroomm aallkkeennyylleennee ggrroouup, alkynylene group, -(CH2)kY2, -CH2S(0)- and CH20-, and more preferably, Y is -CH20-
Preferred compounds of this embodiment are those wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof W1 is preferably unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-
In preferred compounds of this embodiment, A is preferably =0 and A1 is a direct bond or
-(CH2)t- More preferred compounds are those wherein A1 is a direct bond and R5 is -OH
Preferred compounds of Formula I, wherein M is
Figure imgf000010_0002
and A is =0
are represented in Table 1 With respect to the representation of -W1, the lower bond is the point of attachment to -NH- and the upper bond is the point of attachment to -R- The entry entitled ~R — R5 depicts that portion of the particular compound represented by
Figure imgf000010_0003
Figure imgf000011_0001
Figure imgf000012_0001
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0001
Figure imgf000029_0001
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
In another preferred embodiment of Formula I, M is
Figure imgf000041_0001
In
this embodiment, more preferred compounds are those wherein A is =0, R is -(CH2)n- and X is -C(O)- Y is preferably chosen from -0-,-S-, -S(O)-, -S(0)2- and - Y*,and more preferably, is -0-
Preferred compounds of this embodiment are those wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof W1 is preferably unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-
In this embodiment of Formula I, A is preferably =0 and A2 is a direct bond or -(CH2)e- More preferred compounds are those wherein A is a direct bond and R is -OH
Figure imgf000041_0002
=0, are represented in Table 2 With respect to the representation of -W1, the lower bond is the point of attachment to -NH- and the upper bond is the point of attachment to -R- The entry entitled -R — R8 depicts that portion of the particular compound represented by
X7
X°> V_
Figure imgf000042_0003
In anothe
Figure imgf000042_0001
r preferred embodiment of Formula I, M is In this
embodiment, preferred compounds are those wherein A is =0, R 10 i ■s -C02H and q is 0 or 1. More preferred are compounds wherein R ,ιo i •s -C02H, q is 0 or 1, most preferably 0, and m is 2.
When A is =0, L is preferably chosen from
Figure imgf000042_0002
Figure imgf000043_0001
More preferably, L is chosen from
Figure imgf000043_0002
Most preferably, L is chosen from
Figure imgf000044_0001
Figure imgf000044_0002
Preferred compounds of Formula I, wherein R is -CH2- and X is =0, are those wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof. W1 is preferably unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-.
Preferred compounds of Formula I, wherein M is
Figure imgf000044_0003
A is =0, R
is -CH2- and X is =0, are represented in Table 3. With respect to the representation of -W1, the lower bond is the point of attachment to -NH- and the upper bond is the point of attachment to -R- The entry entitled -N — Z depicts that portion of the particular compound represented by
Figure imgf000044_0004
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Yet another preferred embodiment of Formula I includes compounds wherein M is _R11_Z3_Q2_L1
Preferably, A is =0, R is -CH2- and X is =0. Preferably W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof. W1 is preferably unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-.
In compounds wherein Q2 is R R and Z3 is a divalent aliphatic hydrocarbon moiety,
preferred compounds are those wherein R 11 i os A. or -NR12, more preferably NR12, wherein
R12 is chosen from -H, lower alkyl group and substituted lower alkyl group, most preferably dihydroxy lower alkyl group. Preferred choices for Z is a divalent aliphatic hydrocarbon moiety having 4, 5 or 6 carbon atoms. A preferred choice for W1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-.
X
In compounds wherein Q is R R and Z is
Figure imgf000051_0002
R ,π i •s preferably
14
-NR -. In these compounds, x and y are preferably 1. Preferred choices for R include -H. -OH and -F A preferred choice for W1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-. In compounds wherein Q2 is Ύ R 17R 8 and Z3 is Y ° CH , R11 is preferably
chosen from -O- and -NR1 -, preferably wherein R12 is chosen from -H and lower alkyl group Preferably, R17 and R18 are each -H A preferred choice for W1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-
In compounds wherein Q2 is
Figure imgf000052_0001
and Z3 is , R11 is preferably
-NR12-, wherein R12 is preferably lower alkyl group Preferred compounds of this embodiment also include those wherein at least one of R 17 and R 18 is lower alkyl group or substituted lower alkyl group
In compounds wherein Q2 is
Figure imgf000052_0002
, R11 is preferably
-NH- and R1 and R1 are each preferably -H A preferred choice for W1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to -NH-
In compounds wherein Q2 is chosen from aryl group, substituted aryl group and
Figure imgf000052_0003
, and more preferably from phenyl group and phenyl group substituted at the point
of attachment to Z3 ,Z3 is preferably a divalent aliphatic hydrocarbon moiety
Yet another embodiment of the invention is a compound represented by Formula π,
Figure imgf000052_0004
wherein the substituents W, W1, R11 and Z3 are defined as in Formula I, and L3 is chosen from
erein R ,20 is preferably chosen from -H and lower alkyl, CH,
Figure imgf000053_0001
Still another embodiment of the invention is a compound represented by Formula HI,
Figure imgf000053_0002
wherein the substituents W, W1, and R11 are defined as m Formula I, and d is chosen from 0 and 1, and f is chosen from 1 and 2
L-R11_Z3_Q2_L1
Preferred compounds of Formula I, wherein M is ' , A is =0, R is
-CH2- and X is =0, are represented in Table 4 With respect to the representation of -W1, the lower bond is the point of attachment to -NH- and the upper bond is the point of attachment to -R- The entry entitled — R J — L1 depicts that portion of the particular compound represented by
Figure imgf000053_0003
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
The principles of the present invention also encompass prodrugs in the scope of Formula I, and compounds representative thereof include those wherein R5 or R8 is a lower alkoxy group, and those wherein R10 or R19 is a lower alkoxycarbonyl group.
The principles of the present invention also provide a method for inhibiting cell adhesion, and in particular, VLA-4 mediated cell adhesion at α4βl receptor sites in a mammal, wherein the method comprises administering an effective amount of a compound represented by Formula I. As used herein, inhibiting cell adhesion is intended to include inhibiting, suppressing and preventing VLA-4 mediated cell adhesion-associated conditions, including but not limited to, inflammation and cell adhesion-associated immune or autoimmune responses.
The principles of the present invention therefore also provide a method of treating a condition associated with VLA-4 mediated cell adhesion, wherein the method comprises administering to a mammal in need of such treatment, an effective amount of a compound represented by Formula I. Such conditions include for example, but are not limited to, inflammatory and autoimmune responses, diabetes, asthma, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. As used herein, "treatment" of a mammal is intended to include prophylaxis as well. The compounds of the present invention may be administered as a monotherapy, or in combination with antiinflammatory or immunosuppressive agents. Such combination therapies can involve the administration of the various pharmaceuticals as a single dosage form or as multiple dosage forms administered at the same time or at different times.
Any suitable route of administration may be employed for providing a patient with an effective amount of a compound of the present invention. Suitable routes of administration may include, for example, oral, rectal, nasal, buccal, parenteral (such as, intravenous, intrathecal, subcutaneous, intramuscular, intrasternal, intrahepatic, intralesional, intracranial, intra-articular, and intra-synovial), transdermal (such as, for example, patches), and the like. Due to their ease of administration, oral dosage forms, such as, for example, tablets, troches, dispersions, suspensions, solutions, capsules, soft gelatin capsules, and the like, may be preferred. Administration may also be by controlled or sustained release means and delivery devices. Methods for the preparation of such dosage forms are well known in the art.
Pharmaceutical compositions incorporating compounds of the present invention may include excipients, a pharmaceutically acceptable carrier, in addition to other therapeutic ingredients. Excipients such as starches, sugars, microcrystalline cellulose, diluents, lubricants, binders, coloring agents, flavoring agents, granulating agents, disintegrating agents, and the like may be appropriate depending upon the route of administration. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.
The compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorgamc or organic bases. Suitable pharmaceutically acceptable base addition salts include, but are not limited to, ammonium salts, alkali metal salts, metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, organic salts made from chloroprocaine, choline, N.N'-dibenzylethylenediamine, dicyclohexylamine, diethanolamine, ethylenediamine, lysine, meglumine (N-methylglucamine) and procaine, as well as salts with amino acids, such as arginine, lysine, and so forth.
Where the compounds of the invention have a basic moiety, such as an amino group, the compounds may be used in the form of pharmaceutically acceptable non-toxic organic or inorganic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfomc, methanesulfomc, fumaπc, glucomc, glutamic, hydrobromic, hydrochlonc, lactic, maleic, malic, mandehc, nitnc, pamoic, pantothemc, phosphonc, succinic, sulfunc, tartanc, p- toluenesulfomc acids, and the like Particularly prefened are citnc, hydrochlonc, maleic, fumanc, phosphonc, sulfunc, tartanc and -toluenesulfonic acids Compounds of the invention may also be in the form of hydrates
DETAILED DESCRIPTION OF THE INVENTION Abbreviations & Definitions The following terms and abbreviations have the indicated meamng throughout this disclosure
2 29933EE H HEEKK cceellllss = 293E human embryonic kidney cells
Ac acetyl antι-α4-PE conjugated = monoclonal antibody against integnn α4 subumt, phycoerythnn conjugated anti-βl-FITC conjugated = monoclonal antibody against integrin βl subumt, fluorescein conjugated 5βl integnn α5βl, fibronectin receptor, VLA-5 αvβ3 integnn αvβ3, vitronectm receptor 4β7 integnn α4β7
Bn benzyl
Boc r-butoxycarbonyl
BSA bovine serum albumin c- cyclo- cDNA complementary DNA
CHO cells Chinese Hamster Ovary cells -ClPh para-chlorophenyl
CMV promoter cytomegalovirus promoter
OT-CPBA 3-chloroperoxybenzoιc acid
DAST diethylaminosulfur tnfluonde
DCM dichloromethane = methylene chloride = CH2C12
D DEELLFFIIAA dissociation enhanced lanthamde fluor-immune assay
DIAD diisopropyl azodicarboxylate
DIC diisopropylcarbodiimide
DIEA NN-diisopropylethylamine DMAP 4-N,N-dimethylaminopyridine
DMEM Dulbecco's Modified Eagle's Medium
DMF N/V-dimethylformamide
DTPA Diethylenetriaminepentaacetic acid EDC 1 -ethyl-3 -(3 -dimefhylaminopropyl)carbodiimide
Et20 ethyl ether
FACS fluorescence cell sorting
Fmoc 9-fluorenylmethoxycarbonyl
GPIIb/IIIa integrin αllbβ3, fϊbrinogen receptor HEPES N-(2-hydroxyethyl)piperazine-N' -(2-ethanesulfonic acid)
HMDS 1,1, 1,3,3,3-hexamethyldisilzane
HOAc acetic acid
HOBt 1 -hydroxybenzotriazole human IgGl human immunoglobulin Gl ICAM intracellular adhesion molecule
LDV Leu-Asp-Val
LFA-1 and Mac-1 Lymphocyte function-related antigen
LiHMDS lithium 1,1,1,3,3,3 -hexamethyldisilazane
Me methyl p-MeOPh para-methoxyphenyl nM nanomolar
PBS phosphate buffered saline
PEG polyethylene glycol
Ph phenyl PhOH phenol
PyBroP bromo-tris-pynolidinphosphonium hexafluorophosphate
RPMI medium Russell Park Memorial Institute medium
TFA trifluoroacetic acid
TFAA trifluoroacetic acid anhydride THF tetrahydrofuran
TLC thin-layer chromatography
TMS trimethylsilyl
Ts toluenesulfonyl
VCAM-1 (D1D7) vascular cell adhesion molecule (containing one to seven immuloglobulin domains) VCAM-IgG fusion protein = a VCAM IgG fusion protein containing the one to seven immunoglobulin domains of human VCAM-1 (D1D7) attached above the hinge region of an IgGl molecule
"Alkyl group" is intended to include linear or branched hydrocarbon radicals and combinations thereof of 1 to 20 carbons. "Lower alkyl group" means alkyl groups of from 1 to about 10, preferably from 1 to about 8, and more preferably, from 1 to about 6 carbon atoms. Examples of such radicals include methyl, ethyl, «-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, wo-amyl, hexyl, octyl groups and the like.
"Alkylene group" means a divalent radical formed by removing a hydrogen atom from an
"alkyl group."
"Aryl group" means a radical formed from an aromatic hydrocarbon ring of 4 to about 16 carbon atoms, preferably of 6 to about 12 carbon atoms, and more preferably of 6 to about 10 carbon atoms. The rings may optionally be substituted with 1-3 substituents selected from alkyl, halogen, hydroxy, alkoxy, aryloxy, haloalkyl, phenyl and heteroaryl. Examples of aryl groups are phenyl, biphenyl, 3,4-dichlorophenyl and naphthyl.
"Arylene group" means a divalent radical formed by removing a hydrogen atom from an "aryl group."
"Arylalkyl group" denotes a structure comprising an alkyl attached to an aryl ring. Examples include benzyl, phenethyl, 4-chlorobenzyl, and the like.
"Cycloalkyl group" refers to a saturated hydrocarbon ring radical of from 3 to 12 carbon atoms, and preferably from 3 to 8 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, adamantyl, myrtanyl groups and the like. "Lower cycloalkyl group" refers to cycloalkyl of 3 to 6 carbons.
"Cycloalkylene group" means a divalent radical formed by removing a hydrogen atom from a "cycloalkyl group." "Divalent Ct to C20 aliphatic hydrocarbon moiety" includes alkylene, cycloalkylene, alkenylene, alkynylene groups and combinations thereof. Examples include ethylene, propylene, propynylene, 2,4-heptadienylene groups and the like.
"Heterocyclyl group" refers to a cyclic radical having from 1 to 6 carbon atoms, preferably 3 to 6 carbon atoms, and from 1 to 4 heteroatoms chosen from O, N and S. Examples include: pyrrolyl, pyridinyl, pyrazolyl, triazolyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, imidazolyl, indolyl, thienyl, furyl, azetidiyl, tetrazolyl, 2-pyrrolinyl, 3-pynolinyl, pynolindinyl, 1,3-dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3 -triazolyl, 1,3,4-thiadiazolyl, 2H-pyranyl, 4H-pyranyl, piperidinyl, 1,4-dithianyl, morpholinyl, fhiomorpholinyl, pyrazinyl, piperazinyl, 1,3,5-triazinyl, 1,2,5-trithianyl, benzo(b)thiophenyl, benzimidazolyl, quinolinyl groups and the like.
"Heterocyclylene group" means a radical formed by removing a hydrogen atom from a "heterocyclyl group."
"Heteroaryl group" refers to an aromatic cyclic radical having from 1 to 12 carbon atoms, preferably 1 to 6 carbon atoms, and from 1 to 4 heteroatoms chosen from O, N and S; or a bicyclic 9- or 10-membered heteroaromatic ring system containing 1-4 heteroatoms selected from O, N and S. The methine H atoms of a heterocyclyl or heteroaryl structure may be optionally substituted with alkyl, alkoxy or halogen. Examples include: imidazolyl, pyridyl, indolyl, thienyl, benzopyranyl, thiazolyl, furyl, benzimidazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, pyrimidinyl, pyrazinyl, tetrazolyl, pyrazolyl groups and the like.
"Heteroarylene group" means a divalent radical formed by removing a hydrogen atom from a "heteroaryl group."
"Alkoxy group" means a straight, branched or cyclic hydrocarbon configuration and combinations thereof, including from 1 to 20 carbon atoms, preferably from 1 to 8 carbon atoms, more preferably from 1 to 4 carbon atoms, and an oxygen atom at the point of attachment.
Suitable alkoxy groups include methoxy, ethoxy, w-propoxy, isopropoxy, n-butoxy, /'so-butoxy, sec- butoxy, te -butoxy, cyclopropoxy, cyclohexyloxy groups and the like. "Lower alkoxy group" refers to alkoxy groups having from 1 to 4 carbon atoms. "Alkenyl group" refers to an unsaturated acyclic hydrocarbon radical in so much as it contains at least one double bond. "Lower alkenyl group" refers to such radicals containing from 2 to 10 carbon atoms, preferably from 2 to 8 carbon atoms and more preferably from 2 to 6 carbon atoms. Examples of suitable alkenyl radicals include propenyl, buten-1-yl, isobutenyl, penten-1-yl, 2-methylbuten-l-yl, 3-methylbuten-l-yl, hexen-1-yl, hepten-1-yl, and octen-1-yl groups and the like.
"Alkenylene group" means a divalent radical formed by removing a hydrogen atom from an "alkenyl group."
"Alkynyl group" refers to an unsaturated acyclic hydrocarbon radical containing at least one triple bond. Examples include ethynyl, propynyl groups, and the like.
"Alkynylene group" means a divalent radical formed by removing a hydrogen atom from an alkynyl group."
"Substituted alkyl group" means a linear or branched alkyl group wherein at least one hydrogen atom attached to an aliphatic carbon is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro. Examples of such substituent groups include methyl, isopropyl, methoxy, ethoxy, propoxy, amino, methylamino, phenyl, naphthyl groups, chlorine, fluorine and the like.
"Substituted alkylene group" means a linear or branched alkylene group wherein at least one hydrogen atom attached to an aliphatic carbon is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
"Substituted cycloalkyl group" means a cycloalkyl group wherein at least one hydrogen atom attached to a ring carbon atom is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
"Substituted cycloalkyene group" means a cycloalkylene group wherein at least one hydrogen atom attached to a ring carbon is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
"Substituted aryl group" means an aryl group wherein at least one methine hydrogen atom attached to an aromatic carbon is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
Substituted arylene group" means an arylene group wherein at least one hydrogen atom attached to an aromatic carbon is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
"Substituted heteroaryl group" or "substituted heterocyclyl group" means a heteroaryl or heterocyclyl group wherein at least one hydrogen atom attached to a ring thereof is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
"Substituted heteroarylene group" or "substituted heterocyclylene group" means a heteroarylene or heterocyclylene group wherein at least one hydrogen atom attached to a ring thereof is replaced with a substituent such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, alkoxycarbonylalkyl, haloalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro. "Substituted arylalkyl group" means an arylalkyl having one or more substituents such as alkyl, amino, alkoxy, hydroxy, aryl, cyano, carboxy, alkoxycarbonyl, monoalkylamino, alkyloxy, cyanoalkyl, cycloalkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, arylthio, carboxyalkyl, haloalkyl, alkoxycarbonylalkyl, acylamino, dialkylamino, cyclicamino groups, halogen atom and nitro.
"Halogen" is intended to include for example, F, Cl, Br and I.
The term "prodrug" refers to a chemical compound that is converted to an active agent by metabolic processes in vivo. [See, e.g., N. Boder and J.J. Kaminski, Ann. Rep. Med. Chem. 22:303 (1987) and H. Bundgand, Adv. Drug Delivery Rev., 3:39 (1989)]. The use of prodrug precursors of compounds of the present invention in any of the methods described herein is contemplated and is intended to be within the scope of the invention.
Terminology related to "protected," "protecting" and/or "deprotecting" functionalities is used throughout this application. Such terminology is well understood by persons of skill in the art and is used in the context of processes which involve sequential treatment with a series of reagents. In this context, a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable. The protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or "deprotection" occurs after the completion of the reaction or reactions in which the functionality would interfere. Thus, when a sequence of reagents is specified, as it is in the processes of the invention, the person of ordinary skill can readily envision those groups that would be suitable as "protecting groups" for the functionalities involved.
In the case of the present invention, the functionalities that must be protected are amines. Suitable groups for that purpose are discussed in standard textbooks in the field of chemistry, such as Protective Groups in Organic Synthesis by T.W.Greene [John Wiley & Sons, New York, 1991], which is incorporated herein by reference. Particular attention is drawn to the chapter entitled "Protection for the Amino Group" (pages 309-405). Prefened protecting groups include BOC and Fmoc. Exemplary methods for protecting and deprotecting with these groups are found in Greene and Wuts on pages 318 and 327.
The materials upon which the syntheses described herein are performed are refened to as solid supports, beads, and resins. These terms are intended to include: (a) beads, pellets, disks, fibers, gels, or particles such as cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol, poly- acrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with N.N'-bis- acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, etc., i.e., material having a rigid or semi-rigid surface; and (b) soluble supports such as polyethylene glycol or low molecular weight, non-cross-linked polystyrene. The solid supports may, and usually do, have functional groups such as amino, hydroxy, carboxy, or halo groups; where amino groups are the most common.
Tentagel™ NH2 (Rapp Polymere, Tubingen, Germany) is a prefened amine functionalized polyethylene glycol- grafted polystyrene resin. TentagelIM-S-PHB resin has a para- hydroxy benzyl linker which can be cleaved by the use of 90% trifluoroacetic acid in dichloromethane. Techniques for fiinctionalizing the surface of solid phases are well known in the art. Attachment of lysine to the amino groups on a bead (to increase the number of available sites) and subsequent attachment of linkers as well as further steps in a typical combinatorial synthesis are described, for example, in PCT application WO95/30642, the disclosure of which is incorporated herein by reference. In the synthesis described in WO95/30642, the linker is a photolytically cleavable linker, but the general principles of the use of a linker are well illustrated.
Optical Isomers - Diastereomers - Geometric Isomers Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisometric forms which may be defined in terms of absolute stereochemistry as (R)- or (S)- , or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible diastereomers as well as their racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (Z,)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended to include both (£)- and (Z)- geometric isomers. Likewise, all tautomeric forms are intended to be included. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration; thus a carbon-carbon double bond depicted arbitrarily herein as trans may be cis, trans, or a mixture of the two in any proportion.
In view of the above definitions, other chemical terms used throughout this application can be easily understood by those of skill in the art. Terms may be used alone or in any combination thereof. The prefened and more prefened chain lengths of the radicals apply to all such combinations. Utility The compounds of the present invention have demonstrated utility as selective inhibitors at VLA-4 receptors. The inhibitory concentration (IC50) and the VLA-4 selectivity of test compounds for an α4β 1 receptor using in vitro assays are determined in direct binding assays and competitive assays with other integrin receptors such as β2 (LFA-1 and Mac-1), β3 (GPIIb/IIIa and αvβ3) and βl (α4β7). Compounds of the present invention have K, values < 1 μM. Prefened compounds of the invention are those having K, values < 300 nM, more preferably < lOOnM, even more preferably < 50 nM, and most preferably, < 12nM.
Examples of prefened compounds having a K, value < 50 nM are shown below. These examples are provided by way of illustration only, and are not intended to limit the invention thereto.
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Figure imgf000099_0002
X K, OOH
Figure imgf000099_0003
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
In vitro Assays A direct binding assay was used to quantify the inhibitory activity of the compounds. In this assay, VLA-4-expressing cells were seeded in a 96-well microtiter plate. The cells were allowed to grow for 2 days until confluent. Various concentrations of the test compound were added together with 2 nM of the europium-labeled, VCAM-IgG fusion protein. The cells were allowed to incubate at room temperature in the microwells for at least 30 minutes. Following incubation, the microwells were emptied and washed. The amount of europium-labeled VCAM- IgG fusion protein bound was determined by time-resolved fluorescence measurement. Inhibition of binding was determined by quantifying the fluorescence bound to the plate for each of the various concentrations of test compound, as well as for controls containing no test compound.
The VLA-4-expressing cells used in this assay was a CHO cell line stably transfected with the cDNA of the human α4 and βl subunits. Construction and maintenance of the cell line are described in the assay procedures. A VCAM IgG fusion protein containing the one to seven immunoglobulin domains of human VCAM-1 (D1D7) attached above the hinge region of an IgGl molecule was labeled with europium chelates. The preparation and labeling of the fusion protein are described in the assay procedures.
The cell adhesion inhibitory activity of the test compound was determined by blocking the Jurkat cell attachment to the D1D7-VCAM IgG fusion protein. Jurkat cell is a human lymphocytic cell line expressing VLA-4 on cell surface. In this assay, each of the 96-well microtiter wells was coated with 75 ng of the VCAM IgG fusion protein. The wells were then blocked by the addition of 1% bovine serum albumin to remove nonspecific adhesive sites. Varying concentrations of the test compound were added together with the calcein-labeled Jurkat cells. The cells were allowed to adhere to the VCAM coated wells at room temperature for 1 hour in the dark. Following incubation, the plate was washed by immersing face down into a container filled with phosphate buffered saline. The wells were blotted dry on paper towel. Quantitation of the adhered cell was determined by fluorescence measurement. Decreased fluorescence indicated inhibition of cell adhesion by the test compound.
Specificity for α4βl of each test compound among other integrin receptors, namely, β2 (LFA-1 and Mac-1), β3 (GPIIb/IIIa and αvβ3), βl (α5βl) and β7 (α4β7) was examined. LFA-1 binds to ICAM-1 and mediates the emigration of leukocytes into inflammatory sites. Mac-1 binds to a number of ligands, including ICAM-1 and fibrinogen, and plays an important role in neutrophil phagocytosis and oxygen free radical generation. GPIIb/IIIa on platelet surface binds to fibrinogen in plasma and induces platelet aggregation. αvβ3 binds to a number of extracellular matrix proteins, including vitronectin and mediates cell migration and prevents cell apoptosis. α4β7 shares the same ligands as VLA-4 (VCAM-1, MAdCAM-l.and fibronectin), but with different preference. This receptor is expressed on lymphoid cells and is involved in lymphocyte migration to mucosal tissues.
Assays of LFA-1, Mac-1, GPIIb/IIIa and αvβ3 involved coating the purified receptor on a 96-well microtiter plate. The specific ligands for these receptors were labeled with europium chelates. In the assays of LFA-1 and Mac-1, an ICAM-1 IgG fusion protein containing the one to five immunoglobulin domains of human ICAM-1 (D1D5) attached above the hinge region of an IgGl molecule, was used. In the assays of GPIIb/IIIa and αvβ3, europium-labeled fibrinogen and vitronectin, respectively, was used. The purified receptors were allowed to incubate in the wells with various concentrations of test compound, in the presence of europium-labeled ligands. Following incubation, the wells are emptied and washed. The amount of europium-labeled ligand bound was determined by time-resolved fluorescence measurement. Assay of α4β7 is similar to the adhesion inhibition assay of VLA-4 described above, and uses the α4β7-expressing cell, RPMI-8886. A MAdCAM-1 IgG fusion protein containing the one and two immunoglobulin domains of human MAdCAM-1 and mucin-like repeat domain, is used as the corresponding ligand for α4β7.
Eu +- VCAM-1 IgG binding to CHO/VLA-4 cells may be determined as follows. 4B4 cells
(CHO VLA-4 cells) are distributed into each well of a 96-well microtiter plate at 3 x 10 /well. The plate is incubated at 37 °C, 5% C02 for 48 hours and then washed twice with washing buffer, then blot dried. 50 μl of the inhibitor solution diluted with assay buffer (2% DMSO final) is added to each well, followed by 50 μl of Eu3+-VCAM-1 IgG diluted with assay buffer at 2 nM. The plate is incubated at room temperature for at least 30 min. Each well is then washed four times with washing buffer and blot dried. 100 μl of DELFIA Enhancement solution is added to each well, followed by agitation of the plate at room temperature for 5 min. Fluorescence of each sample is then measured (e.g., DELFIA Fluorometer 1234, Wallace, Inc., USA). In this assay, the washing buffer comprises 25 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2,and 4 mM MnCl2; the assay buffer comprises 25 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 4 mM MnCl2, 1% BSA, and 20 μM DTPA.
In Vivo Assays The VLA-4 inhibitors may be further characterized in in vivo assays. One such assay examines the inhibition of eosinophil infiltration into the bronchoalveolar lavage fluid in the mouse (murine) model. In this assay, the animals are treated with cyclophosphamide on day 0. On days 2 and 14, the animals are immunized intraperitoneally with Ascaris suum extract. Seven days later, the animals are treated with various doses of the VLA-4 inhibitor. Shortly after drug administration, the animals are challenged t Ascaris suum extract by instillation into the trachea. Bronchoalveolar lavage of the animal is performed by instilling saline into the lung, 48 hours later. Total cell and eosinophil counts in the lavage are determined.
In the murine model ofAscaris-inώxced bronchial inflammation, one of the representative compounds (example number 32) inhibited eosinophil infiltration by 49% at an oral dosage of 30 mg/kg. By contrast, a representative prior art compound, 4-(N'-2-methylphenylurea)phenylacetyl- LDVP-OH, described in WO 97/03094, did not inhibit eosinophil infiltration (% inhibition = -2%) at an oral dosage of 50 mg/kg.
Other representative compounds were also tested in mice. The dosage, route of administration and inhibitory effect of representative compounds (hereinafter, all tested compounds are referenced by compound number provided in the Synthetic Examples) are shown in Table 5.
TABLE 5
Figure imgf000107_0001
1 two times a day (0 and 8 hrs)
2 three times a day (0, 8 and 16 hrs) The compounds of the present invention may also be further characterized in other in vivo assays, such as the eosioophil accumulation model tested in the rat. Fifty μg of Compound 48/80 was injected into the pleural cavities of male Sprague Dawley rats. After 24 hrs, each cavity was washed twice with Hank's Balanced Salt Solution containing 0.2% EDTA. Total cell and eosinophil counts were determined. Test compounds were given intraveneously, orally or subcutaneously, b.i.d. at 0 and 8 hours. The dosage, route of administration and inhibitory effect for the test compounds are shown in Table 6.
TABLE 6
Figure imgf000108_0001
Mouse Bio-Assay Method A compound was dissolved or suspended with an appropriate solvent at 1 mg/mL. Female Balb/c mice (7-9 weeks old) were given the compound orally. Blood samples were collected from the postcaval vein of the anesthetized mice after fifteen minutes. Serum was prepared and stored at -20 °C. Serum concentration of the compound was determined from inhibitory activities of the diluted serum by a direct binding assay using VLA-4-expressing cells and VCAM-IgG fusion protein. Serum concentration determined by this method correlated well with the concentration determined by LC/MS/MS methodologies. The dosage, route of administration and resulting inhibitory effect for the test compounds are shown in Table 7.
TABLE 7
Figure imgf000108_0002
Figure imgf000109_0001
Pharmakokinetic Evaluations Pharmacokinetic parameters of exemplary compounds, in mouse, rat and monkey models, are shown in Tables 8, 9 and 10.
TABLE 8
Figure imgf000109_0002
Figure imgf000110_0001
total area under the plasma concentration (measured by LC/MS/MS method) versus time curve mean residence time apparent plasma clearance
TABLE 9
Figure imgf000110_0002
total area under the plasma concentration (measured by LC/MS/MS method) versus time curve mean residence time apparent plasma clearance
Pharmacokinetic parameters and the time course of the serum concentration of a single intravenous dosage (2mg/kg) of a representative compound and ATENOLOL {4-[2'-hydroxy-3'- isopropylamino) proppyxy]phenylacetamide; Sigma Chemical Co., code no. A-7655}are summarized in Tables 10 and 11 for the monkey model.
TABLE 10
Figure imgf000111_0001
1 total area under the plasma concentration (measured by the LC/MS/MS method) versus time cu irrvvee
2 apparent plasma clearance
TABLE 11
Figure imgf000111_0002
1 measured by the LC/MS/MS method
Binding assay of VCAM-1 to VLA-4 expressing cells Preparation of VCAM IgG fusion protein A VCAM IgG fusion protein containing the one to seven immunoglobulin domains of
VCAM-1 (D1D7) ligated to the hinge (H), CH2 and CH3 regions of human IgGl was used in the binding assay.
Construction of a stable cell line expressing D1D7-VCAM IgG fusion protein An Epstein-Barr virus based, episomal plasmid containing a D1D7-VCAM IgG fusion gene under transcriptional control of the CMV promoter, was transfected into 293E human embryonic kidney cells. Stably transfected cells were selected using 250 μg/mL hygromycin in DMEM with 10% fetal calf serum. The cells secreted D1D7 VCAM IgG fusion protein into the medium cumulatively for up to 9 days.
Purification of D1D7 VCAM IgG fusion protein The cells were cultured in DMEM with 10% fetal calf serum for 2 days, then changed to
CCM5 medium and cultured for a further 10 days. The medium was centrifiiged, filtered and then incubated overnight with Protein A Sepharose 4. The Protein A Sepharose was washed extensively and the D1D7 VCAM IgG fusion protein bound was eluted using 100 mM citric acid, pH 3.
Preparation of europium Iabeled-D1D7 VCAM IgG fusion protein The D1D7-VCAM IgG fusion protein, at 1 mg/mL, was dialyzed against 50 mM NaHC03, 0.9% NaCl, pH 8.5. The fusion protein was added to one vial of europium-labeling reagent (DELFIA labeling kit from Wallac, Gaithersberg, MD; catalog no. 1244-302) and incubated at room temperature in the dark overnight. The labeled protein was purified using a Sepharose G10 column and assayed for the europium content and protein concentration. The protein was stored at minus 80°C until used.
Construction of cell line expressing VLA-4 (CHO/VLA-4)
A CHO cell line stably transfected with the cDNA of α4 and βl was used in the binding assay. The gene for human 4 was obtained from the American Type Culture Collection and recloned between the Xhol and Xba sites of the mammalian expression vector pCI-neo (Promega, Madison, WI). The β 1 gene was amplified by PCR from human peripheral leukocyte cDNA and engineered such that the start codon was placed in the context of a consensus Kozak sequence. The gene was recloned into pCI-neo downstream of the CMV promoter and chimeric intron.
CHO-K1 cells were stably co-transfected with plasmids encoding the α4 and βl genes, and single cells expressing high levels of VLA-4 were selected by fluorescence cell sorting (FACS). The antibodies used in FACS analysis were: anti-α4-PE conjugated (PharMingen, San Diego, CA) and anti-βl-FITC conjugated (Biosource, Camarillo, CA). A cell line 4B4, which expresses 400,000 and 300,000 sites/cell of the <x4 and βl subunit, respectively, was used in the binding assay. The subunit numbers were determined by FACS analysis, using Quantum Simply Cellular microbeads (Flow Cytometiy Standards Corporation, Puerto Rico) as standards. The cells were maintained in F12 medium, containing 10% fetal bovine serum, 10 mM HEPES, pH 7.5, 0.5 mg/mL G418, using a 1:48 passage/week.
Binding Assay The CHO/VLA-4 cells were seeded in a 96-well microtiter plate at 30,000 cells/well and incubated at 37°C, 5% C02 for 48 hours until confluent. On the day of assay, the wells were emptied and washed twice with 350 μl of a washing buffer containing 25 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2 2 mM MnCl2. The plate was then drained and blotted dry on paper towels to remove buffer.
The test compound was serially diluted in assay buffer (washing buffer together with 0.1% bovine serum albumin, 20 μM DTPA and 1% dimethysulfoxide), in the presence of 2 nM of europium-labeled D1D7-VCAM IgG fusion protein. Final concentrations used ranged from 0.1 nM-10 μM. 50 μl aliquot of the test compound mixture was added to duplicate wells in the plate. Control wells for total binding received no test compound. Non-specific binding wells contained an anti-α4 monoclonal antibody (L25.3, Becton Dickinson, Bedford, MA).
The cells were allowed to incubate with the test compound mixture, in the presence of europium-labeled D1D7-VCAM IgG fusion protein at room temperature for at least 30 minutes. The cells were then washed three times with 350 μl of washing buffer, using a Skatron plate washer and blot dry. An 100 μl aliquot of DELFIA Enhancement solution was added to each well, followed by gentle agitation at room temperature for 10 minutes. The amount of europium-labeled VCAM-IgG fusion protein bound was determined by time-resolved fluorescence measurement (Model: Victor™, Wallac Inc., Gaithersberg, MD).
Percent binding was calculated as: [(FT-FNS) - (F,-FNS)] / (FT-FNS) x 100 wherein Fτ and FNS is the fluorescence signal of the europium labeled D1D7-VCAM IgG fusion protein bound to cells, in the absence of test compound and containing an anti-α4 monoclonal antibody, respectively. F, is the fluorescence in wells containing a test compound. The IC50 (concentration of the inhibitor to inhibit 50% binding of VACM to CHO/VLA-4 cell) was determined by a curve fitting routine, PRIZM (GraphPad Software, Inc., San Diego, CA).
Adhesion of VLA-4 expressing cell to VCAM-1 This secondary functional assay was used to determine the potency of a test compound in inhibiting VLA-4 mediated cell adhesion.
Preparation of VCAM coated plate
A 50 μl aliquot of the D1D7-VCAM IgG fusion protein (1.5 μg/mL in phosphate buffered saline, PBS) was added to each well of a 96-well Costar flat bottom plate (Costar, Franklin Lakes, NJ, catalog no. 2580). The plate was then incubated overnight at 4°C. On the day of assay, the wells were emptied and washed twice with 350 μl of PBS. The plate was then blocked with 100 μl of 1% bovine serum albumin (BSA, Sigma, cat# A9418) in PBS at room temperature for at least a hour.
Cell preparation
Jurkat cell (clone E6-1) was obtained from American Type Cultured Collection and was maintained in RPMI medium, 10 mM HEPES, pH 7.5, 1 mM sodium pyruvate, 10% FCS, using a 1 :64 passage/week. Just prior to running the assay, Jurkat cells were labeled with 5 μM of calcein- AM (Molecular Probe, Eugene, OR, catalog no. C1430) in RPMI medium, at room temperature for 30 min in the dark. Following labeling, cells were washed twice with RPMI medium and resupended at 1 x 106 cells/mL.
Cell adhesion assay
Immediately before the assay, the BSA solution was emptied from the VCAM-coated plate. The plate was then washed twice with RPMI medium. A 100 μl aliquot of the labeled Jurkat cells was added to each well, followed by the addition of 50 μl of the inhibitor solutions. Final inhibitor concentrations range from 1 nM to 10 μM and each concentration was tested in triplicates. The inhibitor and cells were allowed to incubate at room temp for 1 hr in the dark. Following the incubation, the plate was immersed gently into a container filled with PBS, then inverted face down under PBS. The wells were drained and blotted dry on a layer of paper towel. A 50 μl aliquot of 0.1% Triton X-100 was added to each well. The plate was incubated in the dark for 10 min. Adhesion of Jurkat cell was quantitated in a Millipore Cytofluor 2300 System plate reader set at 485 nM excitation and 530 nM emission. The IC50 (concentration of the inhibitor to inhibit 50% Jurkat cell adhesion) was determined by a curve fitting routine, PRIZM (GraphPad Software, Inc., San Diego, CA).
Methods of Synthesis Compounds of the present invention may be prepared by standard chemical synthesis methods, as well as by methods of combinatorial chemistry, such as that described in Published PCT application, WO 95/30642.
Synthetic Examples General methods of synthesis are illustrated by the following examples. The specific embodiments are presented by way of illustration only, and are not intended to limit the invention. Modifications and variations in any given material or process step will be readily apparent to one of skill in the art. Unless otherwise indicated, the solid-phase support used in certain examples is Tentagef "-S-PHB resin. This resin has a para-hydroxy benzyl linker which can be cleaved by the use of 90% trifluoroacetic acid in dichloromethane. The loading for this resin varies between 0.27 and 0.30 mmol/g and is not double loaded. Example 1
Figure imgf000115_0001
A
A three-necked 500 mL round-bottomed flask was charged with 200 mL of THF and NaH
(1.5 g, 62.9 mmol). A solution of l-vinyl-2-pyrrolidinone (6.9 g, 62.9 mmol) and methyl 3- iodobenzoate (15.0 g, 57.3 mmol) in THF (100 mL) was added dropwise to the flask over 15 min. After the addition was complete the reaction mixture was heated to reflux for 1 hr. The reaction vessel was allowed to cool to room temp and then 6 N HC1 (100 mL) was carefully added. The reaction was concentrated in vacuo to remove the THF and then an additional aliquot of 6 N HC1 (100 mL) was added and the reaction was refluxed for 14 hr. The reaction was quenched by the addition of NaHC03 until pH 9 and then the mixture was extracted 3x with EtOAc. The combined organics were dried over MgS04 and concentrated in vacuo to afford a yellow oil.
This oil was then placed in MeOH (100 mL) and cooled to minus 78 °C. NaBH4 (3.5 g, 96.5) was then added portionwise and the reaction was allowed to warm to room temp over 2 hr. The reaction was quenched by the addition of 6 N HC1 until acidic and then made basic by the addition of 40% aqueous NaOH. The solution was extracted 3x with CH2C12, the combined organics were dried over MgS0 , and then concentrated in vacuo to afford 11.4 g as a yellow oil.
The above amine was then Boc-protected by placing the amine in 50% dioxane:H20 (100 mL) and adding K2C03 until basic. To this solution was added Boc-anhydride (9.1 g, 41 mmol) and then allowed to stir for 14 hr at room temp. The reaction was quenched by the addition of 1 N HC1 until acidic. The solution was extracted 3x with EtOAc, dried over MgS04 and concentrated in vacuo to afford a yellow viscous oil. The oil was chromatographed (25% EtOAσhexanes) to afford 7.0 g A.
Figure imgf000115_0002
Hydrochloric acid (gas) was bubbled through 15.8 g (73.5 mmol) 2-bromophenylacetic acid in 100 mL of methanol for 10 min. The resulting solution was partitioned between lOOmL water and 100 mL CH2C1. The organic layer was dried over MgSo4 and the solvent was removed under reduced pressure to give 16.8 g (73.5 mmol) of methyl-2-brompophenylacetate which was combined with 9.0 g (80.8 mmol) of l-vinyl-2-pyrrolidinone, and 100 mL of dry THF under argon in a 250 mL round-bottomed flask.
To this flask was added 3.5 g (147 (mmol) sodium hydride (95%) and the solution was stirred for 10 min at room temp. A reflux condenser was added and the mixture was heated to reflux for 1 hr. The solution was cooled to room temp and the solvent was removed under reduced pressure. A solution of 30 mL aqueous hydrochloric acid and 50 mL water was added to the resultant mixture and was heated to reflux with no condenser until the solution temperature reached 96 °C at which time a condenser was added and the solution was allowed to reflux for 16 hr. The solution was cooled to room temp, made basic with 150 mL of an aqueous solution of 40% sodium hydroxide, extracted with 3 x 125 mL CH2C12, and the combined organic layers were washed with a saturated aqueous solution of sodium chloride, dried over magnesium sulfate, and the solvent was removed under educed pressure to give 15.0 g (63.0 mmol, 86%) of 2-(2- bromobenzyl)-l-pyrolline.
To a solution of 15 g (63 mmol) of 2-(2-bromobenzyl)-l-pyrolline in a solution of 80:20 methanol: aqueous acetic acid cooled to minus 78 °C was added, in portions over a 15 min period, 5.3 g (140.0 mmol) sodium borohydride. The mixture was allowed to stir for 1 hr warming to room temp at which time the solvent was removed under reduced pressure, 150 mL of water was added and the solution was made basic with an aqueous solution of sodium hydroxide which was extracted 10 x 100 mL CH2C12 which resulted in emulsions. The combined organic layers were washed with a saturated aqueous solution of sodium bicarbonate, dried over magnesium sulfate and the solvent was removed in vacuo to give 14.6 g (60.8 mmol, 97%) of the benzyl proline.
To a solution of 14.6 g( 60.8 mmol) of the benzyl proline in a solution of 70 mL of saturated aqueous sodium bicarbonate and 70 mL dioxane was added 15.1 g (67.0 mmol) of di-r- butyl-dicarbonate and the mixture was stirred for 16 hr at room temp. The solution was then partitioned between a 200 mL aqueous solution of hydrochloric acid and 200 mL ethyl acetate. The ethyl acetate layer was washed with 200 mL of a saturated aqueous solution of sodium chloride, dried over MgS04 and the solvent was removed under reduced pressure to give a residue which was purified by flash column chromatography (20%- 100% ethyl acetate/hexane) to give 11.5 g (33.8 mol, 56%) pure A'.
Figure imgf000117_0001
j
A (1.88 g, 5.0 mmol) was placed in a 100 mL round-bottomed flask and dissolved in
DMF (50 mL). To this solution was added Pd(OAc)2 (23 mg, 0.3 mmol), P(o-Tol)3 (12 mg, 0.3 mmol), methyl acrylate (0.47 g, 5.5 mmol), and NaOAc (0.5 g, 5.5 mmol). This mixture was then heated to 80 CC for 14 hr. The reaction mixture was then cooled to room temp and 1 N HCl (100 mL) was added. The solution was then extracted 3x with EtOAc, dried over MgS04, and then concentrated in vacuo to afford a brown oil. This oil was chromatographed with 25%
EtOAc:hexanes to afford 1.32 g of the alkene ester as a colorless viscous oil.
The alkene ester (1.32 g, 4.1 mmol) was then subjected to hydrogenation. The alkene was placed in a Parr hydrogenation bottle, EtOAc (10 mL) and 10% Pd C (100 mg) was added under inert atmosphere. The bottle was then pressurized with hydrogen at 45 psi and shaken for 4 hr at room temp. The solution was then filtered through celite and concentrated in vacuo to afford 1.29 g of the alkane ester.
The alkane ester (1.29 g, 4.0 mmol) was dissolved in THF (30 mL), MeOH (20mL), and water (10 mL) and saponified with LiOH (200 mg, 8.0 mmol). The reaction was stirred at room temp for 3 hr and then poured into 1 N HCl (50 mL). This solution was then extracted 3x with EtOAc, dried over MgS04, and then concentrated in vacuo to afford 1.02 g of the alkane acid as a yellow solid.
The alkane acid (1.02 g, 3.3 mmol) was then deprotected by the addition of a 25% TFA CH2C12 solution and stirred for 2 hr at room temp. The resulting mixture was then concentrated in vacuo and immediately protected by dissolving the deprotected acid in 50% dioxane/water, adding K2C03 (1.2 g), and Fmoc-Cl (1.08 g, 4.0 mmol). This mixture was stirred at room temp for 14 hr and then poured in 1 N HCl (100 mL). The solution was then extracted 3x with EtOAc, dried over MgS04, and then concentrated in vacuo to afford 495 mg 1 as a white crystalline solid.
Figure imgf000118_0001
The dried resin (500 mg, 0.14 mmol) was placed into a small shaker vessel. The vessel was then charged with 9 mL of DMF (2 mg, 0.42 mmol), DIC (102 mg, 0.84 mmol), and DMAP (17 mg, 0.14 mmol). The vessel was subsequently shaken for 16 hr at room temp. The contents were drained and the resin was washed 3x with DMF, MeOH, and CH2C12. The Fmoc group was then removed by the addition of 10 mL of 50% piperidine/DMF to the shaker vessel and shaking for 2 hr at room temp. The resulting amine resin was washed 3x with DMF, MeOH, and CH2C12.
To the above resin was added 9 mL of DMF, 4-[N'-(o-Tolylurea)]-phenylacetic acid (132 mg, 0.42 mmol), PyBroP (196 mg, 0.42mmol), and DIEA (107 mg, 0.84 mmol). The contents were shaken for 14 hr at room temp and then drained and washed 3x with DMF, MeOH, and CH2C12. The compound was then cleaved from the resin and the filtrate was collected and then concentrated in vacuo. The resulting oil was triturated by taking up the oil in MeOH and slowly adding in Et20 until a precipitate formed. This precipitate was collected and dried in vacuo to afford 67 mg 1' as a white crystalline solid. Example 2
Figure imgf000118_0002
A (4.2 g, 11.3 mmol) was placed in a 100 mL round-bottomed flask and dissolved in NEt3
(50 mL). To this solution was added Pd(PPh3)2Cl2 (0.16 g, 0.23 mmol), Cul (21 mg, 0.12 mmol), and trimethylsilylacetylene (1.38 g, 13.5 mmol). This mixture was stirred at room temp for 14 hr. The reaction mixture was quenched by the addition of 1 N HCl (100 mL). The solution was then extracted 3x with EtOAc, dried over MgS04, and then concentrated in vacuo to afford a yellow oil.
This oil was chromatographed with 15% EtOAc:hexanes to afford 3.8 g 2 as a colorless viscous oil.
Figure imgf000118_0003
A solution of dicyclohexylborane was generated by the addition of borane-THF (12.0 mL, 12 mmol), at 0°C to a solution of cyclohexene (2.3 mL) in 6 mL of anhydrous THF. This solution was stirred for an additional 1 hr at 0°C The acetylene (2) (2.0 g, 5.84 mmol) was then added dropwise over 15 min at 0°C and then allowed to warm to room temp over 1 hr. The reaction mixture was then diluted with MeOH (20 mL) and then recooled to 0°C A solution of 2 N NaOH (6 mL) and 30% H202 (3.5 mL) was then added dropwise. The reaction mixture was then stirred at 0°C for 1 hr and then warmed to 40°C for 2.5 hr. The mixture was then cooled to room temp and an additional 6 mL of 2 N NaOH was added. The organics were removed in vacuo and the remaining aqueous solution was extracted 3x Et20 and the organics were discarded. The aqueous extracts were then acidified with 1 N HCl and extracted with EtOAc dried over MgS04, and then concentrated in vacuo to afford 1.7 g of the phenylacetic acid as a tan crystalline solid.
The acid (1.7 g, 5.6 mmol) was then deprotected by the addition of a 25% TFA/CH2C12 solution and stirred for 2 hr at room temp. The resulting mixture was then concentrated in vacuo and immediately protected by dissolving the deprotected acid in 50% dioxane/water, adding K2C03 (15g), and Fmoc-Cl (1.4 g, 5.5 mmol). This mixture was stirred at room temp for 14 hr and then poured in 1 N HCl (100 mL). The solution was then extracted 3x with EtOAc, dried over MgS04, and then concentrated in vacuo to afford 1.7 g 3 as a white crystalline solid.
Figure imgf000119_0001
The dried resin (500 mg, 0.14 mmol) was placed into a small shaker vessel. The vessel was then charged with 9 mL of DMF, 3 (180 mg, 0.42 mmol), DIC (102 mg, 0.84 mmol), and DMAP (17 mg, 0.14 mmol). The vessel was subsequently shaken for 16 hr at room temp. The contents were drained and the resin was washed 3x with DMF, MeOH, and CH2C12. The Fmoc group was then removed by the addition of 10 mL of 50% piperidine/DMF to the shaker vessel and shaking for 2 hr at room temp. The resulting amine resin was washed 3x with DMF, MeOH, and CH2C12.
To the above resin was added 9 mL of DMF, 4-[N'-(o-Tolylurea)]-phenylacetic acid (132 mg, 0.42 mmol), PyBroP (196 mg, 0.42 mmol), and DIEA (107 mg, 0.84mmol). The contents were shaken for 14 hr at room temp and then drained and washed 3x with DMF, MeOH, and CH2C12. The compound was then cleaved from the resin and the filtrate was collected and then concentrated in vacuo. The resulting oil was triturated by taking up the oil in MeOH and slowly adding in Et20 until a precipitate formed. This precipitate was collected and dried in vacuo to afford 52 mg 3' as a white crystalline material.
Example 3
Figure imgf000120_0001
The acetylene (2) was deprotected by placing 2 (0.75 g, 2.1 mmol) in MeOH
(25 mL) and adding to this solution KOH (1.4 g). The resulting solution was stirred at room temp for 1 hr. The reaction mixture was then concentrated in vacuo and acidified with 1 N HCl. The resulting aqueous solution was extracted 3x EtOAc, the combined organics were dried over MgS0 , and then concentrated in vacuo to afford 0.56 g of the deprotected acetylene as a brown oil.
The deprotected acetylene (0.56 g, 2.0 mmol) was then placed into THF (50 mL) and cooled to -78°C LiHMDS (1 M soln, 4.7 mL) was then added dropwise and the reaction was stirred for 30 min. C02 gas was then bubbled through the reaction mixture for 15 min and the reaction was then poured onto C02 solid. The reaction was quenched by the addition of 1 N HCl (100 mL) and the aqueous solution was extracted 3x EtOAc, the combined organics were dried over MgS04, and then concentrated in vacuo to afford the propionic acid (0.71 g) as a white solid.
The alkane acid (0.71 g ) was then deprotected by the addition of a 25% TFA/CH2C12 solution and stirred for 2 hr at room temp. The resulting mixture was then concentrated in vacuo and immediately protected by dissolving the deprotected acid in 50% dioxane/water, adding K2C03 (15 g), and Fmoc-Cl (1.29 g, 4.9 mmol). This mixture was stirred at room temp for 14 hr and then poured in 1 N HCl (100 mlL). The solution was then extracted 3x with EtOAc, dried over MgS04, and then concentrated in vacuo to afford 4 as a brown oil. The oil was then chromatographed with 5% MeOH/ dichloromethane to afford 110 mg of the desired compound.
Figure imgf000120_0002
The dried resin (500 mg, 0.14 mmol) was placed into a small shaker vessel. The vessel was then charged with 9 mL of DMF, 4 (184 mg, 0.42 mmol), DIC (102 mg, 0.84 mmol), and DMAP (17 mg, 0.14 mmol). The vessel was subsequently shaken for 16 hr at room temp. The contents were drained and the resin was washed 3x with DMF, MeOH, and CH2C12. The Fmoc group was then removed by the addition of 10 mL of 50% piperidine/DMF to the shaker vessel and shaking for 2 hr at room temp. The resulting amine resin was washed 3x with DMF, MeOH, and CH2C12.
To the above resin was added 9 mL of DMF, 4-[N'-(o-Tolylurea)]-phenylacetic acid (132 mg, 0.42 mmol), PyBroP (196 mg, 0.42 mmol), and DIEA (107mg, 0.82 mmol). The contents were shaken for 14 hr at room temp and then drained and washed 3x with DMF, MeOH, and CH2C12. The compound was then cleaved from the resin and the filtrate was collected and then concentrated in vacuo. The resulting oil was triturated by taking up the oil in MeOH and slowly adding in Et20 until a precipitate formed. This precipitate was collected and dried in vacuo to afford 27 mg 4' as a white crystalline material. Example 4
Figure imgf000121_0001
The iodide (A) (0.5 g, 1.3 mmol) was placed into THF (20 mL) and cooled to minus
78°C Butyllithium (2.21 mL, 1.6M soln) was added dropwise and then the cooling bath was removed and gaseous C02 was bubbled through for 10 min. The reaction mixture was poured onto dry ice and then 1 M HCl (100 mL) was added. The mixture was extracted 3x EtOAc, the combined organics were dried over MgS04, and then concentrated in vacuo to afford 0.32 g of the benzoic acid as a white crystalline solid.
The benzoic acid (0.32 g, 1.68 mmol) was then deprotected by the addition of a 25% TFA/CH2C12 solution and stirred for 2 hr at room temp. The resulting mixture was then concentrated in vacuo and immediately protected by dissolving the deprotected acid in 50% dioxane/water, adding K2C03 (15 g), and Fmoc-Cl (0.44 g, 1.67 mmol). This mixture was stirred at room temp for 14 hr and then poured in 1 N HCl (100 mL). The solution was then extracted 3x with EtOAc, dried over MgS04, and then concentrated in vacuo to afford 0.38 g 5 as a white crystalline solid.
Figure imgf000122_0001
The dried resin (500 mg, 0.14 mmol) was placed into a small shaker vessel. The vessel was then charged with 9 mL of DMF, 5 (173 mg, 0.42 mmol), DIC (102 mg, 0.84 mmol), and
DMAP (17 mg, 0.14 mmol). The vessel was subsequently shaken for 16 hr at room temp. The contents were drained and the resin was washed 3x with DMF, MeOH, and CH2C12. The Fmoc group was then removed by the addition of 10 mL of 50% piperidine/DMF to the shaker vessel and shaking for 2 hr at room temp. The resulting amine resin was washed 3x with DMF, MeOH, and
CH2012
To the above resin was added 9 mL of DMF, 4-[N'-(o-Tolylurea)]-phenylacetic acid (132 mg, 0.42 mmol), PyBroP (196 mg, 0.42 mmol), and DIEA (107 mg, 0.84 mmol). The contents were shaken for 14 hr at room temp and then drained and washed 3x with DMF, MeOH, and CH2C12 The compound was then cleaved from the resin and the filtrate was collected and then concentrated in vacuo. The resulting oil was triturated by taking up the oil in MeOH and slowly adding in Et20 until a precipitate formed. This precipitate was collected and dried in vacuo to afford 51 mg 5' as a white crystalline material. Example 5 (£)-4-[2-[l-[4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]ethenyl] benzoic acid
Figure imgf000122_0002
To a cold (minus 78 °C), stirred solution of triethyl 4-phosphonomethylbenzoate (904 mg, 3.01 mmol) in THF (20 mL) was added LiHMDS (1.0 M in THF, 3 mL, 3.00 mmol) and the stirring was continued for 1 hr at the same temp. N-Boc prolinal (500 mg, 2.51 mmol) in THF (10 mL) was added to this mixture and the mixture was allowed to warm to room temp for over 1 hr. After being stirred for 2 hr, the mixture was quenched by water and extracted with EtOAc. The extract was washed with brine (200 mL), dried over MgS04, and evaporated. The residue was chromatographed on silica-gel with n-hexane-EtOAc (8:1, v/v) as eluent to give 713 mg (82%) ethyl (£)-4-[2-[l-(fe^-butoxycarbonyl)-2-pyrrolidinyl]ethenyl]benzoate as a colorless crystalline solid, mp 68-70 °C; IR (KBr) 1710, 1697, 1681 cm1; Η-NMR (CDC13) δl.39 (12 H, series of m), 1.77-1.93 (3 H, m), 2.11 (1 H, m), 3.47 (2 H, m), 4.34-4.54 (total 3 H, m), 6.22 (1 H, m), 6.43 (1 H, d, J = 14.2 Hz), 7.39 (2 H, J = 8.3 Hz), 7.97 (2 H, d, J = 8.3 Hz); MS (FAB) m/z 346 (M++l); Anal. Calcd for C20H27NO4: C, 69.54; H, 7.88; N, 4.05. Found: C, 69.52; H, 8.08; N, 4.07.
To a stirred solution of ethyl (£)-4-[2-[l-(fer -butoxycarbonyl)-2-pyrrolidinyl]ethenyl] benzoate (700 mg, 2.03 mmol) in CH2C12 (3 mL) was added TFA (3 mL) and the resulting mixture was stirred for 3 hr. The mixture was concentrated and the residue was made basic by the addition of sat. NaHC03. The mixture was extracted with CHC13 (2 x 100 mL). The combined extracts were dried over Na2C03 and concentrated in vacuo to give 434 mg (87%) ethyl (E)-4-[2-(2- pyrrolidinyl) ethenyl]benzoate as a brown oil. Η-NMR (CDC13) δ 1.39 (3 H, t, J= 7.3 Hz), 1.52- 2.06 (4 H, series of m), 2.93-2.99 (1 H, m), 3.07-3.13 (1 H, m), 3.74 (1 H, q, J= 7.3 Hz), 4.37 (2 H, q, = 7.3 Hz), 6.34 (1 H, dd, J= 15.6, 7.3 Hz), 6.54 (1 H, ά, J = 15.6 Hz), 7.41 (2 H, d, J= 8.3 Hz), 7.97 (2 H, d, J= 8.3 Hz).
A mixture of ethyl (£)-4-[2-(2-pyrrolidinyl)ethenyl]benzoate (434 mg, 1.77 mmol), pentafluorophenyl 4-[N'-(2-methylphenyl)ureido]phenylacetate (797 mg, 1.77 mmol), Et3N (0.37 mL, 2.66 mmol) in DMF (15 mL) was stirred for 15 hr. The mixture was diluted with EtOAc (300 mL). The solution was washed with brine (2 x 200 mL), dried over MgS04, and evaporated off in vacuo. The residue was chromatographed on silica-gel with CHCl3-EtOAc (4: 1) as eluent to give 906 mg (q.y.) ethyl (£)-4-[2-[l-[4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] ethenyl]benzoate as a brown oil. 'H-NMR (CDC13) δ 1.39 (3 H, X, J= 7.3 Hz), 1.83-2.20 (4 H, series of m), 2.24 (3 H, d, J = 4.9 Hz), 3.63 (4 H, m), 4.36 (2 H, q, J= 13 Hz), 4.62 and 4.84 (total 1 H, m), 6.18-6.47 (2 H, m), 7.03-8.02 (14 H, series of m).
A stirred mixture of ethyl (£)-4-[2-[l-[4-[N'-(2-methylphenyl)ureido] phenylacetyl]-2- pyrrolidinyl]ethenyl]benzoate (906 mg, 1.77 mmol) in 0.25 N NaOH (14 mL) and THF (14 mL) was heated under reflux for 3 days. The mixture was poured into ice- IN HCl (200 mL) and the precipitate was collected with suction. The solid was reciystallized from CHCl3-MeOH-n-hexane to give 453 mg (53%) 6 as a light yellow crystalline powder, mp 165-168 °C; IR (KBr) 3282, 2974, 2663, 2537, 1700, 1685 cm 1; 'H-NMR (DMSO-d,) δ 1.74-2.12 (4 H, m), 2.24 (3 H, d, J = 4.9 Hz), 3.35-3.66 (4 H, m), 4.67-4.74 (1 H, m), 6.25-6.41 (1 H, m), 6.53 (1 H, s), 6.93 (1 H, t, J = 7.3 Hz), 7.08-7.92 (12 H, series of m), 9.00 (1 H, m), 12.87 (1 H, br s); MS (FAB) m/z 484 (M++l); Anal. Calcd for C29H29N3O4-0.5H2O: C, 70.71; H, 6.14; N, 8.39. Found: C, 70.46; H, 6.07; N, 8.39.
Example 6 4-[2-[l-[4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]ethyl]benzoic acid
Figure imgf000124_0001
A mixture of (£ )-4-[2-[l-[4-[iV-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] ethenyl]benzoate (200 mg, 0.414 mmol) and 5% Pd C (200 mg) in MeOH (20 mL) was hydrogenated at 1 atm for 1 hr with vigorously stirring. The mixture was filtered and the filtrate was concentrated. The residue was chromatographed on silica-gel with CHCl3-MeOH (4:1) as eluent to give 201 mg (q.y.) 7 as a colorless crystalline powder, mp 180-190 °C; IR (KBr) 3345,
3124, 3060, 3027, 2960, 2927, 2875, 1706, 1672 cm 1; 'H-NMR (DMSO-d6) δ 1.04-3.96 (total 16
H, series of m), 6.91-7.41 (9 H, m), 7.79-7.90 (3 H, m), 8.23 (1 H, br s), 9.31 (1 H, br s); MS (FAB) m/z 486 (M++l); Anal. Calcd for C29H31N304-2.25H20: C, 66.21; H, 6.80; N, 7.99. Found:
C, 65.97; H, 6.20; N, 7.72.
Example 7
(■S -4-[2-[l-[4-[Λ''-(2-methylphenyl)ureido]phenylacetyl]pyrrolidinyl]methoxy]benzoic acid
Figure imgf000124_0002
(S)-4-[2-[l-[3-methoxy-4-(N'-phenylureido)phenylacetyl]pyrrolidinyl]methoxy]benzoic acid
Figure imgf000124_0003
(5)-4-[2-[l-[4-[Λ/'-(2-chlorophenyl)ureido]phenylacetyl]pyrrolidinyl]methoxy]benzoic acid
Figure imgf000124_0004
8, 9 and 10 To a stirred mixture of Boc-prolinol (3.00 g, 14.9 mmol), ethyl p- hydroxybenzoate (2.40 g, 14.5 mmol), and triphenylphosphine (3.91 g, 14.9 mol) in THF (80 mL) was added dropwise diethyl azodicarboxylate (2.86 g, 16.4 mmol) at room temp. After the addition was completed, the resulting mixture was heated under reflux for 2 hr. After cooling, the mixture was concentrated in vacuo. The residue was dissolved in EtOAc and washed successively with 1 N NaOH, water, brine. The EtOAc layer was dried over MgS04 and evaporated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc-n- hexane (1 :4, v/v) as eluent to give 4.88 g (93 %) ethyl (S)-4-(l-ferr-butoxycarbonyl-2-pyrrolidinyl)methoxybenzoate as an oil.
To the above ethyl (S)-4-(l-terNbutoxycarbonyl-2-pyrrolidinyl)mefhoxybenzoate was added MeOH (100 mL) and 1 N NaOH (50 mL). The mixture was stirred for 15 hr at room temp. After removal of MeOH under a reduced pressure, water (50 mL) was added to the residual solution. The aqueous solution was washed with Et20 (x2 ) and then acidified by the addition of 1 N HCl. The mixture was extracted with EtOAc, washed with water, brine, dried over MgS04 and evaporated in vacuo to afford 4.26 g (95 %) (S)-4-(l-/er/-butoxycarbonyl-2-pyrrolidinyl) methoxybenzoic acid as a crystalline solid.
To the above (S)-4-(l-/er/-butoxycarbonyl-2-pyrrolidinyl)methoxybenzoic acid was added CH2C12 (10 mL) and TFA (10 mL). The mixture was stirred at room temp for 1 hr Et20 was added to the mixture and resulting solid was collected. The solid was dissolved in water (100 mL), dioxane (50 mL) and NaHC03 (4.4 g). Fmoc-Cl (3.34 g, 12.9 mmol) was added to the solution, and the resulting mixture was stirred for 20 hr at room temp. The mixture was washed with Et20 (x2) and aqueous layer was separated. The layer was acidified by the addition of 1 N HCl. The mixture was extracted with EtOAc. The extract was washed with water, brine, dried over MgS04 and evaporated in vacuo to afford 5.36 g (91%) (S)-4-(l-Fmoc-2-pyrrolidinyl)methoxybenzoic acid as a viscous oil, which was ciystallized on standing.
Wang resin (0.71 mmol/g, 400 mg) was suspended in a solution of (5)-4-(l-Fmoc-2- pyrrolidinyl) methoxybenzoic acid (500 mg, 1.13 mol), DMAP (35 mg, 0.29 mmol), HOBt (40 mg, 0.30 mmol) and DIC (0.45 mL, 2.9 mmol) in a mixture of DMF (3 mL) and CH2C12 (7 mL). The mixture was shaken for 20 hr and drained. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3) and dried under a reduced pressure to give 522 mg of resin, which was used to prepare 8, 9 and 10.
8 To the above resin (115 mg) was added a solution of piperidine-DMF (50 % v/v, 4 mL) and the mixture was shaken for 1 hr. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3). To the resin was added DMF (4 mL), CH2C12 (2 mL), 4-[JV-(2- methylphenyl)ureido] phenylacetic acid (70 mg, 0.25 mmol), PyBrop (115 mg, 0.25 mmol) and DIEA (0.13 mL, 0.75 mmol). The mixture was shaken for 21 hr and drained. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3). To the resin was added a solution of TFA in CH2C12 (50 % v/v, 4 mL) and the mixture was shaken for 2 hr. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by Sep-Pak column. After removal of the solvent, Et20 was added to the residue and resulting solid was collected to afford 25 mg 8 as a pale yellow crystalline material. MS (FAB) m/z 488 (M++l)
9 To the above resin (60 mg) was added a solution of piperidine in DMF (50 % v/v, 3 mL) and the mixture was shaken for 2 hr. The resin was washed with DMF (x3), MeOH
(x3), CH2C12 (x3). To the resin was added DMF (2 mL), CH2C12 (1 mL) 3-methoxy-4-(N'- phenylureido) phenylacetic acid (40 mg, 0.13 mmol), PyBrop (60 mg, 0.13 mmol) and DIEA (0.060 mL, 0.34 mmol). The mixture was shaken for 40 hr and drained. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3). To the resin was added a solution of TFA in CH2C12 (30 % v/v, 3 mL) and the mixture was shaken for 5 hr. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by Sep-Pak column. After removal of the solvent, Et20 was added to the residue and the solid was collected to afford 8 mg 9 as a crystalline solid. MS (FAB) m/z 504 (M++l)
10 To the above resin (637 mg) was added a solution of piperidine in DMF (50 % v/v, 20 mL) and the mixture was shaken for 4 hr. The resin was washed with DMF (x3), MeOH
(x3), CH2C12 (x3). To the resin was added DMF (12 mL), CH2C12 (8 mL), 4-(Fmoc- amino)phenylacetic acid (530 mg, 1.42 mmol), PyBrop (660 mg, 1.43 mmol) and DIEA (0.62 mL, 3.56 mmol). The mixture was shaken for 60 hr and drained. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3) and dried under a reduced pressure to afford 617 mg of the resin. 57 mg of this resin was added Piperidine in DMF (40 % v/v, 2 mL). The mixture was shaken for 1 hr.
The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3). 2-chlorophenyl isocyanate (0.050 mL, 0.41 mmol) was added to a suspension of resin in THF (1 mL) and CH2C12 (1 mL). The mixture was shaken for 20 hr and drained. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3). To the resin was added a solution of TFA in CH2C12 (25 % v/v, 2 mL) and the mixture was shaken for 1.5 hr. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by Sep-Pak column. After removal of the solvent, Et20 was added to the residue and the solid was collected to afford 2 mg 10 as a crystalline solid. MS (FAB) m/z 508 (M++l) Example 8 (5 -3-[2-[l-[3-methoxy-4-(N'-phenylureido)phenylacetyl]pyrrolidinyl]methoxy] phenylacetic acid
Figure imgf000127_0001
(S)-3-[2-[l-[4-[ V-(2-methylphenyl)ureido]phenylacetyl]pyrrolidinyl]methoxy] phenylacetic acid
Figure imgf000127_0002
11 and 12 To a stirred mixture of Boc-prolinol (3.51 g, 17.5 mmol), methyl ffi-hydroxyphenylacetate (2.90 g, 17.5 mmol), triphenylphosphine (4.60 g, 17.6 mol) in THF (50 mL) was added dropwise diethyl azodicarboxylate (3.05 g, 17.5 mmol) at room temp. After the addition was completed, the mixture was heated under reflux for 3 hr. After cooling, the mixture was concentrated in vacuo. The residue was dissolved in EtOAc, washed successively with 1 N NaOH, water, brine and dried over MgS04. After removal of the solvent, the residue was purified by column chromatography on silica-gel with EtOAc- hexane (1 :4, v/v) as eluent to give 5.49 g (90 %) methyl (S)-3-(l-/e/-/-butoxycarbonyl-2-pyrrolidinyl) methoxyphenylacetate as an oil.
A mixture of the above methyl (S)-3-(l-terf-butoxycarbonyl-2-pyrrolidinyl) methoxy phenylacetate in MeOH (60 mL) and 1 N NaOH (20 mL) was stirred for 8 hr at room temp. After removal of the solvent under a reduced pressure, water (50 mL) was added to the residue. The mixture was extracted with Et20 (x2), and the aqueous layer was acidified by the addition of 1 N HCl. The mixture was extracted with EtOAc. The extract was washed with water, brine, dried over MgS04 and then concentrated in vacuo to afford 4.43 g (88 %) (S -3-(l-/eπ'-butoxycarbonyl -2- pyrrolidinyl)methoxy phenylacetic acid as a viscous oil.
A mixture of the above (S)-3-(l-/erΛ-butoxycarbonyl-2-pyrrolidinyl) methoxyphenyl acetic acid in CH2C12 (10 mL) and TFA (10 mL) was stirred for 1 hr at room temp. Et20 was added to the mixture and allowed to stand. Upper layer was removed by decantation to give an oil. A mixture of this oil in water (100 mL), dioxane (30 mL) and NaHC03 (6.0 g) was added Fmoc-Cl (2.86 g, 11.1 mmol) and the mixture was stirred for 20 hr at room temp. The mixture was extracted with Et20 (x2), and the aqueous layer was acidified by the addition of 1 N HCl. The mixture was extracted with EtOAc. The extract was washed with water, brine, dried over MgS04 and concentrated in vacuo to afford 5.08 g (81 %) (S)-3-(l-Fmoc-2-pyrrolidinyl)methoxyphenylacetic acid as a viscous oil. Wang resin (0.71 mmol/g, 400 mg) was suspended in a solution of (S)-3-(l-Fmoc-2- pyrrolidinyl) methoxyphenylacetic acid (520 mg, 1.14 mol), DMAP (35 mg, 0.29 mmol), HOBt (40 mg, 0.30 mmol) and DIC (0.45 mL, 2.9 mmol) in a mixture of DMF (3 mL) and CH2C12 (7 mL). The mixture was shaken for 20 hr and drained. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3) and dried under a reduced pressure to give 593 mg of resin, which was used for the preparation of 11 and 12.
11 A mixture of the above resin (70 mg) in piperidine-DMF (40 % v/v, 3 mL) was shaken for 1 hr. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3). To the resin was added DMF (1.5 mL), CH2C12 (1.5 mL) 3-mefhoxy-4-(/V'-phenylureido) phenylacetic acid (42 mg, 0.14 mmol), PyBrop (70 mg, 0.15 mmol) and DIEA (0.065 mL, 0.37 mmol). The mixture was shaken for 15 hr and drained. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3). To the resin was added a solution of TFA in CH2C12 (25 % v/v, 2 mL) and the mixture was shaken for 3 hr. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by Sep-Pak column. After removal of the solvent, Et20 was added to the residue and the solid was collected to afford 8 mg 11 as a crystalline solid. MS (FAB) m/z 518 (M++l)
12 A mixture of the above resin (70 mg) in piperidine - DMF (40 % v/v, 3 mL) was shaken for 1 hr. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3). To the resin was added DMF (1.5 mL), CH2C12 (1.5 mL), 4-[N'-(2-methylphenyι)ureido] phenylacetic acid (40 mg, 0.14 mmol), PyBrop (70 mg, 0.15 mmol) and DIEA (0.065 mL, 0.37 mmol). The mixture was shaken for 15 hr and drained. The resin was washed with DMF (x3), MeOH (x3), CH2C12 (x3). A mixture of the resin in TFA-CH2C12 (25 % v/v, 2 mL) was shaken for 3 hr. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by Sep-Pak column. After removal of the solvent, Et20 was added to the residue and the solid was collected to afford 11 mg 12 as a crystalline solid. MS (FAB) m/z 502 (M++l) Example 9
4-[2-[l-[3-methoxy-4-(N'-phenylureido)phenylacetyl]-2-pyrrolidinyl]ethynyl] benzoic acid
To a stirred cold (minus 50 °C) solution of N-boc-prolinal (5.98 g, 30 mmol) and PPh3 (62.95 g, 240 mmol) in CH2C12 (200 mL) was slowly added a solution of CBr4 (39.80 g, 120 mmol) in CH2C12 (50 mL), and the stirring was continued for 1 hr at 0 °C. To this mixture was added sat. NaHC03 and the mixture was extracted with CHC13. The extract was washed with H20, dried over MgS04, and evaporated. The residue was chromatographed on silica-gel with CHC13 and n- hexane-AcOEt (4: 1, v/v) as eluent to give 7.84 g (74%) l-(/e -butoxycarbonyl)-2-(2,2- dibromoethenyl) pyrrolidine as colorless plates, mp 61-63; IR (KBr) 1693 cm '; 'H-NMR (CDC13) δ 1.46 (9 H, s), 1.72-2.19 (4H, m), 3.35-3.45 (2H, m),4.35 (1H, br s), 6.36 (1H, br s); MS (FAB) m/z 352, 354, 356, 35$; Anal. Calcd for C„H17N02Br2: C, 37.21; H, 4.83; N, 3.94. Found: C, 37.14; H, 4.83; N, 4.00.
To a stirred cold (minus 78 °C) solution of l-(ter/-butoxycarbonyl)-2-(2,2- dibromoethenyl) pyrrolidine (7.81 g, 22 mmol) in THF (200 mL) was added n-BuLi (1.59 M in hexane, 28 mL, 44 mmol) over 10 min, and the stirring was continued for 2 hr at the same temp. The reaction was quenched by the addition of sat. NH4C1 and extracted with EtOAc. The extract was washed with brine, dried over MgS04, and evaporated. The residue was chromatographed on silica-gel with w-hexane-AcOEt (10: 1, v/v) as eluent to give 4.15 g (97%) l-(tert-butoxycarbonyl)- 2-ethynyl pyrrolidine as a light yellow oil. 'H-NMR (CDC13) δ 1.48 (9 H, s), 1.82-2.21 (4 H, m), 3.30-3.45 (2 H, m), 4.41-4.52 (1 H, m).
A suspension of ethyl 4-iodobenzoate (1.7 mL, 10 mmol), Pd(PPh3)4 (578 mg, 0.5 mmol), and Cul (190 mmol, 1 mmol) in /-Pr2NH (20 mL) was stirred for 0.5 hr under N2. To this mixture was added a solution of l-(/er -butoxycarbonyl)-2-ethynylpyrrolidine (1.95 g, 10 mmol) in /-Pr2NH (20 mL) for over 10 min. After stirring for 3 hr at room temp, the mixture was poured into H20 and extracted with EtOAc. The extract was washed with brine, dried over MgS04, and evaporated. The residue was chromatographed on silica-gel with w-hexane-AcOEt (10: 1, v/v) as eluent to give 2.77 g (81%) l-(/er/-butyloxycarbonyl)-2-(2-(4-ethoxycarbonylphenyl)ethynyl) pyrrolidine as a colorless oil. 'H-NMR (CDC13) δ 1.37 (3 H, t, =6.8 Hz), 1.49 (9 H, s), 1.85-2.12 (4 H, m), 3.37- 3.51 (2 H, m), 4.37 (2 H, q, .7=6.8 Hz), 4.54-4.77 (1 H, m), 7.44 (2 H, d, .7=7.8 Hz), 7.96 (2 H, d, =7.8 Hz)
To a stirred solution of l-(ter^butoxycarbonyl)-2-[2-(4-ethoxycarbonylphenyl) ethynyl] pyrrolidine (2.75 g, 8 mmol) in CH2C12 (5 mL) was added TFA (5 mL), and the resulting mixture was stirred overnight. The mixture was concentrated in vacuo and made basic with sat. NaHC03 and extracted with CHC13. The extract was washed with brine, dried over MgS04, evaporated to give 1.95 g (q.y.) 2-[2-(4-ethoxycarbonylphenyl) ethynyl]pyrrolidine as a light yellow oil. 'H-NMR (CDC13) δ 1.38 (3 H, t, .7=6.8 Hz), 1.82-2.16 (4 H, m), 3.01-3.48 (2 H, m), 4.00-4.11 (1 H, m), 4.37 (2H, q, .7=6.8 Hz), 4.54-4.77 (1 H, m), 7.44-7.46 (2 H, m), 7.95-7.97 (2 H, m).
A mixture of 3-methoxy-4-(N'-phenylureido)phenylacetic acid (180 mg, 0.6 mmol), 2-(2-
(4-ethoxycarbonylphenyl)ethynyl)pyrrolidine (146 mg, 0.6 mmol), EDC (173 mg, 0.9 mmol), DMAP (73 mg, 0.6 mmol), and cat. HOBt in DMF (10 mL) was stirred overnight The mixture was poured into 1 N HCl and the solid was collected with suction. The residue was dissolved in CHCl3and dried over MgS04. After removal of the solvent, the residue was chromatographed on silica-gel with CHCl3-MeOH (10: 1, v/v) as eluent to give 192 mg (61%) ethyl 4-[2-[l-[3-methoxy- 4-(N'-phenylureido)phenylacetyl]-2-pyrrolidinyl] ethynyllbenzoate as a light yellow amorphous solid. 'H-NMR (CDC13) δ 1.38 (3 H, t, .7=6.8 Hz), 1.98-2.24 (4 H, m), 3.48-3.89 (2 H, m), 3.53 (2 H, s), 3.62 (3 H, s), 4.33-4.40 (2 H, m), 4.78-5.04 (1 H, m), 6.77-8.00 (14 H, m).
To a stirred solution of ethyl 4-[2-[l-[3-methoxy-4-(/V'-phenylureido) phenylacetyl]-2- pyrrolidinyl] ethynyljbenzoate (184 mg, 0.35 mmol) in THF (5 mL) was added 0.25 N NaOH (4 mL). The resulting mixture was stirred overnight. The mixture was poured into H20 and made acidic by the addition of 1 N HCl (1 mL). The solid was collected with suction and dissolved in CHC13. The solution was dried over MgS04 and evaporated. The residue was reciystallized from CHCl3-«-hexane to give 65 mg (37%) 13 as a white crystalline powder, mp 154-157; IR (KBr) 3346, 2952, 2615, 1712, 1693cm'1; 'H-NMR (CDC13) δ 1.92-2.29 (4 H, m), 3.32-3.82 (2 H, m), 3.78 (2 H, s), 3.80 (3 H, s), 4.87-5.11 (1 H, m), 6.77-9.26 (14 H, m), 13.10 (1 H, br s); MS (FAB) m/z 498 (M++l). Example 10
4-[2-[l-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]ethynyl] benzoic acid
Figure imgf000130_0001
A mixture of 3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetic acid (1.45 g, 4.6 mmol), 2-(2-(4-ethoxycarbonylphenyl)ethynyl)pyrrolidine (1.12 g, 4.6 mmol), EDC 1.32 g (6.9 mmol), DMAP (562 mg, 4.6 mmol) in DMF (20 mL) was stirred overnight. The mixture was poured into 1 N HCl and the solid was collected with suction. The solid was dissolved in CHC13 and dried over MgS04. After removal of the solvent, the residue was chromatographed on silica- gel with CHCl3-MeOH (100: 1, v/v) as eluent to give 2.20 g (89%) ethyl 4-[2-[l-[3-methoxy-4-(N'- (2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinyl]ethynyl]benzoate as a white amorphous solid.
'H-NMR (CDC13) δ 1.37-1.41 (3 H, m), 1.94-2.22 (4 H, m), 2.29 (3 H, s), 3.41-3.89 (2 H, m), 3.62 (3 H, s), 3.69 (2 H, s), 4.34-4.40 (2 H, m), 4.72-5.01 (1 H, m), 6.33 (1 H, br s), 6.80-8.06 (12 H, m). To a stirred solution of ethyl 4-[2-[l-[3-methoxy-4-(N'-(2-methylphenyl)ureido]phenyl acetyll-2-pyrrolidinyl]ethynyl]benzoate (2.16 g, 4 mmol) in THF (30 mL) was added 0.25 N NaOH (32 mL) and the stirring was continued overnight. The mixture was poured into H20 and acidified by the addition of 1 N HCl (8 mL). The resulting precipitate was collected with suction and dissolved in CHC13. The solution was dried over MgS04 and evaporated. The residue was reciystallized from CHCl3-«-hexane to give 555 mg (27%) 14 as a white crystalline powder, mp 161-164; IR (KBr) 3338, 2954, 2875, 1707, 1691 cm '; 'H-NMR (CDC13) δ 1.96-2.10 (4 H, m), 2.24 (3 H, s), 3.32-3.81 (2 H, m), 3.62 (2 H, s), 3.81 (3 H, s), 4.87-5.10 (1 H, m), 6.76-8.58 (13 H, m); MS (FAB) m/z 512 (M++l) Example 11 i-[2-[l-[3-methoxy-4-[Λ''-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]ethynyl] phenylacetic acid
Figure imgf000131_0001
A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (141 mg, 0.45 mmol), 2-[2-(3-ethoxycarbonylmethylphenyl)ethynyl]pyrrolidine (116 mg, 0.45 mmol), EDC (130 mg, 0.68 mmol), DMAP (55 mg, 0.45 mmol), cat. HOBt in DMF (10 mL) was stirred overnight The mixture was poured into 1 N HCl and the solid was collected by filtration. The solid was dissolved in CHC13, dried over MgS04, and evaporated. The residue was chromatographed on silica -gel with CHCl3-MeOH (100:1 v/v) as eluent to give an oil, which was dissolved in THF (5 mL). 0.25 N NaOH (4 mL) was added to this solution with stirring. After stirring overnight, the mixture was poured into IN HCl (20mL). The resulting precipitate was collected with suction and dissolved in CHC13 The solution was dried over MgS04 and evaporated. The residue was chromatographed on silica-gel with CHCl3-MeOH (5:1, v/v) as eluent to give 92 mg (39%) 15 as a white amorphous solid. 'H-NMR (CDC13) δ 1.96-2.18 (7 H, m), 3.50-3.88 (9 H, m), 4.78-4.98 (2 H, m), 6.72-7.99 (14 H, m); MS (FAB) m/z 526 (M++1). Example 12 4-[l-[4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinylmethoxy]isophthalic acid
Figure imgf000132_0001
To a stirred solution of pentafluorophenyl ester of 4-[N'-(2-methylphenyl)ureido] phenylacetic acid (2.32 g, 5.15 mmol), dimethyl (5 -4-(2-pyrrolidinylmethoxy)isophthalate (1.51 g,
5.15 mmol) in DMF (20 mL) was added Et3N (1.0 mL, 6.65 mmol), and the mixture was stirred overnight. The resulting mixture was diluted with EtOAc. The solution was washed with brine, dried over MgS04, and evaporated off in vacuo. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (10: 1, v/v) as eluent to give 1.58 g (55%) dimethyl 4-[l-[4-[N'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinylmefhoxy]isophthalate as a yellow crystalline solid. 'H-NMR (CDC13) δ 1.87-2.25 (m, total 7 H), 3.50-3.65 (m, 4 H), 3.85 (s, 3 H), 3.89 (s, 3 H), 4.18-4.31 (m, 2 H), 4.44 (m, 1 H), 6.95-8.45 (m, total 13 H).
To a stirred solution of dimethyl 4-[l-[4-[N'-(2-methylphenyl)ureido] phenylacetyl]-2- pyrrolidinylmethoxy]isophthalate (1.56 g, 2.79 mmol) in THF (30 mL) was added 0.25 N NaOH (20 mL), and the reaction mixture was heated under reflux overnight. The resulting mixture was poured into 1 N HCl, and solid was collected. The crude solid was washed with Et20 to give 574 mg (39%) 16 as a yellow amorphous solid. IR (KBr) 1710 cm'1; 'H-NMR (DMSO-<L.) δ 1.83-2.18 (m, 4 H), 2.24 (s, 3 H), 3.36-4.28 (m, 8 H) 6.91-9.02 (series of m, total 13 H), 12.89 (br s, 1 H); MS (FAB) m/z 532 (M++1). Example 13 4-[2-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] ethenyl] benzoic acid
Figure imgf000132_0002
To a stirred solution of the 4-[2-[2-(Λf-terNbutoxycarbonyl)pyrrolydinylethenyl] benzonitrile (2.26g, 7.57mmol) in CH2C12 (23 mL) was added dropwise a 1.5M solution of diisopropylaluminum hydride (toluene solution) (6.06mL, 9.09mmol) at 0°C for over 15 min. The resulting solution was stirred for3 hr at 0°C The solution was quenched by the addition of sat.NH4Cl. The resulting mixture was filtered through Celite, and the filtrate was extracted with EtOAc. The filtrate was washed with brine, dried over Na2S04 and evaporated in vacuo to afford 1.89 g (83%) 4-[2-[2-(N-/e -butoxy carbonyl)pyrrolidinyl]ethenyl] benzaldehyde as a yellow syrup.
To a stirred solution of NaOH (1.00 g, 25.1 mmol) in water(10 mL) was added a solution of AgN03 (2.13g, 12.5mmol) in CH3CN (10 mL) at 0°C for over 0.5 hr. To the stirred above mixture was added dropwise a solution of 4-[2-[2-(N-tert- butoxycarbonyl) pyrrolydinyl]ethenyl] benzaldehyde (1.89g, 6.27mmol) in CH3CN (lOmL) at 0°C for over 20 min. After the resulting mixture was stirred for a further 3 hr at room temp. The mixture was filtered with suction, and then washed with hot water. After the filtrate was washed with EtOAc, the aqueous layer was acidified by carefully adding 1 N HCl, and then extracted with CHC13. The extract was dried over Na2S04 and evaporated in vacuo to afford 0.700g (35% for 2 steps) 4-[2-[2-(/V-ter/-butoxycarbonyl) pyrrolidinyl]ethenyl] benzoic acid as a pale yellow crystalline material.
To a stirred solution of 4-[2-(2-(7V-/e^-butoxycarbonyl)pyrrolidinyl) ethenyljbenzoic acid (0.700g, 2.21mmol) in MeOH-benzene(l:4, v/v, 30mL) was added dropwise a 2 M-n-hexane solution of TMSCHN2 (1.32mL, 2.65mmol) at room temp. After the solution was stirred for 0.5 hr at room temp, the solution was evaporated in vacuo. The resulting oily residue was chromatographed on silica-gel with EtOAc-«-hexane(l:6, v/v) as eluent to afford 0.64g (88%) methyl 4-[2-[2-(iV-ter/-butoxycarbonyl) pyrrolidinyl] ethenyfjbenzoate as a pale yellow crystalline material.
To a stirred solution of methyl 4-[2-[2-(N-terf-butoxycarbonyl)pyrrolidinyl] ethenyl] benzoate (0.64g,1.93mmol) in CH2C12 (5mL) was added TFA (5mL) at room temp. After the mixture was stirred for 1 hr at room temp, the mixture was evaporated in vacuo, The residue was treated with sat. NaHC03and extracted with CHC13. The extract was dried over Na2S04 and evaporated in vacuo to afford 0.45g (100%) methyl 4-[2-(2-pyrrolidinyl)ethenyl]benzoate as a yellow crystalline material. To a stirred mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureιdo]phenylacetic acid (285mg, 0 906mmol), methyl 4-[2-(2-pyrrolydιnyl)ethenyl]benzoate (210mg, 0 906mmol) in DMF (4mL ) was added l-ethyl-3-(3-dιmethylamιnopropyl)carbodιιmιde (EDC) (209mg, 1 09mmol), 1- hydroxybenzotnazole (HOBt) (147mg, 1 09mmol) and 4-dιmethylaπunopyπdιne (DMAP) (llmg, 0 0906mmol) at room temp After the resulting mixture was stirred for 48 hr at room temp, the mixture was poured into ιce-1 N HCl and extracted with EtOAc The extract was dned over Na2S04 and evaporated in vacuo The residue was chromatographed on silica-gel with acetone- toluene (1 4 to 1 1, v/v) as eluent to afford 0 47g (98%) methyl 4-[2-[l-[3-methoxy-4-[N'-(2- methylphenyl)ureιdo] phenylacetyl]-2-pyrrolιdιnyl]ethenyl]benzoate as a white crystalline material
To a stirred solution of methyl 4-[2-[l-[3-methoxy-4-[N'-(2-methylphenyl) ureιdo]phenyl acetyl]-2-pyrrohdιnyl]ethenyl]benzoate (0 47g , 0 891mmol) m THF (5mL) was added 0 25 N NaOH (5 36mL) The resulting mixture was stirred at room temp for 20 hr The mixture was acidified with IN HCl The mixture was extracted with EtOAc The extract was washed with bπne, dned over Na2S04 and evaporated in vacuo to afford 430mg (94%) 17 as a white crystalline mateπal 'H-NMR (400MHz, DMSO-d6) δ 1 78-2 13 (4H, m), 2 50 (3H, s), 3 44 -3 68 (4H, m), 3 75 and 3 82 (3H, s), 4 71 (1H, m), 6 26-8 59 (15H, m) Example 14 4-[2-[l-[3-methoxy-4-(N'-phenylureιdo)phenylacetyl]-2-pyrrolιdιnyl]ethenyl] benzoic acid
Figure imgf000134_0001
To a stirred solution of 3-methoxy-4-(Λ '-phenylureιdo)phenylacetιc acid (305mg,
1 Olmmol), methyl 4-[2-(2-pyrolydιnyl)ethenyl]benzoate (235mg, 1 Olmmol) in DMF (4mL) was added l-ethyl-3-(3-dιmethylamιnopropyl)carbodιιmιde (232mg, 1 21mmol), 1- hydroxybenzotnazole (HOBt) (164mg, 1 21mmol), and 4-dιmethylamιnopyπdιne (DMAP) (12mg,
0 lOlmmol) at room temp After the mixture was stirred for 48 hr, the mixture was acidified by the addition of 1 N HCl The mixture was extracted with EtOAc The extract was washed with brine, dned over Na2S04 and evaporated in vacuo to give an oily residue The residue was chromatographed on silica-gel with acetone toluene (1 4 to 1 1, v/v) as eluent to afford 0 43g
(83%) methyl 4-[2-[l-[3-methoxy-4-(Λ '-phenylureιdo) phenylacetyl]-2-pyrrohdmyl]ethenyl] benzoate acid as a white ciystalhne matenal To a stirred solution of methyl 4-[2-[l-[3-methoxy-4-(N'-phenylureido) phenylacetyl]-2- pyrrolidinyl]ethenyl]benzoate ( 0.43g, 0.837mmol) in THF (5mL) was added a solution of 0.25 N NaOH (5.04mL) at room temp. After the resulting mixture was stirred for 20 hr, the mixture was acidified by the carefully addition of 1 N HCl. The mixture was extracted with EtOAc. The extract was washed with brine, dried over Na2S04 and evaporated in vacuo to afford 397mg (95%) 18 as a white crystalline material. Η-NMR (400MHz, DMSO-rL,) δ 1.78-2.13 (4H, m), 3.17-3.68 (4H, m), 3.74, 3.82 (3H, s), 4.71 (1H, m), 6.27-9.28 (16H, m). Example 15 4-[2-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]ethyl]benzoic acid
Figure imgf000135_0001
A mixture of 4-[2-[l-[3-methoxy-4-[N'(2-methylphenyl)ureido]phenylacetyl]-2- pyrrolidinyl] ethenyl]benzoic acid (184mg, 0.358mmol) and 5% Pd-C(368mg) in MeOH was hydrogenated in an atmospheric pressure at room temp. After the mixture was stirred for 21 hr at room temp, insoluble catalyst was filtered off and the filtrate was evaporated in vacuo. The residue was chromatographed on silica-gel with MeOH-CHCl3 (1:4 to 1:3, v/v) as eluent to afford 123mg (66%) 19 as a white crystalline material. 'H-NMR (DMSO-c .) δ 1.55-2.03 (m, 6H), 2.24 (s, 3H), 2.60 (m, 2H), 3.17-3.59 (m, 4H), 3.83 (s, 3H), 3.97 (m, 1H), 6.61-8.57 ( m, 13H); MS (FAB) m/z 516 (M++l). Example 16 3-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] methylthiobenzoic acid
Figure imgf000135_0002
To a solution of w-iodophenol (20.0 g, 90.9 mmol) in DMF (200mL) was added 1,4- diazabicyclo [2,2,2]octane (20.4g, 181.8 mmol) and dimethylthiocarbamoyl chloride (16.9 g, 136.4 mmol). The resulting cloudy solution was stirred for 0.5 hr at 35°C and then heated at 75°C for 0.5 hr. After cooling, 300 mL of water was added to the mixture. The solid was collected, washed with water and dried under a reduced pressure to give 27.63 g (99%) <3-/«-iodophenyl dimethylthio carbamate as a pale yellow crystalline powder. IR (KBr) 1540, 1463, 1278, 1193, 1166, 1124cm ';
'H-NMR (400 MHz, CDC13) δ 3.33 (s, 3H), 3.45 (s, 3H), 7.05 - 7.14 (m, 2H), 7.43 (d, J= 1.9 Hz, 1H), 7.58 (dd, J = 1.0, 7.8 Hz, 1H); MS (FAB) m/z 307 (M++l); Anal. Calcd for HINOS: C, 35.19; H, 3.28; N, 4.56. Found: C, 35.23; H,3.40; N, 4.41.
A solution of O/tt-iodophenyl dimethylthiocarbamate (10.0 g, 32.6 mmol) in Ph20 (25mL) was heated at 230°C for 10 hr. After cooling, the reaction mixture was chromatographed on silica-gel with w-hexane-EtOAc (5: 1, v/v)as eluent to give 9.31 g (93%) S-wi-iodophenyl dimethylthio carbamate as a pale yellow oil. 'H-NMR (400 MHz, CDC13) δ 3.08 (br s, 6H), 7.11 (t, J = 7.8 Hz, 1H), 7.46 (d, J = 7.3 Hz, 1H), 7.71 (d, J = 7.3 Hz, 1H), 7.85 (s, 1H); MS (FAB) m/z 307 (M++l).
To a solution of 5-w-iodophenyl dimethylthiocarbamate (5.01 g, 16.31 mmol) in MeOH (20 mL) was added 28%-MeONa in MeOH (3.46 mL, 17.94mmol). The resulting mixture was stirred at room temp for 3.5 hr and then heated at 70°C overnight. After cooling, IN HCl was added. The solvent was removed under a reduced pressure and the residue was diluted with EtOAc. The solution was washed with H20, brine, and dried over Na2S04 The organic layer was concentrated under a reduced pressure. The residue was chromatographed on silica-gel with n- hexane-AcOEt (10: 1, v/v) as eluent to afford 3.42 g (89%) /w-iodothiophenol as an oil. 'H-NMR (400 MHz, CDC13) δ 3.45 (s, 1H), 6.95 (t, J = 7.8 Hz,H),7.23 (d,J= 7.8 Hz 1H), 7.48 (d, J= 7.3 Hz,lH), 7.64 (t, J = 1.5 Hz,lH); MS(EI) m/z 236(M+).
To a stirred solution of N-(ter/-butoxycarbonyl)-2-pyrrolidinylmethanol (4.30 g, 20.0 mmol) in pyridine (40 mL) was added /?-TsCl (5.72 g, 30.0 mmol). The resulting mixture was stirred at room temp for 3 hr. The reaction mixture was quenched with H20, and evaporated off. The residue was diluted with EtOAc and washed with IN HCl, brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel with w-hexane-EtOAc (2: 1, v/v) as eluent to afford 5.76 g (81 %) N-(/e -butoxycarbonyl)-2- pyrrolidinylmethyl/7-toluenesulfonate as a colorless oil. 'H-NMR (400 MHz, CDC13) δ 1.36 and 1.41 (s each, total 9H), 1.82 (br m, 2H), 1.96 (br m, 2H), 2.44 (s, 3H), 3.30 (br m, 2H), 3.89 (br s, 1H), 3.96 (br s, 1H), 4.09 (br m, 1H), 7.34 (br s, 2H), 7.77 (d, J = 8.3 Hz, 2H); MS (FAB) m/z 356 (M++l).
To a stirred mixture of /w-iodothiophenol (2.67 g, 11.31 mmol) and N-(te /-butoxy carbonyl)-2- pyrrolidinylmethyl p-toluenesulfonate (3.34 g, 9.43 mmol) in pyridine (9.4 mL) was added 8N KOH (1.77 mL). The resulting mixture was stirred at room temp overnight The reaction mixture was diluted with EtOAc. The solution was washed with H20, sat. NH4C1 solution, brine, and dried over Na2S04. The organic layer was concentrated under a reduced pressure and the residue was chromatographed on silica-gel with n-hexane-EtOAc (5: 1, v/v) as eluent to afford 1.79 g (45%) [N-(te^-butoxycarbonyl)-2-pyrrolidinyl]methyl 3-iodophenyl sulfide as an oil. 'H-NMR (400 MHz, CDC13) δ 1.45 (s, 9H), 1.78 - 2.01 (br m, 4H), 2.71 (dt, IH), 3.32 - 3.49 (br m, 3H),
3.90 - 4.02 (br m, IH), 7.12 (d, J = 7.8 Hz, IH), 7.18 (d, J= 7.8 Hz, IH), 7.57 (dd, J = 2.0, 8.3 Hz, 2H); MS (FAB) m/z 420 (M++l).
To a stirred solution of [l-(terNbutoxycarbonyl)-2-pyrrolidinyl]methyl 3-iodophenyl sulfide (1.76 g, 4.20 mmol) in DMSO (20 mL) and MeOH (16 mL) was added Et3N (1.28 mL, 9.24 mmol), Pd(OAc)2 (47.1 mg, 0.21 mmol), and l,3-bis(diphenylphosphino)propane (86.6 mg, 0.21mmol), then CO gas was bubbled for 5 min. The resulting mixture was stirred at 70° C overnight. After cooling, the mixture was concentrated. The residue was diluted with EtOAc and washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel with n-hexane-EtOAc (5: 1, v/v) as eluent to afford 1.28 g (87 %) methyl 3-[l-(fe/- -butoxycarbonyl)-2-pyrrolidinyl]methylthiobenzoate as an oil. 'H- NMR (400 MHz, CDC13) δ 1.42 and 1.45 (each s, 9H), 1.79 - 2.05 (br m, 4H) 2.83 (dt, .7= 10.8, 30.3 Hz, IH), 3.34 - 3.54 (br m, 3H), 3.92 (s, 3H), 3.92 and 4.05 (d, J = 7.8 Hz, IH), 7.36 (t, J = 7.8 Hz, IH), 7.63 (br d, J= 14.7 Hz, IH), 7.83 (br d, = 12.7 Hz, IH), 8.04 (s, IH); MS (FAB) m/z 352 (M++l).
To a stirred solution of methyl 3-[l-(ter/-butoxycarbonyι)-2-pyrrolidinyι] methylthio benzoate (1.46 g, 4.16 mmol) in CH2C12 (30 mL) was added TFA (15 mL) at 0°C The resulting mixture was stirred at room temp for 1 hr. The solvent was removed under a reduced pressure and the residue was treated with IN NaOH and extracted with CHC13. The extract was washed with brine, dried over Na2S04, and concentrated under a reduced pressure to afford 947 mg (91%) methyl 3-(2-pyrrolidinyl) methylthio benzoate as a brown oil. Η-NMR (400 MHz, CDC13) δ 1.45 - 1.54 (m, IH), 1.72 - 2.00 (m, 4H) 2.88 - 3.10 (m, 4H), 3.30 (m, IH), 3.92 (s, 3H), 7.34 (t, J = 7.8 Hz, IH), 7.52 (m, IH), 7.84 (m, IH), 8.01 (t, J= 2.0 Hz, IH); MS (FAB) m/z 252 (M++l).
The mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (1.18 g, 3.77 mmol), EDC (1.08 g, 5.65 mmol), DMAP (23 mg, 0.19 mmol) and HOBt (25 mg, 0.19 mmol) in DMF (5 mL) was stirred at room temp for lhr methyl 3-(2-pyrrolidinyl)methylthio benzoate (947 mg, 3.77 mmol) was added to the mixture and the resulting mixture was stirred overnight. After DMAP (460 mg, 3.77 mmol) and HOBt (835 mg, 6.18 mmol) was added and stirred for a further 5 hr. The reaction mixture was diluted with EtOAc. The solution was washed with brine and dried over Na2S04. The solvent was removed under a reduced pressure. The residue was chromatographed on silica-gel with n-hexane-EtOAc (2:3, v/v) a eluent to afford 294.3 mg (14%) methyl 3-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido ]phenylacetyl]-2-pyrrolidinyl]methylthio benzoate as a pale yellowish amorphous. IR (KBr) 2875, 1724, 1620, 1284, 1182cm'1; 'H-NMR (400 MHz, CDC13) δ 1.86 - 2.05 (m, 4H), 2.31(s, 3H), 2.84 (dd, .7 = 9.3, 13.7 Hz, IH), 3.43 - 3.59 (m,5H), 3.73 (s, 3H), 3.92 (s, 3H), 4.33 (m, IH), 6.16 (s, IH), 6.77 - 6.80 (m, 2H), 7.04 (s, IH), 7.16 (t, J = 8.3 Hz, IH), 7.38 (t, = 7.8 Hz, IH), 7.49 (t, = 7.8 Hz, IH), 7.73 (dt, J= 1.0, 7.8 Hz, IH), 7.79 (dd, .7 = 2.0, 6.8 Hz, IH), 8.01 (d, J= 2.0 Hz, IH), 8.05 (dd, = 2.4, 7.8 Hz, IH); MS (FAB) m/z 548 (M++l).
To a stirred solution of methyl 3-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinyl]methylthiobenzoate (148.2 mg, 0.271 mmol) in THF (7.4 mL) and H20 (1.8 mL) was added LiOH (19.4 mg, 0.812 mmol), and the resulting mixture was stirred for 9 hr at room temp. The mixture was treated with IN HCl and extracted with CHC13. The extract was washed with brine and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was purified by preparative TLC eluting with CHCl3-MeOH (10: 1, v/v), and crystallized from w-hexane-EtOAc to afford 89.7mg (62%) 20 as a white powder. IR (KBr) 2960, 1708cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.82 - 2.01 (m, 4H), 2.24 (s, 3H), 2.93 (dd, .7 = 9.3, 12.7 Hz, IH), 3.40 - 3.54 (m, 5H), 3.86 (s, 3H), 4.13 (br m, IH), 6.74 (d, = 8.3 Hz, IH), 6.87 (d, J = 1.5 Hz, IH), 6.94 (t, J = 7.8 Hz, IH), 7.10 - 7.17 (m, 2H), 7.42 (t, J = 7.8 Hz, IH), 7.70 (d, J = 7.8 Hz, IH), 7.74 (d, J = 8.3 Hz, IH), 7.79 (d, J = 7.8 Hz, IH), 7.84 (s, IH), 8.00 (d, J= 8.3 Hz, IH), 8.48 (s, IH), 8.57 (s, IH); MS (FAB) m/z 534 (M++l). Example 17 3-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]methylsulfonyl] benzoic acid
Figure imgf000138_0001
To a stirred solution of methyl 3-[[l-[3-mefhoxy-4-| '-(2 -methyl phenyl)ureido]phenyl acetyl]-2-pyrrolidinyl]methylthio]benzoate (131.8 mg, 0.241 mmol) in CH2C12 (3 mL) was added M-CPBA (130.5 mg, 0.529 mmol) at 0°C The reaction mixture was stirred at room temp for 0.5 hr. The mixture was diluted with CHC13 and quenched with sat. Na2S203 solution The organic layer was separated, washed with sat. NaHC03 solution, brine, and dried over Na2S04. The solvent was removed under a reduced pressure to afford methyl 3-[[l-[3-methoxy-4-[N'-(2-methylphenyl) ureidojphenyl acetyl]-2-pyrrolidinyl]-methylsulfonyl]benzoate as an amorphous solid. To a stirred solution of this crude compound in THF (7.4 mL) and H20 (1.8 mL) was added LiOH (17.3 mg, 0.723 mmol), and the stirring was continued overnight at room temp. The reaction mixture was diluted with CHC13 and washed with IN HCl, then brine, and dried over Na2S0 . The solvent was removed under a reduced pressure and the residue was purified by preparative TLC with CHC13- MeOH (10:1, v/v) as eluent, and the crude solid was reciystallized from w-hexane-EtOAc to afford 69.9 mg (51%) 21 as a white crystalline powder, mp 243 - 245; IR (KBr) 3354, 2974, 1533cm 1; 'H-NMR (400 MHz, DMSO-cU δ 1.80 - 2.00 (m, 4H), 2.24 (s, 3H), 3.19 - 3.62 (m, 6H), 3.82 (s,
3H), 4.18 (m, IH), 6.67 (d, J = 8.8 Hz, IH), 6.80 (d, = 1.0 Hz, IH), 6.93 (t, = 7.3 Hz, IH), 7.10 - 7.17 (m, 2H), 7.66 (t, J= 7.8 Hz, IH), 7.78 (d, J = 8.3 Hz, IH), 7.91 - 7.99 (m, 2H), 8.20 (d, J = 7.3 Hz, IH), 8.34 (s, IH), 8.48 (s, IH), 8.56 (s, IH); MS (FAB) m/z 566 (M++l); Anal Calcd for C29H31N307S 1HCMH20: C, 56.17; H, 5.53; N, 6.78. Found: C, 55.92; H.5.58; N, 6.71. Example 18
4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] methylsulfonyl] benzoic acid
Figure imgf000139_0001
To a stirred solution of methyl 4-[[l-[3-methoxy-4-[N'-(2-methyl phenyl)ureido] phenylacetyl]-2-pyrrolidinyl]methylfhio]benzoate (300 mg, 0.548 mmol) in CH2C12 (6 mL) was added /M-CPBA (297 mg, 1.206 mmol) at 0°C, and the reaction mixture was stirred at room temp for 1 hr. The mixture was diluted with CHC13> and quenched with sat. Na2S203 solution. The separated organic layer was washed with sat. NaHC03 solution, brine, and dried over Na2S04. The solvent was removed under a reduced pressure to afford methyl 4-[[l-[3-mefhoxy-4-[N'-(2- methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]-methylsulfonyl]benzoate as a crude yellow oil. To a stirred solution of this crude compound in THF (4.4 mL) and H20 (1. lmL) was added LiOH (39.4 mg, 1.643 mmol), and the stirring was continued overnight at room temp. The reaction mixture was diluted with CHC13 and washed with IN HCl, brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was purified by preparative TLC eluting with CHCl3-MeOH (10: 1, v/v), and crystallized from n-hexane-EtOAc to afford 128.0 mg (41%) 22 as a white powder. IR (KBr) 3388, 2974, 1537, 1298, 1155cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.80 - 1.98 (m, 4H), 2.24 (s, 3H), 2.54 (s, IH), 3.20 - 3.70 (m, 5H), 3.82 (s, 3H), 4.16 (br m, IH), 6.67 (dd, .7 = 1.5, 8.3 Hz, IH), 6.80 (d, J= 1.5 Hz, IH), 6.93 (d, .7= 7.3 Hz, IH), 7.10 -
7.16 (m, 2H), 7.78 (d, 7 = 7.3 Hz, IH), 7.95 (d, J = 8.3 Hz, 2H), 7.98 (d, J = 8.3 Hz, IH), 8.14 (d,
J= 8.3 Hz, 2H), 8.49 (s, IH), 8.57 (s, IH); MS (FAB) m/z 566 (M++l)^4«α/. Calcd for
C29H31N307S 3H20: C.56.21; H, 6.02; N, 6.78. Found: C, 56.76; H,5.37; N, 6.70.
Example 19
4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pynOlidinyl] methylthio] benzoic acid
Figure imgf000140_0001
To a stirred solution of /J-iodophenol (20.0 g, 90.9 mmol) in DMF (200 mL) was added 1,4-diazabicyclo [2,2,2]octane (20.4g, 181.8 mmol) and dimethylthiocarbamoyl chloride (16.9 g, 136.4 mmol). The resulting solution was stirred for 3.5 hr at 75°C. After cooling, 300mL of water was added. The solid was collected with suction and was dissolved in EtOAc. The EtOAc layer was washed with water, dried over Na2S04, and evaporated under a reduced pressure. The crude solid was reciystallized from H20 to give the 26.75 g (96%) 0-/>-iodophenyl dimethylthiocarbamate as a pale a yellow crystalline powder. IR (KBr) 1479, 1207, 827cm '; 'H-
NMR (400 MHz, CDC13) δ 3.37 (s, 3H), 3.45 (s, 3H), 6.83 (d, = 8.8 Hz, 2H), 7.69 (d, J= 8.3 Hz, 2H); MS (FAB) m/z 307 (M++ 1); Anal. Calcd for CHINOS: C, 35.19; H, 3.28; N, 4.56. Found: C, 35.17; H,3.35; N, 4.44.
A stirred solution of O-p-iodophenyl dimethylthiocarbamate (10.0 g, 32.6 mmol) in Ph20 (25mL) was heated at 230°C for 5.5 hr. After cooling, the reaction mixture was chromatographed on silica-gel with H-hexane-EtOAc (3: 1, v/v) as eluent to give 2.55 g (26%) S-p-iodophenyl dimethylthio carbamate as a white crystalline powder. IR (KBr) 3299, 1651, 1469, 1371cm"'; 'H- NMR (400 MHz, CDC13) δ 3.03 (br s, 3H), 3.08 (br s, 3H), 7.21 (d, = 8.3 Hz, 2H), 7.70 (d, J = 8.3 Hz, 2H); MS (FAB) m/z 308 (M++l); Anal. Calcd for CHINOS: C.35.19; H,3.28; N,4.56. Found: C,35.49; H,3.28; N, 4.43.
To a solution of S-p-iodophenyl dimethylthiocarbamate (2.55 g, 8.31 mmol) in MeOH (10 mL) was added MeONa (495 mg, 9.14mmol), and the resulting mixture was stirred at 70°C overnight. After cooling, IN HCl was added and the mixture was concentrated under a reduced pressure. The residue was diluted with EtOAc and washed with H20, brine, and dried over Na2S04 The organic layer was concentrated under a reduced pressure and the residue was chromatographed on silica-gel with «-hexane EtOAc (5: 1, v/v) as eluent to afford 1.75 g (89%)/?- iodothiophenol as a pale yellow crystalline solid. IR (KBr) 2559, 1097, 1002, 806cm '; 'H-NMR (400 MHz, CDC13) δ 3.43 (s, IH), 7.10 (d, J= 8.3 Hz, 2H), 7.53 (d, J= 8.3 Hz, 2H); MS (FAB) m/z 236 (M++l); Anal. Calcd for C6H5IS: C, 30.53; H, 2.13. Found: C, 30.57; H, 2.15.
To a stirred mixture of ?-iodothiophenol (1.75 g, 7.43 mmol) and N-(tert- butoxycarbonyl)-2- pyrrolidinylmethyl/7-toluenesulfonate (2.39 g, 6.75 mmol) in pyridine (12.7 mL) was added 8N KOH (1.27 mL) at room temp, and the resulting mixture was stirred for 4 hr at the same temp. The reaction mixture was diluted with EtOAc. The solution was washed with H20, sat. NH4C1, brine, and dried over Na2S04. The organic layer was concentrated under a reduced pressure. The residue was chromatographed on silica-gel with n-hexane-EtOAc (5: 1, v/v) as eluent to afford 1.49 g (53%) [N-(fer -butoxycarbonyl)-2-pyrrolidinyl]methyl 4-iodophenyl sulfide as a pale yellowish oil. 'H-NMR (400 MHz, CDC13) δ (s, 9H), 1.78 - 2.01(br m, 4H), 2.71 (dt, IH), 3.32 - 3.49 (br m, 3H), 3.90 - 4.02 (br m, IH), 7.12 (d, = 7.8 Hz,lH), 7.18 (d,J = 7.8Hz, l),7.57(dd,J= 2.0,8.3Hz,2H);MS(FAB)w z 420(M++1).
To a stirred solution of [l-(terr-butoxycarbonyl)-2-pyrrolidinyl]methyl 4-iodophenyl sulfide (1.49 g, 3.56 mmol) in DMSO (16 mL) and MeOH (13mL) was added Et3N (1.09 mL, 7.84 mmol), Pd(OAc)2 (40 mg, 0.178 mmol), and l,3-bis(diphenylphosphino)propane (73.4 mg, 0.178 mmol). To the stirred resulting mixture was induced CO gas for 5 min, and the mixture was stirred at 70°C overnight. After cooling, the mixture was concentrated to a small volume. The residue was diluted with EtOAc, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel with n-hexane-EtOAc (5:1, v/v) as eluent to afford 1.16 g (93%) methyl 4-[l-(tert-butoxycarbonyl)-2- pyrrolidinyl]methylthiobenzoate as an oil. 'H-NMR (400 MHz, CDC13) δ 1.51 and 1.47 (each s, 9H), 1.78 - 2.05 (br m, 4H) 2.77 (dt, J = 10.8, 37.1 Hz, IH), 3.34 - 3.58 (m, 3H), 3.89 (s, 3H), 4.03 (br d, J = 27.3 Hz, IH), 7.38 (d, J = 7.3 Hz, IH), 7.47 (d, J = 7.3 Hz, IH), 7.92 (br s, 2H); MS (FAB) m/z 352 (M++l).
To a stirred solution of methyl 4-[l-(tert-butoxycarbonyl)-2-pyrrolidinyl]methylthio benzoate (1.16 g, 3.32 mmol) in CH2C12 (20 mL) was added TFA (4 mL), and the mixture was stirred at room temp for 1.5 hr. The solvent was removed under a reduced pressure and the residue was treated with IN NaOH. The mixture was extracted with CHC13. The extract was washed with brine, dried over KOH, and concentrated under a reduced pressure to afford 767 mg (92%) methyl 4-(2-pyrrolidinyl) methylthio benzoate as a yellow oil. 'H-NMR (400 MHz, CDC13) δ (dt, J = 3.9, 12.7 Hz, IH), 1.85 - 2.09 (m, 2H) 2.13 (m, IH), 3.11 - 3.27 (m, 3H), 3.40 (dd, = 6.8, 13.2 Hz, IH), 3.54 (dd, = 7.3, 15.1 Hz, IH), 3.89 (s, 3H), 5.07 (br, IH), 7.38 (d, J= 8.3 Hz, 2H), 7.91 (d, J = 8.3 Hz, 2H); MS (FAB) z 252 (M++l).
To a stirred mixture of 3-methoxy-4-[/V'-(2-methylphenyl)ureido]phenylacetic acid (1.30 g, 4.136 mmol), Et3N (0.63 mL, 4.549 mmol) in DMF (20 mL) was added pentafluorophenyl trifluoroacetate at 0°C The resulting mixture was stirred at room temp for 1 hr. The mixture was poured into water (60 mL) and precipitate was collected with suction. The crude solid was washed with 0. IN HCl, H20, n-hexane, and dried at 40°C to afford 1.91 g (96%) pentafluorophenyl 3- methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetate as a pale brownish crystalline powder. IR (KBr) 1785,1224, 1216cm '; 'H-NMR (400 MHz, CDC13) δ 2.29 (s, 3H), 3.76 (s,3H), 3.90 (s, 2H), 6.49 (s, IH), 6.81 (d, J = 1.5 Hz, IH), 6.91 (dd, J = 1.5, 8.3 Hz, IH), 7.15 (t, J= 7.3 Hz, 3H), 7.24 (m, IH), 7.50 (d, J = 7.8 Hz, IH), 8.17 (d, J= 7.8 Hz, IH); MS (FAB) m/z 481 (M++l); Anal. Calcd for C30H33N3O5S-l/4H2O: C, 57.51; H, 3.57; N, 5.83. Found: C, 57.40; H,3.75; N, 5.68.
A mixture of pentafluorophenyl 3-methoxy-4-| V'-(2-methylphenyl)ureido] phenylacetate
(1.47 g, 3.05 mmol), methyl 4-(2-pyrrolidinyl)methylthiobenzoate (767 mg, 3.05 mmol), Et3N (0.51 mL, 3.66 mmol) in DMF (15 mL) was stirred overnight at room temp. The reaction mixture was diluted with EtOAc, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel with n-hexane-EtOAc (1:2, v/v) as eluent to afford 1.366 g (82%) methyl 4-[[l-[3-methoxy-4-[N-(2- methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] methylthio]benzoate as a white crystalline powder. IR (KBr) 1785,1224, 1216cm '; 'H-NMR (400 MHz, CDC13) δ 1.88 - 1.99 (m, 4H), 2.30 (s, 3H), 2.75 (dd, J= 9.8, 13.2 Hz, IH), 3.43 - 3.55 (m,3H), 3.56 (s, 2H), 3.64 (dd, J= 1.1, 14.2 Hz, IH), 3.73 (s, 3H), 3.88 (s, 3H), 4.33 (m, IH), 6.29 (s, IH), 6.78 - 6.81 (m, 2H), 7.11 - 7.26 (m, 5H), 7.50 (d, J = 8.3 Hz, 3H), 7.93 (d, /= 8.8 Hz, 2H), 8.07 (d, J = 7.8 Hz, IH); MS (FAB) m/z 548 (M++l); Anal. Calcd for C30H33N3O5S l/4H2O: C, 65.26; H, 6.12; N, 7.61. Found: C, 65.48; H,6.20; N, 7.47.
To a stirred solution of methyl 4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinyl]methylthio]benzoate (300 mg, 0.548 mmol) in THF (5.5 mL) and H20 (1.1 mL) was added LiOH (39.4mg, 1.643 mmol), and the reaction mixture was stirred at room temp overnight and at 50°C for 9 hr. The mixture was diluted with CHC13. The solution was washed with IN HCl, brine, and dried over Na2S04. The solvent was removed under a reduced pressure, and the obtained crude solid was reciystallized from w-hexane-EtOAc-MeOH to afford 218.6 mg (75%) 23 as a white crystalline powder. IR (KBr) 3318,2952, 1596, 1536, 1299, 1155cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.82 - 2.05 (m, 4H), 2.25 (s, 3H), 2.91 (dd, J = 9.8, 13.2 Hz, IH), 3.47 - 3.52 (m, 3H), 3.57 (s, 2H), 3.87 (s, 3H), 4.14 (br m, IH), 6.76 (d, = 1.5, 8.3 Hzd, IH), 6.89 (d, J= 1.5 Hz, IH), 6.94 (t, J= 7.3 Hz, IH), 7.11 - 7.19 (m, 2H), 7.57 (d, J = 8.3 Hz, 2H), 7.80 (d, J= 8.3 Hz, IH), 7.83 (d, J= 8.3 Hz, 2H), 8.02 (d, J = 8.3 Hz, IH), 8.49 (s, IH), 8.58 (s, IH); MS (FAB) m/z 534 (M++l); Anal. Calcd for C29H31N305S-5/4H20: C, 62.63; H, 6.07; N, 7.36; S, 5.77. Found: C, 62.62; H,5.74; N, 7.36; S, 5.67. Example 20
4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyιτolidinyl] methylsulfinyl] benzoic acid
Figure imgf000143_0001
To a stirred solution of methyl 4-[[l-[3-methoxy-4-[Λr' -(2 -methyl phenyl)ureido] phenylacetyl]-2-pyrrolidinyl]methylthio]benzoate (264 mg, 0.482 mmol) in CH2C12 (5.2 mL) was added m-CPBA (118.8 mg, 0.482 mmol) at 0°C, and the mixture was stirred at room temp for 1 hr. The mixture was diluted with CHC13, and quenched with sat. Na2S203 . The separated organic layer was washed with sat. NaHC03, brine, and dried over Na2S04. The solvent was removed under a reduced pressure to afford methyl 4-[[l-[3-methoxy-4-[N '-(2-mefhylphenyl)ureido] phenylacetyl]-2-pyrrolidinyl] methylsulfinyl] benzoate as a crude amorphous solid. To a stirred solution of this crude compound in THF (4 mL) and H20 (lmL) was added LiOH (34.6 mg, 1.45 mmol), and the stirring was continued overnight at room temp. The mixture was diluted with CHC13, washed with IN HCl, brine, and dried over Na2S04. The solvent was removed under a reduced pressure, and the obtained crude solid was reciystallized from «-hexane-CHCl3-MeOH to afford 193.2 mg (73%) 24 as a white crystalline powder. IR (KBr) 3338, 2956, 1708, 1529, 1299, 1207, 1155cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.70 - 2.06 (m, 4H), 2.24 (s, 3H), 2.90 (dd, J = 8.3, 13.2 Hz, IH), 3.02 - 3.08 (m, IH), 3.16 - 3.25 (m, IH), 3.41 - 3.60 (m, 3H), 3.84 (s, 3H), 4.40 (br s, IH), 6.74 (d, .7= 7.8 Hz, IH), 6.87 (s, IH), 6.94 (d, .7 = 7.3 Hz, IH), 7.11 - 7.17 (m, 2H), 7.75 - 7.81 (m, 3H), 7.98 - 8.05 (m, IH), 8.10 (d, J= 8.3 Hz, 2H), 8.46 (s, IH), 8.56 (s, IH); MS (FAB) m/z 550 (M++l), 572 (M++Na); Anal. Calcd for C29H31N306S-3/2H20: C, 60.40; H, 5.94; N, 7.29. Found: C, 60.15; H,5.82; N, 6.90. Example 21
(S - 4-[l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacethyl]-2-pyrrolidinylmethoxy] benzoic acid.
Figure imgf000144_0001
To a stirred solution of methyl 4-hydroxybenzoate (1.96 g, 12.88 mmol), Λ-Boc-prolinol
(2.59 g, 12.87 mmol) and PPh3 (4.06 g, 15.48 mmol) in THF (40 mL) was added DIAD (3.10 mL,
15.74 mmol). The resulting mixture was heated under reflux for 14 hr. The mixture was evaporated off in vacuo and the residue was purified by column chromatography on silica-gel with w-hexane-EtOAc (6: 1, v/v) as eluent to give 3.34 g (77%) methyl (S)-4-[l-(ter/-butoxycarbonyl)-2- pyrrolidinylmethoxy] benzoate as an oil. 'H-NMR (CDC13) δ 1.48 (s, 9 H), 1.67 (d, .7=9.3 Hz, 1
H), 1.87-2.03 (m, 3 H), 3.36-3.43 (m,2H), 3.87-4.09 (m,lH), 4.13-4.20 (m,2 H, 6.94 (d, .7=8.3 Hz, 2H), 7.98 (d, .7=8.3 Hz, 2H).
A mixture of methyl (S)-4-[l-(ferr-butoxycarbonyl)-2-pyrrolicunylmethoxy] benzoate (3.34 g, 9.96 mmol) in TFA (20 mL) and CH2C12 (35 mL) was stirred at room temp for 15 hr. The mixture was concentrated in vacuo and made basic with sat. NaHC03. The mixture was extracted with CHC13, washed with brine, and dried over Na2C03. The organic layer was evaporated to give 1.70 g (73%) methyl (5)-4-(2-pyrrolidinylmethoxy)benzoate as a yellow oil. 'H-NMR (CDC13) δ 1.54-1.61 (m, 1 H), 1.77-1.86 (m, 2 H), 1.87-1.97 (m, 1 H), 2.00 (bs, 1 H), 2.93-3.06 (m, 2 H), 3.52-3.57 (m, 1 H), 3.88 (s, 3 H), 3.90-3.99 (m, 2 H), 6.92 (d, .7=9.0 Hz, 2 H), 7.98 (d, .7=9.0 Hz, 2 H)
A mixture of 3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetic acid (428 mg, 1.36 mmol), methyl (S)-4-(2-pyrrolidinylmethoxy)benzoate (330 mg, 1.40 mmol), EDC (312 mg, 1.63 mg), HOBt (220 mg, 1.63 mmol), and a catalytic amount of DMAP in DMF (15 mL) was stirred for 6 hr. The resulting mixture was diluted with EtOAc, washed with 0.5 N HCl, sat. NaHC03, brine, and dried over MgS04. The solvent was evaporated off in vacuo to give an oily residue, which was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1, v/v) as eluent to give 540 mg (75%) methyl (5)-4-[l-[3-methoxy-4-[N'-(2- methylphenyl)ureido]phenylacetyl]-2-pyrrolidinylmethoxy] benzoate as an oil. 'H-NMR (CDC13) δ 1.81-2.12 (m, 4 H) 2.88 (bs, 3 H), 3.48-3.61 (m, total 7 H), 3.88 (s, 3 H), 4.10-4.21 (m, 2 H), 4.42- 4.46 (m, 1 H), 6.75-8.08 (series of m, total 13 H). To a stirred solution of methyl (S)-4-[l-[3-methoxy-4-| V'-(2-methylphenyl) ureido] phenylacetyl]-2-pyrrolidinylmethoxy]benzoate (540 mg, 1.02 mmol) in THF (10 mL) was added 0.25 N NaOH (10 mL). The resulting mixture was heated under reflux for 16 hr. The mixture was poured into 1 N HCl and the solid was collected. The crude solid was washed with Et20 to give 278 mg (53%) 25 as a white amorphous solid. IR (KBr) 1708 cm '; 'H-NMR (DMSO-cL.) δ 1.83- 2.14 (m, 4 H), 2.21 (s, 3 H), 2.46 (s, 2 H), 3.78 (s, 3 H), 3.95-4.02 (m, 1 H), 4.13-4.16 (m, 1 H), 4.24 (bs, 1 H), 6.51-7.98 (series of m, 12 H), 8.43 (s, 1 H), 8.53 (s, 1 H), 12.57 (bs, 1 H); MS (FAB) m/z 517 (M+). Example 22 l-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]benzoyl]-Z,-prolyl]-4-piperidinylacetic acid
Figure imgf000145_0001
A mixture of 3-methoxy-4-nitrobenzoic acid (229mg, l.lόmmol), fer/-butyl 4-(l- prolylpiperidinyl)acetate (344mg, l.lόmmol), HOBt (188mg, 1.39mmol), DMAP (14.2mg,
0.116mmol), and EDC (267mg, 1.39mmol) in DMF (7mL) was stirred for 22 hr at room temp. The mixture was diluted with EtOAc (50mL) and washed successively with 1 N HCl, sat. NaHC03, and H20. The organic layer was dried over Na2S04 and evaporated in vacuo. The residue was chromatographed on silica-gel with MeOH:CHCl3 (1:30, v/v) as eluent to afford 520mg (94%) tert- buty l-(3-methoxy-4-mtrobenzoyl)prolyl-4-(l-piperidinyl)acetate as a white ciystalline material. 'H-NMR (CDC13) δ 1.12-1.33 and 1.62-2.23 (each m,9H), 1.44 (s,9H), 2.65,3.13,3.47, 3.67, 4.44, and 4.61 (each m, 8H), 3.99 (s, 3H), 5.05 (m, IH), 7.21 (d, =8.3Hz, IH), 7.31 (s, IH), 7.86 (d, =8.3Hz, IH).
A stirred mixture oftert-bu y l-(3-methoxy-4-nitrobenzoyl)prolyl-4-(l-piperidinyl) acetate (0.52g, 1.09mmol) and 5% Pd-C (2.08g) in MeOH (lOmL) was hydrogenated under an atmospheric pressure for 94 hr at room temp. Insoluble catalyst was removed, and the filtrate was evaporated in vacuo. The residue was chromatographed on silica-gel with MeOH:CHCl3 (1:40 to 1:6 , v/v) as eluent to afford 279mg (57%) tert-buty l-(4-amino-3-methoxybenzoyl)prolyl-4-(l- piperidinyl)acetate as a white crystalline material. 'H-NMR (CDC13) δ 1.16-2.17, 2.69, 3.06, 3.67, 4.12, and 4.59 (each m, 17H), 3.86 (s, 3H), 5.10 (m, IH), 6.64 (m, IH), 7.12 (each m, 2H). To a stirred solution of tert-buty l-(4-amino-3-methoxybenzoyl)-Z,-prolyl-4-(l-piperidinyl) acetate (279mg, 0.627mmol) and Et3N (0.0876mL, 0.627mmol) in THF (4mL) was added dropwise o-tolyl isocyanate (0.0777mL, 0.627mmol) at room temp, and the resulting mixture was stirred for a further 21 hr at room temp. Ice water was added to the mixture and the precipitate was collected with suction. The crude solid was purified by silica-gel column chromatography with MeOH:CHCI3 (1:40, v/v) as eluent to afford 254mg (70%) tert-b tyl l-[l-[3-methoxy-4-[N'-(2- methylphenyl)ureido] benzoyl]-Z,-prolyl]-4-(l-piperidinyl)acetate as a crystalline solid. 'H-NMR (CDC13) δ 1.43 (s, 9H), 1.13-1.25 and 1.76-2.14 (each m, 9H), 2.60, 3.18, 3.71, 4.06, and 4.57 (each m, 8H), 3.67 (s, 3H), 5.06 (m, IH), 6.63, and 6.90 (s, 2H), 6.98-7.23, and 7.64 (each m, 5H), 7.56 (d, J=7.8Hz, IH), 8.21 (d, =8.8Hz, IH).
A solution of tert-butyl l-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] benzoyljprolyi]- 4-(l-piperidinyl)acetate (254mg, 0.440mmol) in CH2C12 (6mL) and TFA (6mL) was stirred for 5 hr at room temp. The mixture was poured into ice water. The solid was collected with suction, washed with water and air-dried to afford 179mg (78%) 26 as a white crystalline solid. 'H-NMR ( DMSO-d6) δ 0.47, 1.05, 1.44, and 1.62-1.99 (each m, 9H), 2.49 (s, 3H), 2.15-2.30, 2.35, 2.56, 2.78, 3.09, 3.04-3.80, 4.05, 4.15, and 4.32 (each m, 8H), 3.92 (s, 3H), 4.92(m, IH), 6.82, 6.95, 7.11, 7.77, 8.20, 8.57, and 8.75 (m, 9H); MS (FAB) m/z 523 (M+ +l); Anal. Calcd for C28H34N406 : C, 64.35; H, 6.56; N, 10.72. Found : C, 55.58; H, 5.89; N, 8.75. Example 23 (S)-3-methoxy-4-[l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl methoxyjbenzoic acid
Figure imgf000146_0001
To a stirred solution of ethyl 4-hydroxy-3-methoxybenzoate (3.00 g, 15.29 mmol), (S)-N-
Boc-prolinol (3.08 g, 15.30 mmol), Ph3P (4.81 g, 18.34 mmol) in THF (50 mL) was added DIAD (3.61 mL, 18.33 mmol) at 0°C. The resulting mixture was heated under reflux 6.5 hr. After cooling to room temp, the mixture was evaporated and purified by column chromatography on silica-gel with CHCl3-MeOH (50:1, v/v) as eluent to give ethyl (S)-3-methoxy-4-[l-( er/- butoxycarbonyl)-2-pyrrolidinyl methoxy] benzoate as a gum. The above ethyl (5)-3-methoxy-4-[l-
(terf-butoxycarbonyl)-2-pyrrolidinylmethoxy] benzoate was dissolved in CH2C12 (50 mL) and TFA (45 mL). The mixture was stirred for 2 days at room temp. The resulting mixture was concentrated in vacuo and made basic with sat. NaHC03. The mixture was extracted with CH2C12, washed with brine, and dried over MgS04. The solvent was evaporated and the residue was purified by column chromatography on silica-gel with CHCl3-MeOH (20:1, v/v) as eluent to give 3.27 g (77% for 2 steps) ethyl (S)-3-methoxy-4-(2-pyrrolidinylmethoxy) benzoate as a yellow oil. 'H-NMR (CDC13) δ 1.39 (t, 3 H, .7=7.1 Hz), 1.52-1.59 (m, 1 H), 1.76-1.88 (m, 2 H), 1.92-2.01 (m, IH), 2.92-3.06 (m, 2 H), 3.56-3.63 (m, 1 H), 3.90 (s, 3 H), 3.91-4.02 (m, 2 H), 4.35 (q, 2 H, .7=7.1 Hz), 6.89 (d, 1 H, .7=8.3 Hz), 7.54 (d, 1 H, .7=2.0 Hz), 7.65 (dd, 1 H, .7=2.0, 8.3 Hz).
To a stirred solution of ethyl (S)-3-methoxy-4-(2-pyrrolidinylmethoxy)benzoate (424 mg, 1.52 mmol) in DMF (8 mL) was added pentafluorphenyl ester of 3-mefhoxy-4-|7V'-(2- mefhylphenyl) ureido]phenylacetic acid (728 mg, 1.52 mmol) and Et3N (0.26 mL, 1.87 mmol). And the resulting mixture was stirred at room temp overnight. The mixture was diluted with EtOAc, washed with 1 N HCl, sat. NaHC03, brine, and dried over MgS04. The solvent was evaporated off in vacuo and the residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1, v/v) as eluent to give 830 mg (95%) ethyl (S -3-methoxy-4-[l-[3-methoxy-4- [N'-(2-methylphenyl)ureido]phenyl acetyl]-2-pyrrolidinyl methoxy]benzoate as an amorphous solid. 'H-NMR (CDC13) δ 1.38 (t, 3 H, .7=7.3 Hz), 1.88-2.20 (m, 4 H, m), 2.24 (m, 3 H), 3.44-3.50 (m, 1 H), 3.53-3.58 (m, 7 H), 3.82 (s, 3 H), 4.09-4.17 (m, 1 H), 4.22-4.25 (m, 1 H), 4.35 (q, 2 H, .7=7.3 Hz), 4.38-4.49 (m, 1 H), 6.71-6.78 (m, 1 H), 6.99 (d, 1 H, J=8.3 Hz), 7.04-7.07 (m, IH), 7.16-7.19 (m, 2 H), 7.49-7.66 (m, 3 H), 8.06 (d, 1 H, .7=8.3 Hz).
To a stirred solution of ethyl (5 -3-methoxy-4-[[l-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetyl]-2-pyrrolidinyl]methoxy]benzoate (760 mg, 1.32 mmol) in THF (10 mL) was added 0.25 N NaOH (10 mL), and the resulting mixture was heated under reflux overnight. After cooling to room temp, the mixture was poured into 1 N HCl (100 mL) and the solid was collected. The crude solid was washed with Et20 to give 429 mg (59%) 27 as a yellow amorphous solid, mp 132-135; IR (KBr) 1707 cm '; 'H-NMR (DMSO-d«) δ 1.84-2.18 (m, 4 H), 2.25 (s, 3 H), 2.49-2.51 (m, 2 H), 3.29-3.59 (m, 4 H), 3.80 (s, 3 H), 3.82 (s, 3 H), 4.00-4.05 (m, 1 H), 6.53-8.01 (m, 10 H), 8.45 (s, 1 H), 8.54 (s, 1 H), 12.63 (bs, 1 H); MS (FAB) m/z 548 (M++l). Example 24 (S)-4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinylmethoxy] phthalic acid
Figure imgf000148_0001
To a stirred solution of dimethyl 4-hydroxyphthalate (3.00 g, 14.27 mmol), JV-Boc- prolinol (2.87 g, 14.26 mmol), Ph3P (4.49 g, 17.12 mmol) in THF (50 mL) was added DIAD (3.40 mL, 17.27 mmol) at 0°C. Then the resulting mixture was heated under reflux overnight. The resulting mixture was evaporated and the residue was purified by column chromatography on silica-gel with /i-hexane-EtOAc (3: 1, v/v) as eluent to give 5.75 g (q.y.) dimethyl ( )-4-[l-(tert- butoxycarbonyl)-2-pyrrolidinyl methoxy] phthalate as an oil. 'H-NMR (CDC13) δ 1.47 (s, 9 H),
1.86-2.05 (m, 4 H), 3.36-3.40 (m, 2 H), 3.87 (m, 3 H), 3.91 (s, 3 H), 3.96-4.19 (m, 3 H), 7.03-7.24
(m, 2 H), 7.80 (m, IH).
To a solution of dimethyl (S)-4-[l-(terf-butoxycarbonyl)-2-pyrrolicunylmethoxy] phthalate
(5.75 g, 14.62 mmol) in CH2C12 (25 mL) was added TFA (20 mL), and the resulting mixture was stirred for 50 min at room temp. The resulting mixture was concentrated in vacuo and made basic with sat. NaHC03. The mixture was extracted with CH2C12, washed with brine, dried over MgS04, and evaporated off in vacuo. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1, v/v) as eluent to give 790 mg (18%) dimethyl (S)-4-(2- pyrrolidinylmethoxy) phthalate as a brown oil. Η-NMR (CDC13) δ 1.48-1.57 (m, 1 H), 1.72-1.84 (m, 2 H), 1.89-1.98 (m, 2 H), 2.91-3.03 (m, 2 H), 3.48-3.54 (m, 1 H), 3.82-3.97 (m, total 8 H), 6.98 (dd, 1 H, .7=2.4, 8.8 Hz), 7.06 (d, 1 H, .7=2.4 Hz), 7.78 (d, 1 H, .7=8.8 Hz).
To a stirred solution of dimethyl (S)-4-(2-pyrrolidinylmethoxy)phthalate (212 mg, 0.72 mmol) in DMF (8 mL) was added pentafluorophenyl ester of the 3-methoxy-4-[/V'-(2- methylphenyl)ureido] phenylacetic acid (346 mg, 0.72 mmol) and Et3N (120 ml, 0.86 mmol), and the mixture was stirred overnight The resulting mixture was diluted with EtOAc, washed with 1 N HCl, sat. NaHC03, brine, and dried over MgS0 . The solvent was evaporated off in vacuo to give 413 mg (97%) dimethyl (5 -4-[l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-2- pyrrolidinylmethoxy]phthalate as an oil. 'H-NMR (CDC13) δ 1.92-2.12 (m, 4 H), 2.29 (br s, 3 H), 3.51-3.64 (m, 7 H), 3.87 (s, 3 H), 3.89 (s, 3 H), 4.10-4.19 (m, 2 H), 4.44 (m, 1 H), 6.73-8.02 (series of m, total 12 H).
To a stirred solution of dimethyl (S)-4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinylmethoxy]phthalate (413 mg, 0.70 mmol) in THF (10 mL) was added 0.25 N NaOH (10 mL) at room temp, and then the resulting mixture was heated under reflux overnight. After cooling to room temp, the reaction mixture was poured into 1 N HCl (100 mL). The solid was collected, washed with water and air-dried. The crude solid was washed with Et20 to give 310 mg (79%) 28 as a yellow amorphous solid. IR (KBr) 1701 cm '; 'H-NMR (DMSO-cL.) δ 1.87-2.18 (m, 4 H), 2.25 (s, 3 H), 2.50 (s, 2 H), 3.38-3.60 (m, 4 H), 3.83 (s, 3 H), 4.00-4.14 (m, 1 H), 6.74-8.02 (series of m, 10 H), 8.46 (s, 1 H), 8.54 (s, 1 H); MS (FAB) m/z 562 (M++l). Example 25
3-chloro-4-[[l-[3-methoxy-4-[Λf'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]methoxy] benzoic acid
Figure imgf000149_0001
To a stirred solution of methyl 3-chloro-4-hydroxybenzoate (600 mg, 3,215mmol), N-tert- butoxycalbonylprolinol (647,1 mg, 3,215 mmol), and Ph3P (1.01 g, 3.858 mmol) in THF (10 mL) was added dropwise diisopropyl azodicarboxylate (DIAD) (0.8 mL, 3.890 mmol) at room temp and the mixture was stirred for 3days at room temp, and for 18 hr at 70°C The reaction mixture was evaporated off in vacuo, and the residue was chromatographed on silica-gel with n-hexane:EtOAc (5: 1, v/v) as eluent to give 1.147g (97%) methyl 3-chloro-[l-(/ert-butoxycarbonyl)-2- pyrrolidinyl]methoxy benzoate as an oil. Η-NMR (400 MHz, CDC13) δ 1.46, 1.48 (s each, 9H), 1.59 - 1.63 (br, IH), 1.88 (br s, IH), 2.05 (s, IH), 2.05 - 2.21 (m, 2H), 3.34 - 3.45 (br m, 1.5H), 3.89 (s, 3H), 3.97(br m, 0.5H), 4.21 (br s, 2H), 7.05 (d, J= 8.8 Hz, IH), 7.90 (dd, J = 2.0, 8.8 Hz, IH), 8.04 (d, J = 2.0 Hz, IH); MS (FAB) m/z 370 (M++l).
To a stirred solution of methyl 3-chloro-[l-(ter/-butoxycarbonyl)-2-pyrrolidinyl]methoxy benzoate (1.14 g, 3.10 mmol) in CH2C12 (20 mL) was added TFA (5 mL) at 0°C, and the reaction mixture was stirred at room temp for 2 hr. The solvent was removed under a reduced pressure and the residue was treated with IN NaOH. The mixture was extracted with CHC13. The extract was washed with brine, dried over KOH, and concentrated under a reduced pressure to afford 741 mg (89%) methyl 3-chloro-4-(2-pyrrolidinyl)methoxybenzoate as a yellow oil. 'H-NMR (400 MHz, CDC13) δ 1.60 - 1.67 (m, IH), 1.78 - 2.02 (m, 3H), 2.93 - 2.98 (m, IH), 3.03 - 3.09 (m, IH), 3.59 (dt, .7= 2.0, 9.3 Hz, IH), 3.89(s, 3H), 3.98(dd, J= 6.3, 8.8 Hz, IH), 4.05 (dd, J = 4.9, 9.3 Hz, IH), 6.93 (d, = 8.8 Hz, IH), 7.90 (dd, .7 = 2.0, 8.8 Hz, IH), 8.04 (d, J = 2.0 Hz, IH); MS (FAB) m/z 270 (M++l). The mixture of pentafluorophenyl 3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetate (500 mg, 1.04mmol), methyl 3-chloro-4-(2-pyrrolidinyl)methoxybenzoate (281 mg, 1.04 mmol), Et3N (0.17 mL, 1.25 mmol) in DMF (5 mL) was stirred for 1 hr at room temp. The mixture was diluted with EtOAc, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure, and the residue was chromatographed on silica-gel with n- hexane - EtOAc (1:3, v/v) as eluent to afford methyl 3-chloro-4-[[l-[3-methoxy-4-[Λ^-(2- methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] methoxy]benzoate (620 mg, 1.04 mmol) as a white crystalline solid. To a stirred solution of this compound in THF (8 mL) and H20 (2 mL) was added LiOH (74.9mg, 3.126 mmol), and the mixture was stirred at room temp for 2 days. The mixture was diluted with CHC13, and treated with IN HCl. The solution was washed with brine, dried over Na2S04, and evaporated in vacuo. The crude solid was reciystallized from n-hexane- EtOAc-CHCl3 to afford 561.2 mg (98%) 29 as a white crystalline material. IR (KBr) 1676, 1599, 1487, 1267, 758, 754cm '; Η-NMR (400 MHz, DMSO-cL.) δ 1.82 - 2.24 (m, 4H), 2.25 (s, 3H), 3.48 - 3.60 (m, 4H), 3.78 (s, 3H), 4.18 (m, 2H), 4.31 (m, IH), 6.74 (dd, = 1.5, 8.3 Hz, IH), 6.84 (d, J = 2.0 Hz, IH), 6.91 - 6.95 (m, IH), 7.11 - 7.17 (m, 3H), 7.79 (dd, J = 2.0, 8.3 Hz, 2H), 7.85 (d, J = 2.0 Hz, IH), 7.98 (d, J = 8.3 Hz, IH), 8.53(s, IH), 8.58 (s, IH); MS (FAB) m/z 552 (M++l). Example 26
3,5-dichloro-4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] methoxy] benzoic acid
Figure imgf000150_0001
To a stirred solution of methyl 3,5-dichloro-4-hydroxybenzoate (600mg, 2.714 mmol), N- terr-butoxycarbonylprolinol (546mg, 2.714mmol), and PlrjP (854 mg, 3.257 mmol) in THF (lOmL) was added dropwise DIAD (0.68mL, 3.283 mmol) at room temp and the mixture was stirred for
3 days at room temp, and for 18 hr at 70 °C. The reaction mixture was concentrated and the residue was chromatographed on silica-gel with n-hexane - EtOAc (6: 1, v/v) as eluent to give 988.8 mg
(90%) methyl 4-[l-( ert-butoxycarbonyl)-2-pyrrolidinyl]methoxy-3,5-dichlorobenzoate a pale yellowish oil. Η-NMR (400 MHz, CDC13) δ 1.44 (s, 9H), 1.88 - 2.15 (br m, 3H), 2.34 (br s, IH),
3.40 - 3.44 (m, 2H), 3.92 (s, 3H), 3.92, 4.14 (m, IH), 4.18 (br s, 2H), 7.98 (s, 2H); MS (FAB) m/z
404 (M++l).
To a stirred solution of methyl 4-[l-(terf-butoxycarbonyl)-2-pyrrolidinyl]methoxy-3,5- dichlorobenzoate (988 mg, 3.248 mmol) in CH2C12 (20 mL) was added TFA (5 mL) at 0°C, and the reaction mixture was stirred at room temp for 2 hr. The solvent was removed under a reduced pressure and the residue was treated with IN NaOH. The solution was extracted with CHC13. The extract was washed with brine, dried over Na2S04, and concentrated under a reduced pressure to afford 672 mg (68%) methyl 3,5-dichloro-4-(2-pyrrolidinyl)methoxybenzoate as a pale yellowish oil. Η-NMR (400 MHz, CDC13) δ 1.62 - 1.69 (m, IH), 1.78 - 1.86 (m, 2H), 1.89 - 1.99 (m, IH), 2.92 - 2.98 (m, IH), 3.04 - 3.09 (m, IH), 3.55 - 3.60 (m, IH), 3.91 (s, 3H), 4.01 (dd, J = 6.8, 8.8 Hz, IH), 4.08 (dd, = 4.9, 8.8 Hz, IH), 7.97 (s, 2H); MS (FAB) m/z 304 (M -l).
A mixture of pentafluorophenyl 3-methoxy-4-[N-(2-methylphenyl)ureido] phenylacetate (385.8 mg, 0.803 mmol), methyl 3,5-dichloro-4-(2-pyrrolidinyl)methoxybenzoate (244.3 mg, 0.803 mmol), Et3N (0.13 mL, 0.964 mmol) in DMF (4 mL) was stirred for 1 hr at room temp. The mixture was diluted with EtOAc, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure, and the residue was chromatographed on silica-gel with n- hexane:EtOAc (1:2, v/v) as eluent to afford methyl 3,5-dichloro-4-[[l-[3-methoxy-4-[N-(2- methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] methoxy]benzoate as an oil. To a stirred solution of this compound in THF (8 mL) and H20 (2 mL) was added LiOH (57.7 mg, 2.409 mmol), and the mixture was stirred at room temp overnight. The mixture was concentrated in vacuo, and the residue was diluted with CHC13. The solution was washed with IN HCl, brine, and dried over Na2S04. The solvent was removed under a reduced pressure, and the obtained crude solid was reciystallized from «-hexane-MeOH-CHCl3 to afford 428.2 mg (91%) 30 as a white crystalline powder. IR (KBr) 1618, 1535, 1454, 1257, 754cm 1; 'H-NMR (400 MHz, DMSO-c ,) δ 1.83 - 2.24 (m, 4H), 2.24 (s, 3H), 3.50 - 3.58 (m, 4H), 3.84 (s, 3H), 3.98 - 4.05 (m, IH), 4.15 (dd, J = 2.9, 8.7 Hz, IH), 4.29 (br m, IH), 6.74 (d, J = 8.3 Hz, IH), 6.87 (s, IH), 6.93 (t, J= 7.3 Hz, IH), 7.11 (d, = 7.8 Hz, IH), 7.16 (d, J= 8.3 Hz, IH), 7.79 (d, J = 8.3 Hz,lH), 7.86 (s, IH), 7.87 (d, J = 9.8 Hz, IH), 7.99 (d, = 8.3 Hz, IH), 8.49 (s, IH), 8.58 (s, IH); MS (FAB) m/z 586 (M++l) Example 27
4-[l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinylmethoxy]-3- nitrobenzoic acid
Figure imgf000151_0001
To a stirred solution of 4-hydroxy-3-nitrobenzoic acid (3.00g, 0.0164mol) in MeOH- benzene (1:4, v/v) was added dropwise 2.0 M-H-hexane solution of TMSCHN2 (8.2mL, 0.0164mol) at room temp. After the resulting solution was stirred for 4 hr at room temp, the mixture was evaporated off in vacuo. The oily residue was chromatographed on silica-gel with CHC13 as eluent to afford 4.23g (79%) methyl 4-hydoroxy-3-nitrobenzoate as a pale yellow ciystalline material.
To a stirred mixture of N-/er -butoxycarbonylprolinol (1.02g, 5.07mmol), methyl 4- hydoroxy-3-nitrobenzoate (l.OOg, 5.07mmol), and Ph3P (1.46g, 5.58mmol) in THF (lOmL) was added dropwise diisopropyl azodicarboxylate (DIAD) (95%) (1.16mL, 5.58mmol) at 0°C The resulting mixture was heated under reflux for 46 hr. After cooling, the mixture was evaporated off in vacuo. The residue was dissolved in CH2C12 (lOmL) and added TFA (lOmL). After the solution was stirred for 0.5 hr at room temp, the solution was evaporated in vacuo. Water was added to the residue and washed with EtOAc. The aqueous layer was neutralized by the addition of sat. NaHC03 and extracted with EtOAc. The extract was dried over Na2S04 and evaporated in vacuo to afford 0.698g (49%) methyl 3-nitro-4-(2-pyrrolidinylmethoxy) benzoate as a gum.
A mixture of methyl 3-mtro-4-(2-pyrrolidinylmethoxy)benzoate (0.668g , 2.38mmol), 3- methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (1.12g, 3.57mmol), 1-hydroxybenzo triazole (HOBt) (0.482g, 3.57mmol), 4-dimethylaminopyridine(DMAP) (43.6mg, 0.357mmol), and l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (0.684g, 3.57mmol) in DMF (lOmL) was stirred for 15 hr at room temp. EtOAc was added to the mixture and washed successively with 1 N HCl, sat. NaHC03, and brine. The organic layer was dried over Na2S0 and evaporated in vacuo. The residue was chromatographed on silica-gel with EtOH-CHCl3 (1:20, v/v) as eluent to afford 0.927g (68%) methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacethyl]-2- pyrrolidinylmethoxy]-3-nitrobenzoate as a yellow crystalline material.
A mixture of methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacethyl]-2- pyrrolidinylmethoxy]-3-nitrobenzoate (0.917g, 1.59mmol) in THF (lOmL) and 1 N NaOH (2.38mL, 2.38mmol) was heated under reflux for 2 hr. After cooling, the mixture was poured into ice water and extracted with EtOAc. The extract was washed with brine, dried over Na2S04 and evaporated in vacuo to afford 0.826g (92%) 31 as a yellow crystalline solid. 'H-NMR (400MHz, CDC13) δ 1.91, 2.09 (IH, 3H, each m), 2.28 (3H, s), 3.54-3.62 (4H, m), 3.64 (3H, s), 4.15, 4.59 (each IH, each d, J=7.8Hz), 4.46 (IH, m), 6.66, 7.22 (each IH, each s), 6.72 (IH, d, =8.3Hz), 7.11-7.28 (4H, m), 7.46 (IH, d, =7.8Hz), 7.74 (IH, d, J=7.8Hz), 7.85 (IH, s), 8.17 (IH, dd, .7=2.0, 8.8Hz), 8.48 (IH, d, J=2.4Hz); MS (FAB) m/z 563 (M++l). Example 28
3 -amino-4- [ 1 -[3 -methoxy-4-( V' -(2-methylphenyl)ureido]phenylacetyl] -2-pyrrolidinylmethoxy] benzoic acid
Figure imgf000153_0001
A stirred mixture of 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacethyl]-2- pyrrolidinylmethoxy]-3-nitrobenzoic acid (lOlmg, 0.190mmol) and 5% Pd-C (0.247g ) in methanol was hydrogenated at 1 atin for 48 hr. Insoluble catalyst was removed, and the filtrate was evaporated in vacuo. The residue was chromatographed on silica-gel with EtOH-CHCl3 (1:1, v/v) as eluent to afford 61.0mg (60%) 32 as a crystalline material. 'H-NMR (400MHz, DMSO-c .) δ 1.95 (4H, m), 2.23 (3H, s), 3.60, 3.91, 4.10, 4.34 (5H, each m), 3.81 (3H, s), 4.88 (2H, m), 6.74 (IH, d, =8.3Hz), 6.86-7.28 (5H, m), 7.78 (IH, d, =7.8Hz), 7.99 (IH, d, J=8.3Hz), 8.30 (IH, s), 8.45, 8.55 (each IH, each s); MS (FAB) m/z 533 (M++l). Example 29
4-[2-[l-[4-[N'-(2-fluorophenyl)ureido)-3-methoxyphenylacetyl]-2-pyrrolidinyl]ethynyl] benzoic acid
Figure imgf000153_0002
To a stirred solution of benzyl 4-amino-3-methoxyphenylacetate (1.36 g, 5 mmol) in THF
(20 mL) was added 2-fluorophenyl isocyanate (561 ul, 5 mmol) and a catalytic amount of Et3N.
The resulting mixture was stirred for 3 hr. The mixture was quenched by the addition of H20 (10 mL) and extracted with EtOAc. The extract was washed with brine, dried over MgS04, and evaporated. The residue was chromatographed on silica-gel with CHC13 as eluent to give 2.06 g (q.y.) benzyl 4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenylacetate as a green oil. H-NMR
(CDC1)3 δ 3.63 (2H, s), 3.82 (3H, s), 5.14 (2H, s), 6.79-7.37 (12H, m), 8.01 (IH, d, .7=7.8 Hz),
8.09-8.14 (IH, m).
To a stirred solution of benzyl 4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenylacetate (2.04 g, 5 mmol) in THF (40 mL) was added 0.25 N NaOH (40 mL). The resulting mixture was stirred overnight The mixture was poured into 1 N HCl (10 mL), and the resulting precipitate was collected with suction. The residue was reciystallized from CHCl3-EtOH to give 1.04 g (66%) 4- [N'-(2-fluorophenyl)ureido]-3-methoxyphenylacetic acid as a white crystalline powder, mp 185- 188 (d); Η-NMR (DMSO-c .) δ 3.50 (2H, s), 3.82 (3H, s), 6.78 (IH, dd, .7=1.4 and 8.3 Hz), 6.92 (IH, d, 7=1.4 Hz), 6.95-7.01 (IH, m), 7.10-7.14 (IH, m), 7.19-7.24 (IH, m), 8.01 (IH, d, 7=8.3 Hz), 8.14-8.18 (IH, m), 8.72 (IH, s), 9.17 (IH, s); MS (FAB) m/z 319 (M++l); Anal. Calcd for C16H15N204F: C, 60.37; H, 4.75; N, 8.80. Found: C, 60.20; H, 4.82; N, 8.67.
A mixture of 4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenylacetic acid (255 mg, 0.8 mmol), 2-[2-(4-ethoxycarbonylphenyl)ethynyl]pyrrolidine (195 mg, 0.8 mmol), EDC (230 mg, 1.2 mmol), DMAP (98 mg, 0.8 mmol) in DMF (20 mL) was stirred overnight. The reaction mixture was poured into 1 N HCl and the resulting precipitate was collected with suction and dissolve in CHC13. The solution was dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (100:1, v/v) as eluent to give the desired compound, which was dissolved in THF (8 mL). 0.25 N NaOH (8 mL) was added to this solution and the resulting mixture was stirred overnight. The mixture was poured into 1 N HCl and extracted with CHC13. The extract was washed with brine, dried over MgS04, and evaporated. The residue was reciystallized from CHCl3-w-hexane to givel44 mg (37%) 33 as a pale yellow crystalline powder, mp 152-155 (d); 'H-NMR (DMSO-c .) δ 1.92-2.27 (4 H, m), 2.50 (2 H, s), 3.33-3.78 (2 H, m), 3.80 and 3.82 (total 3 H, s, each), 4.88-5.12 (1 H, m), 6.77-7.24 and 7.99-8.20 ( total 7 H, m), 7.48 and 7.52 (2 H, d, 7=8.3 Hz, each), 7.91 (2H, d, 7=8.3 Hz), 8.72 (IH, s), 9.18 (IH, s), 13.11 (IH, br-s); MS (FAB) m/z 516 (M++l); Anal Calcd for C29H26N3θ5F-2H20: C, 63.15; H, 5.48; N, 7.62. Found: C, 63.58; H, 5.15; N, 7.22. Example 30
4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]methoxy]-3- methylbenzoic acid
Figure imgf000154_0001
To a stirred solution of 4-iodo-2-methylphenol (465 mg, 1.987mmol), N-tert- butoxycarbonylprolinol (400 mg, 1.987 mmol), and Ph3P (625 mg, 2.384 mmol) in THF (7 mL) was added dropwise DIAD (0.5 mL, 2.404 mmol) at room temp, and the mixture was stirred for 13 hr at 70 °C The reaction mixture was concentrated in vacuo and the residue was chromatographed on silica-gel with n-hexane - EtOAc (9:1, v/v) as eluent to give 645.3 mg (78%) 4-[l-(tert- butoxycarbonyl)-2-ρyrrolidinyl] methoxy- l-iodo-3-methylbenzene as a pale yellow oil. 'H-NMR (400 MHz, CDC13) δ 1.47 (s, 9H), 1.83 - 1.89 (m, IH), 1.96- 2.04 (m, 3H), 2.16 (s, 3H), 3.37 - 3.43 (br m, 2H), 3.81, 3.94 (br m each, IH), 4.08 - 4.18 (m, 2H), 6.62 (br s, IH), 7.42 (s, 2H); MS (FAB) m/z 418 (M++l).
To a stirred solution of 4-[l-(/ert-butoxycarbonyl)-2-pyrrolidinyl]methoxy-l-iodo-3- methylbenzene (645.3 mg, 1.546 mmol) in DMSO (7 mL) and MeOH (6 mL) was added Et3N (0.47 mL, 3.401 mmol), Pd(OAc)2 (17.4 mg, 0.077 mmol) and l,3-bis(diphenylphosphino) propane (31.46 mg, 0.077mmol). To the stirrede mixture was induced CO gas for 10 min. The mixture was stirred at 70°C for 2 days and concentrated. The residue was diluted with EtOAc, washed with brine, and dried over Na2S0 . The solvent was removed under a reduced pressure, and the residue was chromatographed on silica-gel with w-hexane - EtOAc (5: 1, v/v) as eluent to afford 301.6 mg (56 %) methyl4-[l-(tert-butoxycarbonyl)-2-pyrrolidinyl] methoxy-3-methylbenzoate as an oil. 'H-NMR (400 MHz, CDC13) δ 1.47 (s, 9H), 1.86 - 2.10 (br m, 4H), 2.33 (s, 3H), 3.32 - 3.50 (br m, 2H), 3.88 (s, 3H), 3.88, 4.04 (br m each, IH), 4.13- 4.20 (m, 2H), 6.89 (br m, IH), 7.82 (s, IH), 7.85 (dd, 7= 2.0, 8.8 Hz, IH); MS (FAB) m/z 350 (M++l).
To a stirred solution of methyl 4-[l-(tert-butoxycarbonyl)-2-pyrrolidinyl]methyloxy-3- methylbenzoate (301.6 mg, 0.863 mmol) in CH2C12 (6 mL) was added TFA (1.2 mL) at 0°C, and the mixture was stirred at room temp for 1 hr. The solvent was removed under a reduced pressure, and the residue was made basic by the addition of IN NaOH. The mixture was extracted with CHC13. The extract was washed with brine, dried over Na2S04, and concentrated under a reduced pressure to afford 192.5 mg (90%) methyl 3-methyl-4-(2-pyrrolidinyl)methoxybenzoate as an oil. 'H-NMR (400 MHz, CDC13) δ 1.58 - 1.65 (m, IH), 1.78- 2.00 (m, 3H), 2.24 (s, 3H), 2.97 (dt, 7 = 6.8, 10.2 Hz, IH), 3.05 (dt, 7 = 5.9, 6.8 Hz, IH), 3.54 - 3.58 (m, IH), 3.87 (s, 3H), 3.92 (dd, 7 = 6.3, 9.3 Hz, IH), 3.99 (dd, 7 = 4.9, 9.3 Hz, IH), 6.81(d, 7= 8.3 Hz, IH), 7.83 (s, IH), 7.85 (dd, 7 = 2.0, 8.3 Hz, IH); MS (FAB) m/z 250 (M++l).
A mixture of pentafluorophenyl 3-methoxy-4-[Λ '-(2-methylphenyl)ureido]phenylacetate
(211.3 mg, 0.44 mmol), methyl 3-methyl-4-(2-pyrrolidinyl)methoxybenzoate (109.7 mg, 0.44 mmol), Et3N (73.6 ul, 0.528 mmol) in DMF (2 mL) was stirred for 1.5 hr at room temp. The reaction mixture was diluted with EtOAc. The solution was washed with brine and dried over Na2S04. The solvent was removed under a reduced pressure, and the residue was chromatographed on silica-gel with «-hexane - EtOAc (1:3, v/v) as eluent to afford methyl 4-[[l-[3-mefhoxy-4-[N'- (2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinyl] methoxy] -3 -methyl benzoate (241.6 mg, q.y.) as an oil. To a stirred solution of this compound in THF (4.4 mL) and H20 (1.1 mL) was added LiOH (32mg, 1.32 mmol), and the reaction mixture was stirred at room temp overnight. The mixture was diluted with CHC13, and acidified by the addition of IN HCl. The solution was washed with brine and dried over Na2S04. The solvent was removed under a reduced pressure, and the obtained crude solid was reciystallized from «-hexane-EtOAc-CHCl3-MeOH to afford 126.3 mg (54%) 34 as a white crystalline powder. IR (KBr) 1685, 1606, 1454, 1257, 752cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.87 - 2.10 (m, 4H), 2.12 (s, 3H), 2.25 (s, 3H), 3.51 - 3.71 (m, 4H), 3.76 (s, 3H), 4.08 - 4.18 (m, 2H), 4.34 (m, IH), 6.74 (dd, 7= 1.5, 9.8 Hz, IH), 6.84 (d, 7 = 1.5 Hz, IH), 6.94 (t, 7 = 6.8 Hz, IH), 7.06 (d, 7 = 8.8 Hz, IH), 7.12 (d, 7= 7.8 Hz, IH), 7.16 (d, 7 = 7.8 Hz, IH), 7.72 (s,lH), 7.76 (dd, 7 = 2.0, 8.3 Hz, IH), 7.79 (d, 7 = 7.8 Hz, IH), 7.99 (d, 7= 8.3 Hz, IH), 8.46 (s, IH), 8.54 (s, IH); MS (FAB) m/z 532 (M++l); Anal. Calcd for C30H33N3O6 l/2H2O: C, 66.65; H, 6.34; N, 7.77. Found: C, 66.16; H, 6.37; N, 7.50. Example 31 (S)-4-[l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinylmethoxy] isophthalic acid
Figure imgf000156_0001
To a solution of dimethyl 4-acetoxyisophthalate (1.52 g, 6.03 mmol) in MeOH (70 mL) was added sat. NaHC03, and the resulting mixture was stirred for 3 hr at room temp. The resulting mixture was poured into 1 N HCl and extracted with EtOAc. The extract was washed with sat. NaHC03, brine, and dried over MgS04. The solvent was evaporated to give 1.27 g (q.y.) dimethyl 4-hydroxy isophthalate as a white crystalline powder. 'H-NMR (CDC13) δ 3.91 (s, 3 H),
3.99 (s, 3 H), 7.01 (d, 1 H, 7=8.8 Hz), 8.11 (dd, 1 H, 7=2.4, 8.8 Hz), 8.55 (d, 1 H, 7=2.4 Hz)
To a stirred solution of dimethyl 4-hydroxyisophthalate (1.27 g, 6.04 mmol), (S)-N-Boc- Prolinol (1.22 g, 6.06 mmol), PPh3(1.90 g, 7.24 mmol) in THF (30 mL) was added DIAD (1.43 mL, 7.26 mmol)at room temp. The resulting stirred mixture was then heated under reflux for 15 hr. After cooling to room temp, the resulting mixture was evaporated and the residue was purified by column chromatography on silica-gel with w-hexane-EtOAc (3: 1, v/v) as eluent to give 2.10 g (88%) dimethyl (S)-4-[l-(ter/-butoxycarbonyl)-2-pyrrolidinylmethoxy]isophthalate as a yellow oil. Η-NMR (CDC13) δ 1.26 (s, 9 H), 1.85-2.16 (m, 3 H), 3.36-3.46 (m, 2 H), 3.90 (s, 6 H), 4.11-4.31 (m, 2 H), 4.95-5.02 (m, 2 H), 7.09 (dd, 1 H, 7=9.3, 24.9 Hz), 8.11-8.14 (m, 1 H), 8.46 (d, 1 H, 7=9.3 Hz)
A mixture of dimethyl (5 -4-[l-(rert-butoxycarbonyl)-2-pyrrolidinylmethoxy] isophthalate (2.01 g, 5.11 mmol), TFA (20 mL), and CH2C12 (25 mL) was stirred for 1.5 hr at room temp. The resulting mixture was concentrated in vacuo and made basic with sat. NaHC03. The mixture was extracted with CH2C12, washed with brine, dried over Na2C03, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (9: 1, v/v) as eluent to give 0.80 g (53%) dimethyl (S)-4-(2-pyrrolidinylmethoxy)isophthalate as a yellow oil. 'H-NMR (CDC13) δ 1.71 (m, 1 H), 1.89 (m, 2 H), 2.00 (m, 1 H), 3.05-3.13 (m, 2 H), 3.67 (m, 1 H), 3.90 (s, 3 H), 3.91 (s, 3 H), 4.05-4.18 (m, 2 H), 7.00 (d, 1 H, 7=8.8 Hz), 8.14 (dd, 1 H, 7=2.4, 8.8 Hz), 8.50 (d, 1 H, 7=2.4 Hz).
To a stirred solution of dimethyl (5)-4-(2-pyrrolidinylmethoxy)isophthalate (616 mg, 2.10 mmol) in DMF (13 mL) was added pentafluoro ester of 3-methoxy-4-[Λ^'-(2-methylphenyl)ureido] phenylacetic acid (1.00 g, 2.08 mmol) and Et3N (425 μl, 3.12 mmol), and the resulting mixture was stirred for 3.5 hr at room temp. The resulting mixture was diluted with EtOAc, washed with 1 N HCl, sat. NaHC03, brine, and dried over Na2S04. After removal of the solvent, the residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1, v/v) as eluent to give 1.41 g(qy.) dimethyl (5 -4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2- pyrrolidinylmethoxy] isophthalate as a yellow oil. Η-NMR (CDC13) δ 1.86-2.29 (m, 4 H), 2.30 (s, 3 H), 3.47-3.57 (m, 2 H), 3.58 (s, 3 H), 3.59 (s, 2 H), 3.83 (s, 3 H), 3.91 (s, 3 H), 4.22-4.37 (m, 2 H), 4.42-4.47 (m, 1 H), 6.44-8.46 (series of m, 12 H).
To a stirred solution of dimethyl (S)-4-[l-[3-methoxy-4-[N'-(2- methylphenyl)ureido]phenyl acetyl] -2-pyrrolidinylmethoxy]isophthalate (1.41 g, 2.39 mmol) in THF (20 mL) was added 0.25 N NaOH (20 mL), and the resulting mixture was then heated under reflux overnight. After cooling to room temp, the mixture was poured into 1 N HCl (150 mL) and the solid was collected. The crude solid was reciystallized from CHCl3-MeOH to give 140 mg (10%) 35 as a white crystalline powder. Η-NMR (CDC13) δ 1.83-2.18 (m, 4 H), 2.24 (s, 3H), 3.44-3.55 (m, 4H), 3.59 (s, 2 H), 3.80 (s, 3 H), 4.05-4.24 (m, 2 H), 4.28-4.32 (m, 1 H), 6.73-8.55 (series of m, total 12 H); MS (FAB) m/z 562 (M÷+l); Anal Calcd. for C30H31N3O8-4H2O: C, 56.87; H, 6.20; N, 6.63. Found: C, 56.73; H, 5.56: N, 6.52. Example 32
3-methoxy-4-[2-[l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-2- pyrrolidinyl] ethynyl] benzoic acid
Figure imgf000158_0001
A stirred mixture of methyl 3-methoxy-4-nitrobenzoate (1.20 g, 5.7 mmol) and 5% Pd-C
(l.Og) in EtOH (30 mL) and THF (20 mL) was hydrogenated overnight at 1 atm. The mixture was filtered and the filtrate was evaporated. The residue was chromatographed on silica-gel with CHC13 as eluent, and the solid obtained was further purified by recrystallization from CHCl3-n-hexane to give 805 mg (78%) methyl 4-amino-3-methoxybenzoate as white plates, mp 126-128; IR (KBr)
3475, 1700 cm 1; IH-NMR (CDC13) δ 3.86 (3H, s), 3.89 (3H, s), 4.21 (2H, br s), 6.66 (IH, d, 7=8.3
Hz), 7.45 (IH, d, 7=1.9 Hz), 7.54 (IH, dd, 7=1.9 and 8.3 Hz); MS (FAB) m/z 182 (M++l); Anal. Calcd for ^NO;,: C, 59.66; H, 6.12; N, 7.73. Found: C, 59.65; H, 6.15; N, 7.65.
A stirred solution of methyl 4-amino-3-methoxybenzoate (725 mg, 4 mmol) in EtOH (10 mL) was added to dil.H2S04 (prepared from H2S04 0.5 mL and H20 10 mL) at 0°C A solution of NaN02 (331 mg, 4.8 mmol) in H20 (10 mL) was added to the mixture. After stirring for 0.5 hr at the same temp, the mixture was poured into a cooled (0°C), stirred suspended solution of KI (1.83 g, 11 mmol) and cat. Cu in H20 (100 mL). The mixture was vigorously stirred for 1 hr at room temp and extracted with CHC13. The extract was washed with brine, dried over MgS04, and evaporated. The residue was chromatographed on silica-gel with «-hexane-EtOAc (10: 1, v/v) as eluent to give a mixture of methyl 4-iodo-3-methoxybenzoate and methyl 3-methoxybenzoate (748 mg) as a colorless oil.
To this oil was added Pd(PPh3)4 (150 mg, 0.13 mmol), Cul (57 mg, 0.3 mmol) and i-
Pr2NH (10 mL). The mixture was stirred for 1 hr under N2 and a solution of l-(tert- butoxycarbonyl)-2-ethynylpyrrolidine (488 mg, 2.5 mmol) in /-Pr2NH (10 mL) was added to the mixture. After stirring for 2 hr, the mixture was poured into H20 and extracted with EtOAc. The extract was washed with brine, dried over MgS04, and evaporated. The residue was chromatographed on silica-gel with w-hexane-EtOAc (5: 1, v/v) as eluent to give 431 mg (48%) 1- (tert-butoxycarbonyl)-2-[2-(2-methoxy-4-methoxycarbonylphenyl) ethynyl]pyrrolidine as a yellow oil. 'H-NMR (CDC13) δ 1.49 (9 H, s), 1.77-2.14 (4 H, m), 3.36-3.51 (2 H, m), 3.90 (3 H, s), 3.91 (3 H, s), 4.60-4.81 (1 H, m), 7.36-7.39 (1 H, m), 7.51 ( 1 H, s), 7.55-7.57 (1 H, m). To a stirred solution of l-(/ert-butoxycarbonyl)-2-[2-(2-methoxy-4-methoxycarbonyl phenyl)ethynyl]pyrrolidine (395 mg, 1.1 mmol) in CH2C12 (3 mL) was added TFA (3 mL). The resulting mixture was stirred for 1 hr. The mixture was concentrated in vacuo and made basic by the addition of sat. NaHC03, and extracted with CHC13. The extract was washed with H20, dried over MgS04, and evaporated to give 238 mg (84%) 2-[2-(2-methoxy-4-methoxycarbonylphenyl) ethynyl]pyrrolidine as a yellow oil. 'H-NMR (CDC13) δ 1.81-2.16 (4 H, m), 2.97-3.17 (2 H, m), 3.91 (6 H, s), 4.13-4.15 (1 H, m), 7.41 (1 H, d, 7=8.3 Hz), 7.51 (1 H, s), 7.56 (1 H, d, 7=8.3 Hz).
A mixture of 2-[2-(2-methoxy-4-methoxycarbonylphenyl)ethynyl]pyrrolidine (233 mg, 0.9 mmol), 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (314 mg, 1 mmol), EDC (268 mg, 1.4 mmol), DMAP (110 mg, 0.9 mmol) in DMF (10 mL) was stirred overnight. The mixture was poured into 1 N HCl and the resulting solid was collected with suction. The solid obtained was dissolved in CHC13, and the solution was dried over MgS04 and evaporated. The residue was subjected to short column chromatography on silica-gel with EtOAc as eluent to give an oil. The oil was dissolved in THF (5 mL) and 0.25 N NaOH was added to this solution with stirring. The solution was poured into ice-1 N HCl to give a solid. The solid was collected, washed with water, and air-dried. The crude solid was reciystallized from CHCl3-«-hexane to give 215 mg (44%) 36 as a white crystalline powder, mp 141-145; IR (KBr) 3338, 2956, 2935, 2875, 2593, 1711 cm '; 'H- NMR (DMSO-dg) δ 1.91-2.14 (4 H, m), 2.24 (3 H, s), 3.38-3.68 (4 H, m), 4.88-5.08 (1 H, m), 6.76-8.56 (12 H, m); MS (FAB) m/z 542 (M++1). Example 33
3-Λ^,N-dimethylamino-4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-2- pyrrolidinylmethoxy]benzoic acid
Figure imgf000159_0001
A stirred mixture of methyl 4-hydroxy-3-nitrobenzoate (3.22g, 0.0163mol) and 5% Pd-C (12.9g) in MeOH (30mL) was hydrogenated under an atmospheric pressure for 70 hr at room temp. Insoluble catalyst was removed, and the filtrate was evaporated in vacuo. The residue was chromatographed on silica-gel with EtOH-CHCl3 (1:20 , v/v) as eluent to afford 1.89g (69%) methyl 3-amino-4-hydroxybenzoate as a pale brown syrup.
A stirred mixture of methyl 3-amino-4-hydroxybenzoate (1.07g, 6.40mmol) and 5% Pd-C (2.14g) in MeOH (20mL) and 37% aq. formaldehyde (1.08mL, 0.0122mol) and 1 N HCl (6.1mL) was hydrogenated under an atmospheric pressure for 26 hr at room temp. Insoluble catalyst was removed, and the filtrate was evaporated in vacuo. The residue was chromatographed on silica-gel with EtOAc-fl-hexane (1:10, v/v) as eluent to afford 0.817g (70%) methyl 3- N, N- dimethylamino)-4-hydroxybenzoate as a syrup.
To a stirred mixture of methyl 3-(N, N-dimethylamino)-4-hydroxybenzoate (0.817g, 4.18mmol), N-ter/-butoxycarbonylprolinol (0.926g, 4.60mmol), Ph3P (1.21g, 4.60mmol) in THF (20mL) was added dropwise DIAD (95%) (0.953mL, 4.60mmol) at 0°C. The resulting mixture was heated under reflux for 41 hr. After cooling, the mixture was evaporated off in vacuo. The residue was chromatographed on silica-gel with EtOAc -n-hexane (1: 10 to 1:6, v/v) as eluent to give a syrup which was used for the subsequent reaction without further purification. This syrup was dissolved in CH2C12 (lOmL) and added TFA (lOmL). After the solution was stirred for 5 hr at room temp, the solution was evaporated in vacuo. Water was to the residue and washed with CHC13. The aqueous layer was neutralized by the addition of sat. NaHC03 and extracted with CHC13. The extract was dried over Na2S04 and evaporated in vacuo to afford 1.03g (89%) methyl 3-(N, N-dimethylamino)-4-(2-pyrrolidinylmethoxy)benzoate as a gum.
A mixture of methyl 3-(N, N-dimethylamino)-4-(2-pyrrolidinylmethoxy)benzoate (0.529g, 1.90mmol), 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (0.597g, 1.90mmol), HOBt (0.308g, 2.28mmol), 4-dimethylaminopyridine(DMAP) (23.2mg, 0.190mmol), and 1-ethyl- 3-(3-dime laminopropyl)carbodiimide (EDC) (0.437g, 2.28mmol) in DMF (lOmL) was stirred for 15 hr at room temp. The mixture was neutralized by the carefully addition of 1 N HCl and extracted with EtOAc. The extract was dried over Na2S04 and evaporated in vacuo to afford 0.607g (56%) methyl 3-N,N-dimethylamino-4-[l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]- phenylacetyl]-2-pyrrolidinyl methoxy]benzoate as a white ciystalline material.
A mixture of methyl 3-N,N-dimethyIamino-4-[l-[3-methoxy-4-[N'-(2-methylphenyl) ureido]-phenylacetyl]-2-pyrrolidinylmethoxy]benzoate (0.600g, 1.04mmol) in THF (lOmL) and 0.25 N NaOH (5mL, 1.25mmol) was stirred for 21 hr at room temp. CHC13 was added to the mixture and extracted with a mixture of water(100mL)-lN NaOH (4mL). The extract was neutralized with sat. NH4C1 and extracted withCHCl3. The extract was dried over Na2S04 and evaporated in vacuo to afford 428mg (70%) 37 as a white crystalline solid. 'H-NMR (400MHz, DMSO-c ,) δ 1.88, 1.99 and 2.11 (4H, each m), 2.24 (3H, s), 2.67 (6H, s), 3.33 (2H, m), 3.58 (2H, m), 4.05-4.32 (3H, m), 6.75 (IH, d, 7=7.3Hz), 6.92-6.95 (IH, m), 7.05 (IH, d, 7=8.3Hz), 7.11-7.17 (2H, m), 7.42 (IH, s), 7.52 (IH, d, 7=7.8Hz), 7.79 (IH, d, 7=7.8Hz), 8.00 (IH, d, 7=7.8Hz), 8.31 (IH, s), 8.46, 8.55 (each IH, each s); MS (FAB) m/z 533 (M++l). Example 34
3-fluoro-4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]methoxy] benzoic acid
Figure imgf000161_0001
To a stirred solution of 4-bromo-2-fluorophenol (217 ul, 2.002 mmol), N-tert- butoxycarbonyl prolinol (403 mg, 2.002 mmol), and Ph3P (630 mg, 2.403 mmol) in THF (7 mL) was added DIAD (477 ul, 2.423 mmol) at room temp. The resulting mixture was stirred for 6 hr at room temp and then overnight at 70 °C The mixture was concentrated in vacuo and the residue was chromatographed on silica-gel with w-hexane - EtOAc (5:1, v/v) as eluent to give 549.4 mg (73%) l-bromo-4-[l-(tert-butoxycarbonyl)-2-pynolidinyl]methoxy-3-fluorobenzene as an oil. 'H- NMR (400 MHz, CDC13) δ 1.46 (s, 9H), 1.85 (br m, IH), 1.90 - 2.10 (br s, 3H), 3.30 - 3.47 (m, 2H), 3.85, 4.04 (br s each, IH), 4.11 - 4.20 (m, 2H), 6.82 - 6.98 (m, IH), 7.13 - 7.26 (m, 2H); MS (FAB) m/z 374 (M++l).
To a stirred solution of l-bromo-4-[l-(/er/-butoxycarbonyl)-2-pyrrolidinyl] methoxy-3- fluorobenzene (549.4 mg, 1.468 mmol) in DMSO (6 mL) and MeOH (5 mL) was added Et3N (448 ul, 3.229 mmol), Pd(OAc)2 (36.2 mg, 0.161 mmol), and l,3-Λ/5(diphenylphosphino)propane (66.4 mg, 0.16 lmmol). To the mixture was induced CO gas for 10 min. The resulting mixture was stirred at 70°C for 2 days under a current of CO. After the mixture was concentrated, the residue was diluted with EtOAc. The solution was washed with brine and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel eluting with w-hexane:EtOAc (5:1, v/v) as eluent to afford 323.0 mg (62 %) methyl 4-[l-(tert- butoxycarbonyl)-2-pyrrolidinyl] methoxy-3-fluorobenzoate as a pale yellow oil. 'H-NMR (400 MHz, CDC13) δ 1.47 (s, 9H), 1.87(br s, IH), 1.95 - 2.10 (m, 3H), 3.34 - 3.44 (br m, 2H), 3.89 (s, 3H), 3.94 and 4.11 - 4.26 (br m each, 3H), 7.03 - 7.11 (m, IH), 7.75 - 7.80 (m, 2H); MS (FAB) m/z 354 (M++l).
To a stirred solution of methyl 4-[l-(terr-butoxycarbonyl)-2-pyrrolidinyl ]methoxy-3- fluorobenzoate (323.0 mg, 0.914 mmol) in CH2C12 (6.5 mL) was added TFA (1.3 mL) at 0°C, and the mixture was stirred 1.5 hr at room temp. The solvent was removed under a reduced pressure and the residue was made basic by the addition of IN NaOH. The mixture was extracted with CHC13. The extract was washed with brine, dried over Na2S04, and concentrated under a reduced pressure to afford 174.8 mg (76%) methyl 3-fluoro-4-(2-pyrrolidinyl)methoxybenzoate as a brownish oil. 'H-NMR (400 MHz, CDC13) δ 1.54 - 1.63 (m, IH), 1.76 - 2.02 (m, 3H), 2.93 - 3.07 (m, 2H), 3.57 (ddd, 7= 4.9, 6.9, 14.3 Hz, IH), 3.89 (s, 3H), 3.97 (dd, 7= 6.8, 9.3 Hz, IH), 4.04 (dd, 7= 5.0, 8.8 Hz, IH), 6.98 (t, 7= 17.6 Hz.lH), 7.73 (dd, 7= 2.0, 11.7 Hz, IH), 7.78 (dt, 7 = 2.0, 8.8 Hz,lH); MS (FAB) m/z 253 (M++l).
A mixture of pentafluorophenyl 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetate (324.5 mg, 0.676 mmol), methyl 3-fluoro-4-(2-pyrrolidinyl)methoxybenzoate (171.1 mg, 0.676 mmol), Et3N (113 ul, 0.811 mmol) in DMF (5 mL) was stirred for 2 hr at room temp. The mixture was diluted with EtOAc, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel with n-hexane:EtOAc (1:2, v/v) as eluent to afford methyl 3-fluoro-4-[[l-[3-methoxy-4-[Λr'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinyl]methoxy] benzoate (365.1 mg, 0.664 mmol) as an oil. To a stirred solution of this compound in THF (4.4 mL) and H20 (1.1 mL) was added LiOH (46.3 mg, 1.932 mmol), and the reaction mixture was stirred at room temp overnight. The mixture was diluted with CHC13 and acidified by the addition of IN HCl. The separated organic layer was washed with brine and dried over Na2S04. The solvent was removed under a reduced pressure, and the obtained crude solid was reciystallized from n-hexane-EtOAc-CHCl3 to afford 102 mg (30%) 38 as a white crystalline powder, mp 123 - 126; IR (KBr) 1616, 1537, 1282, 756cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.87 - 2.09 (m, 4H), 2.25 (s, 3H), 3.48 - 3.57 (m, 2H), 3.60 (s, 2H), 3.83 (s, 3H), 4.11 - 4.16 (m, IH), 4.24 (dd, 7= 2.9, 9.8 Hz, IH), 4.28 - 4.34 (br s, IH), 6.74 (dd, 7 = 1.5, 8.3 Hz, IH), 6.87 (s, IH), 6.94 (t, 7= 7.3 Hz, IH), 7.12 (d, 7= 7.8 Hz, IH), 7.15 (t, 7 = 8.3 Hz, IH), 7.34 (t, 7= 8.8 Hz, IH), 7.66 (dd, 7 = 2.0, 12.2 Hz, IH), 7.73 (d, 7= 9.3 Hz, IH), 7.79 (d, 7 = 8.3 Hz, IH), 7.99 (d, 7= 7.8 Hz, IH), 8.46 (s, IH), 8.55 (s, IH); MS (FAB) m/z 536 (M++l); Anal. Calcd for C29H30FN3O6 0.5H2O: C, 63.96; H, 5.74; N, 7.72; F; 3.49. Found: C, 64.11; H, 5.80; N, 7.39; F, 3.54. Example 35 4-[l-[4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenylacetyl]-2-pyrrolidinyl]methoxy-3-methoxy benzoic acid
Figure imgf000163_0001
A mixture of 4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenylacetic acid (318 mg, 1 mmol), 2-(2-methoxy-4-ethoxycarbonyl)phenoxymethylpyrrolidine (279 mg, 1 mmol), EDC (288 mg, 1.5 mmol), and DMAP (122 mg, 1 mmol) in DMF (20 mL) was stirred overnight. The mixture was poured into 1 N HCl and the resulting solid was collected with suction. The solid was dissolved in CHC13 and dried over MgSO,. After removal of the solvent, the residue was chromatographed on silica-gel with CHCl3MeOH (100: 1, v/v) as eluent to give an oil, which was dissolved in THF:MeOH (4:1, v/v, 10 mL). 0.25 N NaOH (8 mL) was added to the solution and the resulting stirred mixture was heated under reflux for 3 hr. The mixture was poured into 1 N HCl. The resulting solid was collected with suction, dissolved in CHC13, dried over MgS04, and evaporated. The residue was recrystallized from CHCl3-n-hexane-ether to give 329 mg (60%) 39 as a white crystalline powder, mp 140-144; IR (KBr) 3338, 2956, 2875, 2607, 1709 cm '; Η-NMR (CDC13) δ 1.95-2.25 (4 H, m), 3.45-4.50 (12 H, m), 6.66-8.15 (12 H, m); MS (FAB) m/z 552 (M++l). Example 36
2-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]methoxy] pyridine-5- carboxylic acid
Figure imgf000163_0002
To a stirred solution of 6-hydroxynicotinic acid (500 mg, 3.594 mmol) in benzene (8 mL) and MeOH (2 mL) was added dropwise TMSCHN2 (1.97 mL, 3.953 mmol) at 0°C, and the mixture was stirred overnight at room temp. The reaction mixture was quenched by the addition of AcOH, and the resulting mixture was concentrated in vacuo. The residue was chromatographed on silica-gel with w-hexane-EtOAc (1:3, v/v) as eluent to give 269.8 mg (49%) methyl 2- hydroxypyridine-5-carboxylate as a white crystalline powder. IR (KBr) 3062, 1657, 1654, 1612, 1435, 1300, 1113,775, 642cm '; 'H-NMR (400 MHz, CDC13) δ 3.87 (s, 3H), 6.58 (d, 7= 9.8 Hz, IH), 7.99 (dd, 7= 2.4, 9.8 Hz, IH), 8.19 (d, 7= 2.4 Hz, IH); MS (FAB) m/z 154 (M++l); Anal. Calcd for C7H7N03 1/4H20: C, 53.33; H, 4.80; N, 8.89. Found: C, 53.58; H, 4.65; N, 8.87.
To a stirred solution of methyl 2-hydroxypyridine-5-carboxylate (269.8 mg, 1.762mmol), N-/er/-butoxycarbonylprolinol (354.6 mg, 1.762 mmol), and Ph3P (554.6 mg, 2.114 mmol) in THF (10 mL) was slowly added DIAD (0.42 mL, 2.114 mmol) at room temp, and the resulting mixture was stirred for 6 hr at 70 °C The reaction mixture was concentrated and the residue was chromatographed on.silica-gel with «-hexane:EtOAc (5: 1, v/v) as eluent to give 262.5 mg (44%) methyl 2-[[l-(ter/-butoxycarbonyl)-2-pyrrolidinyl]methoxy]pyridine-5-carboxylate as an oil. 'H- NMR (400 MHz, CDC13) δ 1.47 (s, 9H), 1.85 - 1.98 (m, 4H), 3.37 (br s, 2H), 3.92 (s, 3H), 4.12 - 4.33 (br m, 2H),4.4 (brs, lH),6.75(m, 1H),8.15 (m, IH), 8.79 (m, IH); MS (FAB) m/z 337 (M++l).
To a stirred solution of methyl 2-[[l-(tert-butoxycarbonyl)-2-pyrrolidinyI]methoxy] pyridine-5-carboxylate (262.5mg, 0.870 mmol) in CH2C12 (5.3 mL) was added TFA (1.1 mL) at 0°C, and the resulting mixture was stirred at room temp for 1 hr. The solvent was removed under a reduced pressure and the residue was made basic by the addition of the IN NaOH, and extracted with CHC13. The extract was washed with brine, dried over Na2S04, and concentrated under a reduced pressure to afford 173.1 mg (94%) methyl 2-[(2-pyrrolidinyl)methoxy]pyridine-5- carboxylate as a pale yellowish oil. 'H-NMR (400 MHz, CDC13) δ 1.49 - 1.58 (ddt, 7 = 6.8, 8.8 Hz, IH), 1.72 - 1.87 (m, 2H), 1.90 - 1.99 (m, IH), 2.92 - 3.05 (m, 2H), 3.50 -3.57 (dddJ =4.4,7.3, 15.1 Hz, IH), 3.91 (s, 3H), 4.23 (dd, 7= 7.8, 10.7 Hz, IH), 4.38 (dd, 7 = 4.4, 10.7 Hz, IH), 6.78 (d, 7 = 8.8 Hz, IH), 8.15 (dd, 7= 2.4, 8.8 Hz, IH), 8.80 (d, 7 = 2.4 Hz, IH); MS (FAB) m/z 237 (M++l).
A mixture of pentafluorophenyl 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetate (351.7 mg, 0.732 mmol), methyl 2-[(2-pyrrolidinyl)methoxy]pyridine-5-carboxylate (173.0 mg, 0.732 mmol), Et3N (122.4 μl, 0.878 mmol) in DMF (5.2 mL) was stined for 1 hr at room temp. The mixture was diluted with EtOAc, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel with n- hexane:EtOAc (1:5, v/v) as eluent to afford methyl 2-[[l-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetyl]-2-pyrrolidinyl]methoxy] pyridine-5-carboxylate (338.4 mg, 87%) as an oil. To a stirred solution of this compound in THF (5.6 mL) and H20 (1.4 mL) was added LiOH (45.7 mg, 1.91 mmol), and the reaction mixture was stirred at room temp overnight. The mixture was diluted with CHC13, and treated with sat. NH4C1, washed with brine, dried over Na2S04. The solvent was removed under a reduced pressure, and the obtained crude solid was recrystallized from w-hexane-Et20-CHCl3-MeOH to afford 193.8 mg (59%) 40 as a white crystalline powder, mp 125 - 128; IR (KBr) 1716, 1600, 1533, 1255cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.67 - 2.03 (m, 4H), 2.50 (s, 3H), 3.33 - 3.42 (m, IH), 3.52 (m, 2H), 3.58 (d, 7= 4.4 Hz, IH), 3.83 (s, 3H), 4.27 - 4.31 (m, 2H), 4.42 - 4.47 (m, IH), 6.73 (d, 7= 7.8 Hz, IH), 6.87 - 6.95 (m, 3H), 7.11 - 7.17 (m, 2H), 7.79 (d, 7 = 8.3 Hz, IH), 7.99 (d, 7 = 8.3 Hz, IH), 8.14 (dd, 7= 2.0, 8.8 Hz, IH), 8.46 (s, IH), 8.56 (s, IH), 8.69 (d, 7 = 2.0 Hz, IH), 13.06 (br s, IH); MS (FAB) m/z 519 (MXl); Anal. Calcd for C28H30N4O6 l/2H2O: C, 63.75; H, 5.92; N, 10.62. Found: C, 63.61; H, 5.94; N, 10.27. Example 37 3-methoxy-4-[2-[4-[ΛT-(2-methylphenyl)ureido]benzyl]-4-thiazolyl]methoxybenzoic acid
Figure imgf000165_0001
To a stirred solution of phosphorous pentasulfide (27.4 g, 123.34 mmol) and freshly prepared anhydrous Na2S (4.8 g, 61.67 mmol) in THF (200 mL) was added p-nitrobenzyl cyanide
(2.0 g, 12.33 mmol) at room temp. The resulting mixture was stirred for 17 hr at room temp. The mixture was diluted with EtOAc and washed with 10% K^O^ The aqueous layer was extracted with CH2C12. The extract was dried over Na2S04 and concentrated in vacuo. The residue was chromatographed on silica-gel with w-hexane:EtOAc (5: 1 to 2: 1, v/v) as eluent to give 1.53g (64%) 4-nitrobenzyl carbothioamide as a pale yellow crystalline material. IR (KBr) 1529, 1446, 1326, 1315, 858cm 1; 'H-NMR (400 MHz, CDC13) δ 4.15 (s, 2H), 7.51 (d, 7 = 8.3 Hz, 2H), 8.24 (d, 7 = 8.8 Hz, 2H); MS (FAB) m/z 197 (M++l); Anal. Calcd for C8H8N202S: C, 48.97; H, 4.11; N, 14.28; S; 16.34. Found: C, 48.69; H, 4.06; N, 14.07; S; 16.10.
To a stirred solution of 4-nitrobenzylcarbothioamide (502.0 mg, 2.558 mmol) in EtOH (5 mL) was added l,3-dichloro-2-propanone (649.6 mg, 5.16 mmol) and the mixture was heated under reflux for 1 hr. The mixture was concentrated and the residue was diluted with CHC13. The solution was washed with IN NaOH, brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel with «-hexane:EtOAc (4: 1, v/v) as eluent to afford 495.2 mg (72 %) 4-[2-(4-nitrobenzyl)thiazolyl]methyl chloride as a pale yellow oil. 'H-NMR (400 MHz, CDC13) δ 4.43 (s, 2H), 4.68 (s, 2H), 7.23 (s, IH), 7.49 (d, 7 = 8.8 Hz, 2H), 8.20 (d, 7= 8.8 Hz, 2H); MS (FAB) m/z 269 (M++l).
To a stirred solution of vanillic acid ethyl ester (308.0 mg, 1.570 mmol) and MeONa (89 mg, 1.570 mmol) in MeOH (6.5 mL) was added a solution of 4-[2-(4-nitrobenzyl)thiazolyl] methyl chloride (211.0 mg, 0.785 mmol) in MeOH (1.4 mL) at 0°C. The resulting mixture was stirred at room temp for 16 hr, and heated under reflux for 1 day. The solvent was removed under a reduced pressure and the residue was extracted with CHC13. The extract was washed with H20, brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel with M-hexane:EtOAc (2: 1, v/v) as eluent to afford 201.7 mg (60 %) ethyl 3-methoxy-4-[2-(4-nitrobenzyl)-4-thiazolyl]methoxybenzoate as a pale yellow oil. 'H-NMR (400 MHz, CDC13) δ 1.39 (t, 7 = 7.3 Hz, 3H), 3.93 (s, 3H), 4.36 (q, 7= 7.3 Hz, 2H), 4.44 (s, 2H), 5.31 (s, 2H), 6.97 (d, 7= 8.3 Hz, IH), 7.28 (s, IH), 7.48 (d, 7= 8.8 Hz, 2H), 7.57 (d, 7 = 2.0 Hz, IH), 7.64 (dd, 7 = 2.0, 8.3 Hz, IH), 8.20 (d, 7= 8.8 Hz, 2H); MS (FAB) m/z 429 (M++l).
A stirred solution of ethyl 3-methoxy-4-[2-(4-aminobenzyl)-4-thiazolyl methoxybenzoate (201.7 mg, 0.471 mmol) and 5% Pd/C (40 mg) in EtOH (8 mL) was hydrogenated at 1 atm for 24 hr. The mixture was filtered and the filtrate was concentrated. The residue was chromatographed on silica-gel with «-hexane:EtOAc (1: 1, v/v) as eluent to afford 87.8 mg (47%) ethyl 3-methoxy-4- [2-(4-aminobenzyl)-4-thiazolyl]methoxybenzoate as a yellowish ciystalline powder. 'H-NMR (400 MHz, CDC13) δ 1.38 (t, 7= 7.3 Hz, 3H), 3.93 (s, 3H), 4.21 (s, 2H), 4.35 (q, 7 = 7.3 Hz, 2H), 5.30 (s, 2H), 6.66 (dd, 7= 2.0, 6.4 Hz, 2H), 6.97 (d, 7= 8.3 Hz, IH), 7.09 (d, 7= 8.3 Hz, 2H), 7.18 (s, IH), 7.56 (d, 7= 2.0 Hz, IH), 7.64 (dd, 7= 2.0, 8.3 Hz, IH); MS (FAB) m/z 399 (M++1).
To a solution of ethyl 3-methoxy-4-[2-(4-aminobenzyl)-4-thiazolyl]methoxybenzoate (87.8 mg, 0.220 mmol) in THF (2.0 mL) was added triethylamine (30.5 ul, 0.220 mmol) and o- tolyl isocyanate (30 μl), and the reaction mixture was stirred at room temp for 21 hr. The reaction mixture was poured into ice-water and the resulting precipitates filtered off. The filtrate was extracted with CHC13, washed with H20, and brine. The extract was dried over Na2S04. The solvent was removed under a reduced pressure to afford 110.4 mg (94 %) ethyl 3-methoxy-4-[2-[4- [N'-(2-methylphenyl) ureido]benzyl]-4-thiazolyl] methoxybenzoate as a pale yellow crystalline powder. IH-NMR (400 MHz, CDC13) δ 1.38 (t, 7 = 7.3 Hz, 3H), 2.28 (s, 3H), 3.92 (s, 3H), 4.28 (s, 2H), 4.35 (q, 7= 7.3 Hz, 2H), 5.29 (s, 2H), 6.20(s, IH), 6.47 (s, IH), 6.97 (d, 7= 8.8 Hz, IH), 7.20 (s, IH), 7.24 (s, 2H), 7.27 (s, 2H), 7.33 (d, 7= 8.3 Hz, 2H), 7.49 (d, 7= 7.3 Hz, IH), 7.56 (d, 7 = 2.0 Hz, IH), 7.63 (dd, 7 = 2.0, 8.3 Hz, IH); MS (FAB) m/z 532 (M++l).
To a stirred solution of ethyl 3-methoxy-4-[2-[4-[N'-(2-methylphenyl)ureido] benzyl]-4- thiazolyl]methoxybenzoate in THF (1.6 mL) and H20 (0.4 mL) was added LiOH (6.0 mg, 0.249 mmol), and the mixture was stirred at room temp for 1 hr, and heated under reflux for 8 hr. The mixture was concentrated and diluted with CHC13. The solution was made basic by the addition of IN NaOH. The aqueous extract was acidified by the addition of IN HCl and extracted with CHC13. The extract was washed with brine and dried over Na2S04. The solvent was removed under a reduced pressure and the obtained crude solid was recrystallized from «-hexane-EtOAc-EtOH to afford 59.6 mg (57%) 41 as a white crystalline powder, mp 243 - 245; IR (KBr) 3282, 1685, 1637, 1600, 1554, 1516, 1278, 1234, 763, 748cm '; Η-NMR (400 MHz, DMSO-c .) δ 2.27 (s, 3H), 3.83 (s, 3H), 4.30 (s, 2H), 5.21 (s, 2H), 6.97 (t, 7= 7.3 Hz, IH), 7.15 - 7.24 (m, 3H), 7.29 (d, 7 = 8.8 Hz, 2H), 7.47 (d, 7 = 8.3 Hz, 2H), 7.50 (s, IH), 7.58 (d, 7= 8.3 Hz, IH), 7.62 (s, IH), 7.86 (d, 7 = 7.8 Hz, IH), 7.97 (s, IH), 9.09 (s, 1H),12.70 (br s, IH); MS (FAB) m/z 504 (NT+1); Anal. Calcd for C27H25N305S-1/4H20: C, 63.83; H, 5.06; N, 8.27. Found: C, 63.74; H, 4.99; N, 8.10. Example 38
4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-methyl-2-pyrrolidinyl] methoxy]- 3-nitrobenzoic acid
Figure imgf000167_0001
To a stirred solution of the N-/ert-butoxycarbonylproline (6.00g, 0.0279mol) in
MeOH:benzene (1:4, v/v) was added dropwise 2.0 M-w-hexane solution of TMSCHN2 (16.7mL,
0.0334mol) at room temp. After the resulting solution was stirred for lhr at room temp, the mixture was evaporated off in vacuo to afford 6.39g (100%) N-fe -butoxycarbonylproline methyl ester as a yellow syrup. Η-NMR (CDC13) δ 1.41 (s, 9H), 1.85-1.98 (m, 4H), 2.21-2.28 (m, 2H),
3.72 (s, 3H), 4.29 (m, IH).
To a stirred solution of diisopropylamine (2.02mL, 0.0144mol) in THF (30mL) was added dropwise 1.59 M w-hexane solution of «-BuLi (9.06mL, 0.0144mol) at minus 78°C for over 5 min. The resulting solution was stirred for 20 min at minus 78 °C. To the solution was added dropwise N-ter/-butoxycarbonylproline methyl ester (3.00g, 0.013 lmmol) in THF (30mL) at minus 78°C for over 5 min. The resulting solution was stirred for 10 min at minus 78°C To the solution was added dropwise Mel (0.900mL, 0.0144mol) at minus 78°C. The resulting solution was stirred for 30 min at minus 78°C The solution was quenched by the addition of sat. NH4C1. The resulting mixture was extracted with CHC13. The extract was washed with water, dried over Na2S04, and evaporated in vacuo to afford 3.20g (q.y.) N-tert-butoxycarbonyl-2-methylproline methyl ester as a yellow syrup. 'H-NMR (CDC13) δ 1.33 (s, 9H), 1.38 (s, 3H), 1.72-2.20 (m, 4H) 3.27-3.59 (m, 2H) 3.63 (d, 7=6.3Hz, 3H).
To a stirred solution of N-tert-butoxycarbonyl-2-methylproline methyl ester (3.20g, 0.013 lmol) in THF (20mL) was added IN NaOH (15.7mL) at room temp. After the resulting mixture was stirred for 24 hr, the mixture was diluted with water and washed with EtOAc. The separated aqueous layer was acidified by the addition of IN HCl, and extracted with EtOAc. The extract was dried over Na2S04 and evaporated in vacuo to afford 1.71g(57%) N-tert- butoxycarbonyl-2-methylproline as a yellow syrup. 'H-NMR (CDC13) δ 1.42 (s, 9H), 1.48 (s, 3H), 1.88-2.31 (m, 4H), 3.34-3.57 (m, 2H), 9.35 (br s, IH)
To a stirred solution of N-tert-butoxycarbonyl-2-methylproline (l. lOg, 4.80mmol) in THF (20mL) was added dropwise BH3-SMe2 (0.546mL, 5.76mmol) at room temp. After the resulting mixture was stirred for 6 hr at 80°C, the mixture was evaporated in vacuo. The residue was diluted with MeOH, washed with n-hexane (3x), and evaporated in vacuo to afford 0.648g (60%) 7\f- e - -butoxycarbonyl-2-hycuOxymethyl-2-methylpyrrolidine as a yellow syrup. 'H-NMR (CDC13) δ 1.47 (s, 9H), 1.76-2.05 (m, 4H), 3.28-3.48 (m, 2H), 3.66 (m, 2H, d).
To a stirred solution of N-ter/-butoxycarbonyl-2-hydroxymethyl-2-methylpyrrolidine (0.648g, 3.01mmol), methyl 4-hydroxy-3-nitrobenzoate (0.593g, 3.01mmol), and Ph3P (0.868g, 3.31mmol) in THF (lOmL) was added dropwise DIAD (95%) (0.686mL, 3.31mmol) at 0°C After the resulting mixture was stirred for 24hr at 80 °C, the mixture was evaporated in vacuo. The residue was diluted with CH2C12 (5mL) and added TFA (5mL). After the resulting mixture was stirred for 2hr at room temp, the mixture was evaporated in vacuo. The residue was diluted with 0.5N HCl and extracted with CHC13. The aqueous layer was neutralized with sat. NaHC03, and extracted with CHC13. The extract was dried over Na2S04 and evaporated in vacuo to afford 0.188g (21%) methyl 3-nitro-4-(2-methyl-2-pyrrolidinylmethoxy) benzoate as a yellow syrup.
A mixture of methyl 3-nitro-4-(2-methyl-2-pyrrolidinylmethoxy)benzoate (0.188g, 0.920mmol), 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (0.289g, 0.920mmol), HOBt (0.149g, 1. lOmmol), DMAP (11.2mg, 0.0920mmol) and EDC (0.21 lg, 1. lOmmol) in DMF (5mL) was stirred for 14hr at room temp. EtOAC was added to the mixture and the solution was washed successively with 0.5 N HCl, sat. NaHC03, and brine. The organic layer was dried over Na2S04 and evaporated in vacuo to afford 0.489g (q.y.) methyl 4-[[l-[3-methoxy-4-[Λr'-(2- methylphenyl)ureido] phenylacetyl]-2-methyl-2-pyrrolidinyl]methoxy]-3-nitrobenzoate as a yellow crystalline material. 'H-NMR (CDC13) δ 1.26 (d, 7=5.9Hz), 1.85-4.50 (m, lOH), 2.30 (s, 3H), 3.67 (s, 2H), 3.92 (s, 3H), 6.36 (s, 2H), 6.75-7.52 (m, 7H), 8.02 (d, 7=7.8Hz, IH), 8.15 (d, 7=8.8Hz, IH), 8.47 (s, IH). A stirred mixture of 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2- methyl-2-pyrrolidinyl]methoxy]-3-nitrobenzoate (0.489g, 0.828mmol) in MeOH (5mL) and IN NaOH (1.24mL) was heated under reflux for 2hr After cooling, the mixture was diluted with water and extracted with CHC13. The aqueous layer was acidified with IN HCl, and extracted with CHC13. The extract was dried over Na2S04 and evaporated in vacuo to afford 0.366g (99%) 42 as a yellow crystalline material. Example 39
4-[4-hydroxy-l-[3-methoxy-4-[Λf'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinylmethoxy]- 3- methoxybenzoic acid
Figure imgf000169_0001
A stirred mixture of 4-[4-benzyloxy-l-[3-methoxy-4-[/V'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinylmethoxy] -3 -methoxybenzoate (440 mg, 0.645 mmol) and 5% Pd/C
(400 mg) in AcOH:EtOH (1 : 1, v/v, 100 mL) was hydrogenated at 1 atm for 5 hr. The mixture was filtered to remove the catalyst and the filtrate was concentrated in vacuo. The residue was chromatographed on silica-gel with CHCl3:EtOH (10: 1, v/v) as eluent to give 90 mg (24%) ethyl 4- [4-hydroxy-l-[3-methoxy-4-[/V'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinylmethoxy]-3- mefhoxybenzoate as a pale yellow oil. Η-NMR (CDC13) δ 1.39 (3 H, t, 7= 7.3 Hz), 2.04-2.37 (total 5 H, m), 3.44-4.70 (16 H, series of m), 6.63 (1 H, s), 6.70-6.80 (2 H, m), 6.84 (1 H, d, 7= 8.3 Hz), 7.11 (1 H, t, 7 = 7.8 Hz), 7.20-7.24 (3 H, m), 7.45 (1 H, d, 7= 2.0 Hz), 7.59 (2 H, dd, 7 = 8.3, 2.0 Hz), 8.01 (1 H, d, 7 =7.8 Hz).
A stirred mixture of ethyl 4-[4-hydroxy-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinylmethoxy]-3-methoxybenzoate (90 mg, 0.152 mmol) in 0.25 N NaOH (5 mL, 1.25 mmol) and THF (5 mL) was heated under reflux overnight. The mixture was poured into ice-1 N HCl (200 mL). The precipitate was collected with suction and recrystallized from CHCl3-MeOH-«-hexane to give 40 mg (47%) 43 as a colorless amorphous solid. 'H-NMR (DMSO- c .) δ 1.92-2.11 (2 H, m), 2.24 (3 H, s), 3.31-5.07 (14 H, series of m), 6.73 (1 H, d, 7 = 8.3 Hz), 6.84 (1 H, s), 6.93 (1 H, t, 7 = 7.8 Hz), 7.01-7.17 (3 H, m), 7.44 (1 H, s), 7.52 (1 H, d, 7 = 8.8 Hz), 7.79 (1 H, d, 7= 8.3 Hz), 7.99 (1 H, d, 7 = 7.8 Hz), 8.46 (1 H, s), 8.55 (1 H, s), 12.67 (1 H, br s); MS (FAB) m/z 564 (M++l). Example 40
(25,47?)-3 -amino-4-[4-hydroxy-l -[3 -methoxy-4-[N' -(2-methylphenyl)ureido]phenylacetyl] -2- pyrrolidinyl] methoxybenzoic acid
Figure imgf000170_0001
To a stirred solution of (2S,4Λ)-4-benzyloxy-l-(te Nbutoxycarbonyl)-2-prolinol (891 mg,
2.9 mmol), methyl 4-hydroxy-3-nitrobenzoate (572 mg, 2.9 mmol),and PPh3 (839 mg, 3.2 mmol) in THF (6 mL) was added DIAD (630 mL, 3.2 mmol) and the mixture was heated under reflux overnight. After removal of the solvent, the residue was chromatographed on silica-gel with n- hexane:EtOAc (1:1) and toluene:EtOAc (10: 1, v/v) as eluent to give 700 mg (50%) methyl (2S,4R)-4-[4-benzyloxy-l-(/er/-butoxycarbonyl)-2-pyrrolidinyl]methoxy-3-nitrobenzoate as a pale yellow oil.
To a stirred solution of methyl (2S, 4R)-4-[4-benzyloxy-l-(te -butoxycarbonyl)-2- pyrrolidinyl] methoxy-3-nitrobenzoate (681 mg, 1.4 mmol) in CH2C12 (2 mL) was added TFA (2 mL), and the resulting mixture was stirred for 2 hr. After the reaction mixture was concentrated, the residue was made basic by the addition of sat. NaHC03 and extracted with CHC13. The extract was washed with H20, dried over MgS04, and evaporated to give 511 mg (95%) methyl (2S,4Λ)-4- [4-benzyloxy-2-pyrrolidinyl]methoxy-3-mtrobenzoate as a yellow oil.
A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (409 mg, 1.3 mmol), methyl (2S,4R)-4- (benzyloxy-2-pyrrolidinyl)methoxy-3-nitrobenzoate (502 mg, 1.3 mmol), EDC (383 mg, 2 mmol), and DMAP (159 mg , 1.3 mmol) in DMF (20 mL) was stirred for 3 days. The mixture was poured into 1 N HCl and the resulting precipitate was collected with suction. The residue was dissolved in CHC13 and dried over MgS0 . After removal of solvent, the residue was chromatographed on silica-gel with CHCl3:MeOH (200:1, v/v) as eluent to give 680 mg (91%) methyl (2S,4Λ)-4-[4-benzyloxy-l-[3-methoxy-4-[Λf'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinyl]methoxy-3-nitrobenzoate as a white amorphous solid.
A solution of methyl (2S,4R)-4- [4-benzyloxy-l-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetyl]-2-pyrrolidinyl]methoxy-3-nitrobenzoate (676 mg, 0.99 mmol) and 5% Pd-C (1 g) in EtOH: AcOH (1: 1, v/v, 30 mL) was hydrogenated at 1 aim for 6 hr. The mixture was filtered and the filtrate was evaporated to give an oil, which was made basic by the addition of sat. NaHC03. The mixture was extracted with EtOAc. The extract was washed with brine, dried over MgS04,.and evaporated. The residue was recrystallized from CHCl3-EtOH-«-hexane as eluent to give 120 mg (22%) 44 as a pale yellow crystalline powder. MS (FAB) m/z 549 (M++l) Example 41 4-[[4-fluoro-l-[3-methoxy-4-[/* '-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] methoxy]-
3 -methoxybenzoic acid
Figure imgf000171_0001
A stirred mixture of ethyl 4-[4-benzyloxy-l-(teA-/-butoxycarbonyl)-2-pyrrolidinyl]methoxy-
3 -methoxybenzoate (1.189 g, 2.449 mmol) and 5% Pd-C (240 mg) in EtOH (10 mL) was hydrogenated overnight at room temp. The mixture was filtered to remove the catalyst and the filtrate was concentrated in vacuo to give ethyl 4-[l-(tert-butoxycarbonyl)-4-hydroxy-2- pyrrolidinyl]methoxy-3-methoxybenzoate (735.3 mg, 76%) as a pale yellow oil. To a stirred cold (minus 78°C) solution of DAST (0.491 mL, 3.718 mmol) in CH2C12 (7.4 mL) was added dropwise a solution of this compound in CH2C12 (2mL), and the resulting mixture was stirred overnight. The mixture was quenched with water and extracted with CHC13. The extract was washed with brine and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel with «-hexane:EtOAc (3: 1, v/v) as eluent to afford 418.7 mg (57%) ethyl 4-[l-(/er/-butoxycarbonyl)-4-fluoro-2-pyrrolidinyl]methoxy-3-methoxybenzoate as an oil. 'H-NMR (400 MHz, CDC13) δ L39 (t, 7 = 7.3 Hz, 3H), 1.49 (s, 9H), 2.16 (br m, IH), 2.58 (dd, 7 = 15.6, 19.0 Hz, IH), 3.60 - 3.75 (m, 2H), 3.91 (s, 3H), 3.97 (t, 7 = 9.3 Hz, IH), 4.35 (q, 7 = 7.3 Hz, 2H), 4.33 - 4.53 (m, 2H), 5.25 (d, 7 = 52.7 Hz, IH), 7.04 (dd, 7= 7.8, 56.2 Hz, IH), 7.55 (s, IH), 7.65 (br s, IH); MS (FAB) m/z 398 (M++l).
To a stirred solution of ethyl 4-[l-(/e^-butoxycarbonyl)-4-fluoro-2-pyrrolidinyl]methoxy-
3-mefhoxybenzoate (482.2 mg, 1.213 mmol) in CH2C12 (10.0 mL) was added TFA (1.9 mL) at 0°C, and the mixture was stirred at room temp for 2 hr. The solvent was removed under a reduced pressure and the residue was made basic by the addition of IN NaOH and extracted with CHC13. The extract was washed with brine, dried over Na2S04, and concentrated under a reduced pressure to afford 348.7 mg (97%) ethyl 4-(4-fluoro-2-pyrrolidinyl)methoxy-3-methoxybenzoate as a brownish oil. 'H-NMR (400 MHz, CDC13) δ 1.39 (t, 7= 6.8 Hz, 3H), 1.97 (ddt, 7= 1.5, 5.4, 14.7 Hz,lH), 2.27 (dddd, 7 = 5.9, 8.8, 14.7, 32.7 Hz,lH), 3.02 (ddd, 7 = 3.9, 13.1, 35.2 Hz, IH), 3.36 (dd, 7 = 12.7, 21.5 Hz,lH), 3.65 (m, IH), 3.90 (s, 3H), 4.09 (m, IH), 4.35 (q, 7= 6.8 Hz, 2H), 5.17, 5.31 (br m each, IH), 6.90 (d, 7 = 8.3 Hz, IH), 7.75 (d, 7 = 2.0 Hz, IH), 7.65 (dd, 7= 2.0, 8.3 Hz, IH); MS (FAB) m/z 298 flVr+l).
A mixture of pentafluorophenyl 3-methoxy-4-[N'-(2-methylphenyl)ureido ]phenylacetate (404.0 mg, 0.840 mmol), ethyl 4-(4-fluoro-2-pyrrolidinyl)methoxy-3-methoxybenzoate (250.0 mg, 0.840 mmol), Et3N (141μl, 1.009 mmol) in DMF (4.0 mL) was stirred for 1 hr at room temp. The mixture was diluted with EtOAc, washed with water, brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the residue was chromatographed on silica-gel with n- hexane:EtOAc (1:3, v/v) to afford 502 mg (q.y.) of ethyl 4-[[4-fluoro-l-[3-methoxy-4-[N'-(2- methylphenyl)ureido] phenylacetyl]-2-pyrrolidinyl]methoxy]-3-methoxybenzoate as a yellow oil. To a stirred solution of this compound in THF (8.0 mL) and H20 (2.0 mL) was added LiOH (60.4mg, 2.520 mmol), and the mixture was stirred at room temp, overnight, and 50CC for 1 day. The mixture was diluted with CHC13, and extracted with IN NaOH. The aqueous layer was acidified by the addition of IN HCl and extracted with CHC13. The extract was washed with brine and dried over Na2S04. The solvent was removed under a reduced pressure and the obtained crude solid was recrystallized from EtOAc-CHCl3-EtOH-n-hexane to afford 294.8 mg (62%) 45 as a white crystalline powder. IR (KBr) 2958, 2937, 1687, 1601, 1531, 1454, 1419, 1267, 1214,
1029cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.86 - 2.09 (m, 5H), 2.06 (s, 3H), 2.25 (s, 3H), 3.47 - 3.67 (m, 6H), 3.76 (s, 3H), 4.05 - 4.12 (m, 2H), 4.30 - 4.31 (m, IH), 6.51 (s, IH), 6.55 (s, IH), 6.73 - 6.95 (m, 2H), 7.11 - 7.17 (m, 2H), 7.64 (s, IH), 7.79 (d, 7 = 7.8 Hz, IH), 7.99 (d, 7 = 7.8 Hz, IH), 8.47 (s, IH), 8.55 (s, IH); MS (FAB) m/z 566 (M++l); Anal. Calcd for C30H32FN3O7-l/2H2O: C, 62.71; H, 5.79; F, 3.31; N, 7.31. Found: C, 63.13; H, 6.17; F, 3.12; N, 7.04.
Example 42
3-acetylamino-4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl methoxy]benzoic acid
Figure imgf000173_0001
A solution of 3-amιno-4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureιdo] phenylacetyl]-2- pyrrolιdιnylmethoxy]benzoιc acid (130mg, 0 244mmol) and DMAP (2 9mg, 0 0244mmol) in pyndine (5mL) and acetic anhydnde (5mL) was stirred for 2 hr at room temp The mixture was evaporated off m vacuo (exess acetic anhydnde was azeotropically removed with toluene) Water was added to the residue, and extracted with CHC13 The extract was dned over Na2S04 and evaporated in vacuo The residue was chromatographed on silica-gel with MeOH CHC13 (1 15 to 1 1, v/v) as eluent to afford 29mg (21%) 46 as a white crystalline matenal 'H-NMR (DMSO-c .) δ 1 80-2 30 (m, 4H), 2 04 (s, 3H), 2 26 (s, 3H), 3 33(s, 3H), 3 40-4 80 (m, 7H), 6 59 (s, IH), 6 74(d, 7=8 3Hz, IH), 6 79 (d, 7=8 8Hz, IH), 7 07-7 57 (m, 6H), 7 75 (d, 7=8 8Hz, IH), 8 07 (d, 7=8 3Hz, IH), 8 41 and 8 96 (each s, each IH), MS (FAB) m/z 575 (M++l) Example 43 3-chloro-2-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureιdo]phenylacetyl]-2-pyrrolιdιnyl] methoxy] pyndιne-5-carboxylιc acid
Figure imgf000173_0002
To a stirred solution of 3-chloro-2-hydroxypyndιne-5-carboxyhc acid (1 g, 5 762 mmol) in benzene (16 mL) and MeOH (4 mL) was added dropwise TMSCHN2 (3 17 mL, 6 338 mmol) at
0°C, and the resulting mixture was stirred overnight at room temp The reaction mixture was quenched by the addition of AcOH and the mixture was evaporated off The residue was suspended in water and precipitate was collected The crude solid was washed with Et20, and dned under a reduced pressure to give 728 1 mg (67%) methyl 3-chloro-2-hydroxypyndιne-5- carboxylate as a white crystalline powder IR (KBr) 1655, 1282, 1245, 769cm ', 'H-NMR (400 MHz, DMSO-c .) δ 3 79 (s, 3H), 8 01 (s, IH), 8 06 (s, IH), MS (FAB) m/z 188 (M++1), Anal Calcd for C7IL,C1N03 C, 44 82, H, 3 22, Cl, 18 90, N, 7 47 Found C, 44 74, H, 3 22, Cl, 19 00, N, 7 34
To a stirred solution of methyl 3-chloro-2-hydroxypyndιne-5-carboxylate (300 mg, 1 599 mmol), N-ter/-butoxycalbonylprohnol (321 9 mg, 1 599 mmol), and Ph3P (503 mg, 1 919 mmol) in THF (3 mL) was slowly added DIAD (378 μl, 1.919 mmol) at room temp, and the mixture was stirred for 13 hr at 70 °C The mixture was concentrated and the residue was chromatographed on silica-gel with n-hexane - EtOAc (3: 1, v/v) as eluent to give 235.6 mg (40%) methyl 3-chloro-2- [[l-( e^-butoxycarbonyl)-2-pyrrolidinyl]methoxy]pyridine-5-carboxylate as a pale yellowish oil. 'H-NMR (400 MHz, CDC13) δ 1.46 (s, 9H), 1.87 (m, IH), 2.05 (br s, 3H), 3.43 (br s, 2H), 3.92 (s, 3H), 4.17, 4.26 (br s each, IH), 4.45 - 4.51 (m, IH), 4.50 (s, IH), 8.21 (s, IH), 8.67 (d, 7 = 2.0 Hz, IH); MS (FAB) m/z 371 (M++l).
To a stirred solution of methyl 3-chloro-2-[[l-(ter >utoxycarbonyl)-2- pyrrolidinyl] methoxy] pyridine-5-carboxylate (235.6mg, 0.635 mmol) in CH2C12 (5.0 mL) was added TFA (1.0 mL) at 0°C, and the reaction mixture was stirred at room temp for 2 hr. The solvent was removed under a reduced pressure. The residue was made basic by the addition of IN NaOH and extracted with CHC13. The extract was dried over Na2S04, concentrated under a reduced pressure to afford 172.3 mg (q.y.) methyl 3-chloro-2-[(2-pyrrolidinyl)methoxy]pyridine-5- carboxylate as a pale yellowish oil. 'H-NMR (400 MHz, CDC13) δ 1.55 - 1.63 (m, IH), 1.76 - 1.99 (m, 3H), 2.93 - 2.99 (m, IH), 3.02 - 3.08 (m, IH), 3.57 -3.62 (m, IH), 3.92 (s, 3H), 4.33 (dd, 7 = 7.3, 10.7 Hz, IH), 4.44 (dd, 7= 4.4, 10.7 Hz, IH), 8.21 (d, 7= 2.0 Hz, IH), 8.67 (d, 7= 2.0 Hz, IH); MS (FAB) m/z 111 (M++l).
The mixture of pentafluorophenyl 3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetate (317.0 mg, 0.660 mmol), methyl 3-chloro-2-[(2-pyrrolidinyl)methoxy] pyridine-5- carboxylate (172.0 mg, 0.635 mmol), Et3N (105 ul, 0.756 mmol) in DMF (2.0 mL) was stirred for 1 hr at room temp. The mixture was diluted with EtOAc, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure to afford methyl 3-chloro-2-[[l-[3- methoxy-4-[Λr-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinyl]methoxy]pyridine-5- carboxylate as a brownish oil. To a stirred solution of this compound in THF (6.0 mL) and H20 (2.0 mL) was added LiOH (45.3 mg, 1.89 mmol), and the reaction mixture was stirred for 5 hr at room temp. The mixture was diluted with «-hexane and extracted with IN-NaOH. The aqueous layer was acidified by the addition of IN HCl and extracted with CHC13. The extract was washed with brine, dried over Na2S04. The solvent was removed under a reduced pressure and the obtained crude solid was recrystallized from «-hexane-EtOAc-EtOH to afford 242.2 mg (70%) 47 as an orange crystalline powder, mp 122 - 125; IR (KBr) 3354, 1709, 1593, 1535, 1454, 1257cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.67 - 2.03 (m, 4H), 2.50 (s, 3H), 3.33 - 3.42 (m, IH), 3.52 (m, 2H), 3.58 (d, 7= 4.4 Hz, IH), 3.83 (s, 3H), 4.27 - 4.31 (m, 2H), 4.42 - 4.47 (m, IH), 6.73 (d, 7 = 7.8 Hz, IH), 6.87 - 6.95 (m, 3H), 7.11 - 7.17 (m, 2H), 7.79 (d, 7 = 8.3 Hz, IH), 7.99 (d, 7= 8.3 Hz, IH), 8.14 (dd, 7 = 2.0, 8.8 Hz, IH), 8.46 (s, IH), 8.56 (s, IH), 8.69 (d, 7= 2.0 Hz, IH), 13.06 (br s, IH); MS (FAB) m/z 553 (M++l); Anal. Calcd for C28H29C1N406: C, 60.81; H, 5.29; N, 10.31. Found: C, 60.98; H, 5.50; N, 9.46. Example 44
2-[[l-[4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenylacetyl]-2-pyrrolidinyl ]methoxy] pyridine-5- carboxylic acid
Figure imgf000175_0001
To a stirred solution of 6-hydroxynicotinic acid (2 g, 14.38 mmol) in benzene (32 mL) and MeOH (8 mL) was added dropwise TMSCHN2 (1.97 mL, 3.953 mmol) at 0°C, and the resulting mixture was stirred for 2hr at room temp. The mixture was quenched by the addition of AcOH and concentrated in vacuo. The residue was suspended in water and the solid was collected. The crude solid was washed with Et20, and dried in vacuo to give 1.566 g (71%) methyl 2- hydroxypyridine-5-carboxylate as a pale brown crystalline powder. IR (KBr) 1655, 1645, 1610, 1433, 1300, 1113, 777, 642cm '; 'H-NMR (400 MHz, DMSO-c .) δ 3.77 (s, 3H), 6.37 (d, 7 = 9.8
Hz, IH), 7.99 (dd, 7 = 2.4, 9.8 Hz, IH), 8.03 (d, 7 = 2.4 Hz, IH); MS (FAB) m/z 154 (M++l); Anal. Calcd for C7H7N03: C, 54.90; H, 4.61; N, 9.15. Found: C, 54.89; H, 4.60; N, 9.13.
To a stirred solution of methyl 2-hydroxypyridine-5-carboxylate (1.00 g, 6.529 mmol), N- /er/-butoxycarbonylprolinol (1.31 g, 6.529 mmol), and Ph^ (2.06 g, 7.836 mmol) in THF (10 mL) was added DIAD (1.54 mL, 7.836 mmol) at room temp, and the resulting mixture was stirred for 13 hr at 70 °C. The mixture was concentrated and the residue was chromatographed on silica-gel with «-hexane:EtOAc (3: 1, v/v) as eluent to give 712.3 mg (32%) methyl 2-[[\-{tert- butoxycarbonyl)-2-pyrrolidinyl] methoxy]pyridine-5-carboxylate as a pale yellow oil. 'H-NMR (400 MHz, CDC13) δ 1.47 (s, 9H), 1.85 - 1.98 (m, 4H), 3.37 (br s, 2H), 3.92 (s, 3H), 4.12 - 4.33 (br m, 2H), 4.48 (brs, IH), 6.75 (m, IH), 8.15 (m, IH), 8.79 (m, IH); MS (FAB) m/z 337 (M++l).
To a stirred solution of methyl 2-[[l-(fer/-butoxycarbonyl)-2- pyrrolidinyl]methyloxy]pyridine -5 -carboxylate (232.3mg, 0.691 mmol) in CH2C12 (4.6 mL) was added TFA (0.9 mL) at 0°C, and the reaction mixture was stirred at room temp for 2 hr. The solvent was removed under a reduced pressure and the residue was made basic by the addition of IN NaOH. The aqueous solution was extracted with CHC13, washed with brine, and the dried over Na2S04. The solvent was evaporated under a reduced pressure to afford 146.2 mg (90%) methyl 2-(2-pynolidinyl)methoxypyridine-5-carboxylate as an oil. 'H-NMR (400 MHz, CDC13) δ 1.49 - 1.58 (m, IH), 1.72 - 2.18 (m, 3H), 2.92 - 3.05 (m, 2H), 3.50 -3.57 (m, IH), 3.91 (s, 3H), 4.23 (dd, 7= 8.0, 10.7 Hz, IH), 4.38 (dd, 7= 4.4, 10.3 Hz, IH), 6.78 (d, 7 = 8.8 Hz, IH), 8.15 (dd, 7 = 2.4, 8.8 Hz, IH), 8.80 (d, 7 = 2.4 Hz, IH); MS (FAB) m/z 237 (M++l).
The mixture of pentafluorophenyl 4-[N-(2-fluorophenyl)ureido]-3-methoxy-phenylacetate (314.8 mg, 0.650 mmol), methyl 2-[(2-pyrrolidinyl)methoxy]pyridine-5-carboxylate (146.2 mg, 0.619 mmol), Et3N (103 ul, 0.743 mmol) in DMF (1.5 mL) was stirred for 1 hr at room temp. The mixture was diluted with Et20, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure to afford methyl 2-[[l-[4-[N'-(2-fluorophenyl)ureido]-3- methoxyphenylacetyl]-2-pyrrolidinyl] methoxy]pyridine-5-carboxylate as a crude pale yellow oil.
To a stirred solution of this compound in THF (6.0 mL) and H20 (2.0 mL) was added LiOH (44.5 mg, 1.857 mmol), and the reaction mixture was stirred for 17 hr at room temp. The mixture was diluted with w-hexane and made basic by the addition of IN NaOH. The aqueous layer was acidified by IN HCl and extracted with CHC13. The extract was washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure and the obtained crude solid was recrystallized from w-hexane-EtOAc-EtOH to afford 202.5 mg (63%) 48 as a white crystalline powder. IR (KBr) 1602, 1537, 1456, 1265, 752cm '; H-NMR (400 MHz, DMSO-c ,) δ 1.67 - 2.03 (m, 4H), 2.50 (s, 3H), 3.33 - 3.42 (m, IH), 3.52 (m, 2H), 3.58 (d, 7= 4.4 Hz, IH), 3.83 (s, 3H), 4.27 - 4.31 (m, 2H), 4.42 - 4.47 (m, IH), 6.73 (d, 7= 7.8 Hz, IH), 6.87 - 6.95 (m, 3H), 7.11 - 7.17 (m, 2H), 7.79 (d, 7= 8.3 Hz, IH), 7.99 (d, 7= 8.3 Hz, IH), 8.14 (dd, 7= 2.0, 8.8 Hz, IH), 8.46 (s, IH), 8.56 (s, IH), 8.69 (d, 7 = 2.0 Hz, IH), 13.06 (br s, IH); MS (FAB) m/z 523 (M++l); Anal. Calcd for C27H27FN406 1/2H20: C, 61.01; H, 5.31; N, 10.54. Found: C, 61.52; H, 5.39; N, 10.01. Example 45
4- [ 1 -[3 -methoxy-4-[N' -(2-methylphenyl)ureido]phenylacetyl] -2-pyrrolidinylmethyl] - 1 -piperazinyl acetic acid
Figure imgf000176_0001
To a stirred suspension of 1-benzylpiperazine (5 g, 28.4 mmol) and K2C03 (5.89 g, 42.6 mmol) in DMF (30 mL) was added ethyl bromoacetate (4.74 g, 28.4 mmol) at room temp. The resulting mixture was stirred for a further 3 hr. The mixture was diluted with EtOAc (300 mL), washed with brine (2 x 100 mL), dried over MgS04 and evaporated. The residue was chromatographed on silica-gel with CHCl3:EtOH (10: 1, v/v) as eluent to give 7.45 g (q.y.) ethyl 4- benzyl-1-piperazinylacetate as a yellow oil. 'H-NMR (CDC13) δ 1.27 (3 H, t, 7 = 7.3 Hz), 2.88- 2.96 (8 H, m), 3.20 (2 H, s), 3.52 (2 H, s), 4.18 (2 H, q, 7= 7.3 Hz), 7.22-7.32 (5 H, m).
A stirred solution of ethyl 4-benzyl-l-piperazinylacetate (2.00 g, 7.62 mmol) and 5% Pd/C (2 g) in AcOH:EtOH (1 : 1, 40 mL) was hydrogenated at 1 atm for 8 hr. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was made basic by the addition of saturated NaHC03 and extracted with CHC13 (2 x 200 mL). The combined extracts were dried over K2C03 and evaporated to give 1.16g (88%) ethyl 1-piperazinylacetate as a yellow oil. 'H-NMR
(CDC13) δ 1.26-1.30 (3 H, m), 1.67(1 H, br s), 2.55(4 H, m), 2.92-2.96(4 H, m), 3.19-3.20(2 H, m), 4.16-4.22(2 H, m).
To a stirred solution of N-Boc-7-prolinol (1.00 g, 5.02 mmol) and ethyl 1 -piperazinyl acetate (864 mg, 5.02 mmol) in MeOH:AcOH (10:1, v/v, 11 mL) was added NaBH3CN (664 mg, 10.0 mmol) at room temp. After being stirred overnight, the mixture was poured into ice water
(100 mL) and made basic by the addition of NaHC03. The mixture was extracted with CHC13 (2 x 200 mL). The combined extracts were dried over Na2C03 and evaporated. The residue was chromatographed on silica-gel with CHCl3:EtOH (10: 1, v/v) as eluent to give 1.20 g (67%) ethyl 4- [l-(te -butoxy carbonyl)-2-pyrrolidinylmethyι]-l-piperazinylacetate as a colorless oil. 'H-NMR (CDC13) δ 1.27 (3 H, t, 7 = 7.3 Hz), 1.46-1.47 (9 H, m), 1.79-3.96 (total 19 H, series of m), 4.19 (2 H, q, 7 = 7.3 Hz).
A mixture of ethyl 4-[l-(fer/-butoxycarbonyl)-2-pyrrolidinylmethyl]-l-piperazinylacetate (1.20 g, 3.38 mmol) in TFA (5 mL) and CH2C12 (5 mL) was stirred overnight. After removal of the solvent, the residue was made basic by the addition of sat. NaHC03. The mixture was extracted with CHC13 (2 x 200 mL). The combined extracts were dried over Na2C03 and evaporated to give 386 mg (45%) ethyl 4-(2-pyrrolidinylmethyl)- 1-piperazinylacetate as a yellow oil. MS (FAB) 256 (M++l).
To a stirred solution of ethyl 4-(2-pyrrolidinylmethyl)- 1-piperazinylacetate (380 mg, 1.49 mmol) and 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (468 mg, 1.49 mmol) in DMF (10 mL) was added EDCHC1 (428 mg, 2.24 mmol), HOBt, and DMAP (cat). After being stirred overnight, the mixture was diluted with EtOAc (300 mL), washed with brine (2 x 200 mL), and dried over MgS04. After removal of the solvent, the residue was chromatographed on silica- gel with CHCl3:EtOH (9:1, v/v) as eluent to give 257 mg (31%) ethyl 4-[l-[3-methoxy-4-[N'-(2- methylphenyl) ureido] phenylacetyl]-2-pyrrolidinylmethyl]- 1-piperazinylacetate as a yellow foam. 'H-NMR (CDC13) δ 1.24-1.29 (3 H, m), 1.69-4.24 (total 29 H, series of m), 6.41 (1 H, m), 6.81 (2 H, m), 7.13-7.26 (4 H, m), 7.52 (1 H, d, 7 = 7.3 Hz), 8.04 (1 H, d, 7 = 8.3 Hz).
To a stirred solution of ethyl 4-[l-[3-methoxy-4-[Λ '-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinylmethyl]- 1-piperazinylacetate (250 mg, 0.453 mmol) in THF (4 mL) was added 0.25 N NaOH (3.6 mL). The resulting mixture was stirred overnight. The mixture was adjusted to pH 7.5 by the addition of 1 N HCl and extracted with CHCl3:MeOH (4: 1, 3 x 100 mL). The combined extracts were dried over MgS04 and evaporated. The crude solid was recrystallized from CHCl3-MeOH-«-hexane to give 40 mg (17%) 49 as a colorless crystalline powder, mp 160- 170 °C; 'H-NMR (DMSO-c .) δ 1.74-4.08 (total 27 H, series of m), 6.73 (1 H, d, 7= 7.8 Hz), 6.87 (1 H, s), 6.93 (1 H, t, 7 = 7.8 Hz), 7.11-7.17 (2 H, m), 7.79 (1 H, d, 7 = 7.8 Hz), 8.00 (1 H, dd, 7 = 7.8, 2.4 Hz), 8.47 (1 H, s), 8.56 (1 H, s); MS (FAB) 524 (M++l); Anal. Calcd for C28H37N505-HC1Η20: C, 58.17; H, 6.97; N, 12.11. Found: C, 58.26; H, 7.26; N, 11.53. Example 46
Figure imgf000178_0001
To a suspension of 4-aminophenylacetic acid (10 g, 66 mmol) in 1: 1 CH2Cl2:acetone (100 mL) was added o-tolyisocyanate (8.8 g, 66 mmol). The mixture was heated to reflux for 4 hr at which time a white precipitate had formed. The precipitate was filtered and the solid washed generously with 1 : 1 CH2Cl2:acetone. The solid was recrystallized with hot methanol and dried under vacuum to yield 14.1 g (75% yield) of the desired 4-(o-tolylureido)phenylacetic acid 50.
Example 47
Figure imgf000178_0002
To a suspension of 2-amino-4-thiazoleacetic acid (4 g, 25 mmol) in 1 : 1 CH2Cl:acetone
(100 mL) was added o-tolylisocyanate (3.5 g, 26 mmol). The mixture was heated to reflux for 8 hr at which time a yellow precipitate had formed, the precipitate was filtered and the solid washed generously with 1:1 CH2Cl2:acetone. The solid was recrystallized with hot methanol and dried under vaccum to yield 4.8 g (66% yield) of the desired 2-(o-tolylureido)-4-thiazoleacetic acid 51. Example 48
4-[[l-[3-methoxy-4-[N,-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinylmethylamino]benzoic acid
Figure imgf000179_0001
A stirred mixture of methyl 4-aminobenzoate (1.52 g, 10.04mmol) and l-ter/-butoxy carbonyl prolinal (3.00 g, 15.06 mmol) in toluene (30 mL) was heated under reflux for 3 hr. After cooling to room temp, the solvent was evaporated in vacuo. The solid was dissolved in MeOH (27 mL) and AcOH (3 mL), then NaBH3CN (1.33 g, 20.08mmol) was added to the mixture, and the resulting mixture was stirred overnight at room temp. The reaction mixture was quenched with water, and the solvent was removed under a reduced pressure. Water was added to the residue, and extracted with EtOAc. The extract was washed with H20, brine, and dried over Na2S04. The solvent was removed under a reduced pressure, and the residue was chromatographed on silica-gel with n-hexane - EtOAc (3:1, v/v) as eluent to afford 2.17g (65%) 4-[l-(ter/-butoxycarbonyl)-2- pyrrolidinylmethylamino] benzoate as a pale yellow oil. Η-NMR (400 MHz, CDC13) δ 1.48 (s, 9H), 1.51 - 2.09 (m, 4H), 3.05 - 3.07 and 3.43 - 3.48 (br m, IH), 3.18 (br s, IH), 3.36 (br s, 2H),
3.84 (s, 1H),4.06 - 4.08, 4.20 - 4.24 (br m each, IH), 6.49 - 6.65 (m, 2H), 7.84 (d, 7= 8.3 Hz, 2H); MS (FAB) m/z 335 (M++l).
To a stirred solution of methyl 4-[l-(ter butoxycarbonyl)-2-pyrrolidinylmethylamino] benzoate (2.17 g, 6.490 mmol) in CH2C12 (44 mL) was added TFA (8.7 mL) at 0°C, and the resulting mixture was stirred overnight at room temp. The solvent was removed under a reduced pressure and the residue was treated with IN NaOH. The mixture was extracted with CH2C12. The extract was washed with brine, dried over Na2S04, and the solvent was concentrated under a reduced pressure to afford 1.34 g (88%) methyl 4-(2-pyrrolidinylmethylamino)benzoate as a brown oil, which is used to the subsequent reaction without further purification.
The mixture of the above methyl 4-(2-pyrrolidinylmethylamino)benzoate (397.8 mg, 1.69 mmol), 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (587.1 mg, 1.87mmol), EDC (HCl) (486 mg, 2.54 mmol), HOBt (23 mg, 0.17 mmol), and DMAP (21 mg, 0.17 mmol) in DMF (4 mL) was stirred overnight at room temp. The mixture was diluted with EtOAc, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure. The residue was chromatographed on silica-gel with CHC13 - MeOH (50: 1, v/v) as eluent to afford 882mg (98%) methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl methylamino]benzoate as a brown amorphous solid, which is used to the subsequent reaction without further purification.
To a stirred solution of the above methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinylmethylamino]benzoate (882 mg, 1.662 mmol) in THF (18 mL) and MeOH (5.0 mL) was added IN NaOH (5.0 mL, 5.000 mmol), and the mixture was heated under reflux for 3 days. The mixture was concentrated. The residue was treated with IN HCl and extracted with CH2C12. The extract was washed with brine, dried over Na2S04, and evaporated in vacuo. The solid was recrystallized from w-hexane - diisopropyl ether - CHC13 - MeOH to afford 180.5 mg (21%) 52 as a pale yellow amorphous solid. IR (KBr) 1604, 1535, 1511, 1454, 1255,
1224, 1174cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.79 - 1.99 (br m, 4H), 2.25 (s, 3H), 2.90 - 2.94 (m, IH), 3.35 - 3.62 (m, 6H), 3.87 (s, 3H), 4.12 - 4.15 (br s, IH), 6.63 - 6.78 (m, 4H), 6.89 - 6.95 and 7.11 - 7.17 (m each, 3H), 7.65 (d, 7 = 8.3 Hz, 2H), 7.80 (d, 7 = 8.3 Hz, IH), 8.02 (d, 7 = 8.3 Hz, IH), 8.47 (s, IH), 8.57 (s, IH), 12.0 (br s, IH); MS (FAB) m/z 517 (M++l); Anal. Calcd for C29H32N405-1H20: C, 65.15; H, 6.41; N, 10.48. Found: C, 65.45; H, 6.33; N, 10.02. Example 49
4-[N-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyιτolidinylmethyl]-Λf- methylamino]benzoic acid
Figure imgf000180_0001
To a mixture of methyl 4-[N-(2-pyrrolidinyl)methylamino]benzoate (600 mg, 1.794 mmol), 37%-formaldehyde (1.79 mL, 23.32 mmol), and NaBH3CN (368 mg, 5.561 mmol) in CH3CN (6.0 mL) was added dropwise AcOH (0.205 mL, 3.588 mmol), and the resulting mixture was stirred for 2 hr at room temp. The reaction mixture was quenched by the addition of sat. NaHC03, and extracted with EtOAc. The extract was washed with brine and dried over Na2S04. The solvent was removed under a reduced pressure, and the residue was chromatographed on silica-gel with «-hexane - EtOAc (3: 1, v/v) as eluent to afford 645 mg (100%) methyl 4-[N-[l- (ter -butoxycarbonyl)-2-pyrrolidinylmethyl]-Λ -methylamino]benzoate as a colorless oil. 'H-NMR (400 MHz, CDC13) δ 1.50 (s, 9H), 1.76 - 1.91 (m, 4H), 3.07 (s, 3H), 3.15 - 3.43 (m, 3H), 3.67 - 3.71 (m, IH), 3.85 (s, 3H), 4.11 - 4.17 (m, IH), 4.37 (s, IH), 6.75 (d, 7= 8.3 Hz, 2H), 7.89 (d, 7 = 8.8 Hz, 2H); MS (FAB) m/z 349 (M++l). To a stirred solution of methyl 4-[N-[l-(/er/-butoxycarbonyl)-2-pyrrolidinylmethyl]-N- methylamino]benzoate (645 mg, 1.794 mmol) in CH2C12 (6.5 mL) was added TFA (1.3 mL) at 0°C, and the mixture was stirred overnight at room temp. The solvent was removed under a reduced pressure and the residue was treated with IN NaOH solution. The mixture was extracted with CH2C12. The extract was washed with brine, dried over Na2S04, and the solvent was concentrated under a reduced pressure to afford 363.2 mg (82%) of methyl 4-[N-(2-pyrrolidinyl)methyl-N- methyl]aminobenzoate as a yellowish oil, which is used to the subsequent reaction without further purification.
The mixture of methyl 4-[Λf-(2-pyrrolidinyl)methyl-N-methyl]aminobenzoate (191.8 mg, 0.772 mmol), 3-methoxy-4-(N'-2-methylphenylureido)phenylacetic acid (258.1 mg, 0.811 mmol), EDC (hydrochloride) (221.9 mg, 1.158 mmol), HOBt (10.0 mg, 0.077 mmol), and DMAP (9.4 mg, 0.077 mmol) in DMF (2.0 mL) was stirred for 3 hr at room temp. The reaction mixture was diluted with Et20, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure to afford 482.5 mg methyl 4-[N-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-2-pyirolidinylmethyl]-N-methylamino]benzoate as a white amorphous powder, which is used to the subsequent reaction without further purification.
To a stirred solution of methyl 4-[N-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl acetyl]-2-pyrrolidinylmethyl]-Λ^-methylamino]benzoate in THF (5.0 mL) was added IN NaOH (6.2 mL, 6.2 mmol), and the mixture was heated under reflux for 3 days. The reaction mixture was concentrated in vacuo. The residue was neutralized with IN HCl, and extracted with CH2C12. The extract was washed with sat. NH4C1, brine, dried over Na2S04, and evaporated in vacuo. The crude solid was recrystallized from w-hexane-CHCl3-MeOH-isopropylether to afford 102.8 mg (25%, 2steps) 53 as a pale yellow amorphous solid, mp 144 - 146; IR (KBr) 3325, 1600, 1529, 1454, 1284, 1257, 1184cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.73 - 1.91 (m, 3H), 2.03 - 2.11 (m, IH), 3.03 (s, 3H), 3.16 (dd, 7= 9.3, 14.2 Hz, IH), 3.37 - 3.60 (m, 4H), 3.76 - 3.80 (m, IH), 3.86 (s, 3H), 4.25 (br s, IH), 6.75 (dd, 7= 1.5, 8.3 Hz, IH), 6.86 (d, 7= 1.5 Hz, IH), 6.90 (d, 7= 8.8 Hz, 2H), 6.95 - 7.01 (m, IH), 7.12 (t, 7 = 7.8 Hz, IH), 7.20 - 7.25 (m, IH), 7.73 (d, 7 = 8.8 Hz, 2H), 8.01 (d, 7 = 7.8 Hz, IH), 8.16 - 8.20 (m, IH), 8.73 (s, IH), 9.19 (d, 7 = 2.0 Hz, IH), 12.0 (br s, IH); MS (FAB) m/z 535 (M++l); Anal. Calcd for C29H31FN405- 1/2H20: C, 64.08; H, 5.93; N, 10.31; F, 3.49. Found: C, 64.17; H, 5.84; N, 10.06; F, 3.26. Example 50 4- [N- [ 1 - [-4- [N -(2-fluoropheny l)ureido] -3 -methoxyphenylacetyl] -2 -pyrrolidinylmethyl] -N- methylamino] -3 -nitrobenzoic acid
Figure imgf000182_0001
To a mixture of methyl 4-fluoro-3-nitrobenzoate (1.58 g, 4.666 mmol) and [l-(tert- butoxycarbonyl)-2-pyrrolidinyl]methylamine (500 mg, 2.333 mmol) in DMF (8.0 mL) was added K2C03 (967 mg, 6.999 mmol), the resulting mixture was stirred for 3 hr at room temp. The reaction mixture was diluted with EtOAc, washed with water, and dried over Na2S04. The solvent was removed under a reduced pressure, and the residue was chromatographed on silica-gel with n- hexane - EtOAc (3: 1, v/v) as eluent to afford 834.9 mg (91%) of methyl 4-[N-[l-(/er/- butoxycarbonyl)-2-pyrrolidinylmethyl]-N-methyl]amino-3-nitrobenzoate as a pale yellow oil, which is used to the subsequent reaction without further purification.
To a ice-cooling solution of the above oil in CH2C12 (8.3 mL) was added TFA (1.7 mL), and the reaction mixture was stirred overnight at room temp. The solvent was removed under a reduced pressure. The residue was treated with IN-NaOH and extracted with CHC13. The extract was washed with brine, dried over Na2S04, and evaporated under a reduced pressure to afford 553.6 mg (90%) methyl 4-[N-(2-pyrrolidinylmethyl)-Λ^-methyl]amino-3-nitrobenzoate as a pale yellow oil. Η-NMR (400 MHz, CDC13) δ 1.31 - 1.40 (m, IH), 1.74 - 2.05 (m, 4H), 2.73 - 2.79 (m, IH), 2.81 - 2.99 (m, IH), 2.94 (s, 3H), 3.29 -3.55 (m, 2H), 3.89 (s, 3H), 7.14 (d, 7= 9.3 Hz, IH), 7.98 (dd, 7= 2.0, 8.8 Hz, IH), 8.42 (d, 7 = 2.0 Hz, IH); MS (FAB) m/z 294 (M++l).
A mixture of 3-methoxy-4-[N'-(2-fluorophenyl)ureido]phenylacetic acid (630.0 mg, 1.979 mmol), methyl 3-mtro-4-[N-(2-pyrrolidinyl)methyl-N-methylamino]benzoate (553.0 mg, 1.885 mmol), EDC(Hydrochloride) (542.0 mg, 2.827 mmol), HOBt (25.5 mg, 0.189 mmol), and DMAP (23.1 mg, 0.189 mmol) in DMF (5.0 mL) was stirred at room temp, for 2 hr. The mixture was diluted with Et 0, washed with brine, and dried over Na2S04. The solvent was removed under a reduced pressure, and the residue was chromatographed on silica-gel with CHC13 - MeOH (30: 1, v/v) as eluent to afford 1.18 g (100%) methyl 4-[A 1-[3-methoxy-4-[N'-(2-fluorophenyl)ureido] phenylacetyl]-2-pyrrolidinyl methyl] -N-methylamino] -3 -nitrobenzoate as a yellow foam, which is used to the subsequent reaction without further purification.
To a stirred solution of the above methyl 4-[N-[l-[3-methoxy-4-[Λf -(2-fluorophenyl) ureido]phenylacetyl]-2-pyrrolidinylmethyl]-N-methylainino]-3-nitrobenzoate (2.50 mg, 0.421 mmol) in THF (3.0 mL) was added IN NaOH (1.5 mL, 1.500 mmol), and the mixture was heated under reflux overnight. After cooling, the mixture was concentrated to a small volume. The residue was treated with IN HCl, and extracted with CHC13. The extract was washed with brine, dried over Na2S04, and evaporated in vacuo. The crude solid was recrystallized from «-hexane - diethyl ether - CHC13 - MeOH to afford 194.9 mg (80%) of 54 as a yellow amorphous solid. IR (KBr) 1685, 1610, 1529, 1454, 1284, 1259, 1228 cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.63 - 1.91 (m, 3H), 2.04 - 2.07 (br s, IH), 2.60 (br s, IH), 2.80 (s, IH), 2.99 (s, 2H), 3.05 - 3.10 (m, IH), 3.32 - 3.58 (m, 3H), 3.76 - 3.81 (m, IH), 3.81 (s, 3H), 4.25 (br s, IH), 6.68 (t, 7= 3.9 Hz, IH), 6.71 (d, 7 = 8.8 Hz, IH), 6.81 - 6.96 (m, IH), 7.07 (t, 7 = 7.3 Hz, IH), 7.17 (dd, 7= 7.8, 9.8 Hz, IH), 7.48 (t, 7 = 7.8 Hz, IH), 7.85 (d, 7 = 8.8 Hz, IH), 7.97 (t, 7 = 8.8 Hz, IH), 8.11 - 8.20 (m, 2H), 8.68 (s, IH), 9.14 (s, IH), 12.8 (br s, IH); MS (FAB) m/z 580 (M++1); Anal. Calcd for C29H30FN5O7-l/4H2O: C, 59.63; H, 5.26; N, 11.99; F, 3.25.Found:C,59.68;H,5.34;N, 11.80; F, 3.21. Example 51 3-amino-4-[/V-methyl-[l-[4-[Λ^'-(2-fluorophenyl)ureido]-3-methoxy-phenylacetyl]-2-pyrrolidinyl methyl] -JV-methylamino]benzoic acid
Figure imgf000183_0001
A stirred solution of methyl 4-[Λ^-[l-[4-[N'-(2-fluorophenyl)ureido]-3-methoxy- phenylacetyl]-2-pyrrolidinylmethyl]-N-methylamino]-3-nitrobenzoate (901.0 mg, 1.518 mmol) in MeOH (18.0 mL) was hydrogenated over 5%Pd-C (1.35 g) at 45psi overnight. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was made basic with IN NaOH solution and extracted with CHC13. The extract was washed with brine, dried over Na2S04, and the solvent was removed under a reduced pressure. The residue was chromatographed on silica-gel with CHC13 - MeOH (24:1, v/v) as eluent to afford 283.7 mg (48%) methyl 3-amino-4-[N-[l-[4- [ΛT -(2-fluorophenyl)ureido] -3 -methoxy-phenylacetyl] -2-pyrrolidinylmethyl] -N-methylamino] benzoate as a brownish amorphous solid, which was used to the subsequent reaction without further purification.
To a stirred solution of the above compound in THF (3.0 mL) was added IN NaOH solution (1.5 mL, 1.500 mmol), and the mixture was refluxed overnight. The mixture was concentrated, treated with IN HCl, and extracted with CHC13. The extract was washed with brine, dried over Na2S0 , and evaporated in vacuo. The solid was recrystallized from n-hexane - diethyl ether - CHC13- MeOH to afford 179.8 mg (65%) 55 as a white amorphous solid. IR (KBr) 1614, 1601, 1537, 1454, 1228, 1219, 1184 cm '; 'H-NMR (400 MHz, DMSO-c .) δ 1.60 - 2.20 (m, 4H), 2.61 - 2.68 (m, IH), 2.89 (s, 3H), 3.13 - 3.18 (m, IH), 3.40 - 3.61 (m, 4H), 3.85 (s, 3H), 4.01 (br m, IH), 4.93 (br s, 2H), 6.50 - 7.31 (m, 8H), 8.01 (dd, 7 = 2.9, 8.3 Hz, IH), 8.18 (t, 7 = 8.3 Hz, IH), 8.71 (s, IH), 9.17(d, 7= 1.5 Hz, IH), 12.3 (br s, IH); MS (FAB) /M/Z 550 (M*+l); /!α/. Calcd for C29H32FN505-1/4H20: C, 62.86; H, 5.91; N, 12.64; F, 3.43. Found: C, 62.71; H, 6.00; N, 12.39; F, 3.16. Example 52 4-[l-[4-[N,-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]methylamino]benzoic acid
Figure imgf000184_0001
To a stirred mixture of methyl 4-[(2-pyrrolidinyl)methylamino]benzoate (220 mg, 0.94 mmol), 4- [JV-(2-methylphenyl)ureido]phenylacetic acid (285 mg, 0.94 mmol), 4-DMAP (140 mg, 1.13 mmol) and catalytic amount of HOBT in DMF (7 ml) was added EDCHC1 (220 mg, 1.13 mmol) at room temperature. The resulting mixture was stirred at room temperature for 20 hr. The mixture was pored into ice-water. The solid was collected, washed with water and air-dried. The crude solid was purified by silica-gel (20 ml) column chromatography with CHC13- EtOAc (3:1, v/v) to CHC13- EtOH (9: 1, v/v) as eluent to give methyl 4-[l-[4-[JV-(2-methylphenyl)ureido] phenyl acetyl]-2-pyrrolidinyl]methylamino]benzoate (400 mg, 85%) as a gum. 'H-NMR (CDCl3)δ 1.75- 2.05 (series of m, 4 H), 2.24 (s, 3 H), 3.18 and 3.27 (each m, each 1 H), 3.51 (m, 2 H), 3.60 (s, 2 H), 3.83 (s, 3 H), 4.52 (m, 1 H), 6.52 (m, 3 H), 6.81 (s, 1 H), 7.11-7.25 (series of m, 7 H), 7.53 (m, I H), 7.81 (d, 7= 8.8 Hz, 2H).
A mixture of methyl 4-[l-[4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] methylamino]benzoate (280 mg, 0.56 mmol) in THF (3 ml) and 0.25N NaOH (6.8 ml, 1.75 mmol) was stirred for 3 hr at 60-70 °C. After cooling, the mixture was poured into ice-lN HCl (3 ml). The solid was collected, washed with water and air-dried. The crude crystalline material was recrystallized from CHCl3-EtOH-IPE to give 56 (180 mg, 66%) as fine needles. MW 486.56 IR (KBr) n 3367, 3294, 1712, 1606, 1539 cm '; 'H-NMR (CDCl3-DMSO-c .) δ 1.80-2.05 (series of m, 4 H), 2.26 (s, 3 H), 2.94(m, 1 H), 3.38 and 3.56 (series of m, 3 H), 3.57 (s, 2 H), 4.23 (m,2 H), 6.48 (br s, 1 H), 6.69 (d, 7 = 8.8 Hz, 2H), 6.91 (t, 7 = 7 Hz, 1 H), 6.91 (m, 4 H), 7.39 (d, 7 = 8.3 Hz, 2H), 7.66 (d, 7= 8.8 Hz, 2H), 7.80 (m, 2 H), 8.88 (s, 1 H), 11.76 (s, 1 H); MS(FAB) m/z 487 (M+ +1); Anal. Calcd for C28H30N4O4O.75xH2O: C, 67.24; H, 6.45; N, 11.20. Found: C, 67.13; H, 6.32; N, 11.01. Example 53 methyl 4-[l-[4-[Λ -(2-chlorophenyl)ureido]-3-methoxylphenylacetyl]-(25)-pyrrolidinyl] methoxybenzoate
Figure imgf000185_0001
4-[l-[4-[Λf'-(2-chlorophenyl)ureido]-3-methoxylphenylacetyl]-(25)-pyrrolidinyl]methoxybenzoic acid
Figure imgf000185_0002
To a stirred solution of 2S-pyrrolidinemethanol (15.1 g, 149.5 mmol) in dioxane (100 ml) was added a solution of (Boc)20 (32.6 g, 164.4 mmol) in dioxane (100 ml). The reaction mixture was stirred at room temperature for 18 hr, and concentrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc-hexane (1:5 ,v/v) as eluent to give (l-tert- butoxycarbonyl-(2S)-pyrrolidinyl)methanol (31.6 g, quant.) as a colorless oil. 'H-NMR (CDC13) δ 1.47 (s, 9H), 1.60-2.00 (m, 3H), 3.25-3.70 (4H, m), 3.92-4.00 (m, IH).
To a stirred solution of (l-te -/-butoxycarbonyl-(25)-pyrrolidinyl)methanol (4.02 g, 20.0 mmol), methyl 4-hydroxybenzoate (3.04 g, 20.0 mmol) and Ph^ (6.28 g, 24 .0 mmol) in THF (50 ml) was added DIAD (4.85 g, 24.0 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 18 hr. The mixture was concentrated in vacuo. The residue was purified by column chromatography on silica gel with w-hexane-EtOAc (5: 1, v/v) as eluent to give methyl 4- (l-/er -butoxycarbonyl-(25 -pyrrolidinyl)methoxybenzoate (5.4 g, 81% ) as a pale yellow oil. 'H- NMR (CDC13) δ 1.47 (s, 9H), 1.88-2.04 (m, 4H), 3.41 (m, 2H), 3.91 (s, 3H), 3.90-3.92 (m, IH), 4.11-4.16 (m, 2H), 6.94 (d, 7 = 8.6 Hz, 2H), 7.94 (d, 7 = 8.3 Hz, 2H).
To a stirred solution of methyl 4-(l-terf-butoxycarbonyl-2S-pyrrolidinyl)methoxybenzoate (2.1 g, 6.27 mmol) in CH2C12 (9.0 ml) was added TFA (6.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The extract was washed with brine ,dried over Na2S04 , and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (470 mg, 2.0 mmol), 4-|7V-(2- chlorophenyl) uredio]-3-methoxyphenylacetic acid (669 mg, 2.0 mmol), HOBt (405 mg, 3.0 mmol), and triethylamine (554 ml, 4.0 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDC HCl (576 mg, 3.0 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with w-hexane-EtOAc (1:4, v/v) as eluent to give 57 (900 mg, 82%) as a colorless oil. MW 552.02 Η-NMR (CDC13) δ 2.04-2.10 (m, 4H), 3.51-3.70 (m, 6H), 3.87 (s, 3H), 4.11-4.18 (m, 2H), 6.77-6.88 (m, 4H), 7.23-7.34 (m, 4H), 7.91-7.96 (m, 2H), 8.17-8.19 (m, IH).
The mixture was stirred at 70 °C for 24 hr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to 58 (640 mg, 94%) as a white crystalline solid. MW 537.99 mp 126-130 °C; IR (KBr) 3324, 2938, 2877, 1604, 1533, 1249, 1166, 750 cm 1; 'H-NMR (DMSO-c .) δ 1.93- 2.05 (m, 4H), 3.52-3.61 (m, 5H), 3.82 (s, 3H), 3.99-4.01 (m, 2H), 4.18-4.20 (m, IH), 4.29 (m, IH), 6.74-6.76 (d, IH, 7 = 8.3 Hz), 6.87 (s, IH), 6.99-7.04 (m, 3H), 7.25-7.29 (m, IH), 7.41-7.43 (d, 1H, 7 = 8.1 Hz), 7.86-7.91 (m, 2H), 7.95-7.97 (m, IH), 8.09-8.11 (d, 1H, 7 = 8.3 Hz), 8.87-8.92 (m,lH); MS (FAB) m/z 538 (M++l); Anal calcd for C28H28N3O6 0.5H2O: C, 61.48; H, 5.34; N, 7.68; Cl, 6.48. Found: C, 61.46; H, 5.36; N, 7.62; Cl, 6.50. For Na salt of 58 : Anal. Calcd for C28H27N306-Na-1.5H20: C, 57.29; H, 5.15; N, 7.16. Found: C, 57.48; H, 5.04; N, 6.99. Example 54 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxylphenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoic acid
Br H H OMe 59
To a stirred solution of methyl 4-(2S-pyrrolidinyl)methoxybenzoate (470 mg, 2.0 mmol), 4-|7V-(2- bromophenyl)uredio]-3-methoxyphenylacetic acid (758 mg, 2.0 mmol), HOBt (405 mg, 3.0 mmol), and triethylamine (554 ml, 3.0 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDC HCl (576 mg, 3.0 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1:4, v/v) as eluent to give methyl 4- [ 1 - [4 - [Λr'-(2-bromophenyl)ureido] -3 -methoxylphenylacetyl] -(2S)-pyrrolidinyl] methoxybenzoate (1.0 g, 84%) as a colorless oil. 'H-NMR (CDC13) δ 2.04-2.10 (m, 4H), 3.52-3.54 (m, IH), 3.62 (s, 2H), 3.70 (s, 3H), 3.88 (s, 3H), 4.13-4.19 (m, 2H), 6.79-6.94 (m, 4H), 7.20-7.31 (m, IH), 7.91-8.12 (m, 2H), 8.13-8.15 (m, IH).
To a stirred solution of methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxylphenylacetyl]-(2S)- pyrrolidinyl]methoxybenzoate (780 mg, 1.31 mmol) in THF (10.0 ml) and MeOH (5.0 ml) was added IN NaOH (2.0 ml, 2.0 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 59 (730 mg, 96%) as a white crystalline solid. MW 582.44 mp 120-125 °C; IR (KBr) 3318, 2938, 1604, 1529, 1166, 1025 cm' '; 'H-NMR (DMSO-ctøδ 1.92-1.96 (m, 4H), 3.52-3.60 (m, 5H), 3.82 (s, 3H), 3.98-4.02 (m,lH), 4.16-4.19 (m, IH), 4.29 (m, IH), 6.75 (d, 7 = 8.3 Hz, IH), 6.87 (m,lH), 6.94-7.04 (m, 3H), 7.29- 7.33 (m, IH), 7.57-7.59 (m, IH), 7.85-7.96 (m, 4H), 8.72 (s, IH), 8.91 (s, IH); MS (FAB) m/z 582 (M++l); Anal calcd for C28H28NABrl.0H2O: C, 56.01; H, 5.04; N, 7.00; Br, 13.31. Found: C, 56.12; H, 4.98; N, 6.96; Br, 13.57.. Example 55 3-amino-4-[l-[4-[N'-(2-hydroxyphenyl)ureido]-3-methoxyphenylacetamido]-2-pyrrolidinyl methoxy]benzoic acid
Figure imgf000187_0001
To a stirred solution of 2-nitrophenol (10.0 g, 72.0 mmol) and K2C03 (9.96 g, 72.0 mmol) in DMF
(150 mL) was added dropwise benzyl bromide (9.40 mL, 79.2 mmol) at 0 °C After being stirred at room temperature for 3 hr, the reaction mixture was diluted with water, which was extracted with Et20. The extracts were washed with brine, dried over Na2S04, and concentrated to dryness.
Chromatography of the residue with hexane - EtOAc (2 : 1, v/v) as eluent gave 2-benzyloxy nitrobenzene (14.7 g, 89%) as a yellow oil. 'H-NMR (CDC13) δ 5.24 (s, 2H), 7.04 (t, 7 = 7.8 Hz,
IH), 7.12 (d, 7= 7.8 Hz, IH), 7.31 - 7.50 (m, 5H), 7.51 (d, 7= 1.5 Hz, IH), 7.86 (dd, 7 = 7.8, 1.5
Hz, IH).
To a stirred solution of 2-benzyloxynitrobenzene (9.92 g, 43.3 mmol) and NiCl2 (20.3 g, 157mmol) in MeOH (350 mL) was added portionwise NaBH4 (8.09 g, 214 mmol) at 0 °C. After disappearing of the starting material (monitored by TLC), the mixture was evaporated off. The black precipitate was dissolved in IN HCl, then acidic solution was alkalified by the addition of IN NaOH and extracted with EtOAc. The extracts were washed brine, dried over Na2S04, and concentrated to dryness. Chromatography of the residue with CHC13 as eluent gave 2-benzyloxy aniline (8.60 g, 100 %) as a reddish oil. 'H-NMR (CDC13) δ 3.71 (broad s ,2H), 5.06 (s, 2H), 6.68 - 6.86 (m, 4H), 7.32 - 7.44 (m, 5H); FAB-MS m/z 200 (M++l).
To a solution of 2-benzyloxyaniline (1.15 g, 5.77 mmol) in benzene (60 mL) was added triphosgene (1.27 g, 6.35 mmol) and Et3N (2.60 mL, 17.3 mmol) at 0 °C The reaction mixture was heated under reflux for 20 hr. The resulting mixture was filtrated and washed with hexane, and the filtrate was concentrated to leave a residual oil, which was chromatographed with hexane - EtOAc (4 : 1, v/v) as eluent to afford tert-butyl 4-[Λr-(2-benzyloxyphenyl)ureido]-3-mefhoxy phenylacetate (2.38 g, 89 %) as a yellow oil. 'H-NMR (CDC13) δ 1.44 (s, 9H), 3.44 (s, 2H), 3.78 (s, 3H), 5.07 (s, 2H), 6.73 (dd, 7= 8.0, 1.7 Hz, IH), 6.78 (d, 7= 1.7 Hz, IH), 6.90 - 6.98 (m, 3H), 7.07 (s, IH), 7.29 (s, IH), 7.33- 7.38 (m, 5H), 7.91 (d, 7= 8.0 Hz, IH), 8.14 (m, IH).
To a solution of ter/-butyl 4-[N'-(2-benzyloxyphenyl)ureido]-3-methoxyphenylacetate (2.35 g, 5.08 mmol) in CH2C12 (25 mL) was added TFA (25 mL) at 0 °C After being stirred at room temperature, for 3 hr, the mixture was concentrated. The residue was dissolved in IN NaOH and washed with Et20. The basic water layer was poured into ice - IN HCl and the resulting mixture was extracted with CHC13 - MeOH (4 : 1, v/v). The extracts were washed with brine, dried over Na2S0 , and concentrated to dryness. The residue was dissolved in isopropyl ether and hexane was added to this solution until the crystallization was completed. The solid was collected to give 4- [N'-(2-benzyloxyphenyl)ureido]-3-methoxyphenylacetic acid (1.59 g, 77 %) as a brownish solid. 'H-NMR (DMSO-rf6) δ 3.50 (s, 2H), 3.85 (s, 3H), 5.26 (s, 2H), 6.76 (d, 7= 8.3 Hz, IH), 6.83 -
6.89 (m, 2H), 6.91 (s, IH), 7.01 (dd, 7 = 8.3, 2.3 Hz, IH), 7.31 (t, 7 = 7.3 Hz, IH), 7.39 (t, 7 = 7.3 Hz, 2H), 7.49 (d, 7 = 7.3 Hz, 2H), 7.97 (d, 7 = 8.3 Hz, IH), 8.04 (d, 7 = 8.3 Hz, IH), 8.80 (s, IH), 8.86 (s, IH), 12.24 (broad s, IH); FAB-MS m/z 407 (M++l).
To a solution of 4-[N'-(2-benzyloxyphenyl)ureido]-3-methoxyphenylacetic acid (1.12 g, 2.76 mmol), methyl 4-(2-pyrrolidinylmethoxy)-3-mtrobenzoate (890 mg, 2.76 mmol), HOBt (74.0 mg, 0.55 mmol), DMAP (67.0 mg, 0.55 mmol), and Et3N (0.58 mL, 4.13 mmol) in THF (15 mL) was added EDCHCl (792 mg, 4.13 mmol). After being stirred at room temperature for 12 hr, the reaction mixture was diluted with water and extracted with EtOAc. The extracts were washed with brine, dried over Na2S04, and concentrated to dryness. Chromatography of the residue with EtOAc as eluent gave methyl 4-[l-[4-[Λ -(2-benzyloxyphenyl)ureido]-3-methoxyphenylacetamido ]-2-pyrrolidinylmethoxy]-3-mtrobenzoate (1.52 g, 82 %) as a yellow amorphous solid. 'H-NMR (CDC13) δ 1.91 (m, IH), 1.95 - 2.17 (m, 3H), 3.47 - 3.53 (m, 2H), 3.56 (s, 2H), 3.60 (m, IH), 3.68 (s, 3H), 3.90 (s, 3H), 4.11 (d, 7 = 7.3 Hz, IH), 4.45 (m, IH), 5.08 (s, 2H), 6. 70 (dd, 7= 8.3, 1.9 Hz, IH), 6.75 (d, 7 = 1.9 Hz, IH), 6.91 - 6.99 (m, 3H), 7.16 (s, IH), 7.18 (d, 7 = 8.3 Hz, IH), 7.33 - 7.40 (m, 6H), 7.91 (d, 7= 8.3 Hz, IH), 8.11 - 8.16 (m, 2H), 8.46 (s, IH).
A solution of methyl 4-[l-[4-[/V-(2-benzyloxyphenyl)ureido]-3-methoxyphenylacetamido]-2- pyrrolidinylmethoxy]-3-nitrobenzoate (1.52 g, 2.27 mmol) in MeOH (20 mL) and THF (5 mL) was hydrogenated over 5 % Pd-C (wet, 52.2%; 1.21 g) under hydrogen atmosphere (4 kg/cm2) at room temperature After being stirred for 17 hr, the catalyst was filtered off and the filtrate was concentrated to dryness. Chromatography of the residue with EtOAc as eluent gave methyl 3- amino-4-[ 1 -[4-[ΛT -(2-hydroxyphenyl)ureido] -3 -methoxyphenylacetamido] -2-pyrrolidinylmethoxy] benzoate (1.12 g, 90 %) as a brownish amorphous solid. 'H-NMR (CDC13) δ 1.97 - 2.10 (m, 4H), 3.44 (s, 3H), 3.52 - 3.63 (m, 2H), 3.85 (s, 3H), 4.10 - 4.18 (m, 2H), 4.53 (m, IH), 6.65 - 6.67 (m, 4H), 6.93 - 7.02 (m, 3H), 7.33 (d, 7= 2.2 Hz, IH), 7.36 (dd, 7= 8.3, 2.2 Hz, IH), 7.60 (s, IH), 7.69 (d, 7 = 8.3 Hz, IH), 8.08 (s, IH), 9.47 (broad s, IH); FAB-MS m/z 549 (M++l).
To a solution of methyl 3-amino-4-[l-[4-[N'-(2-hydroxyphenyl)ureido]-3-methoxyphenyl acetamido]-2-pyrrolidinylmethoxy]benzoate (1.12 g, 2.04 mmol) in THF - MeOH (4 : 1, v/v; 20 mL) was added IN NaOH (4.20 mL, 4.20 mmol). After being stirred at room temperature for 24 hr, the reaction mixture was concentrated. The residue was diluted with water and neutralized with IN HCl at 0 °C. The mixture was extracted with CHC13 - MeOH (4 : 1, v/v) .which was washed with brine, dried over Na2S04, and concentrated to dryness. Chromatography of the residue with CHC13 : MeOH (5 : 1, v/v) as eluent gave 60 (352 mg, 32 %) as a pale yellow amorphous solid. MW 534.56 IR (KBr) 3282, 3062, 3025, 2952, 2865, 1629, 1546, 1509, 1454, 1419 cm '; Η-NMR (DMSO-rf6) δ 1.87 - 2.04 (m, 4H), 3.48 - 3.57 (m, 2H), 3.60 (s, 2H), 3.79 (s, 3H), 3.94 (dd, 7 = 9.5, 7.6 Hz, IH), 4.12 (dd, 7= 9.5, 3.9 Hz), 4.35 (m, IH), 4.87 (broad s, IH), 6.70 - 6.91 (m, 6H), 7.16 (dd, IH, 7= 8.3, 2.0 Hz, IH), 7.26 (d, 7 = 2.0 Hz, IH), 7.96 (d, 7 = 8.3 Hz, IH), 7.97 (d, 7 = 8.3 Hz, IH), 8.80 (s, IH), 8.82 (s, IH); FAB-MS m z 535 (M++1); Anal. Calcd for C28H30N4O7-4.5H2O: C, 55.63; H, 6.39; N, 9.10. Found: C, 55.08; H, 5.06; N, 8.69. Example 56 5-[[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-2-pyrrolidinyl]methylamino] pyridine-2-carboxylic acid
Figure imgf000190_0001
5-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureιdo]phenylacetyl]-2-pyrrolιdιnyl]methylamιno] pyndιne-2-carboxylιc acid
Figure imgf000190_0002
To a stirred solution of 5-(methoxycarbonyl)pyndιne-2-carboxyhc acid (2 5 g, 13 8 mmol) and 4-
DMAP (340 mg, 2 8 mmol) in tert-BaOΑ (15 ml) was added Boc20 (6 g, 27 6 mmol) at room temperature After stirnng for 2 hr at room temperature, ice and 0 2 N HCl (20 ml) was added to the mixture and extracted with CH2C12 The extracts were washed with sat NaHC03, dned over
Na2S04, and evaporated The residue was chromatographed on silica gel (50ml) with CH2C12 as eluent to give methyl 6-ter/-butoxycarbonylnιcotinate (2 92 g, 89%) as needles IR (KBr) 2729,
1736, 1720, 1590, 1570 cm ', MS (FAB) m/z 238 (M+ +1), Anal Calcd for C12H15N04 C, 60 75, H,
6 37, N, 5 90 Found C, 60 72, H, 6 46, N, 5 78
A mixture of methyl 6-te -butoxycarbonylnιcotιnate (1 2 g, 5 06 mmol) m THF (15 ml) and 0 25 N NaOH (40 ml, 10 mol) at an ambient temperature for 0 5 hr The mixture was poured into ice-lN HCl (10 ml) The solid was collected, washed with water and air-dπed The crude solid was recrystallized from CHCl3-EtOH-IPE to afford 6-ferr-butoxycarbonylnιcotιnιc acid (850 mg, 76%) as needles IR (KBr) n3095, 1728, 1705 cm ', 'H-NMR (DMAO-c .) δ 1 63 (s, 9 H), 8 09 (m, 1 H), 8 17 (m, 1 H), 8 42 (dt, 7 = 2 4 and 8 3 Hz, 1 H), 9 21 (t, 7 = 2 4 and 8 8Hz, 1 H), MS (FAB) m/z 224 (M+ +l), Anal Calcd for C29H33N306 C, 36 18, H,3 18, N, 3 84 Found C, 36 85, H, 3 35, N, 3 79
To a stirred mixture of 6-te -butoxycarbonylnιcotιnιc acid (1 9 g, 8 51 mmol) and tnethylamine (1 17 g, 11 49 mmol) in tert-BυOH (30 ml) and toluene (30 ml) was added a solution of diphenyl phosphoryl azide (2 93 g, 10 64 mmol) in toluene (3 ml) at room temperature The resulting mixture was then heated at reflux for 5 hr After cooling, ice and IN HCl (5ml) was added to the mixture and extracted with toluene The extracts were washed with bnne, dned over Na2S04, and evaporated The residue was chromatographed on silica gel (50ml) with toluene- EtOAc (5 1, v/v) as eluent to give tert-bu yl 5-ferNbutoxycarbonyamιno-2-pyndιnecarboxylate (1 9 g, 76%) as a gum 'H-NMR (CDC13) δ 1 53 (s, 9 H), 1 63 (s, 9 H), 6 82 (br s, 1 H), 8 01 (d, 7 = 8 8 Hz, 1 H), 8 17 (m, 1 H), 8 46 (d, 7 = 2 4 Hz, 1 H) To a stirred mixture of tert-bu yl 5-terNbutoxycarbonyamino-2-pyridinecarboxylate (1.9 g, 6.45 mmol) in CH2C12 (20 ml) was added TFA (5 ml). The mixture was evaporated off, and the residue was dissolved in EtOH (30 ml). HCl-gas was induced to the solution with stirring at 0-10 °C for 10 min. The resulting stirred mixture was then heated at reflux for 10 hr. After cooling, N2-gas was induced to remove of large excess of HCl-gas for 15 min. the mixture was evaporated off. The residue was alkalized by the addition of sat. NaHC03, and extracted with CH2C12. The extracts were washed with brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica gel (30ml) with CHCl3-EtOH (98:2, v/v) as eluent to give ethyl 5- amino-2 -pyridine carboxylate (700 mg, 65%) as a crystalline material. IR (KBr) n 3423, 3190, 1708, 1657, 15873338, 3296, 1691, 1641 cm '; 'H-NMR (CDCl3)δ 1.42 (t, 7= 7.0 Hz, 3 H), 4.11 (br s, 1 H), 4.43(q, 7 = 7.0 Hz, 2 H), 6.99 (dd, 7= 2.7 and 8.5 Hz, 1 H), 7.95 (d, 7 = 8.5 Hz, 1 H), 8.16 (d, 7 = 2.7 Hz, 1 H); MS (FAB) m/z 167 (M+); Anal. Calcd for C27H29C1N406: C, 57.47; H, 6.63; N, 16.76. Found: C, 57.27; H, 5.99; N, 16.72.
A stirred mixture of ethyl 5-amino-2-pyridinecarboxylate (660 mg, 3.95 mmol) and 1- te -butoxycarbonyprolinal (1.1 g, 5.33 mmol) in toluene (10 ml) was heated at reflux for 1 hr, during which time water was azeotropically removed with Dean-Stark water-trap. After cooling, the mixture was evaporated in vacuo. The residue was dissolved in MeOH-AcOH (9:1, v/v, 30ml). To the stirred solution was added NaBH3CN (500 mg, 7.90 mmol) at 0-5 °C. The resulting mixture was stirred for a further 12 hr at room temperature. The mixture was piured into ice-sat NaHC03 (50 ml), and extracted with CH2C12. The extracts were washed with brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica gel (50ml) with CHC13- EtOAc (98:2, v/v) as eluent to give ethyl 5-[Λ -[2-(l-terNbutoxycarbony)pyrrolichnyl]methylamino] pyridine-2-carboxylate (1.1 g, 70%) as a gum. 'H-NMR (CDC13) δ 1.38 (s, 9 H), 1.42 (s, 6 H), 3.93 (s, 3 H), 4.29 (s, 2 H), 4.67 (br s, 1 H), 7.15 (d, 7 = 8.8 Hz, 1 H), 8.18 (dd, 7 = 1.7 and 8.8Hz, I H), 8.52 (d, 7 = 1.7 Hz, IH).
A mixture of ethyl 5-[[2-(l-før -butoxycarbony)pyrrolidinyl]methylamino]pyridine-2- carboxylate (800 mg, 2.29 mmol) in CH2C12 (17 ml) and TFA (3 ml) was stirred at room temperature for 3 hr. The mixture was evaporated, and the residue was made basic with sat. NaHC03. The mixture was extracted with CH2C12. The extracts were washed with brine, dried over Na2S04-Na2C03, and evaporated to give ethyl 5-[(2-pyrrolidinyl)methylamino]pyridine-2- carboxylate (460 mg, 81%) as a gum. 'H-NMR (CDC13) δ 1.32 (t, 7 = 7 Hz, 3 H), 1.58-2.10 (series of m, 4 H), 3.12-3.28 (series of m, 3 H), 3.65 (m, 1 H), 4.30 (be q, 7 = 7 Hz, 2 H), 6.27 (br, 1 H), 6.59 (dd, 7 = 2.4 and 8.5 Hz, 1 H), 7.65 (d, 7 = 8.5 Hz, 1 H), 7.94 (d, 7 = 2.4 Hz, IH).
To a stirred mixture of ethyl 5-[(2-pyrrolidinyl)methylamino]pyridine-2-carboxylate (220 mg, 0.88 mmol), 4-[Λ^-(2-chlorophenyl)ureido]-3-mefhoxyphenylacetic acid (300 mg, 0.88 mmol), 4- DMAP (135 mg, 1.10 mmol) in DMF (7 ml) was added EDC HCl (215 mg, 1.10 mmol) at room temperature. The resulting mixture was stirred at room temperature for 20 hr. The mixture was pored into ice-water. The solid was collected, washed with water and air-dried. The crude solid was purified by silica gel (30ml) column chromatography with CHC13- EtOH (98:2, v/v) as eluent and crystallized with Et20 to give 5-[l-[4-[Λ^-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-2- pyrrolidinyl]methylamino]pyridine-2 -carboxylate (420 mg, 84%) as fine needles. IR (KBr) 3319, 1703, 1628, 1585, 1529 cm '; 'H-NMR (CDCl3)δ 1.38 (t, 7= 7 Hz, 3 H), 1.73-2.17 (series of m, 4 H), 3.19 and 3.54 (each m, each 1 H), 3.63 (s, 2 H), 3.70 (s, 3 H), 4.39 (be q, 7 = 7 Hz, 2 H), 4.55 (m, 1 H), 6.02 (br s, 1 H), 6.78-6.84 (series of s and m, 3 H), 6.98 (dt, 7 = 2.4 and 8.0 Hz, 1 H), 7.16 (s, 1 H), 7.21-7.26 (series of m, 3 H), 7.34 (dd, 7= 2.4 and 8.0 Hz, 1 H), 7.90 (d, 7 = 8.3 Hz, IH), 7.98 (m, 2H), 8.16 (dd, 7 = 1.2 and 8.8 Hz, IH); MS (FAB) m/z 566 (M+ +l); Anal. Calcd for C29H32C1N505 H20: C, 59.63; H, 5.87; N, 12.37. Found: C, 60.06; H, 5.76; N, 11.95.
A mixture of ethyl 5-[[l-[4-[Λ^-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-2- pyrrolidinyl]methylamino]pyridine-2-carboxylate (300 mg, 0.53 mmol) in THF:MeOH (1:1, v/v, 16 ml) and 0.25N NaOH (11 ml, 2.75 mmol) was stirred for 3 hr at room temperature. The mixture was poured into ice-lN HCl (3 ml). The solid was collected, washed with water and air- dried. The crude crystalline material was collected with CH2C12-Et20 to give 61 (180 mg, 63%) as an amorphous solid. MW 537.99 IR (KBr) 3319, 1701, 1620, 1585, 1533 cm '; 'H-NMR (CDC13) δ 'H-NMR (DMSO-cL.) δ 1.80-2.05 (series of m, 4 H), 2.99 (m, 1 H), 3.50- 3.59 (series of m, 3 H), 3.60 (s, 2 H), 3.86 (s, 3 H), 4.11 (m, 1 H), 6.78 (d, 7= 8.5 Hz, 1 H), 6.91 (s, 1 H), 6.94 (m, 1 H), 7.02 (m, 1 H), 7.14 (dd, 7 = 2.5 and 8.5 Hz, 1 H), 7.28 (t, 7 = 7.0 Hz, 1 H), 7.45 (d, 7= 8.0 Hz, 1 H), 7.78 (d, 7 = 8.8 Hz, 1 H), 7.97 (d, 7= 8.3 Hz, 1 H), 8.08 (br s, 1 H), 8.11 (m, 1 H), 8.89 (s, 1
H), 8.94 (s, 1 H); MS (FAB) m/z 538 (M+ +\); Anal. Calcd for C27H28ClN505 1.5xH20: C, 57.39; H, 5.53; N, 12.39. Found: C, 57.37; H, 5.54; N, 11.74.
To a stirred mixture of ethyl 5-[(2-pyrrolidinyl)methylamino]pyridine-2-carboxylate (230 mg, 0.923 mmol), 3-methoxy-4-[Λ/'-(2-methylphenyl)ureido]phenylacetic acid (290 mg, 0.923 mmol), 4-DMAP (145 mg, 1.15 mmol) in DMF (7 ml) was added EDC HCl (225 mg, 1.15 mmol) at room temperature. The resulting mixture was stirred at room temperature for 20 hr. The mixture was pored into ice-water. The solid was collected, washed with water and air-dried. The crude solid was purified by silica gel (30ml) column chromatography with CHC13- EtOH (98:2, v/v) as eluent to give ethyl 5-[[l-[3-methoxy-4-[Λ^-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl] methylamino]pyridine-2-carboxylate (400 mg, 80%) as fine needles. IR (KBr) n 3325, 1709, 1618, 1585, 1531 cm '; 'H-NMR (CDC13) δ 1.39 (t, 7= 7 Hz, 3 H), 1.73-2.07 (series of m, 4 H), 2.28 (s, 3 H), 3.12 and 3.49 (each m, each 1 H), 3.60 (s, 2 H), 4.39 (br q, 7= 7 Hz, 2 H), 4.53 (m, 1 H), 6.07 (br s, 1 H), 6.23 (br s, 1 H), 6.75-6.77 (series of s and m, 2 H), 6.82 (dd, 7= 3.0 and 8.5 Hz, 1 H), 7.09-7.22 (series of m, 3 H), 7.49 (d, 7= 8.0 Hz, 1 H), 7.90 (d, 7= 8.5 Hz, IH), 7.98 (d, 7= 2.6 Hz, IH), 8.06 (d, 7 = 8.8 Hz, IH); MS (FAB) m/z 546 (M+ +1); Anal. Calcd for C30H35N5O5 1.5xH2O: C, 52.92; H, 6.69; N, 12.23. Found: C, 63.11; H, 6.48; N, 11.96.
A mixture of ethyl 5-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2- pyrrolidinyl]methylamino]pyridine-2-carboxylate (D91-4596) (290 mg, 0.53 mmol) in THF:MeOH (1:1, v/v, 16 ml) and 0.25N NaOH (11 ml, 2.75 mmol) was stirred for 3 hr at room temperature. The mixture was poured into ice-lN HCl (3 ml). The solid was collected, washed with water and air-dried. The crude crystalline material was collected with CH2C12-Et20 to give 62 (170 mg, 62%) as an amorphous solid. MW 517.58 IR (KBr) 3283, 1701, 1618, 1529 cm '; 'H-NMR (CDC13) δ 'H-NMR (DMSO-c .) δ 1.78-2.04 (series of m, 4 H), 2.25 (s, 3 H), 2.95-3.55 (series of m, 4 H), 3.59 (s, 2 H), 3.87 (s, 3 H), 4.11 (m, 1 H), 6.75-7.24 (series of m, 7 H), 7.83-7.97 (series of m, 3 H), 8.01 (d, 7= 8.3 Hz, 1 H), 8.13 (d, 7= 2.6 Hz, I H), 8.11 (m, 1 H), 8.47 (s, 1 H), 8.57 (s, 1 H); MS (FAB) m/z 518 (M+ +1); Anal. Calcd for C28H31N505-2.5xH20: C, 60.50; H, 6.39; N, 12.60. Found: C, 60.31; H, 6.28; N, 12.10. Example 57
2-[l-[[4-[/V-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-2-pyrrolidiny]methoxy]pyridine-5- carboxylic acid
Figure imgf000193_0001
To a stirred solution of methyl 2-hydroxy-5-pyridinecarboxylate (2.0 g, 13.06 mmol), PPh3 (4.2 g,
15.93 mmol) and l-fe -butoxycarbony-(Z)-prolinol (2.63 g, 13.06 mmol) in THF (25 ml) was added a solution of DIAD (3.3 g, 15.67 mmol) in THF (5 ml) at 0-10 °C The resulting stirred mixture was then heated at reflux for 3 hr. After cooling, the mixture wsa evaporated in vacuo. The residue was chromatographed on silica-gel (120ml) with n-hexane-EtOAc (4:1, v/v) as eluent to give methyl 2-[2-(l-ter -butoxycarbony)pyrrolidinyl]methoxypyridine-5-carboxylate (3.0 g, 68%) as a gum. 'H-NMR (CDC13) δ 1.46 (s, 9 H), 1.82-2.04 (series of m, 4 H), 3.45 (m, 2 H), 3.91 (s, 3 H), 4.10-4.32 (series of m, 2 H), 4.48 (m, 1 H), 6.32 (br, 1 H), 6.75 (d, 7 = 8.8 Hz, 1 H), 8.15 (dd, 7= 2 and 8.8Hz, 1 H), 8.79 (d, 7= 2 Hz, IH).
A mixture of methyl 2-[2-(l-/er butoxycarbony)pyrrolidinyl]methoxypyridine-5- carboxylate (2.9 g, 8.62 mmol) in CH2C12 (80 ml) and TFA (20 ml) was stined at room temperature for 3 hr. The mxture was evaporated, and the residue was alkalized with sat. NaHC03. The mixture was extracted with CH2C12. The extracts were washed with brine, dried over Na2S04-Na2C03, and evaporated to give methyl 2-(2-pyrrolidinyl)methoxypyridine-5- carboxylate (1.2 g, 59%) as a gum. 'H-NMR (CDCl3)δ 1.58-2.050 (series of m, 4 H), 2.90-3.02 (series of m, 2 H), 3.87 and 3.90 (each s, 3 H), 4.23 (m, 1 H), 4.37 (m, 1 H), 6.33 (br, 1 H), 6.78 (d, 7= 8.5 Hz, 1 H), 8.15 (dd, 7= 2.2 and 8.8 Hz, 1 H), 8.79 (d, 7= 2.2 Hz, IH).
To a stirred mixture of methyl 2-(2-pyrrolidinyl)methoxypyridine-5-carboxylate (370 mg, 1.57 mmol), 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (525 mg, 1.57 mmol), 4- DMAP (230 mg, 1.88 mmol) in DMF (10 ml) was added EDC HCl (360 mg, 1.88 mmol) at room temperature. The resulting mixture was stirred at room temperature for 20 hr. The mixture was pored into ice-water. The solid was collected, washed with water and air-dried. The crude solid was purified by silica-gel (30ml) column chromatography with CHC13- EtOH (98:2, v/v) as eluent and crystallized with Et20 to give methyl 2-[l-[4-[Λ -(2-chlorophenyl)ureido]-3-methoxyphenyl acetyl]-2-pyrrolidinylmethoxy]pyridine-5-carboxylate (600 mg, 69%) as an amorphous solid. 'H-NMR (CDC13) δ .21 and 2.01 (each m, 4 H), 3.45-4.50 (series of s and m, 13 H which contains amide-isomers), 6.58-8.83 (series of s and m, 12 H which contains amide-isomers)
A mixture of methyl 2-[l-[4-[7V-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-2- pyrrolidinylmethoxy]pyridine-5-carboxylate (230 mg, 0.415 mmol) in THF (1 ml) and 0.25N NaOH (4 ml, 1 mmol) was stirred for 14 hr at room temperature and for 3 hr at 60 °C Afrter cooling, the mixture was poured into ice-lN HCl (2 ml). The solid was collected, washed with water and air-dried. The crude crystalline material was purified by preparative TLC plate with CHCl3-EtOH (9: 1, v/v) as eluent and crystallized with Et20 to give 63 (150 mg, 67%) as an amorphous solid. MW 538.98 IR (KBr) 3329, 1709, 1601, 1533 cm '; 'H-NMR (CDC13) δ 1.85- 2.05 (series of m, 4 H), 3.50-3.60 (series of m, 2 H), 3.82 (s, 3 H), 3.86 (s, 2 H), 4.29 (m, 1 H), 4.42 (m, 1 H), 6.72-7.05 (series of m, 4 H), 7.28 (m, 1 H), 7.43 (d, 7= 8 Hz, 2 H), 7.95 (d, 7 = 8.3 Hz, 1 H), 8.09 (d, 7 = 8.3 Hz, 2 H), 8.64 (m, 1 H), 8.89 (s, 1 H), 8.93 (s, 1 H); MS (FAB) m/z 539 (M+ ); Anal. Calcd for C27H28ClN406-1.3xH20: C, 57.55; H, 5.47; N, 9.94. Found: C, 57.94; H, 5.00; N, 9.45. Example 58
5-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-2-pyrrolidinylmethoxy]pyridine-2- carboxylic acid
Figure imgf000195_0001
To a stirred mixture of methyl 5-(2-pyrrolidinyl)methoxypyridine-2-carboxylate (370 mg, 1.57 mmol), 4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (595 mg, 1.57 mmol), 4- DMAP (230 mg, 1.88 mmol) in DMF (10 ml) was added EDC HCl (360 mg, 1.88 mmol) at room temperature. The resulting mixture was stirred at room temperature for 20 hr. The mixture was pored into ice-water. The solid was collected, washed with water and air-dried. The crude solid was purified by silica-gel (30ml) column chromatography with CHC13- EtOH (98:2, v/v) as eluent and crystallized with Et20 to give methyl 5-[l-[4-[Λ/,-(2-bromophenyl)ureido]-3-methoxypheny lacetyl] -2 -pyrrolidinylmethoxy]pyridine-2 -carboxylate (650 mg, 69%) as an amorphous solid. IR (KBr) n 3323, 1720, 1624, 1601, 1527 cm 1; 'H-NMR (CDC13) δ 1.22 and 2.00 (each m, 4 H),
3.48-4.55 (series of s and m, 13 H which contains amide-isomers), 6.93-8.82 (series of s and m, 12 H which contains amide-isomers); MS (FAB) m/z 597 (M+ -1) and 599 (M+ +1); Anal. Calcd for C28H30BrN4O6-1.0xH2O: C, 54.55; H, 5.23; N, 9.09. Found: C, 54.13; H, 5.03; N, 9.33.
A mixture of methyl 5-[l-[4-[Λ^-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-2- pyrrolidinylmethoxy]pyridine-2 -carboxylate (300 mg, 0.5 mmol) in THF:MeOH (1:1, v/v, 2 ml) and 0.25N NaOH (4 ml, 1 mmol) was stirred for 3 hr at room temperature and for 5 hr at 60 °C. Afrter cooling, the mixture was poured into ice-lN HCl (2 ml). The solid was collected, washed with water and air-dried. The crude crystalline material was purified by preparative TLC plate with CHCl3-EtOH (9:1, v/v) as eluent and crystallized with Et20 to give 64 (180 mg, 62%) as an amorphous solid. MW 583.43 IR (KBr) n 3319, 1705, 1685, 1601, 1529 cm '; 'H-NMR (DMSO- cL.) δ 1.82-2.05 (series of m, 4 H), 3.48-3.58 (series of m, 2 H), 3.82 (s, 3 H), 3.86 (s, 2 H), 4.42- 4.55 (series of m, 3 H), 6.72-6.98 (series of m, 4 H), 7.32 (t, 7= 8 Hz, 1 H), 7.60 (d, 7 = 8 Hz, 1 H), 7.95 (m, 2 H), 8.08 (m, 1 H), 8.63 (m, 1 H), 8.64 (m, 1 H), 8.89 (s, 1 H), 8.93 (s, 1 H); MS (FAB) m/z 583 (M+ ); Anal. Calcd for C27H28BrN4O6-2.0xH2O: C, 52.26; H, 5.20; N, 9.03. Found: C, 52.72; H, 4.63; N, 8.50. Example 59
4-[l-[3-[A^'-(2-bromophenyl)ureido]-2-methoxy-6-pyridylacetyl]-(4S)-fluoro-(2S)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000196_0001
To a stined solution of ethyl 3-amino-2-methoxy-6-pyridylacetate (1.61 g, 7.66 mmol) in THF (10 ml) were added 2-bromophenylisocyanate (948 ml, 7.66 mmol) and Et3N (107 ml, 0.776 mmol). After stirring overnight, the mixture was poured into H20 (100 ml) and extracted with CHC13- MeOH (4: 1, 2 x 200 ml). The combined extracts were dried over MgS04 and evaporated. The residue was recrystallized from CHCl3-MeOH-hexane to give ethyl 3-[N'-(2-bromophenyl)ureido]- 2-methoxy-6-pyridylacetate (2.91 g, 93%) as a colorless crystalline powder, mp 160-163 °C; 'H- NMR (DMSO-c .) δ 1.19 (dt, 7= 7.1, 0.7 Hz, 3 H), 3.69 (s, 2 H), 3.95 (s, 3 H), 4.07-4.13 (m, 2 H), 6.90 (d, 7= 7.8 Hz, 1 H), 6.99 (t, 7 = 7.8 Hz, 1 H), 7.33 (t, 7 = 7.8 Hz, 1 H), 7.61 (d, 7= 7.8 Hz, 1 H), 7.96 (dd, 7 =7.8, 1.5 Hz, 1 H), 8.31 (d, 7 = 7.8 Hz, 1 H), 8.82 (s, 1 H), 9.12 (s, 1 H); MS (FAB) m/z 408 (M+), 410 (M++2); Anal Calcd for C17H18BrN3O4-0.25 H20: C, 49.47; H, 4.52; 9.96. Found: C, 49.34; H, 4.48; N, 9.96.
A mixture of ethyl 3-[N'-(2-bromophenyl)ureido]-2-methoxy-6-pyridylacetate (2.90 g, 7.10 mmol), 0.25 N NaOH (56.8 ml, 14.2 mmol), and THF (50 ml) was stirred for 5 h. The mixture was neutralized with 1 N HCl and the resulting precipitate was collected by filtration. The residue was recrystallized from CHCl3-MeOH-hexane to give 3-[N'-(2-bromophenyl)ureido]-2- methoxy-6-pyridylacetic acid (2.40 g, 89%) as a colorless crystalline powder, mp 195-197 °C; ,H- NMR (DMSO-c .) δ 3.59 (s, 2 H), 3.95 (s, 3 H), 6.88 (d, 7 = 8.1 Hz, 1 H), 6.97-7.01 (m, 1 H), 7.33 (t, 7= 7.3 Hz, 1 H), 7.61 (d, 7= 8.1 Hz, 1 H), 7.95-7.97 (m, 1 H), 8.29 (d, 7= 8.1 Hz, 1 H), 8.81 (s, 1 H), 9.10 (s, 1 H), 12.35 (br s, 1 Η); Anal Calcd for C15H14BrN304: C, 47.39; H, 3.71; N, 11.05. Found: C, 47.27; H, 3.59; N, 10.86.
To a stirred solution of 3-[Λ -(2-bromophenyl)ureido]-2-methoxy-6-pyridylacetic acid
(751 mg, 1.97 mmol) and methyl (4S)-fluoro-(2S)-pyrrolidinylmethoxybenzoate (500 mg, 1.97 mmol) in DMF (10 ml) were added EDC HCl (566 mg, 2.96 mmol), DMAP (cat), and HOBt (cat.). After stirring overnight, the mixture was partitioned between EtOAc (200 ml) and brine (200 ml). The phases were separated. The organic phase was washed with brine (100 ml), dried over MgS04, and evaporated. The resulting residue was chromatographed on silica gel with CHCl3-MeOH (20: 1) as eluent to give methyl 4-[l-[3-[N'-(2-bromophenyl)ureido]-2-methoxy-6- pyridylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoate (1.16 g, 96%) as a yellow viscous solid.
A mixture of methyl 4-[l-[3-[N'-(2-bromophenyl)ureido]-2-methoxy-6-pyridylacetyl]- (4S>fluoro-(2S)-pyrrolidinylmethoxy]benzoate (1.16 g, 1.88 mmol), 0.25 N NaOH (15 ml, 3.75 mmol), and THF (15 ml) was stirred overnight. The mixture was neutralized with 1 N HCl and extracted with CHCl3-MeOH (4: 1, 2 x 200 ml). The combined extracts were dried over MgS04 and evaporated. The resulting residue was chromatographed on silica gel with CHCl3-MeOH (40: 1 to 10: 1) as eluent to give 65 as a pale yellow amorphous solid. MW 601.42 'H-NMR (DMSO-c .) δ 2.27-2.39 (m, 2 H), 3.33-4.84 (series of m, 10 H), 5.33-5.53 (m, 1 H), 6.87-6.90 (m, 1 H), 6.99 (t, 1 H, 7 = 7.6 Hz), 7.08 (d, 2 H, 7 = 9.0 Hz), 7.34 (t, 1 H, 7 = 7.6 Hz), 7.61 (d, 1 H, 7 = 7.8 Hz), 7.88 (d, 2 H, 7= 9.0 Hz), 7.97 (d, 1 H, 7= 8.3 Hz), 8.28-8.32 (m, 1 H), 8.81-8.82 (m, 1 H), 9.10-9.12 (m, 1 H), 12.66 (br s, 1 H); MS (FAB) /z 601 (M+), 603 (M++2); Anal. Calcd for C27H26BrFN406: C, 53.92; H, 4.36; N, 9.32. Found: C, 52.37; H, 4.62; N, 8.38. Example 60
4-[(4S)-fluoro-l-[4-[Λ''-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoic acid
Figure imgf000197_0001
To a stirred solution of 4-[jV'-(2-methylphenyl)ureido]phenylacetic acid (337 mg, 1.18 mmol) and methyl 4-[(45 -fluoro-(2S)-pyrrolidinylmethoxy]benzoate (300 mg, 1.18 mmol) in DMF (10 ml) were added EDCHCl (339 mg, 1.77 mmol), HOBt (cat.) and DMAP (cat.). The reaction mixture was stirred overnight. The mixture was partitioned between EtOAc (200) and H20 (200 ml) and the organic phase was separated. The organic phase was washed with brine (200 ml), dried over MgS04, and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (50: 1) to give methyl 4-[(4S)-fluoro-l-[4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl methoxy]benzoate (613 mg, quant) as a yellow viscous oil. Η-NMR (CDCl3)δ 2.03-2.55 (series of m, total 5 H), 3.47-4.21 (series of m, total 7 H), 4.44-4.60 (m, 3 H), 5.21 and 5.34 (m, each, total 1 H), 6.87-7.16 (m, 8 H), 7.52-7.55 (m, 3 H), 7.93 (d, 7= 8.8 Hz, 2 H), 7.99 (d, 7= 8.8 Hz, 1 H).
To a stirred solution of methyl 4-[(4S)-fluoro-l-[4-[N'-(2-methylphenyl)ureido] phenylacetyl]-(25 -pyrrolidinylmethoxy]benzoate (613 mg, 1.18 mmol) in THF (10 ml) was added 0.25 N NaOH (9.4 ml, 2.36 mmol). The mixture was refluxed for 1 day. After cooling to rt, the mixture was poured into 1 N HCl (50 ml) and extracted with CHCl3-MeOH (5:1, 2 x 200 ml). The combined extracts were dried over MgS04 and evporated. The residue was chromatographed on silica gel with CHCl3-MeOH (10:1) to give 66 (378 mg, 63%) as a colorless amorphous solid. MW 505.54 'H-NMR (DMSO-d^δ .08-2.30 (m, total 5 H), 3.47-4.63 (series of m, 7 H), 5.30-5.50 (m, 1 H), 6.94 (t, 7= 7.3 Hz, 1 H), 7.02-7.17 (m, 6 H), 7.37-7.41 (m, 2 H), 7.82-7.96 (m, 4 H), 9.05 (s, 1 H); MS (FAB) m/z 506 (M++l); Anal. Calcd for C28H28FN3Os-1.75 H20: C, 62.62; H, 5.91; N, 7.82. Found: C, 62.23; H, 5.63; N, 7.18. Example 61 4-[(4.S -fluoro-l-[3-methoxy-4-[A^-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000198_0001
To a stirred solution of l-(fe/^butoxycarbonyl)-(4S)-fluoro-(2S)-proline (1.85 g, 7.93 mmol) in
THF (15 ml) was added BH3 DMS (0.75 ml, 7.93 mmol) at room temperature. After being heated at reflux for 5 h with stirring, the mixture was cooled to room temperature and concentrated in vacuo. The resulting residue was quenched by the addition of H20 (100 ml) and extracted with
CHC13 (2 x 200 ml). The combined extracts were washed with brine (100 ml), dried over MgS04, and evaporated. The residue was chromatographed on silica gel with CHCl3-EtOAc (4: 1) as eluent to give l-(/er^-butoxycarbonyl)-(4S)-fluoro-(25)-pyrrolidinylmethanol (1.76 g, quant) as a colorless oil. 'H-NMR (CDC13) δ 1.48 (s, 9 H), 1.64 (m, 1 H), 1.97-2.28 (m, 2 H), 3.53-3.87 (series of m, 4
H), 4.09-4.25 (m, 1 H), 5.09 and 5.22 (m, each, total 1 H).
To a stirred mixture of l-(/e^-butoxycarbonyl)-(4S)-fluoro-(2S)-pyrrolidinylmethanol (500 mg, 2.28 mmol), methyl 4-hydroxybenzoate (416 mg, 2.74 mmol), Ph-f (719 mg, 2.74 mmol) in THF (10 ml) was added DIAD (0.54 ml, 2.74 mmol) at room temperature. The mixture was heated to reflux for 5 h with stirring. After cooling to room temperature, the mixture was concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-EtOAc as eluent (10: 1 to 4:1) to give methyl 4-[l-(ter butoxycarbonyl)-(4S)-fluoro-(2S)-pyrrolidinyl mefhoxy]benzoate (597 mg, 74%) as a colorless oil. 'H-NMR (CDC13) δ 1.49-1.59 (m, 9 H), 2.05- 2.21 (m, 1 H), 3.56-4.43 (series of m, 8 H), 5.19 and 5.32 (m, each, total 1 H), 6.97 (m, 2 H), 7.98 (d, 7 = 8.5 Hz, 2 H). A mixture of methyl 4-[l-(ter butoxycarbonyl)-(45)-fluoro-(2S)-pyrrolidinylmethoxy] benzoate (590 mg, 1.67 mmol) and TFA (5 ml) in CH2C12 (5 ml) was stirred for 3 h. After the mixture was concentrated in vacuo, the residue was made basic with sat. NaHC03 and extracted with CHC13 (2 x 200 ml). The combined extracts were dried over K2C03 and evaporated to give methyl 4-[(4S)-fluoro-(2S pyrrolidinylmefhoxy]benzoate (414 mg, 98%) as a yellow solid. 'H- NMR (CDC13) δ 1.89-2.02 (m, 1 H), 2.16-2.31 (m, 1 H), 2.98 (m, 1 H), 3.35 (m, 1 H), 3.46-3.68 (m, 1 H), 3.86 (s, 3 H), 4.00-4.08 (m, 2 H), 5.16 and 5.29 (t, each, 7= 4.7 Hz, total 1 H), 6.91 (d, 7 = 8.8 Hz, 2 H), 7.96 (d, 7 = 8.8 Hz, 2 H).
A mixture of methyl 4-[(4S)-fluoro-(25)-pyrrolidinylmethoxy]benzoate (205 mg, 0.810 mmol), 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (254 mg, 0.810 mmol), EDC HCl (233 mg, 1.22 mmol), HOBt (cat.), and DMAP (cat.) in DMF (10 ml) was stirred overnight. The mixture was diluted with EtOAc (200 ml), washed with brine (2 x 100 ml), dried over MgS04, and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (20:1) as eluent to give methyl 4-[(4S)-fluoro-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoate (445 mg, quant) as a light brown viscous. 'H- NMR (CDCl3)δ 2.05-2.55 (m, total 6 H), 3.55-4.13 (m, 11 H), 4.48-4.60 (m, 2 H), 5.20 and 5.33 (each m, total 1 H), 6.29 (s, 1 H), 6.79 (m, 2 H), 6.96 (d, 7 = 8.8 Hz, 2 H), 7.11-7.25 (m, 3 H), 7.48 (d, 7= 7.6 Hz, 1 H), 7.93-8.09 (m, 4 H).
A mixture of methyl 4-[(4S)-fluoro-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-(25)-pyrrolidinylmethoxy]benzoate (445 mg, 1.62 mmol) and 0.25 N NaOH (15 ml, 3.75 mmol) in THF (15 ml) was stirred overnight at room temperature then for 2 h at reflux. The mixture was acidified with 1 N HCl and extracted with CHCl3-MeOH (4: 1, 2 x 200 ml). The combined extracts were dried over MgS04 and evaporated. The residue was chromtographed on silica gel with CHCl3-MeOH (10: 1) as eluent to give 67 (260 mg, 30%) as a pale yellow amorphous solid. MW 535.56 'H-NMR (DMSO-c .) δ 2.25-2.51 (m, 5 H), 3.33-4.41 (series of m, 10 H), 5.30-5.50 (m, 1 H), 6.75-7.17 (m, 7 H), 7.79 (d, 7 = 8.1 Hz, 1 H), 7.87-8.04 (m, 3 H), 8.48 (m, 1 H), 8.58 (m, 1 H); MS (FAB) m/z 536 (M++1); Anal. Calcd for C29H30FN3O6-H2O: C, 62.92; H, 5.83; N, 7.59. Found: C, 62.40; H, 5.82; N, 6.93. Example 62 4-[l-[4-[N'-(2-Bromophenyl)ureido]-3-methoxyphenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000200_0001
A mixture of methyl 4-[(45 -fluoro-(2S)-pyrrolidinylmethoxy]benzoate (501 mg, 1.98 mmol), 4-
[N'-(2-bromophenyl) eido]-3-methoxyphenylacetic acid (750 mg, 1.98 mmol), EDCHCl (569 mg, 2.97 mmol), HOBt (cat) and DMAP (cat.) in DMF (10 ml) was stirred overnight. The mixture was diluted with EtOAc (300 ml), washed with brine (100 ml), dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHCl3-EtOAc (4: 1) to CHC13-
MeOH (10: 1) as eluent to give methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl acetyl]-(45 -fluoro-(2S)-pynolidinylmethoxy]benzoate (1.29 g, quant) as a brown viscous oil. 'H-
NMR (CDC13) δ 2.05-2.58 (m, 2 H), 3.49-4.17 (series of m, 12 H), 4.52-4.65 (m, 2 H), 6.82-7.33 (series of m, 8 H), 7.53 (dd, 7 = 8.1, 1.5 Hz,lH), 7.95-8.02 (m, 4H), 8.14 (dd, 7 = 8.3, 1.7 Hz, IH).
A mixture of methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(4S)- fluoro-(25)-pyrrolidinylmethoxy]benzoate (1.29 g, 2.10 mmol) and 0.25 N NaOH (17 ml, 4.20 mmol) in THF (20 ml) was refluxed for 5 h with stirring. The mixture was poured into ice-cooled 1 N HCl (100 ml) and extracted with CHCl3-MeOH (4: 1, 2 x 200 ml). The combined extracts were dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHC13-
MeOH (10: 1) as eluent to give 68 (860 mg, 68%) as a colorless amorphous solid. MW 600.43 'H- NMR (DMSO-c ,) δ 2.24-2.31 (m, 2 H), 3.21-4.63 (series of m, 10 H), 5.31-5.51 (m, 1 H), 6.74- 7.10 (m, 5 H), 7.32 (t, 7= 7.8 Hz, 1 H), 7.60 (d, 7= 7.8 Hz, 2 H), 7.87-7.99 (m, 4 H), 8.74-8.75 (m, 1 H), 8.92-8.94 (m, 1 H); MS (FAB) m/z 601 (M++l); Anal. Calcd for C28H27BrFN306-2 H20: C, 52.84; H, 4.91; N, 6.60. Found: C, 52.38; H, 4.62; N, 5.99. For Na salt of 68: mp 180-182 °C; Anal. Calcd for C28H27BrFN3NaO6-0.75 H20: C, 52.88; H, 4.36; N, 6.61. Found: C, 52.97; H, 4.36; N, 6.61. Example 63 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000200_0002
A mixture of methyl 4-[(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoate (205 mg, 0.810 mmol), 3- methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (254 mg, 0.810 mmol), EDC HCl (233 mg, 1.22 mmol), HOBt (cat.) and DMAP (cat.) in DMF (10 ml) was stirred overnight The mixture was diluted with EtOAc (200 ml), washed with brine (2 x 100 ml), dried over MgS04, and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (20:1) as eluent to give methyl 4-[l-[4-[iV -(2 -chlorophenyl)ureido]-3-methoxyphenylacetyl]-(45)-fluoro-(2S)- pyrrolidinylmethoxy]benzoate (376 mg, 81%) as a yellow foam. 'H-NMR (CDC13) δ 2.07-2.56 (m, 2 H), 3.57-4.14 (series of m, 11 H), 4.50-4.61 (m, 2 H), 5.22 and 5.35 (series of m, total 1 H), 6.80-7.33 (series of m, 9 H), 7.93-8.00 (m, 3 H), 8.16 (d, 7= 8.1 Hz, 1 H).
A mixture of methyl methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]- (4S)-fluoro-(25 -pyrrolidinylmethoxy]benzoate (376 mg, 0.660 mmol) and 0.25 N NaOH (15 ml, 3.75 mmol) in THF (15 ml) was stirred overnight at room temperature then for 2 h at reflux. The mixture was acidified with 1 N HCl and extracted with CHCl3-MeOH (4: 1, 2 x 200 ml). The combined extracts were dried over MgS04 and evaporated. The residue was chromtographed on silica gel with CHCl3-MeOH (20:1) as eluent to give 69 (260 mg, 30%) as a pale yellow amorphous solid. MW 555.98 'H-NMR (DMSO-c .)δ 2.24-2.501 (m, 2 H), 3.48-4.65 (series of m, 10 H), 5.30-5.50 (m, 1 H), 6.75-7.08 (m, 5 H), 7.29 (t, 7= 7.3 Hz, 1 H), 7.43-7.45 (m, IH), 7.89- 7.98 (m, 2 H), 7.99 (d, 7= 8.3 Hz, 1 H), 8.09 (d, 7 = 7.1 Hz, 1 H), 8.90-8.96 (m, 2 H); MS (FAB) m/z 556 (M++l); Anal. Calcd for C28H27C1FN306 1/4H20: C, 60.00; H, 4.95; N, 7.50. Found: C, 59.67; H, 5.08; N, 7.10. Example 64 4-[l-[4-[N'-(2-bromophenyl)ureido]phenylacetyl]-(4S)-fluoro-(25 -pyrrolidinylmethoxy]benzoic acid
Figure imgf000201_0001
Methyl 4-[l-(4-benzyloxycarbonylaminophenylacetyl)-(4S)-fluoro-(2S)-pyrrolidinylmethoxy] benzoate (300 mg, 0.576 mmol) was tsdded EtOH-THF (5: 1, 30 ml) and the solution was hydrogenated over 5% Pd/C (300 ml) for 12 h while stirring. The mixture was filtered to remove the catalyst. The filtrate was concentrated under a reduced pressure. The residue was chromatographed on silica gel with CHCl3-MeOH (20: 1) as eluent to give methyl 4-[l-(4- aminophenylacetyl)-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoate (200 mg, 90%) as a yellow oil. 'H-NMR (CDC13) δ 2.01-2.56 (series of m, 2 H), 3.50-4.14 (series of m, 5 H), 4.45-4.62 (m, 2 H), 5.21 and 5.34 (each m, total 1 H), 6.60-6.65 (m, 2 H), 6.88 (d, 7= 8.8 Hz, 0.5 H), 6.99-7.05 (m, 3.5 H), 7.95-8.00 (m, 2 H). methyl 4-[l-(4-aminophenylacetyl)-(45)-fluoro-(2S)-pyrrolidinylmethoxy]benzoate (200 mg, 0.518 mmol) was dissolved THF (10 ml). Et3N (108 ul, 0.776 mmol) and 2-bromophenylisocyanate (96 ul, 0.776 mmol) were added to the solution. The mixture was stirred overnight and diluted with EtOAc (200 ml). The solution was washed with brine (100 ml), dried over MgS04, and the solvent was removed under a reduced pressure. The residue was chromatographed on silica gel with
CHCl3-EtOAc (4: 1) to CHCl3-MeOH (10:1) as eluent to give methyl 4-[l-[4-[N'-(2-bromophenyl) ureido]phenylacetyl]-(4S)-fluoro-(2S -pyrrolidinylmethoxy]benzoate (303 mg, quant) as a yellow oil. 'H-NMR (CDC13) δ 2.08-2.60 (series of m, 2 H), 3.56-4.69 (series of m, 10 H), 5.28 and 5.40 (m, each, total 1 H), 6.84-6.92 (m, 3 H), 7.03-7.10 (m, 3 H),7.14(d, 7=8.1 Hz,l H), 7.23 (t, 7= 8.1 Hz, 1 H), 7.39-7.44 (m, 2 H), 7.89 (d, 7 = 8.1 Hz, 1 H), 7.98-8.03 (m, 2H), 8.09(d, 7= 8.1 Hz, IH).
Methyl 4-[l-[4-[N' -(2 -bromophenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S -pyrrolidinyl-methoxy] benzoate (300 mg, 0. 13 mmol) was dissolved THF (5 ml), and 0.25 N NaOH (4.0 ml, 1.00 mmol) was added to this solution. After being stirred for 3 days, the mixture was poured into 1 N HCl (100 ml), and extracted with CHCl3-MeOH (5: 1, 2 x 200 ml). The combined extracts were dried over MgS04 and the solvent was removed under a reduced pressure. The residue was chromatographed on silica gel with CHCl3-MeOH (10: 1) to give 70 (209 mg, 71%) as a colorless amorphous solid. MW 570.41 'H-NMR (DMSO-c ,)δ 2.24-2.51 (m, 2 H), 3.36-4.64 (series of m, 7 H), 5.31-5.50 (m, 1 H), 6.97 (t, 7= 7.8 Hz, 1 H), 7.04 (d, 7 = 8.5 Hz, 1 H), 7.09 (d, 7= 8.8 Hz, 1 H), 7.14-7.20 (m, 2 H), 7.34 (t, 7= 7.8 Hz, 1 H), 7.38-7.43 (m, 2 H), 7.61 (d, 7= 8.1 Hz, 1 H), 7.87-7.92 (m, 2 H), 8.08 (d, 7= 8.1 Hz, 1 H), 8.15 (s, 1 H), 9.45-9.47 (m, 1 H), 12.66 (br s, 1 H); MS (FAB) m/z 572 (M++2), 570 (M+); Anal. Calcd for C27H25BrFN305 1.5 H20: C, 54.28; H, 4.72; N, 7.03. Found: C, 54.67; H, 4.51; N, 6.61. Example 65 4-[l-[4-[N'-(2-iodophenyl)ureido]-3-methoxyphenylacetyl]-(4S -fluoro-(25)-pyrrolidinylmethoxy] benzoic acid
Figure imgf000202_0001
To a stirred solution of tert-but l 4-amino-3-methoxyphenylacetate (1.94 g, 8.16 mmol) in THF
(20 ml) was added 2-iodophenylisocyanate (2.0 g, 8.16 mmol) and Et3N (114 ul, 0.816 mmol).
After stirring overnight, the mixture was poured into 1 N HCl (200 ml). The resulting precipitate was collected by fϊltlation and dissolved in CHC13 (200 ml). The solution was dried over MgS04 and evaporated to give tert-butyl 4-[λr'-(2-iodophenyl)ureido]-3-mefhoxyphenylacetate (3.93 g, quant) as a pale yellow amorphous solid. 'H-NMR (CDCl3)δ 1.44 (s, 9 H), 3.49 (s, 2 H), 3.85 (s, 3 H), 6.78-6.88 (m, 4 H), 7.07 (s, 1 H), 7.31-7.35 (m, 1 H), 7.76 (dd, 7= 7.8, 1.5 Hz, 1 H), 7.95 (d, 7 = 8.3 Hz, 1 H), 7.99 (dd, 7 = 8.3, 1.5 Hz, 1 H). MS (ESI), m/z 483 (M++l).
A stirred mixture of ter/-butyl 4-[Λp-(2-iodophenyl)ureido]-3-methoxyphenylacetate (3.93 g, 8.16 mmol) and TFA (5 ml) in CH2C12 (5 ml) was refluxed for 3 h. After cooling to rt, the mixture was concentrated in vacuo and H20 (50 ml) was added to this residue. The resulting precipitate was collected by filtration and purified by column chromatography on silica gel with CHCl3-MeOH (9: 1) as eluent to give 4-[Λ^-(2-iodophenyl)ureido]-3-methoxyphenylacetic acid (2.89 g, 83%) as a pale yellow crystalline powder. 'H-NMR (DMSO-d^δ 3.62 (s, 2 H), 3.88 (s, 3 H), 6.78 (d, 7= 8.3 Hz, 1 H), 6.83-6.87 (m, 1 H), 6.94 (s, 1 H), 7.32-7.36 (m, 1 H), 7.69 (dd, 7 = 8.3, 1.5 Hz, 1 H), 7.84 (dd, 7= 8.3, 1.5 Hz, 1 H), 7.97-8.00 (m, 1 H), 8.55 (m, 1 H), 8.82 (m, 1 H), 12.26 (br s, 1 H).
A mixture of 4-[N'-(2-iodophenyl)ureido]-3-methoxyphenylacetic acid (505 mg, 1.18 mmol), methyl 4-[(45)-fluoro-(2S)-pyιτolidinylmethoxy]benzoate (300 mg, 1.18 mmol), EDCHCl (339 mg, 1.77 mmol), DMAP (catatlytic amount) and HOBt (catalytic amount) in DMF (10 ml) was stirred overnight. The mixture was diluted with EtOAc (300 ml) and washed with brine (2 x 200 ml). The solution was dried over MgS04 and evaporated. The resulting residue was chromatographed on silica gel with CHCl3-EtOAc (4:1) as eluent to give methyl 4-[l-[4-[N'-(2- iodophenyl)ureido]-3-methoxyphenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoate (500 mg, 64%) as a colorless viscous oil. 'H-NMR (CDC13) δ 07-2.58 (m, 2 H), 3.59-4.20 (m, 11 H), 4.51-4.64 (m, 2 H), 5.24 and 5.37 (m, each, total 1 H), 6.80-6.91 (m, 5 H), 6.98 (d, 7 = 8.8 Hz, 2 H), 7.34 (t, 7 = 7.8 Hz, 1 H), 7.78 (dd, 7 = 7.8, 1.2 Hz, 1 H), 7.95-8.02 (m, 4 H).
To a stirred solution of methyl 4-[l-[4-[N'-(2-iodophenyl)ureido]-3-methoxyphenyl acetyl]-(4S)-fluoro-(25)-pyrrolidinylmethoxy]benzoate (500 mg, 0.756 mmol) in THF (6 ml) was added 0.25 N NaOH (6 ml). The stirring was continued overnight at room temperature then 5 h at reflux. After cooling to rt, the solution was poured into 1 N HCl (100 ml) and extracted with CHCl3-MeOH (4: 1, 2 x 200 ml). The combined extracts were dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (10:1) as eluent to give 71 (295 mg, 60%) as a colorless amorphous solid. MW 647.43 'H-NMR (DMSO-c ,)δ 2. 2.09-2.31 (m, 2 H), 3.33-4.41 (series of m, 10 H), 5.30-5.50 (m, 1 H), 6.77-6.92 (m, 3 H), 7.03-7.09 (m, 2 H), 7.34 (t, 7 = 8.1 Hz, 1 H), 7.69 (dd, 7 = 8.3, 1.5 Hz, 1 H), 7.83-7.99 (m, 4 H), 8.54 (m, 1 H), 8.82 (m, 1 H); MS (FAB) m/z 648 (M++l); Anal. Calcd for C28H27FIN304: C, 51.94; H, 4.20; N, 6.49. Found: C, 51.17; H, 4.53; N, 5.76. Example 66 4-[(4S)-fluoro-l-[4-(N'-phenylureido)phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoic acid
Figure imgf000204_0001
To a stirred solution of ethyl 4-aminophenylacetate (6.43 g, 35.9 mmol) and Et3N (5.50 ml, 39.5 mmol) in THF (70 ml) was added phenyl isocyanate (3.90 ml, 35.9 mmol), and the reaction mixture was stirred at room temperature for 4 days. Resulting precipitate was collected under a reduced pressure and the filtrate was washed with n-hexane to give ethyl 4-(N'-phenylureido) phenylacetate (9.64 g, 90%) as a white ciystalline powder, mp 153-155°C; 'H-NMR (CDCl3)δ 1.26 (t, 7 = 7.1 Hz, 3 H), 3.52 (s, 2 H), 4.15 (q, 7 = 7.1 Hz, 2 H), 6.98-7.04 (m, 1 H), 7.07-7.11 (m, 4 H), 7.18-7.25 (m, 5 H), 7.42 (s, 1 H); MS (FAB) m/z 299 (M++l); Anal. Calcd for C17H18N203: C, 68.44; H, 6.08; N, 9.39. Found: C, 68.22; H, 6.10; N, 9.36.
To a stirred solution of ethyl 4-(W-phenylureido)phenylacetate (9.64 g, 32.3 mmol) in THF (80 ml) was added 0.5 N NaOH (80 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl. The resulting precipitate was collected under a reduced pressure and the crude solid was recrystallized from MeOH-CHCl3 to give 4-( V '-phenylureido)phenylacetic acid (8.14 g, 93%) as a white crystalline powder. MS (FAB) m/z 271 (M++l); Anal. Calcd for C15H14N203: C, 66.66; H, 5.22; N, 10.36. Found: C, 66.45; H, 5.22; N, 10.30.
A mixture of 4-(N'-phenylureido)phenylacetic acid (310 mg, 1.15 mmol), methyl 4-[(4S)- fluoro-(2S)-pyrrolidinylmethoxy]benzoate (287 mg, 1.13 mmol), EDCHCl (260 mg, 1.36 mmol), HOBt (185 mg, 1.37 mmol), and Et3N (190 ml, 1.36 mmol) in DMF (5 ml) was stirred at room temperature overnight. The mixture was diluted with H20, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 50: 1, v/v) as eluent to give methyl 4- [(4S)-fluoro- 1 - [4-(iV '-phenylureido)phenylacetyl] -(25)-pyrrolidinylmethoxy]benzoate (570 mg, 99%) as a pale yellow foam. 'H-NMR (CDC13) δ 2.07-2.58 (m, 2 H), 3.55-3.56 (m, 1 H), 3.69- 3.98 (series of s and m, total 6 H), 4.01-4.08 and 4.21-4.25 (each m, 1 H), 4.46-4.65 (m, 2 H), 5.23-5.25 and 5.38 (each m, 1 H), 6.88-7.07 (m, 7 H), 7.15-7.20 (m, 2 H), 7.28-7.30 (m, 2 H), 7.34 and 7.40 (each s, 1 H), 7.71 and 7.81 (each s, 1 H), 7.91-7.95 and 7.99-8.01 (each m, 2 H); MS (ESI) m/z 506 (M++l).
To a stirred solution of methyl 4-[(45 -fluoro-l-[4-(Λr'-phenylureido)phenylacetyl]-(2S)- pyrrolidinylmethoxy]benzoate (570 mg, 1.13 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml), and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl, and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-IPE to give 72 (348 mg, 63%) as a white crystalline powder. MW 491.51 mp 169-17PC; 'H-NMR (DMSO-c .) δ 2.24-2.36 (m, 2 H), 3.47-4.08 (m, 5 H), 4.20-4.64 (m, 2 H), 5.31-5.50 (m, 1 H), 6.94-7.46 (series of m, total 11 H), 7.87-7.92 (m, 2 H), 8.64-8.67 (m, 2 H), 12.63 (br s, 1 H); MS (FAB) m/z 492 (M++l); Anal. Calcd for C27H26FN3061/4H20: C, 65.38; H, 5.38; N,8.47; F,3.83. Found: C,65.13; H.5.38; N.8.25; F.3.78 Example 67
4-[(45)-fluoro-l-[3-methyl-4-(N'-phenylureido)phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoic acid
Figure imgf000205_0001
To a stirred solution of tert-butyl 4-amino-3-methylphenylacetate (1.20 g, 5.42 mmol) and Et3N
(830 ml, 5.95 mmol) in THF (10 ml) was added phenyl isocyanate (650 ml, 5.98 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated to a small volume and diluted with n-hexane. Resulting precipitate was collected under a reduced pressure and the filtrate was washed with M-hexane to give tert-bvfiyl 3-methyl-4-
(N'-phenylureido)phenylacetate (1.12 g, 61%) as a white crystalline powder, mp 143-145°C; 'H-
NMR (CDC13) δ 1.47 (s, 9 H), 2.09 (s, 3 H), 3.47 (s, 2 H), 6.44 (s, 1 H), 7.01-7.07 (m, 4 H), 7.16-
7.27 (m, 2 H), 7.30-7.33 (m, 2 H), 7.45-7.47 (m, 1 H).
To a stirred solution of tert-bvti l 3-methyl-4-(W-phenylureido)phenylacetate (1.12 g, 3.29 mmol) in CH2C12 (10 ml) was added TFA (10 ml) and the reaction mixture was stirred at room temperature for 4 hr. The reaction mixture was concentrated to a small volume and poured into ice-H20. The resulting precipitate was collected under a reduced pressure and the crude solid was recrystallized from MeOH-CHCl3 to give 3-methyl-4-(N'-phenylureido)phenylacetic acid (680 mg, 73%) as white needles. Η-NMR (DMSO-cL.) δ 2.22 (s, 3 H), 3.46 (s, 2 H), 6.93-7.05 (m, 3 H), 7.25-7.29 (m, 2 H), 7.43-7.46 (m, 2 H), 7.72-7.74 (m, 1 H), 7.90 (s, 1 H), 8.98 (s, 1 H), 12.26 (br s, 1 H); Anal. Calcd for C16H16N203: C, 67.59; H, 5.67; N, 9.85. Found: C, 67.47; H, 5.68; N, 9.73.
A mixture of 3-methyl-4-(N'-phenylureido)phenylacetic acid (301 mg, 1.06 mmol), methyl 4- [(4S)-fluoro-(2S>pyrrolidinylmethoxy]benzoate (268 mg, 1.06 mmol), EDCHCl (243 mg, 1.27 mmol), HOBt (172 mg, 1.27 mmol), and Et3N (180 ml, 1.29 mmol) in DMF (5 ml) was stirred at room temperature overnight. The mixture was diluted with H20, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 60: 1, v/v) as eluent to give methyl 4- [(4S -fluoro- 1 - [3 -methyl-4-(N -phenylureido)phenylacetyl] -(2S)-pyrrolidinylmethoxy] benzoate (550 mg, q.y.) as a white foam. 'H-NMR (CDC13) δ 1.79 and 1.87 (each s, 3 H), 2.04- 2.61 (m, 2 H), 3.52-3.54 (m, 1 H), 3.73-4.27 (series of s and m, total 7 H), 4.47-4.67 (m, 2 H), 5.26-5.27 and 5.40 (each m, 1 H), 6.79-6.99 (m, 6 H), 7.14-7.18 (m, 2 H), 7.27-7.31 (m, 2 H), 7.40-7.44 (m, 1 H), 7.89-8.01 (m, 3 H); MS (ESI) m/z 520 (M++l).
To a stirred solution of methyl 4-[(4S)-fluoro-l-[3-methyl-4-(N'-phenylureido) phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoate (550 mg, 1.06 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml), and the reaction mixture was heated under reflux for 2 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl, and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-IPE to give 73 (226 mg, 42%) as a white crystalline powder. MW 505.54 mp 130-135°C; 'H-NMR (DMSO-c ,) δ 2.18-2.30 (series of s and m, total 5 H), 3.47-3.92 (series of m, total 5 H), 4.03-4.63 (m, 2 H), 5.31-5.50 (m, 1 H), 6.94-7.10 (m, 5 H), 7.26-7.30 (m, 2 H), 7.45-7.47 (m, 2 H), 7.70- 7.75 (m, 1 H), 7.87-7.92 (m, 3 H), 8.96-8.98 (m, 1 H), 12.63 (br s, 1 H); MS (ESI) m/z 506 (M++l); Anal Calcd for C28H28FN305.1/2H20: C, 65.36; H, 5.68; N, 8.17; F, 3.69. Found: C, 65.61; H, 5.71; N, 7.84; F, 3.60. Example 68
4-[(4S)-fluoro-l-[4-[N'-(2-fluorophenyl)ureido]-3-methylphenylacetyl]-(25 -pyrrolidinylmethoxy] benzoic acid
Figure imgf000206_0001
To a stined solution of tert-but l 4-amino-3-methylphenylacetate (1.09 g, 4.93 mmol) and Et3N (755 ml, 5.42 mmol) in THF (10 ml) was added 2-fluorophenyl isocyanate (610 μl, 5.44 mmol) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated to a small volume and diluted with n-hexane. Resulting precipitate was collected under a reduced pressure and the filtrate was washed with w-hexane to give tert-butyl 4-[N'-(2- fluorophenyl)ureido]-3-methylphenylacetate (1.31 g, 74%) as a white crystalline powder, mp 89- 91°C; 'H-NMR (CDC13) δ 1.47 (s, 9 H), 2.06 (s, 3 H), 3.49 (s, 2 H), 6.62 (s, 1 H), 6.92-7.09 (m, 5 H), 7.21 (br s, 1 H), 7.49-7.51 (m, 1 H), 8.10-8.15 (m, 1 H); Anal Calcd for C20H23FN2O3: C, 67.02; H, 6.47; N, 7.82; F, 5.30. Found: C, 66.74; H, 6.35; N, 7.85; F, 5.69.
To a stirred solution of tert-butyl 4-[N'-(2-fluorophenyl)ureido]-3-methylphenylacetate (1.25 g, 3.49 mmol) in CH2C12 (10 ml) was added TFA (10 ml) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated to a small volume and poured into ice-H20. The resulting precipitate was collected under a reduced pressure and the crude solid was recrystallized from MeOH-CHCl3-IPE to give 4-[N'-(2-fluorophenyl)ureido]-3- methylphenylacetic acid (830 mg, 79%) as white needles. 'H-NMR (DMSO-cL,) δ 2.23 (s, 3 H), 3.47 (s, 2 H), 6.96-7.30 (m, 5 H), 7.74-7.76 (m, 1 H), 8.17-8.20 (m, 1 H), 8.33 (s, 1 H), 8.94 (s, 1 H), 12.27 (br s, 1 H); Anal. Calcd for C16H15FN203: C, 63.57; H, 5.00; N, 9.27; F, 6.28. Found: C, 63.28; H, 5.00; N, 9.14; F, 6.43.
A mixture of 4-[N'-(2-fluorophenyl)ureido]-3-methylphenylacetic acid (321 mg, 1.06 mmol), methyl 4-[(45)-fluoro-(25 -pyrrolidinylmethoxy]benzoate (269 mg, 1.06 mmol), EDCHCl (244 mg, 1.27 mmol), HOBt (172 mg, 1.27 mmol), and Et3N (177 ml, 1.27 mmol) in DMF (5 ml) was stirred at room temperature overnight. The mixture was diluted with H20, and extracted with
EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1, v/v) as eluent to give methyl 4-[(4S)-fluoro-l-[4-[Λr'-(2-fluorophenyl)ureido]-3-methylphenylacetyl]-(2S)-pyrrolidinyl methoxy]benzoate (560 mg, 98%) as a white foam. 'H-NMR (CDCl3)δ 1.78 and 1.86 (each s, 3 H), 2.16-2.65 (m, 2 H), 3.58-3.61 (m, 1 H), 3.74-4.15 (series of s and m, total 7 H), 4.29-4.34 and 4.46-4.49 (each m, 1 H), 4.64-4.73 (m, 1 H), 5.29-5.34 and 5.43-5.47 (each m, 1 H), 6.84-6.97 (m, 6 H), 7.04-7.07 (m, 1 H), 7.21 (br s, 1 H), 7.55-7.59 (m, 1 H), 7.85-8.02 (m, 3 H), 8.18-8.22 (m, 1 H); MS (ESI) m/z 538 (M++l). '
To a stirred solution of methyl 4-[(4S)-fluoro-l-[4-[N'-(2-fluorophenyl)ureido]-3- methylphenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoate (560 mg, 1.04 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml), and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl, and the resulting precipitate was collected under a reduced pressure. The crude solid was reciystallized from MeOH-CHCl3-IPE to give 74 (297 mg, 42%) as a white crystalline powder. MW 523.53 mp 137-143°C; 'H-NMR (DMSO-d6)δ 2.20-2.31 (series of s and m, total 5 H), 3.56-3.92 (series of m, total 5 H), 4.03-4.63 (m, 2 H), 5.31-5.50 (m, 1 H), 6.96-7.26 (series of m, total 7 H), 7.72-7.77 (m, 1 H), 7.87-7.92 (m, 2 H), 8.17-8.22 (m, 1 H), 8.32-8.36 (m, 1 H), 8.94-8.95 (m, 1 H), 12.66 (br s, 1 H); MS (ESI) m/z 524 (M++l); Anal. Calcd for
Figure imgf000208_0001
C, 64.24; H, 5.20; N, 8.03; F, 7.26. Found: C, 64.44; H, 5.75; N, 7.40; F, 6.73. Example 69 4-[(4S -fluoro-l-[4-[N'-(2-trifluoromethylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylmethoxy] benzoic acid
Figure imgf000208_0002
To a stirred solution of ethyl 4-aminophenylacetate (1.13 g, 6.31 mmol) and Et3N (965 ml, 6.92 mmol) in THF (10 ml) was added 2-trifluoromethylphenyl isocyanate (953 ml, 6.31 mmol) and the reaction mixture was stirred at room temperature for 2 days. Resulting precipitate was collected under a reduced pressure and the filtrate was washed with »-hexane to give ethyl 4-[N'-(2- trifluoromethylphenyl)ureido]phenylacetate (1.93 g, 84%) as white needles, mp 137-139°C; 'H-
NMR (CDC13) δ 1.25-1.29 (m, 3 H), 3.59 (s, 2 H), 4.15-4.20 (m, 2 H), 7.05 (br s, 1 H), 7.13-7.23
(m, 6 H), 7.47-7.51 (m, 1 H), 7.54-7.56 (m, 1 H), 8.01-8.03 (m, 1 H).
To a stirred solution of ethyl 4-[iV'-(2-trifluoromethylphenyl)ureido]phenylacetate (1.93 g,
5.27 mmol) in THF (10 ml) was added 1 N NaOH (10 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl. The resulting precipitate was collected under a reduced pressure and the crude solid was recrystallized from MeOH-CHCl3-IPE to give 4-[N'-(2-trifluoromethylphenyl)ureido]phenylacetic acid (910 mg, 51%) as a white crystalline powder, mp 224-225°C; 'H-NMR (DMSO-d6) δ 3.50 (s, 2 H), 7.18 (d, 7 = 8.3 Hz, 2 H), 7.25-7.29 (m, 1 H), 7.40 (d, 7 = 8.3 Hz, 2 H), 7.62-7.69 (m, 2 H), 7.95-7.97 (m, 1 H), 8.06 (s, 1 H), 9.37 (s, 1 H), 12.27 (br s, 1 IT); Anal. Calcd for C16H13F3N203: C, 56.81; H, 3.87; N, 8.28; F, 16.85. Found: C, 56.68; H, 3.87; N, 8.16; F, 16.89.
A mixture of 4-[N'-(2-trifluoromethylphenyl)ureido]phenylacetic acid (302 mg, 0.89 mmol), methyl 4-[(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoate (226 mg, 0.89 mmol), EDCHCl (205 mg, 1.07 mmol), HOBt (145 mg, 1.07 mmol), and Et3N (150 ml, 1.08 mmol) in DMF (5 ml) was stirred at room temperature for 3 days. The mixture was diluted with H20, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 60: 1, v/v) as eluent to give methyl 4-[(45)-fluoro-l-[4-[N'-(2-trifluoromethylphenyl)ureido]phenylacetyl]-(25)- pyrrolidinylmethoxy]benzoate (463 mg, 90%) as a pale yellow foam. Η-NMR (CDC13) δ 2.09- 2.60 (m, 2 H), 3.56-4.12 (series of s and m, total 8 H), 4.26-4.65 (m, 2 H), 5.26-5.29 and 5.39-5.42 (each m, total 1 H), 6.87-6.93 (m, 2 H), 6.99-7.13 (m, 5 H), 7.30-7.33 (m, 1 H), 7.44-7.53 (m, 2 H), 7.88-7.92 (m, 1 H), 7.99-8.04 (m, 2 H), 8.09-8.15 (m, 1 H); MS (ESI) m/z 574 (M++l).
To a stirred solution of methyl 4-[(4S)-fluoro-l-[4-[N'-(2-trifluoromethylphenyl)ureido] phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoate (460 mg, 0.80 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml), and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl, and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-IPE to give 75 (169 mg, 38%) as a white crystalline powder. MW 559.51 mp 130-135°C; 'H-NMR (DMSO-c ,) δ 2.24-2.30 (m, 2 H), 3.51-4.24 (series of m, total 5 H), 4.38-4.40 and 4.61 (each m, total 2 H), 5.31-5.50 (m, 1 H), 7.03-7.42 (series of m, total 7 H), 7.62-7.69 (m, 2 H), 7.87-8.07 (m, 4 H), 9.36-9.37 (m, 1 H), 12.64 (br s, 1 H); MS (ESI) m/z 560 (M++l); Anal. Calcd for C28H25F4N305: C, 60.11; H, 4.50; N, 7.51; F, 13.58. Found: C, 60.10; H, 4.85; N, 7.01; F, 12.90. Example 70
4-[(45 -fluoro-l-[3-methoxy-4-[N'-(2-trifluoromethylphenyl)ureido]phenylacetyl]-(2S)-pynOlidinyl methoxy]benzoic acid
Figure imgf000209_0001
To a stirred solution of tert-butyl 4-amino-3-methoxyphenylacetate (1.11 g, 4.68 mmol) and Et3N (720 ml, 5.17 mmol) in THF (10 ml) was added 2-trifluoromethylphenyl isocyanate (707 ml, 4.68 mmol) and the reaction mixture was stirred at room temperature for 2 days. The reaction mixture was concentrated to a small volume and diluted with n-hexane. Resulting precipitate was collected under a reduced pressure and washed with w-hexane to give tert-butyl 3-methoxy-4-[W-(2- trifluoromethylphenyl)ureido]phenylacetate (1.11 g, 56%) as a white crystalline powder, mp 131- 133°C; 'H-NMR (CDC13) δ 1.44 (s, 9 H), 3.49 (s, 2 H), 3.85 (s, 3 H), 6.83-6.88 (m, 3 H), 6.98 (br s, 1 H), 7.17-7.21 (m, 1 H), 7.52-7.59 (m, 2 H), 7.89-7.91 (m, 1 H), 8.04-8.06 (m, 1 H). To a stirred solution of tert-butyl 3-methoxy-4-[N'-(2-trifluoromethylphenyl)ureido] phenylacetate (1.11 g, 2.62 mmol) in CH2C12 (10 ml) was added TFA (10 ml), and the reaction mixture was stirred at room temperature for 4 hr. The reaction mixture was concentrated to a small volume and poured into ice-H20. The resulting precipitate was collected under a reduced pressure and the crude solid was recrystallized from MeOH-CHCl3-IPE to give 3-methoxy-4-[N'- (2-trifluoromethylphenyl)ureido]phenylacetic acid (839 mg, 87%) as a white crystalline powder, mp 218-220°C; 'H-NMR (DMSO-c .) δ 3.51 (s, 2 H), 3.87 (s, 3 H), 6.76-6.79 (m, 1 H), 6.93-6.94 (m, 1 H), 7.27-7.30 (m, 1 H), 7.61-7.69 (m, 2 H), 7.82-7.84 (m, 1 H), 7.97-7.99 (m, 1 H), 8.71 (s, 1 H), 8.89 (s, 1 H), 12.30 (br s, l TT); Anal. Calcd for C17H15F3N204: C, 55.44; H, 4.11; N, 7.61; F, 15.47. Found: C, 55.30; H, 4.08; N, 7.63; F, 15.13.
A mixture of 3-methoxyl-4-[N'-(2-trifluoromethylphenyl)ureido]phenylacetic acid (353 mg, 0.96 mmol), methyl 4-[(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoate (243 mg, 0.96 mmol), EDCHCl (221 mg, 1.15 mmol), HOBt (156 mg, 1.15 mmol), and Et3N (160 ml, , 1.15 mmol) in DMF (5 ml) was stirred at room temperature overnight. The mixture was diluted with H20, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 60: 1, v/v) as eluent to give methyl 4-[(4S)-fluoro-l-[3-methoxy-4-[N'-(2-trifluoromethylphenyl)ureido] phenylacetyl]- (25)-pyrrolidinylmethoxy]benzoate (570 mg, 98%) as a white foam. 'H-NMR (CDC13) δ 2.05-2.58 (m, 2 H), 3.56-4.21 (series of m, total 11 H), 4.05-4.64 (m, 2 H), 5.23-5.25 and 5.36-5.37 (each m, total 1 H), 6.79-6.82 (m, 2 H), 6.89-7.00 (m, 2 H), 7.16-7.20 (m, 2 H), 7.39-7.43 (m, 1 H), 7.51- 7.59 (m, 2 H), 7.93-8.02 (m, 4 H); MS (ESI) m/z 604 (M++1).
To a stined solution of methyl 4-[(45 -fluoro-l-[3-methoxy-4-[Λ^'-(2-trifluoromethyl phenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoate (570 mg, 0.94 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml), and the reaction mixture was heated under reflux for 2 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl, and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-TPE to give 76 (234 mg, 42%) as a white crystalline powder. MW 589.54 mp 129- 132°C; 'H-NMR (DMSO-c δ 2.23-2.29 (m, 2 H), 3.54-4.38 (series of s and m, total 8 H), 4.40- 4.61 (m, 2 H), 5.30-5.36 and 5.43-5.49 (each m, total 1 H), 6.72-6.91 (m, 2 H), 7.02-7.08 (m, 2 H), 7.25-7.29 (m, 1 H), 7.59-7.67 (m, 2 H), 7.81-7.99 (m, 4 H), 8.69-8.70 (m, 1 H), 8.87-8.90 (m, 1 H), 12.67 (br s, 1 H); MS (ESI) m/z 589 (M++l); Anal. Calcd for C29H27F4N306: C, 59.08; H, 4.62; N, 7.13. Found: C, 59.22; H, 5.10; N, 6.58. Example 71
4-[(4S)-fluoro-l-[3-methyl-4-[N'-(2-trifluoromethylphenyl)ureido]phenylacetyl]-(2S)- pyrrolidinylmethoxy]benzoic acid
Figure imgf000211_0001
To a stirred solution of tert-butyl 4-amino-3-methylphenylacetate (927 mg, 4.19 mmol) and Et3N (645 μl, 4.63 mmol) in THF (10 ml) was added 2-trifluoromethylphenyl isocyanate (633 μl, 4.19 mmol) and the reaction mixture was stirred at room temperature for 2 days. The reaction mixture was concentrated to a small volume and diluted with n-hexane. Resulting precipitate was collected under a reduced pressure and the filtrate was washed with n-hexane to give tert-butyl 3- methyl-4-[N,-(2-trifluoromethylphenyl)ureido]phenylacetate (1.06 g, 62%) as a white crystalline powder, mp 178-180°C; 'H-NMR (CDC13) δ 1.44 (s, 9 H), 2.25 (s, 3 H), 3.51 (s, 2 H), 6.38 (br s, 1 H), 7.12-7.18 (m, 3 H), 7.36-7.37 (m, 1 H), 7.49-7.53 (m, 2 H), 8.13-8.16 (m, 1 H).
To a stirred solution of tert-butyl 3-methyl-4-[Λ^'-(2-trifluoromethylphenyl)ureido] phenylacetate (1.06 g, 2.60 mmol) in CH2C12 (10 ml) was added TFA (10 ml) and the reaction mixture was stirred at room temperature for 4 hr. The reaction mixture was concentrated to a small volume and poured into ice-H20. The resulting precipitate was collected under a reduced pressure and the crude solid was recrystallized from MeOH-CHCl3-IPE to give 3-methyl-4-[N'-(2- trifluoromethylphenyl)ureido]phenylacetic acid (702 mg, 77%) as a white crystalline powder, mp 262-263°C; 'H-NMR (DMSO-c .) δ 2.24 (s, 3 H), 3.48 (s, 2 H), 7.03 (d, 7 = 8.3 Hz, 1 H), 7.08 (s, 1 H), 7.26-7.30 (m, 1 H), 7.61-7.69 (m, 3 H), 7.88 (d, 7 = 8.3 Hz, 1 H), 8.39 (s, 1 H), 8.55 (s, 1 H), 12.28 (br s, 1 H); Anal. Calcd for C17H15F3N203: C, 57.96; H, 4.29; N, 7.95; F, 16.18. Found: C, 57.73; H, 4.23; N, 7.92; F, 16.05.
A mixture of 3-methyl-4-[N'-(2-trifluoromethylphenyl)ureido]phenylacetic acid (359 mg, 1.02 mmol), methyl 4-[(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoate (258 mg, 1.02 mmol), EDCHCl (234 mg, 1.22 mmol), HOBt (165 mg, 1.22 mmol), and Et3N (170 μl, 1.22 mmol) in DMF (5 ml) was stirred at room temperature overnight. The mixture was diluted with H20, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 60: 1, v/v) as eluent to give methyl 4-[(4S)-fluoro-l-[3-methyI-4-[N'-(2-trifluoromethylphenyl)ureido]phenylacetyl]- (25)-pyrrolidinylmethoxy]benzoate (612 mg, q.y.) as a white foam. 'H-NMR (CDC13) δ 1.92 and 2.00 (each s, total 3 H), 2.09-2.61 (m, 2 H), 3.56-4.29 (series of m, total 8 H), 4.45-4.48 and 4.59- 4.64 (each m, total 2 H), 5.24-5.30 and 5.38-5.44 (each m, total 1 H), 6.90-7.14 (m, 5 H), 7.22- 7.53 (m, 5 H), 7.90-7.92 (m, 1 H), 8.00-8.06 (m, 2 H); MS (ESI) m/z 588 (M++l).
To a stirred solution of methyl 4-[(4S -fluoro-l-[3-methyl-4-[N'-(2-trifluoromethylphenyl) ureido]phenylacetyl]-(25)-pyrrolidinylmethoxy]benzoate (610 mg, 1.04 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml), and the reaction mixture was heated under reflux for 2 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl, and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-IPE to give 77 (186 mg, 31%) as a white crystalline powder. MW 573.54 mp 123-126°C; Η-NMR
(DMSO-c .) δ 2.19-2.29 (series of s and m, total 5 H), 3.64-4.21 (series of m, total 5 H), 4.36-4.60 (m, 2 H), 5.30-5.36 and 5.43-5.49 (each m, total 1 H), 6.97-7.08 (m, 4 H), 7.24-7.28 (m, 1 H), 7.59-7.68 (m, 3 H), 7.85-7.90 (m, 3 H), 8.37-8.39 (m, 1 H), 8.54-8.55 (m, 1 H), 12.67 (br s, 1 H); MS (ESI) m/z 573 (M+). Example 72
4-[(4S)-fluoro-l-[3-methyl-4-[7V'-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000212_0001
A mixture of 3-methyl-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (250 mg, 0.84 mmol), methyl 4-[(4S -fluoro-(2S)-pyrrolidinyl]methoxybenzoate (400 mg, 1.06 mmol), EDC HCl (242 mg, 1.26 mmol) and DMAP (154 mg, 1.26 mmol) in DMF (5 ml) was stirred at room temperature for 21 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [50 g, CHCl3/MeOH (50/1)], and then was purified on TLC [CHClj/acetone (10/1)] to give methyl 4-[(45 -fluoro-l-[3- methyl-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoate (342 mg, 76%) as a colorless amorphous solid. IR (KBr) 3356, 2951, 1716, 1651, 1604, 1537, 1252 cm '; 'H-NMR (CDC13) δ 2.07 (d, 7= 6.6 Hz, 2H), 2.12 (s, 3H), 2.27 (m, IH), 2.24 (s, 3H), 2.30-2.59 (m, IH), 3.60 (d, 7= 5.3 Hz, IH), 3.65-4.23 (m, 3H), 3.87 (s, 3H), 4.50-4.62 (m, IH), 5.31 (d, 7 = 52.4 Hz, 1H), 6.23 (d, 7 = 11.2 Hz, IH), 6.26 (d, 7= 11.9 Hz, IH), 6.87-7.27 (m, 8H), 7.54-7.65 (m, 3H), 7.94-8.01 (m, 2H); MS (FAB) m/z 534 (M++l); Anal. Calcd for C30H32FN3O5 0.7H2O: C, 65.97; H, 6.16; F, 3.48; N, 7.69. Found: C, 66.04; H, 6.07; F, 3.55; N, 7.64.
To a stirred solution of methyl 4-[(4S)-fluoro-l-[3-methyl-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoate (227 mg, 0.425 mmol) in THF (3.4 ml) was added 0.25 N NaOH (3.4 ml). After stirring at room temperature for 4 days, the mixture was acidified with IN HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was purified on preparative-TLC [CHCVMeOH (10/1)] to give 78 (190 mg, 86%) as a colorless amorphous solid. MW 519.56 IR (KBr) 3356, 2974, 1604, 1537, 1454, 1252 cm '; 'H-NMR (DMSO-c .) δ 2.24 (s, 3H), 2.26 (s, 3H), 3.60 (d, 7 = 3.7 Hz, 2H), 3.65-4.65 (m, 8H), 5.31-5.50 (m, IH), 6.92-7.18 (m, 7H), 7.67-7.92 (m, 4H), 8.22-8.32 (m, 2H); MS (FAB) m/z 520 M++l); Anal Calcd for C29H30FN3O7-l. lH2O: C, 64.58; H 6.02; F.3.52; N.7.79. Found: C, 64.71; H, 5.90; F, 3.24; N, 7.51. Example 73
4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methylphenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000213_0001
To a stirred mixture of tert-butyl 4-amino-3-methylphenylacetate (1.00 g, 4.52 mmol), 2- chlorophenyl isocyanate (0.55 ml, 4.52 mmol) in THF (10 ml) was added Et3N (0.13 ml, 0.90 mmol) at room temperature. After 6 h stirring, the reaction mixture was concentrated in vacuo.
The residue was triturated by the addition of w-hexane, to give tert-butyl 4-[N' -(2-chlorophenyl) ureido]-3-methylphenylacetate (1.57 g, 93%) as a pale yellow powder, mp 104-106 °C (dec); 'H-
NMR (CDC13) δ 1.45 (s, 9H), 2.28 (s, 3H), 3.51 (s, 2H), 6.33 (br, IH), 6.96 (t, 7 = 7.6 Hz, IH),
7.08 (br, IH), 7.16-7.30 (m, 4H), 7.42 (m, IH), 8.2 (d, 7= 8.1 Hz, IH).
To a stirred solution of tert-butyl 4-[N'-(2-chlorophenyl)ureido]-3-methylphenylacetate (1.57 g, 4.19 mmol) in CH2C12 (10 ml) was added TFA (6 ml) at room temperature. After 4 h stirring, the mixture was concentrated in vacuo. The residue was triturated by the addition of water to give 4-[N'-(2-chlorophenyl)ureido]-3-methylphenylacetic acid (1.33 g, 100%) as a yellow powder, mp 243-245 °C (dec); 'H-NMR (CDC13) δ 2.24 (s, 3H), 3.47 (s, 2H), 6.99-7.08 (m, 3H), 7.28 (t, 7= 7.6 Hz, IH), 7.44 (dt, 7 = 8.0, 2.4 Hz, IH), 7.66 (dd, 7= 8.3, 1.9 Hz, IH), 8.13 (dd, 7 = 6.1, 1.7 Hz, IH), 8.61 (d, 7= 6.3 Hz, 2H); MS (ESI), m/z 319 (M++l), 321 (M++3); Anal. Calcd for C16H15C1N203 .7TFA: C, 59.33; H, 4.65; Cl, 10.85; N, 8.57. Found: C, 59.23; H, 4.64; Cl, 10.90; N, 8.40.
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methylphenylacetic acid (252 mg, 0.79 mmol), methyl 4-[(45)-fluoro-(2S)-pyrrolidinyl]methoxybenzoate (200 mg, 0.79 mmol), EDC HCl (227 mg, 1.20 mmol) and DMAP (147 mg, 1.20 mmol) in DMF (5 ml) was stirred at room temperature for 17 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was purified on TLC [CHCVacetone (10/1)], to give methyl 4- [l-[4-[iV'-(2-chlorophenyl)ureido]-3-methylphenylacetyl]-(4S)-fluoro-(2S -pyrrolidinyl] methoxybenzoate (390 mg, 89%) as a colorless amorphous solid. IR (KBr) 3340, 2951, 1712,
1624, 1604, 1533, 1438 cm '; 'H-NMR (CDC13) δ 1.92-2.05 (m, 3H), 2.07-2.63 (m, 2H), 3.61 (d, 2H, 7 = 8.8 Hz), 3.70-4.15 (m, 5H), 4.25-4.67 (m, 2H), 5.26-5.44 (m, IH), 6.84-8.19 (m, 13H); MS (FAB) m/z 554 (M++l), 556 (M++3).
To a stirred solution of methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methylphenyl acetyl]-(4S -fluoro-(2S)-pyrrolidinyl]methoxybenzoate (268 mg, 0.484 mmol) in THF (3.8 ml) was added 0.25 N NaOH (3.8 ml). After stirring at room temperature for 1 days, the mixture was acidified with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was purified on TLC [CHCl^eOH (10/1)] to give 79 (124 mg, 47%) as a colorless amorphous solid. MW 539.98 IR (KBr) 3346, 2976, 1709, 1685, 1604, 1533, 1439 cm '; 'H-NMR (DMSO-ds) δ 2.20 (s, 3H, one of isomers), 2.24 (s, 3H, one of isomers), 2.30 (m, IH), 3.60 (s, 2H), 3.71-4.62 (m, 6H), 5.30-5.50 (m, IH), 7.01-7.09 (m, 5H), 7.28 (t, 7 = 7.8 Hz, IH), 7.44 (d, 7 = 8.1 Hz, IH), 7.66 (t, 7 = 8.1 Hz, IH), 7.87 (d, 7= 7.1 Hz, 2H), 8.13 (d, 7 = 7.9 Hz, IH), 8.62 (d, 7= 6.1 Hz, 2H); MS (FAB) m/z 540 (M++l), 542 (M++3). For Na sal Λnα/. Calcd for C28H27ClFN3O7-Na 0.5EtOH-1.5H2O: C, 56.91; H, 5.27; Cl, 5.79; F, 3.10; N, 6.87. Found: C, 56.60; H, 4.98; Cl, 5.88; F, 3.08; N, 6.52. Example 74
4-[l-[4-[Λf'-(2-bromophenyl)ureido]-3-methylphenylacetyl]-(4S)-fIuoro-(2S)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000214_0001
to a stirred mixture of tert-butyl 4-amino-3-methylphenylacetate (780 mg, 3.30 mmol), 2-bromo phenyl isocyanate (0.41 ml, 3.30 mmol) in THF (7 ml) was added Et3N (0.092 ml, 0.66 mmol) at room temperature. After 3 h stirring, the reaction mixture was concentrated in vacuo. The residue was triturated by the addition of n-hexane, to give tert-butyl 4-[N'-(2-bromophenyl) ureido]-3- methylphenylacetate (1.57 g, 93%) as a pale yellow powder, mp 138-145 °C (dec); 'H-NMR (CDC13) δ 1.44 (s, 9H), 2.33 (s, 3H), 3.51 (s, 2H), 6.90 (dt, 7= 9.0, 1.4 Hz, IH), 6.98 (br, IH), 7.18-7.31 (m, 4H), 7.39 (dd, 7 = 8.1, 2.9 Hz, IH), 7.44 (d, 7 = 8.0 Hz, IH), 8.22 (d, 7= 8.3 Hz, 2TT); Anal. Calcd for C20H22BrN2O3 0.2H2O: C,56.80; H.5.58; N,6.62. Found: C.56.85; H,5.42; N, 6.62.
To a stirred solution of tert-butyl 4-[N'-(2-bromophenyl)ureido]-3-methylphenylacetate
(1.27 g, 3.03 mmol) in CH2C12 (10 ml) was added TFA (5 ml) at room temperature. After 1 h stirring, the mixture was concentrated in vacuo. The residue was triturated by the addition of water, to give 4-[N'-(2-bromophenyl)ureido]-3-methylphenylacetic acid (1.05 g, 95%) as a pale yellow powder, mp 245-248 °C (dec); 'H-NMR (CDC13) δ 2.24 (s, 3H), 3.48 (s, 2H), 6.96 (dt, 7 = 7.3, 1.5 Hz, IH), 7.02 (d, 7 = 8.3 Hz, IH), 7.07 (s, IH), 7.32 (t, 7 = 8.1 Hz, IH), 7.59-7.66 (m, 2H), 8.44 (s, IH), 8.62 (s, IH); MS (ESI), m/z 363 (M++l), 365 (M++3); Anal. Calcd for C16H15BrN2O3 0.7H2O: C, 51.13; H, 4.40; Br, 21.26; N, 7.45. Found: C, 50.84; H, 4.62; Br, 21.72; N, 7.18.
A mixture of 4-[N'-(2-bromophenyl)ureido]-3-methylphenylacetic acid (287 mg, 0.79 mmol), methyl 4-[(4S)-fluoro-(2S)-pyrrolidinyl]methoxybenzoate (200 mg, 0.79 mmol), EDCHCl (228 mg, 1.20 mmol), HOBT (160 mg, 1.19 mmol) and Et3N (0.55 ml, 3.95 mmol) in DMF (5 ml) was stirred at room temperature for 4 days. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was purified on TLC [CHClj/acetone (10/1)], to give methyl 4-[(2S,4S)-l-[4-[N'-(2-chlorophenyl)meido]-3-methylphenylacetyl]-4-fluoro-2- pyrrolidinyl]methoxybenzoate (440 mg, 93%) as a colorless amorphous solid. 'H-NMR (CDC13) δ 1.90 andl.97 (eachs, 3H, amide isomers), 2.05-2.62 (m, 2H), 3.58 (d, 7 = 8.1 Hz, IH), 3.77 (m, IH), 3.86 and 3.89 (eachs, 3H, amide isomers), 3.92-4.64 (m, 5H), 5.24-5.42 (m, IH), 6.83-7.23 (m, 6H), 7.41-7.62 (m, 4H), 7.86-8.09 (m, 3H); MS (ESI), m/z 598 (M++l), 600 (M++3).
To a stirred solution of methyl 4-[l-[4-[Λ -(2-bromophenyl)ureido]-3-methylphenyl acetyl]-(4S -fluoro-(25 -pyrrolidinyl]methoxybenzoate (440 mg, 0.74 mmol) in THF (6.0 ml), 0.25 N NaOH (6.0 ml) was added. After stirring at room temperature for 1 days, the mixture was acidified with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was purified on TLC [CHCl^eOH (10/1)] to give 80 (229 mg, 53%) as a colorless amorphous solid. MW 584.44 IR (KBr) 3325, 2972, 1709, 1604, 1529, 1252 cm '; Η-NMR (DMSO-c .) δ 2.25 (s, 3H), 2.31 (m, IH), 3.17 (s, IH), 3.60 (d, 7 = 4.7 Hz, 2H), 3.83-4.67 (m, 5H), 5.31-5.51 (m, IH), 6.97 (t, 7 = 7.3 Hz, IH), 7.02-7.09 (m, 5H), 7.33 (t, 7 = 8.0 Hz, IH), 7.61 (d, 7= 7.8 Hz, IH), 7.64 (d, 7 = 8.3 Hz, IH), 7.87 (d, 7= 8.3 Hz, 2H), 7.90 (d, 7 = 8.8 Hz, IH), 8.44-8.65 (m, 2H); MS (ESI), m/z 584 (M++l), 586 (M++3); Anal. Calcd for C28H27BrFN3O7-0.4H2O: C, 56.84; H, 4.74; Br, 13.51; F, 3.21; N, 7.10. Found: C, 56.91; H, 4.93; Br, 13.23; F, 3.15; N, 6.88. For Na salt of 80 : Anal. Calcd for
C28H27BrFN307 Na l.8H20: C, 52.64; H, 4.67; Br, 12.51; F, 2.97; N, 6.58. Found: C, 53.04; H, 4.67; Br, 12.95; F, 3.28; N, 6.11. Example 75 4-[l-[4-[Λ^'-(2-chlorophenyl)ureido]-3-methylphenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoic acid
Figure imgf000216_0001
To a stirred solution of methyl 4-(l-tert-butoxycarbonyl-(2S)-pyrrolidinyl)methoxybenzoate (2.0 g,
5.9 mmol) in EtOH (10.0 ml) was added coned HCl (3.0 ml) at 0 °C. The reaction mixture was stirred at room temperatme for 4.0 hr. The mixture was concentrated in vacuo. The resulting solid was collected and washed with EtOH-Et20 to give methyl 4-(2S-pyrrolidinyl)methoxybenzoate HCl salt (1.4 g, 87%) as a white crystalline solid. 'H-NMR (CDC13) δ 1.90-2.25 (m, 4H), 3.25-3.45
(m, 2H), 3.88 (s, 3H), 3.90-4.00 (m, IH), 4.25-4.45 (m, 2H), 6.96 (d, 7 = 8.5 Hz, 2H), 7.95 (d, 7 =
8.5 Hz, 2H).
To a stirred solution of methyl 4-[(2S)-pyrrolidinyl]methoxybenzoate HCl salt (135 mg, 0.5 mmol), 4-[7V-(2-chlorophenyl)medio]-3-methylphenylacetic acid (159 mg, 0.5 mmol), HOBt (68 mg, 0.5 mmol), and triethylamine (278 ml, 2.0 mmol) in THF (5.0 ml) and MeCN (5.0 ml) was added
EDCHCl (144 mg, 0.75 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with «-hexane-EtOAc(l:2 ,v/v) as eluent to give methyl 4-[l-[4-[Λ''-(2-chlorophenyl)ureido]-3-methylphenylacetyl]-2-pyrrolidinyl] methoxybenzoate (220 mg, 82%) as a colorless oil. 'H-NMR (CDC13) δ 1.91 and 1.97 (each s, total 3H), 2.00-2.20 (m, 4H), 3.55-3.65 (m, 4H), 3.87 and 3.89(each s, total 3H),4.10-4.20 (m,2H), 4.51 (m, IH), 6.86-7.04 (m, 6H), 7.20-7.53 (m, 4H), 7.89-8.01 (m, 2H), 8.22 (d, 7= 8.3 Hz, IH).
To a stirred solution of methyl 4-[l-[4-[N'-(2-cMorophenyl)ureido]-3-methylphenylacetyl]-2S- pyrrolidinyl] methoxybenzoate (220 mg, 0.41 mmol) in THF (8.0 ml) and MeOH (4.0 ml) was added IN NaOH (0.8ml, 0.8 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 81 (220 mg, quant) as a white crystalline solid. MW 521.99 mp 122-124 °C; IR (KBr) 3340, 1710, 1685, 1604, 1533, 1511, 1438 cm '; 'H-NMR (DMSO-c .) δ 1.81-2.11 (m, 4H), 2.18 and 2.20 (each s, total 3H), 3.45-3.80 (m, 4H), 3.95-4.05 (m, IH), 4.12-4.20 (m, IH), 4.21-4.31 (m, IH), 6.99-7.06 (m, 5H), 7.26-7.30 (m, IH), 7.44 (d, 7 = 7.8 Hz, IH), 7.62-7.64 (m, IH), 7.85-7.90 (m, 2H), 8.13 (d, 7= 6.8 Hz, IH), 8.60-8.62 (m, 2H); MS (FAB) m/z 522 QΛ++l); Anal calcd for C28H28N305C1 .2H20: C, 63.99; H, 5.45; N, 7.99. Found: C, 63.90; H, 5.40; N, 7.72. Example 76 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methylphenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoic acid
Figure imgf000217_0001
To a stirred solution of methyl [(2S -pyrrolidinyl]methoxybenzoate HCl salt (135 mg, 0.5 mmol),
4-[Λ/'-(2-bromophenyl)uredio]-3-methylphenylacetic acid (181 mg, 0.5 mmol), HOBt (68 mg, 0.5 mmol), and triethylamine (278 ml, 2.0 mmol) in THF (5.0 ml) and MeCN (5.0 ml) was added EDC HCl (144 mg, 0.75 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1/2, v/v) as eluent to give methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methylphenylacetyl]-(2S)- pyrrolidinyl]methoxybenzoate (290 mg, quant) as a colorless oil. "H-NMR (CDC13) δ 1.95 and 2.01 (each s, total 3H), 2.00-2.20 (m, 4H), 3.50-3.65 (m, 4H), 3.87 and 3.89 (each s, total 3H), 4.10-4.20 (m, 2H), 4.50 (m, IH), 6.85-7.06 (m, 6H), 7.24-7.28 (m, IH), 7.40-7.44 (m, 3H), 7.89- 8.16 (m, 2H), 8.17-8.18 (m, IH).
To a stirred solution of methyl 4-[l-[4-[/V'-(2-bromophenyl)ureido]-3-methylphenylacetyl]-2S- pyrrolidinyl] methoxybenzoate (290 mg, 0.5 mmol) in THF (8.0 ml) and MeOH (4.0 ml) was added IN NaOH (1.0 ml, 1.0 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 82 (240 mg, 85%) as a white crystalline solid. MW 566.44 mp 125-130 °C; IR (KBr) 3340, 1604, 1529, 1434 cm '; 'H-NMR (DMSO-cL,) δ 1.80-2.10 (m, 4H), 2.18 and 2.20 (each s, total 3H), 3.45-3.80 (m, 4H), 3.95-4.05 (m, IH), 4.15-4.20 (m, IH), 4.25-4.30 (m, IH), 6.94-7.06 (m, 5H), 7.30-7.34 (m, IH), 7.59-7.62 (m, 2H), 7.85-7.90 (m, 2H), 8.01 (d, 7 = 8.1 Hz, IH), 8.44 (s, IH), 8.62 (s, IH); MS (FAB) m/z 566 (M+); Anal. calcd for C28H28N3O5Br-0.5H2O: C, 58.44; H, 5.08; N, 7.30. Found: C, 58.57; H, 4.99; N, 7.18. Example 77
4-[l-[3 -methyl-4-[N '-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoic acid
Figure imgf000218_0001
A mixture of 3-methyl-4-[Λλ'-(2-methylphenyl)ureido]phenylacetic acid (438 mg, 1.47 mmol), methyl 4-[(25)-pyrrolidinylmethoxy]benzoate (420 mg, 1.79 mmol), EDCHCl (410 mg, 2.14 mmol), HOBt (228 mg, 1.69 mmol) and Et3N (240 ml, 1.72 mmol) in DMF (5 ml) was stirred at room temperature overnight. The mixture was diluted with H20 and extracted with EtOAc. The extract was washed with brine, dried over Na2S0 , and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1 to 25: 1, v/v) as eluent to give methyl 4-[l-[3-methyl-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pyrrolidinylmethoxy] benzoate (760 mg, quant.) as a white foam. 'H-NMR (CDC13) δ 1.89 (s, 3 H), 1.94-2.14 (m, 4 H), 2.16 (s, 3 H), 3.50-3.69 (m, 4 H), 3.87 (s, 3 H), 4.09-4.17 (m, 2 H), 4.42-4.45 (m, 1 H), 6.85-7.02 (m, 6 H), 7.10-7.16 (m, 3 H), 7.51-7.53 (m, 1 H), 7.62-7.64 (m, 1 H), 7.91-7.94 (m, 2 H); MS (FAB) /n/z 516 (M++l).
To a stirred solution of methyl 4-[l-[3-methyl-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoate (420 mg, 0.71 mmol) in THF (7 ml) was added 0.5 N NaOH (7 ml) and the reaction mixture was heated under reflux for 2 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was purified by recrystallization from CHC13- IPE to give 83 (526 mg, 69%) as a white crystalline powder. MW 501.57 mp 191-193°C; 'H- NMR (DMSO-d6) δ 1.87-2.10 (m, 4 H), 2.20 (s, 3 H), 2.26 (s, 3 H), 3.44-3.79 (series of m, total 4 H), 3.99-4.45 (series of m, total 3 H), 6.91-7.17 (series of m, total 7 H), 7.66-7.68 (m, 1 H), 7.80- 7.90 (m, 3 H), 8.19-8.21 (m, 2 H), 12.62 (br s, 1 H); MS (FAB) m/z 502 (M++l); «α/. Calcd for C29H31N305 1/4H20: C, 68.83; H, 6.27; N, 8.30. Found: C, 68.81; H, 6.17; N, 8.23. Example 78
4-[(4S)-fluoro-l-[4-[N'-(2-methoxyphenyl)ureido]-3-methylphenylacetyl]-(2S)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000219_0001
To a stirred solution of tert-butyl 4-amino-3-methylphenylacetate (1.36 g, 6.15 mmol) and triethylamine (170 ml, 1.23 mmol) in THF (30 ml) was added 2-methoxyphenyl isocyanate (820 ml, 6.15 mmol), and the resulting mixture was stirred for 27 h. The mixture was concentrated to a small volume in vacuo, and hexane was added to the residue to give precipitate, which was collected by filtration to give tert-butyl 4-[N'-(2-methoxyphenyl)ureido]-3-methylphenylacetate (1.74 g, 76%) as a white crystalline material, mp 157-158 °C; 'H-NMR (CDC13) δ 1.46 (s, 9 H), 2.30 (s, 3 H), 3.50 (s, 2 H), 3.76 (s, 3 H), 6.43 (s, 1 H), 6.83 (br d, 7= 8.4 Hz, 1 H), 6.95 (br d, 7 = 8.0 Hz, 1 H), 6.98-6.99 (m, 2 H), 7.13 (brs, 1 H), 7.23 (br s, 1 H), 7.48 (d, 7= 8.8 Hz, 1 H), 8.14 (d, 7= 8.4 Hz, 1 H); MS (ESI) m/z 371 (M++H).
To a stirred solution of tert-butyl 4-[N'-(2-methoxyphenyl)ureido]-3-methylphenylacetate (1.32 g, 3.56 mmol) in CH2C12 (15 ml) was added trifluoroacetic acid (10 ml), and the resulting mixture was heated under reflux for 30 min. The mixture was concentrated in vacuo and added water to give precipitate which was collected by filtration. The crude solid was recrystallized from EtOH/hexane to give 4-[Λ '-(2-methoxyphenyl)ureido]-3-methylphenylacetic acid (932 mg, 83%) as a white powder, mp 260-264 °C; 'H-NMR (CD3OD) δ 2.30 (s, 3 H), 3.55 (s, 2 H), 4.87 (s, 3 H), 6.87-6.92 (m, 2 H), 6.97-6.99 (m, 2 H), 7.10-7.24 (m, 2 H), 7.53-7.58 (m, 1 H), 8.04 (d, 7 = 7.2 Hz, 1 H); MS (ESI) m/z 314 (M+).
To a stirred solution of 4-[N'-(2-methoxyphenyl)ureido]-3-methylphenylacetic acid (336 mg, 1.07 mmol), methyl 4-[(45)-fluoro-(25 -pyrrolidinylmethoxy]benzoate (271 mg, 1.07 mmol) and N,N- dimethylaminopyridine (130 mg, 1.07 mmol) in DMF (10 ml) was added EDCHCl (226 mg, 1.18 mmol) at rt, and the resulting mixture was stirred for 20 h. The mixture was poured into 1N-HC1 aq. and extracted with EtOAc. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHC13- MeOH (10 : 1) as eluent to give methyl 4-[(4ιS)-fluoro-l-[4-[N'-(2-methoxyphenyl)ureido]-3- methylphenylacetyl]-(25)-pyrrolidinylmethoxy]benzoate (583 mg, 99%) as a colorless amorphous solid. 'H-NMR (CDC13) mixture of rotamars, δ 2.05 and 2.12 (s, total 3 H), 2.05-2.61 (m, 2 H), 3.55-4.73 (series of m, 13 H), 4.51-4.66 (m, 2 H), 5.26-5.40 (m, 1 H), 6.72-7.01 (series of m, 8 H), 7.38-8.13 (series of m, 3 H); MS (ESI) m/z 550 (M++H).
To a stirred solution of methyl 4-[(4S)-fluoro-l-[4-[N'-(2-methoxyphenyl)ureido]-3- methylphenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoate (557 mg, 1.01 mmol) in MeOH-THF (1 : 1, 10 ml) was added LON-NaOH aq. (4.05 ml, 4.05 mmol) at rt, and the resulting mixture was heated at 60°C for 2 h. The mixture was poured into 1N-HC1 aq. and extracted with EtOAc. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give 84 (492 mg, 91%) as a colorless amorphous solid. MW 535.56 'H-NMR (CD3OD), mixture of rotamars, δ 2.96 (s, 3 H), 2.11-2.45 (m, 2 H), 3.64-4.15 (series of m, 5 H), 3.91 (s, 3 H), 4.41-4.45 (m, 1 H), 4.52-4.61 (m, 1 H), 5.25-5.38 (m, 1 H), 6.84-7.10 (series of m, 7 H), 7.54-7.58 (m, 1 H), 7.93 (d, 7= 8.8 Hz, 2 H), 8.02 (d, 7 = 8.8 Hz, 2 H); MS (ESI) m/z 536 (M++H), 538 (M++Na+). Example 79
4-[(4S)-fluoro-l-[4-[N'-(2-methoxyphenyl)ureido]phenylacetyl]-(2S)-pyrro-lidinylmethoxy] benzoic acid
Figure imgf000220_0001
To a stirred solution of ethyl 4-amino-3-methylphenylacetate (1.32 g, 7.37 mmol) and triethylamine (205 ml, 1.47 mmol) in THF (20 ml) was added 2-methoxyphenyl isocyanate (980 ml, 7.37 mmol), and the resulting mixture was stirred for 23 h. The mixture was concentrated to a small volume in vacuo and hexane was added to the residue to give precipitate, which was collected to give ethyl 4-[N'-(2-methoxyphenyl)ureido]phenylacetate (2.44 g, quant.) as a white ciystalline material, mp 107-109 °C; 'H-NMR (CDC13) δ 1.26 (t, 7 = 7.1 Hz, 3 H), 3.56 (s, 3 H), 3.79 (s, 3 H), 4.15 (q, 7 = 7.1 Hz, 2 H), 6.82-6.85 (m, 1 H), 6.91-7.00 (m, 2 H), 7.08 (s, 1 H), 7.17 (d, 7 = 8.5 Hz, 2 H), 7.27 (d, 7 = 8.6 Hz, 2 H), 7.33 (s, 1 H), 8.07-8.10 (m, 1 H); MS (ESI) m/z 329 (M++H).
To a stirred solution of ethyl 4-[N'-(2-methoxyphenyl)ureido]phenylacetate (2.22 g, 6.78 mmol) in MeOH (30 ml) was added 1.0 -NaOH aq. (10.2 ml, 10.2 mmol), and the resulting mixture was stirred overnight. W-HC1 (aq.) was added and the mixture was concentrated in vacuo. Water was added to the residue to give precipitate, which was collected by filtration. The crude solid was recrystallized from EtOH/hexane to give 4-[N'-(2-methoxyphenyl)ureido] phenylacetic acid as a white powder (1.87 g, 92%). mp 165-168 °C; 'H-NMR (CD3OD) δ 2.30 (s, 3 H), 3.55 (s, 2 H), 4.87 (s, 3 H), 6.87-6.92 (m, 2 H), 6.97-6.99 (m, 2 H), 7.10-7.24 (m, 2 H), 7.53- 7.58 (m, 1 H), 8.04 (d, 7 = 7.2 Hz, 1 H); MS (ESI) m/z 300 (M+).
To a stirred solution of 4-[N'-(2-methoxyphenyl)ureido]phenylacetic acid (353 mg, 1.18 mmol), methyl 4-[(4S)-fluoro-(25 -pyrrolidinylmethoxy]benzoate (298 mg, 1.18 mmol) and N,N- dimethylaminopyridine (144 mg, 1.18 mmol) in DMF (10 ml) was added EDCHCl (226 mg, 1.18 mmol) at rt, and the resulting mixture was stirred for 22 h. The mixture was poured into 1N-HC1 aq. and extracted with EtOAc. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vαcuo. The residue was chromatographed on silica gel with CHC13- MeOH (10 : 1) to give methyl 4-[(4S)-fluorol-[4-[N'-(2-methoxyphenyl)ureido]phenylacetyl]-(21S)- pyrrolidinylmethoxy]benzoate (594 mg, 94%) as a colorless amorphous solid. 'H-NMR (CDC13) mixture of rotamars, δ 2.05-2.58 (series of m, 2 H), 3.55-4.25 (series of m, 5 H), 3.77 (s, 3 H), 3.87-3.90 (m, 3 H), 4.50-4.63 (m, 2 H), 5.23-5.37 (m, 1 H), 6.81-6.84 (m, 1 H), 6.91-6.99 (m, 4 H), 7.09-7.12 (m, 2 H), 7.18-7.26 (m, 2 H), 7.45-7.53 (m, 2 H), 7.91-8.03 (m, 2 H), 8.10-8.12 (m, 1 H); MS (ESI) m/z 536 (M++H).
To a stirred solution of methyl 4-[(4S)-fluoro-l-[4-|N'-(2-methoxyphenyl)ureido] phenylacetyl]-(2S -pyrrolidinylmethoxy]benzoate (568 mg, 1.06 mmol) in MeOH-THF (1 : 1, 10 ml) was added l.ON-NaOH aq. (4.24 ml, 4.24 mmol) at rt, and the resulting mixture was heated at 60°C for 1 h. The mixture was poured into lN-HCl aq. and extracted with EtOAc. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vαcuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give 85 (516 mg, 93%) as a colorless amorphous solid. MW 521.54 'H-NMR (CD3OD), mixture of rotamars, δ 2.12-2.46 (m, 2 H), 3.65-4.19 (series of m, 5 H), 3.88 (s, 3 H), 4.42-4.45 (m, 1 H), 4.52-4.62 (m, 1 H), 5.24-5.39 (m, 1 H), 6.85-6.91 (m, 1 H), 6.94-7.03 (series of m, 4 H), 7.14-7.19 (m, 2 H), 7.35-7.40 (m, 2 H), 7.92-7.96 (m, 2 H), 8.02-8.04 (m, 1 H); MS (ESI) m/z 521 (M++H), 544 (M++Na+). Example 80 4-[(4S)-fluoro-l-[4-[Λ^'-(2-methoxyphenyl)ureido]-3-methoxyρhenylacetyl]-(2S)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000222_0001
To a stirred solution of tert-butyl 4-amino-3-methoxylphenylacetate (1.41 g, 5.94 mmol) and triethylamine (165 ml, 1.19 mmol) in THF (20 ml) was added 2-methoxyphenyl isocyanate (790 ml, 5.94 mmol), and the resulting mixture was stirred for 4 days. The mixture was concentrated to a small volume in vacuo, and hexane was added to the residue to give precipitate, which was collected to give tert-butyl 4-[N'-(2-methoxyphenyl)ureido]-3-methoxylphenylacetate (2.06 g,
90%) as a white crystalline material, mp 132-134 °C; 'H-NMR (CDC13) δ 1.46 (s, 9 H), 3.50 (s, 2
H), 3.87 (s, 3 H), 3.88 (s, 3 H), 6.84 (s, 1 H), 6.87-6.90 (m, 2 H), 6.98-7.03 (m, 2 H), 7.12 (s, 1 H), 7.16 (s, I H), 8.06 (d, 7 = 8.4 Hz, 1 H), 8.13 (dd, 7 = 7.2, 2.0 Hz, 1 H); MS (ESI) m/z 387 (M++H).
To a stirred solution of tert-butyl 4-[N'-(2-methoxyphenyl)ureido]-3-methoxylphenyl- acetate (2.01 g, 5.20 mmol) in CH2C12 (15 ml) was added trifluoroacetic acid (10 ml), and the resulting mixture was heated under reflux for 30 min. The mixture was concentrated in vacuo.
Water was added to the residue to give precipitate, which was collected by filtration. The crude solid was recrystallized from EtOH/hexane to give 4-[Λ?'-(2-methoxyphenyl)ureido]-3-methoxy phenylacetic acid as white powder (1.40 g, 82%). mp 182-185 °C; 'H-NMR (CD3OD) δ 3.55 (s, 2 H), 3.88 (s, 3 H), 3.89 (s, 3 H), 6.80-6.99 (m, 5 H), 7.94 (d, 7= 8.4 Hz, 1 H), 8.00 (d, 7= 7.2 Hz, 1 H); MS (ESI) m/z 330 (M+).
To a stirred solution of 4-[N'-(2-methoxyphenyl)ureido]-3-methoxyphenylacetic acid (353 mg, 1.07 mmol), methyl 4-[(4S)-fluoro-(2S)-pynolidinylmethoxy]benzoate (271 mg, 1.07 mmol) and N,N-dimethylaminopyridine (131 mg, 1.07 mmol) in DMF (10 ml) was added EDCHCl (224 mg, 1.18 mmol) at rt, and the resulting mixture was stirred for 14 h. The mixture was poured into IN- HC1 aq. and extracted with EtOAc. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give methyl 4-[(45 -fluoro-l-[4-[N' -(2-methoxyphenyl) ureido]-3-methoxyphenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoate (372 mg, 61%) as a colorless amorphous solid. 'H-NMR (CDC13), mixture of rotamars, δ 2.04-2.57 (series of m, 2 H), 3.58-4.18 (series of m, 5 H), 3.79 and 3.83 (s, total 3 H), 3.86 (s, 3 H), 3.87 (s, 3 H), 4.51-4.63 (m, 2 H), 5.22-5.36 (m, 1 H), 6.80-6.89 (m, 3 H), 6.94-7.03 (m, 4 H), 7.15-7.25 (m, 2 H), 7.94-8.01 (m, 2 H), 8.04-8.11 (m, 2 H); MS (ESI) m/z 566 (M++H).
To a stirred solution of methyl 4-[(4S)-fluoro-l-[4-[N'-(2-methoxyphenyl)ureido]-3-methoxy phenyl-acetyl]-(2S)-pyrrolidinylmethoxy]benzoate (356 mg, 0.63 mmol) in MeOH-THF (1 : 1, 10 ml) was added l.ON-NaOH aq. (1.88 ml, 1.88 mmol) at rt, and the resulting mixture was heated at 60°C for 2 h. The mixture was poured into LV-HC1 aq. and extracted with EtOAc. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give 86 (335 mg, 97%) as a colorless amorphous solid. MW 551.56 'H-NMR (CD3OD), mixture of rotamars, δ 2.14-2.48 (m, 2 H), 3.69-4.20 (series of m, 5 H), 3.88 (s, 3 H), 3.89 (s, 3 H), 4.46-4.57 (m, 2 H), 5.27-5.41 (m, 1 H), 6.79-7.04 (m, 7 H), 7.90-8.02 (m, 4 H); MS (ESI) m/z 552 (M++H). Example 81
4-[l-[4-[N'-(2,6-dichlorophenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S -pyrrolidinyl]methoxy benzoic acid
Figure imgf000223_0001
To a mixture of ethyl 4-aminophenylacetate (1.62 g, 9.04 mmol) and 2,6-dichlorophenyl isocyanate (1.70 g, 9.04 mmol) in THF (40 ml) was added Et3N (0.25 ml, 1.81 mmol) at room temperature. After 2 h stirring, the reaction mixture was concentrated in vacuo. The residue was triturated by the addition of n-hexane, to give ethyl 4-[N'-(2,6-dichlorophenyl)ureido] phenyl acetate (3.19 g, 96%) as a colorless powder, mp 168-170 °C (dec); 'H-NMR (CDC13) δ 1.25 (t, 7 = 7.1 Hz, 3H), 3.56 (s, 2H), 4.14 (q, 7= 7.1 Hz, 2H), 6.50 (br, IH), 6.67 (br, IH), 7.12-7.52 (m, IK).
To a stirred solution of ethyl 4-[N'-(2,6-dichlorophenyl)ureido]phenylacetate (3.19 g, 8.69 mmol) in THF (70 ml), 0.25 N NaOH (70 ml) was added. After stirring at room temperature for 17 h, the solvent was concentrated in vacuo. The residue was triturated by the addition of water, to give 4- [N'-(2,6-dichlorophenyl)ureido]phenylacetic acid (2.44 g, 82%) as colorless powder, mp 262-263 °C (dec); 'H-NMR (DMSO-cL.) δ 3.48 (s, 2H), 7.14 (d, 7= 8.3 Hz, 2H), 7.31 (t, 7= 8.3 Hz, IH), 7.37 (d, 7= 8.3 Hz, 2H), 7.52 (d, 7= 8.0 Hz, 2H), 8.18 (s, IH), 8.90 (s, IH), 12.22 (br, IH); MS (ESI) m/z 339 (M++l), 341 (M++3), 343 (M++5).
A mixture of 4-[N'-(2,6-dichlorophenyl)ureido]phenylacetic acid (268 mg, 0.79 mmol), methyl 4- [(2S,45)-4-fluoro-2-pyrrolidinyl]methoxybenzoate (200 mg, 0.79 mmol), EDCHCl (227 mg, 1.19 mmol), HOBT (161 mg, 1.19 mmol) and Et3N (0.55 ml, 3.95 mmol) in DMF (4 ml) was stirred at room temperature for 18 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was purified on TLC [CHCl^eOH (10/1)], to give tmethyl 4-[l-[4-[N'-(2,6-dichlorophenyl)meido]phenylacetyl]-(45)-fluoro-(2S)-pyrrolidinyl] methoxybenzoate (465 mg, 100%) as a colorless amorphous solid. 'H-NMR (CDC13) δ 2.05-2.57 (m, 2H), 3.60 (d, 2H, 7= 3.4 Hz), 3.64-3.84 (m, 2H), 3.88 and 3.89 (each s, 3H, amide isomers), 3.92-4.63 (m, 3H), 5.22-5.38 (m, IH), 6.87 and 6.89 (each d, each 7= 7.9 Hz, 2H, amide isomers), 7.01-7.17 (m, 6H), 7.28 (m, 2H), 7.36 (br, IH), 7.92 (d, 7 = 8.8 Hz, IH), 7.79 (d, 7= 8.8 Hz, IH); MS (ESI) m/z 574 (M++ 1), 576 (M++3), 578 (M++5).
To a solution of methyl 4-[(2S,4S)-l-[4-[/V'-(2,6-dichlorophenyl)meido]phenylacetyl]-4-fIuoro-2- pyrrolidinyl] methoxybenzoate (465 mg, 0.809 mmol) in THF (40 ml), 0.25 N NaOH (40 ml) was added. After stirring at room temperature for 11 h, the mixture was acidified with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was purified on TLC [CHCl-j/MeOH (10/1)], to give 87 (340 mg, 75%) as a colorless powder. MW 560.40 mp 168-172 °C (dec); IR (KBr) 3340, 1711, 1685, 1604, 1240, 773 cm 1; Η-NMR (DMSO-cL.) δ 2.22-2.30 (m, 2H), 3.61 (d, 7 = 7.4 Hz, 2H), 3.70- 4.75 (m, 6H), 5.30-5.49 (m, IH), 7.02-7.18 (m, 5H), 7.28-7.41 (m, 4H), 7.52 (dd, 7= 8.0, 2.9 Hz, 2H), 7.86 (m, 2H), 8.29 (br, IH), 9.01 (br, IH), 12.66 (br, IH); MS (ESI) m/z 560 (M++1), 562 (M++3), 564 (M++5); Anal. Calcd for C27H24Cl2FN3O5 0.5H2O: C, 56.95; H, 4.43; Cl, 12.45; F, 3.34; N, 7.38. Found: C, 57.04; H, 4.34; Cl, 12.98; F, 3.27; N, 7.21. Example 82 4-[l-[4-[Λ^'-(2,6-dichlorophenyl)ureido]-3-methoxyphenylacetyl]-(45)-fluoro-(2S)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000224_0001
To a mixture of tert-butyl 4-amino-3-methoxyphenylacetate (2.15 g, 9.04 mmol), 2,6- dichlorophenyl isocyanate (1.70 g, 9.04 mmol) in THF (40 ml) was added Et3N (0.25 ml, 9.04 mmol) at room temperature. After 18 h stirring, the reaction mixture was concentrated in vacuo. The residue was triturated by the addition of n-hexane, to give tert-butyl 4-[N'-(2,6- dichlorophenyl)ureido]-3-meιhoxyphenylacetate (2.27 g, 59%) as a colorless powder, mp 177-181 °C (dec); 'H-NMR (CDC13) δ 1.43 (s, 9H), 3.74 (s, 2H), 3.83 (s, 3H), 6.34 (s, IH), 6.81 (s, IH), 6.84 (d, 7 = 8.3 Hz, IH), 7.06 (br, IH), 7.27 (t, 7= 8.1 Hz, IH), 7.39 (d, 7 = 8.1 Hz, 2H), 8.04 (d, 7 = 8.3 Hz, IH).
To a stirred solution of tert-butyl 4-[N'-(2,6-dichlorophenyl)meido]-3-methoxyphenylacetate (2.27 g, 5.34 mmol) in CH2C12 (50 ml) was added TFA (20 ml) at room temperature. After 2 h stirring, the mixture was concentrated in vacuo. The residue was triturated by the addition of water, to give 4-[Λf'-(2,6-dichlorophenyl)ureido]-3-methoxyphenylacetic acid (1.50 g, 76%) as a colorless powder, mp 246-249 °C (dec); 'H-NMR (DMSO-d6) δ 3.49 (s, 2H), 3.88 (s, 3H), 6.75 (d, 7 = 8.3 Hz, IH), 6.93 (s, IH), 7.30 (t, 7 = 7.8 Hz, IH), 7.52 (d, 7 = 8.0 Hz, 2H), 7.97 (d, 7= 8.0 Hz, IH), 8.40 (s, IH), 8.86 (s, IH), 12.23 (br, IH); MS (ESI) m/z 369 (M++l), 371 (M++3), 373 (M++5).
A mixture of 4-[N'-(2,6-dichlorophenyl)ureido]-3-methoxyphenylacetic acid (288 mg, 0.78 mmol), methyl 4-[(25,45 -4-fluoro-2-pyrrolidinyl]methoxybenzoate (200 mg, 0.79 mmol), EDC HCl (227 mg, 1.19 mmol), HOBT (161 mg, 1.19 mmol) and Et3N (0.55 ml, 3.95 mmol) in DMF (4 ml) was stirred at room temperature for 18 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [50 g, CHCl3/MeOH(40/l)] to give methyl 4-[l-[4-[Λr'-(2,6-dichlorophenyl)ureido]-3-methoxyphenyl acetyl]-(4S)-fluoro-(2S -pyrrolidinyl]methoxybenzoate (530 mg, 100%) as a colorless amorphous solid. 'H-NMR (CDC13) δ 2.03-2.62 (m, 2H), 3.61 (d, 2H, 7 = 4.7 Hz), 3.62-3.66 (m, 2H), 3.73 and 3.77 (each s, 3H, amide isomers), 3.78-3.85 (m, IH), 3.87 and 3.88 (each s, 3H, amide isomers), 3.95-4.63 (m, 4H), 5.22-5.36 (m, IH), 6.82 (s, IH), 6.88 (d, 7 = 8.8 Hz, IH), 6.95 (d, 7 = 8.8 Hz, 2H), 7.14-7.25 (m, IH), 7.38 (d, 7= 8.1 Hz, 2H), 7.94-8.10 (m, 3H); MS (ESI) m/z 604 Or+1), 606 (M++3), 608 (M++5).
To a solution of methyl 4-[l-[4-[N'-(2,6-dichlorophenyl)ureido]-3-methoxyphenylacetyl]-(4S)- fluoro-(25 -pyrrolidinyl]methoxybenzoate (530 mg, 0.78 mmol) in THF (40 ml), 0.25 N NaOH (40 ml) was added. After stirring at room temperature for 11 h, the mixture was acidified with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was purified on TLC [CHCL/MeOH (10/1)] to give 88 (420 mg, 75%) as a colorless amorphous solid. MW 590.43 mp 162-168 °C (dec); IR (KBr) 3346,
2974, 1709, 1604, 1533, 1254 cm '; 'H-NMR (DMSO-cL.) δ 1.98-2.36 (m, 2H), 3.58 (s, 2H), 3.78- 3.95 (m, 6H), 4.02-4.68 (m, 2H), 5.31-5.50 (m, IH), 6.71-7.09 (m, 4H), 7.31 (t, 7= 7.8 Hz, IH), 7.53 (d, 7 = 8.1 Hz, 2H), 7.87 (d, 7 = 8.1 Hz, 2H), 7.88-8.00 (m, IH), 8.30-8.40 (m, IH), 8.89 (s, IH); MS (ESI) m/z 590 (M++l), 592 (MX?), 594 (M++5); /iα/. Calcd for C28H26C12FN306-1.5H20: C,54.47; H,4.73; F,3.08; N,6.81. Found: C.54.53; H,4.49; F, 2.93; N, 6.65. Example 83
4-[(2S,4S)-l-[4-[N'-(2,6-Dichlorophenyl)ureido]-3-methylphenylacetyl]-4-fluoro-2-pyrrolidinyl] methoxybenzoic acid
Figure imgf000226_0001
To a mixture of tert-butyl 4-amino-3-methylphenylacetate (1.88 g, 8.51 mmol), 2,6-dichlorophenyl isocyanate (1.60 g, 8.51 mmol) in THF (40 ml) was added Et3N (0.24 ml, 1.70 mmol) at room temperature. After 3 h stirring, the reaction mixture was concentrated in vacuo. The residue was triturated by the addition of n-hexane, to give tert-butyl 4-[N'-(2,6-dichlorophenyl) eido]-3- methylphenylacetate (2.58 g, 74%) as a colorless powder, mp 243-244 °C (dec); 'H-NMR (CDC13) δ 1.45 (s, 9H), 2.30 (s, 3H), 3.49 (s, 2H), 6.24 (s, 2H), 7.12-7.16 (m, 3H), 7.35 (d, 7= 8.3 Hz, 2H), 7.51 (d, 7 = 7.8 Hz, IH).
To a stined solution of tert-butyl 4-[N'-(2,6-dichlorophenyl)meido]-3-methylphenylacetate (2.58 g, 6.30 mmol) in CH2C12 (50 ml) was added TFA (20 ml) at room temperature. After 2 h stirring, the mixture was concentrated in vacuo. The residue was triturated by the addition of water, to give 4- [N'-(2,6-dichlorophenyl)ureido]-3-methylphenylacetic acid (2.12 g, 95%) as a colorless powder. mp 274-283 °C (dec); 'H-NMR (DMSO-d^) δ 2.24 (s, 3H), 3.46 (s, 2H), 7.00 (d, 7 = 8.6 Hz, IH), 7.06 (s, IH), 7.30 (t, 7= 7.8 Hz, IH), 7.52 (d, 7= 8.3 Hz, 2H), 7.65 (d, 7 = 8.2 Hz, IH), 8.12 (s, IH), 8.50 (s, IH), 12.22 (br, IH); MS (ESI) m/z 353 (TVf+1), 355 (M++3), 357 (M++5).
A mixture of 4-[Λ^'-(2,6-dichlorophenyl)ureido]-3-methylphenylacetic acid (181 mg, 0.51 mmol), methyl 4-[(2S,4S)-4-fluoro-2-pyrrolidinyl]methoxybenzoate (130 mg, 0.51 mmol), EDC HCl (147 mg, 0.77 mmol), HOBT (104 mg, 0.77 mmol) and Et3N (0.35 ml, 2.55 mmol) in DMF (4 ml) was stirred at room temperature for 18 h. The mixture was poured into ice water and extracted with EtOAc The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was purified on TLC [ ΑClJMsOH (20/1)], to give methyl 4-[l-[4-[N'-(2,6-dichlorophenyl)ureido]-3-methylphenylacetyl]-(4S)-fluoro-(2S)- pyrrolidinyljmethoxybenzoate (283 mg, 94%) as a colorless amorphous solid. 'H-NMR (CDC13) δ 1.95-2.61 (m, 3H), 3.55 (br, 2H), 3.67-3.81 (m, 2H), 3.87 (s, 6H), 3.89-4.68 (m, 2H), 5.23-5.43 (m, IH), 6.81-7.10 (m, 6H), 7.13-7.43 (m, 3H), 7.56 (br, IH, one of isomers), 7.73 (br, IH, one of isomers), 7.89-8.00 (m, 2H); MS (ESI) m/z 588 (M++1), 590 (M++3), 592 (M++5).
To a solution of methyl 4-[l-[4-[N'-(2,6-dichlorophenyl)ureido]-3-methylphenylacetyl]-(4S)- fluoro-(25 -pyrrolidinyl]methoxybenzoate (283 mg, 0.48 mmol) in THF (20 ml), 0.25 N NaOH (20 ml) was added. After stirring at room temperature for 11 h, the mixture was extracted with EtOAc. The remaining aqueous layer was acidified with 1 N HCl and extracted with EtOAc. The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was on TLC [CHClj MeOH (20/1)] to give 89 (450 mg, 67%) as a pale brown amorphous solid. MW 574.43 mp 174-180 °C (dec); IR (KBr) 3330, 3288, 1711, 1685, 1604, 1512, 1242 cm '; 'H-NMR (DMSO-c .) δ 2.24 (m, 3H), 3.61 (d, 2H, 7 = 6.1 Hz), 3.72-4.68 (m, 7H), 5.30-5.50 (m, IH), 6.97- 7.20 (m, 4H), 7.29-7.68 (m, 5H), 7.87 (m, 2H), 8.10-8.95 (m, IH), 12.65 (br, IH); MS (ESI) m/z 574 (M++l), 576 (M++3), 578 (M++5); Anal. Calcd for C28H26Cl2FN3O5 0.5H2O: C, 57.64; H, 4.66; Cl, 12.15, F, 3.26; N, 7.20. Found: C, 57.37; H, 4.44; Cl, 12.64; F, 3.23; N, 7.25. Example 84
4-[ 1 - [3 -chloro-4-|N '-(2-methylphenyl)ureido]phenylacetyl] -(4S)-fluoro-(2S)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000227_0001
To a stirred solution of 3-chlorophenylacetic acid (21.76 g, 127.6 mmol) in dichloroethane (100 ml) was added MeOH (15.6 ml, 383 mmol) and H2S04 (1 ml) at room temperature. After 20 minutes stirring, the mixture was heated at 80 °C for 2 h. The reaction mixture was poured into ice water and extracted with CHC13. The combined extracts were washed with aq. NaHC03 and brine. After dried over Na2S04, the extract was concentrated in vacuo to give methyl 3- chlorophenylacetate (25.4 g, 100%) as a colorless oil. 'H-NMR (CDC13) δ 3.60 (s, 2H), 3.70 (s,
3H), 7.15-7.26 (m, 4H).
To a stirred mixture of methyl 3 -chlorophenylacetate (25.4 g, 128 mmol) in H2S04 (44 ml) was added HN03 (5.5 ml, 138 mmol) at 0 °C. The reaction mixture was gradually raised to room temperature for 4 h. The reaction mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with aq. NaHC03 and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [1 kg, n- hexane/EtOAc (40/1)] to give methyl 3-chloro-4-nitrophenylacetate (11.4 g, 36%) as a yellow oil. 'H-NMR (CDC13) δ 3.69 (s, 2H), 3.74 (s, 3H), 7.33 (dd, 7 = 8.3, 1.5 Hz, IH), 7.49 (d, 7= 1.5 Hz, IH), 7.87 (d, 7 = 8.3 Hz, IH).
A mixture of methyl 3-chloro-4-mtrophenylacetate (10.9 g, 47.5 mmol), reduced iron powder (8.58 g, 153.6 mmol), AcONa-3H20 (6.05 g, 44.5 mmol) and AcOH (17.6 ml) in MeOH/H20 (100/400 ml) was heated at 110 °C for lh. After cooled to room temperature, the reaction mixture was filtered through Celite and the filtered cake was washed with MeOH. The combined filtrate were evaporated and extracted with EtOAc. The combined extracts were washed with brine, dried over Na2S04 and concentrated in vacuo. The residue was chromatographed on silica gel [150 g, CHClj/EtOAc (10/1)] to give methyl 4-amino-3 -chlorophenylacetate (4.58 g, 48%) as a red oil. 'H-NMR (CDC13) δ 3.49 (s, 2H), 3.68 (s, 3H), 4.01 (br, 2H), 6.70 (d, 7 = 7.4 Hz, IH), 6.96 (dd, 7 = 8.1, 2.0 Hz, IH), 7.17 (d, 7 = 2.0 Hz, IH).
To a mixture of methyl 4-amino-3 -chlorophenylacetate (1.00 g, 5.01 mmol) and 2-methylphenyl isocyanate (0.60 ml, 5.01 mmol) in THF (20 ml) was added Et3N (0.14 ml, 1.00 mmol) at room temperature. After 1 day stirring, 2-methylphenyl isocyanate (0.60 ml, 5.01 mmol) was added to the reaction mixture and stirred 17 h. The reaction mixture was concentrated in vacuo. The residue was triturated by the addition of n-hexane to give methyl 3-chloro-4-[N'-(2-methylphenyl) ureido]phenylacetate (1.23 g, 74%) as a colorless powder. 'H-NMR (CDC13) δ 2.34 (s, 3H), 3.54 (s, 2H), 3.68 (s, 3H), 6.24 (br, IH), 6.99 (br, IH), 7.15 (dd, 7 = 8.3, 2.0 Hz, IH), 7.21-7.31 (m, 5H), 7.44 (d, 7 = 7.6 Hz, IH), 8.20 (d, 7= 8.5 Hz, IH); MS (ESI) m/z 333 (M++1), 335 (MX3).
To a stirred solution of methyl 3-chloro-4-[N'-(2-methylphenyl)ureido]phenylacetate (1.23 g, 3.70 mmol) in THF (30 ml) was added 0.25 N NaOH (30 ml). After stirring at room temperature for 14 h, the solvent was concentrated in vacuo. The residue was triturated by the addition of 1 N HCl and dried over 60 °C for 2 days under a reduced pressure to give 3 -chloro-4-[N '-(2-methylphenyl) ureido]phenylacetic acid (1.22 g, 100%) as colorless powder. 'H-NMR (DMSO-c .) δ .26 (s, 3H), 3.40 (s, 2H), 6.95 (t, 7 = 7.3 Hz, IH), 7.11 (d, 7 = 7.6 Hz, 2H), 7.16 (d, 7= 7.3 Hz, IH), 7.32 (s, IH), 7.76 (d, 7= 8.0 Hz, IH), 7.94 (dd, 7= 9.3, 1.0 Hz, IH), 8.72 (s, 2H); MS (ESI) m/z 319 (M++l), 321 (M++3), 341 (M++Na). A mixture of 3-chloro-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (319 mg, 1.00 mmol), methyl 4-[(4S)-fluoro-(2S)-pynolidinyl]methoxybenzoate (253 mg, 1.00 mmol), EDCHCl (288 mg, 1.50 mmol), HOBT (203 mg, 1.50 mmol) and Et3N (0.70 ml, 5.00 mmol) in DMF (4 ml) was stirred at room temperature for 15 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S0 , the extracts were concentrated in vacuo. The residue was purified on TLC [CHCVacetone (5/1)] to give methyl 4-[l-[3-chloro-4-[N'-(2-methylphenyl)meido]phenylacetyl]-(4S)-fluoro-(2S)- pyrrolidinyl]methoxybenzoate (480 mg, 87%) as a colorless amorphous solid. 'H-NMR (CDC13) δ 2.10-2.60 (m, 2H), 2.29 (s, 3H), 3.56 (d, 7 = 6.8 Hz, IH), 3.71-3.84 (m, IH), 3.87 and 3.89 (each s, 3H, amide isomers), 3.91-4.20 (m, 3H), 4.49-4.60 (m, 2H), 5.32 (dt, 7 = 53.0, 4.2 Hz, IH), 6.80 (br, IH), 6.89 and 6.95 (each d, 7= 8.8 Hz, 2H, amide isomers), 7.09-7.26 (m, 6H), 7.50 (d, 7 = 7.3 Hz, IH), 7.94 and 8.00 (each d, 7= 8.8 Hz, 2H, amide isomers), 8.10 and 8.15 (each d, 7= 8.3 Hz, IH, amide isomers); MS (FAB) m/z 554 (M++l), 556 (M++3).
To a solution of methyl 4-[l-[3-cMoro-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro- (25)-pyrrolidinyl]methoxybenzoate (480 mg, 0.866 mmol) in THF (30 ml) was added 0.25 N
NaOH (30 ml). After stirring at room temperature for 2 days, the mixture was concentrated under a reduced pressure and acidified with 1 N HCl. The precipitates were collected, washed with water and dried under a reduced pressure to give 90 (374 mg, 80%) as a colorless powder. MW 539.98 IR (KBr) 3354, 3060, 2976, 1709, 1604, 1244 cm '; 'H-NMR (DMSO-c .) δ 2.27 (s, 3H), 2.31 (s, 2H), 3.66 (d, 7 = 7.2 Hz, 2H), 3.71-4.67 (m, 5H), 5.32-5.53 (m, IH), 6.97 (t, 7= 7.3 Hz, IH), 7.04- 7.22 (m, 5H), 7.32 and 7.35 (each d, 7 = 1.7 Hz, IH, amide isomers), 7.77 (d, 7= 7.6 Hz, IH), 7.87 and 7.90 (each d, 7 = 9.0 Hz, 2H, amide isomers), 8.01 and 8.03 (each d, 7= 8.5 Hz, IH, amide isomers), 8.57 and 8.59 (each s, IH, amide isomers), 8.63 and 8.65 (each s, IH, amide isomers), 12.63 (s, IH); MS (ESI) m/z 540 (M++l), 542 (M++3). Example 85
4-[l-[3-chloro-4-[N'-(2-chlorophenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinyl]methoxy benzoic acid
Figure imgf000229_0001
To a mixture of methyl 4-amino-3 -chlorophenylacetate (1.00 g, 5.01 mmol) and 2-chlorophenyl isocyanate (0.60 ml, 5.01 mmol) in THF (20 ml) was added Et3N (0.14 ml, 1.00 mmol) at room temperature. After 1 day stirring, 2-chlorophenyl isocyanate (0.60 ml, 5.01 mmol) was added to the reaction mixture and stirred 17 h. The reaction mixture was concentrated in vacuo. The residue was triturated by the addition of n-hexane to give methyl 3-chloro-4-[N'-(2-chlorophenyl) ureido]phenylacetate (1.35 g, 76%) as a colorless powder. 'H-NMR (CDC13) δ 3.58 (s, 3H), 3.71 (s, 2H), 7.04 (m, 3H), 7.18 (dd, 7 = 8.5, 2.0 Hz, IH), 7.27-7.39 (m, 3H), 8.07 (m, 2H); MS (ESI) m/z 353 (M++l), 355 (M++3), 357 (M++5).
To a stirred solution of methyl 3-chloro-4-[JV '-(2-chlorophenyl)ureido]phenylacetate (1.35 g, 3.82 mmol) in THF (30 ml) was added 0.25 N NaOH (30 ml). After stirring at room temperature for 14 h, the solvent was concentrated in vacuo. The residue was triturated by the addition of 1 N HCl and dried at 60 °C for 2 days under a reduced pressure to give 3-chloro-4-[N'-(2-chlorophenyl) ureido]phenylacetic acid (1.12 g, 86%) as colorless powder. 'H-NMR (DMSO-cL.) δ 3.52 (s, 2H), 7.05 (m, IH), 7.17 (d, 7 = 8.5 Hz, IH), 7.30 (d, 7 = 7.6 Hz, IH), 7.37 (s, IH), 7.46 (dd, 7 = 8.0, 1.5 Hz, IH), 7.95 (dd, 7 = 8.3, 1.2 Hz, IH), 8.07 (d, 7 = 8.3 Hz, IH), 9.00 (d, 7= 8.0 Hz, 2H); MS (FAB) m/z 339 (M++l), 341 (M++3), 343 (M++5).
A mixture of 3-chloro-4-[N'-(2-chlorophenyl)ureido]phenylacetic acid (339 mg, 1.00 mmol), methyl 4-[(2S,4S)-4-fluoro-2-pyrrolidinyl]mefhoxybenzoaιe (253 mg, 1.00 mmol), EDC HCl (288 mg, 1.50 mmol), HOBT (203 mg, 1.50 mmol) and Et3N (0.70 ml, 5.00 mmol) in DMF (4 ml) was stirred at room temperature for 15 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [50 g, CHCyacetone^O/l)] to give methyl 4-[l-[3-chloro-4-[N'-(2-chlorophenyl)ureido]phenylacetyl]- (4S)-fluoro-(25)-pyrrolidinyl]methoxybenzoate (550 mg, 96%) as a colorless amorphous solid. H-NMR (CDC13) δ 2.14-2.64 (m, 2H), 3.59 (d, 7= 11.2 Hz, 2H), 3.78-3.82 (m, IH), 3.86 and 3.89 (each s, 3H, amide isomers), 3.91-4.28 (m, 2H), 4.50-4.79 (m, 2H), 5.34 and 5.39 (each dt, 7 = 52.5, 4.4 Hz, IH, amide isomers), 6.89-6.98 (m, 3H), 7.09-7.13 (m, 2H), 7.22 (dt7= 7.3, 2.2 Hz, IH), 7.29 (dd, 7 = 8.1, 2.0 Hz, IH), 7.79 and 7.86 (each s, IH, amide isomers), 7.86-8.03 (m, 4H), 8.11 (dd, 7 = 8.3, 1.0 Hz, IH); MS (FAB) m/z 574 (M++l), 576 (M++3), 578 (M++5).
To a solution of methyl 4-[l-[3-chloro-4-[N'-(2-chlorophenyl)ureido]phenylacetyl]-(45)-fluoro- (25)-pyrrolidinyl]methoxybenzoate (550 mg, 0.957 mmol) in THF (30 ml) was added 0.25 N NaOH (30 ml). After stirring at room temperature for 2 days, the mixture was concentrated under a reduced pressure and acidified with 1 N HCl. The precipitates were collected, washed with water and dried under a reduced pressure to give 91 (437 mg, 82%) as a colorless powder. MW 560.40 IR (KBr) 3348, 3072, 2954, 1703, 1604,1529, 1439 cm '; 'H-NMR (DMSO-cU δ 2.25-2.42 (m, 2H), 3.67 (d, 7= 8.3 Hz, 2H), 3.81-4.68 (m, 5H), 5.39 and 5.46 (each d, 7 = 54.4 Hz, IH, amide isomers), 7.04-7.10 (m, 3H), 7.18 (d, 7 = 8.3 Hz, IH), 7.31 (t, 7= 8.3 Hz, IH), 7.33 and 7.37 (each s, IH, amide isomers), 7.47 (d, 7 = 8.1 Hz, IH), 7.88 (dd, 7 = 9.0, 3.2 Hz, 2H), 7.98 (dd, 7 = 8.5, 3.0 Hz, IH) m, IH), 8.09 (d, 7= 8.3 Hz, IH), 8.99 (d, 7= 2.9 Hz, IH), 9.02 (s, IH), 12.64 (s, IH); MS (ESI) m/z 560 (M++l), 562 (M++3), 564 (M++5); Anal. Calcd for C27H24Cl2FN3O50.2H2O: C, 57.50; H, 4.36; N, 7.45; Cl, 12.57; F, 3.37. Found: C, 57.72; H, 4.47; N, 7.14; Cl, 12.44; F, 3.44. Example 86 4-[ 1 - [4-[N'-(2-bromophenyl)ureido] -3 -chlorophenylacetyl] -(4S)-fluoro-(2S)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000231_0001
To a mixture of methyl 4-amino-3 -chlorophenylacetate (1.00 g, 5.01 mmol) and 2-bromophenyl isocyanate (0.62 ml, 5.01 mmol) in THF (20 ml) was added Et3N (0.14 ml, 1.00 mmol) at room temperature. After 1 day stirring, 2-bromophenyl isocyanate (0.60 ml, 5.01 mmol) was added to the reaction mixture and stirred 24 h. The reaction mixture was concentrated in vacuo. The residue was triturated by the addition of n-hexane to give methyl 4-[N'-(2-bromophenyl)ureido]-3- chlorophenylacetate (1.34 g, 67%) as a colorless powder. 'H-NMR (CDC13) δ 3.58 (s, 3H), 3.70 (s, 2H), 6.98 (m, 3H), 7.19 (dd, 7= 8.3, 1.9 Hz, IH), 7.32 (m, IH), 7.51 (m, 2H), 8.05 (m, IH); MS (ESI) m/z 398 (M++l), 400 (M++3), 402 (M++5).
To a stirred solution of methyl 4-[N'-(2-bromophenyl)ureido]-3-chlorophenylacetate (1.34 g, 3.37 mmol) in THF (30 ml) was added 0.25 N NaOH (30 ml). After stirring at room temperature for 14 h, the solvent was concentrated in vacuo. The residue was triturated by the addition of 1 N HCl and dried at 60 °C for 2 days under a reduced pressure to give 4-[N'-(2-bromophenyl)ureido]-3- chlorophenylacetic acid (1.03 g, 80%) as colorless powder. 'H-NMR (DMSO-cL.) δ 3.56 (s, 2H), 7.00 (m, IH), 7.17 (dd, 7= 9.0, 1.7 Hz, IH), 7.32-7.40 (m, 2H), 7.62 (dd, 7= 8.0, 1.2 Hz, IH), 7.95 (m, 2H), 8.83 (s, 1), 9.01 (s, H), 12.41 (br, IH); MS(FAB) m/z 385 (M++2),386(M++4),388 (M++6).
A mixture of 4-[N'-(2-bromophenyl)ureido]-3-chlorophenylacetic acid (384 mg, 1.00 mmol), methyl 4-[(4S)-fluoro-(2S)-pyrrolidinyl]methoxybenzoate (253 mg, 1.00 mmol), EDC HCl (288 mg, 1.50 mmol), HOBT (203 mg, 1.50 mmol) and Et3N (0.70 ml, 5.00 mmol) in DMF (4 ml) was stirred at room temperature for 15 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [50 g, CHCl3/acetone(10/l)] to give methyl 4-[l-[4-[N' -(2-bromophenyl)ureido]-3- chlorophenylacetyl]-(4S)-fluoro-(2S)-pyπOlidinyl]methoxybenzoate (530 mg, 86%) as a colorless amorphous solid. 'H-NMR (CDC13) δ 2.14-2.63 (m, 2H), 3.58 (d, 7= 10.0 Hz, IH), 3.73-3.83 (m, IH), 3.86 and 3.89 (each s, 3H, amide isomers), 3.90-4.29 (m, 3H), 4.50-4.69 (m, 2H), 5.33 and 5.37 (each m, IH, amide isomers), 6.88-6.93 (m, 3H), 7.11-7.14 (m 2H), 7.26 (m, IH), 7.46 (d, 7 = 8.1 Hz, IH), 7.62-7.78 (m, 2H), 7.89 and 7.93 (each m, 2H, amide isomers), 8.01 (dd, 7 = 8.8, 1.7 Hz, 2H); MS (FAB) m/z 618 (M+), 620 (M++2), 622 (M++4).
To a solution of methyl 4-[l-[4-[Λ^'-(2-bromophenyl)meido]-3-chlorophenylacetyl]-(4S)-fluoro- (25 -pyrrolidinyl]methoxybenzoate (530 mg, 0.856 mmol) in THF (30 ml) was added 0.25 N NaOH (30 ml). After stirring at room temperature for 2 days, the mixture was concentrated under a reduced pressure and acidified with 1 N HCl. The mixture was extracted with CHCl-j/MeOH (10/1). The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [20 g, CHCl3/acetone(10/l)-CHCl3/MeOH(10/l)] to give 92 (59 mg, 11%) as a colorless amorphous solid. MW 604.85 IR (KBr) 3329, 3060, 2976, 1712, 1526, 1435 cm '; 'H-NMR (DMSO-c .) δ 2.31 (m, H), 3.48-4.68 (m, 7H), 5.32-5.53 (m, IH), 6.99-7.19 (m, 4H), 7.36 (s, IH), 7.63 (dd, 7 = 6.7, 1.2 Hz, IH), 7.86-8.18 (m, 4H), 8.83 (s, IH), 9.02 (s, IH), 12.67 (br, IH); MS (ESI) m/z 604 (M++l), 606 (M++3), 608 (M++5); Anal. Calcd for C27H24BrClFN3O5-0.5H2O: C, 52.83; H, 4.10; N, 6.85; Cl, 5.78; F, 3.09. Found: C, 53.24; H, 4.32; N, 6.43; Cl, 6.01; F, 3.07. Example 87
4-[l-[3-chloro-4-(Λf'-phenylureido)phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinyl]methoxybenzoic acid
Figure imgf000232_0001
To a mixture of methyl 4-amino-3 -chlorophenylacetate (1.31 g, 6.56 mmol) and phenyl isocyanate (0.71 ml, 6.56 mmol) in THF (20 ml) was added Et3N (0.19 ml, 1.33 mmol) at room temperature.
After 15 h stirring, the reaction mixture was concentrated in vacuo. The residue was triturated by the addition of H-hexane to give methyl 3-chloro-4-(N'-phenylureido)phenylacetate (1.79 g, 86%) as a pale brown solid. 'H-NMR (CDC13) δ 3.56 (s, 2H), 3.70 (s, 3H), 6.70 (m, IH), 7.06 (s, IH), 7.14-7.18 (m, 2H), 7.26 (dd, 7= 7.8, 1.9 Hz, IH), 7.33-7.38 (m, 4H), 8.14 (dd, 7= 8.3, 3.0 Hz, IH); MS (ESI) m/z 319 (M++l), 321 (M++3).
To a stirred solution of methyl 3-chloro-4-(iV'-phenylureido)phenylacetate (1.79 g, 5.62 mmol) in THF (30 ml) was added 0.25 N NaOH (30 ml). After stirring at room temperature for 20 h, the solvent was concentrated in vacuo. The residue was triturated by the addition of 1 N HCl and dried at 60 °C for 2 days under a reduced pressure to give 3-chloro-4-(N'-phenylureido) phenylacetic acid (1.58 g, 92%) as pale brown solid. Η-NMR (DMSO-cL,) δ 3.55 (s, 2H), 6.99 (t, 7 = 7.3 Hz, IH), 7.17 (d, 7= 8.3 Hz, IH), 7.29 (t, 7 = 7.6 Hz, 2H), 7.36 (s, IH), 7.46 (d, 7 = 8.0 Hz, 2H), 8.07 (d, 7 = 8.3 Hz, IH), 8.28 (s, IH), 9.37 (s, IH), 12.37 (br, IH).
A mixture of 3-chloro-4-(N'-phenylureido)phenylacetic acid (305 mg, 1.00 mmol), methyl 4- [(2S,4S)-4-fluoro-2-pyrrolidinyl]mefhoxybenzoate (253 mg, 1.00 mmol), EDC HCl (288 mg, 1.50 mmol), HOBT (203 mg, 1.50 mmol) and Et3N (0.70 ml, 5.00 mmol) in DMF (4 ml) was stirred at room temperature for 17 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [30 g, CHCyacetone(20/l)] to give methyl 4-[l-[3-chloro-4-(N'-phenylureido)phenylacetyl]-(45)-fluoro- (25)-pyrrolidinyl]methoxybenzoate (720 mg, 100%) as a colorless amorphous solid. MS (FAB) m/z 540 (M++l), 542 (M++3).
To a solution of methyl 4-[l-[3-chloro-4-(N'-phenylureido)phenylacetyl]-(4S)-fluoro-(2S)- pyrrolidinyl] methoxybenzoate (720 mg, 1.00 mmol) in THF/MeOH (30/30 ml) was added 0.25 N NaOH (30 ml). After stirring at room temperature for 2 h, the reaction mixture was heated at 50 °C for 22 h. After removed the solvent, the resulting residue was acidified with 1 N HCl. The precipitates were collected, washed with water and dried under a reduced pressure to give 93 [412 mg, 78% (2 Steps)] as a colorless powder. MW 525.96 IR (KBr) 3346, 3302, 2976, 1712, 1604, 1240 cm '; 'H-NMR (DMSO-cL.) δ 2.25-2.31 (m, 2H), 3.66 (d, 7 = 7.8 Hz, 2H), 3.71-4.67 (m, 5H), 5.31-5.52 (m, IH), 6.99 (t, 7 = 7.3 Hz, IH), 7.04 and 7.07 (each d, 7 = 8.7 Hz, 2H, amide isomers), 7.14-7.18 (m, IH), 7.29 (t, 7= 7.3 Hz, 2H), 7.35 (d, 7 = 1.7 Hz, IH), 7.46 (d, 7= 7.8 Hz, 2H), 7,87 and 7.90 (each d, 7 = 9.0 Hz, 2H, amide isomers), 8.04 and 8.06 (each d, 7 = 8.5 Hz, IH, amide isomers), 8.26 and 8.28 (each s, IH, amide isomers), 9.36 (s, IH), 12.63 (s, IH); MS (ESI) m/z 526 (M++l), 528 (M++3); Anal. Calcd for C27H23ClFN3O5 0.5H2O: C, 60.62; H, 4.90; N, 7.85; Cl, 6.63; F, 3.55. Found: C, 61.00; H, 5.19; N, 7.40; Cl, 6.66; F, 3.39. Example 88
4-[l-[3-bromo-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinyl ] methoxybenzoic acid
Figure imgf000234_0001
To a stirred solution of 3-bromophenylacetic acid (10.2 g, 47.4 mmol) in dichloroethane (50 ml) was added MeOH (5.8 ml, 142 mmol) and H2S04 (0.5 ml) at room temperature. After 20 minutes stirring, the mixture was heated at 80 °C for 7 h. The reaction mixture was poured into ice water and extracted with CHC13. The combined extracts were washed with aq. NaHC03 and brine. After dried over Na2S04, the extracts were concentrated in vacuo to give methyl 3-bromophenyl acetate (10.8 g, 99%) as a colorless oil. 'H-NMR (CDC13) δ 3.60 (s, 2H), 3.71 (d, 7 = 1.0 Hz, 3H), 7.18- 7.44 (m, 4H).
To a stirred mixture of methyl 3 -chlorophenylacetate (10.8 g, 47.1 mmol) in H2S04 (15.1 ml) was added HN03 (2.8 ml, 70.7 mmol) at 0 °C. The reaction mixture was gradually raised to room temperature for 5.5 h. The reaction mixture was poured into ice water and extracted with CHC13. The combined extracts were washed with aq. NaHC03 and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [500 g, n- hexane/EtOAc (10/1)] to give methyl 3-bromo-4-nitrophenylacetate (3.69 g, 29%) as a yellow oil. 'H-NMR (CDC13) δ 3.68 (s, 2H), 3.73 (s, 3H), 7.38 (dd, 7 = 8.3, 1.2 Hz, IH), 7.67 (d, 7 = 1.3 Hz, IH), 7.83 (d, 7 = 8.3 Hz, IH).
A mixture of methyl 3-bromo-4-nitrophenylacetate (14.8 g, 53.8 mmol), reduced iron powder (9.62 g, 172 mmol), AcONa-3H20 (7.32 g, 53.8 mmol) and AcOH (20.0 ml) in MeOH/H20 (150/600 ml) was heated at 90 °C for lh. After cooled to room temperature, the reaction mixture was filtered through Celite and the filtered cake was washed with MeOH. The combined filtrate were evaporated and extracted with EtOAc. The extracts were washed with brine, dried over Na2S04 and concentrated in vacuo. The residue was chromatographed on silica gel [400 g, CHGs/EtOAc (20/1)] to give methyl 4-amino-3-bromophenylacetate (9.01 g, 69%) as a brown oil. 'H-NMR (CDC13) δ 3.48 (s, 2H), 3.68 (s, 3H), 4.05 (br, 2H), 6.69 (d, 7= 8.3 Hz, IH), 7.00 (dd, 7= 8.1, 2.0 Hz, IH), 7.32 (d, 7 = 2.0 Hz, IH). To a mixture of methyl 4-amino-3-bromophenylacetate (587 mg, 2.40 mmol) and 2-methylphenyl isocyanate (0.287 ml, 2.40 mmol) in THF (2 ml) was added Et3N (33 ml, 0.24 mmol) at room temperature. After 21 h stirring, the reaction mixture was concentrated in vacuo. The residue was triturated by the addition of n-hexane to give methyl 3-bromo-4-[N'-(2-methylphenyl)ureido] phenylacetate (650 mg, 72%) as a pale brown powder. 'H-NMR (CDC13) δ2.34 (s, 3H), 3.53 (s, 2H), 3.68 (s, 3H), 6.18 (br, IH), 6.96 (br, IH), 7.18-7.33 (m, 4H), 7.29 (d, 7 = 4.4 Hz, IH), 7.30 (d, 7= 7.3 Hz, IH), 8.19 (d, 7= 8.3 Hz, IH); MS (ESI) m/z 377 (M+), 379 (MX2).
To a stirred solution of methyl 3-bromo-4-[N'-(2-methylphenyl)ureido]phenylacetate (650 mg, 1.72 mmol) in THF (10 ml) was added 0.25 N NaOH (10 ml). After stirring at room temperature for 14 h, the solvent was concentrated in vacuo. The residue was triturated by the addition of 1 N HCl and dried at 60 °C for 2 days under a reduced pressure to give 3-bromo-4-[N'-(2- methylphenyl)ureido] phenylacetic acid (1.22 g, 100%) as colorless powder. Η-NMR (DMSO-d«) δ 2.26 (s, 3H), 3.32 (s, 2H), 6.93 (m, 2H), 7.10-7.17 (m, 4H), 7.76 (d, 7 = 8.1 Hz, 2H), 8.52 (s, IH); MS (ESI) m/z 385 (M++Na), 387 (M++2+Na).
A mixture of 3-bromo-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (80 mg, 0.22 mmol), methyl 4-[(4S)-fluoro-(2S)-pyrrolidinyl]methoxybenzoate (56 mg, 0.22 mmol), EDC HCl (63 mg, 0.33 mmol), HOBT (45 mg, 0.33 mmol) and Et3N (0.15 ml, 1.10 mmol) in DMF (1 ml) was stirred at room temperature for 18 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was purified on TLC [CHCyacetone (5/1)] to give methyl 4-[l-[3-bromo-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)- pyrrolidinyl ]methoxybenzoate (140 mg, 100%) as a yellow oil. 'H-NMR (CDC13) δ 2.30 (s, 3H), 2.55 (m, IH), 3.56 (d, 7= 6.4 Hz, 2H), 3.70-3.84 (m, 3H), 3.87 (s, 3H), 3.99-4.59 (m, 3H), 5.23- 5.38 (m, IH), 6.83-6.94 (m, 2H), 6.95 (d, 7 = 8.8 Hz, IH), 7.07-7.26 (m, 5H), 7.36-7.63 (m, 2H), 7.94-8.15 (m, 3H); MS (ESI) m/z 598 (M++1), 600 (M++3).
To a solution of methyl 4-[l-[3-bromo-4-[N'-(2-mefhylphenyl)meido]phenylacetyl]-(4S)-fluoro- (2S)-pyrrolidinyl]methoxybenzoate (140 mg, 0.22 mmol) in THF (10 ml) was added 0.25 N NaOH (10 ml). After stirring at room temperature for 14 h, the mixture was concentrated under a reduced pressure and acidified with 1 N HCl. The precipitates were collected, washed with water and dried under a reduced pressure to give 94 (109 mg, 85%) as a colorless powder. MW 584.43 IR (KBr) 3313, 3060, 2976, 1687, 1604, 1525, 1244 cm '; 'H-NMR (DMSO-c .) δ 2.27 (s, 3H), 2.29 (m, 2H), 3.66 (d, 7 = 8.1 Hz, 2H), 3.72-4.68 (m, 5H), 5.31-5.53 (m, IH), 6.92-6.99 (m, IH), 7.04 and 7.07 (each d, 7 = 8.3 Hz, 2H, amide isomers), 7.11-7.21 (m, 3H), 7.48 and 7.51 (s, IH, amide isomers), 7.75 and 7.79 (each d, 7 = 8.1 Hz, IH, amide isomers), 7.86-7.92 (m, 3H), 8.45 and 8.47 (each s, IH, amide isomers), 8.59 (s, IH), 12.64 (s, IH); MS (FAB) m/z 584 (M++l), 586 (M++3); Anal. Calcd for C28H27BrFN305: C, 57.54; H, 4.66; N, 7.19; Br, 13.67; F, 3.25. Found: C, 57.93; H, 4.97; N, 7.04; Br, 13.35; F, 2.89. Example 89
4-[l-[3-bromo-4-[Λr'-(2-chlorophenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000236_0001
To a mixture of methyl 4-amino-3-bromophenylacetate (587 mg, 2.40 mmol) and 2-chlorophenyl isocyanate (0.29 ml, 2.40 mmol) in THF (2 ml) was added Et3N (33 ml, 0.24 mmol) at room temperature. After 21 h stirring, the reaction mixture was concentrated in vacuo. The residue was triturated by the addition of n-hexane to give methyl 3-bromo-4-[W-(2-chlorophenyl)ureido] phenylacetate (710 mg, 74%) as a pale brown powder. 'H-NMR (CDC13) δ 3.57 (s, 2H), 3.70 (s,
3H), 7.02-7.28 (m, 2H), 7.36 (d, 7 = 6.8 Hz, IH), 7.48 (s, IH), 8.00-8.11 (m, 2H); MS (ESI) m/z
397 (M+), 399 (M++2), 401 (M++4).
To a stirred solution of methyl 3-bromo-4-[N'-(2-chlorophenyl)ureido]phenylacetate (710 mg, 1.79 mmol) in THF (10 ml) was added 0.25 N NaOH (10 ml). After stirring at room temperature for 14 h, the solvent was concentrated in vacuo. The residue was triturated by the addition of 1 N HCl and dried at 60 °C for 2 days under a reduced pressure to give 3-bromo-4-[N'-(2-chlorophenyl) ureido]phenylacetic acid (643 mg, 94%) as colorless powder. 'H-NMR (DMSO-c ,) δ 3.56 (s, 2H), 7.05 (m, IH), 7.21 (dd, 7 = 8.6, 1.7 Hz, IH), 7.29 (t, 7 = 7.8 Hz, IH), 7.46 (d, 7 = 8.1 Hz, IH), 7.46 (d, 7= 8.1 Hz, IH), 7.53 (d, 7= 1.7 Hz, IH), 7.83 (d, 7 = 8.3 Hz, IH), 8.06 (d, 7 = 7.6 Hz, IH), 8.86 (s, IH), 8.89 (s, IH), 12.40 (s, IH); MS (ESI) m/z 382 (M++l), 384(M++3).
A mixture of 3-bromo-4-[N'-(2-chlorophenyl)ureido]phenylacetic acid (384 mg, 1.00 mmol), methyl 4-[(4S)-fluoro-(2S -pyrrolidinyl]methoxybenzoate (253 mg, 1.00 mmol), EDC HCl (288 mg, 1.50 mmol), HOBT (203 mg, 1.50 mmol) and Et3N (0.70 ml, 5.00 mmol) in DMF (4 ml) was stirred at room temperature for 18 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [30 g,
Figure imgf000237_0001
to give methyl 4-[l-[3-bromo-4-[N'-(2-chlorophenyl)ureido]phenylacetyl]- (4S)-fluoro-(25)-pyrrolidinyl]methoxybenzoate (640 mg, 100%) as a colorless amorphous solid. 'H-NMR (CDC13) δ 2.07-2.46 (m, 2H), 2.59 (t, 7 = 18.4 Hz, IH), 3.57 (d, 7 = 10.5 Hz, 2H), 3.63- 4.67 (m, 7H), 5.26-5.44 (m, IH), 6.89-6.96 (m, 3H), 7.13 (d, 7= 7.6 Hz, IH), 7.1 (t, 7 = 7.3 Hz, IH), 7.26-7.29 (m, 2H), 7.52-7.94 (m, 4H), 8.01(d, 7 = 8.5 Hz, IH), 8.09 (d, 7= 8.5 Hz, IH); MS (FAB) m/z 618 (M+), 620 (M++3), 622 (M++5).
To a solution of methyl 4-[l-[3-bromo-4-[Λr'-(2-chlorophenyl)meido]phenylacetyl]-(4S)-fluoro- (25)-pyrrolidinyl]methoxybenzoate (640 mg, 1.00 mmol) in THF (40 ml) was added 0.25 N NaOH (40 ml). After stirring at room temperature for 14 h, the mixture was concentrated under a reduced pressure and acidified with 1 N HCl. The precipitates were collected, washed with water and dried under a reduced pressure to give 95 (522 mg, 86%) as a pale yellow powder. MW 604.85 IR (KBr) 3317, 3072, 1709, 1685, 1604, 1529, 1290 cm '; 'H-NMR (DMSO-c .) δ 2.24-2.50 (m, 2H), 3.67 (d, 7= 8.3 Hz, 2H), 3.73-4.68 (m, 5H), 5.31-5.52 (m, IH), 7.03-7.09 (m, 3H), 7.22 (dt, 7= 8.3, 1.7 Hz, IH), 7.30 (d, 7 = 7.3 Hz, IH), 7.46 (dd, 7= 8.0, 1.4 Hz, IH), 7.49 and 7.52 (each d, 7 = 2.0 Hz, IH, amide isomers), 7.80-7.91 (m, 3H), 8.07 (dd, 7 = 8.3, 1.2 Hz, IH), 8.85 and 8.86 (each s, IH, amide isomers), 8.96 and 8.97 (each s, IH, amide isomers), 12.62 (s, IH); MS (FAB) m/z 605 (M++l), 607 (M++3), 609 (M++3), 626 (M++1+Na); Anal. Calcd for C27H24BrClFN3O5-0.8H2O: C, 52.37; H, 4.17; N, 6.79; F, 3.07. Found: C, 52.63; H, 4.12; N, 6.62; F, 2.97. Example 90
4-[ 1 - [3 -bromo-4- [N '-(2-bromophenyl)ureido]phenylacetyl] -(45)-fluoro-(25)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000237_0002
To a mixture of methyl 4-amino-3-bromophenylacetate (587 mg, 2.40 mmol) and 2-bromophenyl isocyanate (0.30 ml, 2.40 mmol) in THF (2 ml) was added Et3N (33 ml, 0.24 mmol) at room temperature. After 4 h stirring, the reaction mixture was concentrated in vacuo. The residue was triturated by the addition of n-hexane to give methyl 3-bromo-4-[jV'-(2-bromophenyl)ureido] phenylacetate (770 mg, 73%) as a pale brown powder. 'H-NMR (CDC13) δ 3.55 (s, 2H), 3.70 (s, 3H), 6.97 (dd, 7= 7.3, 1.5 Hz, IH), 7.22 (dd, 7 = 8.5, 2.2 Hz, IH), 7.29-7.33 (m, 2H), 7.48 (d, 7 = 1.0, 2.2 Hz, IH), 7.54 (dd, 7= 8.0, 1.2 Hz, IH), 8.01 (m, 2H); MS (ESI) m/z 443 (M++l), 445 (M++3), 447 (M++5). To a stirred solution of methyl 3-bromo-4-[iV'-(2-bromophenyl)ureido]phenylacetate (770 mg, 1.74 mmol) in THF (10 ml) was added 0.25 N NaOH (10 ml). After stirring at room temperature for 14 h, the solvent was concentrated in vacuo. The residue was triturated by the addition of 1 N HCl and dried at 60 °C for 2 days under a reduced pressure to give 3 -bromo-4-[N '-(2-bromophenyl) ureido]phenylacetic acid (702 mg, 94%) as colorless powder. Η-NMR (DMSO-c ,) δ 3.56 (s, 2H), 6.99 (dt, 7 = 7.8, 1.5 Hz, IH), 7.21 (dd, 7= 8.3, 1.7 Hz, IH), 7.33 (dt, 7 = 7.1, 1.5 Hz, IH), 7.53 (d, 7= 1.7 Hz, IH), 7.62 (dd, 7= 8.1, 1.5 Hz, IH), 7.82 (d, 7= 8.3 Hz, IH), 7.93 (dd, 7= 8.1, 1.5 Hz, IH), 8.82 (s, IH), 8.86 (s, IH), 12.39 (s, IH); MS (ESI) m/z 428 (M++l), 430(M++3).
A mixture of 3-bromo-4-[N'-(2-chlorophenyl)ureido]phenylacetic acid (428 mg, 1.00 mmol), methyl 4-[(2S,4S)-4-fluoro-2-pyrrolidinyl]methoxybenzoate (253 mg, 1.00 mmol), EDC HCl (288 mg, 1.50 mmol), HOBT (203 mg, 1.50 mmol) and Et3N (0.70 ml, 5.00 mmol) in DMF (4 ml) was stirred at room temperature for 18 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [30 g, CHCl3/acetone(10/l)] to give methyl 4-[l-[3-bromo-4-[Λ '-(2-bromophenyl)ureido]phenylacetyι]- (4S)-fluoro-(2S -pyrrolidinyl] methoxybenzoate (720 mg, 100%) as a colorless amorphous solid. Η-NMR (CDC13) δ 2.07-2.45 (m, 2H), 2.58 (m, IH), 3.58 (d, 7= 9.0 Hz, 2H), 3.63-4.69 (m, 9H), 5.26-5.43 (m, IH), 6.88-6.99 (m, 3H), 7.16 (d, 7= 8.3 Hz, IH), 7.23-7.32 (m, 2H), 7.46 (dd, 7 = 8.1, 1.5 Hz, IH), 7.51-8.20 (m, 5H); MS (FAB) m/z 664 (M+), 666 (M++3), 668 (M++5).
To a solution of methyl 4-[l-[3-bromo-4-[Λ^'-(2-bromophenyl)meido]phenylacetyl]-(4S)-fluoro-
(2S)-pyrrolidinyl]methoxybenzoate (720 mg, 1.00 mmol) in THF (40 ml) was added 0.25 N NaOH (40 ml). After stirring at room temperature for 14 h, the mixture was concentrated in vacuo and acidified with 1 N HCl. The mixture was extracted with CHCl^eOH (10/1). The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [20 g, CHCVacetone
(10/l)-CHCl:/MeOH(20/l)] and triturated by the addition of ether to give 96 (489 mg, 75%) as a colorless amorphous solid. MW 649.30 IR (KBr) 3450, 3313, 3070, 1709, 1684, 1525, 1435 cm 1; Η-NMR (DMSO-c ,) δ 2.25-2.50 (m, 2H), 3.67 (d, 7 = 8.3 Hz, 2H), 3.73-4.68 (m, 5H), 5.31-5.53 (m, IH), 6.98-7.08 (m, 3H), 7.21 (d, 7= 8.2 Hz, IH), 7.34 (t, 7 = 8.8 Hz, IH), 7.50 and 7.53 (each s, IH, amide isomers), 7.62 (d, 7 = 8.0 Hz, IH), 7.80-7.96 (m, 4H), 8.82 (s, IH), 8.85 and 8.86 (each s, IH, amide isomers), 12.63 (br, IH); MS (FAB) m/z 650 (M++1), 652 (M++3), 654 (M++3), 672 (M++Na); Anal. Calcd for C27H24Br2FN3O5 0.9H2O: C, 48.73; H, 3.91; N, 6.31; F, 2.85. Found: C, 48.96; H, 3.98; N, 5.92; F, 2.77. Example 91
4-[l-[4-[N'-(2-me ylphenyl)ureido]-2,3-difluorophenylacetyl]-(45)-fluoro-(2S)-pyrrolidinyl methoxy]benzoic acid.
Figure imgf000239_0001
To a stirred solution of tert-butyl ethyl malonate (5.35 ml, 28.2 mmol) in DMF (150 ml) was added NaH (60% in oil, 3.38 g, 84.7 mmol) at rt. After 20 min, 2,3-difluoronitrobenzene (5 g,
28.2 mmol) in DMF (50 mL) was added dropwise via dropping funnel. Following the addition, the mixture was stirred for 3 hours at rt. The mixture was poured into ice-water and sat. NH4C1 (100 mL). The mixture was extracted with EtOAc and the combined organic layer was washed with 1M HCl and brine, dried over MgS04, filtered and concentrated. The residue was dissolved to dichloromethane (20 mL), and added TFA (20 mL) at rt. The mixture was refluxed for 18 h. The mixture was evaporated in vacuo, coevaporated with toluene (20 mL x 2). The residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC- 5404-FC, linear gradient hexane-EtOAc 10:0 to 1: 1, φ 50 mm x 300 mm, 15 mL/min) to give ethyl 2,3-difluoro-4-nitrophenylacetic acid (5.85 g, 85%) as a yellow oil. 'H-NMR (CDC13) δ 1.30 (m, 3 H), 3.78 (s, 2 H), 4.22 (m, 2 H), 7.22 (m, 1 H), 7.84 (m, 1 H); MS (FAB) m/z 246 (M++l).
To a stirred solution of ethyl 2,3-difluoro-4-nitrophenylacetate (5.85 g, 23.9 mol) in EtOH (100 mL), was added SnCl2 (16.1 g, 71.6 mmol) at rt. The stirring was continued for 18 hours at reflux. After removal of the solvent, the residue was dissolved in CHC13 (100 mL) and poured into ice water-4M NaOH (40 mL of 4M NaOH in 300 mL of ice-water), extracted with CHC13 (100 mL x 2), dried over anhydrous MgS04, and concentrated under a reduced pressure. The residue was chromatographed on silica gel (middle pressure chromatography system YAMAZEN YFLC- 5404, linear gradient of hexane-EtO Ac from 9: 1 to 7:3, φ 50 mm x 500 mm, 15 ml/min) to give ethyl 4-amino-2,3-difluorophenylacetic acid (1.94 g, 38%) as a colorless oil. ' H-NMR (CDC13) δ 1.25 (t, 7 = 7.3 Hz, 3 H), 3.55 (d, 7 = 1.0 Hz, 2 H), 3.78 (brs, 2 H), 4.15 (dd, 7= 7.2 Hz, 14.2 Hz, 2 H), 6.49 (dt, 7 = 1.8, 8.2 Hz, 1 H), 6.78 (m, 1 H); MS (FAB) m/z 216 (M++l).
To a stirred solution of ethyl 4-amino-2,3-difluorophenylacetate (323 mg, 1.5 mmol) in DMF (8 mL), were added triethylamine (0.209 ml, 1.5 mmol) and 2-methylphenyl isocyanate (0.372 ml, 3.0 mmol) at rt. The stirring was continued for 48 hour at 80 ° C. The reaction mixture was evaporated in vacuo, and the solid was suspended to n-hexane. The solid was collected through filtration. The solid was dissolved in THF-MeOH ( 1 : 1 , v/v, 20 mL), and was added 4M NaOH (10 mL) at rt. The stirring was continued for 18 hours at rt. The reaction was poured into IM HCl, and the resulting precipitate was collected through filtration. The solid was recrystallized with CHCl3-n-hexane to give 4-[(2-methylphenyl)ureido]-2,3-difluorophenylacetic acid (200 mg, 42%) as a white solid. Η-NMR (CDC13) δ 2.30 (s, 3 H), 3.35 (s, 2 H), 6.98 (m, 1 H), 7.04 (m, 1 H), 7.18 (d, 7= 7.3 Hz, 2 H), 7.69 (d, 7 = 8.1 Hz, 1 H), 7.90 (m, 1 H); MS (FAB) m/z 321 (M++l).
To a stirred solution of methyl 4-(4-S-4-fluoro-2-pyrrolidinyl)methoxy benzoate (63 mg, 0.25 mmol) and 4-[N'-(2-methylphenyl)ureido]-2,3-difluorophenylacetic acid (82 mg, 0.25 mmol) in DMF (5 mL), were added EDC-HC1 (72 mg, 0.38 mmol), HOBt (69 mg, 0.48 mmol), and DMAP (cat.), and the stirring was continued overnight at rt. The mixture was diluted with EtOAc (50 mL), washed with IM NaOH, IM HCl, and brine, dried over anhydrous MgS04, and concentrated under a reduced pressure. The residue was dissolved in THF-MeOH-H20 (21 mL, 1:1: 1, v/v/v) and the stirring was continued for 6 h at rt. The mixture was poured into IM HCl and extracted with CHCl3-MeOH (9:1, v/v). The combined organic phase was dried over anhydrous MgS04, and concentrated under a reduced pressure. The residue was purified with TLC (Whatman, PLK- 5F, CHCL/MeOH, 20:1, v/v) to give 97 (69 mg, 51%) as a white powder. MW 541.52 ffi. (KBr) 3340, 1604, 1540, 1251, 1168, 754 cm 1; Η-NMR (DMSO-c ,) δ 2.25 (s, 3 H), 2.32 (m, 2 H), 3.68- 4.40 (m, 7 H), 5.32-5.55 (m, 1 H), 6.98 (m, 2 H), 7.05 (d, 7 = 8.8 Hz, 2 H), 7.83 (d, 7 = 8.8 Hz, 2 H), 7.82-7.92 (m, 2 H), 8.40 (s, 1 H), 9.14 (s, 1 H); MS (ESI) m/z 564 (M++Na); Λ«α/. Calcd for C28H26F3N3O5-2.0H2O: C, 58.23; H, 5.24; N, 7.28. Found: C, 58.07, H, 4.84; N, 7.03. Example 92 4-[l-[4-[N'-(2-methylphenyl)meido]-2,5-difluorophenylacetyl]-(45)-fluoro-(2S)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000240_0001
To a stirred solution of di-tert-butyl ethyl malonate (6.32 ml, 28.2 mmol) in DMF (150 ml), was added NaH (60% in oil, 3.38 g, 84.7 mmol) at rt. After 20 min, 2,5-difluoronitrobenzene (5 g,
28.2 mmol) in DMF (50 mL) was added dropwise via dropping funnel. Following the addition, the mixture was stirred for 3 horns at rt. The mixture was poured into ice-water and sat. NH4C1 (100 mL). The mixture was extracted with EtOAc and the combined organic layer was washed with IM HCl and brine, dried over MgS04, filtered and concentrated. The residue was dissolved to dichloromethane (20 mL), and added TFA (20 mL) at rt. The mixture was refluxed for 18 h. The mixture was evaporated in vacuo, coevaporated with toluene (20 mL x 2). The residue was dissolved in MeOH (150 mL), and added cone. H2S04 (5 mL). The mixture was refluxed for 18 h. The mixture was diluted with EtOAc (300 mL), washed with water, IM HCl, and brine, dried over anhydrous MgS04, and concentrated under a reduced pressme. The residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient hexane-EtOAc 10:0 to 1: 1, φ 50 mm x 300 mm, 15 mL/min) to give ethyl 2,5-difluoro-4- nitrophenylacetic acid (6.53 g, 90%) as a yellow oil. Η-NMR (CDC13) δ 3.75 (s, 2 H), 3.76 (s, 3 H), 7.29 (dd, 7= 5.8 Hz, 10.5 Hz, 1 H), 7.81 (dd, 7= 6.0 Hz, 8.4 Hz, 1 H); MS (ESI) m/z 232 (M++l).
To a stirred solution of ethyl 2,5-difluoro-4-nitrophenylacetate (5.88 g, 25.4 mol) in EtOH (100 mL), was added SnCl2 (17.2 g, 76.3 mmol) at rt. The stirring was continued for 18 hours at reflux. After removal of the solvent, the residue was dissolved in CHC13 (100 mL) and poured into ice water-4M NaOH (40 mL of 4M NaOH in 300 mL of ice-water), extracted with CHC13 (100 mL x 2), dried over anhydrous MgS04, and concentrated under a reduced pressure. The residue was chromatographed on silica gel (middle pressure chromatography system YAMAZEN YFLC- 5404, linear gradient of hexane-EtOAc from 9:1 to 7:3, φ 50 mm x 500 mm, 15 ml/min) to give ethyl 4-amino-2,5-difluorophenylacetic acid (2.85 g, 52%) as a colorless oil. ' H-NMR (CDC13) δ 1.28 (t, 7= 7.3 Hz, 3 H), 3.51 (s, 2 H), 3.78 (brs, 2 H), 4.15 (dd, 7= 7.2 Hz, 14.2 Hz, 2 H), 6.47 (dd, 7= 7.5, 10.4 Hz, 1 H), 6.88 (dd, 7= 6.7, 11.0 Hz, 1 H); MS (FAB) m/z 216 (M++l).
To a stirred solution of ethyl 4-amino-2,5-difluorophenylacetate (323 mg, 1.5 mmol) in DMF (8 mL), were added triethylamine (0.209 ml, 1.5 mmol) and 2-methylphenyl isocyanate (0.372 ml, 3.0 mmol) at rt. The stirring was continued for 48 hour at 80 °C. The reaction mixture was evaporated in vacuo, and the solid was suspended to n-hexane. The solid was collected through filtration. The solid was dissolved in THF-MeOH (1 : 1, v/v, 20 mL), and was added 4M NaOH (10 mL) at rt. The stirring was continued for 18 hours at rt. The reaction was poured into IM HCl, and the resulting precipitate was collected through filtration. The solid was recrystallized with CHCl3-«-hexane to give 4-[(2-methylphenyl)ureido]-2,5-difluorophenylacetic acid (214 mg, 46%) as a white solid. Η-NMR (CDC13) δ 2.30 (s, 3 H), 3.35 (m, 2 H), 7.02 (m, 2 H), 7.18 (d, 7 = 7.3 Hz, 2 H), 7.69 (d, 7 = 7.8 Hz, 1 H), 8.03 (m, 1 H); MS (FAB) m/z 321 (M++l).
To a stirred solution of methyl 4-[(4S)-fluoro-(2S)-pyrrolidinyl]methoxybenzoate (63 mg, 0.25 mmol) and 2,5-difluoro-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (82 mg, 0.25 mmol) in DMF (5 mL) was added EDC-HC1 (72 mg, 0.38 mmol), HOBt (69 mg, 0.48 mmol), and DMAP (cat.), and the stirring was continued overnight at rt. The mixture was diluted with EtOAc (50 mL), washed with IM NaOH, IM HCl, and brine, dried over anhydrous MgS04, and concentrated under a reduced pressure. The residue was dissolved in THF-MeOH-H20 (21 mL, 1: 1: 1, v/v/v) and the stirring was continued for 6 h at rt. The mixture was poured into IM HCl and extracted with CHCl3-MeOH (9: 1, v/v). The combined organic phase was dried over anhydrous MgS04, and concentrated under a reduced pressure. The residue was purified with TLC (Whatman, PLK- 5F, CHCl- MeOH, 20:1, v/v) to give 98 (69 mg, 51%) as a white powder. MW 541.52 IR-ATR: 3351, 1604, 1537, 1167, 754 (cm 1); Η-NMR (DMSO) δ 2.25 (s, 3 H), 2.32 (m, 2 H), 3.68-4.70 (m, 7 H), 5.32-5.55 (m, 1 H), 6.97 (t, 7= 7.6 Hz, 1 H), 7.06 (d, 7= 8.5 Hz, 2 H), 7.20 (m, 3 H), 7.87 (d, 7 = 8.8 Hz, 2 H), 7.83-8.04 (m, 2 H), 8.45 (s, 1 H), 9.18 (s, 1 H); MS (ESI) m/z 564 (M++Na); Anal. Calcd for C28H26F3N305 1.75 H20: C, 58.69; H, 5.19; N, 7.33. Found: C, 58.54, H, 4.85; N, 6.98. Example 93
4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-4-fluoro-2-pyrrolidinyl]methylamino benzoic acid
F
Figure imgf000242_0001
4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-4-fluoro-2-pyrrolidinyl]methylamino benzoic acid
Figure imgf000242_0002
To a stirred solution of methyl l-tert-butoxycarbonyl-4-fluoropyrrolidine-2-carboxylate( 1.2 g, 4.85 mmol) in MeOH (5 ml) was added IN NaOH (5 ml) and the mixture was stirred at room temperature for lhr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The mixture was extracted with EtOAc. The extract was washed with water, then dried over Na2S0 , and concentrated in vacuo to give l-tert-butoxycarbonyl-4- fluoropyrrolidine-2-carboxylic acid (1.1 g , quant) as a colorless oil. Η-NMR (CDC13) δ 1.47 (br s, 9H), 2.78-2.83 (br s, 3H), 4.37 (s, 2H), 6.73-6.76 (m, 3H), 7.17 (m, IH).
To a stirred solution of l-tert-butoxycarbonyl-4-fluoropyrrolidine-2-carboxylic acid (1.1 g, 4.7 mmol) in THF (10.0 ml) was added BH3-THF(1.0 M solution in THF, 10.0 ml, 10.0 mmol) at 0°C After stirred at room temperature for 1.0 h. After cooled, the mixture was concentrated in vacuo. Water was added thereto at 0°C, and extracted with EtOAc. The extract was washed with water, then dried over Na2S04, and concentrated in vacuo to give l-tert-butoxycarbonyl-4-fluoro- 2-pyrrolidinylmethanol (1.0 g , quant) as a a colorless oil. Η-NMR (CDC13) δ 1.48 (s, 9H), 2.29- 2.39 (m, IH), 3.38-3.59 (m, 2H), 3.74-3.88 (m, 2H), 4.09-4.14 (m, 2H), 4.85 (m, IH), 5.03 (br s, IH), 5.16 (br s, IH).
To a stirred solution of oxalyl chloride (0.28 ml, 2.3 mmol) in CH2G2 (20.0 ml) was added DMSO (0.39 ml) at -78 °C After 5 minutes, to the mixture was added 1-tert- butoxycarbonyl-4-fluoro-2-pyrrolidinylmethanol (500 mg, 2.28 mmol) in CH C12 (5.0 ml). The mixture was stirred for 30 minutes at -78 °C, and triethylamine (1.6 ml) was added. The mixture was stirred for 30 minutes at -78 °C, and stirred for 30 minutes at room temperature. Water was added to the mixture, and extracted with CH2C12. The organic layer was dried over Na2S04 , and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, methyl 4-aminobenzoate(302 mg, 2.0 mmol), and AcOH (0.13 ml) in DCE (10 ml) was added NaBH(OAc)3 (656 mg, 3.09 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 18 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The extract was washed with brine, dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc- n-hexane (1:3, v/v) as eluent to give methyl 4-(l-tert-butoxycarbonyl-4-fluoro-2-pyrrolidinyl)methylaminobenzoate (541 mg, 77% ) as a pale yellow oil. Η-NMR (CDC13) δ 1.55-1.59 (m, IH), 2.16-2.27 (m, IH), 2.89-3.03 (m, 2H), 3.19-3.28 (m, 2H), 3.69-3.73 (m, IH), 3.84 (s, 3H), 5.15 and 5.29 (each s, total IH), 6.55-6.58 (m, 2H), 7.84-7.86 (m, 2H).
To a stirred solution of methyl 4-(l-tert-butoxycarbonyl-4-fluoro-2-pyrrolidinyl)methylamino benzoate (541 mg, 1.53 mmol) in CH2C12 (8.0 ml) was added TFA (4.0 ml) at 0 °C. The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The extract was washed with brine ,dried over Na2S04 , and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product(151 mg, 0.6 mmol), 4-[N'-(2-chlorophenyl)uredio]-3-methoxyphenylacetic acid (201 mg, 0.6 mmol), HOBt (94 mg, 0.7 mmol), and triethylamine (167 μl, 1, 1.2 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDC HCl (173 mg, 0.9 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc(l:2 ,v/v) as eluent to give methyl 4-[l-[4-[N'- (2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-4-fluoro-2-pyrrolidinyl]methylaminobenzoate
(320 mg, 94%) as an amorphous solid. "H-NMR (CDC13) δ 1.80-1.95 (m, IH), 2.42-2.58 (m, IH), 3.20-3.51 (m, 3H), 3.51-3.76 (m, 5H), 3.84 (s, 3H), 3.85-3.98 (m, IH), 4.67-4.70 (m, IH), 5.10 and 5.23 (s, each, total IH), 5.50 (br s, IH), 6.49-6.52 (m, 2H), 6.78-6.81 (m, 2H), 6.97-7.01 (m, IH), 7.14-7.18 (m, 2H), 7.24-7.36 (m, 2H), 7.80-7.82 (m, 2H), 7.99-8.01 (m, IH), 8.15-8.18 (m, IH).
To a stirred solution of methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenyl acetyl]-4-fluoro-2-pyrrolidinyl]methylaminobenzoate (320 mg, 0.56 mmol) in THF (5.0 ml) and MeOH (3.0 ml) was added IN NaOH (0.8 ml, 0.8 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 99 (280 mg, 90%) as a white crystalline solid. MW 555.00 mp 132-136 °C; IR (KBr) 3332, 2937, 1602, 1531, 1174, 752 cm'1; 'H-NMR (DMSO-cL.) δ 2.00-2.40 (m, 2H), 3.50-3.90 (m, 4H), 3.75-3.85 (m, 5H), 4.27 (m, IH), 5.23 and 5.37 (each s, total IH), 6.51-7.03 (m, 5H), 7.25-7.29 (m, IH), 7.41- 7.44 (m, IH), 7.64-7.68 (m, 2H), 7.92-8.10 (m, 2H), 8.87-8.94 (m, 2H); Anal. calcd for C28H28N4O5FC1 0.6H2O: C, 59.44; H, 5.20; N, 9.90. Found: C, 59.41; H, 5.19; N, 9.72.
To a stirred solution of methyl 4-(l-tert-butoxycarbonyl-4-fluoro-2-pyrrolidinyl)methylamino benzoate (541 mg, 1.53 mmol) in CH2C12 (8.0 ml) was added TFA (4.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The extract was washed with brine, dried over Na2S04, and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (151 mg, 0.6 mmol), 4-[iV-(2-bromophenyl)uredio]-3-methoxyphenylacetic acid (227 mg, 0.6 mmol), HOBt (94 mg, 0.7 mmol), and triethylamine (167 μl, 1.2 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDCHCl (173 mg, 0.9 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (2:3, v/v) as eluent to give methyl 4-[l-[4-[N"- (2 -bromophenyl)ureido]-3-methoxyphenylacetyl]-4-fluoro-2-pyrrolidinyl]methylamino benzoate (280 mg, 76%) as a colorless oil. 'H-NMR (CDC13) δ 1.80-1.98 (m, IH), 1.42-1.58 (m, IH), 3.20- 3.52 (m, 3H), 3.67-3.79 (m, 5H), 3.84 (s, 3H), 3.94-3.97 (m, IH), 4.68-4.71 (m, IH), 5.10 and 5.23 (each s, total IH), 5.51 (br s, IH), 6.50-6.52 (m, 2H), 6.79-7.07 (m, 5H), 7.25-7.33 (m, IH), 7.51-7.53 (m, IH), 7.80-7.83 (m, 2H), 7.98-8.00 (m, IH), 8.11-8.14 (m, IH).
To a stirred solution of methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl acetyl]-4-fluoro-2-pyrrolidinyl]methylaminobenzoate (280 mg, 0.46 mmol) in THF (8.0 ml) and MeOH (8.0 ml) was added IN NaOH (2.8 ml, 2.8 mmol). The mixture was stirred at 70 °C for 18 hr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 100 (260 mg, 95%) as a white crystalline solid. MW 599.45 mp 131-135 °C; IR (KBr) 3332, 2935, 1602, 1529, 1174 cm '; 'H-NMR (DMSO-c .) δ 1.95-2.01 (m, IH), 2.20-2.35 (m, IH), 3.10-3.20 (m, IH), 3.50-3.70 (m,3H), 3.80-3.85 (m, 5H), 4.27 (m, IH), 5.24 and 5.37 (each s, total IH), 6.54-6.99 (m, 5H), 7.30-7.33 (m, IH), 7.58-7.94 (m, 3H), 7.94-7.98 (m, 2H), 8.73 (m, IH), 8.93 (m, IK); Anal. calcd for C28H28N4O5BrF 0.7H2O: C, 54.95; H, 4.84; N, 9.15. Found: C, 54.98; H, 4.81; N, 8.93. Example 94
4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4R)-fluoro-(2S)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000245_0001
A mixture of methyl 4-[(4R)-fluoro-(2S)-pyrrolidinylmethoxy]benzoate (634 mg, 2.50 mmol), 3- methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (787 mg, 2.50 mmol), EDC HCl (718 mg, 3.75 mmol), HOBt (cat), DMAP (cat.) and DMF (10 ml) was stirred overnight. The mixture was diluted with EtOAc (300 ml). The solution was washed with brine (2 x 100 ml), dried over MgS04, and concentrated in vacuo. The residue was chromatographed on silica gel with CHC13- EtOAc (4: 1) as eluent to give methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-(4Λ)-fluoro-(25)-pyrrolidinylmethoxy]benzoate (1.37 g, quant) as a pale yellow viscous solid. 'H-NMR (CDC13) δ 2.24 (s, 3 H), 2.26-2.47 (m, 2 H), 3.46 (s, 3 H), 3.49-3.64 (m, 4 H), 3.87 (s, 3 H), 4.06 (dd, 7= 9.5, 2.0 Hz, 1 H), 4.51-4.62 (m , 2 H), 5.20 and 5.33 (br s, each, total IH), 6.63 (s, 1 H), 6.72 (d, 7 = 8.3 Hz, 1 H), 6.77 (d, 7= 9.0 Hz, 2 H), 7.05 (t, 7= 7.6 Hz, 1 H), 7.16-7.20 (m, 3 H), 7.53 (s, 1 H), 7.63 (d, 7 = 7.8 Hz, 1 H), 7.91 (d, 7= 9.0 Hz, 2 H), 8.07 (d, 7 = 8.1 Hz, I H).
A mixture of methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4R)- fluoro-(25)-pyrrolidinylmethoxy]benzoate (1.37 g, 2.49 mmol), 0.25 N NaOH (20 ml, 5.00 mmol), and THF (20 ml) was stirred for 3 days. The mixture was poured into 1 N HCl (100 ml) and extracted with CHCl3-MeOH (5: 1, 2 x 200 ml). The combined extracts were dried over MgS04 and concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (20: 1 to 4: 1) to give 101 (930 mg, 70%) as a pale yellow amorphous solid. MW 535.56 'H-NMR (DMSO-d6) δ 2.24-2.41 (m, total 5 H), 3.42-4.66 (series of m, 10 H), 5.31 and 5.44 (br s, each, total 1 H), 6.71-7.16 (series of m, 7 H), 7.79 (d, 7 = 8.1 Hz, 1 H), 7.85-7.89 (m, 2 H), 7.98-8.00 (m, 1 H), 8.47 (s, 1 H), 8.55 (s, 1 H); MS(FAB) m/z 536 (M++l). Example 95
4-[(45 -chloro-l-[3-methoxy-4-[N'-(2-chlorophenyl)meido]phenylacetyl]-(2S)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000246_0001
To a stirred solution of methyl 4-(/røns,-l-tert-butoxycarbonyl-4-hydroxy-(2S)-pyrrolidinyl) methoxybenzoate (351 mg, 1.0 mmol) and PhjP (393 mg, 1.5 mmol) in CHC13 (5.0 ml) was added
CC14 (5.0ml) at room temperature. The reaction mixture was stirred at 50°C for 24 hr. The reaction mixture was concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane to «-hexane-EtOAc(4: 1, v/v) as eluent to give methyl 4-(cjs-l-tert- butoxycarbonyl-4-chloro-(2S)-pyrrolidinyl)methoxybenzoate (340 mg, 92%) as a pale yellow oil.
'H-NMR (CDC13) δ 1.48 (s, 9H), 2.38-2.65 (m, 2H), 3.50-3.60 (m, IH), 3.88 (s, 3H), 3.89-4.05
(m, IH), 4.26-4.41 (m, 4H), 6.95-6.97 (m, 2H), 7.98 (d, 7 = 8.5 Hz, 2H).
To a stirred solution of methyl 4-(l-tert-butoxycarbonyl-(4S)-chloro-(2S)-pyrrolidinyl) methoxybenzoate (369mg, 1.0 mmol) in CH2C12 (3.0 ml) was added TFA (3.0 ml) at 0 °C. The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The extract was washed with brine, dried over Na2S04, and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (185 mg, 0.5 mmol), 4-[N'-(2-chlorophenyl)uredio]-3-methoxyphenylacetic acid (167 mg, 0.5 mmol), HOBt (68 mg, 0.5 mmol), and triethylamine (208ml, 1.5 mmol) in THF (8.0 ml) and MeCN (8.0 ml) was added EDC HCl (144 mg, 0.75 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1:2, v/v) as eluent to give methyl 4- [(4S)-chloro-l-[3-methoxy-4-[Λ^'-(2-chlorophenyl)ureido]phenylacetyl]-(2S)-pyrrolidinyl]methoxy benzoate (210 mg, 72%) as a colorless oil. 'H-NMR (CDC13) δ 3.35-3.50 (m, IH), 3.55-3.65 (m, IH), 3.61-3.66 (m, 3H), 3.75 (s, 3H), 3.88 (s, 3H), 3.99-4.04 (m, IH), 4.35-4.40 (m, 3H), 4.48- 4.53 (m, IH), 6.77-7.10 (m, 7H), 7.25-7.36 (m, 2H), 7.93-8.00 (m, 2H), 8.18 (d, 7 = 8.0 Hz, IH).
To a stirred solution of methyl 4-[(4S)-chloro-l-[3-methoxy-4-[N'-(2-chlorophenyl) ureido]phenylacetyl]-(2S)-pyrrolidinyl]mefhoxybenzoate(210 mg, 0.35 mmol) in THF (6.0 ml) and MeOH (3.0 ml) was added IN NaOH (0.7 ml, 0.7 mmol). The mixture was stined at 70 °C for 18 hr. The mixture was concentrate in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 102 (200 mg, 98%) as a white crystalline solid. MW 572.44 mp 126-131 °C; IR (KBr) 3330, 1685, 1604, 1533, 1438 cm '; 'H-NMR (DMSO-cL.) δ 2.15-2.25 (m, IH), 2.58-2.63 (m, IH), 3.58-3.78 (m, 3H), 3.83 (s, 3H), 4.13-4.42 (m, 4H), 4.73 (m, IH), 6.75-7.45 (m, IK), 7.86-8.10 (m, 4H), 8.90 (s, IH), 8.95 (s, IH); MS (FAB) m/z 572 (M++l); Anal calcd for C28H27N306C1: C, 58.75; H, 4.75; N, 7.34. Found: C, 58.93; H, 4.85; N, 7.15. Example 96
4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(4S)-chloro-(2S)-pyιτolidinyl] methoxybenzoic acid
Figure imgf000247_0001
To a stirred solution of methyl 4-[l-tert-butoxycarbonyl-(4S)-chloro-(2S)-pyrrolidinyl] methoxybenzoate (369mg, 1.0 mmol) in CH2C12 (3.0 ml) was added TFA (3.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The extract was washed with brine, dried over Na2S04, and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (185 mg, 0.5 mmol), 4-[A^-(2-bromophenyl)uredio]-3-methoxyphenylacetic acid (190 mg, 0.5 mmol), HOBt (68 mg, 0.5 mmol), and triethylamine (208ml, 1.5 mmol) in THF (8.0 ml) and MeCN (8.0 ml) was added EDC HCl (144 mg, 0.75 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1:2 ,v/v) as eluent to give methyl 4- [l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(45 -chloro-(2S)-pyrrolidinyl] methoxybenzoate (260 mg, 83%) as a colorless oil. 'H-NMR (CDC13) δ 2.32-2.50 (m, IH), 2.53- 2.65 (m, IH), 3.61-3.67 (m, 3H), 3.75 (s, 3H), 3.88 (s, 3H), 3.99-4.03 (m, IH), 4.35-4.40 (m, 3H), 4.45-4.55 (m, IH), 6.78-7.10 (m, IK), 7.28-7.33 (m, IH), 7.52 (d, 7= 8.0 Hz, IH), 7.94-7.99 (m, 3H), 8.14 (d, 7 = 8.3 Hz, IH).
To a stirred solution of methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl acetyl]-(45)-chloro-(2S)-pyrrolidinyl]methoxybenzoate (260 mg, 0.4 mmol) in THF (6.0 ml) and MeOH (3.0 ml) was added IN NaOH (0.8 ml, 0.8 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concentrate in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 103 (210 mg, 83%) as a white crystalline solid. MW 616.89 mp 127-132°C; IR (KBr) 3330, 1685, 1604, 1529, 1434 cm '; 'H-NMR (DMSO-cL) δ 2.18-2.28 (m, IH), 2.60-2.70 (m, IH), 3.55-3.75 (m, 3H), 3.83 (s, 3H), 4.12-4.42 (m, 4H), 4.60-4.75 (m, IH), 6.75-7.06 (m, 5H), 7.30-7.34 (m, IH), 7.60 (d, 7 = 7.3 Hz, IH), 7.86-7.94 (m, 5H), 8.75 (s, IH), 8.94 (s, IH); MS (FAB) m/z 616 (M+), 618 (M++2); Anal, calcd for C28H27N306ClBr: C, 54.52; H, 4.41; N, 6.81. Found: C, 54.98; H, 4.54; N, 6.66. Example 97 4-[(4R)-chloro-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(25)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000249_0001
4-[(4Λ)-chloro-l-[4-[Λ^'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(25)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000249_0002
To a stirred solution of methyl l-(tert-butoxycarbonyl)-(4S)-hydroxy-(25)-pyrrolidinylcarboxylate (1.81 g, 7.34 mmol) in CC14-CH2C12 (20 ml, 1: 1, v/v) was added Ph3P (3.87 mmol, 14.75 mmol) and the reaction mixture was stirred at room temperature for 2 hr. To the mixture was added EtOH (5 ml) and the reaction mixture was stirred at room temperature overnight After removal of the solvent, the residue was purified by column chromatography on silica-gel with n-hexane- EtOAc (3: 1, v/v) as eluent to give Synthesis of methyl 1 -(tert-butoxycarbonyl)-(4Λ)-chloro-(2S)- pyrrolidinylcarboxylate (1.36 g, 70%) as a colorless oil. 'H-NMR (CDC13) δ 1.42 (s, 9 H), 2.32- 2.39 (m, 1 H), 2.49-2.54 (m, 1 H), 3.66-3.92 (series of s and m, total 5 H), 4.44-4.55 (m, 2 H); MS(FAB) m/z 264 (M++l).
To a stirred solution of methyl l-(tert-butoxycarbonyl)-(4R)-chloro-(2S -pyrrolidinyl carboxylate (1.35 g, 5.12 mmol) in THF (10 ml) was added 0.5 N NaOH (10 ml) and the reaction mixture was heated under reflux for 1.5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the mixture was extracted with CHCl3-MeOH (9: 1, v/v). The extract was was washed with brine, dried over Na2S04 and evaporated to give l-(tert-butoxycarbonyl)- (4Λ)-chloro-(2S)-pyrrolidinylcarboxylic acid (1.28 g, quant.) as a colorless oil. 'H-NMR (CDC13) δ 1.44 (s, 9 H), 2.37-2.54 (m, 2 H), 3.68-3.88 (m, 2 H), 4.42-4.45 (m, 2 H).
To a stirred solution of l-(tert-butoxycarbonyl)-(4Λ)-chloro-(2S)-pyrrolidinylcarboxylic acid (1.28 g, 5.13 mmol) in THF (20 ml) was added dropwise BH3DMS (0.60 ml, 6.33 mmol) via a syringe and the reaction mixture was stirred at room temperature for 1 hr. After removal of the solvent, the residue was dissolved in CH2C12. The solution was washed with H20, brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1, v/v) as eluent to give l-(tert-butoxycarbonyl)-(4Λ)-chloroprolinol (0.88 g, 73%) as a colorless oil. 'H-NMR (CDC13) δ 1.48 (s, 9 H), 1.98 (m, 1 H), 2.26-2.32 (m, 1 H), 3.56- 3.65 (m, 2 H), 3.77 (m, 2 H), 4.24 (m, 1 H), 4.41-4.46 (m, 2 H); MS(FAB) m/z 236 (M++l).
To a cooled (0°C), stirred solution of methyl 4-hydroxybenzoate (560 mg, 3.68 mmol), 1- (tert-butoxycarbonyl)-(4Λ)-chloroprolinol (870 mg, 3.69 mmol), Ph3P (1.16 g, 4.42 mmol) in THF (15 ml) was added DIAD (870 ml, 4.42 mmol) and the reaction mixture was heated under reflux for 10 hr. After cooled to room temperature, the mixture was evaporated. The residue was purified by column chromatography on silica-gel with n-hexane-EtOAc (5: 1, v/v) as eluent to give methyl 4-[l-(tert-butoxycarbonyl)-(4Λ)-chloro-(25)-pyrrolidinylmethoxy]benzoate (890 mg, 65%) as a white solid, mp 116-120°C; Η-NMR (CDC13) δ 1.47 (s, 9 H), 2.39-2.53 (m, 2 H), 3.69-3.70 and 4.13-4.17 (m, total 3 H), 3.88 (s, 3 H), 4.30-4.41 (m, 2 H), 4.50-4.55 (m, 1 H), 6.90-6.92 (m, 2 H), 7.96-7.98 (m, 2 H); MS(FAB) m/z 370 (M++l); Anal. Calcd for C18H24C1N05: C, 58.46; H, 6.54; Cl; 9.59; N, 3.79. Found: C, 58.35; H, 6.56; Cl, 9.75; N, 3.77.
To a stirred solution of methyl 4-[l-(tert-butoxycarbonyl)-(4R)-chloro-(2S)- pyrrolidinylmethoxy]benzoate (840 mg, 2.27 mmol) in CH2C12 (10 ml) was added TFA (10 ml) and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo and made basic by sat. NaHC03. The mixture was extracted with CHC13, washed with brine, dried over Na2S04, and evaporated to give methyl 4-[(4Λ)-chloro-(25 - pyrrolidinylmethoxy] benzoate (580 mg, 95%) as a white solid, mp 61-64°C; 'H-NMR (CDC13) δ 1.85 (br s, 1 H), 2.03-2.10 (m, 1 H), 2.29-2.35 (m, 1 H), 3.19-3.31 (m, 2 H), 3.88 (s, 3 H), 3.92- 4.06 (m, 3 H), 4.53-4.56 (m, 1 H), 6.91 (d, 7 = 8.8 Hz, 2 H), 7.98 (d, 7 = 8.8 Hz, 2 H); MS (FAB) m/z 270 (M++l).
A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (385 mg, 1.22 mmol), methyl 4-[(4Λ)-chloro-(2S)-pyrrolicunylmethoxy]benzoate (330 mg, 1.22 mmol), EDCHCl (281 mg, 1.47 mmol), HOBt (200 mg, 1.48 mmol) and Et3N (205 ml, 1.47 mmol) in THF (10 ml) was stirred at room temperature overnight. The mixture was diluted with H20 and extracted with EtOAc. The extract was washed with brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 50: 1, v/v) as eluent to give methyl 4-[(4Λ)-chloro-l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-(2S)- pyrrolidinylmethoxy]benzoate (670 mg, 97%) as a white foam. 'H-NMR (CDC13) δ 2.28 (s, 3 H), 2.33-2.57 (m, 2 H), 3.50 (s, 3 H), 3.59-3.60 (m, 2 H), 3.75-3.82 (m, 2 H), 3.88 (s, 3 H), 4.06-4.09 (m, 1 H), 4.51-4.63 (m, 3 H), 6.65-6.80 (m, 5 H), 7.09-7.13 (m, 1 H), 7.20-7.27 (m, 3 H), 7.56- 7.58 (m, 1 H), 7.91-7.93 (m, 2 H), 8.05-8.07 (m, 1 H); MS(FAB) m/z 566 (M++l). To a stirred solution of methyl 4-[(4Λ)-chloro-l-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoate (480 mg, 0.85 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 2 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was dissolved in CHCl3-MeOH and evaporated. The residue was washed with Et20 to give 104 (355 mg, 76%) as a white amoiphous solid. MW 552.02 mp 128-132°C; Η-NMR (DMSO-d δ 2.25 (s, 3 H), 2.29-2.46 (m, 2 H), 3.57-
3.73 (m, 2 H), 3.78 (s, 3 H), 3.81-3.99 (m, 2 H), 4.11-4.31 (m, 2 H), 4.43-4.45 and 4.64-4.67 (each m, total 1 H), 4.83-4.85 (m, 1 H), 6.71-7.17 (m, 7 H), 7.78-7.80 (m, 1 H), 7.87-7.91 (m, 2 H), 7.99-8.01 (m, 1 H), 8.47 (s, 1 H), 8.56 (s, 1 H), 12.66 (br s, 1 H); MS(FAB) m/z 552 (M++l); Anal. Calcd for C29H30ClN3O63/4H2O: C, 61.59; H, 5.61; Cl, 6.27; N, 7.43. Found: C, 61.56; H, 5.51; Cl, 6.68; N, 7.26.
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (400 mg, 1.19 mmol), methyl 4-[(4R)-chloro-(2S)-pyrrolidinylmethoxy]benzoate (320 mg, 1.19 mmol), EDCHCl (275 mg, 1.43 mmol), HOBt (195 mg, 1.44 mmol) and Et3N (200 ml, 1.43 mmol) in THF (10 ml) was stirred at room temperature overnight. The mixture was diluted with H20 and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100:1, v/v) as eluent to give methyl 4-[(4Λ)-chloro-l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(2S)- pyrrolidinylmethoxy]benzoate (690 mg, 98%) as a pale yellow foam. 'H-NMR (CDC13) δ 2.35-
2.41 (m, 1 H), 2.49-2.59 (m, 1 H), 3.55 (s, 3 H), 3.57-3.70 (m, 2 H), 3.73-3.86 (m, 2 H), 3.88 (s, 3 H), 4.06-4.09 (m, 1 H), 4.54-4.66 (m, 3 H), 6.67-6.81 (m, 4 H), 6.95-6.99 (m, 1 H), 7.23-7.25 (m, 1 H), 7.29-7.33 (m, 1 H), 7.47-7.49 (m, 2 H), 7.90-7.99 (m, 3 H), 8.18-8.21 (m, 1 H); MS(FAB) m/z 586 (M++l).
To a stirred solution of methyl 4-[(4Λ)-chloro-l-[4-[Λr'-(2-chlorophenyl)ureido]-3- methoxyphenylacetyl]-(25 -pyrrolidinylmethoxy]benzoate (410 mg, 0.70 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was dissolved in CHCl3-MeOH and evaporated. The residue was washed with Et20 to give 105 (282 mg, 70%) as an amoiphous solid. MW 572.44 mp 131-136°C; 'H-NMR (DMSO-cL,) δ 2.29-2.35 (m, 1 H), 2.44-2.47 (m, 1 H), 3.58-
3.74 (m, 2 H), 3.78 (s, 3 H), 3.81-3.99 (m, 2 H), 4.10-4.32 (m, 2 H), 4.44-4.46 and 4.66 (each m, total 1 H), 4.84 (m, 1 H), 6.74-7.04 (m, 5 H), 7.26-7.30 (m, 1 H), 7.43-7.45 (m, 1 H), 7.87-7.91 (m, 2 H), 7.96 (d, 7 = 8.3 Hz, 1 H), 8.09 (d, 7 = 8.3 Hz, 1 H), 8.90 (s, 1 H), 8.94 (s, 1 K); Anal Calcd for C28H27C12N3063/4H20: C, 57.39; H, 4.90; Cl, 11.66; N, 7.17. Found: C, 57.57; H, 4.94; Cl, 11.66; N, 6.89. Example 98
4-[(4S)-hydroxy-l-[4-[N'-(2-methylphenyl)meido]phenylacetyl]-(2S)-pyrrolidinyl]methoxybenzoic acid
Figure imgf000252_0001
To a stirred solution of methyl 4-[(4S)-acetoxy-l-tert-butoxycarbonyl-(25)-pyrrolidinyl]methoxy benzoate (2.31 g, 5.87 mmol) in CH2C12 (46 ml) was added TFA (10 ml) at room temperature. After 3.5 h stirring, the mixture was concentrated in vacuo. The residue was diluted by the addition of CH2C12 and 1 N NaOH, which were extracted with CH2C12 The combined extracts were washed with brine, dried over Na2S04, which was concentrated in vacuo. The residue was chromatographed on silica gel [100 g, CHCVMeOH^O/l)] to give tmethyl 4-[(45)-acetoxy-(2S)- pyrrolidinyl]mefhoxybenzoate (1.89 mg, 100%) as a pale purple solid. Η-NMR (CDC13) δ 2.10 (s, 3H), 2.14 (m, IH), 2.65 (m, IH), 3.52-3.63 (m, H), 3.89 (s, 3H), 4.18 (m, IH), 4.28 (d, 7 = 5.9 Hz, 2H), 5.38 (m, IH), 6.93 (d, 7 = 8.8 Hz, 2H), 7.99 (d, 7= 8.8 Hz, 2H).
A mixture of 3-methoxy-4-[Λ/"-(2-methylphenyl)ureido]phenylacetic acid (343 mg, 1.09 mmol), methyl 4-[(4S -acetoxy-(2S -pyrrolidinyl]methoxybenzoate (320 mg, 1.09 mmol), EDC HCl (313 mg, 1.64 mmol), HOBT (222 mg, 1.64 mmol) and Et3N (0.76 ml, 5.45 mmol) in DMF (7 ml) was stirred at room temperature for 16 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S0 , the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [50 g, CHCyAectone (5/1)], to give methyl 4-[(4S)-acetoxy-l-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetyl]-(25)-pyrrolidinyl]methoxybenzoate (520 mg, 81%) as a brown amorphous solid. 'H-NMR (CDC13) δ 2.00 (s, 3H, one of isomers), 2.03 (s, 3H, one of isomers), 2.28 (m, 5H), 3.54 (s, IH), 3.58 (s, 2H), 3.64 (s, IH), 3.67 and 3.69 (each s, 3H, amide isomers), 3.85 (d, 7 = 5.4 Hz, IH), 3.88 (s, 3H), 4.04 (t, 7= 9.3 Hz, IH), 5.27-5.34 (m, IH), 6.51 (m, IH), 6.76-6.89 (m, 2H), 6.94 (d, 7 = 8.1 Hz, IH), 7.14 (m, IH), 7.25 (m, 4H), 7.53 (d, 7 = 8.3 Hz, IH), 7.96 (d, 7 = 8.0 Hz, IH), 8.00-8.10 (m, 2H); MS (ESI) m/z 590 (M++l). To a solution of methyl 4-[(4S)-acetoxy-l-[4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2S - pyrrolidinyl]methoxybenzoate (520 mg, 0.882 mmol) in THF (30 ml), 0.25 N NaOH (30 ml) was added. After stirring at room temperature for 2 days, the mixture was extracted with EtOAc. The aqueous layer was acidified with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were washed with brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was crystallized by the addition of CHC13, EtOH and ether to give 106 (68 mg, 14%) as a colorless powder. MW 533.57 mp 148-152 °C (dec); IR (KBr) 3356, 2939, 1687, 1604, 1533, 1454, 1255 cm 1; Η-NMR (DMSO-cL.) δ 1.95-2.09 (m, 2H), 2.25 (s, 3H), 3.59 (d, 7 = 5.9 Hz, 2H), 3.71 (m, IH), 3.81 and 3.85 (each s, 3H, amide isomers), 4.13-4.47 (m, 4H), 5.19 (br, IH), 6.70-7.21 (m, 7H), 7.79 (d, 7 = 7.9 Hz, IH), 7.86 (d, 7= 8.8 Hz, 2H), 8.01 (d, 7 = 8.3 Hz, IH), 8.47 (s, IH), 8.57 (s, IH); MS (ESI) m/z 533 (M++l); Anal. Calcd for C29H31N307- 1H20: C, 63.15; H, 6.03; N, 7.62. Found: C, 63.29; H, 5.76; N, 7.46. Example 99 4-[l-[4-[N'-(2-chlorophenyl)meido]-3-methoxyphenylacetyl]-(45)-hydroxy-(2S)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000253_0001
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (342 mg, 1.02 mmol), methyl 4-[(25',4S)-4-acetoxy-2-pyrrolidinyl]methoxybenzoate (300 mg, 1.02 mmol), EDCHCl
(293 mg, 1.53 mmol), HOBT (207 mg, 1.53 mmol) and Et3N (0.71 ml, 5.10 mmol) in DMF (6 ml) was stirred at room temperature for 15 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [50 g, CHCL/Aectone (5/1)], to give methyl 4-[(45)-acetoxy-l-[4-[N'-(2-chlorophenyl)ureido]-3- methoxyphenylacetyl]-(2S -pyrrolidinyl] methoxybenzoate (510 mg, 82%) as a pale brown amoiphous solid. 'H-NMR (CDC13) δ 2.01and 2.04 (each s, 3H, amide isomers), 2.17 (m, 2H), 3.56-3.66(m, 3H), 3.61 (s, 3H), 3.88 (s, 3H), 3.89(m, IH), 4.07 (t, 7= 9.6 Hz, IH), 4.45 (dd, 7 = 9.2, 3.4 Hz, IH), 4.56 (m, IH), 5.31-5.39 (m, IH), 6.80-7.01 (m, 4H), 7.23 (d, 7 = 8.1 Hz, 4H), 7.34 (d, 7 = 8.1Hz, 1 H), 7.95 (d, 7 = 8.5 Hz, IH), 8.00 (m, IH), 8.18 (d, 7= 8.3 Hz, IH); MS (ESI) m/z 610 (M++l), 612 (M++3).
To a solution of methyl 4-[(45)-acetoxy-l-[4-[Λr'-(2-chlorophenyl)meido]-3-methoxyphenylacetyl] -(2S)-pyrrolidinyl]methoxybenzoate (510 mg, 0.836 mmol) in THF (30 ml), 0.25 N NaOH (30 ml) was added. After stirring at room temperature for 2 days, the mixture was extracted with EtOAc. The aqueous layer was acidified with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were washed with brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was crystalized by the addition of EtOH and ether to give 107 (22 mg, 5%) as a colorless powder. MW 553.99 mp 138-142 °C (dec); IR (KBr) 3334, 2939, 1685, 1604, 1533, 1439, 1248 cm '; 'H-NMR (DMSO-c .) δ 1.93-2.14 (m, 2H), 3.60 (d, 7= 5.7 Hz, 2H), 3.71 (m, IH), 3.81 and 3.85 (each s, 3H, amide isomers), 4.14-4.50 (m, 4H), 5.19 (br, IH), 6.72 and 6.76 (each m, IH, amideisomers), 6.85 and 6.90 (each s, IH, amide isomers), 7.00- 7.08 (m, 3H), 7.28 (t, 7 = 7.3 Hz, IH), 7.43 (dd, 7 = 8.1, 1.2 Hz, IH), 7.86-7.95 (m, 2H), 7.97 (d, 7 = 8.1 Hz, IH), 8.10 (dd, 7 = 8.3, 1.5 Hz, IH), 8.90 (s, IH), 8.94 (s, IH), 12.64 (br, IH); MS (ESI) m/z 554 (M++l), 556 (M++3); Anal. Calcd for C28H28C1N307: C, 60.71; H, 5.05; Cl, 6.40; N, 7.58. Found: C, 60.47; H, 5.37; Cl, 6.31; N, 7.19. Example 100 4-[(4S)-acetoxy-l-[4-[N'-(2-bromophenyl)meido]phenylacetyl]-(2S -pyrrolidinyl]methoxybenzoic acid
Figure imgf000254_0001
A mixture of 4-[N'-(2-bormophenyl)ureido]-3-methoxyphenylacetic acid (387 mg, 1.02 mmol), methyl 4-[(45)-acetoxy-(2S)-pyrrolidinyl]methoxybenzoate (300 mg, 1.02 mmol), EDCHCl (293 mg, 1.53 mmol), HOBT (207 mg, 1.53 mmol) and Et3N (0.71 ml, 5.10 mmol) in DMF (6 ml) was stirred at room temperature for 15 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [50 g, CHCyAectone (5/1)], to give methyl 4-[(4S)-acetoxy-l-[4-[N'-(2-bromophenyl)ureido] phenylacetyl]-(25)-pyrrolidinyl]methoxybenzoate (510 mg, 76%) as a yellow oil. 'H-NMR (CDC13) δ 2.01 and 2.04 (each s, 3H, amide isomers), 2.31 (m, 2H), 3.54-3.68 (m, 3H), 3.76 (s, 2H), 3.88 (s, 3H), 3.89-4.58 (m, 4H), 5.31-5.36 (m, IH), 6.81-6.96 (m, 5H), 7.19-7.32 (m, 3H), 7.51 (d, 7= 8.0 Hz, IH), 7.93-8.00 (m, 3H), 8.13 (d, 7= 8.3 Hz, IH); MS (ESI) m/z 654 (M++l), 656 (M++3).
To a solution of methyl 4-[(4S)-acetoxy-l-[4-[N'-(2-bromophenyl)ureido]phenylacetyl]-(2S)- pyrrolidinyl]methoxybenzoate (510 mg, 0.779 mmol) in THF (30 ml), 0.25 N NaOH (30 ml) was added. After stirring at room temperature for 2 days, the mixture was extracted with EtOAc. The remaining aqueous layer was acidified with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were washed with brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was crystalized by the addition of EtOH and ether, to give 108 (87 mg, 19%) as a pale brown powder. MW 598.44 mp 143-151 °C (dec); IR (KBr) 3332, 2937, 1685, 1604, 1529, 1529, 1435 cm '; 'H-NMR (DMSO-cU δ 1.92-2.14 (m, 2H), 3.60 (d, 7= 5.9 Hz, IK), 3.72 (m, IH), 3.81 and 3.85 (each s, 3H, amide isomers), 4.14-4.49 (m, 4H), 5.19 (br, IH), 6.72 and 6.75 (each m, IH, amide isomers), 6.85 and 6.90 (each m, IH, amide isomers), 6.97 (t, 7= 6.1 Hz, IH), 7.06 (d, 7= 8.8 Hz, 2H), 7.32 (t, 7= 7.1 Hz, IH), 7.60 (dd, 7= 7.8, 1.2 Hz, IH), 7.86 (d, 7= 8.8 Hz, 2H), 7.87-7.97 (m, 3H), 8.74 (s, IH), 8.93 (s, IH), 12.60 (br, IH); MS (ESI) m/z 559 Of+1), 561 (M++3); Anal. Calcd for C28H28BrN3O70.1H20: C, 56.03; H, 4.74; Br, 13.31; N, 7.00. Found: C, 55.80; H, 4.84; Br, 13.64; N, 6.66. Example 101
4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(4Λ)-hydroxy-(2S)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000255_0001
To a stirred solution of methyl 4-[(4Λ)-acetoxy-l-(tert-butoxycarbonyl)-(25 -pyrrolidinylmethoxy] benzoate (835 mg, 2.12 mmol) in CH2C12 (5 ml) was added TFA (5 ml) and the reaction mixture was stirred at room temperature for 1 hr. The mixture was concentrated in vacuo and made basic by sat. NaHC03. The mixture was extracted with CHC13, washed with brine, dried over K2C03 and evaporated to give methyl 4-[(4Λ)-acetoxy-(25)-pyrrolidinylmethoxy]benzoate (580 mg, 95%) as a brown oil. 'H-NMR (CDC13) δ 1.86-1.93 (m, 1 H), 2.00-2.12 (series of s and m, total 5 H), 3.03-3.29 (m, 1 H), 3.73-3.80 (m, 1 H), 3.88 (s, 3 H), 3.93-4.01 (m, 2 H), 5.27-5.30 (m, 1 H), 6.91 (d, 7 = 9.0 Hz, 2 H), 7.98 (d, 7 = 9.0 Hz, 2 H); MS (FAB) m/z 294 (M++l).
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (365 mg, 1.09 mmol), methyl 4-[(4R)-acetoxy-(25)-pyrrolidinylmethoxy]benzoate (320 mg, 1.09 mmol),
EDCHCl (250 mg, 1.30 mmol), HOBt (180 mg, 1.33 mmol) and Et3N (182 ml, 1.31 mmol) in THF (5 ml) was stirred at room temperature for 2 days. The mixture was diluted with H20 and extracted with EtOAc. The extract was washed with brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1, v/v) as eluent to give methyl 4-[(4Λ)-acetoxy-l-[4-[Λf '-(2-chlorophenyl)ureido]-3-methoxyphenyl acetyl]-(25 -pyrrolidinylmethoxy]benzoate (500 mg, 75%) as a white foam. 'H-NMR (CDC13) δ 2.01 (s, 3 H), 2.03-2.05 (m, 1 H), 2.20-2.26 (m, 1 H), 2.37-2.43 (m, 1 H), 3.59 (s, 2 H), 3.62 (s, 3 H), 3.66-3.87 (m, 2 H), 3.89 (s, 3 H), 4.07-4.09 (m, 1 H), 4.48-4.51 (m, 1 H), 4.59 (m, 1 H), 6.70- 6.82 (m, 4 H), 6.97-7.01 (m, 1 H), 7.24-7.35 (m, 4 H), 7.92-7.98 (m, 3 H), 8.12-8.21 (m, 1 H); MS (FAB) m/z 610 (M++l).
To a stirred solution of methyl 4-[(4R)-acetoxy-l-[4-[N'-(2-chlorophenyl)ureido]-3- methoxyphenylacetyl]-(25 -pyrrolidinylmethoxy]benzoate (500 mg, 0.82 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux overnight. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was purified by recrystallization from CHC13-IPE to give 109 (223 mg, 49%) as a white crystalline powder. MW 553.99 mp 137-
142°C; 'H-NMR (DMSO-cL.) δ 1.95-2.09 (m, 2 H), 3.41-3.43 (m, 1 H), 3.57 (m, 3 H), 3.78 (s, 3 H), 4.07-4.40 (series of m, total 4 H), 5.07 (m, 1 H), 6.72-6.74 (m, 1 H), 6.85 (m, 1 H), 6.99-7.03 (m, 3 H), 7.25-7.29 (m, 1 H), 7.42-7.43 (m, 1 H), 7.85-7.87 (m, 2 H), 7.93-7.95 (m, 1 H), 8.07- 8.09 (m, 1 H), 8.88 (s, 1 H), 8.92 (s, 1 H), 12.65 (br s, 1 H); MS (FAB) m/z 554 (M++l); Anal. Calcd for C28H28C1N307 1/2H20: C, 59.73; H, 5.19; Cl, 6.30; N, 7.46. Found: C, 59.58; H, 5.32; Cl, 6.99; N, 7.21. Example 102
4-[(47?)-hydroxy- 1 -[3 -methoxy-4-[Λ '-(2-methylphenyl)ureido]phenylacetyl]-(2S)-pynolidinyl methoxy]benzoic acid
Figure imgf000256_0001
A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (320 mg, 1.02 mmol), methyl 4-[(4R)-acetoxy-(2S)-pyrrolidinylmethoxy]benzoate (300 mg, 1.02 mmol), EDCHCl (235 mg, 1.23 mmol), HOBt (166 mg, 1.23 mmol) and Et3N (171 ml, 1.23 mmol) in THF (5 ml) was stirred at room temperature for 2 days. The mixture was diluted with H20 and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1, v/v) as eluent to give methyl 4-[(4R)-acetoxy-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2S)- pyrrolidinylmethoxy]benzoate (420 mg, 70%) as a white foam. 'H-NMR (CDC13) δ 1.99 (s, 3 H), 2.02-2.05 (m, 1 H), 2.15-2.41 (series of s and m, total 5 H), 3.55 (s, 3 H), 3.57 (s, 2 H), 3.63-3.73 (m, 2 H), 3.89 (s, 3 H), 4.07-4.10 (m, 1 H), 4.45-4.48 (m, 1 H), 4.57 (m, 1 H), 6.56 (s, 1 H), 6.66 (m, 1 H), 6.75-6.82 (m, 3 H), 7.11-7.24 (m, 4 H), 7.54-7.56 (m, 1 H), 7.92-7.94 (m, 2 H), 8.05- 8.07 (m, 1 H); MS (FAB) m/z 590 (M++l).
To a stirred solution of methyl 4-[(4Λ)-acetoxy-l-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetyl]-(25)-pyrrolidinylmethoxy]benzoate (420 mg, 0.71 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux overnight. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was purified by recrystallization from CHC13-IPE to give 110 (182 mg, 48%) as a white crystalline powder. MW 533.57 mp 178-182°C; 'H-NMR (DMSO-cL.) δ 1.92-2.10 (m, 2 H), 2.23 (s, 3 H), 3.40-3.44 (m, 1 H), 3.56-3.67 (m, 3 H), 3.78 (s, 3 H), 4.05-4.39 (series of m, total 4 H), 5.06 (m, 1 H), 6.71-7.01 (m, 5 H), 7.10-7.16 (m, 2 H), 7.77-7.79 (m, 1 H), 7.85-7.89 (m, 2 H), 7.98-8.00 (m, 1 H), 8.45 (s, 1 H), 8.54 (s, 1 H), 12.59 (br s, 1 H); MS (FAB) m/z 534 (M++l); Anal. Calcd for C29H3ιN3071/2H20: C, 64.20; H, 5.94; N, 7.74. Found: C, 64.35; H, 5.83; N, 7.68. Example 103 4-[(4S)-fluoro-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinylmethyl]-l- piperazinylacetic acid
Figure imgf000257_0001
To a stirred solution of N-(tert-butoxycarbonyl) (4S)-fluoroprolinol (1.26 g, 5.75 mmol), Et3N (4 ml, 28.5 mmol) and DMSO (4.1 ml, 57.5 mmol) in CH2C12 (20 ml) was added S03 pyridine (2.74 g, 17.2 mmol). After 5 h stirring, the mixture was evaporated to remove CH2C12 and diluted with Et20 (200 ml). The solution was washed with 1 N HCl (200 ml) and brine (200 ml), dried over MgS04 and evaporated. The resulting residue was chromatographed on silica gel with hexane- EtOAc (4: 1) to give N-(tert-butoxycarbonyl) (4S)-fluoroprolinal (628 mg, 50%) as a yellow oil. 'H-NMR (CDC13) δl.41-1.47 (m, 9 H), 2.02-2.48 (m, 2 H), 3.47-3.94 (m, 2 H), 4.16 and 4.29 (each d, each 7= 9.8 Hz, total 1 H), 5.13 and 5.26 (each s, total 1 H).
To a stirred solution of N-(tert-butoxycarbonyl) (4S)-fluoroprolinal (1.44 g, 6.63 mmol), ethyl 1-piperazinylacetate (1.71 g, 9.94 mmol) and AcOH (759 ul, 13.3 mmol) in MeOH (20 ml) was added NaBH3CN (880 mg, 13.3 mmol). The reaction mixture was stirred overnight and evaporated. The residue was quenched with sat. NaHC03 (100 ml) and evaporated with CHC13 (2 x 200 ml). The combined extracts were dried over MgS04 and evaporated. The oily residue was chromatographed on silica gel with CHCl3-MeOH (20:1) to give ethyl 4-[l-(tert-butoxycarbonyl)- (45)-fluoro-2-pyrrolidinylmethyl]-l-piperazinylacetate (2.38 g, 95%) as a yellow oil.
A mixture of ethyl 4-[l-(tert-butoxycarbonyl)-(4S)-fluoro-2-pyrrolidinylmethyl]-l- piperazinylacetate (2.38 g, 6.37 mmol), TFA (5 ml) and CH2C12 (5 ml) was stirred for 3 h. The mixture was evaporated and the residue was made basic with sat. NaHC03 (100 ml). The mixture was extracted with CHCl3-MeOH (4:1, 2 x 150 ml) and the combined extracts were dried over K2C03 and evaporated to give ethyl 4-[(45)-fluoro-2-pyrrolidinylmethyl]-l-piperazinylacetate (1.44 g, 83%) as a brown oil. 'H-NMR (CDC13) δ 1.27 (dt, 7= 7.1, 2.0 Hz, 3 H), 1.66-3.35 (series of m, 17 H), 4.18 (dq, 7 = 7.1, 2.0 Hz, 2 H), 5.09 and 5.22 (each m, total 1 H).
A mixture of ethyl 4-[(4S)-fluoro-2-pynolidinylmethyl]-l-piperazinylacetate (1.44 g, 5.27 mmol), 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (1.66 g, 5.27 mmol), EDC HCl (1.52 g, 7.91 mmol), HOBt (cat.) and DMAP (cat.) in DMF (10 ml) was stirred overnight. The mixture was diluted with EtOAc-MeOH (10:1, 220 ml). The solution was washed with brine (200 ml), dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (20: 1) as eluent to give ethyl 4-[(45)-fluoro-l-[3-methoxy-4-[N'-(2- methylphenyl) ureido]phenylacetyl]-2-pyrrolidinylmethyl]- 1-piperazinylacetate (2.47 g, 82%) as a yellow viscous solid. 'H-NMR (CDC13) δ 1.24-1.29 (m, 3 H), 1.92-4.36 (series of m, 7 H), 5.16 and 5.29 (each m, total 1 H), 6.43 (s, 1 H), 6.74-6.81 (m, 2 H), 7.12-7.29 (m, 4 H), 7.50 (d, 7 = 7.8 Hz, 1 H), 8.01-8.07 (m, 1 H).
A mixture of ethyl 4-[(4S -fluoro-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2- pyrrolidinylmethyl]- 1-piperazinylacetate (1.0 g, 1.76 mmol) and 0.25 N NaOH (14 ml, 3.50 mmol) in THF (15 ml) was stirred overnight. The mixture was neutralized with 1 N HCl and evaporated. The residue was purified by ion exchage resin (DIAION, HP20) with H20 to MeOH as eluent to give 111 MW 541.61 (400 mg, 40%) as a pale yellow amorphous solid. 'H-NMR (CD3OD) δ 2.00-3.95 (series of m, 24 H), 4.34-4.40 (m, 1 H), 5.23 and 5.36 (m, each, total 1 H), 6.78-6.82 (m, 1 H), 6.92 (m, 1 H), 7.00-7.04 (m, 1 H), 7.09-7.23 (m, 4 H), 7.59 (d, 7= 7.1 Hz, 1 H), 7.99-8.02 (m, 1 H); MS(FAB) m/z 542 (M++1). Example 104 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-4,4-difluoro-2-pyrrolidinylmethyl]-l- piperazinylacetic acid
Figure imgf000259_0001
To a stirred mixture of l-(tert-butoxycarbonyl)-4,4-difluoro-2-pyrrolidinylmethanol (2.11 g, 8.89 mmol), Et3N (6.2 ml, 44.5 mmol), DMSO (6.3 ml, 88.9 mmol) in CH2C12 (20 ml) was added S03 pyridine (4.25 g, 26.7 mmol). After 3 h stirring, the mixture was concentrated in vacuo and diluted with Et20 (200 ml). The resulting mixture was washed with 1 N HCl (100 ml) and brine (100 ml), dried over MgS04, and concentrated in vacuo. The residue was chromatographed on silica gel with hexane-EtOAc (4: 1) as eluent to give l-(tert-butoxycarbonyl)-4,4-difluoro-2- pyrrolidinecarbaldehyde (1.40 g, 67%) as a yellow oil. 'H-NMR (CDC13) δ 1.45-1.52 (m, 9 H), 2.49 (m, 2 H), 3.75-3.88 (m, 2 H), 4.29-4.42 (m, 1 H), 9.54 and 9.60 (s, each, total 1 H).
To a stirred solution of l-(tert-butoxycarbonyl)-4,4-difluoro-2-pyrrolidinecarbaldehyde (1.40 g,
5.95 mmol) and ethyl 1-piperazinylacetate (1.02 g, 5.95 mmol) in MeOH-AcOH (12:1, 13 ml) was added NaBH3CN (787 mg, 11.9 mmol) at 0°C After 3 days stirring, the mixture was quenched by addition of sat. NaHC03 (100 ml) and extracted with CHC13 (2 x 200 ml). The combined extracts were dried over MgS04 and concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (20: 1) as eluent to give ethyl 4-[l-(tert-butoxycarbonyl)-4,4-difluoro-2- pyrrolidinylmethyl]- 1-piperazinylacetate (822 mg, 35%) as a yellow oil. 'H-NMR (CDC13) δ 1.27 (t, 7= 7.1 Hz, 3 H), 1.46 (m, 9 H), 1.64 (m, 2 H), 2.39-2.64 (m, 10 H), 3.19 (s, 2 H), 3.42-4.05 (series of m, 3 H), 4.18 (q, 7 = 7.1 Hz, 2 H).
A solution of ethyl 4-[l-(tert-butoxycarbonyl)-4,4-difluoro-2-pyrrolidinylmethyl]-l- piperazinylacetate (820 mg, 2.09 mmol) and TFA (5 ml) in CH2C12 (5 ml) was stirred for 1 h. The mixture was concentrated in vacuo and the residue was made basic with sat. NaHC03. The resulting mixture was extracted with CHCl3-MeOH (5: 1, 2 x 200 ml). The combined extracts were dried over K2C03 and concentrated in vacuo to give ethyl 4-(4,4-difluoro-2 -pyrrolidinyl methyl)- 1- piperazinylacetate (493 mg, 81%) as a brown oil. 'H-NMR (CDC13) δ 1.27 (t, 7 = 7.1 Hz, 3H), 1.91 (m, 2 H), 2.27-2.60 (m, 10 H), 3.09-3.34 (m, 4 H), 3.46-3.53 (m, 1 H), 4.19 (q, 7= 7.1 Hz, 2 H).
A mixture of ethyl 4-(4,4-difluoro-2-pyrrolidinylmethyl)- 1-piperazinylacetate (490 mg, 1.69 mmol), 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (567 mg, 1.69 mmol), EDC HCl (486 mg, 2.54 mmol), HOBt (cat.) and DMAP (cat.) in DMF (10 ml) was stirred overnight. The mixture was diluted with EtOAc (250 ml), washed with brine (2 x 200 ml), dried over MgS04, and concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-EtOAc (4:1) to CHCl3-MeOH (10:1) as eluent to give ethyl 4-[l-[4-[N' -(2-chlorophenyl) ureιdo]-3-methoxyphenylacetyl]-4,4-dιfluoro-2-pyrτolιdιnylmethyl]-l-pιperazιnylacetate (973 mg, 95%) as a yellow viscous oil 'H-NMR (CDC13) δ 1 25 (t, 7 = 7 1 Hz, 3 H), 2 31-2 68 (m, 12 H), 3 17-3 20 (m, 2 H), 3 52-3 91 (m, 4 H), 4 10-4 48 (seπes of m, 3 H), 6 75-6 84 (m, 2 H), 7 00 (dt, 7= 7 8, 1 5 Hz, 1 H), 7 16-7 29 (m, 3 H), 7 35 (dd, 7 = 8 3, 1 5 Hz, 1 H), 8 00 (d, 7= 8 3 Hz, 1 H), 8 18 (dd, 7 = 8 3, 1 5 Hz, I H)
To a stirred solution of ethyl 4-[l-[4-[N'-(2-chlorophenyl)ureιdo]-3-meιhoxyphenylacetyl]-4,4- dιfluoro-2-pyrrolιdιnylmethyl]-l-pιperazιnylacetate (292 mg, 0 480 mmol) in THF (4 ml) was added 0 25 N NaOH (3 8 ml, 0 960 mmol) After 2 days stirnng, the nuxtiire was neutralized with 1 N HCl and extracted with CHCl3-MeOH (4 1, 2 x 200 ml) The combined extracts were dned over MgS04 and concentrated in vacuo The residue was purified by tin layer column chromatography on silica gel with CHCl3-MeOH (5 1) to give 112 MW 580 02 (81 7 mg, 29%) as a pale yellow amorphous solid MW 580 02 'H-NMR (DMSO-cL.) δ 2 24-2 50 (senes of m, 12 H), 3 40-4 47 (senes of m, 10 H), 6 76 (d, 7= 8 1 Hz, 1 H), 6 88 (s, 1 H), 7 02 (t, 7 = 8 1 Hz, 1 H), 7 28 (t, 7 = 8 1 Hz, 1 H), 7 44 (d, 7 =8 1 Hz, 1 H), 7 97 (d, 7 = 8 1 Hz, 1 H), 8 08 (d, 7 = 8 1 Hz, 1 H), 8 96-8 99 (m, 2 H) MS (FAB) m/z 580 (M++l) Example 105
4-[l-[3-methoxy-4-[A^'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-phenoxy-(2S)-pyrrolidinyl] methyl- 1-pιperazιnylacetic acid
Figure imgf000260_0001
To a stirred mixture of methyl (2S,47?)-l-tert-butoxycarbonyl-4-hydroxy-2-pyrrolιdιnylcarboxylate (4 69 g, 19 1 mmol), phenol (1 98 g, 21 0 mmol) and PPh3 (5 51 g, 21 0 mmol) in THF (80 ml) was added DIAD (4 13 ml, 21 0 mmol) at room temperature under an atmosphere of mtrogen The mixture was stirred over night After removal of the solvent, the resulting residue was chromatographed on silica gel [700 g, CHCL/EtOAc (10/1)], to give methyl (2S,4S)-l-tert- butoxycarbonyl-4-phenoxy-2-pyrrohdinylcarboxylate (5 31 g, 86%) as a colorless oil 'H-NMR
(CDC13) δ 1 43 (br, 9H, one of isomers), 1 48 (br, 9H, one of isomers), 2 48 (m, IH), 3 75 (br, 3H), 4 42-4 96 (m, 2H), 6 88-7 35 (m, 5H)
To a stirred solution of methyl (2S,4S)-l-tert-butoxycarbonyl-4-phenoxy-2-pyrrolιdιnylcarboxylate (5 31 g, 16 5 mmol) in THF (132 ml) was added 0 25 N NaOH (132 ml, 33 0 mmol) at room temperature The resulting mixture was stirred over night After removal of the solvent, the mixture was acidified by the addition of 1 N HCl and extracted with CHC13 The combined extracts were washed with brine, dned over Na2S04 and evaporated The residue was recrystallized from n-nexαne-CHCl3, to give (2S,4S)-l-tert-butoxycarbonyl-4-phenoxy-2- pyrrohdinylcarboxyhc acid (2 96 g, 58%) as a white powder 'H-NMR (DMSO-cL.) δ 1 36 (s, 9H), 2 16 (d, 7= 13 2 Hz, IH), 2 56 (m, IH), 3 46 (m, IH), 3 71 (dt, 7 = 12 0, 5 4 Hz, IH), 4 26 (dt, 7 = 9 5, 7 1 Hz, IH), 4 99 (m, IH), 6 85 (m, 2H), 6 94 (t, 7 = 7 3 Hz, IH), 7 28 (t, 7 = 7 3 Hz, IH)
To a stirred solution of (2S,45)-l-tert-butoxycarbonyl-4-phenoxy-2-pyrrohdιnylcarboxylιc acid (2 39 g, 7 76 mmol) in THF (50 ml) was added BH3 DMS (1 55 ml, 15 5 mmol) at 0 °C After 10 nun stirnng at the same temperature, the mixture was allowed to room temperature and then heated at 50 °C for 2 h After cooling to room temperature, the nuxtiire was concentrated m vacuo and quenched by the addition of water at 0 °C The mixture was extracted with EtOAc The combined extracts were washed with bnne, dned over Na2S0 and evaporated The residue was chromatographed on silica gel [60 g .CHCl^eOH (50/1)] to give (2S,4S)-l-tert-butoxycarbonyl- 4-phenoxy-2-pyrrolιdιnylmethanol (2 83 g, 100%) as a colorless oil 'H-NMR (CDC13) δ 1 47 (s, 9H), 1 95 (br, IH), 2 36 (m, IH), 3 56-3 74 (m, 3H), 3 89-4 52 (m, 3H), 4 85 (br, IH), 6 84 (dd, 7 = 8 8, 1 2 Hz, 2H), 6 97 (t, 7 = 7 2 Hz, IH), 7 29 (t, 2H, 7= 7 8 Hz)
To a stirred mixture of (2S,45)-l-tert-butoxycarbonyl-4-phenoxy-2-pyrrolιdιnylmethanol (2 75 g, 9 37 mmol), Et3N (7 84 ml, 56 2 mmol), DMSO (6 66 ml, 9 37 mmol) m CH2C12 (30 ml) at 0 °C was added S03 pyndine (4 47 g, 28 1 mmol), then the resulting mixture was allowed to raise to room temperature After 2 5 h stirnng, the mixture was concentrated in vacuo To the resulting mixture was added water and extracted with Et20 The combined extracts were washed with bnne, dned over Na2S04 and concentrated in vacuo The residue was chromatographed on silica gel [100 g, CHCyacetone (5/1)] to give (2S,45)-l-tert-butoxycarbonyl-4-phenoxy-2-pyrrohdιne carbaldehyde (2 54 g, 93%) as a yellow oil 'H-NMR (CDC13) δ 1 45 (s, 9H, one of isomers), 1 49 (s, 9H, one of isomers), 2 17 (br, 2H), 3 65-4 31 (m, 3H), 4 91 (br, IH), 6 79 (d, 7= 7 8 Hz, IH), 6 77 (m, IH), 7 28 (m, 2H), 9 66 (m, IH)
To a stirred mixture of l-tert-butoxycarbonyl-(4S)-phenoxy-(2S)-pyrrohdinecarbaldehyde (1 36 g, 4 67 mmol), ethyl 1 -piperazinylacetate (1 61 g, 9 37 mmol) m THF (30 ml) was added NaBH(OAc)3 (1 98 g, 9 34 mmol) at room temperature After 3 h stirnng, the mixture was quenched by the addition of water and extracted with EtOAc The combined extracts were washed with aq NaHC03 and bnne The orgamc layer was dned over Na2S04 and concentrated m vacuo The residue was chromatographed on silica gel [50 g, CHCl^eOH (10/1)], to give ethyl 4-[l- tert-butoxycarbonyl-(45)-phenoxy-(25 -pyrrolιdιnyl] methyl- 1 -piperazinylacetate (1 05 g, 50%) as a colorless oil 'H-NMR (CDC13) δ 1 27 (t, 7= 7 3 Hz, 3H), 1 57 (s, 9H), 2 18 (m, IH), 2 33-2 74 (m, 9H), 3 17 (s, 2H), 3 52-4 10 (m, 5H), 4 17 (q, 7 = 7 3 Hz, 2H), 4 89 (br, IH), 6 84 (d, 7 = 6 8 Hz, 2H), 6 95 (m, IH), 7 26 (m, 3H) To a stirred solution of ethyl 4-[l-tert-butoxycarbonyl-(4S)-phenoxy-(25)-pyrrolidinyl]methyl-l- piperazinylacetate (1.05 g, 2.35 mmol) in CH2C12 (20 ml) was added TFA (20 ml) at room temperature. After 3 h stirring, the mixture was concentrated in vacuo, which was diluted with CHCl3-MeOH (10/1) and made basic by the addition of 1 N NaOH. The combined reaction mixture was extracted with CHCl3-MeOH (10/1). The organic layer was washed with brine, dried over NaS04 and concentrated, to give ethyl 4-[(45)-phenoxy-(25 -pyrrolidinyl]methyl-l- piperazinylacetate (1.12 g, quant.) as a brown oil, which was used without further purification. Η-NMR (CDC13) δ 1.25 (tt, 7 = 7.1, 7.1 Hz, 3H), 1.91 (d, 7= 12.0 Hz, IH), 2.42-2.85 (m, 10H), 3.22 (s, 2H), 3.50 (s, 2H), 3.54-3.82 (m, 2H), 4.15 (q, 7= 7.1 Hz, 2H), 4.98 (br, IH), 6.84 (d, 7 = 8.1 Hz, 2H), 6.76 (t, 7= 7.1 Hz, IH), 7.26-7.31 (m, 3H), 7.40 (br, IH).
A mixture of 4-[N'-(2-methylphenyl)ureido]-3-mefhoxyphenylacetic acid (337 mg, 1.07 mmol), ethyl 4-[(4S)-phenoxy-(2S)-pyrrolidinyl]methyl-l-piperazinylacetate (373 mg, 1.07 mmol), EDCHCl (308 mg, 1.61 mmol) and DMAP (197 mg, 1.61 mmol) in DMF (6 ml) was stirred at room temperature for 18 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [50 g, CHClj/MeOH (50/1)], to give ethyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]- (4S)-phenoxy-(25 -pyrrolidinyl]methyl-l-piperazinylacetate (430 mg, 62%) as a colorless amorphous solid. 'H-NMR (CDC13) δ 1.25 (t, 7 = 7.8 Hz, 3H), 1.98-2.17 (m, 2H), 2.26 (s, 3H), 2.36-2.82 (m, 11H), 3.13 (s, IH), 3.17 (s, IH), 3.55 (d, 7 = 2.4 Hz, IH), 3.66 (d, 7 = 0.9 Hz, 3H), 3.67-3.84 (m, 2H), 3.98-4.35 (m, 3H), 4.85-4.95 (m, IH), 6.27-6.89 (m, 6H), 7.08 (t, 7 = 7.3 Hz, IH), 7.19 (d, 7 = 6.8 Hz, IH), 7.28 (m, 2H), 7.41 (d, 7 = 4.9 Hz, IH), 7.55 (d, 7= 7.8 Hz, IH), 8.05 (dd, 7 = 7.3, 2.2 Hz, IH). For HCl salt: a pale brown amoiphous solid. IR (KBr) 3265, 3059, 1747, 1533, 1225 cm '; MS (FAB) m/z 644 (M++l); Anal. Calcd for C36H45N506-HCl-2.1H20: C, 60.22; H, 7.05; N, 9.75. Found: C, 59.97; H, 6.72; N, 9.54.
To a solution of ethyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-phenoxy- (25)-pyrrolidinyl]methyl-l-piperazinylacetate (240 mg, 0.373 mmol) in THF (3.0 ml), 0.25 N NaOH (3.0 ml) was added. After stirring at room temperature for 20 h, the mixture was neutralized with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was triturated by the addition of ether, to give 113 MW 615.72 (143 mg, 62%) as a white powder. IR (KBr) 3346, 2949, 1633, 1533, 1227 cm '; Η-NMR (DMSO-cL.) δ 1.76 (m, IH), 2.18 (br, 2H), 2.25 (s, 3H), 2.42-2.83 (m, 9H), 3.17 (s, IH), 3.20 (s, IH), 3.38 (m, IH), 3.70 (s, 2H), 3.72-3.78 (m, 2H), 3.85 (s, 3H, one of isomers), 3.87 (s, 3H, one of isomers),.3.95 (m, IH), 4.27 (br, IH), 5.08 (m, IH), 6.75 (d, 7 = 8.3 Hz, IH), 6.93 (m, 5H), 7.14 (m, 2H), 7.30 (d, 7 = 7.6 Hz, IH), 7.79 (d, 7 = 9.0 Hz, IH), 8.02 (m, IH), 8.50 (s, IH), 8.58 (s, IH); MS (FAB) m/z 616(M++1); Anal. Calcd for C34H41N5O6 0.1EtOH-2H2O: C, 62.58; H, 7.00; N, 10.67. Found: C, 62.73; H, 6.58; N, 10.24. Example 106
4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(4S)-phenoxy-(2S)-pynolidinyl] methyl- 1-piperazinylacetic acid
Figure imgf000263_0001
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (358 mg, 1.07 mmol), ethyl 4-[(4S)-phenoxy-(25)-pyrrolidinylmethyl]-l-piperazinylacetate (373 mg, 1.07 mmol), EDC HCl (308 mg, 1.61 mmol) and DMAP (197 mg, 1.61 mmol) in DMF (6 ml) was stirred at room temperature for 18 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [50 g, CHClj/MeOH (50/1)] to give ethyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]- (4S)-phenoxy-(2S)-pyrrolidinyl]methyl-l-piperazinylacetate (320 mg, 45%) as a colorless amorphous solid. Η-NMR (CDC13) δ 1.25 (qq, 7= 7.3, 7.3 Hz, 3H), 2.05-2.20 (m, 2H), 2.35-2.80 (m, IH), 3.12 and 3.18 (each s, IH, amide isomers), 3.57 (d, 7 = 5.4 Hz, IH), 3.66 and 3.38 (each s, 3H, amide isomers), 3.70-3.90 (m, 2H), 4.02-4.43 (m, 3H), 4.88-4.97 (m, IH), 6.83-6.99 (m, 6H), 7.18-7.32 (m, 3H), 7.68 (d, 7 = 8.3 Hz, IH), 7.74 (s, IH), 8.16 (dd, 7 = 8.3, 1.4 Hz, IH). For HCl salt: a pale brown amoiphous solid. IR (KBr) 3300, 2978, 1745, 1533, 1225 cm '; MS (FAB) m/z 664 (M++l), 666 (M++3); Anal. Calcd for C35H42C1N506-HC1-2.4H20: C, 56.51; H, 6.48; N, 9.41. Found: C, 56.51; H, 6.18; N, 9.28.
To a solution of ethyl 4-[l-[4-[iV-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(4S)-phenoxy- (2S -pyrrolidinyl]methyl-l-piperazinylacetate (181 mg, 0.273 mmol) in THF (2.2 ml), 0.25 N NaOH (2.2 ml) was added. After stirring at room temperature for 20 h, the mixture was neutralized with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was triturated by the addition of ether to give 114 (133 mg, 77%) as a white powder. MW 636.14 IR (KBr) 3317, 2949, 1701, 1631, 1595, 1225 cm 1; 'H-NMR (DMSO-cL.) δ 2.13-3.05 (m, UK), 3.22 and 3.36 (each s, 2H, amide isomer), 3.38 (m, IH), 3.60 (s, 2H), 3.71 (m, IH), 3.85 (s, 3H), 3.95 (m, IH), 4.28 (br, IH), 5.06 (m, IH), 6.76 (d, 7 = 8.3 Hz, IH), 6.91-7.03 (m, 5H), 7.29 (m, 3H), 7.44 (d, 7 = 7.9 Hz, IH), 7.97 (dd, 7= 8.1, 4.1 Hz, IH), 8.08 (d, 7= 7.0 Hz, IH), 8.91 (s, IH), 8.95 (s, IH); MS (FAB) m/z
636(M++1), 638(M++3); Anal. Calcd for C33H38ClN5O60.2EtOH 1.3H2O: C, 59.98; H, 6.30; N, 10.47. Found: C, 60.25; H, 6.12; N, 10.11. Example 107
4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(4S)-phenoxy-(2S)-pynolidinyl] methyl- 1-piperazinylacetic acid
Figure imgf000264_0001
A mixture of 4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (406 mg, 1.07 mmol), ethyl 4-[(4S)-phenoxy-(2S)-pyrrolidinyl]methyl-l-piperazinylacetate (373 mg, 1.07 mmol),
EDC HCl (308 mg, 1.61 mmol) and DMAP (197 mg, 1.61 mmol) in DMF (6 ml) was stirred at room temperature for 18 h. The mixture was poured into ice water and extracted with EtOAc.
The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [50 g,
CHCVMeOH (50/1)] to give ethyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]- (45)-phenoxy-(2S)-pyrrolidinyl]methyl-l-piperazinylacetate (560 mg, 74%) as a colorless amoφhous solid. 'H-NMR (CDC13) δ 1.25 (tt, 7 = 7.1, 7.1 Hz, 3H), 2.04-2.84 (m, 13H), 3.12 and 3.18 (each s, IH, amide isomers), 3,57 (d, 7 = 4.4 Hz, IH), 3.66 and 3.68 (each s, 3H, amide isomers), 3.68-3.87 (m, 3H), 4.05-4.41 (m, 2H), 4.87-4.96 (m, IH), 6.76-6.98 (m, 6H), 7.20-7.33 (m, 3H), 7.46 (d, 7 = 8.1 Hz, IH), 7.67 and 7.71 (each s, IH, amide isomers), 7.78 and 7.81 (each s, IH, amide isomers), 7.95 (d, 7 = 8.3 Hz, IH), 8.09 (d, 7 = 8.1 Hz, IH). For HCl salt: a pale brown amoφhous solid. IR (KBr) 3384, 2978, 1745, 1340, 1120 cm '; MS (FAB) m/z 708 (M++l), 710 (M++3); Anal. Calcd for C35H42BrN306'HCl-2.5H20: C, 53.20; H, 6.12; N, 8.86. Found: C, 52.98; H, 5.79; N, 8.66.
To a solution of ethyl 4-[l-[4-[ -(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(4S)-phenoxy- (2S)-pyrrolidinyl]methyl-l-piperazinylacetate (330 mg, 0.466 mmol) in THF (3.7 ml), 0.25 N NaOH (3.7 ml) was added. After stirring at room temperature for 20 h, the mixture was neutralized with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was triturated by the addition of ether, to give 115 (217 mg, 68%) as a white powder. MW 680.59 IR (KBr) 3315, 3095, 2941, 1631, 1529, 1435 cm '; 'H-NMR (DMSO-c .) δ 1.75 (m, IH), 2.18 and 2.23 (each s, 2H, amide isomers), 2.30-2.78 (m, 9H), 3.15 (2, 2H), 3.47 (m, IH), 3.58 (s, 2H), 3.60-3.82 (m, 3H), 3.84 (m, 3H), 3.93 (m, IH), 4.26 (br, IH), 5.08 (m, IH), 6.75 (d, 7= 7.8 Hz, IH), 6.98 (m, 5H), 7.30 (m, 3H), 7.60 (dd, 7 = 8.1, 2.2 Hz, IH), 7.94 (m, 2H), 8.75 (s, IH), 8.93 (s, IH); MS(FAB) m/z 680(M++1),
82(M++3); ^nα/. Calcd for C33H38BrN5O6 0.2EtOH-2H2O: C, 55.27; H, 6.00; N, 9.65. Found: C, 55.32; H, 5.56; N, 9.25. Example 108
4-[(45)-(4-carboxyphenoxy)-l-[3-methoxy-4-[Λ^'-(2-methylphenyl)uriedo]phenylacetyl]-(2S)- pynolidinylmethoxy]benzoic acid
Figure imgf000265_0001
To a stirred solution of methyl l-(tert-butoxycarbonyl)-(4Λ)-hydroxy-(25)-pyrrolidinylcarboxylate
(10.4 g, 0.04 mol) and imidazole (8.66 g, 0.13 mol) in DMF (40 ml) was added TBS-C1 (7.03 g,
0.05 mol) and the reaction mixture was stirred at 60°C for 3 hr. After cooled to room temperature, the mixture was diluted with brine, and extracted with Et20. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with n-hexane-EtOAc (5: 1, v/v) as eluent to give methyl l-(tert-butoxycarbonyl)-(47?)-
(tert-butyldimethylsilyloxy)-(25)-pyrrolidinylcarboxylate (15.0 g, 98%) as a colorless oil. 'H-NMR
(CDC13) δ 0.06 (s, 6 H), 0.87 (s, 9 H), 1.41 and 1.46 (each s, 9 H), 1.99-2.03 (m, 1 H), 2.16-2.18
(m, 1 H), 3.31-3.42 (m, 1 H), 3.56-3.63 (m, 1 H), 3.73 and 3.74 (each s, 3 H), 4.31-4.42 (m, 2 H);
MS (ESI) m/z 360 (M++l).
To a stirred solution of methyl l-(tert-butoxycarbonyl)-(4Λ)-(tert-butyldimethylsilyloxy)-(2S)- pyrrolidinylcarboxylate (15.0 g, 0.04 mol) in THF (60 ml) was added 1 N NaOH (60 ml) and the reaction mixture was stirred at 60°C for 2 hr. After cooled to room temperature, the mixture was concentrated to a small volume, acidified with 1 N HCl, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated to give l-(tert-butoxycarbonyl)-(4R)- (tert-butyldimethylsilyloxy)-(2S)-pyrrolidinylcarboxylic acid (12.8 g, 89%) as a colorless oil. 'H- NMR (CDC13) δ 0.07 and 0.08 (each s, 6 H), 0.87 (s, 9 H), 1.49 (s, 9 H), 2.06-2.11 (m, 1 H), 2.41- 2.44 (m, 1 H), 3.40-3.59 (m, 2 H), 4.36-4.50 (m, 2 H); MS (ESI) m/z 346 (M++l).
To a cooled (0°C) stirred solution of l-(tert-butoxycarbonyl)-(4Λ)-(tert-butyldimethylsilyloxy)- (2S)-pyrrolidinylcarboxylic acid (12.8 g, 0.04 mol) in THF (150 ml) was added dropwise BH3DMS (5.30 ml, 0.06 mol) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched by sat. NH4C1, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with toluene-acetone (5: 1, v/v) as eluent to give l-(tert-butoxy carbonyl)-(4Λ)-(tert-butyldimethylsilyloxy)-(2S)-prolinol (10.5 g, 85%) as a colorless oil. Η-NMR (CDC13) δ 0.06 (s, 6 H), 0.87 (s, 9 H), 1.47 (s, 9 H), 1.58-1.63 (m, 1 H), 1.93-1.98 (m, 1 H), 3.32- 3.44 (m, 2 H), 3.51-3.57 (m, 1 H), 3.67-3.71 (m, 1 H), 4.13-4.15 (m, 1 H), 4.27 (m, 1 H), 4.87- 4.89 (m, 1 H).
To a cooled (0°C), stirred solution of methyl 4-hydroxybenzoate (4.81 g, 0.03 mol), l-(tert- butoxycarbonyl)-(4Λ)-(tert-butyldimethylsilyloxy)-(25 -prolinol (10.5 g, 0.03 mol), and Ph3P (9.96 g, 0.04 mol) in THF (160 ml) was added dropwise DIAD (7.48 ml, 0.04 mol) and the reaction mixture was heated under reflux for 7 hr. After cooled to room temperature, the mixture was evaporated. The residue was purified by column chromatography on silica-gel with n-hexane- EtOAc (6: 1, v/v) to give methyl 4-[l-(tert-butoxycarbonyl)-(4/?)-(tert-butyldimethylsilyloxy)-(2S - pyrrolidinylmethoxy]benzoate (9.58 g, 65%) as a white solid, mp 86-88°C; Η-NMR (CDC13) δ 0.08 (s, 6 H), 0.88 (s, 9 H), 1.46 (s, 9 H), 2.04-2.15 (m, 2 H), 3.29-3.48 (m, 2 H), 3.88 (s, 3 H),
4.06-4.30 (m, 3 H), 4.46-4.51 (m, 1 H). 6.91-6.93 (m, 2 H), 7.96-7.98 (m, 2 H); MS (ESI) m/z 466 (M++l).
To a cooled (0°C), stirred solution of methyl 4-[l-(tert-butoxycarbonyl)-(4Λ)-(tert-butyldimethyl silyloxy)-(2S)-pyrrolidinylmefhoxy]benzoate (1.49 g, 3.20 mmol) in THF (15 ml) was added TBAF (6.40 ml, 6.40 mmol, 1 M solution in THF) and the reaction mixture was stirred at room temperature for 2 hr. The mixture was diluted with EtOAc, washed with H20, brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with toluene-acetone (5: 1, v/v) as eluent to give methyl 4-[l-(tert-butoxycarbonyl)-(4R)-hydroxy-(2S)- pyrrolidinylmethoxy]benzoate (1.05 g, 93%) as a white solid, mp 103-105°C; Η-NMR (CDC13) δ 1.46 (s, 9 H), 2.11-2.28 (m, 2 H), 3.49-3.60 (m, 2 H), 3.88 (s, 3 H), 4.15-4.34 (m, 3 H), 4.53-4.57 (m, 1 H), 6.91 (d, 7 = 8.6 Hz, 2 H), 7.97 (d, 7 = 8.6 Hz, 2 H); MS (ESI) m/z 352 (M++l).
To a cooled (0°C), stirred solution of methyl 4-hydroxybenzoate (0.56 g, 3.68 mmol), methyl 4-[l- (tert-butoxycarbonyl)-(4Λ)-hydroxy-(2S)-pyιτolidinylmethoxy]benzoate (1.30 g, 3.70 mmol), and Ph3P (1.16 g, 4.42 mmol) in THF (20 ml) was added dropwise DIAD (0.87 ml, 4.42 mmol) and the reaction mixture was stined at room temperature for 3 hr. The mixture was evaporated and the residue was purified by column chromatography on silica-gel with n-hexane-EtOAc (6: 1, v/v) as eluent to give methyl 4-[l-(tert-butoxycarbonyl)-(4,S)-(4-methoxycarbonylphenoxy)-(2<S - pyrrolidinylmethoxy]benzoate (1.80 g, q.y.) as a colorless oil. 'H-NMR (CDC13) δ 1.49 (s, 9 H), 2.31-2.38 (m, 1 H), 2.45-2.49 (m, 1 H), 3.64-3.77 (m, 2 H), 3.88 (s, 6 H), 4.07-4.15 (m, 1 H), 4.33-4.44 (m, 2 H), 4.95-5.01 (m, 1 H), 6.85 (d, 7 = 8.8 Hz, 2 H), 6.94 (br s, 2 H), 7.97 (d, 7 = 8.8 Hz, 4 H); MS (ESI) m/z 486 (M++l). To a stirred solution of methyl 4-[l-(tert-butoxycarbonyl)-(45)-(4-methoxycarbonyl phenoxy)-(2S)-pyrrolidinylmethoxy]benzoate (1.80 g, 3.71 mmol) in CH2C12 (15 ml) was added TFA (15 ml) and the reaction mixture was stirred at room temperature for 1.5 hr. The mixture was concentrated in vacuo, made basic by sat. NaHC03, and extracted with CHC13. The extract was washed with brine, dried over K2C03, and evaporated to give methyl 4-[(4S)-(4- methoxycarbonyl phenoxy)-(2S)-pyrrolidinylmethoxy]benzoate (1.50 g, q.y.) as a pale yellow oil. 'H-NMR (CDC13) δ 1.87-1.92 (m, 1 H), 2.41-2.48 (m, 1 H), 3.18-3.23 (m, 1 H), 3.34-3.37 (m, 1 H), 3.60-3.66 (m, 1 H), 3.88 (s, 3 H), 3.89 (s, 3 H), 4.04-4.13 (m, 2 H), 4.94-5.00 (m, 1 H), 6.87- 6.93 (m, 4 H), 7.96-8.00 (m, 4 H); MS (ESI) m/z 386 (M++l).
A mixture of 3-methoxy-4-[Λr'-(2-meιhylphenyl)ureido]phenylacetic acid (400 mg, 1.27 mmol), methyl 4-[(45)-(4-methoxycarbonylphenoxy)-(25 -pyrrolidinylmethoxy]benzoate (491 mg, 1.27 mmol), EDCHCl (293 mg, 1.53 mmol), HOBt (207 mg, 1.53 mmol), and Et3N (215 μl, 1.54 mmol) in THF (10 ml) was stirred at room temperature overnight. The mixture was diluted with H20, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (60:1 to 50: 1, v/v) as eluent to give methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)uriedo] phenylacetyl]-(45 -(4-methoxycarbonylphenoxy)-(2S)-pyrrolidinylmethoxy]benzoate (532 mg, 61%) as a white foam. 'H-NMR (CDC13) δ 2.26-2.49 (series of s and m, total 5 H), 3.56-3.93 (series of s and m, total 13 H), 4.07-4.59 (series of m, total 3 H), 5.01 (m, 1 H), 6.69-6.94 (m, 7 H), 7.09-7.13 (m, 1 H), 7.20-7.31 (m, 3 H), 7.52-7.57 (m, 1 H), 7.92-8.00 (m, 4 H), 8.06-8.09 (m, 1 H); MS (ESI) m/z 682 (M++l).
To a stirred solution of methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)uriedo]phenylacetyl]-(4S)- (4-methoxycarbonylphenoxy)-(2S)-pyrrolidinylmethoxy]benzoate (532 mg, 0.78 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected. The crude solid was recrystallized from MeOH-CHCl3-Et20 to give 116 (125 mg, 25%) as a pale yellow crystalline powder. MW 653.68 mp 154-159°C; 'H-NMR (DMSO )2.24 (s, 3 H), 2.38-2.49 (m, 2 H), 3.63 (s, 2 H), 3.67-3.88 (series of s and m, total 4 H), 4.01-4.06 and 4.15-4.19 (each m, total 2 H), 4.27-4.31 and 4.38-4.42 (each m, total 2 H), 5.18- 5.25 (m, 1 H), 6.72-6.77 (m, 1 H), 6.85-7.16 (series of m, total 8 H), 7.78-7.89 (m, 5 H), 7.99-8.02 (m, 1 H), 8.46 (s, 1 H), 8.57 (s, 1 H), 12.65 (br s, 2 H); MS (ESI) m/z 654 (M++l); Anal. Calcd for C36H35N3091/2H20: C, 65.25; H, 5.48; N, 6.34. Found: C, 65.29; H, 5.54; N, 6.20. Example 109
4-[(4S)-(4-carboxyphenoxy)-l-[4-[N'-(2-chlorophenyl)uriedo]-3-methoxyphenylacetyl]-(2S)- pyrrolidinylmethoxyjbenzoic acid
Figure imgf000268_0001
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (420 mg, 1.25 mmol), methyl 4-[(4S)-(4-methoxycarbonylphenoxy)-(2S)-pyrrolidinylmethoxy]benzoate (483 mg, 1.25 mmol), EDCHCl (288 mg, 1.50 mmol), HOBt (203 mg, 1.50 mmol), and Et3N (210 μl, 1.51 mmol) in THF (10 ml) was stirred at room temperature overnight. The mixture was diluted with H20, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1, v/v) as eluent to give methyl 4-[l-[4-[N'-(2-chlorophenyl)uriedo]-3-methoxyphenylacetyl]- (4S)-(4-methoxycarbonylphenoxy)-(25 -pyrrolidinylmethoxy]benzoate (488 mg, 55%) as a white foam. Η-NMR (CDC13) δ 2.28-2.51 (m, 2 H), 3.62-3.94 (series of s and m, total 13 H), 4.07-4.62 (series of m, total 3 H), 4.99-5.03 (m, 1 H), 6.78-6.99 (m, 7 H), 7.23-7.34 (m, 2 H), 7.42-7.52 (m, 2 H), 7.92-8.01 (m, 5 H), 8.17-8.20 (m, 1 H); MS (ESI) m/z 702 (M++l).
To a stirred solution of methyl 4-[l-[4-[N'-(2-chlorophenyl)uriedo]-3-methoxyphenylacetyl]-(4S)- (4-methoxycarbonylphenoxy)-(2S)-pyrrolidinylmethoxy]benzoate (488 mg, 0.70 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 3 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected. The crude solid was recrystallized from MeOH-CHCl3-Et20 to give 117 (137 mg, 29%) as a white crystalline powder. MW 674.10 mp 150-153°C; 'H-NMR (DMSO-c .) δ and 4.17-4.21 (each m, total 2 H), 4.30-4.34 and 4.40-4.45 (each m, total 2 H), 5.20-5.27 (m, 1 H), 6.77-6.81 (m, 1 H), 6.89-6.92 (m, 1 H), 7.01-7.08 (m, 5 H), 7.27-7.31 (m, 1 H), 7.43-7.46 (m, 1 H), 7.86-7.92 (m, 4 H), 7.97-8.00 (m, 1 H), 8.10-8.12 (m, 1 H), 8.91 (s, 1 H), 8.96 (s, 1 H), 12.65 (br s, 2 H); MS (ESI) m/z 674 (M++l); Anal. Calcd for C35H32C1N3091/4H20: C, 61.95; H.4.83; N,6.19; Cl,5.22. Found: C,61.77; H,4.86; N,6.13; Cl, 5.49. Example 110
4-[l-[4-[Λ^'-(2-bromophenyl)uriedo]-3-methoxyphenylacetyl]-(4S)-(4-carboxyphenoxy)-(2S)- pyrrolidinylmethoxy]benzoic acid
Figure imgf000269_0001
A mixture of 4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (464 mg, 1.22 mmol), methyl 4-[(4S)-(4-methoxycarbonylphenoxy)-(2S)-pyιτolidinylmethoxy]benzoate (472 mg, 1.22 mmol), EDCHCl (282 mg, 1.47 mmol), HOBt (200 mg, 1.48 mmol), and Et3N (205 μl, 1.47 mmol) in THF (10 ml) was stirred at room temperature overnight. The mixture was diluted with H20, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (60:1 to 50:1, v/v) as eluent to give methyl 4-[l-[4-[N'-(2-bromophenyl)uriedo]-3-methoxyphenyl acetyl]-(45)-(4-methoxycarbonylphenoxy)-(2S)-pyrrolidinylmethoxy]benzoate (379 mg, 41%) as a white foam. 'H-NMR (CDC13) δ 2.28-2.51 (m, 2 H), 3.59-3.95 (series of s and m, total 13 H), 4.07-4.62 (series of m, total 3 H), 4.99-5.03 (m, 1 H), 6.79-6.95 (m, 7 H), 7.27-7.36 (m, 3 H), 7.49-7.51 (m, 1 H), 7.93-8.01 (m, 5 H), 8.11-8.14 (m, 1 H); MS (ESI) m/z IM (M++l).
To a stirred solution of methyl 4-[l-[4-[Λf'-(2-bromophenyl)uriedo]-3-methoxyphenylacetyl]-(4S)- (4-methoxycarbonylphenoxy)-(2S)-pyrrolidinylmethoxy]benzoate (379 mg, 0.51 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected. The crude solid was purified by preparative TLC to give 118 (51 mg, 14%) as a pale yellow amoφhous solid. MW 718.55 'H-NMR (DMSO-c .) δ 2.20-2.40 (m, 2 H), 3.65-3.89 (series of m, total 6 H), 4.02-4.63 (series of m, total 4 H), 5.19-5.26 (m, 1 H), 6.74-7.06 (m, 7 H), 7.30-7.34 (m, 1 H), 7.59-7.61 (m, 1 H), 7.83-7.96 (m, 6 H), 8.74 (s, 1 H), 8.93 (s, 1 H); Anal. Calcd for C35H32BrN3092H20: C, 55.71; H, 4.81; N, 5.57. Found: C, 55.92; H, 4.80; N, 5.30. Example 111
4-[(4S)-(4-carboxyphenoxy)-l-[4-[N'-(2-methylphenyl)uriedo]phenylacetyl]-(25)-pyrrolidinyl methoxyjbenzoic acid
Figure imgf000269_0002
A mixture of 4-[N'-(2-methylphenyl)ureido]phenylacetic acid (328 mg, 1.15 mmol), methyl 4- [(4S)-(4-methoxycarbonylphenoxy)-(2S -pyrrolidinylmethoxy]benzoate (444 mg, 1.15 mmol), EDCHCl (265 mg, 1.38 mmol), HOBt (187 mg, 1.38 mmol), and Et3N (195 μl, 1.40 mmol) in THF (10 ml) was stirred at room temperature overnight. The mixture was diluted with H20, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04) and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (60:1 to 50: 1, v/v) as eluent to give methyl 4-[(4S)-(4-methoxycarbonylphenoxy)-l-[4-[N,-(2-methyl phenyl)uriedo]phenylacetyl]-(25)-pyrrolidinylmethoxy]benzoate (332 mg, 44%) as a white foam. 'H-NMR (CDC13) δ 2.13 (s, 3 H), 2.24-2.48 (m, 2 H), 3.52-3.90 (series of s and m, total 10 H), 4.05-4.58 (series of m, total 3 H), 5.01 (m, 1 H), 6.78-6.90 (m, 4 H), 6.98-7.20 (m, 8 H), 7.51-7.56 (m, 2 H), 7.90-8.00 (m, 4 H); MS (ESI) m/z 652 (M++l).
To a stined solution of methyl 4-[(4S)-(4-methoxycarbonylphenoxy)-l-[4-[N'-(2-methyl phenyl)uriedo]phenylacetyl]-(2S)-pyrrolidinylmethoxy]benzoate (332 mg, 0.51 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 3 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected. The crude solid was recrystallized from MeOH-CHCI3-Et20 to give 119 (118 mg, 37%) as a white crystalline powder. MW 623.65 mp 157-160°C; 'H-NMR (DMSO-cL.) δ 2.20-2.25 (series of s and m, total 4 H), 2.39-2.47 (m, 1 H), 3.64 (s, 2 H), 3.68-3.89 (m, 1 H), 4.02-4.08 and 4.16-4.20 (each m, total 2 H), 4.29-4.33 and 4.39-4.43 (each m, total 2 H), 5.20- 5.26 (m, 1 H), 6.92-6.96 (m, 1 H), 7.02-7.08 (m, 4 H), 7.12-7.18 (m, 4 H), 7.39-7.41 (m, 2 H), 7.84-7.92 (m, 6 H), 9.01 (s, 1 H), 12.65 (br s, 2 H); MS (ESI) m/z 624 (M++l); Anal. Calcd for C35H33N3081H20: C, 65.51; H, 5.50; N, 6.55. Found: C, 65.48; H, 5.36; N, 6.52. Example 112
4-[4-(2,4-difluorophenoxy)-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2- pyrrolidinylmethoxybenzoic acid
Figure imgf000270_0001
To a stirred solution of methyl l-(tert-butoxycarbonyl)-4-hydroxyproline (4.0 g, 16.3 mmol), Ph^
(5.14 g, 19.6 mmol), and 2,4-difluorophenol (2.55 g, 19.6 mmol) in THF (50 ml) was added DIAD
(3.9 ml, 19.6 mmol), and the mixture was heated at reflux for 3 h. After cooling to room temperature, the mixture was concntrated in vacuo and the residue was chromatographed on silica gel with CHCl3-EtOAc (4: 1) to give methyl l-(tert-butoxycarbonyl)-4-(2,4-difluorophenoxy) pyrrolidine-2-carboxylate (5.82 g, quant) as yellow oil. To a stirred solution of methyl l-(tert-butoxycarbonyl)-4-(2,4-difluorophenoxy)pyrrolidine-2- carboxylate (5.82 g, 16.3 mmol) in THF (130 ml) was added 0.25 N NaOH (130 ml, 32.6 mmol). The resulting mixture was stirred overnight. The mixture was poured into 1 N HCl (100 ml) and extracted with CHC13 (2 x 200 ml). The extracts were dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHCl3-EtOAc (4: 1) as eluent to give l-(tert- butoxycarbonyl)-4-(2,4-difluorophenoxy)pyrrolidine-2-carboxylic acid (2.55 g, 46%) as a colorless foam. 'H-NMR (CDC13) δ 1.42-1.47 (m, 9 H), 2.29-2.74 (series of m, 2 H), 3.66-3.71 (m, 2 H), 4.46-4.51 (m, 1 H), 4.83 (m, 1 H), 6.73-6.95 (m, 3 H).
To a stirred solution of l-(tert-butoxycarbonyl)-4-(2,4-difluorophenoxy)pyrrolidine-2-carboxylic acid (2.55 g, 7.43 mmol) in THF (50 ml) was added BH3-DMS (452 ul, 7.43 mmol). The mixture was heated at reflux overnight After cooling to room temperature, the mixture was concntrated in vacuo and quenced by the addition of H20 (100 ml). The mixture was extracted with CHC13 (2 x 200 ml), dried over MgS04, and evaporated. The residue was chromatographed on silica gel with CHCl3-EtOAc (4: 1) as eluent to give l-(tert-butoxycarbonyl)-4-(2,4-difluorophenoxy)-2- pyrrolidinylmethanol (1.76 g, 72%) as a colorless oil. Η-NMR (CDC13) δ 1.45 (s, 9 H), 2.28-2.36 (m, 2 H), 3.58-4.99 (series of m, 8 H), 6.74-6.90 (m, 3 H).
To a stirred solution of l-(tert-butoxycarbonyl)-4-(2,4-difluorophenoxy)-2-pyrrolidinylmethanol (500 mg, 1.52 mmol), methyl 4-hydroxybenzoate (277 mg, 1.82 mmol), and Ph3P (477 mg, 1.82 mmol) in THF (10 ml) was added DIAD (358 ul, 1.82 mmol), and the mixture was heated at reflux for 5 h. After cooling to room temperature, the mixture was concentrated in vacuo and the residue was chromatographed on silica gel with CHCl3-EtOAc (20: 1) as eluent to give methyl 4-[l -(tert- butoxycarbonyl)-4-(2,4-difluorophenoxy)-2-pyrrolidinylmethoxy]benzoate (529 mg, 75%) as a colorless oil. Η-NMR (CDC13) δ 1.46 (s, 9 H), 2.20-2.47 (m, 2 H), 3.64 (m, 2 H), 3.86 (s, 3 H), 4.07-4.43 (m, 3 H), 4.86 (m, 1 H), 6.74-6.87 (m, 3 H), 6.94 (d, 2 H, 7 = 8.5 Hz), 7.95 (d, 2 H, 7 = 8.5 Hz).
To a stirred solution of methyl 4-[l-(tert-butoxycarbonyl)-4-(2,4-difluorophenoxy)-2-pyrrolidinyl methoxy]benzoate (529 mg, 1.15 mmol) in CH2C12 (5 ml) was added TFA (5 ml). The mixture was stirred overnight. The mixture was concentrated in vacuo and the residue was made basic by the addition of sat. NaHC03. The mixture was extracted with CHC13 (2 x 100 ml). The extracts were dried over K2C03 and evaporated to give methyl 4-[4-(2,4-difluorophenoxy)-2-pyrrolidinyl methoxy]benzoate (385 mg, 92%) as a yellow oil. 'H-NMR (CDC13) δ 1.89-1.95 (m, 1 H), 2.28- 2.35 (m, I H), 3.09 (dd, 7= 12.5, 4.9 Hz, 1 H), 3.33 (d, 7 = 12.5 Hz, 1 H), 3.60 (m, 1 H), 3.86 (s, 3 H), 4.10 (d, 7 = 5.6 Hz, 2 H), 4.84 (m, 1 H), 6.73-6.89 (m, 3 H), 6.91 (d, 7 = 8.5 Hz, 2 H), 7.96 (d, 7 = 8.5 Hz, 2 H).
A mixture of methyl 4-[4-(2,4-difluorophenoxy)-2-pyrrolidinylmethoxy]benzoate (380 mg, 1.05 mmol), 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (329 mg, 1.05 mmol),
EDCHCl (302 mg, 1.58 mmol), and catalytic amount of HOBt and DMAP in DMF (10 ml) was stirred for 3 days. The mixture was diluted with EtOAc (200 ml) and washed with brine (2 x 200 ml). After removal of the solvent, residue was chromatographed on silica gel with CHCl3-EtOAc (4: 1) to CHCl3-MeOH (10:1) as eluent to give methyl 4-[4-(2,4-difluorophenoxy)-l-[3-methoxy-4- [N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinylmethoxybenzoate (693 mg, quant). 'H- NMR (CDC13) δ2.16-2.53 (m, 5 H), 3.61-4.93 (series of m, 14 H), 6.48-8.12 (series of m, 16 H). To a stirred solution of methyl 4-[4-(2,4-difluorophenoxy)-l-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetyl]-2-pyrrolidinylmethoxybenzoate (693 mg, 1.05 mmol) in THF (8 ml) was added 0.25 N NaOH (8.4 ml, 2.10 mmol). The mixture was stirred overnight. The mixture was poured into 1 N HCl (200 ml) and the resulting precipitate was collected with suction. The solid was chromatographed on silica gel with CHCl3-MeOH (50: 1 to 10: 1) as eluent to give 120 (323 mg, 48%) as a colorless amoφhous soid. MW 645.65 'H-NMR (DMSO-cL,) δ 2.25 (s, 3 H), 2.35 (m, 2 H), 3.33-5.18 (series of m, 11 H), 6.75 (dd, 1 H, 7= 8.3, 1.7 Hz), 6.87-7.30 (series of m, 8 H), 7.79 (d, 1 H, 7= 8.3 Hz), 7.85-7.90 (m, 3 H), 8.01 (d, 1 H, 7 = 8.3 Hz), 8.49 (s, 1 H), 8.57 (s, 1 H); MS (FAB) m/z, 646 (M++l). Example 113
4-[l-[4-[7V'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-4-(6-quinolyloxy-2S-pyrrolidinyl] methoxybenzoic acid
Figure imgf000272_0001
To a stirred solution of methyl (/røns-l-tert-butoxycarbonyl-4-hydroxy-2-pyrrolidinyl) methoxy benzoate (1.0 g, 3.0 mmol), 6-hydroxyquinoline (435 mg, 3.0 mmol), and Ph^5 (943 mg,
3.6 mmol) in THF (10 ml) was added DIAD (727 mg, 3.6 mmol) at 0 °C The reaction mixture was stirred at room temperature for 18 hr. The mixture was concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1:2, v/v) . To a stirred solution of the product in CH2C12 (6.0 ml) was added TFA (6.0 ml) at 0 °C. The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The extract was washed with brine .dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl2(l% to 10%,v/v) as eluent to give methyl 4-[(4S)- [(6-quinolyloxy-(2S)-pyrrolidinyl)]methoxybenzoate (900 mg, 82%) as a pale yellow oil. 'H-NMR (CDC13) δ 1.92-2.10 (m, IH), 2.45-2.55 (m, IH), 3.20-3.30 (m, IH), 3.38-3.50 (m, IH), 3.60-3.70 (m, IH), 3.88 (s, 3H), 4.05-4.18 (m, 2H), 5.03 (m, IH), 6.91 (d, 7= 8.5 Hz, IH), 7.02 (d, 7 = 2.7 Hz, IH), 7.35-7.38 (m, 2H), 7.96 (d, 7 = 8.5 Hz, IH), 8.00-8.05 (m, 2H), 8.76 (d, 7= 3.2 Hz, IH).
To a stirred solution of methyl 4-(4S-(6-quinolyloxy-2S-pyrrolidinyl)methoxybenzoate
(300 mg, 0.79mmol), 4-[Λ -(2-chlorophenyl)uredio]-3-methoxyphenylacetic acid (264 mg, 0.79 mmol), HOBt (107 mg, 0.79 mmol), and triethylamine (330 ml, 2.37 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDC HCl (228 mg, 1.2 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03 then dried over Na2S04, and concentrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc to EtOH-EtOAc (10%, v/v) as eluent to give methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3- methoxyphenylacetyl]-4-(6-quinolyloxy-(21S)-pyrrolidinyl]methoxybenzoate (520 mg, 95%) as a colorless oil. 'H-NMR (CDC13) δ 2.30-2.60 (m, 3H), 3.64 (s, 2H), 3.73 (s, 3H), 3.80-3.95 (m, IH), 3.87 (s, 3H), 4.15-4.30 (m, IH), 4.50-4.70 (m, 2H), 5.11 (br s, IH), 6.81-7.01 (m, 6H), 7.26 -7.39 (m, 6H), 7.93-8.03 (m, 5H), 8.19 (d, 7 = 8.3 Hz, IH), 8.80 (s, IH).
To a stirred solution of methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenyl acetyl]-4-(6-quinolyloxy-2S-pyrrolidinyl]methoxybenzoate (520 mg, 0.75 mmol) in THF (10.0 ml) and MeOH (5.0 ml) was added IN NaOH (1.5 ml, 1.5 mmol). The mixture was stirred at 60 °C for 18 hr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 121 (450 mg, 88%) as a white crystalline solid. 681.13 mp 129-133 °C; IR (KBr) 3332, 1704, 1604, 1531, 1419, 1222, 1166 cm '; 'H-NMR (DMSO-cL.) δ 2.25-2.55 (m, IK), 3.67 (s, 2H), 3.82 (s, 3H), 3.81-3.92 (m, IH), 4.02-4.15 (m, 2H), 4.40-4.50 (m, 2H), 5.25-5.40 (m, IH), 5.33-7.07 (m, 5H), 7.26-7.49 (m, 5H), 7.83-8.23 (m, 6H), 8.73-8.74 (m, IH), 8.90 (s, IH), 8.94 (s, IH); MS (FAB) m/z 681 (M++l); Anal, calcd for C37H33N4O7C1 0.5H2O: C, 64.39; H, 4.97; N, 8.12. Found: C, 64.22; H, 4.90; N, 7.96. Example 114
4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(4S)-(6-quinolyloxy-(2S)- pyrrolidinyl] methoxybenzoic acid
Figure imgf000274_0001
To a stirred solution of methyl 4-(4S-(6-qmnolyloxy-2S-pyrrolidinyl)methoxybenzoate
(300 mg, 0.79mmol), 4-[N'-(2-bromophenyl)uredio]-3-methoxyphenylacetic acid (299 mg, 0.79 mmol), HOBt (107 mg, 0.79 mmol), and triethylamine (330 ml, 2.37 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDC HCl (228 mg, 1.2 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03 then dried over Na2S04, and concentrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc to EtOH-EtOAc (10%, v/v) as eluent to give methyl 4-[l-[4-[N'-(2-bromophenyl)meido]-3- methoxyphenylacetyl]-(4S)-(6-quinolyloxy-(2S)-pyrrolidinyl]methoxybenzoate (530 mg, 91%) as a colorless oil. 'H-NMR (CDC13) δ 2.30-2.62 (m, 3H), 3.65 (s, 2H), 3.75 (s, 3H), 3.80-3.95 (m, IH), 3.93 (s, 3H), 4.10-4.30 (m, IH), 4.50-4.70 (m, 2H), 5.11 (br s, IH), 6.82-6.98 (m, 6H), 7.15-7.39 (m, 5H), 7.52 (d, 7 = 8.0 Hz, IH), 7.93-8.03 (m, 5H), 8.14 (d, 7= 8.3 Hz, IH), 8.80 (s, IH).
To a stirred solution of methyl 4-[l-[4-[W-(2-bromophenyl)ureido]-3-methoxyphenyl acetyl]-4-(6-quinolyloxy-2S-pyrrolidinyl]methoxybenzoate(530 mg, 0.72 mmol) in THF (10.0 ml) and MeOH (5.0 ml) was added IN NaOH (1.4 ml, 1.4 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 122 (460 mg, 88%) as a white crystalline solid. MW 725.59 mp 149-153 °C; IR (KBr) 3332, 1704, 1604, 1527, 1222, 1164 cm '; 'H-NMR (DMSO-c .) δ 2.28-2.58 (m, 2H), 3.67 (s, 2H), 3.82 (s, 3H), 3.85-3.90 (m, IH), 4.05-4.15 (m, 2H), 4.40-4.50 (m, 2H), 5.20-5.32 (m, IH), 6.77-7.07 (m, 5H), 7.31-7.61 (m, 5H), 7.83-7.97 (m, 5H), 8.21-8.22 (m, IH), 8.73-8.74 (m, 2H), 8.92 (s, IH); MS (FAB) m/z 725 (M+), 727 (M++2); Anal calcd for
Figure imgf000274_0002
C, 60.50; H, 4.67; N, 7.63; Br, 10.88. Found: C, 60.51; H, 4.60; N, 7.52; Br, 11.06. Example 115 4-[(25,45)-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-4-(2-naphthyloxy)-2- pyrrolidinyl] methoxybenzoic acid
Figure imgf000275_0001
To a stirred mixture of methyl (2S,4R)-l-tert-butoxycarbonyl-4-hydroxy-2- pyrrolidinylcarboxylate (4.22 g, 17.2 mmol), 2-naphthol (2.73 g, 18.9 mmol) and PPh3 (4.96 g, 18.9 mmol) in THF (80 ml) was added DIAD (3.72 ml, 18.9 mmol) at room temperature under an atmosphere of nitrogen. After stirring over night, the mixture was concentrated in vacuo. The residue was chromatographed on silica gel [600 g, CHGs/EtOAc (10/1)], to give methyl (2S,4S)-l- tert-butoxycarbonyl-4-(2-naphthyloxy)-2-pyrrolidinylcarboxylate (5.37 g), which was used without further purification.
To a stirred solution of methyl (2S,45)-l-tert-butoxycarbonyl-4-(2-napthhyloxy)-2- pyrrolidinyl carboxylate (5.37 g) in THF (116 ml) was added 0.25 N NaOH (116 ml, 29.0 mmol) at room temperature. The resulting mixture was stirred over night. After removal of the solvent, the mixtiire was acidified by the addition of 1 N HCl and extracted with CHC13. The combined extracts were washed with brine, dried over Na2S04 and evaporated. The residue was recrystallized from n-hexane-CRCl3, to give (2S,45 -l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2- pyrrolidinylcarboxylic acid [4.44 g, 85%(2 steps)] as a white powder. 'H-NMR (DMSO-cL.) δ 1.37 and 1.41 (s, 9H, amide isomers), 2.26 (d, 7 = 13.9 Hz, IH), 2.65 (m, IH), 3.47 (d, 7= 11.5 Hz, IH), 3.81 (m, IH), 4.30 (m, IH), 5.14 (m, IH), 7.02-7.86 (m, IK).
To a stirred solution of (25,4S)-l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2- pyrrolidinylcarboxylic acid (1.12 g, 3.13 mmol) in THF (30 ml) was added BH3-DMS (0.63 ml, 6.3 mmol) at 0 °C. The mixture was raised to room temperature immediately and then heated at 50 °C for 1.5 h. After cooling to room temperature, the mixture was quenched by the addition of water at 0 CC and extracted with EtOAc. The combined extracts were washed with brine, dried over Na2S04 and evaporated. The residue was chromatographed on silica gel [50 g, CHCl3/MeOH (50/1)], to give (2S,4S)-l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2-pyrrolidinylmethanol (1.10 g, 100%) as a pale yellow oil. 'H-NMR (CDC13) δ 1.48 (s, 9H), 2.45 (m, IH), 3.58-4.80 (m, 4H), 5.01 (br, IH), 7.04-7.99 (m, IK).
To a stirred mixtiire of (25,45)- l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2-pyrrolidinyl methanol (640 mg, 1.86 mmol), methyl 4-hydroxybenzoate (283 mg, 1.86 mmol) and PPh3 (488 mg, 1.86 mmol) in THF (18 ml) was added DIAD (0.37 ml, 1.86 mmol) at room temperature under an atmosphere of nitrogen. The mixture was stined over night. After removal of the solvent, the resulting residue was chromatographed on silica gel [100 g, n-nexαne/EtOAc(2/l)], to give methyl 4-[(2S,4S)-l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2-pyrrolidinyl]methoxybenzoate (830 mg, 93%) as a colorless oil. 'H-NMR (CDC13) δ 1.50 (d, 7 = 8.3 Hz, 9H), 2.34 (m, IH), 2.53 (d, 7= 14.2 Hz, IH), 3.72-3.85 (m, IH), 3.86 and3.87 (s, 3H, amide isomers), 4.17 (m, IH), 4.26- 4.52 (m, 2H), 5.06 (br, IH), 6.87 (d, 7= 8.8 Hz, IH), 6.94 (d, 7= 8.8 Hz, 2H), 7.04 (br, 2H), 7.33 (t, 7 = 7.3 Hz, IH), 7.42 (t, 7= 7.3 Hz, IH), 7.64-8.02 (m, 5H).
To a stirred solution of methyl 4-[(25,4S)-l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2- pyrrolidinyl] methoxybenzoate (870 mg, 1.74 mmol) in CH2C12 (24 ml) was added TFA (6 ml) at room temperature. The mixture was stirred over night, which was concentrated in vacuo. The residue was diluted with CH2C12 and made basic by the addition of 1 N NaOH, which was extracted with CH2C12. The organic layer was washed with brine, dried over NaS04 and concentrated. The residue was chromatographed on silica gel [100 g, n-hexane/EtOAc(2/l)], to give methyl 4-[(2S,4S)-4-(2-naphthyloxy)-2-pyrrolidinyl]methoxybenzoate (750 mg, 100%) as a black oil 'H-NMR (CDC13) δ 1.99 (dd, 7= 14.2, 5.6 Hz, IH), 2.48 (m, IH), 3.22 (dd, 7 = 12.2, 4.6 Hz, IH), 3.43 (d, 7 = 12.5 Hz, IH), 3.67 (m, IH), 3.86 and 3.87 (s, 3H, amide isomers), 4.11 (m, 2H), 5.04 (m, IH), 6.83 (d, 7= 8.5 Hz, IH), 6.89 (d, 7 = 8.8 Hz, 2H), 7.07 (d, 7 = 2.0 Hz, IH), 7.12 (d, 7 = 9.0 Hz, IH), 7.33 (dt, 7 = 8.1, 1.2 Hz, IH), 7.44 (dt, 7= 6.8, 1.2 Hz, IH), 7.70 (d, 7 = 8.1 Hz, IH), 7.75 (dd, 7= 9.0, 5.1 Hz, 2H), 7.90 (d, 7= 8.5 Hz, IH), 7.96 (dd,7 = 6.8, 2.0 Hz, 2H).
A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (333 mg, 0.106 mmol), methyl 4-[(2S,4S)-4-(2-naphthyloxy)-2-pyrrolidinyl]methoxybenzoate (400 mg, 1.06 mmol), EDCHCl (305 mg, 1.59 mmol) and DMAP (194 mg, 1.59 mmol) in DMF (10 ml) was stirred at room temperature for 3 days. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [100 g, n- Λexαne/EtOAc(l/l)CHCl3/MeOH(50/l)], to give methyl 4-[(2S,4S)-l-[3-methoxy-4-[N'-(2- methylphenyl)ureido]phenylacetyl]-4-(2-naphthyloxy)-2-pyrrolidinyl]methoxybenzoate (520 mg, 73%) as a pale brown amoφhous. 'H-NMR (CDC13) δ 2.28 (s, 3H), 2.29 (m, IH), 2.55 (d, 7 =
14.2 Hz, IH), 3.60 (d, 7 = 3.4 Hz, 2H), 3.66 (d, 7 = 3.7 Hz, 3H), 3.68-4.00 (m, 5H), 4.05-4.67 (m, 3H), 5.09 (br, IH), 6.61 (s, IH), 6.77 (m, 2H), 6.87 (d, 7= 8.8 Hz, IH), 6.94-7.54 (m, 8H), 7.68- 8.09 (m, 8H); MS (ESI) m/z 674 (M++l).
To a solution of methyl 4-[(25,45)-l-[3-methoxy-4-[Λ^'-(2-methylphenyl)meido] phenylacetyl]-4-(2-naphthyloxy)-2-pyrrolidinyl]methoxybenzoate (415 mg, 0.616 mmol) in THF (4.9 ml), 0.25 N NaOH (4.9 ml) was added. After stirring at room temperature for 3 days, the mixture was acidified with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was purified on TLC [CHC eOH (10/1)], to give 123 (180 mg, 44%) as a colorless amoφhous. MW 659.73 IR (KBr) 3354, 2937, 1685, 1601, 1533, 1255 cm '; 'H-NMR (DMSO-c .) δ 2.24 (s, 3H), 2.25-2.43 (m, 2H), 3.65 (s, 2H), 3.81 (s, 3H), 3.83 (m, IH), 4.05-4.70 (m, 4H), 5.21-5.33 (br, IH), 6.76 (d, 7 = 7.3 Hz, IH), 6.86-7.35 (m, 9H), 7.44 (t, 7 = 7.3 Hz, IH), 7.76-7.89 (m, 6H), 8.01 (d, 7= 8.3 Hz, IH), 8.48 (s, IH), 8.56 (s, IH); MS (FAB) m/z 660(M++1). Example 116
4-[(2S,4S)-l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-4-(2-naphtyloxy)-2- pyrrolidinyl]methoxybenzoic acid
Figure imgf000277_0001
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (310 mg, 0.93 mmol), methyl 4-[(2S,45)-4-(2-naphthyloxy)-2-pyrrolidinyl]methoxybenzoate (350 mg, 0.93 mmol), EDC HCl (267 mg, 1.40 mmol) and DMAP (171 mg, 1.40 mmol) in DMF (10 ml) was stirred at room temperature for 3 days. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [100 g, n- /2e αne/EtOAc(l/l)CHCl3/MeOH(50/l)], to give methyl 4-[(2S,4S)-l-[4-[N'-(2-chlorophenyl) ureido]-3-methoxyphenylacetyl]-4-(2-naphthyloxy)-2-pyrrolidinyl]methoxybenzoate (450 mg, 68%) as a pale brown amoφhous. 'H-NMR (CDC13) δ 2.32 (m, IH), 2.58 (d, 7 = 14.5 Hz, IH), 3.63 (d, 7= 2.7 Hz, IH), 3.70 (s, 3H), 3.86 (s, 3H), 3.84-3.95 (m, 2H), 4.15-4.64 (m, 4H), 5.11 (br, IH), 6.79-7.06 (m, IK), 7.21-7.46 (m, IK), 1.66-1.11 (m, 3H), 7.92 (d, 7 = 8.8 Hz, IH), 7.97 (m, IH), 8.17 (d, 7 = 8.4 Hz, IH); MS (ESI) m/z 694 (M++l), 696 (M++3).
To a solution of methyl 4-[(2S,45 -l-[4-[Λf'-(2-chlorophenyl)ureido]-3-methoxyphenyl acetyl]-4-(2-naphthyloxy)-2-pyrrolidinyl]methoxybenzoate (381 mg, 0.535 mmol) in THF (4.3 ml), 0.25 N NaOH (4.3 ml) was added. After stirring at room temperature for 3 days, the mixture was acidified with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was purified on TLC [CHCl3/MeOH (10/1)] to give 124 (140 mg, 39%) as a colorless amoφhous. MW 680.15 IR (KBr) 3323, 2935, 1704, 1601, 1529, 1529, 1508 cm '; 'H-NMR (DMSO-cL.) δ 2.27-2.49 (m, 2H), 3.65 (s, 2H), 3.81 (s, 3H), 3.83 (m, IH), 4.05-4.71 (m, 4H), 5.30 (br, IH), 6.77 (d, 7 = 7.8 Hz, IH), 6.87-7.16 (m, 4H), 7.14 (dd, 7= 8.8, 2.2 Hz, IH), 7.27 (t, 7= 7.3 Hz, IH), 7.29-7.46 (m, 4H), 7.76-7.86 (m, 5H), 7.96 (d, 7 = 8.3 Hz, IH), 8.08 (dd, 7 = 8.3, 1.2 Hz, IH), 8.90 (s, IH), 8.93 (s, IH); MS (FAB) m/z 680 (M++l), 682 (M++3); Anal. Calcd for C38H34C1N307- 1H20: C, 65.37; H, 5.20; N, 6.02. Found: C, 65.43; H, 5.11; N, 5.93. Example 117
2-[(2S,45 -l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-4-(2-naphιhyloxy)-2- pyrrolidinyl]methoxy-5-pyridinecarboxylic acid
Figure imgf000278_0001
To a stirred mixture of methyl (25,4Λ)-l-tert-butoxycarbonyl-4-hydroxy-2- pyrrolidinylcarboxylate (4.22 g, 17.2 mmol), 2-naphthol (2.73 g, 18.9 mmol) and PPh3 (4.96 g,
18.9 mmol) in THF (80 ml) was added DIAD (3.72 ml, 18.9 mmol) at room temperature under an atmosphere of nitrogen. After stirring over night, the mixture was concentrated in vacuo. The residue was chromatographed on silica gel [600 g, CHCl^tOAc (10/1)], to give methyl (25,45)- l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2-pyrrolidinylcarboxylate (5.37 g), which was used to the next reaction without further purification.
To a stirred solution of methyl (25,45)- l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2- pyrrolidinyl carboxylate (5.37 g) in THF (116 ml) was added 0.25 N NaOH (116 ml, 29.0 mmol) at room temperature. The resulting mixture was stirred over night After removal of the solvent, the mixture was acidified by the addition of 1 N HCl and extracted with CHC13. The combined extracts were washed with brine, dried over Na2S04 and evaporated. The residue was recrystallized with n-λexαne-CHCl3, to give (25,45)- l-tert-butoxycarbonyl-4-(2-naphfhyloxy)-2- pyrrolidinylcarboxylic acid [4.44 g, 85%(2 steps)] as a white powder. 'H-NMR (DMSO-d6) δ 1.37 and 1.41 (s, 9H, amide isomers), 2.26 (d, 7= 13.9 Hz, IH), 2.65 (m, IH), 3.47 (d, 7 = 11.5 Hz, IH), 3.81 (m, IH), 4.30 (m, IH), 5.14 (m, IH), 7.02-7.86 (m, IK). To a stirred solution of (25,45)-l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2- pyrrolidinylcarboxylic acid (1.12 g, 3.13 mmol) in THF (30 ml) was added BH3-DMS (0.63 ml, 6.3 mmol) at 0 °C The mixture was raised to room temperature immediately and then heated at 50 °C for 1.5 h. After cooling to room temperature, the mixtme was quenched by the addition of water at 0 °C and extracted with EtOAc. The combined extracts were washed with brine, dried over Na2S04 and evaporated. The residue was chromatographed on silica gel [50 g, CHCl^eOH (50/1)], to give (25, 45)-l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2 -pyrrolidinylmethanol (1.10 g, 100%) as a pale yellow oil. 'H-NMR (CDC13) δ 1.48 (s, 9H), 2.45 (m, IH), 3.58-4.80 (m, 4H), 5.01 (br, IH), 7.04-7.99 (m, IK).
To a stirred mixture of (25,45)-l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2-
' pyrrolidinylmethanol (484 mg, 1.41 mmol), methyl 2-hydroxy-5-pyridinecarboxylate (216 mg, 1.41 mmol) and PPh3 (370 mg, 1.41 mmol) in THF (15 ml) was added DIAD (0.28 ml, 1.41 mmol) at room temperature under an atmosphere of nitrogen . The mixture was stirred over night. After removal of the solvent, the resulting residue was chromatographed on silica gel [50 g, n- exαne/EtOAc(2/l)], to give methyl-2-[(25,45)-l-tert-butoxycarbonyl-4-(2-naphthyloxy)-2- pyrrolidinyl]methoxypyridine-5-carboxylate (170 mg, 25%) as a colorless oil. 'H-NMR (CDC13) δ 1.47 (s, 9H), 2.37 (m, IH), 2.46 (d, 7= 14.2 Hz, IH), 3.71-4.00 (m, 2H), 3.89 (s, 3H), 4.30-4.56 (m, 2H), 4.74 (dd, 7= 9.8, 4.6 Hz, IH), 5.06 (br, IH), 6.70 (d, 7= 8.8 Hz, 2H), 7.05-7.09 (m, 2H), 7.33 (t, 7= 6.9 Hz, IH), 7.42 (t, 7 = 6.9 Hz, IH), 7.67-7.75 (m, 3H), 8.09 (d, 7 = 8.8 Hz, IH), 8.77 (d, 7 = 2.2 Hz, IH).
To a stined solution of 5-carboxymethyl-2-[(25,45)-l-tert-butoxycarbonyl-4-(2- napthyloxy)-2-pyrrolidinyl]methoxypyridine (170 mg, 0.36 mmol) in CH2C12 (5 ml) was added TFA (2 ml) at room temperature. After 2 h stirring, the mixture was concentrated in vacuo, which was diluted with CH2C12 and basified by the addition of 1 N NaOH. The combined reaction mixture was extracted with CH2C12. The organic layer was washed with brine, which were dried over NaS04 and concentrated. The residue was purified on TLC [CHCl^eOH (10/1)], to give methyl 2-[(25,45)-4-(2-naphthyloxy)2-pyrrolidinyl]methoxypyridine-5-carboxylate (107 mg, 80%) as a colorless oil Η-NMR (CDC13) δ 1.95 (m, IH), 2.27 (br, IH), 2.46 (m, IH), 3.19 (dd, 7 = 12.2, 4.9 Hz, IH), 3.41 (d, 7 = 12.2 Hz, IH), 3.65 (m, IH), 3.89 (s, 3H), 4.58 (m, 2H), 5.00 (br, IH), 6.77 (d, 7 = 8.8 Hz, IH), 7.06 (br, IH), 7.11 (dd, 7 = 8.8, 2.7 Hz, IH), 7.31-7.45 (m, 2H), 7.69-7.76 (m, 3H), 8.13 (dd, 7 = 8.8, 2.4 Hz, IH), 8.78 (d, 7= 2.2 Hz, IH). A mixture of 3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetic acid (89 mg, 0.283 mmol), methyl-2-[(25,45)-4-(2-naphthyloxy)-2-pyrrolidinyl]methoxypyridine-5-carboxylate (107 mg, 0.78 mmol), EDC HCl (81 mg, 0.425 mmol) and DMAP (52 mg, 0.425 mmol) in DMF (3 ml) was stirred at room temperature for 18 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over
Na2S04, the extracts were concenfrated in vacuo. The residue was purified on TLC [CHCl^eOH (10/1)], to give 2-[(25,45 -l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-4-(2- naphthyloxy)-2-pyrrolidinyl]methoxy-5-pyridinecarboxylic acid methyl ester (193 mg, 100%) as a colorless amoφhous. •H-NMR (CDC13) δ 2.27 (d, 7= 3.2 Hz, 3H), 2.30 (m, IH), 2.49 (dd, 7 = 14.2, 2.0 Hz, IH), 3.60 (d, 7 = 3.9 Hz, IH), 3.67 (d, 7 = 5.9 Hz, 3H), 3.81 (s, IH), 3.85 (s, IH), 3.88 and 3.91 (s, 3H, amide isomers), 3.95 (m, IH), 4.02-5.09 (m, 4H), 6.67 (d, 7 = 8.8 Hz, IH), 6.73-7.13 (m, 3H), 7.20-7.45 (m, 7H), 7.53 (t, 7 = 7.8 Hz, IH), 7.67-7.77 (m, 3H), 8.02-8.84 (m, 3H). For HCl salt: a pale brown amoφhous. IR (KBr) 3346, 2951, 1720, 1601, 1533, 1281 cm'1; MS (FAB) m/z 675 (M++l).
To a solution of 2-[(25,45)-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-4- (2-naphthyloxy)-2-pyrrolidinyl]methoxy-5-pyridinecarboxylic acid methyl ester (158 mg, 0.23 mmol) in THF (1.8 ml), 0.25 N NaOH (1.8 ml) was added. After stirring at room temperature for 22 h, the mixture was neutralized with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined exfracts were dried over Na2S04 and concenfrated in vacuo. The residue was purified on TLC [CHCL MeOH (5/1)] to give 125 (51 mg, 34%) as a colorless amoφhous solid. MW 660.72 IR (KBr) 3354, 2956, 1601, 1533, 1255, 1022 cm 1; 'H-NMR (DMSO-c .) δ 2.24 (s, 3H), 3.30-5.32 (m, 13H), 6.72-8.82 (m, 19H); MS (FAB) m/z 661(M++1); Anal. Calcd for C38H36N4O7-0.5EtOH-lH2O: C, 66.75; H, 5.89; N, 7.98. Found: C, 66.39; H, 5.55; N, 7.66. Example 118
4-[5-(R)-benzyloxymethyl-l-[4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-(5)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000280_0001
To a stirred solution of benzyl-(5)-glycidyl ether (5.0 g, 30.5 mmol) in THF (100 ml) was added allylmagnesium chloride (1.0 Min Et20, 30.5 ml, 30.5 mmol) at -78°C, and the resulting mixture was gradually warmed up to rt with stirnng The mixture was poured into water and concenfrated in vacuo, then exfracted with CHC13 The organic layer was dned over anhydrous Na2S0 and concenfrated in vacuo The residue was chromatographed on silica gel with hexane- EtOAc (5 1) as eluent to give l-benzyloxy-2-(Λ)-hydroxy-5-hexene (2 18 g, 35%) as a colorless oil 'H-NMR (CDC13) δ 1 52-1 60 (m, 2 H), 2 11-2 25 (m, 2 H), 2 34 (d, 7 = 3 2 Hz, I H), 3 35 (dd, 7 = 9 6, 8 0 Hz, 1 H), 3 52 (dd, 7= 9 6, 3 2 Hz, 1 H), 3 84-3 86 (m, 1 H), 4 57 (s, 2 H), 4 96- 5 07 (senes of m, 2 H), 5 78-5 88 (m, 1 H), 7 29-7 38 (m, 5 H), MS (ESI) m/z, 224 (M++NH4 +)
To a stirred solution of l-benzyloxy-2-(Λ)-hydroxy-5-hexene (2 18 g, 10 5 mmol), tπphenylphosphine (3 32 g, 12 7 mmol) and phthahmide (1 86 g, 12 7 mmol) was added diisopropyl azodicarboxylate (2 62 ml, 12 7 mmol) at rt, and the resulting mixture was stirred for overmght at rt The mixtiire was concenfrated in vacuo and exfracted with EtOAc The organic layer was washed with water, drying over anhydrous Na2S04, then concenfrated in vacuo The residue was chromatographed on silica gel with hexane-EtOAc (5 1) as eluent to give 1- benzyloxy-2-(5)-phthalιmιdo-5-hexene (2 95 g, 83%) as a colorless oil 'H-NMR (CDC13) δ 1 76- 1 84 (m, 2 H), 2 06 (dd, 7= 14 4, 6 8 Hz), 2 H, 2 12-2 22 (m, I K), 3 69 (dd, 7= 10 0, 5 6 Hz, 1
H), 4 00 (t, 7 = 9 6 Hz, 1 H), 4 46 (d, 7 = 12 O Hz, 1 H), 4 53 (d, 7 = 12 0 Hz, 1 H), 4 51-4 58 (m, 1 H), 4 91-4 99 (senes of m, 2 H), 5 72-5 79 (m, 1 H)7 21-7 26 (m, 5 H), 7 71-7 83 (senes of m, 2 H), MS (ESI) m/z, 336 (M++H)
To a stirred solution of l-benzyloxy-2-(5)-phthalimido-5-hexene (2 95 g, 8 80 mmol) in EtOH (30 ml) was added hydrazine hydrate (80% in water, 460 ml, 11 4 mmol) at rt, and the resulting mixture was heated under reflux for 7 5 h with stirnng The solution was filtered, and the filtrate was concentrated in vacuo The residue was poured into aq NaHC03 and exfracted with CHC13 The organic layer was dned over anhydrous Na2S04, then concenfrated in vacuo to give 2- (5)-aπuno-l-benzyloxy-5-hexene (1 90 mg, quant ) as a colorless oil 'H-NMR (CDC13) δ 1 37- 1 55 (senes of m, 4 H), 2 08-2 19 (m, 2 H), 2 99-3 03 (m, 1 H), 3 25 (dd, 7 = 9 2, 7 6 Hz, 1 H), 3 45 (dd, 7 = 9 2, 4 0 Hz, 1 H), 4 53 (s, 2 H), 4 94-5 06 (senes of m, 2 H), 5 76-5 85 (m, 1 H), 7 27-7 37 (m, 5 H), MS (ESI) m/z, 206 (M++H), 247 (M++H+CH3CN)
To a stirred solution of 2-(5)-amιno-l-benzyloxy-5-hexene (1 89 g, 9 21 mmol) and tnethylamine (1 28 ml, 9 21 mmol) in CH2C12 (20 ml) was added benzoyl chlonde (1 07 ml, 9 21 mmol) at rt, and the resulting mixture was stirred for 23 h The mixture was poured into water and extracted with CH2C12 The organic layer was washed with water, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with hexane- EtOAc (5 : 1) as eluent to give N-[2-(5)-(l-benzyloxy)-5-hexenyι]benzamide (2.67 g, 94%) as a colorless needles, mp 78-79 °C; 'H-NMR (CDC13) δ 1.76-1.82 (m, 2 H), 2.11-2.17 (m, 2 H), 3.59 (brs, 2 H), 4.29-4.35 (m, 1 H), 4.54 (dd, 7= 19.2, 12.0 Hz, 2 H), 4.96-5.05 (series of m, 2 H), 5.78- 5.89 (m, 1 H), 6.39 (d, 7 = 8.0 Hz, 1 H), 7.27-7.51 (m, 8 H), 7.74 (d, 7= 7.2 Hz, 2 H); MS (ESI) m/z, 310 (M++H).
To a stirred solution of N-[2-(5)-(l-benzyloxy)-5-hexenyl]benzamide (2.41 g, 7.79 mmol) in CH3CN-H20 (3 : 1, 40 ml) was added iodine (2.97 g, 23.4 mmol) in one portion, and the resulting mixture was stirred for 20 h. The mixture was poured into aq.Na2S203 and concentrated in vacuo, then exfracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S0 , then concentrated in vacuo. The residue was dissolved in CH2C12 (30 ml) and was added di-tert-butyl dicarbonate (2.55 g, 11.7 mmol), Et3N (1.63 ml, 11.7 mmol) and N, N- dimethyl aminopyridine (180 mg, 1.47 mmol), and the resulting mixture was stirred overnight at rt. The mixture was poured into water and exfracted with CH2C12. The organic layer was washed with water, drying over Na2S04, and concentrated in vacuo. The residue was chromatographed on silica gel with hexane-EtOAc (5 : 1) to give 7Vr-Boc-2-(5)-benzoyloxymethyl-5-(5)-benzyloxy methylpyrrolidine (1.27 g, 38%) as a colorless oil. 'H-NMR (CDC13) δ 1.41 and 1.49 (s, total 9 H), 1.85-2.00 (series of m, 4 H), 3.33-4.59 (series of m, 8 H), 7.26-7.32 (m, 5 H), 7.41-7.46 (m, 2 H), 7.54-7.57 (m, 1 H), 8.02 (d, 7 = 7.6 Hz, 2 H); MS (ESI) m/z, 426 (M++H), 448 (M++Na+).
To a stirred solution of N-Boc-2-(S)-benzoyloxymethyl-5-(5)-benzyloxymethylpyrrolidine
(1.23 g, 2.89 mmol) in MeOH (30 ml) was added NaOH (1.0 M in water, 3.47 ml, 3.47 mmol) at rt, and the resulting mixture was stirred for 4 h. The mixture was neufralized with aq. W-HC1 and concenfrated in vacuo, then exfracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with hexane-EtOAc (3 : 1) as eluent to give N-Boc-5-(5)-hydroxymethyl-2-(5)- benzyloxymethyl pyrrolidine (847 mg, 91%) as a colorless oil. Η-NMR (CDC13) δ 1.41 (s, 9 H), 1.57 (brs, I H), 1.95-1.97 (m, 2 H), 2.05-2.18 (m, 1 H), 3.36 (t, 7 = 8.4 Hz, 1 H), 3.56-3.62 (m, 2 H), 3.67-3.72 (m, 2 H), 3.95 (brs, 1 H), 4.03 (brs, 1 H), 4.51 (s, 1 H), 7.28-7.37 (m, 5H); MS (FAB) m/z, 322 (M++H).
To a stirred solution of Λ^-Boc-2-(5)-hydroxymethyl-5-(5)-benzyloxymethylpyrrolidine
(388 mg, 1.21 mmol), triphenylphosphine (380 mg, 1.45 mmol) and methyl 4-hydroxybenzoate (220 mg, 1.45 mmol) was added diisopropyl azodicarboxylate (200 ml, 1.45 mmol) at rt, and the resulting mixture was stirred overnight. The mixture was concentrated in vacuo and exfracted with EtOAc. The organic layer was washed with water, drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with hexane-EtOAc (3 : 1) as eluent to give methyl 4-[2-(5)-(Λ^-Boc-5-(5 -benzyloxymethyl)pyrrolidinylmethoxy]benzoate (462 mg, 84%) as a colorless oil: 'H-NMR (CDC13) δ 1.40 and 1.48 (s, total 9 H), 1.98-2.13 (m, 4 H), 3.83 and 3.85 (s, 3 H), 3.33-4.25 (series of m, 4 H), 4.47-4.59 (m, 2 H), 6.91-6.96 (m, 2 H), 7.26-7.34 (m, 5 H), 7.95-7.98 (m, 2 H); MS (FAB) m/z, 456 (M++H), 478 (M++Na+).
To a stirred solution of methyl 4-[2-(5)-(N-Boc-5-(5)-benzyloxymethyl)pyrrolidinyl methoxy] benzoate (446 mg, 0.98 mmol) in CH2C12 (10 ml) was added trifluoroaceticacid (10 ml) at rt, and the resulting mixtiire was stirred for 1 h. The mixture was concenfrated in vacuo and poured into aq.NaHC03, then exfracted with CHC13. The. organic layer was washed with water, drying over anhydrous Na2S04, then concenfrated in vacuo to give methyl 4-[2-(5)-(5-(5)- benzyloxymethyl) pyrrolidinylmethoxy]benzoate (363 mg, quant.) as yellowish oil. The product was used for next reactions without further purification. 'H-NMR (CDC13) δ 1.43-1.65 (m, 2 H), 1.93-2.07 (m, 3 H), 3.36-3.68 (series of m, 4 H), 3.89 (s, 3 H), 3.86-3.93 (over lap, 2 H), 4.55 (s, 2 H), 6.90 (d, 7 = 8.4 Hz, 2 H), 7.26-7.37 (m, 5 H), 7.97 (d, 7 = 8.4 Hz, 2 H); MS (FAB) m/z, 356 (M++H).
To a stirred solution of methyl 4-[2-(5 -(5-(5)-benzyloxymethyl)pyrrolidinylmethoxy] benzoate (115 mg, 0.32 mmol), 4-[/V'-(2-methylphenyl)ureido]phenylacetic acid (92.0 mg, 0.32 mmol) and Λ N-dimethylaminopyridine (52.0 mg, 0.42 mmol) in DMF (10 ml) was added EDCHCl (81.0 mg, 0.42 mmol) at rt, and the resulting mixture was stirred overnight. The reaction mixture was poured into water and exfracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (20 : 1) as eluent to give methyl 4-[5-(Λ)-benzyl oxymethyl-l-[4-[Λ^'-(2-methylphenyl)ureido]phenylacetamido]-2-(S -pyrrolidinylmethoxy] benzoate (169 mg, 84%) as a colorless amoφhous solid. 'H-NMR (CDC13), mixture of rotamars δ 1.92-2.18 (m, 3 H), 2.24 and 2.25 (s, total 3 H), 2.20-2.31 (overlap, 1 H), 3.39-3.70 (series of m, 4 H), 3.87 and 3.89 (s, total 3 H), 4.17 and 4.18 (s, total 2 H), 4.30-4.45 (series of m, 2 H), 4.53 (s, 2 H), 6.43-7.13 (series of m, 9 H), 7.20-7.36 (series of m, 7 H), 7.58-7.99 (series of m, 3 H); MS (FAB) m/z, 622 (M++H). To a stined solution of methyl 4-[5-(7?)-benzyloxymethyl-l-[4-[N' -(2-methylphenyl) ureido] phenylacetyl]-2-(5)-pyrrolidinylmefhoxy]benzoate (156 mg, 0.24 mmol) in MeOH-THF (1 : 5, 12 ml) was added l.O -NaOH (1.2 ml, 1.20 mmol) at rt, and the resulting mixture was heated at 80°C with stirring for 7 h. The mixture was poured into 1JV-HC1, then exfracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (5 : 1) as eluent to give 126 (94.0 mg, 65%) as a colorless amoφhous solid. MW 607.70 'H-NMR (CD3OD), mixture of rotamars δ 1.85-2.35 (series of m, 4 H), 2.43-2.92 (series of m, 5 H), 2.28 (s, 3 H), 3.55-4.55 (series of m, 10 H), 6.85-7.95 (series of m, 17 H); MS (ESI) m/z, 630 (M*+Na+). Example 119
4-[5-(/?)-benzyloxymethyl-l-[4-[Λ^'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-2-(5)- pyrrolidinylmethoxy]benzoic acid
Figure imgf000284_0001
To a stirred solution of methyl 4-[2-(5)-(5-(5)-benzyloxymethyl)pyrrolidinylmethoxy] benzoate (117 mg, 0.33 mmol), 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (110 mg, 0.33 mmol) and N,N-dimethylaminopyridine (50.0 mg, 0.40 mmol) in DMF (10 ml) was added EDCHCl (76.0 mg, 0.40 mmol) at rt, and the resulting mixture was stirred overnight The reaction mixture was poured into water and extracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (20 : 1) as eluent to give methyl 4-[5-(R)- benzyloxymethyl-l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-2-(5)-pyrrolidinyl methoxyjbenzoate (189 mg, 85%) as a colorless amoφhous solid. 'H-NMR (CDC13), mixture of rotamars δ 1.91-2.30 (series of m, 4 H), 3.39-3.74 (series of m, 3 H), 3.73 (s, 2 H), 4.15-4.02 (m, 2 H), 4.32-4.44 (m, 1 H), 4.54 (s, 2 H), 6.71-7.02 (series of m, 5 H), 7.06 (s, 1 H), 7.17 (s, 1 H), 7.24-7.40 (series of m, 7 H), 7.89-8.22 (series of m, 4 H); MS (FAB) m/z, 672 (M++H).
To a stirred solution of methyl 4-[5-(R)-benzyloxymethyl-l-[4-[jV'-(2-chlorophenyl) ureido]-3-methoxyphenylacetyl]-2-(S)-pyrrolidinylmethoxy]benzoate (169 mg, 0.25 mmol) in MeOH-THF (2 : 5, 7 ml) was added l.OM-NaOH (750 ml, 0.75 mmol) at rt, and the resulting mixture was heated at 80°C with stirring for 2 h. The mixture was poured into 1N-HC1, then exfracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (15 : 1) as eluent to give 127 (114 mg, 69%) as a colorless amoφhous solid. MW 658.14 'H- NMR (CD3OD), mixture of rotamars δ 1.88-2.37 (series of m, 4 H), 3.51-4.49 (series of m, 8H ), 3.64 and 3.73 (s, total 3 H), 4.86 (s, 2 H), 6.85-7.95 (series of m, 16 H); MS (ESI) m/z, 658 (M++H), 680 (M++Na+); nα/. Calcd for C36H36C1N307H20: C, 63.95; H, 5.66; N, 6.21. Found: C, 63.65; H, 5.40: N, 5.95. Example 120
4-[5-(R)-benzyloxymethyl-l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-2-(5)- pyrrolidinylmethoxy]benzoic acid
Figure imgf000285_0001
To a stirred solution of methyl 4-[2-(5)-(5-(5)-benzyloxymethyl)pyrrolidinylmethoxy] benzoate (119 mg, 0.34 mmol), 4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (127 mg, 0.34 mmol) and JVN-dimethylaminopyridine (50.0 mg, 0.40 mmol) in DMF (10 ml) was added EDCHCl (77.0 mg, 0.40 mmol) at rt, and the resulting mixture was stirred overnight. The reaction mixture was poured into water and extracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (20 : 1) as eluent to give methyl 4-[5-(7?)- benzyloxymethyl-l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-2-(5)-pynolidinyl methoxyjbenzoate (217 mg, 90%) as a colorless amoφhous solid. 'H-NMR (CDC13), mixture of rotamars δ 1.92-2.31 (series of m, 4 H), 3.39-3.73 (series of m, 3 H), 3.65 (s, 2H), 4.15-4.02 (m, 2 H), 4.32-4.44 (m, 1 H), 4.54 (s, 2 H), 6.71-6.99 (series of m, 5 H), 7.04 (s, 1 H), 7.11 (s, 1 H), 7.22-7.39 (series of m, 7 H), 7.51-8.17 (series of m, 4 H); MS (FAB) m/z, 716 (M+), 718 (M++2).
To a stirred solution of methyl 4-[5-(Λ)-benzyloxymethyl-l-[4-[N'-(2-bromophenyl) ureido]-3-methoxyphenylacetyl]-2-(5)-pyrrolidinylmethoxy]benzoate (178 mg, 0.25 mmol) in MeOH-THF (2 : 5, 7 ml) was added l.OM-NaOH (750 ml, 0.75 mmol) at rt, and the resulting mixture was heated at 80°C with stirring for 1.5 h. The reaction mixture was poured into 1N-HC1, then extracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHC13- MeOH (15 : 1) as eluent to give 128 (159 mg, 91%) as a colorless amoφhous solid. MW 702.59 'H-NMR (CD3OD), mixture of rotamars δ 1.88-2.35 (series of m, 4 H), 3.51-4.49 (series of m, 8 H), 3.64 and 3.72 (s, total 3 H), 4.87 (s, 2 H), 6.65-8.05 (series of m, 16 H); MS (ESI) m/z, 702 (M+), 704 (M++2); Anal Calcd for C36H36BrN307H20: C, 60.00; H, 5.32; N, 5.83. Found: C, 59.66; H, 5.04: N, 5.65. Example 121
3-[5-(7?)-benzyloxymethyl-l-[4-[N'-(2-methylphenyl)meido]-3-methoxyphenylacetyl]-2-(5)- pyrrolidinylmethoxy]benzoic acid
Figure imgf000286_0001
To a stirred solution of N-Boc-2-(5)-hydroxymethyl-5-(5)-benzyloxymethylpyrrolidine
(415 mg, 1.29 mmol), friphenylphosphine (410 mg, 1.55 mmol) and methyl 3-hydroxybenzoate (240 mg, 1.55 mmol) was added diisopropyl azodicarboxylate (320 ml, 1.55 mmol) at rt, and the resulting mixtiire was stirred overnight. The mixture was concentrated in vacuo, then the residue was chromatographed on silica gel with hexane-EtOAc (3 : 1) as eluent to give methyl 3-[2-(S)-(N-
Boc-5-(5)-benzyloxymethyl)pyrrolidinylmethoxy]benzoate (513 mg, 87%) as a colorless oil: 'H-
NMR (CDC13) δ 1.40 and 1.46 (s, total 9 H), 1.95-2.20 (series of m, 4 H), 3.33-3.72 (series of m, 2 H), 3.82-4.00 (m, 1 H), 3.90 and 3.91 (s, total 3 H), 4.09-4.21 (m, 3 H), 4.21-4.57 (m, 2 H), 7.11-
7.15 (m, 1 H), 7.26-7.37 (m, 6 H), 7.53-7.65 (m, 2 H); MS (ESI) m/z, 456 (M++H).
To a stirred solution of methyl 3-[2-(5)-(N-Boc-5-(5)-benzyloxymethyl)pyrrolidinyl- methoxy] benzoate (501 mg, 1.10 mmol) in CH2C12 (10 ml) was added trifluoroacetic acid (10 ml) at rt, and the resulting mixture was stirred for 1 h. The mixture was concentrated in vacuo and poured into aq.NaHC03, the exfracted with CHC13. The organic layer was washed with water, drying over anhydrous Na2S04, and concenfrated in vacuo to give methyl 3-[2-(5)-(5-(5)- benzyloxymethyl) pyrrolidinyl-methoxy]benzoate (387 mg, quant.) as yellowish oil. The product was used for next reactions without further purification. 'H-NMR (CDC13) δ 1.26-1.65 (m, 2 H), 1.94-2.04 (m, 3 H), 3.37-3.52 (m, 2 H), 3.63-3.66 (m, 1 H), 3.85-3.93 (m, 1 H), 3.91 (s, 3 H), 4.55 (s, 2 H), 7.09-7.11 (m, 1 H), 7.27-7.54 (m, 6 H), 7.54-7.55 (m, IH), 7.61-7.63 (m, 2 H); MS (ESI) m/z, 35 (M++H).
To a stirred solution of methyl 3-[2-(5)-(5-(5)-benzyloxymethyl)pyrrolidinylmethoxy] benzoate (140 mg, 0.39 mmol), 4-[Λ^'-(2-methylphenyl)ureido]-3-methoxyphenylacetic acid (125 mg, 0.39 mmol) and N,N-dimethylaminopyridine (58.0 mg, 0.47 mmol) in THF (15 ml) was added EDCHCl (90.0 mg, 0.47 mmol) at rt, and the resulting mixture was stirred overnight. The reaction mixture was poured into water and extracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give methyl 3-[5-(R)- benzyloxymethyl-l-[4-[Λ^'-(2-methylphenyl)ureido]-3-methoxyphenylacetyl]-2-(5)-pyιτolidinyl methoxy]benzoate (256 mg, quant.) as a colorless amoφhous solid. 'H-NMR (CDC13), mixture of rotamars δ 1.67 (s, 3 H), 1.97-2.40 (series of m, 4 H), 3.42-3.85 (series of m, 5 H), 3.60 (s, 3 H), 3.95 and 3.97 (s, total 3 H), 4.15-4.26 (m, 2 H), 4.36-4.49 (m, 1 H), 4.59 (s, 2 H), 6.32 and 6.36 (s, total 1 H), 6.75-6.87 (series of m, 2 H), 7.20 (brs, 2 H), 7.16-7.72 (series of m, 10 H), 8.03-8.09 (m, 1 H); MS (ESI) m/z, 652 (M++H).
To a stirred solution of methyl 3-[5-(/?)-benzyloxymethyl-l-[4-[/V'-(2-methylphenyl) ureido] -3 -methoxyphenylacetyl]-2-(5 -pyrrolidinylmethoxy]benzoate (185 mg, 0.28 mmol) in MeOH-THF (2 : 5, 7 ml) was added l.OM-NaOH (860 ml, 0.86 mmol) at rt, and the resulting mixture was heated at 60°C with stirring for 1 h. The reaction mixture was poured into 1N-HC1, then exfracted with CHC13. The organic layer was washed with brine, drying over anhydrous
Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHC13- MeOH (5 : 1) as eluent to givel29 (171 mg, 94%) as a colorless amoφhous solid. MW 637.72 'H-NMR (CD3OD), mixture of rotamars δ 1.89-2.37 (series of m, 4 H), 2,29 (s, 3 H), 3.52-4.53 (series of m, 8 H), 3.66 and 3.74 (s, total 3 H), 4.85 (s, 2 H), 6.66-7.98 (series of m, 16 H); MS (ESI) m/z, 638 (M++H), 660 (M++Na+); Anal. Calcd for C37H39N307H20: C, 67.77; H, 6.30; N, 6.41. Found: C, 67.40; H, 5.95: N, 6.14. Example 122
3-[5-(Λ)-benzyloxymethyl-l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-2-(S)- pyrrolidinylmethoxy]benzoic acid
Figure imgf000287_0001
To a stirred solution of methyl 3-[2-(5)-(5-(5)-benzyloxymethyl)pyrrolidinylmethoxy] benzoate (118 mg, 0.33 mmol), 4-[Λ '-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (112 mg, 0.33 mmol) and JV,N-dimethylaminopyridine (50.0 mg, 0.40 mmol) in THF (15 ml) was added
EDCHCl (80.0 mg, 0.40 mmol) at rt, and the resulting mixture was stirred overnight. The reaction mixture was poured into water and extracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give methyl 3-[5-(/?)- benzyloxymethyl-l-[4-[N'-(2-chlorophenyl)meido]-3-methoxyphenylacetamido]-2-(5)- pyrrolidinylmethoxy]benzoate (226 mg, quant.) as a colorless amoφhous solid. 'H-NMR (CDC13), mixture of rotamars δ 1.99-2.40 (series of m, 4 H), 3.43-3.92 (series of m, 5 H), 3.67 (s, 3 H), 3.98 and 4.02 (s, total 3 H), 4.18-4.29 (m, 2 H), 4.36-4.51 (m, 1 H), 4.60 (s, 2 H), 6.75-6.92 (series of m, 2 H), 7.01-7.22 (series of m, 4 H), 7.29-7.53 (series of m, 9 H), 7.62-8.26 (series of m, 3 H); MS (ESI) m/z, 672 (M++H).
To a stirred solution of methyl 3-[5-(Λ)-beιιzyloxymethyl-l-[4-[/X(2-chlorophenyl) ureido]-3-methoxyphenylacetyl]-2-(5)-pyrrolidinylmethoxy]benzoate (169 mg, 0.25 mmol) in MeOH-THF (2 : 5, 7 ml) was added l.OM-NaOH (760 ml, 0.76 mmol) at rt, and the resulting mixture was heated at 60°C with stirring for 1.5 h. The reaction mixture was poured into 1JV-HC1, then exfracted with CHC13. The organic layer was washed with brine, dryed over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHC13- MeOH (5 : 1) as eluent to give 130 (155 mg, 94%) as a colorless amoφhous solid. MW 658.14 'H-NMR (CD3OD), mixture of rotamars δ 1.89-2.35 (series of m, 4 H), 3.52-4.53 (series of m, 8 H), 3.68 and 3.75 (s, total 3 H), 4.85 (s, 2 H), 6.68-8.03 (series of m, 16 H); MS (ESI) m/z, 658 (M++H), 680 (M++Na+); Λ«α/. Calcd for C36H36C1N307H20: C, 63.95; H, 5.66; N, 6.21. Found: C, 64.01; H, 5.38: N, 5.96. Example 123
3-[5-(Λ)-benzyloxymethyl-l-[4-[Λr'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-2-(5)- pyrrolidinylmethoxy]benzoic acid
Figure imgf000288_0001
To a stirred solution of methyl 3-[2-(5)-(5-(5)-benzyloxymethyl)pyrrolidinylmethoxy] benzoate (116 mg, 0.33 mmol), 4-[N'-(2-bromophenyl)ureido]-3-mefhoxyphenylacetic acid (124 mg, 0.33 mmol) and N,N-dimethylaminopyridine (48.0 mg, 0.39 mmol) in THF (15 ml) was added EDCHCl (75.0 mg, 0.39 mmol) at rt, and the resulting mixture was stirred overnight. The reaction mixture was poured into water and exfracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give methyl 3-[5-(R)- benzyloxymethyl-l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-2-(5)-pyrrolidinyl methoxy]benzoate (209 mg, 89%) as a colorless amoφhous solid. 'H-NMR (CDC13), mixture of rotamars δ 1.99-2.37 (series of m, 4 H), 3.43-3.91 (series of m, 5 H), 3.70 (s, 3 H), 3.93 and 3.96 (s, total 3 H), 4.19-4.28 (m, 2 H), 4.37-4.51 (m, 1 H), 4.60 (s, 2 H), 6.77-7.11 (series of m, 6 H), 7.28-7.74 (series of m, 10 H), 7.91-7.95 (series of m, 1 H), 8.20-8.23 (series of m, 1 H); MS (ESI) m/z 116 (M+), 718 (M++2).
To a stirred solution of methyl 3-[5-(R)-benzyloxymethyl-l-[4-[N' -(2-bromophenyl) ureido]-3-methoxyphenylacetyl]-2-(5)-pyrrolidinylmethoxy]benzoate (176 mg, 0.25 mmol) in MeOH-THF (2 : 5, 7 ml) was added l.OM-NaOH (760 ml, 0.76 mmol) at rt, and the resulting mixture was heated at 60°C with stirring for 1.5 h. The reaction mixture was poured into 1N-HC1, then exfracted with CHC13. The organic layer was washed with brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHC13- MeOH (5 : 1) as eluent to give 131 (156 mg, 88%) as a colorless amoφhous solid. MW 702.59 'H-NMR (CD3OD), mixture of rotamars δ 1.89-2.37 (series of m, 4 H), 2,29 (s, 3 H), 3.52-4.53 (series of m, 8 H), 3.68 and 3.75 (s, total 3 H), 4.85 (s, 2 H), 6.67-7.95 (series of m, 16 H); MS (ESI) m/z, 702 (M++H), 704 (M++Na+); Anal. Calcd for C36H36BrN307H20: C, 60.00; H, 5.32; N, 5.83. Found: C, 59.65; H, 5.02: N, 5.65. Example 124 4-[(25, 45) -4-methoxy-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2 -pyrrolidinyl] methoxybenzoic acid
Figure imgf000289_0001
To a stirred mixture of (25,4Λ)-l-tert-butoxycarbonyl-2-tert-butyldiphenylsilyloxymethy-
4-hydroxypyrrolidine (21.7 g, 47.6 mmol), acetic acid (3.0 ml, 52.4 mmol) and PPh3 (12.5 g, 52.4 mmol) in THF (330 ml) was added DIAD (9.4 ml, 47.6 mmol) at room temperature under an atmosphere of nitrogen. After 2 h stirring the same temperature, the mixture was heated at 50 °C for 2 h . After cooling to room temperature, the reaction mixture was concenfrated in vacuo. The resulting residue was chromatographed on silica gel [1 Kg, n-hexane/EtOAc(5/l)], to give (25,45)-4-acetoxy-l-tert-butoxycarbonyl-2-tert-butyldiphenylsilyloxymethypyrrolidine (23.3 g, 99%) as a colorless oil. 'H-NMR (CDC13) δ 1.06 (s, 9H), 1.35 and 1.43 (s, 9H, amide isomers), 1.92 (br, 3H), 2.20-2.45 (m, 2H), 3.31-4.07 (m, 5H), 5.17-5.30 (m, IH), 7.36-7.44 (m, 6H), 7.65- 7.71 (m, 4H).
To a stirred mixture of (25,45)-4-acetoxy-l-tert-butoxycarbonyl-2-tert-butyldiphenyl silyloxy methypyrrolidine (23.3 g, 46.9 mmol) and acetic acid (6.0 ml, 104.8 mmol) in THF (470 ml) was added TBAF (93.8 ml, 93.8 mmol) at 0 °C After 24 h stirring, the mixture was concentrated in vacuo. The resulting residue was diluted with EtOAC and aq. NH4C1 and extracted with EtOAc. The combined extracts were washed with brine, which were dried over Na2S04 and concnfrated in vacuo. The residue was chromatographed on silica gel [700 g, CHCV EtOAc (4/1)], to give (25,45)-4-acetoxy-l-tert-butoxycarbonyl-2-pyrrolidinemethanol (9.70 g, 8%) as a colorless oil. 'H-NMR (CDC13) δ 1.47 (s, 9H), 1.63 (m, IH), 1.81 (m, IH), 2.07 (s, 3H), 2.34 (m, IH), 3.42 (dd, 7 = 12.7, 0.9 Hz, IH), 3.62-3.85 (m, 3H), 4.48 (br, IH), 5.20 (br, IH).
To a stirred mixture of (25,45)-4-acetoxy-l-tert-butoxycarbonyl-2-pyrrolidinemethanol (9.70 g, 37.4 mmol), p-hydroxybenzoic acid methyl ester (5.69 g, 37.4 mmol) and PPh3 (10.8 g, 41.1 mmol) in THF (200 ml) was added DIAD (8.10 ml, 41.1 mmol) at room temperature. After 1.5 h stirring, the mixture was concenfrated in vacuo. The resulting residue was chromatographed on silica gel [700 g, CHCl-ZEtOAc (10/1)], to give methyl 4-[(25,45)-4-acetoxy-l-tert- butoxycarbonyl-2-pyrrolidinyl]methoxybenzoate (11.8 g, 81%) as a pale yellow oil. 'H-NMR (CDC13) δ 1.48 (s, 9H), 2.03 (s, 3H), 2.27 (m, 2H), 3.46 (m, IH), 3.72 (m, IH), 3.88 (s, 3H), 3.98 (t, 7= 9.0 Hz, IH), 4.21-4.47 (m, 2H), 5.31 (br, IH), 6.96 (br, 2H), 7.98 (d, 7 = 8.8 Hz, 2H).
To a stirred solution of methyl 4-[(25,45)-4-acetoxy-l-tert-butoxycarbonyl-4-hydroxy-2- pyrrolidinyl] methoxybenzoate (7.43 g, 18.9 mmol) in MeOH (150 ml) was added cat. K2C03 at room temperature. After 1 day stirring, the mixtiire was concenfrated in vacuo. The resulting residue was recrystallized by the addition of CHCl3-n- exαne, to give methyl 4-[(25,45)-l-tert- butoxycarbonyl-4-hydroxy-2-pyrrolidinyl]methoxybenzoate (5.76 g, 87%) as a colorless solid. 'H- NMR (CDCL) δ 1.46 (s, 9H), 2.11 (m, IH), 2.35 (br, IH), 3.27-3.65 (m, 2H), 3.89 (s, 3H), 4.07- 4.54 (m, 4H), 6.96 (d, 7 = 6.9 Hz, 2H), 7.99 (d, 7= 6.9 Hz, 2H).
To a stirred solution of methyl 4-[(25,45)-l-tert-butoxycarbonyl-4-hydroxy-2-pyrrolidinyl] methoxybenzoate (2.10 g, 5.98 mmol) in THF (60 ml) was added 60% oil NaH (359 mg, 8.97 mmol) at 0 °C. After 15 minutes stirring, Mel (1.20 ml, 8.97 mmol) was added to the mixture was added at same temperature, and the resulting mixture was allowed to raise to room temperature for over 1 h. Then 60% oil NaH (359 mg, 8.97 mmol) and Mel (1.20 ml, 8.97 mmol) was added to the reaction mixture at room temperature and stirred for 14 h. The reaction mixture was poured into ice water and extracted with CHC13. The combined extracts were washed with aq. NaHC03 and brine. After dried over Na2S04, the exfracts were concenfrated in vacuo. The residue was chromatographed on silica gel [50 g, n-nexαne/EtOAc(4/l)], to give methyl 4-[(25,45)-l-tert- butoxycarbonyl-4-methoxy-2-pynolidinyl]methoxybenzoate (1.32 g, 60%) as a colorless oil. 'H- NMR (CDC13) δ 1.48 (s, 9H), 2.05 (m, IH), 2.29 (d, 7= 14.2 Hz, IH), 3.30 (s, 3H), 3.36-4.38 (m, 4H), 6.76 (br, 2H), 7.97 (d, 7= 8.8 Hz, 2H).
To a stirred solution of methyl 4-[(25,45)-l-tert-butoxycarbonyl-4-methoxy-2- pyrrolidinyl] methoxybenzoate (2.38 g, 3.61 mmol) in CH2C12 (46 ml) was added TFA (23 ml) at room temperature. After 14 h stirring, the mixture was concentrated in vacuo. The residue was diluted by the addition of CH2C12 and 1 N NaOH, and exfracted with CH2C12 The combined extracts were washed with brine, dried over Na2S0 , which was concenfrated in vacuo. The residue was chromatographed on silica gel [50 g, CHCIj/MeOH (20/1)], to give methyl 4-[(25,45)- 4-methoxy-2-pyrrolidinyl]methoxybenzoate (950 mg, 99%) as a yellow oil. Η-NMR (CDC13) δ 2.16 (t, 7 = 5.3 Hz, IH), 2.72 (s, IH), 2.95 (d, 7= 6.8 Hz, IH), 3.11 (d, 7 = 11.0 Hz, IH), 3.26 (t, 7 = 1.9 Hz, 3H), 3.52 (br, IH), 3.84 (d, 7 = 1.7 Hz, 3H), 3.92 (s, IH), 4.00 (d, 7= 4.1 Hz, 2H), 6.88 (m, 2H), 7.94 (m, 2H).
A mixture of 3-methoxy-4-[/V'-(2-methylphenyl)ureido]phenylacetic acid (375 mg, 1.19 mmol), methyl 4-[(25,45)-4-methoxy-2-pyrrolidinyl]methoxybenzoate (317 mg, 1.19 mmol), EDC HCl (342 mg, 1.79 mmol), HOBT (242 mg, 1.79 mmol) and Et3N (0.83 ml, 5.95 mmol) in DMF (5 ml) was stirred at room temperature for 13 h. The mixture was poured into ice water and exfracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concenfrated in vacuo. The residue was chromatographed on silica gel [50 g, CHCL/Aectone
Figure imgf000291_0001
(20/1)], to give methyl 4-[(25,45)-4-methoxy-l-[3- methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]methoxybenzoate (650 mg, 98%) as a pale brown amoφhous solid Η-NMR (CDC13) δ 2.03 (m, IH), 2.31 (s, 3H), 2.32 (m, IH), 3.29 (d, 7 = 1.0 Hz, 3H), 3.57-3.68 (m, 5H), 3.88 (d, 7 = 1.0 Hz, 3H), 3.99-4.06 (m, 2H), 4.46 (m, IH), 6.19 (m, IH), 6.80 (s, IH), 6.81 (d, 7 = 9.0 Hz, IH), 6.96-7.19 (m, 4H), 7.29 (m, 2H), 7.50 (d, 7 = 6.7 Hz, IH), 7.95-8.10 (m, 3H); MS (ESI) m/z 562 (M++l).
To a solution of methyl 4-[(25,45)-4-methoxy-l-[3-methoxy-4-[N'-(2-methylphenyl) ureido] phenylacetyl]-2-pyrrolidinyl]methoxybenzoate (650 mg, 1.16 mmol) in THF (18.5 ml), 0.25 N NaOH (18.5 ml) was added. After stirring at room temperature for 12 h, the mixture was acidified with 1 N HCl and exfracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concenfrated in vacuo. The residue was chromatographed on silica gel [50 g, CHClyMeOH (20/1)] to give 132 (540 mg, 85%) as a colorless amoφhous solid. MW 547.60 IR (KBr) 3354, 2937, 1709, 1685, 1604, 1533, 1454 cm 1; Η-NMR (DMSO-c .) δ 2.11 (m, 2H), 2.25 (s, 3H), 3.22 (s, 3H), 3.49-3.78 (m, 4H), 3.82 and 3.86 (s, 3H, amide isomers), 3.87-4.52 (m, 4H), 6.71-7.17 (m, IK), 7.79 (d, 7= 8.1 Hz, IH), 7.86-8.03 (m, 3H), 8.45-8.57 (m, 2H), 12.64 (br, IH); MS (ESI) m/z 548 (M++l); Anal. Calcd for C30H33N3O7 lNa-1.5H2O: C, 60.29; H, 6.07; N, 7.03. Found: C, 59.90; H, 5.59; N, 6.69. Example 125
4-[(25,45)-l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-4-methoxy-2-pyrrolidinyl] methoxybenzoic acid
Figure imgf000292_0001
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (398 mg, 1.19 mmol), methyl 4-[(25,45)-4-methoxy-2-pyrrolidinyl]methoxybenzoate (317 mg, 1.19 mmol),
EDCHCl (342 mg, 1.79 mmol), HOBT (242 mg, 1.79 mmol) and Et3N (0.83 ml, 5.95 mmol) in DMF (5 ml) was stirred at room temperature for 13 h. The mixture was poured into ice water and exfracted with EtOAc. The combined exfracts were washed with ice water and brine. After dried over Na2S04, the exfracts were concenfrated in vacuo. The residue was chromatographed on silica gel [50 g, CHCL/Aectone (10/l)CHCL/MeOH (20/1)], to give methyl 4-[(25,45)-l-[4-[N'-(2- chlorophenyl)ureido]-3-methoxyphenylacetyl]-4-methoxy-2-pyrrolidinyl]methoxybenzoate (600 mg, 87%) as a colorless amoφhous solid Η-NMR (CDC13) δ 1.99-2.06 (m, IH), 2.34 (d, 7 = 13.9 Hz, IH), 3.30 (s, 3H), 3.59 (d, 7= 7.4 Hz, IH), 3.62 (d, 7 = 3.2 Hz, 2H), 3.83 (s, 3H), 3.88 (s, 3H), 4.00-4.18 (m, 3H), 4.42-4.51 (m, 2H), 6.82-7.07 (m, IK), 7.28 (d, 7= 8.3 Hz, IH), 7.35 (dd, 7 = 7.9, 1.5 Hz, IH), 7.94-8.00 (m, 3H),8.18(d, 7= 8.3Hz, IH); MS (ESI) m/z 582 (M++l), 584 (M++3).
To a solution of methyl 4-[(25,45)-l-[4-[Λ^'-(2-chlorophenyl)ureido]-3-methoxyphenyl acetyl]-4-methoxy-2-pyrrolidinyl] methoxybenzoate (600 mg, 1.03 mmol) in THF (16 ml), 0.25 N NaOH (16 ml) was added. After stirring at room temperature for 12 h, the mixture was acidified with 1 N HCl and exfracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concentrated in vacuo. The residue was purified on TLC [CHCl^eOH (10/1)] to give 133 (495 mg, 75%) as a colorless amoφhous solid. MW 568.02 IR (KBr) 3330, 3070, 2937, 1709, 1685, 1604, 1533 cm 1; Η-NMR (DMSO-c .) δ 2.11 (m, 2H), 3.22 (s, 3H), 3.56-3.78 (m, 4H), 3.81 and 3.85 (s, 3H, amide isomers), 3.88-4.56 (m, 4H), 6.73 and 6.77 (d, 7 = 8.1 Hz, IH, amide isomers), 6.85 and 6.91 (s, IH, amide isomers), 7.01-7.07 (m, 3H), 7.28 (t, 7= 8.1 Hz, IH), 7.43 (d, 7 = 8.1 Hz, IH), 7.85-7.94 (m, 2H), 7.97 (d, 7 = 8.6 Hz, IH), 8.09 (d, 7 = 8.3 Hz, IH), 8.90-8.95 (m, 2H); MS (FAB) m/z 570 (M÷+l), 572 (M++3). Example 126
4-[(25,45)-l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-4-methoxy-2 -pyrrolidinyl] methoxybenzoic acid
Figure imgf000293_0001
A mixtiire of 4-[Λ^'-(2-bormophenyl)ureido]-3-methoxyphenylacetic acid (451 mg, 1.19 mmol), methyl 4-[(25,45)-4-methoxy-2-pyrrolidinyl]methoxybenzoate (317 mg, 1.19 mmol),
EDC HCl (342 mg, 1.79 mmol), HOBT (242 mg, 1.79 mmol) and Et3N (0.83 ml, 5.95 mmol) in
DMF (5 ml) was stirred at room temperature for 13 h. The mixture was poured into ice water and exfracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S0 , the exfracts were concenfrated in vacuo. The residue was chromatographed on silica gel [50 g, CHClj/Aectone (10/1)], to give methyl 4-[(25,45)-l-[4-[N'-(2-bromophenyl)ureido]-3- methoxy phenylacetyl]-4-methoxy-2-pyrrolidinyl] methoxybenzoate (760 mg, 100%) as a yellow oil. 'H-NMR (CDC13) δ 1.99-2.32 (m, IH), 2.34 (d, 7= 13.4 Hz, IH), 3.30 (s, 3H), 3.59 (m, IH), 3.63 (d, 7 = 3.2 Hz, 2H), 3.68 (dd, 7= 12.2, 5.1 Hz, IH), 3.81 (br, 3H), 3.88 (s, 3H), 3.91-4.16 (m, 2H), 4.49-4.51 (m, 2H), 6.82-7.15 (m, IK), 7.31 (t, 7= 8.1 Hz, IH), 7.52 (d, 7= 8.1 Hz, IH), 7.93- 8.00 (m, 3H), 8.14 (d, 7= 8.3 Hz, IH); MS (ESI) m/z 626 (M++l), 628 (M++3).
To a solution of methyl 4-[(25,45)-l-[4-[N'-(2-bromophenyl)ureido]phenylacetyl]-4- methoxy-2-pyrrolidinyl]mefhoxybenzoate (760 mg, 1.19 mmol) in THF (19 ml), 0.25 N NaOH (19 ml) was added. After stirring at room temperature for 12 h, the mixture was acidified with 1 N
HCl and extracted with CHCl3-MeOH (10/1). The combined exfracts were dried over Na2S04 and concentrated in vacuo. The residue was chromatographed on silica gel [50 g, CHOs/MeOH (20/1)] to give 134 (580 mg, 78%) as a colorless amoφhous solid. MW 612.47 IR (KBr) 3330, 2935, 1709, 1685, 1604, 1529, 1434 cm 1; 'H-NMR (DMSO-cL.) δ 2.11 (m, 2H), 3.22 (s, 3H), 3.58- 3.78 (m, 4H), 3.81 and 3.86 (s, 3H, amide isomers), 3.92-4.52 (m, 4H), 6.72 (d, 7 = 8.6 Hz, IH), 6.77 (d, 7 = 8.3 Hz, IH), 6.85 and 6.91 (s, IH, amide isomers), 6.97 (t, 7= 7.1 Hz, IH), 7.02 and 7.06 (d, 7 = 8.6 Hz, 2H, amide isomers), 7.32 (t, 7 = 7.3 Hz, IH), 7.59 (dd, 7 = 8.1, 1.0 Hz, IH), 7.94 (dd, 7 = 8.1, 1.2 Hz, 2H), 7.95-7.98 (m, 2H), 8.74 (s, IH), 8.94 (s, IH), 12.63 (br, IH); MS (FAB) m/z 612 (M++l), 614 (M++3). Example 127
4-[(47?)-methoxy-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(25)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000294_0001
To a stirred solution of l-(tert-butoxycarbonyl)-(4Λ)-methoxy-(25)-pyrrolidinylcarboxylic acid (2.87 g, 11.7 mmol) in THF (25 ml) was added BH3DMS (1.66 ml, 17.5 mmol) at room temperature and the reaction mixture was stirred at room temperature overnight. The mixture was evaporated and the residue was dissolved with CH2C12. The solution was washed with H20, brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica- gel with CHCl3-MeOH (50: 1, v/v) as eluent to give l-(tert-butoxycaroonyl)-(4Λ)-methoxy-(25)- prolinol (1.79 g, 66%) as a colorless oil. Η-NMR (CDC13) δ 1.47 (s, 9 H), 1.69-1.73 (m, 1 H), 2.12-2.17 (m, 1 H), 3.31 (s, 3 H), 3.37-3.40 (m, 1 H), 3.53-3.62 (m, 2 H), 3.68-3.73 (m, 1 H), 3.83-
3.87 (m, 1 H), 4.04-4.07 (m, 1 H), 4.90-4.92 (m, 1 H); MS (FAB) m/z 232 (M++l).
To a stirred solution of methyl 4-hydroxybenzoate (1.18 g, 7.76 mmol), l-(tert-butoxy carbonyl)-(4Λ)-methoxy-(25)-prolinol (1.79 g, 7.74 mmol) and Ph^ (2.44 g, 9.30 mmol) in THF (30 ml) was added DIAD (1.83 ml, 9.29 mmol) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was evaporated. The residue was filtered on silica-gel with toluene-acetone (5: 1, v/v) as eluent to give the crude product. The crude product was dissolved in CH2C12 (20 ml). The solution was added TFA (20 ml) and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated in vacuo and made basic by sat. NaHC03. The mixture was extracted with CHC13, washed with brine, dried over K2C03, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (30:1 to 30:2, v/v) as eluent to give methyl 4-[(4Λ)-mefhoxy-(25)-pyrrolidinyl methoxy]benzoate (1.67 g, 81% for 2 steps) as a reddish brown oil. 'H-NMR (CDC13) δ 1.65-1.72 (m, 1 H), 1.89 (bs, 1 H), 2.05-2.22 (m, 1 H), 2.95-3.15 (m, 2 H), 3.31 (s, 3 H), 3.69-3.76 (m, 1 H),
3.88 (s, 3 H), 3.91-4.06 (m, 3 H), 6.89-6.92 (m, 2 H), 7.96-7.98 (m, 2 H); MS (FAB) m/z 266 (M++l). A mixture of 3-methoxy-4-[N'-(2-methylphenyi)ureido]phenylacetic acid (470 mg, 1.50 mmol), methyl 4-[(4Λ)-methoxy-(25 -pyrrolidinylmethoxy]benzoate (396 mg, 1.49 mmol), EDCHCl (343 mg, 1.79 mmol), HOBt (242 mg, 1.79 mmol) and Et3N (250 ml, 1.79 mmol) in THF (10 ml) was stirred at room temperature overnight. The mixture was diluted with H20 and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1, v/v) as eluent to give methyl 4-[(4R)-methoxy-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl acetyl]-(2S)-pyrrolidinylmethoxy]benzoate (822 mg, 98%) as a white foam. 'H-NMR (CDC13) δ 2.14-2.24 (m, 2 H), 2.27 (s, 3 H), 3.25 (s, 3 H), 3.51 (s, 3 H), 3.58-3.73 (m, 4 H), 3.88 (s, 3 H), 3.98-4.09 (m, 2 H), 4.40-4.53 (m, 2 H), 6.67-7.29 (senes of m, total 9 H), 7.57-7.59 (m, 1 H), 7.91-7.93 (m, 2 H), 8.04-8.06 (m, 1 H); MS (FAB) m/z 562 (M++l).
To a stirred solution of methyl 4-[(4R)-methoxy-l-[3-methoxy-4-[N'-(2-methylphenyl) ureido] phenylacetyl]-(25)-pyrrolidinylmethoxy]benzoate (517 mg, 0.92 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixtiire was heated under reflux for 3 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was purified by recrystallization from MeOH- CHCl3-rPE to give 135 (144 mg, 29%) as a white crystalline powder. MW 547.60 mp 112- 115°C; 'H-NMR (DMSO-cL.) δ 2.04-2.17 (m, 2 H), 2.25 (s, 3 H), 3.21 (s, 3 H), 3.56-3.75 (m, 4 H), 3.79 (s, 3 H), 4.04-4.35 (m, 4 H), 6.73-7.17 (series of m, total 7 H), 7.79-7.81 (m, 1 H), 7.87-7.89 (m, 2 H), 7.99-8.01 (m, 1 H), 8.47 (s, 1 H), 8.55 (s, 1 H), 12.63 (bs, 1 H); MS (FAB) m/z 548
(M++l); Anal. Calcd for C30H33N3O71/4H20: C, 65.26; H, 6.12; N, 7.61. Found: C, 65.36; H, 6.45; N, 7.24. Example 128 4-[l-[4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenylacetyl]-(4R)-methoxy-(25)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000295_0001
A mixture of 4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenylacetic acid (476 mg, 1.50 mmol), methyl 4-[(4R)-methoxy-(25 -pyrrolidinylmethoxy]benzoate (397 mg, 1.50 mmol),
EDCHCl (344 mg, 1.79 mmol), HOBt (243 mg, 1.80 mmol) and Et3N (250 ml, 1.79 mmol) in THF (10 ml) was stirred at room temperature overnight. The mixture was diluted with H20 and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1, v/v) as eluent to give methyl 4-[l-[4-[Λ^'-(2-fluorophenyl)ureido]-3-methoxyphenylacetyl]-(4Λ)- methoxy-(25)-pyrrolidinylmethoxy]benzoate (806 mg, 95%) as a pale yellow foam. 'H-NMR (CDC13) δ 2.14-2.37 (m, 2 H), 3.28 (s, 3 H), 3.44 (s, 3 H), 3.48-3.74 (m, 4 H), 3.88 (s, 3 H), 4.02- 4.15 (m, 2 H), 4.43-4.58 (m, 2 H), 6.63-7.10 (series of m, total 7 H), 7.68-7.73 (m, 1 H), 7.89-8.02 (m, 4 H), 8.16-8.20 (m, 1 H); MS (FAB) m z 566 (M++l).
To a stirred solution of methyl 4-[l-[4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenyl acetyl]-(4Λ)-methoxy-(25)-pyrrolidinylmethoxy]benzoate (491 mg, 0.87 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 3 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was purified by recrystallization from MeOH- CHC13-IPE to give 136 (173 mg, 36%) as a white crystalline powder. MW 551.56 mp 111-116°C; 'H-NMR (DMSO-cL,) δ 2.08-2.17 (m, 2 H), 3.21 (s, 3 H), 3.56-3.73 (m, 4 H), 3.78 (s, 3 H), 4.04- 4.33 (m, 4 H), 6.74-7.22 (series of m, total 7 H), 7.87-7.89 (m, 2 H), 7.99-8.01 (m, 1 H), 8.16-8.20 (m, 1 H), 8.70 (s, 1 H), 9.18 (s, 1 H), 12.64 (br s, 1 H); MS (FAB) m/z 552 (M++l); Anal. Calcd for C29H30FN3O70.15H2O: C, 62.84; H,5.51; F,3.43; N.7.58. Found:C, 63.08; H, 5.83; F, 3.30; N, 7.15. Example 129
4- [ 1 - [4-[N '-(2-chlorophenyl)ureido] -3 -methoxyphenylacetyl] -(4R)-methoxy-(25)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000296_0001
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (460 mg, 1.37 mmol), methyl 4-[(4Λ)-methoxy-(25)-pyrrolidinylmethoxy]benzoate (365 mg, 1.38 mmol), EDCHCl (316 mg, 1.65 mmol), HOBt (223 mg, 1.65 mmol) and Et3N (230 ml, 1.65 mmol) in THF (10 ml) was stirred at room temperature overnight. The mixture was diluted with H20 and exfracted with EtOAc. The extract was washed with brine, dried over Na2S04 and evaporated.
The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1, v/v) as eluent to give methyl 4-[l-[4-[Λ^'-(2-chlorophenyl)meido]-3-methoxyphenylacetyl]-(4R)- methoxy-(25)-pyrrolidinylmethoxy]benzoate (801 mg, q. y.) as a white foam. 'H-NMR (CDC13) δ 2.13-2.36 (m, 2 H), 3.27 (s, 3 H), 3.58 (s, 3 H), 3.61-3.73 (m, 4 H), 3.88 (s, 3 H), 4.06-4.14 (m, 2 H), 4.43-4.56 (m, 2 H), 6.70-6.99 (series of m, total 5 H), 7.23-7.42 (m, 4 H), 7.90-8.00 (m, 3 H), 8.17-8.20 (m, 1 H); MS (FAB) m/z 582 (M++l). To a stined solution of methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenyl acetyl]-(4Λ)-methoxy-(25)-pyrrolidinylmethoxy]benzoate (541 mg, 0.93 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 3 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was purified by recrystallization from MeOH- CHC13-IPE to give 137 (281 mg, 53%) as a white crystalline powder. MW 568.02 mp 116-119°C; 'H-NMR (DMSO-c .) δ 2.08-2.17 (m, 2 H), 3.21 (s, 3 H), 3.56-3.73 (m, 4 H), 3.79 (s, 3 H), 4.04- 4.33 (m, 4 H), 6.75 (d, 7 = 8.3 Hz, 1 H), 6.87 (s, 1 H), 7.02 (d, 7 = 8.3 Hz, 3 H), 7.28 (t, 7 =7.8Hz, 1 H), 7.44 (d, 7 = 7.8 Hz, 1 H), 7.87-7.89 (m, 2 H), 7.96 (d, 7 = 8.3 Hz, 1 H), 8.10 (d, 7 = 8.3 Hz, 1 H), 8.89 (s, 1 H), 8.93 (s, 1 H), 12.63 (br s, 1 H); MS (FAB) m/z 568 (M++l); Anal. Calcd for
C29H30ClN3O71/4H20: C,60.84;H,5.37;C1,6.19;N,7.34. Found: C, 61.03; H, 5.56; Cl, 6.27; N, 7.03. Example 130
4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(4R)-methoxy-(25)-pyrrolidinyl methoxy]benzoic acid
OMe
Figure imgf000297_0001
A mixture of 4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (600 mg, 1.58 mmol), methyl 4-[(4Λ)-meιhoxy-(25)-pyrrolidinylmethoxy]benzoate (420 mg, 1.58 mmol), EDCHCl (364 mg, 1.90 mmol), HOBt (214 mg, 1.58 mmol) and Et3N (265 ml, 1.90 mmol) in THF (15 ml) was stirred at room temperature overnight The mixture was diluted with H20 and exfracted with EtOAc. The extract was washed with brine, dried'over Na2S04, and evaporated.
The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1, v/v) as eluent to give methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(4 ?)- methoxy-(25)-pyrrolidinylmethoxy]benzoate (1.01 g, q.y.) as a pale yellow foam. 'H-NMR (CDC13) δ 2.13-2.33 (m, 2 H), 3.27 (s, 3 H), 3.57 (s, 3 H), 3.61-3.72 (m, 4 H), 3.88 (s, 3 H), 4.05- 4.14 (m, 2 H), 4.43-4.57 (m, 2 H), 6.70-7.00 (series of m, total 5 H), 7.29-7.52 (m, 4 H), 7.92-8.01 (m, 3 H), 8.12-8.15 (m, 1 H); MS (FAB) m/z 626 (M++l).
To a stirred solution of methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-mefhoxyphenyl acetyl]-(4R)-methoxy-(25)-pyrrolidinylmethoxy]benzoate (697 mg, 1.11 mmol) in THF (8 ml) was added 0.5 N NaOH (8 ml) and the reaction mixtiire was heated under reflux for 2 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was purified by recrystallization from MeOH- CHC13-IPE to give 138 (252 mg, 37%) as a white ciystalline powder. MW 612.47 mp 125-130°C; 'H-NMR (DMSO-C .) δ 2.08-2.17 (m, 2 H), 3.21 (s, 3 H), 3.60-3.72 (m, 4 H), 3.79 (s, 3 H), 3.95- 4.33 (m, 4 H), 6.75-7.08 (series of m, total 5 H), 7.31-7.34 (m, 1 H), 7.59-7.61 (m, 1 H), 7.87-7.89 (m, 2 H), 7.93-7.96 (m, 2 H), 8.73 (s, 1 H), 8.91 (s, 1 H), 12.63 (br s, 1 H); MS (FAB) m/z 612 (M++l); Λnα/. Calcd for C29H30BrN3O7: C, 56.87; H, 4.94; Br, 13.05; N, 6.86. Found: C, 56.67; H, 4.97; Br, 13.07; N, 6.68. Example 131
4-[4,4-difluoro-l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinylmethoxy] benzoic acid
Figure imgf000298_0001
To a stirred solution of N-Boc proline methyl ester (2 .0 g, 8.15 mmol) in CH2C12 were added 3 A molecular sieves (2 g) and PDC (4.60 g, 12.2 mmol). The mixture was stirred for 3 days. The mixture was filtered through a Celiete pad and the filtrate was evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (10:1) as eluent to give methyl l-(tert- butoxycarbonyl)-4-oxopyrrolidine-2-carboxylate (1.13 g, 57%) as a colorless oil. 'H-NMR (CDC13) δ 1.46-1.48 (m, 9 H), 2.56-2.61 (m, 1 H), 2.88-3.00 (m, 1 H), 3.77 (s, 3 H), 3.82-3.88 (m, 2 H),
4.71-4.83 (m, 1 H).
To a cold (-78°C), stirred solution of methyl l-(tert-butoxycarbonyl)-4-oxopyrrolidine-2- carboxylate (1.13 g, 4.65 mmol) in CH2C12 (20 ml) was added methylDAST (1.1 ml, 11.6 mmol). The mixture was allowed to warm to room temperature. After 15 h stirring, the mixture was poured into H20 (50 ml) and extracted with EtOAc (200 ml). The extract was washed with brine (2 x 200 ml), dried over MgS0 , and evaporated. The residue was chromatographed on silica gel with CHCl3-EtOAc (20: 1) as eluent to give methyl l-(tert-butoxycarbonyl)-4,4-difluoropyrrolidine -2-carboxylate (885 mg, 72%) as a yellow oil. 'H-NMR (CDC13) δ 1.42 and 1.47 (s, each, total 9 H), 2.46 (ddd, d= 26.9 13.7, 5.1 Hz,lH), 2.62-2.78 (m, IH), 3.75-3.95 (m, 5H), 4.43-4.57 (m,lH).
To a stirred solution of methyl l-(tert-butoxycarbonyl)-4,4-difluoropyrrolidine-2-carboxylate (885 mg, 3.34 mmol) in THF (25 ml) was added 0.25 N NaOH (26.7 ml, 6.67 mmol) and the stirring was continued for 1 h. The mixture was poured into 1 N HCl (100 ml) and extracted with CHC13 (2 x 200 ml). The combined exfracts were washed with brine (100 ml), dried over MgS04, and evaporated to give l-(tert-butoxycarbonyl)-4,4-difluoropyrrolidine-2-carboxylic acid (775 mg, 92%) as a yellow crystalline solid, mp 113-117 °C; 'H-NMR (CDC13) δ 1.44 and 1.49 (s, each, total 9 H), 2.53-2.80 (m, 2 H), 3.71-3.90 (m, 2 H), 4.20-4.61 (m, 1 H); MS (FAB) m/z, 252 (M++l); Anal. Calcd for C10H15F2O4: C, 47.81; H, 6.02; N, 5.58. Found: C, 48.06; H, 6.05; N,
5.45.
To a stirred solution of N-(tert-butoxycarbonyl) 4,4-difluoroproline (3.00 g, 11.9 mmol) in THF (20 ml) was added BH3-DMS (1.1 ml, 11.9 mmol) at room temperature. The mixture was heated at reflux for 2 h. After cooling to room temperature, the mixture was concnfrated in vacuo. The residue was quenched by the addition of H20 (100 ml) and extracted with CHC13 (2 x 200 ml). The combined extracts were dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHCl3-EtOAc (4: 1) as eluent to give l-(tert-butoxycarbonyl)-4,4-difluoro-2- pyrrolidinylmethanol (2.11 g, 75%) as a colorless oil. Η-NMR (CDC13) δ 1.48 (s, 9 H), 2.04-2.55 (m, 2 H), 3.59-4.17 (m, 5 H).
To a stirred mixture of l-(tert-butoxycarbonyl)-4,4-difluoro-2-pyrrolidinylmethanol (600 mg, 2.53 mmol), methyl 4-hydroxybenzoate (462 mg, 3.03 mmol), Ph3P (795 mg, 3.03 mmol) in THF (10 ml) was added DIAD (597 ul, 3.03 mmol) at room temperature. The mixtiire was heated at reflux for 3 h with stirring. After cooling to room temperature, the mixture was concnfrated in vacuo. The residue was chromatographed on silica gel with hexane-EtOAc (4: 1) as eluent to give methyl 4-[l-(tert-butoxycarbonyl)-4,4-difluoro-2-pyrrolidinylmethoxy]benzoate (831 mg, 88%) as a colorless oil. 'H-NMR (CDC13) δ 1.48 (s, 9 H), 2.53-2.61 (m, 2 H), 3.63-4.41 (series of m, total 8 H), 6.94 (d, 7 = 8.8 Hz, 2 H), 7.99 (d, 7= 8.8 Hz, 2 H).
A mixture of methyl 4-[l-(tert-butoxycarbonyl)-4,4-difluoro-2-pyrrolidinylmethoxy] benzoate (830 mg, 2.23 mmol) and TFA (5 ml) in CH2C12 (5 ml) was stirred for 3 h and concnfrated in vacuo. The residue was made basic with sat. NaHC03 and exfracted with CHC13 (2 x 200 ml). The combined exfracts were dried over K2C03 and concnfrated in vacuo to give methyl 4-(4,4-difluoro-2-pyrrolidinylmethoxy)benzoate (550 mg, 91%) as a pale yellow solid. 'H-NMR
(CDC13) δ 2.19 (m, 1 H), 2.43 (m, 1 H), 3.19-3.41 (m, 2 H), 3.77 (m, 1 H), 3.89 (s, 3 H), 4.00-4.09 (m, 2 H), 6.92 (d, 7 = 9.0 Hz, 2 H), 7.99 (d, 7 = 9.0 Hz, 2 H); MS (FAB) m/z 272 (M++l); Anal. Calcd for C,3H15F2N03: C, 57.56; H, 5.57; N, 5.16. Found: C, 57.65; H, 5.67; N, 5.16.
A mixture of methyl 4-(4,4-difluoro-2-pyrrolidinylmethoxy)benzoate (540 mg, 1.99 mmol), 3-methoxy-4-[N'-(2-methylphenyl)meido]phenylacetic acid (626 mg, 1.99 mmol), EDC HCl (572 mg, 2.99 mmol), HOBt (cat.), and DMAP (cat.) in DMF (10 ml) was stirred overnight. The mixture was diluted with EtOAc (300 ml), washed with brine (2 x 100 ml), dried over MgS04, and concnfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (20: 1) as eluent to give methyl 4-[4,4-difluoro-l-[3-methoxy-4-[W-(2- methylphenyl)ureido] phenylacetyl]-2-pyrrolidinylmethoxy]benzoate (1.00 g, 89%) as a colorless foam. 'H-NMR (CDC13) δ 2.31 (s, 3 H), 2.47-2.63 (m, 2 H), 3.52-3.97 (series of s and m, total 10 H), 4.07-4.30 (m, 2 H), 4.67-4.69 (m, 1 H), 6.45 (s, 1 H), 6.65 (d, 7= 1.7 Hz, 1 H), 6.74-6.76 (m, 1 H), 6.84 (d, 7 = 8.8 Hz, 2 H), 7.14 (m, 2 H), 7.24 (m, 2 H), 7.52-7.54 (m, 1 H), 7.94 (d, 7= 8.8 Hz, 2 H), 8.09 (d, 7 = 8.1 Hz, 1 H).
A mixture of methyl 4-[4,4-difluoro-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl- acetyl]-2-pyrrolidinylmethoxy]benzoate (1.00 g, 1.76 mmol) and 0.25 N NaOH (14 ml, 3.50 mmol) in THF (14 ml) was stirred overnight. The mixture was acidified with 1 N HCl and extracted with CHCl3-MeOH (10: 1, 2 x 200 ml). The combined exfracts were dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (20: 1 to 10: 1) as eluent to give 139 (658 mg, 68%) as a colorless crystalline powder. MW 553.55 mp 135-140 °C; 'H-NMR
(DMSO-d6) δ 2.23 (s, 3 H), 2.49-2.73 (m, 2 H), 3.36-4.55 (series of m, 10 H), 6.73 (d, 7= 8.3 Hz, 1 H), 6.84 (s, 1 H), 6.93 (t, 7= 7.3 Hz, 1 H), 7.00 (d, 7= 8.3 Hz, 2 H), 7.10-7.16 (m, 2 H), 7.78 (d, 7= 8.3 Hz, 1 H), 7.86 (d, 7 = 8.3 Hz, 2 H), 8.00 (d, 7= 8.3 Hz, 1 H), 8.47 (s, 1 H), 8.56 (s, 1 H); MS (FAB) m/z, 554 (M++l); Anal Calcd for C29H29F2N306-3/4H20: C, 61.42; H, 5.44; N, 7.06. Found: C, 61.30; H, 5.44; N, 7.06. Example 132
4-[l-[4-[ '-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-4,4-clifluoro-2-pyrrolidinylmethoxy] benzoic acid
Figure imgf000300_0001
A mixture of methyl 4-(4,4-difluoro-2-pyrrolidinylmethoxy)benzoate (229 mg, 0.845 mmol), 4-
[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (283 mg, 0.845 mmol), EDC HCl (243 mg, 1.27 mmol), HOBt (cat), DMAP (cat.), and DMF (10 ml) was stirred overnight. The mixture was diluted with EtOAc (300 ml). The solution was washed with brine (2 x 100 ml), dried over
MgS04, and concnfrated in vacuo. The residue was chromatographed on silica gel with CHC13- EtOAc (20: 1 to 4: 1) as eluent to give methyl 4-[l-[4-[N'-(2-chlorophenyi)ureido]-3-methoxy phenylacetyl]-4,4-difluoro-2-pyrrolidinylmethoxy]benzoate (482 mg, 97%) as a colorless viscous solid. 'H-NMR (CDC13) δ 2.50-2.67 (m, 2 H), 3.54-4.71 (series of m, 13 H), 6.69 (d, 7 = 1.5 Hz, 1 H), 6.76 (d, 7 = 8.3 Hz, 1 H), 6.84 (d, 7= 8.8 Hz, 2 H), 6.98 (dt, 7= 7.8, 1.5 Hz, 1 H), 7.23-7.27 (m, 1 H), 7.33 (d, 7 = 8.3 Hz, 1 H), 7.39 (m, 2 H), 7.94 (d, 7 = 8.8 Hz, 2 H), 8.00 (d, 7= 8.3 Hz, 1 H), 8.19 (dd, 7 = 8.3, 1.5 Hz, I H).
A mixture of methyl methyl 4-[l-[4-[N'-(2-chlorophenyl)meido]-3-methoxyphenylacetyl]- 4,4-difluoro-2-pyrrolidinylmethoxy]benzoate (480 mg, 0.816 mmol), 0.25 N NaOH (6.5 ml, 1.65 mmol), and THF (20 ml) was stirred for 3 days. The mixture was poured into 1 N HCl (100 ml) and extracted with CHCl3-MeOH (5:1, 2 x 200 ml). The combined exfracts were dried over MgS04 and concntrated in vacuo. The residue was chromatographed on silica gel with CHC13- MeOH (20: 1 to 5: 1) to give 140 (270 mg, 58%) as a pale yellow amoφhous solid. MW 573.97 'H-NMR (DMSO-c .) δ 2.45-2.74 (m, 2 H), 3.63-4.83 (series of m, 10 H), 6.76 (d, 7= 8.3 Hz, 1 H), 6.87 (s, 1 H), 7.00-7.05 (m, 3 H), 7.26-7.30 (m, 1 H), 7.44 (dd, 7 =8.3, 1.2 Hz, 1 H), 7.88-7.93 (m, 2 H), 7.98 (d, 7 = 8.3 Hz, 1 H), 8.10 (d, 7= 8.3 Hz, 1 H), 8.92 (s, 1 H), 8.96 (s, 1 H); MS (FAB) m/z 574 (M++l); Anal. Calcd for C28H26C1F2N306Η20: C, 56.81; H, 4.77; N, 7.10. Found: C, 56.75; H, 4.69; N, 6.79. Example 133
4-[(2Λ,37?,45 -3,4-isopropylidenedioxy-l-[4-[N'-(2-methylphenyl)ureido]-3-methoxyphenylacetyl]- 2-pyrrolidinyl]methoxybenzoic acid
Figure imgf000301_0001
To a solution of methyl (25,3Λ,45)-l-benzyloxycarbonyl-3,4-isopropylidenedioxy-2-pyrrolidinyl carboxylate (10.7 g, 31.9 mmol) in THF (250 ml), 0.25 N NaOH (255 ml) was added. After stirring at room temperature for 24 h, the mixture was acidified with 1 N HCl and exfracted with
EtOAc. The combined exfracts were washed with brine, which were dried over Na2S04 and concenfrated in vacuo, to give (25,3Λ,45)-l-benzyloxycarbonyl-3,4-isopropylidenedioxy-2- pyrrolidinylcarboxylic acid (9.87 g, 96%) as a colorless oil. Η-NMR (CDC13) δ 1.32 (s, 3H), 1.46
(d, 7 = 2.7 Hz, 3H), 3.61(m, IH), 3.82 and 3.92 (d, 7= 12.7 Hz, IH, amide isomers), 4.58 and 4.64
(s, IH, amide isomers), 4.77 (t, 7= 5.1 Hz, IH), 4.83 and 4.89 (d, 7 = 5.9 Hz, lH,amide isomers),
5.15 and 5.19 (m, 2H, amideisomers), 7.31-7.37 (m, 5H). To a stirred solution of (25,3Λ,45)-l-benzyloxycarbonyl-3,4-isopropylidenedioxy-2-pyrrolidinyl carboxylic acid (9.87 g, 30.7 mmol) in THF (200 ml) was added BH3 DMS (6.14 ml, 61.4 mmol) at 0 °C The mixture was allowed to room temperature and then heated under reflux for 2 h. After cooling to room temperature, the mixture was concentrated in vacuo and quenched by the addition of water at 0 °C The mixture was exfracted with EtOAc. The combined exfracts were washed with water and brine, which were dried over Na2S04 and concenfrated in vacuo. The residue was chromatographed on silica gel [200 g, CHClj/MeOH (20/1)], to give (2R,3R,4S)-l -benzyloxy carbonyl-3,4-isopropylidenedioxy-2-pyrrolidinylmethanol (10.1 g, 100%) as a colorless oil. 'H- NMR (CDC13) δ 1.31 (s, 3H), 1.45 (s, 3H), 3.56-4.74 (m, IK), 5.14 (s, 2H), 7.34 (m, 5H).
To a stirred mixture of (2R,3R,45)-l-benzyloxycarbonyl-3,4-isopropylidenedioxy-2-pyrrolidinyl methanol (312 mg, 0.64 mmol), methyl >-hydroxybenzoate (67 ml, 0.70 mmol), PPh3 (184 mg, 0.70 mmol) in THF (7 ml) was added DIAD (138 ml, 0.70 mmol) at 0 °C under an atmosphere of nitrogen. The mixture was allowed to reach room temperature and stirred for 3 h. After removal of the solvent, the resulting residue was chromatographed on silica gel [10 g, n-hexane/EtOAc (4/1)], to give methyl 4-[(27?,37?,4S)-benzyloxycarbonyl-3,4-isopropylidenedioxy-2-pyrrolidinyl] methoxybenzoate (321 mg, 83%) as a colorless oil. 'H-NMR (CDC13) δ 1.01 (s, 6H), 1.03 (s, 3H), 2.23 (m, IH), 2.63 (m, IH), 3.61 (d, 7 = 12.5 Hz, IH), 3.80-4.27 (m, 4H), 4.84 (br, IH), 5.01 and 5.08 (ABq, 7 = 12.2 Hz, IH, amide isomers), 6.75-6.87 (m, 3H), 7.19-7.63 (m, 15H).
A suspension of methyl 4-[(2Λ,3R,45)-l-benzyloxycarbonyl-3,4-isopropylidenedioxy-2- pyrrolidinyl]methoxybenzoate (2.37 g, 5.76 mmol) and 10% Pd/C (240 mg ) in EtOH (170 ml) was stirred at room temperature under an atmosphere of hydrogen. After 1 day stirring, the catalyst and solvent were changed for 10% Pd/C (500 mg) and THF (50 ml). The suspension was stirred at room temperature under an atmosphere of hydrogen for 5 days. After removed the catalyst by filtration, the filtrates were concentrated in vacuo. The residue was chromatographed on silica gel [100 g, CHCVacetone (20/1)], to give methyl 4-[(2/c",3R,45)-3,4-isopropylidenedioxy-2- pyrrolidinyl]methoxybenzoate (930 mg, 53%) as a brown oil. 'H-NMR (CDC13) δ 1.35 (s, 3H), 1.50 (s, 3H), 3.02 (dd, 7 = 13.7, 4.1 Hz, IH), 3.13(d, 7= 13.7 Hz, IH), 3.58 (t, 7 = 6.3 Hz, IH), 3.88 (s, 3H), 3.90 (dd, 7= 9.3, 6.6 Hz, IH), 4.02 (dd, 7= 9.5, 3.9 Hz, IH), 4.74 (d, 7= 5.6 Hz, IH), 4.79 (m, IH), 6.90 (d, 7 = 9.0 Hz, 2H), 7.98 (d, 7 = 9.0 Hz, 2H).
A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (437 mg, 1.39 mmol), methyl 4-[(2Λ,3Λ,45)-3,4-isopropylidenedioxy-2-pyrrolidinyl]methoxybenzoate (428 mg, 1.39 mmol), EDCHCl (400 mg, 2.09 mmol) and DMAP (170 mg, 1.39 mmol) in DMF (12 ml) was stirred at room temperature for 20 h. The mixture was poured into ice water and extracted with EtOAc. The combined extracts were washed with ice water and brine. After dried over Na2S04, the extracts were concentrated in vacuo. The residue was chromatographed on silica gel [70 g, CHCVacetone (10/1)], to give methyl 4-[(2R,3R,4S -3,4-isopropylidenedioxy-l-[4-[N'-(2- methylphenyl)meido]-3-methoxyphenylacetyl]-2-pyrrolidinyl]methoxybenzoate (840 mg, 100%) as a colorless amoφhous solid IR (KBr) 3354, 2985, 2939, 1716, 1533, 1254 cm '; 'H-NMR (CDC13) δ 1.31 (s, 3H), 1.42 (s, 3H), 2.05 (s, 3H), 3.50 (s, 3H), 3.55-3.88 (m, 4H), 3.89 (s, 3H), 4.13 (m, IH), 4.67 (br, IH), 4.78 (d, 7 = 6.1 Hz, IH), 4.88 (t, 7 = 5.6 Hz, IH), 6.46 (s, IH), 6.62 (d, 7= 1.5 Hz, IH), 6.74 (m, 3H), 7.05 (s, IH), 7.14 (d, 7 = 7.3 Hz, IH), 7.23 (m, 2H), 7.57 (d, 7 = 7.8 Hz, IH), 7.91-8.08 (m, 3H); MS (ESI) m/z 604 (M++l); Anal. Calcd for C33H37N3O8 0.6H2O: C, 64.50; H, 6.27; N, 6.84. Found: C, 64.38; H, 6.18; N, 6.66.
A mixture of methyl 4-[(2Λ,3R,45)-3,4-isopropylidenedioxy-l-[4-[N'-(2-methylphenyl)ureido]-3- methoxyphenylacetyl]-2-pyrrolidinyl]methoxybenzoate (183 mg, 0.303 mmol) and g.HCl-MeOH (6 ml) was stirred at room temperature for 17 h. The mixture was concentrated in vacuo. The residue was purified on TLC [CHCla/MeOH (10/1)], to give methyl 4-[(2Λ,37?,45)-3,4-dihydroxy- l-[4-[N'-(2-methylphenyl)ureido]-3-methoxyphenylacetyl]-2-pyrrolidinyl]methoxybenzoate (162 mg, 95%) as a colorless amoφhous solid IR (KBr) 3342, 1716, 1604, 1535, 1255 cm 1; 'H-NMR (CDC13) δ 2.25 (br, 3H), 3.33-3.75 (m, 7H), 3.87 (s, 3H), 4.10 (d, 7 = 8.3 Hz, IH), 4.24 (s, 2H), 4.37 (m, 2H), 6.62-7.94 (m, 13H); MS (ESI) m/z 564 (M++l).
To a solution of methyl 4-[(2R,3R,4S)-3,4-isopropylidenedioxy-l-[4-[N'-(2-methylphenyl)ureido]- 3-methoxyphenylacetyl]-2-pynolidinyl]methoxybenzoate (490 mg, 0.812 mmol) in THF (9.8 ml), 0.25 N NaOH (9.8 ml) was added. After stirring at room temperature for 4 days, the mixture was acidified with 1 N HCl and exfracted with CHCl3-MeOH (10/1). The combined exfracts were dried over Na2S0 and concenfrated in vacuo to give 141 (445 mg, 93%) as a colorless amoφhous solid. MW 689.64 IR (KBr) 3354, 2983, 2937, 1707, 1604, 1533 cm '; 'H-NMR (DMSO-cL.) δ .24 and 1.26 (s, 3H, amide isomers), 1.26 and 1.32 (s, 3H, amide isomers), 2.24 (s, 3H), 3.40 (dd, 7 = 14.0, 5.1 Hz, IH), 3.60 (m, 2H), 3.71 (m, IH), 3.76 (s, 3H), 3.82 (s, 3H), 3.92-4.96 (m, 5H), 6.74 and 6.78 (m, IH, amide isomers), 6.83-7.16 (m, 6H), 7.79 (d, 7= 8.3 Hz, IH), 7.87 (t, 7= 9.1 Hz, 2H), 8.01 (m, IH), 8.49 (d, 7= 3.4 Hz, IH), 8.57 (s, IH); MS (FAB) m/z 590(M++1); Anal. Calcd for C32H35N3Og-2.3H20: C, 60.90; H, 6.32; N, 6.66. Found: C, 61.00; H, 6.00; N, 6.27. Example 134
4-[(2Λ, 3R,4S)-3 ,4-dihydroxy- 1 -[4- [N '-(2-methylphenyl)ureido] -3 -methoxyphenylacetyl] -2- pyrrolidinyl] methoxybenzoic acid
Figure imgf000304_0001
To a solution of methyl 4-[(2Λ,3R,45)-3,4-dihydroxy-l-[4-[N'-(2-methylphenyl)ureido]-3- methoxyphenylacetyl]-2-pyrrolidinyl]methoxybenzoate (63 mg, 0.112 mmol) in THF (0.89 ml), 0.25 N NaOH (0.89 ml) was added. After stirring at room temperature for 3 days, the mixture was acidified with 1 N HCl and extracted with CHCl3-MeOH (10/1). The combined extracts were dried over Na2S04 and concenfrated in vacuo to give 142 (54 mg, 88%) as a colorless amoφhous solid. MW 549.57 IR (KBr) 3356, 2958, 2927, 1685, 1604, 1535, 1255 cm '; 'H-NMR (DMSO-cL.) δ
2.24 (s, 3H), 3.40 (m, IH), 3.58 (s, 2H), 3.66 (dd, 7= 9.8, 6.6 Hz, IH), 3.80 (s, 3H), 3.99-4.30 (m, 5H), 5.10 (br, IH), 6.72 (d, 7= 8.1 Hz, IH), 6.85 (s, IH), 6.93 (t, 7 = 7.3 Hz, IH), 7.03 (d, 7= 8.8 Hz, 2H), 7.14 (t, 7= 8.8 Hz, 2H), 7.79 (d, 7 = 8.1 Hz, 2H), 7.86 (d, 7 = 8.8 Hz, 2H), 7.99 (d, 7 = 8.3 Hz, IH), 8.46 (s, IH), 8.56 (s, IH); MS (ESI) m/z 550(M++1); Anal. Calcd for C29H31N3O8 0.85H2O: C, 61.66; H, 5.83; N, 7.44. Found: C, 62.09; H, 5.93; N, 6.95. Example 135
4-[(27?,3R,45)-l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-3,4-isopropylidenedioxy- 2-pyrrolidinyl] methoxybenzoic acid
Figure imgf000304_0002
A mixtiire of 4-[N'-(2-chlorophenyl)meido]-3-methoxyphenylacetic acid (487 mg, 1.45 mmol), methyl 4-[(27?,3R,45)-3,4-isopropylidenedioxy-2-pyrrolidinyl]methoxybenzoate (447 mg, 1.45 mmol), EDC HCl (418 mg, 2.18 mmol) and DMAP (177 mg, 1.45 mmol) in DMF (12 ml) was stirred at room temperature for 19 h. The mixture was poured into ice water and exfracted with EtOAc. The combined exfracts were washed with ice water and brine. After dried over Na2S04, the extracts were concenfrated in vacuo. The residue was chromatographed on silica gel [70 g, CHCyacetone (10/1)], to give methyl 4-[(2Λ,3Λ,45)-l-[4-[Λ^'-(2-chlorophenyl)ureido]-3- methoxyphenylacetyl]-3,4-isopropylidenedioxy-2-pyrrolidinyl]methoxybenzoate (850 mg, 94%) as a colorless amoφhous solid IR (KBr) 3329, 2939, 1716, 1627, 1531, 1254 cm '; 'H-NMR (CDC13) δ 1.33 (s, 3H), 1.43 (s, 3H), 3.56 (s, 3H), 3.61 (s, IH), 3.64 (s, IH), 3.70 (m, IH), 3.79 (d, 7 = 10.4 Hz, IH), 3.88 (s, 3H), 4.14 (dd, 7 = 9.8, 2.2 Hz, IH), 4.40 (dd, 7= 9.8, 3.4 Hz, IH), 4.67 (s, IH), 4.80 (d, 7 = 6.1 Hz, IH), 4.90 (t, 7 = 4.6 Hz, IH), 6.65 (d, 7 = 1.7 Hz, IH), 6.71-6.84 (m, 3H), 6.98 (dt, 7 = 7.6, 1.5 Hz, IH), 7.27 (m, 2H), 7.33 (dd, 7 = 8.0, 1.2 Hz, 2H), 7.90-8.01 (m, 3H), 8.20 (dd, 7 = 8.3, 1.5 Hz, IH); MS (ESI) m/z 624 (M++l), 626 (M++3); nα/. Calcd for C32H34N308 1.4H20: C, 59.19; H, 5.71; N, 6.47. Found: C, 58.85; H, 5.35; N, 6.21.
A mixture of methyl 4-[(2Λ,3R,45)-l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-3,4- isopropylidenedioxy-2-pyrrolidinyl]methoxybenzoate (177 mg, 0.284 mmol) and g.HCl-MeOH (4 ml) was stirred at room temperature for 2 days. The mixtiire was concenfrated in vacuo. The residue was purified on TLC [CHCl^eOH (15/1)], to give methyl 4-[(2Λ,37?,45)-l-[4-[N'-(2- chlorophenyl)ureido] -3 -methoxyphenylacetyl] -3 ,4-isopropylidenedioxy-2-pyrrolidinyl] methoxybenzoate (140 mg, 85%) as a colorless amoφhous solid IR (KBr) 3338, 2949, 1712, 1623, 1604, 1533 cm '; 'H-NMR (CDC13) δ 2.27 (m, IH), 2.79 (m, IH), 3.53 (dd, 7= 10.5, 5.9 Hz, IH), 3.63 (s, 3H), 3.88 (s, 3H), 4.21 (d, 7 = 7.8 Hz, IH), 4.31 (m, 2H), 4.43 (dd, 7 = 9.8, 4.4 Hz, IH), 4.52 (t, 7= 4.6 Hz, IH), 6.71 (s, IH), 6.80 (m, 3H), 6.99 (t, 7 = 7.3 Hz, IH), 7.16 (s, IH), 7.21 (s, IH), 7.39 (d, 7 = 8.1 Hz, IH), 7.91 (d, 7= 8.6 Hz, 2H), 8.16 (d, 7 = 8.3 Hz, IH); MS (ESI) m/z 584 (M++l), 586 (M++3).
To a solution of methyl 4-[(2Λ,3R,45 -l-[4-[N-(2-chlorophenyl)meido]-3-methoxyphenylacetyl]- 3, 4-isopropylidenedioxy-2-pyrrolidinyl] methoxybenzoate (511 mg, 0.819 mmol) in THF (9.8 ml), 0.25 N NaOH (9.8 ml) was added. After stirring at room temperature for 20 h, the mixture was acidified with 1 N HCl and exfracted with CHCl3-MeOH (10/1). The combined exfracts were dried over Na2S04 and concentrated in vacuo to give 143 (504 mg, 100%) as a colorless amoφhous solid. MW 610.05 IR (KBr) 3330, 2983, 2937, 1711, 1689, 1604, 1533, 1252 cm '; 'H-NMR (DMSO-cL.) δ 1.26 (s, 3H), 1.32 (s, 3H), 3.40 (m, IH), 3.60 and3.61 (d, 7 = 2.5 Hz, 3H, amide isomers), 3.62 (m, IH), 3.78 and 3.83 (s, 3H, amideisomers), 4.16 (m, 2H), 4.42-4.98 (m, 3H), 6.74-7.15 (m, 6H), 7.28 (t, 7 = 7.3 Hz, IH), 7.43 (d, 7 = 8.1 Hz, IH), 7.78-7.97 (m, 4H), 8.08 (d, 7 = 8.3 Hz, IH), 8.89 (s, IH), 8.92 (s, IH), 12.68 (br, IH); MS (ESI) m/z 610 (M++l), 612 (M++3). Example 136
4- [(2R,3R,4S)- 1 - [4-[N'-(2-chlorophenyl)ureido] -3 -methoxyphenylacetyl] -3 ,4-ciihydroxy-2- pyrrolidinyl] methoxybenzoic acid
Figure imgf000305_0001
To a solution of methyl 4-[l-[4-[Λ/^'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-3,4- dihydroxy-2-pynolidinyImethoxy]benzoate (63 mg, 0.108 mmol) in THF (0.80 ml), 0.25 N NaOH (0.80 ml) was added. After stirring at room temperature for 3 days, the mixture was acidified with 1 N HCl and exfracted with CHCl3-MeOH (10/1). The combined exfracts were dried over Na2S04 and concenfrated in vacuo to give 144 (61 mg, 100%) as a colorless amoφhous solid. MW 569.99 IR (KBr) 3338, 1687, 1604, 1533, 1255, 1169, 1036 cm '; 'H-NMR (DMSO-c .) δ 3.59 (d, 7= 5.5 Hz, 2H), 3.61 (m, IH), 3.66 (dd, 7= 10.0, 7.1 Hz, IH), 3.80 (s, 3H), 4.00-4.33 (m, 5H), 5.10 (br, IH), 6.74 (d, 7= 8.3 Hz, IH), 6.87 (s, IH), 7.03 (m, 3H), 7.28 (t, 7= 8.3 Hz, IH), 7.43 (d, 7= 6.6 Hz, IH), 7.87 (d, 7= 8.5 Hz, 2H), 7.95 (d, 7= 8.3 Hz, IH), 8.09 (d, 7= 8.3 Hz, IH), 8.32 (s, IH), 8.89 (s, IH), 8.93 (s, IH); MS (ESI) m/z 570 (M++l), 572 (M++3); Anal. Calcd for
C28H28C1N308-1.4H20: C, 57.19; H, 5.14; N, 7.15. Found: C, 57.52; H, 5.22; N, 6.76. Example 137
4-[l-[4-[N'-(2-methylphenyl)ureido]-3-methoxyphenylacetyl]-5-(Λ)-phenyl-2-(5)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000306_0001
To a stirred solution of benzy N-Boc-pyrroglutarate (8.93 g, 28.0 mmol) in THF (100 ml) was added phenyllithium (1.0 Min Et20-cyclohexane, 33.5 ml, 33.5 mmol) at -78°C, and the resulting mixture was gradually warmed up to -40°C, then stirred overnight. aq.NH4Cl was added to the reaction mixture, THF was removed in vacuo, then exfracted with EtOAc. The organic layer was washed with water and , drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with hexane-EtOAc (4 : 1) as eluent, then recrystallized from hexane-EtOAc to give benzyl [2-(5)-(N-Boc-amino)-5-oxo-6-phenyl]pentanoate (5.02 g, 45%) as a colorless needles, mp 85-87 °C; Η-NMR (CDC13) δ 1.43 (s, 9 H), 2.07-2.19 (m, 1 H), 2.27-2.36 (m, 1 H), 2.97-3.13 (m, 2 H), 4.44 (brs, 1 H), 5.19 (dd, 7= 25.2, 12.0 Hz, 2 H), 5.19 (overlap, 1 H), 7.28-7.98 (series of m, 10 H); MS (ESI) m/z, 322 (M++H).
To a stirred solution of benzyl [2-(5)-(N-Boc-amino)-5-oxo-6-phenyl]pentanoate (2.20 g, 5.54 mmol) in CH2C12 (50 ml) was added trifluoroacetic acid (15 ml) at rt, and the resulting mixture was stirred for 2 h. The mixture was concenfrated in vacuo and poured into aq.NaHC03, then extracted with EtOAc. The organic layer was dried over anhydrous Na2S04, then concentrated in vacuo to give benzyl 5-phenyl-5-pyrroline-2-(5)-carboxylate (1.60 g, quant.) as yellowish solid. The product was used for next reaction without further purification: 'H-NMR (CDC13) δ 2.20-2.29 (m, 1 H), 2.32-2.42 (m, 1 H), 2.96-3.05 (m, 1 H), 3.12-3.21 (m, 1 H), 4.96-5.00 (m, 1 H), 5.24 (s, 2 H), 7.31-7.49 (m, 8 H), 7.88-7.91 (m, 2 H); MS (ESI) m/z, 280 (M++H).
A mixtiire of benzyl 5-phenyl-5-pyrroline-2-(5)-carboxylate (1.59 g, 5.69 mmol) and Pd/C (10%, 128 mg) in MeOH (30 ml) was stirred under H2 at rt for 28 h. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was dissolved in CH3CN-H20 (3 : 2, 25 ml), then was added di-tert-butyl dicarbonate (1.86 g, 8.54 mmol) and 1.0 -NaOH (8.54 ml, 8.54 mmol), and the resulting mixture was stirred for 30 min. The mixture was concenfrated in vacuo and poured into aq.NaHC03, then extracted with EtOAc. The organic layer was washed with water, saturated brine, drying over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (9 : 1) and recrystallized from hexane-EtOAc to give N-Boc-5-(R)-phenyl-(5)-proline (810 mg, 49%) as a colorless solid. Mp 113-117 °C; 'H- NMR (CDC13) δ 1.13 (s, 9 H), 1.43 (brs, 1 H), 1.96 (brs, 1 H), 2.09 (brs, 1 H), 2.31-2.34 (m, 1 H), 2.46 (brs, 1 H), 4.52 (brs, 1 H), 4.69 (brs, 1 H), 7.22-7.37 (m, 5 H).
To a stined solution of N-Boc-5-(R)-phenyl-2-(5)-proline (1.14 g, 3.91 mmol) in THF (20 ml) was added 10 -BH3Me2S (780 ml, 7.82 mmol) at rt, and the resulting mixture was heated under reflux for 30 min. The mixture was poured into aq.1N-HC1 and exfracted with EtOAc. The organic layer was dried over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give /V-Boc-2-(5)-hydoxymethyl-5-(Λ)- phenylpyrrolidine (1.11 g, quant.) as a colorless oil: 'H-NMR (CDC13) δ 1.19 (brs, 9 H), 1.65 (brs, 1 H), 1.83-1.90 (m, 1 H), 1.98-2.06 (m, 1 H), 2.22-2.31 (m, 1 H), 3.75-3.86 (m, 2 H), 4.16-4.19 (m, 1 H), 4.83 (t, 7 = 6.8 Hz, 1 H), 4.89 (brs, 1 H), 7.19-7.31 (m, 5 H); MS (ESI) m/z, 278 (M++H).
To a stirred solution of N-Boc-2-(5)-hydoxymethyl-5-(R)-phenylpyrrolidine (1.10 g, 3.97 mmol), triphenylphosphine (1.25 g, 4.76 mmol) and methyl 4-hydroxybenzoate (724 mg, 4.76 mmol) was added diisopropyl azodicarboxylate (955 ml, 4.76 mmol) at rt, and the resulting mixture was stirred at 60°C for 45 min. The mixture was concenfrated in vacuo, and the residue was chromatographed on silica gel with hexane-EtOAc (4 : 1) as eluent to give methyl 4-[N-Boc-5-(7?)- phenyl-2-(5)-pyrrolidinylmethoxy]benzoate (1.31 g, 80%) as a colorless oil. 'H-NMR (CDC13) δ 1.19 and 1.47 (brs, total 9 H), 2.09-2.15 (m, 3 H), 2.33-2.37 (m, 1 H), 3.94 (s, 3 H), 4.30 (brs, 1 H), 4.41 (brs, 2 H), 4.77 (brs, 1 H), 7.03 (d, 7= 8.8 Hz, 2 H), 7.24-7.36 (m, 5 H), 8.03-8.06 (m, 2 H); MS (ESI) m/z, 412 (MXH). To a stirred solution of methyl 4-[N-Boc-5-(Λ)-phenyl-2-(5)-pyrrolidinylmethoxy] benzoate (1.28 g, 3.11 mmol) in CH2C12 (30 ml) was added trifluoroacetic acid (10 ml) at rt, and the resulting mixtiire was stirred for 45 min. The mixture was concentrated in vacuo and poured into aq.NaHC03, then exfracted with CHC13. The organic layer was washed with water, drying over anhydrous Na2S04, and concenfrated in vacuo to give methyl 4-[5-(Λ)-phenyl-2-(5)-pirrolidinyl methoxy]benzate (363 mg, quant.) as yellowish oil. The product was used for next reactions without further purification. 'H-NMR (CDC13) δ 1.71-1.83 (m, 2 H), 2.03-2.10 (m, 1 H), 2.15-2.24 (m, 1 H), 3.68-3.74 (m, 1 H), 3.89 (s, 3 H), 4.01-4.09 (m, 2 H), 4.28 (t, 7= 7.2 Hz, 1 H), 6.95 (d, 7 = 8.8 Hz, 2 H), 7.22-7.27 (m, 1 H), 7.33 (t, 7= 8.0 Hz, 2 H), 7.42 (d, 7= 7.6 Hz, 2 H), 8.00 (d, 7 = 8.8 Hz, 2 H); MS (ESI) m/z, 312 (M++H) 353 (M++CH3CN).
To a stirred solution of methyl 4-[5-(Λ)-phenyl-2-(5)-pirrolidinylmethoxy]benzoate (135 mg, 0.43 mmol), 4-[N'-(2-methylphenyl)ureido]-3-methoxyphenylacetic acid (136 mg, 0.43 mmol) and NN- dimethylaminopyridine (52.9 mg, 0.43 mmol) in DMF (10 ml) was added EDCHCl (90.8 mg, 0.48 mmol) at rt, and the resulting mixture was stirred overnight. The reaction mixture was poured into water and exfracted with EtOAc. The organic layer was washed with brine, drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with hexane- EtOAc (1 : 5) as eluent to give methyl 4-[l-[4-[N'-(2-methylphenyl)ureido]-3-methoxyphenyl acetyl]-5-(Λ)-phenyl-2-(S)-pyrrolidinylmethoxy]benzoate (271 mg, quant.) as a colorless amoφhous solid. 'H-NMR (CDC13) δ 2.00-2.18 (m, 3 H), 2.31-2.41 (m, 1 H), 2.27 (s, 3 H), 3.31 (s, 2 H), 3.67 (s, 3 H), 3.89 (s, 3 H), 4.35-4.48 (m, 2 H), 4.60 (brs, 1 H), 4.92 (t, 7 = 6.8 Hz, 1 H), 6.51 (d, 7 = 8.4 Hz, 1 H), 6.62 (s, 1 H), 6.96 (d, 7= 8.8 Hz, 1 H), 7.11-7.40 (series of m, 8 H), 7.51 (d, 7 = 8.0 Hz, 1 H), 7.97-8.00 (m, 2 H); MS (ESI) m/z, 608 (M++H).
To a stirred solution of methyl 4-[l-[4-[Λ^'-(2-methylphenyl)ureido]-3-methoxyphenylacetyl]-5- (Λ)-phenyl-2-(5)-pynolidinylmeιhoxy]benzoate (243 mg, 0.40 mmol) in MeOH-THF (1 : 1, 10 ml) was added l.OM-NaOH (2.4 ml, 2.40 mmol) at rt, and the resulting mixture was heated at 60°C with stirring for 1.5 h. The reaction mixture was poured into LV-HC1, then exfracted with CHC13. The organic layer was washed with brine and dried over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) to give 145 (224 mg, 94%) as a colorless amoφhous solid. MW 593.67 'H-NMR (CD3OD), mixture of rotamars, δ 2.00-2.19 (m, 3 H), 2.28 and 2.30 (s, total 3 H), 2.45-2.49 (m, 1 H), 3.37 (dd, 7= 39, 16 Hz, 2 H), 3.77 and 3.80 (s, total 3 H), 3.92-5.18 (series of m, 4 H), 6.48-8.03 (series of m, 16 H); MS (FAB) m/z, 594 (M++H). Example 138
4-[l-[4-[Λ^'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-5-(Λ)-phenyl-2-(5)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000309_0001
To a stirred solution of methyl 4-[5-(R)-phenyl-2-(5)-pirrolidinylmethoxy]benzoate (142 mg, 0.46 mmol), 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (153 mg, 0.46 mmol) and N,N- dimethylaminopyridine (55.7 mg, 0.46 mmol) in DMF (10 ml) was added EDCHCl (95.7 mg, 0.50 mmol) at rt, and the resulting mixture was stirred overnight. The reaction mixture was poured into water and extracted with EtOAc. The organic layer was washed with brine, drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with hexane- EtOAc (1 : 5) as eluent to give methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenyl acetyl]-5-(Λ)-phenyl-2-(5)-pyrrolidinylmethoxy]benzoate (260 mg, 90%) as a colorless amoφhous solid. 'H-NMR (CDC13) δ 2.00-2.19 (m, 3 H), 2.35-2.44 (m, 1 H), 3.35 (s, 2 H), 3.76 (s, 3 H), 3.89 (s, 3 H), 4.38-4.48 (m, 2 H), 4.63 (brs, 1 H), 4.94 (t, 7 = 7.2 Hz, 1 H), 6.53 (d, 7= 8.4 Hz, 1 H), 6.66 (s, 1 H), 6.96-7.01 (m, 3 H), 7.12-7.42 (series of m, 8 H), 7.87 (d, 7 = 8.0 Hz, 1 H), 7.98 (d, 7 = 8.8 Hz, 2 H), 8.17-8.19 (m, 1 H); MS (ESI) m/z, 627(M+), 628 (M++H).
To a stirred solution of methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-5-(Λ)- phenyl-2-(5)-pyrrolidinylmethoxy]benzoate (251 mg, 0.40 mmol) in MeOH-THF (1 : 1, 10 ml) was added l.OM-NaOH (2.4 ml, 2.40 mmol) at rt, and the resulting mixture was heated at 60°C with stirring for 1.5 h. The reaction mixture was poured into 1N-HC1, then extracted with CHC13. The organic layer was washed with brine and dried over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) to give 146 (181 mg, 74%) as a colorless amoφhous solid. MW 614.09 'H-NMR (CD3OD), mixture of rotamars, δ 1.99-2.19 (m, 3 H), 2.42-2.53 (m, 1 H), 3.38 (dd, 7= 39, 15 Hz, 2 H), 3.79 and 3.80 (s, total 3 H), 3.94-5.19 (series of m, 4 H), 6.49-8.05 (series of m, 16 H); MS (FAB) m/z, 614 (M++H); Anal. Calcd for C35H34C1N306H20: C, 65.06; H, 5.62; N, 6.50. Found: C, 65.03; H, 5.75; N, 6.45. Example 139 4- [ 1 - [4- [X -(2 -bromophenyl)ureido] -3 -methoxyphenylacetyl] -5 -(Λ)-phenyl-2 -(5)-pyrrolidinyl ethoxy]benzoic acid
Figure imgf000310_0001
To a stirred solution of methyl 4-[5-(R)-phenyl-2-(5)-pirrolidinylmethoxy]benzoate (146 mg, 0.47 mmol), 4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (178 mg, 0.47 mmol) and N,N- dimethylaminopyridine (57.4 mg, 0.47 mmol) in DMF (10 ml) was added EDCHCl (99.0 mg, 0.52 mmol) at rt, and the resulting mixture was stirred overnight. The reaction mixture was poured into water and exfracted with EtOAc. The organic layer was washed with brine, drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with hexane- EtOAc (1 : 5) as eluent to give methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl acetyl]-5-(i?)-phenyl-2-(S)-pyrrolidinylmethoxy]benzoate (288 mg, 91%) as a colorless amoφhous solid. 'H-NMR (CDC13) δ 2.00-2.20 (m, 3 H), 2.34-2.43 (m, 1 H), 3.35 (s, 2 H), 3.72 (s, 3 H), 3.89 (s, 3 H), 4.38-4.49 (m, 2 H), 4.62 (brs, 1 H), 4.94 (t, 7 = 7.2 Hz, IH), 6.54 (d, 7 = 8.4 Hz, IH), 6.67 (s, 1 H), 6.91-7.05 (m, 4 H), 7.28-7.42 (series of m, 7 H), 7.51 (d, 7 = 8.0 Hz, 2 H), 7.87 (d, 7 = 8.4 Hz, 1 H), 7.99 (d, 7 = 8.8 Hz, 2 H), 8.14 (d, 7= 8.4 Hz, 2H); MS (ESI) m/z, 672 (M+), 674 (M++2).
To a stirred solution of methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-5-(R)- phenyl-2-(5)-pyrrolidinylmefhoxy]benzoate (270 mg, 0.40 mmol) in MeOH-THF (1 : 1, 10 ml) was added l.OM-NaOH (2.0 ml, 2.0 mmol) at rt, and the resulting mixture was heated at 60°C with stirring for 1 h. The reaction mixture was poured into 1/V-HCl, then exfracted with CHC13. The organic layer was washed with brine and dried over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) to givel47 (212 mg, 80%) as a colorless amoφhous solid. MW 658.54 Η-NMR (CD3OD), mixture of rotamars, δ 1.99-2.19 (m, 3 H), 2.42-2.53 (m, 1 H), 3.38 (dd, 7= 39, 16 Hz, 2H), 3.79 and 3.80 (s, total 3 H), 3.94-5.19 (series of m, 4 H), 6.49-8.00 (series of m, 16 H); MS (FAB) m/z, 658 (M+), 660 (M++2). Example 140
4-[l-[4-[N'-(2,6-dichlorophenyl)ureido]-3-meιhoxyphenylacetyl]-5-(Λ)-phenyl-2-(5)-pyrrolidinyl methoxy]benzoic acid
Figure imgf000310_0002
To a stirred solution of methyl 4-[5-(R)-phenyl-2-(5)-pirrolidinylmethoxy]benzoate (109 mg, 0.35 mmol), 4-[N'-(2,4-dιchlorophenyl)ureιdo]-3-methoxyphenylacetic acid (129 mg, 0 35 mmol) and N,N-dιmethylamιnopyπdιne (42 8 mg, 0 35 mmol) in DMF (10 ml) was added EDCHCl (73 4 mg, 0 39 mmol) at rt, and the resulting mixture was stirred for 6 h The reaction mixture was poured into water and extracted with EtOAc The organic layer was washed with bnne, drying over anhydrous Na2S04, then concentrated in vacuo The residue was chromatographed on silica gel with hexane-EtOAc (1 4) as eluent to give methyl 4-[l-[4-[N'-(2,6-dιchlorophenyl)ureιdo]-3- methoxyphenylacetyl]-5-(Λ)-phenyl-2-(5)-pyrrolιdιnylmethoxy]benzoate (208 mg, 90%) as a colorless amoφhous solid Η-NMR (CDC13) δ 2 00-2 21 (m, 3 H), 2 33-2 39 (m, 1 H), 3 31 (s, 2 H), 3 69 (s, 3 H), 3 88 (s, 3 H), 4 34-4 45 (m, 2 H), 4 59 (brs, 1 H), 4 93 (t, 7 = 6 8 Hz, 1 H), 6 47 (d, 7= 8 0 Hz, 1 H), 6 63 (s, 1 H), 6 68 (s, 1 H), 6 92-6 95 (m, 2 H), 7 12-7 41 (senes of m, 9 H), 7 96-8 01 (m, 4 H), MS (FAB) m/z, 662 (M++H)
To a stirred solution of methyl 4-[l-[4-[N'-(2,6-dιchlorophenyl)ureιdo]-3-methoxyphenylacetyl]-5- (Λ)-phenyl-2-(5)-pyrrohdιnylmethoxy]benzoate (186 mg, 0 28 mmol) in MeOH-THF (1 1, 10 ml) was added 1 Q -NaOH (1 4 ml, 1 4 mmol) at rt, and the resulting mixture was heated at 60°C with stirnng for 2 5 h The reaction mixture was poured into 1N-HC1, then exfracted with CHC13 The organic layer was washed with brine and dned over anhydrous Na2S04, then concenfrated in vacuo The residue was chromatographed on silica gel with CHCl3-MeOH (10 1) to give 148 (166 mg, 91%) as a colorless amoφhous solid MW 648 53 'H-NMR (CDC13) δ 2 00-2 18 (m, 3 H), 2 34-2 40 (m, 1 H), 3 33 (s, 2 H), 3 68 (s, 3 H), 4 37-4 47 (m, 2 H), 4 61 (brs, 1 H), 4 94 (t, 7 = 6 8 Hz, 1 H), 6 48 (d, 7= 8 0 Hz, 1 H), 6 63 (s, 1 H), 6 96 (d, 7= 8 4 Hz, 3 H), 7 12-7 38 (senes of m, 9 H), 7 95 (d, 7 = 8 0 Hz, 1 H), 8 01 (d, 7 = 8 8 Hz, 2 H), MS (FAB) m/z, 648 (M++H) Example 141
4-[l-[4-[N'-(2-bromophenyl)ureιdo]-3-methylphenylacetyl]-5-(R)-phenyl-2-(5)-pyrrohdιnyl methoxy]benzoιc acid
Figure imgf000311_0001
To a stirred solution of methyl 4-[5-(Λ)-phenyl-2-(5)-pιrrohdιnylmethoxy]benzoate (125 mg, 0 40 mmol), 4-[Λ^'-(2-bromophenyl)ureιdo]-3-methylphenylacetιc acid (146 mg, 0 40 mmol) and N,N- dimethylaminopyndme (49 0 mg, 0 40 mmol) in DMF (10 ml) was added EDCHCl (84 1 mg, 0 44 mmol) at rt, and the resulting mixture was stirred for 6 h The reaction mixture was poured into water and exfracted with EtOAc The orgamc layer was washed with bnne, drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with hexane- EtOAc (1 : 4) as eluent to give methyl 4-[l-[4-[Λ^'-(2-bromophenyl)ureido]-3-methylphenylacetyl]- 5-(7?)-phenyl-2-(5)-pyrrolidinylmethoxy]benzoate (238 mg, 90%) as a colorless amoφhous solid. 'H-NMR (CDC13) δ 1.92 (s, 3 H), 2.09-2.27 (m, 3 H), 2.42-2.50 (m, 1 H), 3.22-3.41 (m, 2 H), 3.88 (s, 3 H), 4.39 (d, 7 = 4.4 Hz, 1 H), 4.64 (brs, 1 H), 5.00 (t, 7= 6.8 Hz, 1 H), 6.72 (s, 1 H), 6.81- 6.93 (series of m, 8 H), 7.22-7.42 (series of m, 6 H), 8.01 (d, 7 = 8.4 Hz, 2 H), 8.13 (d, 7= 8.0 Hz, IH ); MS (FAB) m/z, 656 (M+), 658 (M÷+2).
To a stirred solution of methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methylphenylacetyl]-5-(R)- phenyl-2-(5)-pyrrolidinylmethoxy]benzoate (216 mg, 0.33 mmol) in MeOH-THF (1 : 1, 10 ml) was added l.OM-NaOH (1.7 ml, 1.7 mmol) at rt, and the resulting mixture was heated at 60°C with stirring for 2.5 h. The reaction mixture was poured into 1N-HC1, then extracted with CHC13. The organic layer was washed with brine and dried over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) to give 149 (166 mg, 91%) as a colorless amoφhous solid. MW 642.54 Η-NMR (CDC13) δ 2.01 (s, 3 H), 2.05-2.25 (m, 3 H), 2.43-2.48 (m, 1 H), 3.34 (dd, 7= 45, 16 Hz, 2 H), 4.38-4.45 (m, 2 H), 4.66 (brs, 1 H), 4.99 (t, 7 = 6.8 Hz, 1 H), 6.77 (s, 1 H), 6.82-6.88 (m, 2 H), 6.94 (d, 7= 8.8 Hz, 2 H), 7.15-7.55 (series of m, 10 H), 8.00 (d, 7= 8.8 Hz, 2 H), 8.14 (d, 7 = 7.2 Hz, 1 H); MS (FAB) m/z 642 (M+), 644 (M++2). Example 142 4-[l-[4-[N'-(2-methylphenyl)ureido]-3-methoxyphenylacetyl]-5-(i?)-methyl-2-(5)-pyrrolidinyl mefhoxy]benzoic acid
Figure imgf000312_0001
To a stirred solution of benzy N-Boc-pyrroglutarate (7.55 g, 23.6 mmol) in THF (100 ml) was added MeLi (1.1 A/ in Et20, 28.4 ml, 32.4 mmol) at -78°C, and the resulting mixtiire was gradually warmed up to rt, then stirred overnight. aq.NH4Cl was added to the reaction mixture,
THF was removed in vacuo, then extracted with EtOAc. The organic layer was washed with water and , drying over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with hexane-EtOAc (3 : 1) as eluent to give benzyl [2-(5)-(N-Boc- amino)-5-oxo-6-methyl]pentanoate (5.02 g, 45%) as a colorless needles, mp 85-87 °C; 'H-NMR (CDC13) δ 1.43 (s, 9 H), 1.61-2.15 (series of m, 3 H), 2.09 (s, 3H), 2.41-2.55 (m, 2 H), 4.30 (brs, 1
H), 4.70 (d, 7= 5.6 Hz, 1 H), 5.12-5.21 (m, 2H), 7.29-7.37 (m, 5 H); MS (ESI) m/z, 336 (M++H). To a stirred solution of benzyl [2-(5)-(N-Boc-amino)-5-oxo-6-methyl]pentanoate (4.46 g, 13.3 mmol) in CH2C12 (50 ml) was added trifluoroacetic acid (20 ml) at rt, and the resulting mixture was stirred for 1.5 h. The mixture was concenfrated in vacuo, and dissolved in toluene, then evaporated to give benzyl 5-methyl-5-pyrroline-2-(5)-carboxylate trifluoroacetic acid salt (5.74 g, quant.) as a crude brown oil. This compound (1.97 g, 5.94 mmol) in MeOH (30 ml) was added Pd/C (10%, 153 mg), and the resulting mixture was stirred for 3 days under H2 atomosphere. The mixtiire was filtered, and the filtrate was concenfrated in vacuo to give 5-methyl-5-pyrrolidine-2- (5)-carboxylic acid trifluoroacetic acid salt (956 mg, 66%) as a crude white solid. To a solution of this compound (939 mg, 3.86 mmol) and di-tert-buyl dicarbonate in MeCN-water (15 : 1, 16 ml) was added l.OM-NaOH (8.49 mmol, 8.49 ml) at rt, and the resulting mixture was stirred for lh. The resultiong mixture was evaporated and poured into aq.-LV-HCl, then exfracted with CHCl^eOH (5 : 1). The organic layer was dried over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (7 : 1) to give JV-Boc-5- (Λ)-methyl-(5)-proline (711 mg, 80%) as a colorless oil. Η-NMR (CD3OD) δ 1.27 (d, 7 = 6.0 Hz, 3H), 1.41-1.46 (m, 9H), 1.62-1.64 (m, IH), 1.96-2.01 (m, 2H), 2.22 (brs, IH), 3.94 (brs, IH), 4.17 (brs, IH).; MS (ESI) m/z, 230 (M++H).
To a stirred solution of N-Boc-5-(Λ)-methyl-2-(5)-proline (1.03 g, 4.49 mmol) in THF (20 ml) was added 10 -BH3Me2S (1.57 ml, 15.7 mmol) at rt, and the resulting mixture was heated under reflux for 5 h. The mixture was poured into aq. LV-HC1 and exfracted with EtOAc. The organic layer was dried over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with hexane-AcOEt (1 : 3) as eluent to give N-Boc-2-(5)- hydoxymethyl-5-(Λ)-methylpyrrolidine (838 mg, 87%) as a colorless oil: Η-NMR (CDC13) δ 1.17 (d, 7= 6.0 Hz, 3H), 1.48 (s, 9H), 1.48-1.64 (m, 2H), 1.90-2.11 (m, 2H), 3.52-3.57 (m, IH), 3.68- 3.70 (m, IH), 3.94-4.13 (m, IH).
To a stirred solution of N-Boc-2-(S)-hydoxymethyl-5-(7?)-methylpyrrolidine (820 mg, 3.81 mmol), triphenylphosphine (1.10 g, 4.19 mmol) and methyl 4-hydroxybenzoate (580 mg, 3.81 mmol) was added diisopropyl azodicarboxylate (841 ml, 4.19 mmol) at rt, and the resulting mixture was stirred at 60°C for 1 h. The mixture was concenfrated in vacuo, and the residue was chromatographed on silica gel with hexane-EtOAc (5 : 1) as eluent to give methyl 4-[N-Boc-5-(7?)- methyl-2-(5)-pyrrolidinylmethoxy]benzoate (1.32 g, 80%) as a colorless oil. Η-NMR (CDC13) δ 1.24 (brs, 3 H), 1.49 (s, 9 H), 1.55-1.70 (m, 2 H), 1.94-2.11 (m, 2 H), 3.88 (s, 3 H), 3.88 (overlap, IH), 4.06-4.20 (m, 2H), 6.93-6.96 (m, 2H), 7.97 (d, 7= 8.8 Hz, 2 H); MS (ESI) m/z, 350 (M++H). To a stirred solution of methyl 4-[N-Boc-5-(Λ)-methyl-2-(5)-pyrrolidinylmethoxy] benzoate (1.29 g, 3.70 mmol) in CH2C12 (30 ml) was added trifluoroacetic acid (10 ml) at rt, and the resulting mixture was stirred for 35 min. The mixture was concentrated in vacuo and poured into aq.NaHC03, then exfracted with CHC13. The organic layer was washed with water, drying over anhydrous Na2S04, and concenfrated in vacuo to give methyl 4-[5-(R)-methyl-2-(5)-pirrolidinyl methoxy]benzate (871 mg, 95%) as a colorless oil. The product was used for next reactions without further purification. Η-NMR (CDC13) δ 1.18 (d, 7= 6.4 Hz, 3 H), 1.30-1.40 (m, I H), 1.59-1.67 (m, 1 H), 1.87-1.97 (m, 2 H), 3.19-3.27 (m, 1 H), 3.49-3.55 (m, 1 H), 3.87 (s, 3 H), 3.89- 4.05 (m, 2 H), 6.89 (d, 7 = 8.8 Hz, 2 H), 7.96 (d, 7= 8.8 Hz, 2 H); MS (ESI) m/z, 250 (M++H)
To a stirred solution of methyl 4-[5-(R)-methyl-2-(5)-pirrolidinylmethoxy]benzoate (141 mg, 0.57 mmol), 4-[Λ^'-(2-methylphenyl)ureido]-3-methoxyphenylacetic acid (178 mg, 0.57 mmol) and N,N- dimethylaminopyridine (69.0 mg, 0.57 mmol) in DMF (10 ml) was added EDCHCl (120 mg, 0.62 mmol) at rt, and the resulting mixture was stirred overnight The reaction mixture was poured into water and exfracted with EtOAc. The organic layer was washed with brine, drying over anhydrous Na2S0 , then concenfrated in vacuo. The residue was chromatographed on silica gel with EtOAc as eluent to give methyl 4-[l-[4-[#'-(2-methylphenyl)ureido]-3-methoxyphenyl acetyl]-5-(Λ)- methyl-2-(5)-pyrrolidinylmethoxy]benzoate (297 mg, 96%) as a colorless amoφhous solid. 'H- NMR (CDC13) δ 1.24-1.34 (m, 3 H), 1.93-2.18 (series of m, 4 H), 2.28 (s, 3 H), 3.65 (s, 3 H), 3.88 (s, 3 H), 3.62-3.87 (m, 3 H), 4.11-4.38 (series of m, 3 H), 6.42-8.06 (series of m, 13 H); MS (ESI) m/z, 546 (M++H).
To a stirred solution of methyl 4-[l-[4-[N'-(2-methylphenyl)ureido]-3-methoxyphenylacetyl]-5- (R)-methyl-2-(5)-pyrrolidinylmethoxy]benzoate (279 mg, 0.51 mmol) in MeOH-THF (1 : 1, 10 ml) was added l.OM-NaOH (2.56 ml, 2.56 mmol) at rt, and the resulting mixture was heated at 60°C with stirring for 2 h. The reaction mixture was poured into 1N-HC1, then exfracted with CHC13. The organic layer was washed with brine and dried over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (15 : 1) to give 150 (269 mg, 99%) as a colorless amoφhous solid. MW 531.60 'H-NMR (CD3OD), mixture of rotamars, δ 1.28-1.35 (m, 3 H), 1.74-2.21 (series of m, 4 H), 2.28 (s, 3 H), 3.71-4.37 (series of m, 6 H), 6.76- 7.99 (series of m, 11 H); MS (ESI) m/z, 532 (M++H). Example 143
4-[/ an5-4-amino-l-[3-methoxy-4-[/V'-(2-methylphenyl)ureido]phenylacetyl]-(25)-pyiTolidinyl] methoxybenzoic acid
Figure imgf000315_0001
To a solution of methyl 4-( αns-4-amino-l-tert-butoxycarbonyl-(25)-pyrrolidinyl) methoxybenzoate (1.0 g, 2.86 mmol) and TEA (1.2 ml, 8.6 mmol) in CH2C12 (20.0 ml) was added trifluoroacetic anhydride (720 mg, 3.43 mmol) at 0°C After stirred for 2.5 hr at room temperature, water was added to the solution and extracted with CH2C12. The extract was washed with water, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc-n-hexane (1:3 ,v/v) as eluent to give methyl 4- (/rαn5-l-tert-butoxycarbonyl-4-trifluoroacetamido-(25)-pyrrolidinyl)methoxybenzoate (940 mg , 74%) as a colorless oil. 'H-NMR (CDC13) δ 1.46 (s, 9H), 2.02-2.18 (m, IH), 2.41-2.52 (m, IH), 3.30-3.45 (m, IH), 3.80-3.90 (m, IH), 3.88 (s, 3H), 4.00-4.30 (m, 3H), 4.65-4.75 (m, IH), 6.50 (br s, IH), 6.91-6.94 (m, 2H), 7.96-7.99 (m, 2H).
To a stirred solution of methyl 4-(/røns-l-tert-butoxycarbonyl-4-trifluoroacetamido-(25)- pyrrolidinyl)methoxybenzoate (470 mg, 1.05 mmol) in CH2C12 (10.0 ml) was added TFA (5.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concenfrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The extract was washed with brine, dried over Na2S04, and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 3-methoxy-4-[Λ -(2-methylphenyl)urecϋo]phenylacetic acid (314 mg, 1.0 mmol), HOBt (162 mg, 1.2 mmol), and triethylamine (417 ml, 3.0 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDCHCl (288 mg, 1.5 mmol) at 0 °C. The reaction mixture was stined at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The organic layer was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S0 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc-n-hexane (3: 1, v/v) as eluent to give methyl 4-[trans-l- [3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-4-trifluoroacetamido-(25)-pyrrolidinyl] methoxybenzoate (350 mg , 52%) as a colorless oil. 'H-NMR (CDC13) δ 2.01-2.10 (m, IH), 2.31 (s, 3H), 2.42-2.48 (m, IH), 3.45-3.50 (m, IH), 3.56-3.59 (m, 5H), 3.89 (s, 3H), 4.07-4.14 (m, 2H), 4.38-4.42 (m, IH), 4.50-4.60 (m, IH), 4.72-4.80 (m, IH), 6.33 (s, IH), 6.60-6.85 (m, 3H), 7.06- 7.26 (m, 3H), 7.48-7.52 (m, IH), 7.93-8.05 (m, 3H). To a stirred solution of methyl 4-[ ran5-l-[3-methoxy-4-[ V'-(2-methylphenyl)ureido]phenylacetyl]-
4-trifluoroacetamido-(25)-pyrrolidinyl]methoxybenzoate (150 mg, 0.23 mmol) in THF (3.0 ml) and MeOH (2.0 ml) was added IN NaOH (0.70 ml, 0.70 mmol). The mixture was stirred at 60 °C for 18 hr. The mixture was concenfrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 151
(100 mg, 81%) as a white crystalline solid. MW 532.59 mp 170-171 °C; IR (KBr) 3264, 2937,
1604, 1535, 1415, 1376, 1255, 1224, 1033 cm '; 'H-NMR (DMSO-c .) δ 1.80-1.90 (m, IH), 2.10-
2.20 (m, IH), 2.24 (s, 3H), 3.55-3.80 (m, 3H), 3.57 (s, 2H), 4.08-4.18 (m, 2H), 4.36-4.60 (m, IH),
6.72-7.16 (m, IK), 7.77-8.01 (m, 4H), 8.46 (s, IH), 8.54 (s, IH); MS (FAB) m/z 532 (M++l); Anal. calcd for C29H32N4O6-2.0H2O: C, 61.26; H, 6.38; N, 9.85. Found: C, 61.07; H, 6.32; N, 9.58.
Example 144 methyl 4-[//-αns-4-amino-l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-(25)- pyrrolidinyl] methoxybenzoate HCl salt
Figure imgf000316_0001
To a stirred solution of methyl 4-[/rans-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-
4-trifluoroacetamido-(25)-pyrrolidinyl]methoxybenzoate (200 mg, 0.31 mmol) in MeOH (4.0 mml) was added water (2.0 ml) and K2C03 (138 mg, 1.0 mml) at room temperature. After stirred for
18hr at room temperature, water was added to the mixture and exfracted with CH2C12. The extract was washed with water, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl2 (5:95 to 15:85, v/v) as eluent. The product was dissolved in EtOH (5.0 ml), and IN HCl (in EtOH) (1.0 ml, 1.0 mmol) was added thereto. The mixtiire was concenfrated in vacuo to give 152 (120 mg, 63%) as an amoφhous solid. MW 546.61 IR (KBr) 3382, 2948, 2879, 1604, 1533, 1286, 1255, 771 cm '; 'H-NMR (DMSO-cL.) δ 2.25 (s, 3H), 2.10-2.30 (m, 2H), 3.59-3.70 (m, 3H), 3.77-3.80 (m, 8H), 4.00-4.24 (m, 2H), 4.47-4.67 (m, IH), 6.70-7.16 (m, IK), 7.77-8.00 (m, 4H), 8.49 (s, IH), 8.55 (s, IH); MS (FAB) m/z 547 (M++l); Anal, calcd for C30H34N4O6 HCH.4H2O: C, 59.24; H, 6.26; N, 9.21; Cl, 5.83 Found: C, 59.42; H, 6.42; N, 9.04; Cl, 6.11. Example 145 4-[/rαn5-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-4-methylamino-(25)- pyrrolidinyl] methoxybenzoic acid
Figure imgf000317_0001
To a stirred solution of methyl 4-(frσnj-l-tert-butoxycarbonyl-4-trifluoroacetamido-(25)- pyrrolidinyl)methoxybenzoate (520 mg, 1.17 mmol) in DMF (10.0 ml) was added K2C03 (321 mg,
2.33 mmol) and Mel (330 mg, 2.33 mmol) at room temperature. The reaction mixture was stirred at 50°C for 18 hr. Water was added to the mixture and exfracted with EtOAc. The organic layer was washed with water, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc-n-hexane (1:2 ,v/v) as eluent to give methyl 4-[ rani,-l-tert-butoxycarbonyl-4-(Λ^-methyl-trifluoroacetamido)-(25)-pyrrolidinyl] methoxybenzoate (390 mg , 73%) as a colorless oil. 'H-NMR (CDC13) δ 1.46 (9H, s), 2.12-2.40 (m, 2H), 2.96 and 3.05 (each s, total 3H), 3.28-3.70 (m, 2H), 3.88 (s, 3H), 3.95-4.42 (m, 3H), 5.10-
5.40 (m, IH), 6.89-6.91 (m, 2H), 7.96-8.00 (m, 2H).
To a stirred solution of methyl 4-[/røns-l-tert-butoxycarbonyl-4-(N-methyl-trifluoro acetoamido)-(25)-pyrrolidinyl]methoxybenzoate (390 mg, 0.85 mmol) in CH2C12 (8.0 ml) was added TFA (5.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concenfrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The extract was washed with brine, dried over Na2S04, and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 3-methoxy-4-[N'-(2-methylphenyl)uredio]phenylacetic acid (279 mg, 0.89 mmol), HOBt (143 mg, 1.1 mmol), and triethylamine (246 ml, 1.77 mmol) in THF (8.0 ml) and MeCN (8.0 ml) was added EDC HCl (255 mg, 1.3 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The extract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc-n-hexane (4: 1 ,v/v) as eluent to give methyl 4- røns-l- [3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-4-(N-methyl-trifluoroacetoamido)-(25)- pyrrolidinyl]methoxybenzoate (480 mg , 82%) as a colorless oil. 'H-NMR (CDC13) δ 2.18-2.35 (m, 2H), 2.31 (s, 3H), 2.87 and 2.97 (each s, total 3H), 3.45-3.46 (m, 3H), 3.47 (s, 3H), 3.49 (s, 2H), 3.88 (s, 3H), 4.30-4.70 (m, 2H), 5.20-5.40 (m, IH), 6.38-6.43 (m, IH), 6.67-6.86 (m, 4H), 7.09-7.24 (m, 4H), 7.51-7.54 (m, IH), 7.93-8.08 (m, 3H). To a stirred solution of methyl 4-[/rαnj-l-[3-methoxy-4-[Λr'-(2-methylphenyl)ureido]phenylacetyl]-
4-(N-methyl-Λ^-trifluoroacetylamino)-(25)-pyrrolidinyl]methoxybenzoate (240 mg, 0.37 mmol) in
THF (5.0 ml) and MeOH (3.0 ml) was added IN NaOH (1.27 ml, 1.27 mmol). The mixture was stirred at 60 °C for 18 hr. The mixture was concentrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 153 (140 mg, 70%) as a white crystalline solid. MW546.61 mp 162-164 °C; IR (KBr)
3338, 1604, 1535, 1255, 1033, 755 cm '; 'H-NMR (DMSO-cL.) δ 1.85-1.95 (m, IH), 2.10-2.20 (m,
IH), 2.24 (s, 3H), 2.34 and 2.39 (each s, total 3H), 3.41-3.71 (m, 3H), 3.58 (s, IK), 3.80 (s, 3H),
4.05-4.20 (m, 2H), 4.36-4.60 (m, IH), 6.73-7.16 (m, IK), 7.77-8.01 (m, 4H), 8.45 (s, IH), 8.53 (s, IH); MS (FAB) m/z 547 (M++l); Anal calcd for C30H34N4O6-2.5H2O: C, 60.90; H, 6.64; N, 9.47.
Found: C, 61.01; H, 6.50; N, 9.31.
Example 146 methyl 4-[^ -αn5-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-4-methylamino-(25)- pyrrolidinyl]methoxybenzoate
Figure imgf000318_0001
To a stined solution of methyl 4-[^ran*-l-[3-methoxy-4-[Λ '-(2-methylphenyl)ureido]phenylacetyl]- 4-(N-methyltrifluoroacetamido)-(25)-pyrrolidinyl]methoxybenzoate (240 mg, 0.36 mmol) in THF (5.0 mml) and MeOH (5.0 ml) was added water (2.0 ml) and K2C03 (138 mg, 1.0 mml) at room temperature. After stirred for 18hr at room temperature, water was added to the mixture and extracted with CH2C12. The extract was washed with water, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl2 (5/95 to 20/80, v/v) as eluent. The product was dissolved in EtOH (5.0 ml), and IN HCl (in EtOH) (0.71 ml, 0.71 mmol) was added thereto. The mixture was concenfrated in vacuo to give 154 (180 mg, 85%) as an amoφhous solid. MW 560.64 IR (KBr) 3311, 2692, 2453, 1712, 1604, 1533 cm '; 'H-NMR (DMSO-d6) δ 2.24 (s, 3H), 2.15-2.30 (m, 2H), 2.60 (br s, 3H), 3.60-4.20 (m, 5H), 3.78-3.81 (m, 8H), 4.47-4.70 (m, IH), 6.71-7.16 (m, IK), 7.77-8.00 (m, 4H), 8.48 (s, IH), 8.55 (s, IH), 9.21 (br s, 2H); MS (FAB) m/z 561 (M++l); Anal, calcd for C31H36N406-HC1- 1.4H20: C, 59.83; H, 6.45; N, 9.00; Cl, 5.70. Found: C, 60.08; H, 6.51; N, 8.68; Cl, 5.99. Example 147 4-[ ran*-4-dimethylamino-l-[3-methoxy-4-[Af'-(2-methylphenyl)ureido]phenylacetyl]-(25)- pyrrolidinyl] methoxybenzoic acid
Figure imgf000319_0001
To a stirred solution of /rαn^- l-tert-butoxycarbonyl-(25)-hydroxymethyl-4-hycUOxypyrrolidine (2.17 g, 10.0 mmol) and imidazole (2.04 g, 30.0 mmol) in DMF (50 ml) was added TBDPS-C1 (3.03 g, 11.0 mmol) at 0 °C The reaction mixture was stined at room temperature for 18 hr. Water was added thereto, and extracted with EtOAc. The extract was washed with water, then dried over Na2S04, and concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc(3:2 ,v/v) as eluent to give trans-l-tert- butoxycarbonyl-(25)-(tert-butyldiphenylsilyloxy)methyl-4-hydroxypyrrolidine (1.5 g , 33%) as a white crystalline solid. 'H-NMR (CDC13) δ 1.03 (s9H), 1.25 and 1.32 (each s, 9H), 1.90-2.10 (m, IH), 2.30-2.40 (m, IH), 3.40-3.80 (m, 3H), 3.95-4.15 (m, 2H), 4.45-4.55 (m, IH), 7.37-7.39 (m, 6H), 7.63-7.64 (m, 4H).
To a stirred solution of frøns-l-tert-butoxycarbonyl-(25)-(tert-butyldiphenylsilyloxy) methyl-4-hydroxypyrrolidine (910 mg, 2.0 mmol) and Ph3P (628 mg, 2.4 mmol) in THF (20 ml)
I was added CBr4 (993mg, 3.0 mmol) at room temperature. The reaction mixture was stirred at room temperature for 0.5 hr. n-Hexane (40ml) was added thereto. The resulting solid was filtered off, and dried in vacuo. The residue was purified by column chromatography on silica gel with n- hexane to n-hexane-EtOAc (3:2, v/v) as eluent to give czs-4-bromo-l-tert-butoxycarbonyl-(25)- (tert-butyldiphenylsilyloxy)methylpyrrolidine (1.0 g, quant.) as a pale yellow oil. 'H-NMR (CDC13) δ 1.06 (s, 9H), 1.31 and 1.45 (each s, 9H), 2.63 (m, 2H), 3.49 (m, IH), 3.89-4.14 (m, 5H), 7.35-7.42 (m, 6H), 7.64-7.66 (, 4Hm).
To a stined solution of cw-4-bromo-l-tert-butoxycarbonyl-(25)-(tert-butyldiphenylsilyloxy) methylpyrrolidine (480 mg, 0.93 mmol) in DMF (5 ml) was added NaN3 (241 mg, 3.70 mmol) at room temperature. The reaction mixture was stirred at 70 for 3 days. Water was added thereto, and extracted with EtOAc. The extract was washed with water, then dried over Na2S04, and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. The solution of the crude residue in EtOH (10 ml) was hydrogenated over 10% Pd-C under an atmospheric pressure at room temperahire for 4 hr. The catalyst was filtered off, and the filtrate was concentrated in vacuo to give /ran5-4-amino-l-tert-butoxycarbonyl-(25)-(tert- butyldiphenylsilyloxy)methylpyrrolidine (400 mg, 95%) as a colorless oil. 'H-NMR (CDC13) δ 1.06 (s, 9H), 1.32 and 1.45 (each s, total 9H), 2.20-2.35 (m, IH), 3.05-3.18 (m, IH), 3.55-4.05 (m, 6H), 7.35-7.41 (m, 6H), 7.61-7.69 (m, 4H).
To a stined solution of /rαn5-4-amino-l-tert-butoxycarbonyl-(25)-(tert-butyldiphenylsilyloxy) methylpyrrolidine (400 mg, 0.88 mmol), AcOH (120 ml, 2.0 mmol), and 37% HCHO aq (500 ml) in MeOH (10 ml) was added NaBH3CN (11 lmg, 1.76 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 18 hr. After concenfrated in vacuo, water was added and extracted with CH2C12. The extract was dried over Na2S04> and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl2 (3 :97, v/v) as eluent to give rαns-l-tert-butoxycarbonyl-(25)-(tert-butyldiphenylsilyloxy)methyl-4-dimethylaminopyrrolidine (330 mg, 78%) as a pale yellow oil. Η-NMR (CDC13) δ 1.06 (s, 9H), 1.33 and 1.45 (each s, total 9H), 1.80-2.25 (m, 2H), 2.23 (br s, 6H), 2.95-4.05 (m, 6H), 7.36-7.39 (m, 6H), 7.63-7.65 (m, 4H).
To a stirred solution of ran5-l-tert-butoxycarbonyl-(25)-(tert-butyldiphenylsilyloxy)methyl-4- dimethylaminopyrrolidine (330 mg, 0.68 mmol) in THF (5 ml) was added TBAF (1.0 M solution in THF, 1.0 ml, 1.0 mmol) at 0 °C The reaction mixture was stirred at room temperature for 2 hr. The mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl2 (3:97 to 20:80, v/v) as eluent to give /røns-l-tert-butoxycarbonyl-4- dimethylamino-(25)-hydroxymethylpyrrolidine (180 mg, quant.) as a pale yellow oil. 'H-NMR (CDC13) δ 1.47 (s, 9H), 2.23 (s, 6H), 1.65-1.75 (m,2H),2.75-4.10 (m, 4H), 3.61 (d, 7 = 5.6 Hz, 2H).
To a stirred solution of /ron^-l-tert-butoxycarbonyl-4-dimethylamino-(25)-hydroxymethyl pyrrolidine (180 mg, 0.73 mmol), methyl 4-hydroxybenzoate (114 mg, 0.75 mmol), and Ph^ (296 mg, 1.13 mmol) in THF (10 ml) was added DIAD (227mg, 1.13 mmol) at 0 °C The reaction mixture was stirred at 70 °C for 18 hr. The mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1:2, v/v) to MeOH- CH2C12(5:95, v/v) as eluent to give methyl 4-[^ranj-l-tert-butoxycarbonyl-4-dimethylamino-(25)- pyrrolidinyl]methoxybenzoate (180 mg, 68%) as a pale yellow oil. 'H-NMR (CDC13) δ 1.46 (s, 9H), 1.80-1.95 (m, IH), 2.20-2.23 (m, IH), 2.24 (s, 6H), 2.90-2.95 (m, IH), 3.10-3.30 (m, IH), 3.50-3.65 (m, IH), 3.88 (s, 3H), 3.95-4.35 (m, 3H), 6.93-6.95 (m, 2H), 7.96-7.98 (m, 2H).
To a stirred solution of methyl 4-(frøns-l-tert-butoxycarbonyl-4-dimethylamino-(25)- pyrrolidinyl)methoxybenzoate (200 mg, 0.53 mmol) in CH2C12 (6 ml) was added TFA (3ml) at 0°C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The exfract was washed with brine ,dried over Na2S04 , and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 3-methoxy-4-[Λ -(2-methylphenyl)uredio]phenylacetic acid (166 mg, 0.53 mmol), HOBt (71 mg, 0.53 mmol), and triethylamine (140 ml, 1.10 mmol) in THF (5 ml) and MeCN (5 ml) was added EDC HCl (152mg, 0.79 mmol) at 0 °C. The reaction mixtrae was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The exfract was washed with sat. NaHC03, then dried over Na2S04, and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc to
CH2Cl2-MeOH(8:92, v/v) as eluent to give methyl 4-[/rønj-4-dimethylamino-l-[3-methoxy-4-[N'- (2-methylphenyl) ureido]phenylacetyl]-(25)-pyrrolidinyl]methoxybenzoate (260 mg , 86%) as a colorless oil. 'H-NMR (CDC13) δ 1.95-2.15 (m, 3H), 2.23 (s, 6H), 2.31 (s, 3H), 3.30-3.34 (m, IH), 3.57 (s, 2H), 3.61 (s, 3H), 3.70-3.75 ( m, IH), 4.11-4.15 (m, 2H), 4.45-4.50 (m, IH), 6.34 (s, IH), 6.72-6.88 (m, 4H), 7.08-7.24 (m, 4H), 7.51-7.53 (m, IH), 7.92-8.07 (m, 3H).
To a stirred solution of methyl 4-[^αn -4-dimethylamino-l-[3-methoxy-4-[Λ/'-(2- methylphenyl) ureido] phenylacetyl]-2-pyrrolidinyl] methoxybenzoate (260 mg, 0.45 mmol) in THF (4.0 ml) and MeOH (2.0 ml) was added IN NaOH (0.90 ml, 0.90 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concentrate in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 155 (200 mg, 79%) as a white crystalline solid. MW 560.64 mp 145-150 °C; IR (KBr) 3355, 2948, 1698, 1604, 1533, 1454, 1417, 1255, 1226, 1166, 1035, 755 cm '; 'H-NMR (DMSO- cL.) δ 1.82-1.98 (m, IH), 2.08-2.11 (m, IH), 2.20 (s, 6H), 2.25 (s, 3H), 3.40-3.60 (m, 3H), 3.64 (s, 2H), 3.82 (s, 3H), 4.01-4.16 (m, 2H), 4.36 (m, IH), 6.74-7.15 (m, IK), 7.77-8.02 (m, 4H), 8.44 (s, IH), 8.54 (s, IH); MS (FAB) m/z 561 (M++l); Anal, calcd for C31H36N406-1.2H20: C, 63.95; H, 6.65; N, 9.62. Found: C, 63.82; H, 6.72; N, 9.44. Example 148 methyl 4-[ rans,-4-dimethylamino-l-[3-methoxy-4-[N' -(2-methylphenyl)ureido]phenylacetyι]-(25)- pyrrolidinyl] methoxybenzoate HCl salt
Figure imgf000322_0001
To a stirred solution of ^rαn5'-4-[4-dimethylamino-l-[3-methoxy-4-[N'-(2-methylphenyl) ureido] phenylacetyl-(25)-pyrrolidinyl]methoxybenzoic acid (80 mg, 0.14 mmol) in toluene (4.0 ml) and MeOH (1.0 ml) was added TMSCHN2 (2.0 M in hexane, 100 ml, 0.20 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1.5 hr. The mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH- CH2C12(5:95, v/v) as eluent. The product was dissolved in EtOH (5.0 ml), and IN HCl (in EtOH) (244μ 1, , 0.244mmol) was added thereto. The mixture was concenfrated in vacuo to give 156 (72 mg, 88%) as an amoφhous solid. MW 574.67 IR (KBr) 3345, 2950, 2586, 1712, 1604, 1511, 1454, 1284, 1255, 1170, 1114, 1029, 850, 771 cm'1; Η-NMR (DMSO-cL.) δ 2.25 (s, 3H), 2.35-2.37 (m, 2H), 2.77-2.81 (m, 6H), 3.62-3.71 (m, 2H), 3.79-3.81 (m, 8H), 3.99-4.16 (m, 3H), 4.50-4.70 (m, IH), 6.74-7.16 (m, IK), 7.77-8.01 (m, 4H), 8.48 (s, IH), 8.55 (s, IK); Anal, calcd for C32H38N4O6-1.0HCl 1.2 H20: C, 60.74; H, 6.59; N, 8.85. Found: C, 61.03; H, 6.78; N, 8.33. Example 149 4- [c/.s-4-dimethylamino- 1 - [3 -methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl] -(25)- pyrrolidinyl]methoxybenzoic acid
Figure imgf000322_0002
To a stirred solution of c/s-l-tert-butoxycarbonyl-(25)-(tert-butyldiphenylsilyloxy)methyl-
4-hydroxypyrrolidine (1.82 mg, 4.0 mmol), phthalimide (647 mg, 4.4 mmol), and Ph3P (1.26 g, 4.8 mmol) in THF (20 ml) was added DIAD (889 mg, 4.4 mmol) at 0 °C The reaction mixture was stirred at room temperature for 18 hr. The mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (5/1, v/v) as eluent to give N-[cis- 1 -tert-butoxycarbonyl-(25 -(tert-butyldiphenylsilyloxy)methyl-4- pyrrolidinyl]phthalimide (1.6 g, 69%) as an amoφhous solid. Η-NMR (CDC13) δ 1.07 (s, 9H), 1.30 and 1.44 (each s, total 9H), 2.27-2.37 (m, IH), 2.94-2.96 (m, IH), 3.81-4.09 (m, 5H), 4.72
(m, IH), 7.37-7.38 (m, 6H), 7.67-7.74 (m, 6H), 7.84-7.86 (m, 2H). To a stirred solution of A -[ -l-tert-butoxycarbonyl-(25)-(tert-butylchphenylsilyloxy) methyl-4-pyrrolidinyl]phthalimide (1.60 g, 2.74 mmol) in EtOH (8 ml) was added NH2NH2»H2O(206 mg, 4.11 mmol) at room temperature. The reaction mixture was stirred at 70 for 1 hr. The mixture was concentrated in vacuo. The resulting solid was filtered off, and washed with CHC13. The filtrate was concenfrated in vacuo. The resulting solid was filtered off, and washed with CHC13. The filtrate was concenfrated in vacuo to give c/.s-4-amino-l -tert- butoxycarbonyl-(25)-(tert-butyl diphenylsilyloxy) methylpyrrolidine (1.3 g, quant) as a pale yellow oil. The crude product was used to the subsequent reaction without further purification. 'H-NMR (CDC13) δ 1.06 (s, 9H), 1.30 and 1.45 (each s, total 9H), 1.59 (m, IH), 1.85 (m, IH), 2.94 (m, IH), 3.44 (m, IH), 3.78-4.07 (m, 4H), 7.36-7.41 (m, 6H), 7.51-7.65 (m, 4H).
To a stirred solution of c/s-4-amino-l-tert-butoxycarbonyl-(25)-(tert-butyldiphenyl ilyloxy) methylpyrrolidine (1.24 g, 2.74 mmol), AcOH (374μl, 5.48 mmol), and 37% HCHO aq (1.0 ml) in MeOH (20 ml) was added NaBH3CN (345 mg, 5.48 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 18 hr. After concenfrated in vacuo, water was added and exfracted with CH2C12. The exfract was dried over Na2S04 and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl2 (3/97, v/v) as eluent to give c/5,-l-tert-butoxycarbonyl-(25)-(tert-butyldiphenylsilyloxy)methyl-4-dimethylamino pyrrolidine (1.1 g, 83%) as a pale yellow oil. 'H-NMR (CDC13) δ 1.05 (s, 9H), 1.29 and 1.45 (each s, total 9H), 1.95-2.04 (m, IH), 2.20-2.26 (m, IH), 2.27 (s, 6H), 2.54 (m, IH), 3.00-3.02 (m, IH), 3.62-4.03 (m, 4H), 7.34-7.41 (m, 6H), 7.63-7.65 (m, 4H).
To a stirred solution of cw-l-tert-butoxycarbonyl-2-(tert-butyldiphenylsilyloxy)methyl-4-dimethyl amino pyrrolidine (1.1 g, 2.27 mmol) in THF (10 ml) was added TBAF (1.0 M solution in THF) (4.5 ml, 4.5 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 hr. The mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl2 (3/97 to 20/80, v/v) as eluent to give c/.s-l-tert-butoxycarbonyl-4- dimethylamino-(25)-hydroxymethylpyrrolidine (580 mg, quant.) as a pale yellow oil. 'H-NMR (CDC13) δ 1.47 (s, 9H), 1.25-1.96 (m, 2H), 2.25 (s, 6H), 2.53-2.58 (m, IH), 3.17-4.02 (m, 5H).
To a stirred solution of cw-l-tert-butoxycarbonyl-4-dimethylamino-(25)-hydroxymethylpyrrolidine (555 mg, 2.27 mmol), methyl 4-hydroxybenzoate (380 mg, 2.5 mmol), and PhjP (1.07 g, 4.09 mmol) in THF (10 ml) was added DIAD (826 mg, 4.09 mmol) at 0 °C The reaction mixture was stirred at 70 °C for 18 hr. The mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1/2, v/v)MeOH-CH2Cl2(5/95, v/v) as eluent to give methyl 4-(c;5-l-tert-butoxycarbonyl-4-dimethylamino-(25)-pyrrolidinyl)methoxy benzoate (260 mg, 30%) as a pale yellow oil. 'H-NMR (CDC13) δ 1.45 (s, 9H), 1.70-1.90 (m, IH), 2.26 (s, 6H), 2.33 (m, IH), 2.57 (m, IH), 3.06 (m, IH), 3.85-4.23 (m, 4H), 3.88 (s, 3H), 6.93 (m, 2H), 7.95 (m, 2H).
To a stirred solution of methyl 4-(c j-l-tert-butoxycarbonyl-4-dimethylamino-(25 - pyrrolidinyl) methoxybenzoate (208 mg, 0.55 mmol) in CH2C12 (6 ml) was added TFA (3ml) at 0°C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concenfrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The exfract was washed with brine ,dried over Na2S04 , and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 3-methoxy-4-[N'-(2-methylphenyl)uredio]phenylacetic acid (173 mg, 0.55 mmol), HOBt (74 mg, 0.55 mmol), and triethylamine (153μl, 1.1 mmol) in THF (6 ml) and MeCN (6 ml) was added EDC HCl (160 mg, 0.83 mmol) at 0°C The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The extract was washed with sat. NaHC03, then dried over Na2S04, and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc-CH2Cl2- MeOH (5/95, v/v) as eluent to give methyl 4-[c/'s-4-cumethylaπuno-l-[3-methoxy-4-[Λr'-(2- methylphenyl) ureido]phenylacetyl]-(25)-pynolidinyl]methoxybenzoate (270 mg , 47%) as a colorless oil. 'H-NMR (CDC13) δ 1.95-2.04 (m, IH), 2.25 (s, 6H), 2.32 (s, 3H), 2.61 (m, IH), 3.21 (m, IH), 3.56-3.58 (m, 5H), 3.80-3.83 (m, IH), 3.88 (s, 3H), 4.18-4.20 (m, IH), 4.41-4.45 (m, 2H), 6.36 (s, IH), 6.68-6.85 (m, 4H), 7.08-7.25 (m, 4H), 7.52-7.55 (m, IH), 7.91-8.07 (m, 3H).
To a stirred solution of methyl 4-[c/'j-4-dimethylamino-l-[3-methoxy-4-[jV'-(2- methylphenyl) ureido] phenylacetyl]-(25)-pyrrolidinyl]methoxybenzoate (270 mg, 0.47 mmol) in THF (4.0 ml) and MeOH (2.0 ml) was added IN NaOH (1.0 ml, 1.0 mmol). The mixture was stirred at 70 °C for 18 hr. The mixture was concentrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 157 (170 mg, 65%) as a white crystalline solid. MW 560.64 mp 147-150 °C; IR (KBr) 3353, 2952, 1700, 1604, 1533, 1454, 1415, 1255, 1166, 1035, 755 cm '; 'H-NMR (DMSO-c .) δ :1.83-1.84 (m, IH), 2.08-2.10 (m, IH), 2.21 (br s, 6H), 2.24 (s, 3H), 3.00 (m, 2H), 3.60 (s, 2H), 3.78 (s, 3H), 3.85-4.29 (m, 4H), 6.71-7.16 (m, IK), 7.77-8.01 (m, 4Hm), 8.46 (s, IH), 8.54 (s, IH); MS (FAB) m/z 561 (M+H)+; Anal, calcd for C31H36N406»2 H20: C, 62.40; H, 6.76; N, 9.39. Found: C, 62.51; H, 6.60; N, 9.36. Example 150 methyl 4-[c/5-4-dimethylamino-l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(25)- pyrrolidinyl]methoxybenzoate HCl salt
Figure imgf000325_0001
To a stined solution of 4-[c/s-4-cumethylamino-l-[3-methoxy-4-[JV'-(2 -methylphenyl) ureido]phenylacetyl]-(25)-pyrrolidinyl]methoxybenzoic acid (80 mg, 0.14 mmol) in toluene (4.0 ml) and MeOH (1.0 ml) was added TMSCHN2 (2.0 M in hexane) (lOOμl, 0.20 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1.5 hr. The mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl2(5/95, v/v) as eluent. The product was dissolved in EtOH (5.0 ml), and IN HCl (in EtOH) (244μl, 0.244mmol) was added thereto. The mixture was concenfrated in vacuo to give 158 (75 mg, 79%) as an amoφhous solid. MW 574.67 IR (KBr) 3345, 2950, 2456, 1712, 1646, 1604, 1511, 1454, 1434, 1415, 1284, 1257, 1168, 1114, 1031, 771 cm '; 'H-NMR (DMSO-c .) δ 2.10-2.20 (m, 2H),
2.25 (s, 3H), 2.83 (m, 6H), 3.60-3.62 (m, 2H), 3.76-3.81 (m, 8H), 4.20-4.33 (m, 4H), 6.71-7.17 (m, 6H), 7.77-7.98 (m, 5H), 8.47 (s, IH), 8.55 (s, 1); MS (FAB) m/z 574 (M+H)+; Anal, calcd for C32H38N4O6 » 1.0 HCl 1.3 H20: C, 60.57; H, 6.61; N, 8.83. Found: C, 60.80; H, 6.82; N, 8.44. Example 151 4- [trans- 1 - [4-[N'-(2-chlorophenyl)ureido] -3 -methoxylphenylacetyl] -4-dimefhylamino-(25)- pyrrolidinyl] methoxybenzoic acid
VMe
Figure imgf000325_0002
To a stirred solution of methyl 4-(/rαns-l-tert-butoxycarbonyl-4-dimethylamino-(25)- pyrrolidinyl) methoxybenzoate (430 mg, 1.1 mmol) in CH2C12 (10.0 ml) was added TFA (5.0 ml) at 0 °C. The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The exfract was washed with brine, dried over Na2S0 , and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stined solution of the crude product, 4-[N'-(2-chlorophenyl)uredio]-3-methoxyphenylacetic acid (368 mg, 1.1 mmol), HOBt (162 mg, 1.2 mmol), and triethylamine (417 ml, 3.0 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDC HCl (288 mg, 1.1 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1:1, v/v) as eluent to give 4-[trans-l-[4-[N'- (2-chlorophenyl) ureido] -3 -methoxylphenylacetyl] -4-dimethylamino-(25)-pyrrolidinyl] methoxy benzoate (530 mg, 78%) as a colorless oil. 'H-NMR (CDC13) δ 1.94-1.99 (m, IH), 2.48 (s, 9H), 3.06-3.12 (m, IH), 3.33-3.38 (m, IH), 3.60 (s, 2H), 3.68 (s, 3H), 3.69-3.80 (m, IH), 3.88 (s, 3H), 4.13-4.20 (m, 2H), 4.56 (m, IH), 6.76-7.00 (m, 5H), 7.22-7.34 (m, 3H), 7.92-8.00 (m, 3H), 8.17- 8.19 (m, IH). For HCl salt: IR (KBr) 3324, 2950, 2454, 1710, 1604, 1511, 1284 cm '; 'H-NMR (DMSO-cL.) δ2.30-2.40 (m, 2H), 2.77-2.80 (m, 6H), 3.60-3.75 (m, 2H), 3.75-3.85 (m, 8H), 4.00- 4.22 (m, 3H), 4.50-4.75 (m, IH), 6.75-7.43 (m, 7H), 7.89-8.09 (m, 4H), 8.87 (s, IH), 8.91 (s, IH); MS (FAB) m/z 595 (M+H)+; Anal, calcd for C31H36N4O6CM.0HC1 1.0H2O: C, 57.23; H, 6.04; N, 8.61; Cl, 10.90. Found: C, 57.43; H, 6.08; N, 8.38; Cl, 10.73.
To a stirred solution of methyl 4-[frans-l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyl phenylacetyl]-4-dimethylamino-(2S)-pyrrolidinyl]methoxybenzoate (190 mg, 0.32 mmol) in THF (3.0 ml) and MeOH (2.0 ml) was added IN NaOH (0.64 ml, 0.64 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concentrate in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 159 (150 mg, 83%) as a white crystalline solid. MW 581.06 mp 159-161°C; IR (KBr) 3318, 2938, 1604, 1531, 1438, 1340 cm 1; Η-NMR (DMSO-cL,) δ 2.10-2.40 (m, 8H), 2.50-2.70 (m, 2H), 3.85-3.90 (m, 5H), 4.02-4.18 (m, 3H), 4.30-4.60 (m, IH), 6.75-7.43 (m, IK), 7.86-8.09 (m, 4H), 8.86 (s, IH), 8.91 (s, IH); MS (FAB) m/z 581 (M+H)+; Anal, calcd for C30H33N4O6CM.2H2O: C, 59.79; H, 5.92; N, 9.30. Found: C, 59.69; H, 5.93; N, 9.09. Example 152 4-[c/ l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxylphenylacetyl]-4-dimethylamino-(25)- pyrrolidinyl] methoxybenzoic acid
Figure imgf000327_0001
To a stirred solution of methyl 4-(c/'s-l-tert-butoxycarbonyl-4-dimethylamino-(25)- pyrrolidinyl) methoxybenzoate (1.2 g, 3.2 mmol) in CH2C12 (10.0 ml) was added TFA (5.0 ml) at 0
°C. The reaction mixture was stined at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The extract was washed with brine ,dried over Na2S04 , and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (278 mg, 1.0 mmol), 4-[N'-(2-chlorophenyl)uredio]-3-methoxyphenylacetic acid
(335 mg, 1.0 mmol), HOBt (135 mg, 1.0 mmol), and triethylamine (417 ml, 3.0 mmol) in THF (4.0 ml) and MeCN (4.0 ml) was added EDC HCl (288 mg, 1.5 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc(l:l ,v/v) as eluent to give methyl 4-[cis-l-[4-[Λ''-(2-chlorophenyl)ureido]-3-methoxylphenylacetyl]-4-dimethylamino-(25)- pyrrolidinyl] methoxybenzoate (500 mg, 84%) as a colorless oil. Η-NMR (CDC13) δ 1.98-2.50 (m, IH), 2.26 (s, 3H), 2.25-2.40 (m, IH), 2.58-2.65 (m, IH), 3.20-3.30 (m, IH), 3.60 (s, 2H), 3.64 (s, 3H), 3.80-3.90 (m, IH), 3.88 (s, 3H), 4.18-4.20 (m, IH), 4.42-4.46 (m, 2H), 6.72-7.00 (m, 4H), 7.20-7.35 (m, 5H), 7.91-7.94 (m, 3H), 8.18-8.21 (m, IH).
To a stirred solution of methyl 4-[cis-l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyl phenylacetyl]-4-dimethylamino-(25)-pyrrolidinyl]methoxybenzoate (250 mg, 0.42 mmol) in THF (5.0 ml) and MeOH (3.0 ml) was added IN NaOH (1.0 ml, 1.0 mmol). The mixture was stirred at 70 °C for 18 hr. The mixture was concenfrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 160 (170 mg, 70%) as a white crystalline solid. MW 581.06 mp 165-167 °C; IR (KBr) 3328, 1604, 1531, 1164, 1033 cm 1; Η-NMR (DMSO-cL.) δ 1.80-1.90 (m, IH), 2.20-2.50 (m, IK), 3.60-3.70 (m, 2H), 3.77-3.81 (m, 5H), 4.00-4.30 (m, 4H), 6.72-7.44 (m,7H), 7.86-8.10 (m, 4H), 8.88-8.92 (m,2H).; MS (FAB) m/z 581 (M++l); Anal, calcd for C30H33N4O6Cl l.lH2O: C, 59.87; H, 6.06; N, 9.31. Found: C, 59.65; H, .5.76; N, 9.09. Example 153
4-[c/ l-[4-[N'-(2-cUorophenyl)raeido]-3-methoxylphenylacetyl]-4-(2-naphthalenesulfonamido)- (25)-pyrrolidinyl]methoxybenzoic acid
Figure imgf000328_0001
To a stirred solution of methyl 4-(c/ l-tert-butoxycarbonyl-4-aιmno-(25)-pyrrolidinyl)methoxy benzoate (200 mg, 0.57 mmol) and TEA (317 ml, 2.3 mmol) in CHC13 (10.0 ml) was added (2- naphthyl)sulfonyl chloride (155 mg, 0.68 mmol) at 0°C The reaction mixture was stirred at room temperature for 18hr. The reaction mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (2:1, v/v) as eluent to give methyl 4-(c/5-l-tert-butoxycarbonyl-4-(2-naphthylsulfonamido)-(25)-pyiTolidinyl) methoxybenzoate (240 mg, 78%) as a pale yellow oil. •H-NMR (CDC13) δ 1.25-1.45 (br s, 9H), 1.70-1.80 (m, IH), 2.20-
2.40 (m, IH), 3.20-3.50 (m, 2H), 3.90 (s, 3H), 3.85-4.15 (m, 3H), 4.55-4.65 (m, IH), 6.90-7.10 (m,
2H), 7.58-8.04 (m, 8H), 8.43(s, IH).
To a stirred solution of methyl 4-(c 5-l-tert-butoxycarbonyl-4-(2-naphthylsulfonamido)- (25)-pyrrolidinyl) methoxybenzoate (240 mg, 0.44 mmol) in CH2C12 (5.0 ml) was added TFA (5.0 ml) at 0 °C. The reaction mixture was stirred at room temperature for 0.5 hr. The mixtiire was concenfrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The exfract was washed with brine, dried over Na2S04, and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 4-[/V-(2-chlorophenyl)uredio]-3-methoxyphenylacetic acid (147 mg, 0.44 mmol), HOBt (59 mg, 0.44 mmol), and triethylamine (275 ml, 1.9 mmol) in THF (6.0 ml) and MeCN (6.0 ml) was added EDC HCl (127 mg, 0.66 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04> and concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1:3, v/v) as eluent to give methyl 4-[cw-l-[4- [A^'-(2-cmorophenyl)ureido]-3-methoxyphenylace1yl]-4-(2-naphthalenesulfonamido)-(25)- pyrrolidinyl]methoxybenzoate (200 mg, 65%) as a colorless oil. Η-NMR (CDC13) δ 1.75-1.80 (m, IH), 2.25-2.40 (m, IH), 3.43 (s, 2H), 3.40-3.50 (m, IH), 3.60 (s, 3H), 3.65-3.75 (m, IH), 3.90 (s, 3H), 3.85-3.92 (m, IH), 3.95-4.00 (m, IH), 4.30-4.40 (m, IH), 4.65-4.75 (m, IH), 6.26 (d, 7= 9.3 Hz, IH), 6.50 (d, 7 = 8.3 Hz, IH), 6.23 (s, IH), 6.86 (d, 7= 8.8 Hz, 2H), 6.75-7.01 (m, IH), 7.23- 7.36 (m, 3H), 7.61-7.96 (m, 9H), 8.20 (d, 7= 8.1 Hz, IH), 8.43 (s, IH).
To a stirred solution of methyl methyl 4-[c/s-l-[4-[Λ^'-(2-chlorophenyl)ureido]-3-methoxylphenyl acetyl]-4-(2-naphthalenesulfonamide)-(25)-pyrrolidinyl]methoxybenzoate (200 mg, 0.26 mmol) in THF (6.0 ml) and MeOH (3.0 ml) was added IN NaOH (0.5 ml, 0.5 mmol). The mixture was stirred at 70 °C for 18 hr. The mixture was concenfrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 161 (210 mg, quant) as a white crystalline solid. MW 743.22 mp 135-142 °C; IR (KBr) 3332, 1685, 1604, 1531, 1421, 1159 cm 1; 'H-NMR (DMSO-c .) δ 1.75-1.85 (m, IH), 2.05-2.15 (m, IH), 3.05-3.15 (m, IH), 3.47 (s, 2H), 3.60-3.80 (m, 2H), 3.73 (s, 3H), 4.05-4.20 (m, 3H), 6.51 (d, 7 = 8.5 Hz, IH), 6.74-7.04 (m, 5H), 7.27-7.31 (m, IH), 7.43-7.45 (m, 2H), 7.66-8.17 (m, 9H), 8.46 (s, IH), 8.91 (d, 7= 9.5 Hz, IH); MS (FAB) m/zl43 (M*+l); Anal, calcd for C38H35N408C1S- 0.5H2O: C, 60.67; H, 4.82; N, 7.45; Cl, 4.26. Found: C, 60.77; H, 4.84; N, 7.21; Cl, 4.90. Example 154
4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-4-(2-mesitylenesulfonamido-(25)- pyrrolidinyl] methoxybenzoic acid
Figure imgf000329_0001
To a stirred solution of methyl 4-(ci5,-l-tert-butoxycarbonyl-4-amino-(25)-pyrrolidinyl) methoxy benzoate (180 mg, 0.51 mmol) and TEA (283 ml, 2.0 mmol) in CHC13 (10.0 ml) was added (2-mesitylene)sulfonyl chloride (122 mg, 0.56 mmol) at 0°C. The reaction mixture was stined at room temperature for 18hr. The reaction mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (3:1, v/v) as eluent to give methyl 4-(c/5-l-tert-butoxycarbonyl-4-(2-mesitylenesulfonamido-(25)-pyrrolidinyl) methoxy benzoate (170 mg, 62%) as a pale yellow oil. 'H-NMR (CDC13) δ 1.40 (s, 9H), 1.85-1.95 (m, IH), 2.29 (s, 3H), 2.35-2.45 (m, IH), 2.62 (s, 6H), 3.80-4.15 (m, 3H), 3.89 (s, 3H), 3.50-3.65 (m, IH), 6.94 (s, 2H), 6.94-7.00 (m, 2H), 7.99 (d, 7= 8.8 Hz, 2H).
To a stirred solution of methyl (c/5,-l-/ert-butoxycarbonyl-4-(2-mesitylenesulfonamido)-(25)- pyrrolidinyl)methoxybenzoate (170 mg, 0.32 mmol) in CH2C12 (5.0 ml) was added TFA (5.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concenfrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The extract was washed with brine ,dried over Na2S04 , and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 4-[/V,-(2-bromophenyl)uredio]-3-methoxyphenylacetic acid (121 mg, 0.32 mmol), HOBt (43 mg, 0.32 mmol), and triethylamine (139 ml, 1.0 mmol) in THF (5.0 ml) and MeCN (5.0 ml) was added EDCHCl (91 mg, 0.48 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The extract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S0 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc(l:4 ,v/v) as eluent to give methyl 4-[l-[4-[N'- (2-bromophenyl)ureido]-3-methoxyphenylacetyl]-4-(2-mesitylenesulfonamido)-(25)-pyrrolidinyl] methoxybenzoate (210 mg, 83%) as a colorless oil. 'H-NMR (CDC13) δ 1.85-1.90 (m, IH), 1.95- 2.05 (m, IH), 2.32 (s, 3H), 2.60 (s, 6H), 3.40-3.50 (m, 3H), 3.60-3.70 (m, 2H), 3.68 (s, 3H), 3.89 (s, 3H), 3.96-3.99 (m, IH), 3.35-3.45 (m, IH), 3.70-3.75 (m, IH), 6.00 (d, 7= 9.5 Hz, IH), 6.57- 7.08 (m, 9H), 7.29 -7.34 (m, IH), 7.51-7.53 (m, IH), 7.92-7.96 (m, 3H), 8.15 (d, 7= 6.8 Hz, IH).
To a stined solution of methyl 4-[l-[3-methoxy-4-[N'-(2-bromophenyl)ureido]phenylacetyl]-4-(2- mesitylenesulfonamido-(25)-pyrrolidinyl]methoxybenzoate (210 mg, 0.26 mmol) in THF (5.0 ml) and MeOH (3.0 ml) was added IN NaOH (0.47 ml, 0.47 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concenfrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 162 (180 mg, 87%) as a white crystalline solid. MW 779.70 mp 130-132 °C; IR (KBr) 3332, 1689, 1604, 1529, 1155 cm '; Η-NMR (DMSO-cL.) δ 1.70-1.85 (m, IH), 2.02-2.12 (m, IH), 2.25 (s, 3H), 2.52 (s, 6H), 3.05-3.12 (m, IH), 3.48 (s, 2H), 3.60-3.70 (m, 2H), 3.77 (s, 3H), 3.90-4.20 (m, 3H), 6.59 (d, 7 = 8.3 Hz, IH), 6.77-6.80 (m, IH), 6.95-7.01 (m, 4H), 7.31-7.35 (m, IH), 7.60 (d, 7= 8.1 Hz, IH), 7.86-7.97 (m, 5H), 8.72-8.76 (m, IH), 8.89-8.93 (m, IH); MS (FAB) m/z 779 (M+), 781 (M++2); Anal, calcd for C37H39N4O8SBr 0.5H2O: C, 56.35; H, 5.11; N, 7.10; Br, 10.13. Found: C, 56.39; H, 5.07; N, 6.89; Br, 10.25. Example 155
4-[l-[4-[Λ''-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-4-dansylamino-(25)-pyrrolidinyl] methoxybenzoic acid
Figure imgf000331_0001
To a stirred solution of methyl 4-(c/5-l-/ert-butoxycarbonyl-4-amino-(2S -pyrrolidinyl)methoxy benzoate (180 mg, 0.51 mmol) and TEA (283 ml, 2.0 mmol) in CHC13 (10.0 ml) was added dansyl chloride (155 mg, 0.68 mmol) at 0°C The reaction mixture was stirred at room temperature for 18hr. The reaction mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (2: 1, v/v) as eluent to give methyl 4-(cis-l- tert-butoxycarbonyl-4-dansylamino-(25)-pyrrolidinyl) methoxylbenzoate (200 mg, 73%) as a pale yellow oil. 'H-NMR (CDC13) δ 1.34 (s, 9H), 1.50-1.60 (m, IH), 2.15-2.25 (m, IH), 2.87 (s, 6H),
3.15-3.22 (m, IH), 3.35-3.45 (m, IH), 3.48-3.52 (m, IH), 3.80-4.10 (m, 3H), 3.91 (s, 3H), 7.01- 7.25 (m, 4H), 7.50-7.53 (m, IH), 8.03 (d, 7= 8.7 Hz, 2H), 8.16 (d, 7= 8.5 Hz, IH), 8.28 (d, 7 =
7.1 Hz, IH), 8.53 (d, 7= 8.5 Hz, IH).
To a stirred solution of methyl 4-(c;'5'-l-tert-butoxycarbonyl-4-dansylamino-(25)-pyrrolidinyl) methoxybenzoate (200 mg, 0.34 mmol) in CH2C12 (5.0 ml) was added TFA (5.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The extract was washed with brine ,dried over Na2S04 , and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 4- [ V-(2-bromophenyl)uredio]-3-methoxyphenylacetic acid (129 mg, 0.34 mmol), HOBt (46 mg, 0.34 mmol), and triethylamine (142 ml, 1.0 mmol) in THF (5.0 ml) and MeCN (5.0 ml) was added EDC HCl (98 mg, 0.51 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-Et0Ac(l:4 ,v/v) as eluent to give methyl 4-[l-[4-[JV-(2-bromophenyl) ureido]-3- methoxyphenylacetyl]-4-dansylamino-(25)-pyrrolidinyl]methoxybenzoate (250 mg, 88%) as a colorless oil. 'H-NMR (CDC13) δ 1.55-1.65 (m, IH), 2.15-2.25 (m, IH), 2.87 (s, 6H), 3.20-3.35 (m, 3H), 3.50-3.55 (m, IH), 3.67 (s, 3H), 3.78-3.81 (m, IH), 3.88-3.93 (m, IH), 3.91 (s, 3H), 4.28- 4.31 (m, IH), 4.65-4.70 (m, IH), 6.35 (d, 7= 9.5 Hz, IH), 6.54 (d, 7 = 8.5 Hz, IH), 6.63 (s, IH), 6.90-7.13 (m, 6H), 7.22-7.31 (m, 2H), 7.50-7.56 (m, 2H), 7.88 (d, 7 = 8.0 Hz, IH), 7.99 ( d, 7 = 9.0 Hz, IH), 8.13-8.16 (m, 2H), 8.27 (d, 7 = 7.6 Hz, IH), 8.56 (d, 7= 8.3 Hz, IH).
To a stirred solution of methyl 4-[l-[4-[Λ^-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-4- dansylamino-25-pyrrolidinyl]methoxybenzoate (250 mg, 0.29mmol) in THF (5.0 ml) and MeOH (3.0 ml) was added IN NaOH (0.52 ml, 0.52 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concenfrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 163 (230 mg, 94%) as a green crystalline solid. MW 830.74 mp 138-141 °C; IR (KBr) 3340, 2940, 1604, 1527, 1421, 1162, 1145 cm '; 'H-NMR (DMSO-c .) δ 1.70-1.80 (m, IH), 1.98-2.06 (m, IH), 2.81 (s, 6H), 3.00-3.10 (m, IH), 3.39-3.40 (m, 2H), 3.50-3.80 (m, 3H), 3.76 (s, 3H), 3.90-4.15 (m, 2H), 6.52 (d, 7 = 9.0 Hz, IH), 6.73-7.00 (m, 4H), 7.22-7.35 (m, 2H), 7.55-7.64 (m, 3H), 7.83-8.48 (m, 8H), 8.71-8.76 (m, IH), 8.88-8.92 (m, IH); MS (FAB) m/z 830 (M+), 832 (M++2); Anal, calcd for C40H40N5O8BrS 0.7H2O: C,56.97; H,.95; N,8.30;Br,9.47.Found:C,57.06; H, 4.86; N, 7.98; Br, 9.66. Example 156 4-[4-methanesulfonamido-l-[4-[Λ^'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(25)- pyrrolidinyl] methoxybenzoic acid
Figure imgf000332_0001
To a stirred solution of methyl 4-(c/5,-4-amino-l-tert-butoxycarbonyl-(25)-pyrrolidinyl)methoxy benzoate (180 mg, 0.51 mmol) and TEA (283 ml, 2.0 mmol) in CHC13 (10.0 ml) was added methanesulfbnyl chloride (88 mg, 0.77 mmol) at 0°C. The reaction mixture was stirred at room temperature for 18hr. The reaction mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1: 1, v/v) as eluent to give methyl 4-(c/\s,-l-tert-butoxycarbonyl-4-methanesulfonamido-(25)-pyrrolidinyl) methoxybenzoate (150 mg, 69%) as a pale yellow oil. 'H-NMR (CDC13) δ 1.45 (s, 9H), 1.98-2.08 (m, IH), 2.52-2.65 (m, IH), 2.99 (s, 3H), 3.40-3.50 (m, IH), 3.55-3.80 (m, IH), 3.89 (s, IH), 4.00-4.70 (m, 4H), 6.98-7.00 (m, 2H), 8.00 (d, 7 = 8.8 Hz, 2H).
To a stirred solution of methyl 4-(c/ l-tert-butoxycarbonyl-4-methanesulfonamido-(25)- pyrrolidinyl) methoxybenzoate (150 mg, 0.43 mmol) in CH2C12 (5.0 ml) was added TFA (5.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The exfract was washed with brine ,dried over Na2S04 , and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 4-[Λ^-(2-bromophenyl)uredio]-3-methoxyphenylacetic acid (163 mg, 0.42 mmol), HOBt (58 mg, 0.43 mmol), and triethylamine (179 ml, 1.3 mmol) in THF (5.0 ml) and MeCN (5.0 ml) was added EDC HCl (144 mg, 0.75 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1 :4, v/v) to EtOH-EtOAc (10%, v/v) as eluent to give methyl 4-[4-methanesulfonamido-l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl acetyl]-(25)-pyrrolidinyl] methoxybenzoate (210 mg, 73%) as a colorless oil. 'H-NMR (CDC13) δ 1.95-2.00 (m, IH), 2.55-2.65 (m, IH), 2.17 (s, 3H), 3.55-3.70 (m, IH), 3.60 (s, 2H), 3.67 (s, 3H), 3.85-3.90 (m, IH), 3.89 (s, 3H), 3.95-4.18 (m, 2H), 4.45-4.55 (m, IH), 4.70-4.80 (m, IH), 5.87 (d, 7 = 9.3 Hz, IH), 6.73-6.95 (m, 5H), 7.09 (s, 2H), 7.28-7.33 (m, IH), 7.51 (d, 7 = 8.0 Hz, IH), 7.93-7.97 (m, 3H), 8.13 (d, 7= 8.3 Hz, IH).
To a stirred solution of methyl 4-[4-methanesulfonamido-l-[4-[N'-(2-bromophenyl) ureido]-3-methoxyphenylacetyl]-(25)-pyrrolidinyl]methoxybenzoate (210 mg, 0.3 mmol) in THF (5.0 ml) and MeOH (3.0 ml) was added IN NaOH (0.8 ml, 0.8 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concenfrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 164 (170 mg, 83%) as a white crystalline solid. MW 675.55 mp 125-128 °C; IR (KBr) 3353, 1689, 1604, 1529, 1419, 1155 cm '; 'H-NMR (DMSO-cL.) δ 1.88-2.00 (m, IH), 2.35-2.45 (m, IH), 2.96 (m, 3H), 3.15-3.23 (m, IH), 3.60 (s, 2H), 3.50-3.70 (m, IH), 3.78 (s, 3H), 3.80-3.90 (m, IH), 3.95- 4.05 (m, IH), 4.10-4.30 (m, 2H), 6.71-7.03 (m, 4H), 7.32 (m, IH), 7.45 (d, 7= 6.8 Hz, IH), 7.60 (d, 7= 7.8 Hz, IH), 7.87-7.95 (m, 4H), 8.74 (s, IH), 8.92 (s, IH); MS (FAB) m/z 675 (M+), 677 (M++2); ; Anal, calcd for C29H31N4O8BrS-0.6H2O: C, 50.75; H, 4.73; N, 8.16. Found: C, 51.04; H, 4.62; N, 7.79. Example 157 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(25 -octahydroindolylmethoxy] benzoic acid X M Mee HHX COOH HHO O OMMXee - ^"y - ^ 1 5
To a stirred solution of octahydroindole-(25)-carboxylic acid (3.00 g, 17.7 mmol) in dioxane (20 ml) was added 1 N NaOH (45 ml) and the solution was stirred at 0°C To the mixture was added
(Boc)20 (4.26 g, 19.5 mmol) in dioxane (25 ml) at 0°C and the reaction mixture was stirred at room temperature for 1 day. The mixture was acidified with 1 N HCl and extracted with EtOAc.
The exfract was washed with brine, dried over Na2S04 and evaporated to give l-(tert-butoxy carbonyl)octahydroindole-(25)-carboxylic acid (4.78 g, q.y.) as a colorless solid, mp 130-132 °C;
'H-NMR (CDC13) δ 1.10-1.46 (series of s and m, total 14 H), 1.65-1.76 (m, 3 H), 1.90-2.18 (m, 2
H), 2.26-2.35 (m, 1 H), 3.77-3.86 (m, 1 H), 4.22-4.34 (m, 1 H); MS (ESI) m/z 270 (M++l).
To a cooled (0°C), stirred solution of l-(tert-butoxycarbonyl)octahydroindole-(25)- carboxylic acid (1.00 g, 3.71 mmol) in THF (10 ml) was added BH3DMS (530 ml, 5.59 mmol) and the reaction mixture was stirred at room temperature overmght. The mixture was quenched by H20 and extracted with EtOAc. The extract was washed with brine, dried over Na2S0 and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1, v/v) as eluent to give l-(tert-butoxycarbonyl)octahydroindole-(25)-methanol (940 mg, 99%) as a colorless oil. 'H-NMR (CDC13) δ 1.05-1.30 (m, 4 H), 1.47 (s, 9 H), 1.49-1.74 (m, 4 H), 1.82- 1.93 (m, 3 H), 2.19-2.26 (m, 1 H), 3.56-3.61 (m, 1 H), 3.70-3.75 (m, 2 H), 3.94-3.96 (m, 1 H); MS (FAB) m/z 256 (M++l).
To a cooled (0°C), stirred solution of methyl 4-hydroxybenzoate (560 mg, 3.68 mmol), 1- (tert-butoxycarbonyl)octahydroindole-(25)-methanol (940 mg, 3.68 mmol) and Ph3P (1.16 g, 4.42 mmol) in THF (20 ml) was added DIAD (870 ml, 4.42 mmol) and the reaction mixture was heated under reflux for 8 hr. After cooled to room temperature, the mixture was evaporated. The residue was purified by column chromatography on silica-gel with n-hexane-EtOAc (5: 1, v/v) as eluent to give methyl 4-[l-(tert-butoxycarbonyl)-(25)-octahydroindolylmethoxy]benzoate (1.16 g, 81%) as a colorless oil. 'H-NMR (CDC13) δ 1.14-1.47 (series of s and m, total 13 H), 1.60-2.13 (series of m, total 6 H), 2.22-2.28 (m, 1 H), 3.75-3.91 (series of s and m, total 4 H), 4.06-4.18 (m, 2 H), 4.37 (m, 1 H), 6.94-6.96 (m, 2 H), 7.96-7.98 (m, 2 H); MS (FAB) m/z 390 (M++l).
To a stirred solution of methyl 4-[l-(tert-butoxycarbonyl)-(25)-octahydroindolylmethoxy] benzoate (1.16 g, 2.98 mmol) in CH2C12 (10 ml) was added TFA (10 ml) and the reaction mixture was stirred at room temperature for 2 hr. The mixture was concenfrated in vacuo, made basic by sat. NaHC03, and extracted with CHC13. The exfract was washed with brine, dried over K2C03) and evaporated to give methyl 4-[(25)-octahydroindolylmethoxy]benzoate (860 mg, q.y.) as a brown oil. 'H-NMR (CDC13) δ 1.23-1.78 (series of m, total 10 H), 2.00-2.09 (m, 2 H), 3.14-3.18 (m, 1 H), 3.55-3.62 (m, 1 H), 3.88 (s, 3 H), 3.96-4.06 (m, 2 H), 6.92 (d, 7= 9.1 Hz, 2 H), 7.97 (d, 7 = 9.1 Hz, 2 H); MS (FAB) m/z 290 (M++l).
A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (298 mg, 0.95 mmol), methyl 4-[(25)-octahydroindolylmefhoxy]benzoate (274 mg, 0.95 mmol), EDCHCl (218 mg, 1.14 mmol), HOBt (154 mg, 1.14 mmol), Et3N (160 ml, 1.15 mmol) in THF (7 ml) was stirred at room temperature overnight. The mixture was diluted with H20 and exfracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 50: 1, v/v) as eluent to give methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(25)-octahydroindolyl methoxy]benzoate (532 mg, 96%) as a white foam. 'H-NMR (CDC13) δ 1.13-2.05 (series of m, total 9 H), 2.14-2.24 (m, 2 H), 2.26 (s, 3 H), 3.60 (s, 2 H), 3.62 (s, 3 H), 3.80-3.85 (m, 1 H), 3.88 (s, 3 H), 4.27-4.37 (m, 3 H), 6.62 (s, 1 H), 6.74-6.76 (m, 2 H), 6.91 (d, 7= 8.8 Hz, 2 H), 7.09-7.13 (m, 1 H), 7.20-7.24 (m, 3 H), 7.55 (d, 7 = 7.8 Hz, 1 H), 7.94 (d, 7= 8.8 Hz, 2 H), 8.04 (d, 7= 7.8 Hz, 1 H); MS (FAB) m/z 586 (M++l).
To a stirred solution of methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl acetyl]-(25)-octahydroindolylmethoxy]benzoate (532 mg, 0.91 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 3 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl, and the resulting precipitate was collected. The crude solid was recrystallized from MeOH-CHCl3-IPE to give 165 (278 mg, 54%) as a white crystalline powder. MW 571.66 mp 130-134°C; 'H-NMR (DMSO-cL.) δ 1.16-2.10 (series of m, total 9 H), 2.15-2.30 (series of s and m, total 4 H), 3.55-3.79 (m, 3 H), 3.81 (s, 3 H), 3.90-3.95 (m, 1 H), 4.17-4.23 (m, 2 H), 4.34-4.36 (m, 1 H), 6.72-6.74 (m, 1 H), 6.87-6.88 (m, 1 H), 6.91-6.95 (m, 1 H), 7.03 (d, 7 = 8.8 Hz, 2 H), 7.10-7.16 (m, 2 H), 7.78-7.80 (m, 1 H), 7.87 (d, 7= 8.8 Hz, 2 H), 7.98-8.00 (m, 1 H), 8.45 (s, 1 H), 8.54 (s, 1 H), 12.61 (br s, 1 H); MS (FAB) m/z 572 (M++l); Anal. Calcd for C33H37N306 1/4H20: C, 68.79; H, 6.56; N, 7.29. Found: C, 68.70; H, 6.82; N, 6.97. Example 158 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(2S)-octahydroindolylmethoxy] benzoic acid
Figure imgf000336_0001
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (307 mg, 0.92 mmol), methyl 4-[(25)-octahydroindolylmethoxy]benzoate (265 mg, 0.92 mmol), EDCHCl (211 mg, 1.10 mmol), HOBt (148 mg, 1.10 mmol), and Et3N (153 ml, 1.10 mmol) in THF (7 ml) was stirred at room temperature overnight. The mixture was diluted with H20 and exfracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100:1 to 50:1, v/v) as eluent to give methyl 4-[ 1 -[4- [N '-(2-chlorophenyl)ureido] -3 -methoxyphenylacetyl] -(25)-octahydroindolyl methoxy]benzoate (550 mg, 99%) as a white foam. 'H-NMR (CDC13) δ 1.15-2.02 (series of m, total 9 H), 2.17-2.33 (m, 2 H), 3.58 (s, 3 H), 3.62 (s, 2 H), 3.84-3.90 (series of s and m, total 4 H), 4.06-4.40 (m, 3 H), 6.71-6.74 (m, 2 H), 6.88-7.00 (m, 3 H), 7.21-7.30 (m, 2 H), 7.62 (s, 2 H), 7.91- 7.95 (m, 3 H), 8.17-8.20 (m, 1 H); MS (FAB) m/z 606 (M++l).
To a stirred solution of methyl 4-[l-[4-[Λ '-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(25 - octahydroindolylmethoxy]benzoate (550 mg, 0.91 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl, and the resulting precipitate was collected. The crude solid was recrystallized from MeOH-CHCl3-IPE to give 166 (286 mg, 53%) as a white crystalline powder. MW 388.29 mp 133-136°C; 'H-NMR (DMSO-cL.) δ 1.16-2.10 (series of m, total 10 H), 2.24-2.27 (m, 1 H), 3.55-3.75 (m, 2 H), 3.80 (s, 3 TT), 3.90-3.96 (m, 1 H), 4.17-4.23 (m, 2 H), 4.34- 4.36 (m, 1 H), 6.73-6.75 (m, 1 H), 6.88 (d, 7= 1.5 Hz, 1 H), 6.99-7.05 (m, 3 H), 7.25-7.30 (m, 1 H), 7.43 (dd, 7 = 1.5, 8.1 Hz, 1 H), 7.87-7.89 (m, 2 H), 7.95 (d, 7 = 8.1 Hz, 1 H), 8.08 (dd, 7= 1.5, 8.3 Hz, 1 H), 8.88 (s, 1 H), 8.92 (s, 1 H), 12.61 (br s, 1 H); MS (FAB) m/z 592 (M++l); Anal. Calcd for C32H34C1N306T/4H20: C.64.42; H, 5.83; N, 7.04; Cl, 5.94. Found: C,64.55; H,6.09; N,6.64; Cl.5.93. Example 159
4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(25)-octahydroindolylmethoxy] benzoic acid
Figure imgf000337_0001
A mixture of 4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (457 mg, 1.21 mmol), methyl 4-[(25)-octahydroindolylmethoxy]benzoate (320 mg, 1.21 mmol), EDCHCl (277 mg, 1.44 mmol), HOBt (196 mg, 1.45 mmol), and Et3N (200 ml, 1.43 mmol) in THF (7 ml) was stirred at room temperature overnight The mixture was diluted with H20 and exfracted with
EtOAc. The exfract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1, v/v) as eluent to give methyl 4-[l-[4-[Λr'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl ]-(25)-octahydroindolyl methoxy]benzoate (423 mg, 54%) as a white foam. 'H-NMR (CDC13) δ 1.15-1.89 (series of m, total 8 H), 1.96-2.02 (m, 1 H), 2.16-2.32 (m, 2 H), 3.63 (s, 2 H), 3.65 (s, 3 H), 3.82-3.86 (m, 1 TT), 3.88 (s, 3 H), 4.30-4.39 (m, 3 H), 6.75-6.77 (m, 2 TT), 6.88-6.93 (m, 3 TT), 7.24-7.31 (m, 1 H), 7.37- 7.50 (m, 3 H), 7.91-7.99 (m, 3 H), 8.12-8.15 (m, 1 H); MS (FAB) m/z 650 (M++l).
To a stirred solution of methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl acetyl]-(25)-octahydroindolylmethoxy]benzoate (420 mg, 0.65 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl, and the resulting precipitate was collected. The crude solid was recrystallized from MeOH-CHCl3-IPE to give 167 (197 mg, 48%) as a white crystalline powder. MW 636.53 mp 118-123°C; Η-NMR (DMSO-cL.) δ 1.16-2.27 (series of m, total 10 T), 3.56-3.75 (m, 3 TT), 3.81 (s, 3 H), 3.90-3.96 (m, 1 H), 4.17-4.23 (m, 2 TT), 4.34-4.36 (m, 1 H), 6.73-6.75 (m, 1 H), 6.88-7.05 (m, 4 TT), 7.30-7.34 (m, 1 H), 7.59-7.61 (m, 1 H), 7.87- 7.96 (m, 4 H), 8.73 (s, 1 TT), 8.91 (s, 1 TT), 12.64 (br s, 1 TT); MS (FAB) m/z 636 QΛ++l); Anal Calcd for C32H34BrN306 l/4H20: C,59.96;H,5.42;N,6.55; Br,12.46. Found: C.60.12; H,5.86; N,6.09; Br, 12.47. Example 160 4-[3-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]acetyl-4-thiazolidinyl]methoxybenzoic acid
Figure imgf000337_0002
To a stirred solution of thiazolidine-4-carboxylic acid (5.0 g, 37.6 mmol) in DMF (50.0 ml) was added (Boc)20 (9.8 g, 45.1 mmol) and TEA (8.0 ml). The reaction mixture was stirred at room temperature for 18 hr. Water was added to the mixture and exfracted with EtOAc. The organic layer was washed with water, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc-n-hexane (1 :3 ,v/v) as eluent to give 3-tert-butoxycarbonylthiazolidine-4-carboxyIic acid (6.5 g , 74%) as a white ciystalline solid. Η-NMR (CDC13) δ 1.49 (br s, 9H), 3.20-3.30 (m, 2H), 4.09-4.87 (m, 3H).
To a stirred solution of 3-tert-butoxycarbonylthiazolidine-4-carboxylic acid (2.3 g, 10.0 mmol) in THF (30 ml) was added BH3 THF(1.0 M solution in THF, 20.0 ml, 20.0 mmol) at 0°C After stirred at room temperature for 1.0 h, the reaction mixture was heated under reflux for 1.0 hr. After cooled, the mixture was concentrated in vacuo. Water was added thereto at 0°C, and extracted with EtOAc. The exfract was washed with water, then dried over Na2S04, and concenfrated in vacuo to give 3-tert-butoxycarbonyl-5-hydroxymethylthiazolidine (2.0 g , quant) as a a colorless oil. Η-NMR (CDC13) δ 1.48 (s, 9H), 2.80-2.85 (m, IH), 3.13-3.17 (m, IH), 3.20-3.30 (m, IH), 3.64-3.70 (m, 2H), 4.34 (br s, IH), 4.60 (br s, IH).
To a stirred solution of 3-tert-butoxycarbonyl-5-hydroxymethylthiazolidine (1.9 g, 8.7 mmol), methyl 4-hydroxybenzoate (1.3 g, 8.7 mmol), and Ph3P (3.2 g, 12.2 mmol) in THF (10 ml) was added DIAD (2.2 g, 10.4 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 18 hr. The mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc- n-hexane (1:9, v/v) as eluent to give methyl 4-(3 -tert- butoxycarbonyl-4-thiazolidinyl)methoxybenzoate (1.6 g, 52% ) as a pale yellow oil. Η-NMR (CDC13) δ 1.49 (s, 9H), 3.11-3.19 (m, 2H), 3.88 (s, 3H), 4.04-4.31 (m, 3H), 4.61 (m, 2H), 6.96 (d, 7 = 8.8 Hz, 2H), 7.98 (d, 7= 8.8 Hz, 2H).
To a stirred solution of methyl 4-(3-tert-butoxycarbonyl-4-thiazolidinyl)methoxybenzoate (440 mg, 1.25 mmol) in CH2C12 (6 ml) was added TFA (3ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concenfrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The exfract was washed with brine ,dried over Na2S04 , and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (0.6 mmol), 3-methoxy-4-[N,-(2-methyl phenyl)uredio]phenylacetic acid (188 mg, 0.6 mmol), HOBt (81 mg, 0.6 mmol), and triethylamine (280 ml, 2.0 mmol) in THF (5 ml) and MeCN (5 ml) was added EDC HCl (173 mg, 0.9 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04, and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1:3, v/v) as eluent to give methyl 4-[3-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenyl]acetyl-4- thiazolidinyl] methoxybenzoate (340 mg , quant) as an amoφhous solid. Η-NMR (CDC13) δ 2.31 (s, 3H), 3.15-3.16 (m, 2H), 3.67-3.69 (m, 5H), 3.88 (s, 3H), 4.09-4.14 (m, 2H), 4.22-4.90 (m, 3H), 6.30 (m, IH), 6.74-6.96 (m, 4H), 7.11-7.25 (m, 4H), 7.49-7.51 (m, IH), 7.95-8.12 (m, 3H).
To a stirred solution of methyl 4-[3-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]acetyl-4- thiazolidinyl] methoxybenzoate (340 mg, 0.62 mmol) in THF (5.0 ml) and EtOH (3.0 ml) was added IN NaOH (0.62 ml, 0.62 mmol). The mixture was stirred at 70 °C for 18 hr. The mixture was concentrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 168 (290 mg, 88%) as a white crystalline solid. MW 535.62 mp 125-128 °C; IR (KBr) 3357, 2937, 1604, 1533, 1419, 1253, 1166, 1033, 773 cm 1; 'H-NMR (DMSO-cL.) δ 2.25 (s, 3H), 3.05-3.20 (m, 2H), 3.71, 3.83, and 3.85 (each s, total 5H), 4.03-4.15 (m, 3H), 4.52-4.76 (m, 2H), 6.15-6.17 (m, IK), 7.78-8.30 (m, 4H), 8.30 (m, IH), 8.56 (m, IH); MS (FAB) m/z 536 (M++l); Anal, calcd for C28H29NAS 0.5H2O: C, 61.75; H, 5.55; N, 7.72. Found: C, 61.72; H, 5.55; N, 7.49. Example 161 4-[3-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-4-thiazolidinyl]methoxybenzoic acid
Figure imgf000339_0001
To a stirred solution of methyl 4-(3-tert-butoxycarbonyl-4-thiazolidinyl)methoxybenzoate (600 mg,
1.7 mmol) in CH2C12 (6,0 ml) was added TFA (6.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concenfrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The exfract was washed with brine ,dried over Na2S04 , and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 4-[N'-(2-chlorophenyl)uredio]-3- methoxyphenylacetic acid (570 mg, 1.7 mmol), HOBt (230 mg, 1.7 mmol), and triethylamine (709 ml, 5.1 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDCHCl (490 mg, 2.55 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The extract was washed with sat NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1: 1, v/v) as eluent to give methyl 4-[3-[4-[Λ^'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-4- thiazolidinyl] methoxybenzoate (900 mg, 93%) as a colorless oil. "H-NMR (CDC13) δ 3.15-3.18 (m, 2H), 3.70 (s, 2H), 3.78 (s, 3H), 3.86 (s, 3H), 4.09-4.93 (m, 5H), 6.80-7.01 (m, 5H), 7.19-7.35 (m, 4H), 7.94-8.18 (m, 4H).
To a stirred solution of methyl 4-[3-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-4- thiazolidinyl] methoxybenzoate (900 mg, 1.6 mmol) in THF (8.0 ml) and MeOH (4.0 ml) was added IN NaOH (3.1 ml, 3.1 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 169 (780 mg, 89%) as a white crystalline solid. MW 556.03 mp 126-129 °C; IR (KBr) 3343, 2937, 1604, 1531, 1421, 1245,
1166, 1035, 752 cm 1; Η-NMR (DMSO-cL.) δ 3.06-3.24 (m, 2H), 3.72-3.85 (m, 5H), 4.02-4.27 (m, 3H), 4.53-4.76 (m, 2H), 6.74-7.44 (m, 7H), 7.87-8.30 (m, 4H), 8.89-8.95 (m, 2H); MS (FAB) m/z 556 (M++l); Anal, calcd for C27H27N3O6ClS 0.7H2O: C, 56.93; H, 5.03; N, 7.38; Cl, 6.22. Found: C, 56.89; H, 4.84; N, 7.42; Cl, 6.35. Example 162
4- [3 -[4-[N'-(2-bromophenyl)ureido] -3 -methoxyphenylacetyl] -4-thiazolidinyl] methoxybenzoic acid
Figure imgf000340_0001
To a stirred solution of methyl 4-(3-tert-butoxycarbonyl-4-thiazolidinyl)methoxybenzoate (560 mg,
1.6 mmol) in CH2C12 (5.0 ml) was added TFA (5.0 ml) at 0 °C. The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The exfract was washed with brine .dried over Na2S04 , and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 4-[N'-(2-bromophenyl)uredio]-3-methoxy phenylacetic acid (599 mg, 1.6 mmol), HOBt (213 mg, 1.6 mmol), and triethylamine (659 ml, 4.7 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDCHCl (455 mg, 2.4 mmol) at 0 °C.
The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and extracted with EtOAc. The exfract was washed with sat. NaHC03,
2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (2:3, v/v) as eluent to give methyl 4-[3-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-4-thiazolidinyl] methoxybenzoate (870 mg, 89%) as a colorless oil. 'H-NMR (CDC13) δ 3.00-3.20 (m, 3H), 3.70 (s, 2H), 3.81 (s, 3H), 3.88 (s, 3H), 4.09-4.23 (m, IH), 4.42 (d, 7 = 8.5 Hz, IH), 4.59 (d, 7= 8.5 Hz, IH), 4.70-4.92 (m, IH), 6.81-7.53 (m, 9H), 7,95-8.15 (m, 4H).
To a stirred solution of methyl 4-[3-[4-[Λ^'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-4- thiazolidinyl] methoxybenzoate (870 mg, 1.4 mmol) in THF (8.0 ml) and MeOH (8.0 ml) was added IN NaOH (2.8 ml, 2.8 mmol). The mixture was stirred at 70 °C for 18 hr. The mixture was concenfrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 170 (740 mg, 87%) as a white crystalline solid. MW 600.48 mp 125-133 °C; IR (KBr) 3332, 2935, 1604, 1527, 1421, 1245, 1166, 1027, 750 cm '; 'H-NMR (DMSO-c .) δ 3.01-3.25 (m, 2H), 3.72-3.85 (m, 5H), 4.02-4.30 (m, 2H), 4.54 (d, 7= 8.8 Hz, IH), 4.74-4.87 (m, 2H), 6.76-7.07 (m, 5H), 7.30-7.34 (m, IH), 7.59 (d, 7 = 8.1 Hz, IH), 7.86-7.98 (m, 4H), 8.74 (s, IH), 8.92-8.94 (s, IH); MS (FAB) m/z 600 (M++l); Anal. calcd for C27H26N30<J3rS .3H20: C, 53.52; H.4.43 N 6.94 Found: C, 53.54; H, 4.45; N, 6.80. Example 163 c/5-4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyπOlidinyl]methylamino] cyclohexanecarboxylic acid
Figure imgf000341_0001
To a stirred solution of 25-pyrrolidinemethanol (2.0 g, 20.0 mmol), 3-methoxy-4-[N-(2-methyl phenyl)uredio]phenylacetic acid (6.28 g, 20.0 mmol), HOBt (71 mg, 0.53 mmol), and triethylamine (5.5 ml, 40.0 mmol) in THF (50.0 ml) and MeCN (40.0 ml) was added EDCHCl (5.7 g, 30.0 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The organic layer was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with EtOAc to MeOH- CH2C12 (1:9, v/v) as eluent to give l-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetyl] -25-pyrrolidinemethanol (7.0 g, 89%) as a white crystalline solid. 'H-NMR (CDC13) δ 1.54-1.58 (m, IH), 1.80-2.04 (m, 3H), 2.27 (s, 3H), 3.42-3.46 (m, IH), 3.54-3.65 (m, 2H), 3.62 (s, 2H), 3.69 (s, 3H), 4.21-4.23 (m, IH), 5.04 (m, IH), 6.68-6.79 (m, 3H), 7.09-7.31 (m, 4H), 7.52 (d, 7 = 7.8 Hz, IH), 8.07 (d, 7= 8.0 Hz, IH).
To a stirred solution of oxalyl chloride (0.3 ml, 3.3 mmol) in CH2C12 (30.0 ml) was added DMSO (6.6 ml, 0.51 mmol) at -78 °C After 5 minutes, to the mixture was added l-[3-methoxy-4-[N'-(2- methylphenyl)ureido]phenylacetyl]-2-pyrrolidinemethanol (1.2 g, 3.0 mmol) in CH2C12 (5.0 ml). The mixture was stirred for 30 minutes at -78 °C, and triethylamine (2.1 ml, 15.0 mmol) was added. The mixture was stirred for 30 minutes at -78 °C, and stirred for 30 minutes at room temperature. Water was added to the mixture, and exfracted with CH2C12. The exfract was washed with water, then dried over Na2S04, and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, benzyl c/.ϊ-4-aminocyclohexanecarboxylaιe (769 mg, 3.3 mmol), and AcOH (0.32 ml) in DCE (10 ml) was added NaBH(OAc)3 (1.1 g, 5.4 mmol) at 0 °C The reaction mixture was stirred at room temperature for 18 hr. The mixture was concenfrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The extract was washed with brine, dried over Na2S0 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl2 (1:9, v/v) as eluent to give benzylcw-4-[[l-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetyl]-2-pyrrolidinyl]methylamino]cyclohexanecarboxylate (1.5 g, 83% ) as an amoφhous solid. 'H-NMR (CDC13) δ 1.40-1.65 (m, 6H), 1.80-1.98 (m, 6H), 2.26 (s, 3H), 2.45- 2.65 (m, 3H), 2.81-2.86 (m, IH), 3.44-3.46 (m, 2H), 3.56 (s, 2H), 3.67 (s, 3H), 3.90-4.15 (m, IH), 5.09 and 5.11 (each s, total 2H), 6.74-6.83 (m, 3H), 7.07-7.20 (m, 4H), 7.31-7.35 (m, 5H), 7.53 - 7.55 (m, IH), 8.02-8.06 (m, IH).
To a stirred solution of benzylcis-4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl acetyl]-2-pyrrolidinyl]methylamino]cyclohexanecarboxylate (1.5 g, 2.45 mmol) in THF (10.0 ml) and MeOH (5.0 ml) was added IN NaOH (3.68 ml, 3.68 mmol). The mixture was stirred at 70 °C for 18 hr. The mixture was concentrated in vacuo, water was added thereto, and neutralized with IN HCl. The mixture was concentrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl (1:5, v/v) as eluent to give c/5-4-[[l-[3-methoxy- 4-[N'-(2 -methyl phenyl)ureido]phenylacetyl]-2-pyrrolidinyl]methylamino]cyclohexanecarboxylic acid 171 (940 mg, 73% ) as an amoφhous solid. MW 522.64 IR (KBr) 3283, 2945, 2860, 1534, 1453, 1415 cm '; 'H-NMR (DMSO-cL.) δ 1.38-2.00 (m, 12H), 2.45 (s, 3H), 2.30-3.95 (m, 4H), 3.22-3.75 (m, 2H), 3.58 (s, 2H), 3.86 (s, 3H), 4.12 (m, IH), 6.73-7.16 (m, 5H), 7.77-7.79 (m, IH), 7.98-8.02 (m, IH), 8.51-8.52 (m, IH), 8.57-8.59 (m, IH); MS (FAB) m/z 523 (M++l); Anal, calcd for C29H38N4O5 0.5NaCl-2.2H2O: C, 58.89; H, 7.23; N, 9.47. Found: C, 59.21; H, 7.11; N, 9.11. Example 164 methyl c/j-4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]methyl amino]cyclohexanecarboxylate HCl salt
Figure imgf000343_0001
SOCl2 was added to MeOH at 0°C After stirred for 5 minutes, c/ 4-[[l-[3-methoxy-4-[N'-(2- methylphenyl)ureido]phenylacetyl] -2-pyrrolidinyl]methylamino]cyclohexanecarboxylic acid (200 mg, 0.38 mmol) was added. The mixture was stirred at room temperature for 5 hr. The mixture was concentrated in vacuo. Aq. NaHC03 was added to the residue, and extracted with CH2C12. The extract was washed with brine, dried over Na2S04, and concentrated in vacuo. The residue was purified by column chromatography on silica gel with MeOH-CH2Cl2 (5:95 to 18:92, v/v) as eluent. The product was dissolved in EtOH (5.0 ml), and IN HCl (in EtOH) (1.0 ml, 1.0 mmol) was added thereto. The mixture was concenfrated in vacuo to give 172 (160 mg, 74%) as an amoφhous solid. MW 536.66 IR (KBr) 3247, 2950, 2875, 1731, 1671, 1612, 1533, 1454, 1205 cm '; 'H-NMR (DMSO-cL.) δ 1.45-2.10 (m, 12H), 2.25 (s, 3H), 2.60-2.70 (m, IH), 2.90-3.20 (m, 3H), 2.50-2.55 (m, 2H), 3.63 (m, 5H), 3.86 (s, 3H), 4.15-4.30 (m, IH), 6.74-7.16 (m, 5H), 7.76- 7.78 (m, IH), 8.00-8.09 (m, IH), 8.54-8.70 (m, IK); MS (FAB) m/z 537 (M++1); Anal, calcd for C3()H40N4θ5-1.0HCH.0H2O: C, 60.95; H, 7.33; N, 9.48; Cl, 6.00. Found: C, 60.87; H, 7.47; N, 8.97: Cl, 5.90. Example 165
4-[N-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]methyl]-N- methylamino]cyclohexanecarboxylic acid
Figure imgf000343_0002
To a stirred solution of methyl c/5-4-[[l-[3-methoxy-4-[N'-(2-mefhylphenyl)ureido]phenylacetyl]-
2-pyrrolidinyl]methylamino]cyclohexanecarboxylate (300 mg, 0.55 mmol), HCHO (300 ml), and
AcOH (66 mg, 1.1 mmol) in MeOH (10.0 ml) was added NaBH3CN (70 mg, 1.1 mmol) at 0 °C
The reaction mixture was stirred at room temperature for 18 hr. After concenfrated in vacuo, water was added and exfracted with CH2C12. The extract was washed with water, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by TLC with MeOH-CH2Cl2 (3 :97, v/v) as eluent to give methyl 4-[N-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2- pyrrolidinylmethyl]-N-methylamino]cyclohexanecarboxylate (160 mg, 52% ) as an amoφhous solid. 'H-NMR (CDC13) δ 1.30-2.20 (m, 12H), 2.27-2.37 (m, 6H), 2.50-2.60 (m, IH), 3.30-3.80 (m, 5H), 3.55 (s, 2H), 3.66-3.73 (m, 6H), 4.10-4.20 (m, IH), 6.60-7.55 (m, IK), 8.03 (m, IH), 8.15 (m, IH). To a stirred solution of methyl 4-[N-[l-[3-methoxy-4-[Λ '-(2-methylphenyl)ureido]phenylacetyl]-2- pyrrolidinylmethyl]-N-methylamino]cyclohexanecarboxylate (100 mg, 0.18 mmol) in THF (5.0 ml) and MeOH (2.5 ml) was added IN NaOH (0.36 ml, 0.36 mmol). The mixture was stirred at 60 °C for 18 hr. The mixture was concenfrated in vacuo, water was added thereto, and neutralized with IN HCl. The mixture was concenfrated in vacuo. The residue was purified by TLC with MeOH- CH2C12 (1/4, v/v) as eluent to give 173 (10 mg, 10% ) as an amoφhous solid. MW 536.66 IR (KBr) 3440, 2954, 1697, 1533, 1454 cm '; 'H-NMR (DMSO-cL.) δ 1,20-2.30 (m, 13H), 2.24 (s, 3H), 2.35-4.00 (m, 13H), 6.50-8.10 (m, 8H), 8.50 (m, IH); MS (FAB) m/z 537 (M++l); Anal, calcd for C30H40N4O5-2.0NaCl-0.8H2O: C, 53.94; H, 6.28; N, 8.39. Found: C, 54.08; H, 6.52; N, 8.04. Example 166
4-[[l-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-(25)-pyrrolidinyl]methoxy] cyclohexanecarboxylic acid
Figure imgf000344_0001
A mixture of methyl 4-(l-tert-butoxycarbonyl-(25)-pyrrolidinyl)methoxybenzoate (1.0 g, 2.9 mmol) and 5% Rh on alumina (500 mg) in EtOH (10.0 ml) and AcOH (1.0 ml) was hydrogenated at room temperature at 5 atin for 36 hr. The catalyst was filtered off, and the filtrate was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n- hexane-EtOAc (6:1, v/v) as eluent to give methyl c/s-4-[(l-tert-butoxycarbonyl-(2S)-pyrrolidinyl) methoxy]cyclohexanecarboxylate (900 mg, 89% ) as a pale yellow oil. 'H-NMR (CDC13) δ 1.46 (s, 9H), 1.46-2.00 (m, 12H), 2.34 (m, IH), 3.20-3.55 (m, 5H), 3.67 (s, 3H), 3.84-3.92 (m, IH).
To a stirred solution of methyl c/5,-4-[(l-tert-butoxycarbonyl-(25)-pyrrolidinyl)methoxy] cyclohexanecarboxylate (900 mg, 2.6 mmol) in CH2C12 (5.0 ml) was added TFA (5.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The extract was washed with brine, dried over Na2S04, and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (200 mg, 0.83 mmol), 3-methoxy-4-[Λ -(2-methylphenyl)uredio]phenylacetic acid (260 mg, 0.83 mmol), HOBt (135 mg, 1.0 mmol), and triethylamine (344μ 1, 1.35-2.10 (m, 12H), 2.15-2.38 (m, IH), 2.29 (m, 3H), 3.20-3.55 (m, 5H), 3.58 (s, 2H), 3.66 (s, 3H), 3.73 (s, 3H), 4.20-4.25 (m, IH), 6.26-6.30 (m, IH), 6.78-6.81 (m, 2H), 7.06-7,23 (m, 3H), 7.51-7.52 (m, IH), 8.01-8.03 (m, IH). To a stirred solution of methyl 4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]-(25)-pyrrolidinyl]methoxy]cyclohexanecarboxylate (460 mg, 0.86 mmol) in THF (10.0 ml) and EtOH (5.0 ml) was added IN NaOH (1.4 ml, 1.4 mmol). The mixture was stirred at 60 °C for 18 hr. The mixture was concenfrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 174 (370 mg, 83%) as a white crystalline solid. MW 523.63 mp 110-113 °C; IR (KBr) 3345, 2937, 1612, 1533, 1454 cm '; 'H-NMR (DMSO-d6) δ 1.00-2.00 (m, 12H), 2.24 (s, 3H), 2.20-2.30 (m, IH), 3.20-3.80 (m, 5H), 3.55 (s, 2H), 3.85 (s, 3H), 4.00-4.18 (m, IH), 6.71-7.16 (m, 5H), 7.78 (d, 7 = 8.0 Hz, IH), 7.90 (d, 7= 8.3 Hz, IH), 8.45 (s, IH), 8.54 (s,lH); MS (FAB) m/z 524 (M++l); Anal, calcd for C29H37N3O6-0.2H2O: C, 66.07; H, 7.15; N, 7.97. Found: C, 66.02; H, 7.14; N, 7.87. Example 167 4-[[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxylphenylacetyl]-(25 -pyrrolidinyl]methoxy] cyclohexanecarboxylic acid
Figure imgf000345_0001
To a stirred solution of methyl 4-[(l-tert-butoxycarbonyl-2-pyrrolidinyl)methoxy] cyclohexane carboxylate (900 mg, 2.6 mmol) in CH2C12 (5.0 ml) was added TFA (5.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat.
NaHC03 was added to the residue, and exfracted with CH2CI2. The exfract was washed with brine
,dried over Na2S04 , and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (200 mg, 0.83 mmol), 4-[jV-(2-chlorophenyl)uredio]-3-methoxyphenylacetic acid (277 mg, 0.83 mmol), HOBt (135 mg, 1.0 mmol), and triethylamine (344 ml, 2.48 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDCHCl (238 mg, 1.24 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1:6, v/v) as eluent to give methyl 4-[[l-[4-[N'- (2-chlorophenyl)ureido] -3 -methoxylphenylacetyl] -(25)-pyrrolidinyl] methoxy] cyclohexane carboxylate (450 mg, 97%) as a colorless oil. 'H-NMR (CDC13) δ 1.35-2.15 (m, 12H), 2.25-2.40 (m, IH), 3.40-3.70 (m, 5H), 3.61 (s, 2H), 3.66 (s, 3H), 3.81 (s, 3H), 4.20-4.30 (m, IH), 6.81-6.99 (m, 3H), 7.17-7.34 (m, 3H), 7.92 -7.94 (m, 2H), 8.17-8.19 (m, 2H). To a stirred solution of methyl 4-[[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxylphenylacetyl]-(25 - pyrrolidinyl] methoxy] cyclohexanecarboxylate (450 mg, 0.86 mmol) in THF (10.0 ml) and MeOH (5.0 ml) was added IN NaOH (1.4 ml, 1.4 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concenfrated in vacuo, water was added thereto, and neutralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 175 (370 mg,
84%) as a white crystalline solid. MW 544.04 mp 111-115 °C; IR (KBr) 3330, 2938, 1704, 1594, 1533, 1438, 1199 cm 1; Η-NMR (DMSO-cL.) δ 1.00-2.00 (m, 12H), 2.20-2.30 (m, IH), 3.20-3.80 ( , 5H), 3.55 (s, 2H), 3.85 (s, 3H), 4.00-4.20 (m, IH), 6.73-6.75 (m, IH), 6.87 (s, IH), 6.99-7.03 (m, IH), 7.25-7.29 (m, IH), 7.42 (d, 7= 7.1 Hz, IH), 7.95 (d, 7= 8.3 Hz, IH), 8.08 (d, 7 = 8.0, IH), 8.78 (s, IH), 8.92 (s, IH); MS (FAB) m/z 544 (M++l); Anal, calcd for C28H34N306C1 .2H20: C, 61.41; H, 6.33; N, 7.67; Cl, 6.47. Found: C, 61.37; H, 6.32; N, 7.56; Cl, 6.55. Example 168
4-[ 1 -[4- [N'-(2-bromophenyl)ureido] -3 -methoxylphenylacetyl] -(25)-pyrrolidinyl] methoxy cyclohexanecarboxilic acid
Figure imgf000346_0001
To a stirred solution of methyl 4-[(l-tert-butoxycarbonyl-2-pyrrolidinyl)methoxy]cyclohexane carboxylate (900 mg, 2.6 mmol) in CH2C12 (5.0 ml) was added TFA (5.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concenfrated in vacuo. Sat.
NaHC03 was added to the residue, and exfracted with CH2C12. The exfract was washed with brine, dried over Na2S04, and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (200 mg, 0.83 mmol), 4-[7V-(2-bromophenyl)uredio]-3-methoxyphenylacetic acid (314 mg, 0.83 mmol), HOBt (135 mg, 1.0 mmol), and triethylamine (344 ml, 2.48 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDC HCl (238 mg, 1.24 mmol) at 0 °C. The reaction mixture was stined at room temperature for 16 hr, and concentrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (1:6, v/v) as eluent to give methyl [4-[l-[4-[N'- (2-bromophenyl)ureido]-3-methoxylphenylacetyl]-(25)-pyrrolidinyl]methoxy]cyclohexane carboxylate (450 mg, 90%) as a colorless oil. 'H-NMR (CDC13) δ 1.30-2.10 (m, 12H), 2.35-2.40 (m, IH), 3.25-3.70 (m, 5H), 3.84 (s, 3H), 4.10-4.25 (m, IH), 6.81-7.06 (m, 4H), 7.25-7.32 (m, 2H), 7.50-7.52 (m, IH), 7.90-7.92 (m, IH), 8.13-8.15 (m, IH). To a stirred solution of methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxylphenylacetyl]-(25)- pyrrolidinyl]methoxycyclohexanecarboxylate (450 mg, 0.74 mmol) in THF (10.0 ml) and MeOH (5.0 ml) was added IN NaOH (1.2 ml, 1.2 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concenfrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 176 (340 mg,
77%) as a white crystalline solid. MW 588.49 mp 108-111 °C; IR (KBr) 3328, 2938, 1702, 1594, 1529, 1434 cm '; 'H-NMR (DMSO-cL,) δ 1.00-2.00 (m, 12H), 2.15-2.25 (m, IH), 3.40-3.75 (m, 5H), 3.48 (s, 2H), 3.85 (s, 3H), 4.04-4.15 (m, IH), 6.70-6.72 (m, IH), 6.87 (s, IH), 6.94-6.98 (m, IH), 7.29-7.33 (m, IH), 7.59 (d, 7 = 8.1 Hz, IH), 7.93-7.95 (m, 2H), 8.73-8.74 (m, IH), 8.91-8.92 (m, IH); MS (FAB) m/z 589 (M++l); Anal, calcd for C28H34N3O6Br0.2H2O: C, 56.80; H, 5.86; N, 7.10; Br, 13.49. Found: C, 56.66; H, 5.83; N, 6.97; Br, 13.66. Example 169
4-[[l-[4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]-(25)-pyrrolidinyl]methoxy]cyclohexane carboxylic acid
Figure imgf000347_0001
To a stirred solution of methyl 4-[(l-tert-butoxycarbonyl-2-pyrrolidinyl)methoxy]cyclohexane carboxylate (450 mg, 1.3 mmol) in CH2C12 (5.0 ml) was added TFA (5.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The exfract was washed with brine, dried over Na S04, and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product, 4-[V-(2- methylphenyl)uredio]phenylacetic acid (375 mg, 1.3 mmol), HOBt (178 mg, 1.3 mmol), and triethylamine (550 ml, 3.9 mmol) in THF (6.0 ml) and MeCN (6.0 ml) was added EDC HCl (380 mg, 1.9 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The residue was purified by column chromatography on silica gel with n- hexane-EtOAc (1:6, v/v) as eluent to give methyl 4-[[l-[4- V'-(2-mefhylphenyl)ureido] phenylacetyl]-(25)-pyrrolidinyl]methoxy]cyclohexanecarboxylate (520 mg, 78%) as a colorless oil. 'H-NMR (CDC13) δ 1.30-2.40 (m, 13H), 2.21 (s, 3H), 3.30-3.80 (m, IK), 3.65 (s, 3H), 4.10-4.30 (m, IH), 6.90-7.20 (m, 8H), 7.40-7.70 (m, 2H). To a stirred solution of methyl 4-[[l-[4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(25)- pyrrolidinyl] methoxy] cyclohexanecarboxylate (520 mg, 1.0 mmol) in THF (10.0 ml) and MeOH (5.0 ml) was added IN NaOH (1.5 ml, 1.5 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concenfrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 177 (450 mg,
91%) as a white crystalline solid. MW 493.60 mp 107-111 °C; IR (KBr) 3353, 2938, 1704, 1540, 1454, 1240 cm '; 'H-NMR (DMSO-c .) δ 1.20-2.00 (m, 12H), 2.23 (s, 3H), 2.22-2.24 (m, IH), 3.20-3.80 (m, IK), 4.00-4.18 (m, IH), 6.90-6.94 (m, IH), 7.10-7.16 (m, 5H), 7.36-7.38 (m, 2H), 7.82-7.87 (m, 2H), 8.89 (s, IH), 12.0 (br s, IH); MS (FAB) m/z 494 (M++l); Anal, calcd for C28H35N3O5 0.2H2O: C, 67.64; H, 7.18; N, 8.45. Found: C, 67.66; H, 7.19; N, 8.24. Example 170 c/5,-4-[l-[4-[7V'-(2-chlorophenyl)ureido]-3-methoxylphenylacetyl]-(25)-octahydroindolylmethoxy] cyclohexanecarboxylic acid
Figure imgf000348_0001
To a stirred solution of [l-tert-butoxycarbonyl-(25)-octahydroindolyl]carboxylic acid (1.0 g, 3.7 mmol) in THF (10.0 ml) was added BH3 THF(1.0 M in THF, 8.0 ml) at 0°C After stirred at room temperature for 1.0 h, the reaction mixture was heated under reflux for 1.5 hr. After cooled, the mixture was concenfrated in vacuo. Water was added thereto at 0°C, and exfracted with EtOAc.
The exfract was washed with water, then dried over Na2S04, and concenfrated in vacuo to give [1- tert-butoxycarboyl-(25)-octahydroindolyl]mefhanol (947 mg, quant) as a a colorless oil.
To a stirred solution of [l-tert-butoxycarboyl-(25)-octahydroindolyl]methanol (947 mg, 3.7 mmol), methyl 4-hydroxybenzoate (565 mg, 3.7 mmol), and PhjP (1.2 g, 4.5 mmol) in THF (10 ml) was added DIAD (984 mg, 4.5 mmol) at 0 °C The reaction mixture was stirred at room temperature for 18 hr. The mixture was concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (9/1, v/v) as eluent to give methyl 4- [l-tert-butoxycarbonyl-(25)-octahydroindolylmethoxy]benzoate (700 mg, 50% ) as a pale yellow oil. 'H-NMR (CDC13) δ 1.10-2.25 (m, 11H), 1.45 (s, 9H), 3.88 (s, 3H), 3.70-4.20 (m, 3H), 4.36 (br s, IH), 6.94 (d, 7= 8.8 H z, 2H), 7.96 (d, 7= 8.5 H z, 2H).
A mixture of methyl 4-[l-tert-butoxycarbonyl-(25)-octahydroindolylmethoxy]benzoate (700 mg, 1.8 mmol) and 5% Rh on alumina (400 mg) in EtOH (10.0 ml) and AcOH (1.0 ml) was hydrogenated at room temperature at 5 atin for 48 hr. The catalyst was filtered off, and the filtrate was concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (7: 1, v/v) as eluent to give methyl c j-4-[l-tert-butoxycarbonyl-(25)-octahydro indolylmethoxy]cyclohexanecarboxylate (600 mg, 85% ) as a pale yellow oil. 'H-NMR (CDC13) δ 1.10-2.35 (m, 20H), 1.44 (s, 9H), 3.45-3.90 (m, 5H), 3.80 (s, 3H).
To a stirred solution of methyl c/ 4-[l-tert-butoxycarbonyl-(25)-octahydroindolylmethoxy] cyclohexanecarboxylate (600 mg, 1.5 mmol) in CH2C12 (6.0 ml) was added TFA (6.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concenfrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The exfract was washed with brine, dried over Na2S04, and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (221 mg, 0.75 mmol), 4-[N'-(2-chlorophenyl)uredio]-3-methoxyphenylacetic acid (250 mg, 0.75 mmol), HOBt (101 mg, 0.75 mmol), and triethylamine (312 ml, 2.3 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDC HCl (216mg, 1.1 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04, and concentrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc(l:3, v/v) as eluent to give methyl cw-4-[l-[4- [N'-(2-chlorophenyl)ureido]-3-methoxylphenylacetyl]-(25)-octahydroindolylmethoxy]cyclohexane carboxylate (430 mg, 94%) as a colorless oil. 'H-NMR (CDC13) δ 1.10-2.40 (m, 20H), 3.45 (br s, IH), 3.62 (s, 2H), 3.66 (s, 3H), 3.73 (s, 3H), 3.60-3.85 (m, 2H), 4.09-4.14 (m, 2H), 6.75-6.98 (m, 3H), 7.22-2.46 (m, 4H), 7.92 (d, 7 = 8.0 Hz, IH), 8.18 (d, 7 = 8.3 Hz, IH).
To a stirred solution of methyl c/5-4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxylphenylacetyl]- (25)-octahydroindolylmethoxy]cyclohexanecarboxylate (430 mg, 0.7 mmol) in THF (10.0 ml) and MeOH (5.0 ml) was added IN NaOH (1.4 ml, 1.4 mmol). The mixture was stirred at 70 °C for 24 hr. The mixture was concenfrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to givel78 (360 mg, 86%) as a white crystalline solid. MW 598.13 mp 120-121°C; IR (KBr) 3338, 2933, 2859, 1614, 1533, 1438 cm '; 'H-NMR (CDC13) δ 1.05-2.40 (m, 20H), 3.38-3.50 (m, 2H), 3.63 and 3.65 (each s, total 2H), 3.71 and 3.75 (each s, total 3H), 3.70-3.80 (m, IH), 3.93-3.97 (m, IH), 4.15 (br s, IH), 6.75-6.77 (m, 2H), 6.93-6.97 (m, IH), 7.20-7.32 (m, 3H), 7.60-7.63 (m, IH), 7.85 (d, 7 = 8.3 Hz, IH), 8.16 (d, 7 = 8.3 Hz, IH); MS (FAB) m/z 598 (M++l); Anal, calcd for C32H40N3O6Cl- 0.5H2O: C, 63.30; H, 6.81; N, 6.92; Cl, 5.84. Found: C, 63.68; H, 6.81; N, 6.81; Cl, 5.98. Example 171 c/5-4-[l-[4-[/V'-(2-bromophenyl)ureido]-3-methoxylphenylacetyl]-(25)-octahydroindolylmethoxy] cyclohexanecarboxylic acid
Figure imgf000350_0001
To a stirred solution of methyl c/s-4-[l-tert-butoxycarbonyl-(25)-octahydroindolylmethoxy] cyclohexanecarboxylate (600 mg, 1.5 mmol) in CH2C12 (6.0 ml) was added TFA (6.0 ml) at 0 °C.
The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and extracted with CH2C12. The exfract was washed with brine ,dried over Na2S0 , and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (221 mg, 0.75 mmol), 4-[Λ -(2-bromophenyl)uredio]-3-methoxyphenylacetic acid (284 mg, 0.75 mmol), HOBt (101 mg, 0.75 mmol), and triethylamine (312 ml, 2.3 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDC HCl (216mg, 1.1 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The extract was washed with sat. NaHC03, 2 M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc(l:3 ,v/v) as eluent to give methyl c/y-4-[l-[4- [N'-(2-bromophenyl)ureido] -3 -methoxylphenylacetyl] -(25)-octahydroindolylmefhoxy] cyclohexane carboxylate (480 mg, 96%) as a colorless oil. Η-NMR (CDC13) δ 1.10-2.40 (m, 20H), 3.45 (br s, IH), 3.61 (s, 2H), 3.66 (s, 3H), 3.76 (s, 3H), 3.60-3.80 (m, 2H), 4.11-4.14 (m, 2H), 6.76-6.92 (m, 3H), 7.25-7.32 (m, 3H), 7.49 (d, 7= 7.1 Hz, IH), 7.90 (d, 7 = 8.0 Hz, 1), 8.13 (d, 7 = 8.0 Hz, IH).
To a stirred solution of methyl c/5-4-[l-[4-[Λf'-(2-bromophenyl)ureido]-3-methoxylphenylacetyl]- (25)-octahydroindolylmethoxy]cyclohexanecarboxylate (480 mg, 0.73 mmol) in THF (10.0 ml) and MeOH (5.0 ml) was added IN NaOH (1.5 ml, 1.5 mmol). The mixtiire was stirred at 70 °C for 24 hr. The mixture was concentrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 179 (400 mg, 85%) as a white crystalline solid. MW 642.58 mp 115-120 °C; IR (KBr) 3332, 2933, 2859, 1704, 1592, 1529, 1434 cm 1; Η-NMR (CDC13) δ 1.10-2.40 (m, 20H), 3.40-3.50 (m, 2H), 3.61 and 3.63 (each s, total 2H), 3.75 and 3.78 (each s, total 3H), 3.70-3.80 (m, IH), 3.90-3.93 (m, IH), 4.15 (br s, m), 6.76-6.92 (m, 3H), 7.26-7.30 (m, IH), 7.43-7.52 (m, 3H), 7.84-7.86 (m, IH), 8.10- 8.12 (m, IH); MS (FAB) m/z 643 (M++l); Anal, calcd for C32H40N3O6Br0.4H2O: C, 59.15; H, 6.33; N, 6.49; Br, 12.30. Found: C, 59.26; H, 6.33; N, 6.36; Br, 12.37. Example 172
4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2-pyrrolidinyl]carbonylamino] cyclohexanecarboxylic acid
Figure imgf000351_0001
To a stirred solution of benzyl 4-aminocyclohexanecarboxylate (900 mg, 3.9 mmol), boc-proline (830 mg, 3.9 mmol), HOBt (521 mg, 3.9 mmol), and triethylamine (1.6 ml, 11.6 mmol) in CH2C12 (30.0 ml) was added EDC HCl (1.1 g, 5.8 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and extracted with EtOAc. The extract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concenfrated in vacuo. The residue was purified by column chromatography on silica gel with n-hexane-EtOAc (6:1, v/v) as eluent to give benzylc/5,-4-[(l- tert-butoxycarbonyl-2-pyrrolidinyl)carbonylamino]cyclohexanecarboxylate (600 mg , 36%) as an amoφhous solid. Η-NMR (CDC13) δ 1.44 (s, 9H), 1.50-1.90 (m, 12H), 2.20-2.26 (m, IH), 3.25- 3.50 (m, 2H), 3.80-3.90 (m, IH), 4.10-4.25 (m, IH), 5.12 (s, 2H), 7.35-7.36 (m, 5H).
To a stirred solution of benzylc 5-4-[(l-tert-butoxycarbonyl-2-pyrrolidinyl)carbonylamino] cyclohexanecarboxylate (600 mg, 1.4 mmol) in CH2C12 (6.0 ml) was added TFA (3.0 ml) at 0 °C The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concentrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The exfract was washed with brine, dried over Na2S04, and concentrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stined solution of the crude product (300 mg, 0.7 mmol), 3-methoxy-4-[N,-(2-methylphenyl)uredio]phenylacetic acid (220 mg, 0.7 mmol), HOBt (94 mg, 0.7 mmol), and triethylamine (291 ml, 2.1 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDCHCl (201 mg, 1.1 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and extracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The resulting solid was collected and washed with EtOAc to give benzyl 4-[[l-[3-methoxy-4-pV'-(2-methylphenyl)ureido] phenylacetyl]-2-pyrrolidinyl]carbonylamino]cyclohexanecarboxylate (380 mg , 87%) as a white crystalline solid. Η-NMR (CDC13) δ 1.40-2.15 (m, 12H), 2.28 (m, 3H), 2.30-2.50 (m, 2H), 3.40- 3.55 (m, 2H), 3.61 (s, 2H), 3.71 (s. 3H), 3.82 (m, IH), 4.53 (d, 7 = 6.3 Hz, IH), 5.10 (s, 2H), 6.42 (s, IH), 6.77-6.79 (m, 2H), 7.04-7.34 (m, 9H), 7.50-7.52 (m, IH), 8.05-8.07 (m, IH).
To a stirred solution of benzyl 4-[[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-2- pyrrolidinyl]carbonylamino]cyclohexanecarboxylate (380 mg, 0.6 mmol) in THF (10.0 ml) and EtOH (5.0 ml) was added IN NaOH (0.9 ml, 0.9 mmol). The mixture was stirred at 50 °C for 18 hr. The mixture was concentrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 180 (230 mg, 71%) as a white crystalline solid. MW 636.62 mp 136-142 °C; IR (KBr) 3345, 2940, 1650, 1625, 1535, 1454 cm '; 'H-NMR (DMSO-c .) δ 1.40-2.00 (m, 12H), 2.24 (s, 3H), 2.30-2.40 (m, IH), 3.45-3.80 (m, 5H), 3.86-3.87 (m, 3H), 4.30-4.43 (m, IH), 6.65-7.30 (m, 5H), 7.70-7.80 (m, IH), 7.98-8.09 (m, IH), 8.46-8.57 (m, IH); MS (FAB) m/z 537 (M++l); Anal, calcd for C29H36N4O6 0.5 H20: C, 63.84; H, 6.83; N, 10.27. Found: C, 64.18; H, 6.91; N, 9.85. Example 173 4-[[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxylphenylacetyl]-2-pyrrolidinyl]carbonylamino] cyclohexanecarboxylic acid
Figure imgf000352_0001
To a stirred solution of benzylc 5-4-[(l-tert-butoxycarbonyl-2-pyrrolidinyl)carbonylamino] cyclohexanecarboxylate (600 mg, 1.4 mmol) in CH2C12 (6.0 ml) was added TFA (3.0 ml) at 0 °C. The reaction mixture was stirred at room temperature for 0.5 hr. The mixture was concenfrated in vacuo. Sat. NaHC03 was added to the residue, and exfracted with CH2C12. The extract was washed with brine, dried over Na2S04, and concenfrated in vacuo. The crude product was used to the subsequent reaction without further purification. To a stirred solution of the crude product (300 mg, 0.7 mmol), 4-[Λ''-(2-chlorophenyl)uredio]-3-methoxyphenylacetic acid (237 mg, 0.7 mmol), HOBt (94 mg, 0.7 mmol), and triethylamine (291 ml, 2.1 mmol) in THF (10.0 ml) and MeCN (10.0 ml) was added EDC HCl (201 mg, 1.1 mmol) at 0 °C The reaction mixture was stirred at room temperature for 16 hr, and concenfrated in vacuo. Water was added to the residue, and exfracted with EtOAc. The exfract was washed with sat. NaHC03, 2-M citric acid, and sat. NaHC03, then dried over Na2S04 , and concentrated in vacuo. The resulting solid was collected and washed with EtOAc to give benzyl 4-[[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyl phenylacetyl]-2-pyrrolidinyl]carbonylamino]cyclohexanecarboxylate (310 mg , 68%) as a white crystalline solid. 'H-NMR (CDC13) δ 1.40-2.15 (m, 12H), 2.30-2.60 (m, 2H), 3.42-3.55 (m, 2H), 3.64 (s, 2H), 3.84 (s,3H),4.55 (d, 7 =6.1Hz, 1H),5.12 (s,2H), 6.81-7.35(m,12H),7.96-7.98 (m, IH), 8.17-8.19 (m, IH).
To a stirred solution of methyl benzyl 4-[[l-[4-[Λ^-(2-chlorophenyl)ureido]-3-methoxylphenyl acetyl]-2-pyrrolidinyl]carbonylamino]cyclohexanecarboxylate (310 mg, 0.86 mmol) in THF (10.0 ml) and MeOH (5.0 ml) was added IN NaOH (0.7 ml, 0.7 mmol). The mixture was stirred at 50 °C for 18 hr. The mixture was concentrated in vacuo, water was added thereto, and neufralized with IN HCl. The resulting solid was collected, washed with water, and dried in vacuo to give 181 (260 mg, 98%) as a white crystalline solid. MW 557.03 mp 135-140 °C; IR (KBr) 3328, 2938, 1594, 1533,1438, 1203 cm 1; 'H-NMR (DMSO-cL.) δ 1.40-2.20 (m, 12H), 2.30-2.40 (m, IH), 3.40- 3.80 (m, 5H), 3.65-3.85 (m, 3H), 4.30-4.43 (m, IH), 6.66-7.31 (m, 5H), 7.42-8.10 (m, 2H), 8.89- 8.94 (m, 2H); MS (FAB) m/z 557 (M++l); Anal, calcd for C28H33N4O6Cl-0.3H2O: C, 59.79; H, 6.02; N, 9.96; Cl, 6.30. Found: C, 59.86; H, 6.10; N, 9.60; Cl, 6.34. Example 174 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(35)-pyrrolidinyloxy]benzoic acid
Figure imgf000353_0001
To a cooled (0 °C), stirred solution of methyl 4-hydroxybenzoate (1.84 g, 12.1 mmol), (R)-l- benzyl-3-pyrrolidinol (2.00 ml, 12.1 mmol), and Ph3P (3.81 g, 14.5 mmol) in THF (25 ml) was added DIAD (2.86 ml, 14.5 mmol) and the reaction mixture was heated under reflux for 10 hr. After cooled to room temperature, the mixture was evaporated. The residue was purified by column chromatography on silica-gel with n-hexane-EtOAc (3: 1, v/v) as eluent to give methyl 4- [l-benzyl-(35)-pyrrolidinyloxy]benzoate (3.66 g, 97%) as a pale yellow oil. 'H-NMR (CDCI3) δ 1.95-2.02 (m, 1 H), 2.28-2.37 (m, 1 H), 2.57-2.63 (m, 1 H), 2.72-2.81 (m, 2 TT), 2.96-3.01 (m, 1 H), 3.63-3.71 (m, 2 H), 3.87 (s, 3 TT), 4.84-4.89 (m, 1 H), 6.84 (d, 7 = 8.8 Hz, 2 H), 7.23-7.34 (m, 5 H), 7.95 (d, 7 = 8.8 Hz, 2 H).
A solution of methyl 4-[l-benzyl-(35)-pyrrolidinyloxy]benzoate (3.66 g, 11.8 mmol) in MeOH (25 ml) was hydrogenated over Pd(OH)2/C (0.73 g, 20 wt%) overnight. The reaction mixture was filtered to remove the catalyst and the solution was evaporated to give methyl 4-[(35)- pyrrolidinyloxy]benzoate (2.60 g, q.y.) as a pale yellow oil. 'H-NMR (CDC13) δ 1.94-2.01 (m, 2 H), 2.09-2.18 (m, 1 TT), 2.91-2.97 (m, 1 H), 3.04-3.09 (m, 1 H), 3.16-3.23 (m, 2 H), 3.88 (s, 3 H), 4.88-4.91 (m, 1 H), 6.86 (m, 2 H), 7.96-7.98 (m, 2 TT); MS (ESI) /n/z 222 (M++l).
A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (449 mg, 1.43 mmol), methyl 4-[(35)-pyrrolidinyloxy]benzoate (316 mg, 1.43 mmol), EDCHCl (330 mg, 1.72 mmol), HOBt (193 mg, 1.43 mmol), and Et3N (240 ml, 1.72 mmol) in THF (5 ml) was stirred at room temperature overnight. The reaction mixture was diluted with H20, and extracted with EtOAc. The exfract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 50: 1, v/v) as eluent to give methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(35)-pyrrolidinyloxy] benzoate (735 mg, 99%) as a pale yellow oil. 'H-NMR (CDC13) δ 2.03-2.31 (series of s and m, total 5 H), 3.57-3.78 (series of m, total 9 H), 3.88 (s, 3 TT), 4.95-4.99 (m, 1 H), 6.73-7.00 (m, 5 TT), 7.06-7.10 (m, 1 H), 7.18-7.22 (m, 2 H), 7.42-7.46 (m, 1 H), 7.57-7.62 (m, 1 H), 7.95-8.08 (m, 3 H); MS (ESI) m/z 518 (M++l).
To a stirred solution of methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(35)- pyrrolidinyloxy]benzoate (627 mg, 1.21 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 3 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-IPE to give 182 (235 mg, 39%) as a white crystalline powder. MW 503.55 mp 131-135°C; 'H-NMR (DMSO-cL.) δ 2.06-2.27 (series of m, total 5 H), 3.57-3.64 (m, 4 TT), 3.71-3.88 (series of s and m, total 5 H), 5.11 and 5.20 (each m, total 1 H), 6.73-6.77 (m, 1 H), 6.88-6.95 (m, 2 H), 7.02-7.05 (m, 2 H), 7.11-7.17 (m, 2 H), 7.79-7.81 (m, 1 H), 7.88-7.90 (m, 2 TT), 7.98-8.03 (m, 1 H), 8.45-8.47 (m, 1 H), 8.55-8.57 (m,l H), 12.66 (br s, 1 H); MS (ESI) m/z 504 (M++l); Anal. Calcd for C28H29N3063/4H20: C, 65.04; H, 5.95; N, 8.13. Found: C, 65.11; H, 5.99; N, 7.66. Example 175
4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(35 -pyrrolidinyloxy]benzoic acid
Figure imgf000354_0001
A mixture of 4-[Λ^'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (410 mg, 1.22 mmol), methyl 4-[(35)-pyrrolidinyloxy]benzoate (270 mg, 1.22 mmol), EDCHCl (280 mg, 1.46 mmol), HOBt (200 mg, 1.48 mmol), and Et3N (205 ml, 1.47 mmol) in THF (8 ml) was stirred at room temperature overnight. The reaction mixture was diluted with H20, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100:1 to 60:1, v/v) as eluent to give methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(35)-pyrrolidinyloxy] benzoate (652 mg, 99%) as a white solid, mp 200-203 °C; 'H-NMR (CDC13) δ 2.06-2.32 (m, 2 H), 3.60-3.82 (series of m, total 9 H), 3.88 (s, 3 H), 4.97-5.01 (m, 1 H), 6.76-6.86 (m, 4 H), 6.95-6.99 (m, 1 H), 7.23-7.47 (m, 4 H), 7.91-7.99 (m, 3 H), 8.19-8.21 (m, 1 H); MS (ESI) m/z 537 (M+).
To a stirred solution of methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(35)- pyrrolidinyloxy]benzoate (650 mg, 1.21 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-IPE to give 183 (443 mg, 70%) as a pale yellow crystalline powder. MW 523.97 mp 190-193°C; 'H-NMR (DMSO-cL.) δ 2.06-2.27 (m, 2 H), 3.56-3.62 (m, 4 TT), 3.71-3.88 (series of s and m, total 5 H), 5.11 and 5.20 (each m, total 1 H), 6.74-6.78 (m, 1 H), 6.89-6.91 (m, 1 H), 7.00-7.05 (m, 3 H), 7.26-7.30 (m, 1 TT), 7.43-7.45 (m, 1 H), 7.88-7.98 (m, 3 H), 8.08-8.10 (m, 1 H), 8.89-8.95 (m, 2 H), 12.67 (br s, 1 H); MS (ESI) m/z 524 (M++l); Anal. Calcd for C27H26C1N3061/4H20: C, 61.36; H, 5.05; N, 7.95; Cl, 6.71. Found: C, 61.69; H, 5.45; N, 7.29; Cl, 6.91. Example 176 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(35 -pyrrolidinyloxy]benzoic acid
Figure imgf000355_0001
A mixture of 4-[N'-(2-bromophenyl)ureido]-3-mefhoxyphenylacetic acid (540 mg, 1.42 mmol), methyl 4-[(35)-pyrrolidinyloxy]benzoate (315 mg, 1.42 mmol), EDCHCl (328 mg, 1.71 mmol), HOBt (230 mg, 1.70 mmol), and Et3N (240 ml, 1.72 mmol) in THF (8 ml) was stirred at room temperature overnight. The reaction mixture was diluted with H20, and extracted with
EtOAc. The exfract was washed with brine, dried over Na2S0 , and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 50: 1, v/v) as eluent to give methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(35)-pyrrolidinyloxy] benzoate (620 mg, 74%) as a white foam. 'H-NMR (CDC13) δ 2.06-2.33 (m, 2 H), 3.60-3.82 (series of m, total 9 H), 3.89 (s, 3 H), 4.97-5.01 (m, 1 H), 6.77-7.00 (m, 5 H), 7.27-7.40 (m, 3 H), 7.49-7.51 (m, 1 H), 7.91-7.99 (m, 3 H), 8.13-8.17 (m, 1 H); MS (ESI) m/z 583 (M++l). To a stirred solution of methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl acetyl]-(35)-pyrrolidinyloxy]benzoate (620 mg, 1.06 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 2.5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-IPE to give 184 (421 mg, 70%) as a white crystalline powder. MW 568.42 mp 173-175°C; 'H-NMR (DMSO-cL.) δ 2.06-2.28 (m, 2 H), 3.56-3.65 (m, 4 H), 3.71-3.88 (series of s and m, total 5 H), 5.12 and 5.20 (each m, total 1 H), 6.74-6.78 (m, 1 H), 6.89-7.05 (m, 4 H), 7.31-7.34 (m, 1 H), 7.59-7.61 (m, 1 H), 7.88-7.98 (m, 4 TT), 8.73-8.74 (m, 1 TT), 8.91-8.93 (m, 1 H), 12.67 (br s, 1 H); MS (ESI) m/z 569 (M"+l); Anal. Calcd for C27H26BrN306: C, 57.05; H, 4.61; N, 7.39; Br, 14.06. Found: C, 57.57; H, 5.12; N, 6.81; Br, 13.96. Example 177 4-[l-[3 -methoxy-4-[N '-(2-methylphenyl)ureido]phenylacetyl]-(3Λ)-pyrrolidinyloxy]benzoic acid
Figure imgf000356_0001
To a cooled (0°C), stirred solution of methyl 4-hydroxybenzoate (1.78 g, 11.7 mmol), 1-benzyl-
(35)-pyrrolidinol (2.07 g, 11.7 mmol), and Ph3P (3.68 g, 14.0 mmol) in THF (25 ml) was added
DIAD (2.76 ml, 14.0 mmol) and the reaction mixture was heated under reflux for 10 hr. After cooled to room temperature, the mixture was evaporated. The residue was purified by column chromatography on silica-gel with n-hexane-EtOAc (3:1, v/v) as eluent to give methyl 4-[l- benzyl-(3Λ)-pyrrolidinyloxy]benzoate (3.56 g, 98%) as a pale yellow oil. Η-NMR (CDC13) δ
1.95-2.03 (m, 1 TT), 2.28-2.37 (m, 1 TT), 2.57-2.63 (m, 1 H), 2.73-2.81 (m, 2 T), 2.97-3.01 (m, 1
H), 3.63-3.72 (m, 2 TT), 3.87 (s, 3 TT), 4.85-4.90 (m, 1 H), 6.83-6.85 (m, 2 H), 7.27-7.34 (m, 5 H),
7.94-7.97 (m, 2 H); MS (ESI) m/z 312 (M++l).
A solution of methyl 4-[l-benzyl-(3Λ)-pyrrolidinyloxy]benzoate (3.56 g, 11.4 mmol) in MeOH (25 ml) was hydrogenated over Pd(OH)2/C (0.72 g, 20 wt%) overnight. The reaction mixture was filtered to remove the catalyst and the solution was evaporated to give methyl 4-[(37?)- pyrrolidinyloxy]benzoate (2.53 g, q.y.) as a pale yellow oil. 'H-NMR (CDC13) δ 1.94-2.18 (m, 3 H), 2.91-2.97 (m, 1 H), 3.04-3.09 (m, 1 TT), 3.16-3.22 (m, 2 TT), 3.88 (s, 3 TT), 4.88-4.91 (m, 1 H), 6.86-6.89 (m, 2 TT), 7.97-7.99 (m, 2 H); MS (ESI) m/z 263 [M++l+41, (+MeCN)]. A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (460 mg, 1.46 mmol), methyl 4-[(3Λ)-pyrrolidinyloxy]benzoate (324 mg, 1.46 mmol), EDCHCl (337 mg, 1.76 mmol), HOBt (237 mg, 1.75 mmol), and Et3N (245 ml, 1.76 mmol) in THF (10 ml) was stirred at room temperature overnight. The reaction mixture was diluted with H20, and exfracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100:1 to 50:1, v/v) as eluent to give methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(3Λ)-pyrrolidinyloxy] benzoate (583 mg, 77%) as a colorless oil. 'H-NMR (CDC13) δ 2.06-2.23 (m, 2 H), 2.30 (s, 3 H), 3.58-3.89 (series of s and m, total 12 H), 4.95-4.99 (m, 1 H), 6.75-7.00 (m, 4 H), 7.13-7.30 (m, 5 H), 7.52-7.57 (m, 1 H), 7.96-8.03 (m, 3 H); MS (ESI) m/z 518 (M++1).
To a stirred solution of methyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(3R)- pyrrolidinyloxy]benzoate (583 mg, 1.13 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 3 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-Et20 to give 185 (297 mg, 52%) as a white crystalline powder. MW 503.55 mp 158-162°C; 'H-NMR (DMSO-c .) δ 2.08-2.31 (series of s and m, total 5 TT), 3.54-3.89 (series of m, total 9 TT), 5.11 and 5.20 (each m, total 1 TT), 6.72-7.17 (series of m, total 6 H), 7.78-7.80 (m, 1 TT), 7.87-7.90 (m, 2 H), 7.98-8.02 (m, 2 H), 8.46-8.47 (m, 1 T), 8.55-8.57 (m,l TT), 12.66 (br s, 1 T); MS (ESI) m/z 504 (M++l); Anal. Calcd for C28H29N3061/4H20: C, 66.19; H, 5.85; N, 8.27. Found: C, 66.12; H, 5.77; N, 8.21. Example 178 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(3Λ)-pyrrolidinyloxy]benzoic acid
Figure imgf000357_0001
A mixture of 4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (498 mg, 1.49 mmol), methyl 4-[(3R)-pyrrolidinyloxy]benzoate (329 mg, 1.49 mmol), EDCHCl (342 mg, 1.78 mmol), HOBt (241 mg, 1.78 mmol), and Et3N (250 ml, 1.79 mmol) in THF (10 ml) was stirred at room temperature overnight. The reaction mixture was diluted with H20, and exfracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 50: 1, v/v) as eluent to give methyl 4-[l-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetyl]-(3Λ)-pyrrolidinyloxy ]benzoate (561 mg, 70%) as a white form. Η-NMR (CDC13) δ 2.05-2.34 (m, 2 H), 3.59-4.07 (series of s and m, total 12 TT), 4.97-5.02 (m, 1 TT), 6.75-6.86 (m, 4 H), 6.94-7.00 (m, 1 H), 7.22- 7.33 (m, 2H), 7.59-7.66 (m, 2H), 7.92-7.99 (m, 3H), 8.19-8.22 (m, IH); MS (ESI) m/z 538 (M -1).
To a stirred solution of methyl 4-[l-[4-[Λ^'-(2-chlorophenyl)ureido]-3-methoxyphenyl acetyl]-(3Λ)-pyrrolidinyloxy]benzoate (561 mg, 1.04 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-Et20 to give 186 (361 mg, 66%) as a white crystalline powder. MW 523.97 mp 193-194°C; Η-NMR (DMSO-cL,) δ 2.06-2.28 (m, 2 TT), 3.58-3.62 (m, 4 H), 3.71-3.76 (m, 1 H), 3.83-3.89 (series of s and m, total 4 TT), 5.12 and 5.20 (each m, total 1 H), 6.74-6.78 (m, 1 H), 6.90-6.91 (m, 1 H), 7.01-7.05 (m, 3 TT), 7.27-7.30 (m, 1 H), 7.43-7.45 (m, 1 H), 7.88-7.98 (m, 3 TT), 8.08-8.10 (m, 1 T), 8.89-8.96 (m, 2 H), 12.67 (br s, 1 TT); MS (ESI) m/z 524 (M++l); Anal Calcd for C27H26C1N3061/4H20: C, 61.36; H, 5.05; N, 7.95; Cl, 6.71. Found: C, 61.49; H, 5.11; N, 7.72; Cl, 7.08. Example 179
4-[l-[4-[Λ^'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(3R)-pyrrolidinyloxy]benzoic acid
Figure imgf000358_0001
A mixture of 4-[Λ '-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (460 mg, 1.21 mmol), methyl 4-[(3Λ)-pyrrolidinyloxy]benzoate (269 mg, 1.21 mmol), EDCHCl (280 mg, 1.46 mmol), HOBt (197 mg, 1.46 mmol), and Et3N (205 ml, 1.47 mmol) in THF (10 ml) was stirred at room temperature overnight. The reaction mixture was diluted with H20, and extracted with EtOAc.
The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 60: 1, v/v) as eluent to give methyl 4-[l-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(3/?)-pyrrolidinyloxy] benzoate (555 mg, 78%) as a white foam. Η-NMR (CDC13) δ 2.05-2.33 (m, 2 H), 3.60-4.07
(series of s and m, total 12 H), 4.96-5.01 (m, 1 TT), 6.76-6.93 (m, 5 H), 7.28-7.30 (m, 1 H), 7.48-
7.58 (m, 3 H), 7.92-7.99 (m, 3 TT), 8.12-8.16 (m, 1 H); MS (ESI) m/z 582 (MX
To a stirred solution of methyl 4-[l-[4-[Λ^'-(2-bromophenyl)ureido]-3-methoxyphenylacetyl]-(3Λ)- pyrrolidinyloxy]benzoate (555 mg, 0.95 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was recrystallized from MeOH-CHCl3-Et20 to give 187 (330 mg, 61%) as a white crystalline powder. MW 568.42 mp 175-177°C; Η-NMR (DMSO-cL.) δ 1.99-2.27 (m, 2 H), 3.56-3.63 (m, 4 H), 3.71-3.76 (m, 1 H), 3.83-3.89 (series of s and m, 4 H), 5.12 and 5.20 (each m, total 1 H), 6.74-6.78 (m, 1 H), 6.89-7.05 (m, 4 H), 7.30-7.35 (m, 1 H), 7.59-7.61 (m, 1 H), 7.88-7.98 (m, 4 H), 8.74-8.76 (m, 1 H), 8.92-8.95 (m, 1 H), 12.68 (br s, 1 TT); MS (ESI) m/z 569 (M++l); Anal. Calcd for C27H26BrN306: C, 57.05; H, 4.61; N, 7.39; Br, 14.06. Found: C, 56.91; H, 4.66; N, 7.20; Br, 14.59. Example 180
Figure imgf000359_0001
1 gram of Tentagel PHB re ( 0.29 mmol/gm) was tak .en up in DMF 25 mL and Fmoc-(4-carboxymethyl)-piperidine (318 mg, 0.87 mmol) was added. The resin was shaken for 5 min then DIC (220 mg, 0.27 mL, 1.74 mmol) and DMAP (106 mg, 0.87 mmol) were added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in 25 mL of DMF and Fmoc-L- moφholine-2- carboxylic acid (307 mg, 0.87 mmol) was added. The resin was shaken for 5 min then PyBroP (406 mg, 0.87 mmol) and DIEA (123 mg, 0.15 mL, 0.87 mmol) were added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in 25 mL of DMF and 4-o-tolylureidophenylacetic acid (247 mg, 0.87 mmol) was added and the resin was shaken for 5 min. PyBroP (406 mg, 0.87 mmol) and DIEA (123 mg, 0.15 mL, 0.87 mmol) was added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was then taken up in 90% TFA in CH2C12 and shaken for 4 hr. The resin was drained and the eluate collected. The resin was taken up in fresh CH2C12 and shaken for 30 min. The resin was drained and the eluate collected and combined with the first fraction. The solvent was removed under vacuum and the residue was recrystallized from ethyl acetate-hexane, yielding 85 mg 188. Example 181
Figure imgf000360_0001
1 gram of Tentagel PHB resin (loading 0.29 mmol/gm) was taken up in DMF 25 mL and
Fmoc-(4-carboxymethy)-piperidine (318 mg, 0.87 mmol) was added. The resin was shaken for 5 min then DIC (220 mg, 0.27 mL, 1.74 mmol) and DMAP (106 mg, 0.87 mmol) were added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in 25 mL of DMF and Fmoc-L- 4-phenylproline (307 mg, 0.87 mmol) was added. The resin was shaken for 5 min then PyBroP (406 mg, 0.87 mmol) and DIEA (123 mg, 0.15 mL, 0.87 mmol) were added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in 25mL of DMF and 4-o-tolylureidophenylacetic acid (247 mg, 0.87 mmol) was added and the resin was shaken for 5 min. PyBroP (406 mg, 0.87 mmol) and DIEA (123 mg, 0.15 mL, 0.87 mmol) was added and the resin shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was then taken up in 90% TFA in CH2C12 and shaken for 4 hr. The resin was drained and the eluate collected. The resin was taken up in fresh CH2C12 and shaken for 30 min. The resin was drained and the eluate collected and combined with the first fraction. The solvent was removed under vacuum and the residue was recrystallized from ethyl acetate-hexane, yielding 82 mg 189. Example 182
Figure imgf000361_0001
1 gram of Tentagel PHB resin (loading 0.29 mmol/gm) was taken up in DMF 25 mL and
Fmoc-4-carboxymethyl-piperazine (318 mg, 0.87 mmol) was added. The resin was shaken for 5 min DIC (220 mg, 0.27 mL, 1.74 mmol) and DMAP (106 mg, 0.87 mmol) were added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in 25 mL of DMF and Fmoc -L-proline (294 mg, 0.87 mmol) was added. The resin was shaken for 5 min. then PyBroP (406 mg, 0.87 mmol) and DIEA (123 mg, 0.15 mL, 0.87 mmol) were added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CHjOH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in 25 mL of DMF and 4-o-tolylureidophenyl acetic acid (247 mg, 0.87 mmol) was added and the resin was shaken for 5 min. PyBroP (406 mg, 0.87 mmol) and DIEA (123 mg, 0.15 mL, 0.87 mmol) was added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was then taken up in 90% TFA in CH2C12 and shaken for 4 hr. The resin was drained and the eluate collected. The resin was taken up in fresh CH2C12 and shaken for 30 min. The resin was drained and the eluate collected and combined with the first fraction. The solvent was removed under vacuum and the residue was recrystallized from ethyl acetate-hexane, yielding 78 mg 190. Example 183
Figure imgf000362_0001
1 gram of Tentagel PHB resin (loading 0.29 mmol gm) was taken up in DMF 25 mL and
Fmoc-isonipecotic acid (306 mg, 0.87 mmol) was added. The resin was shaken for5 min then DIC (220 mg, 0.27 mL, 1.74 mmol) and DMAP (106 mg, 0.87 mmol) were added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in 25 mL of DMF and Fmoc-L- proline (294 mg, 0.87 mmol) was added. The resin was shaken for 5 min then PyBroP (406 mg, 0.87 mmol) and DIEA (123 mg, 0.15 mL, 0.87 mmol) were added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in 25 mL of DMF and 4-o-tolylureidophenyl acetic acid (247 mg, 0.87 mmol) was added and the resin was shaken for 5 min. PyBroP (406 mg, 0.87 mmol) and DIEA (123 mg, 0.15 mL, 0.87 mmol) was added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was then taken up in 90% TFA in CH2C12 and shaken for 4 hr. The resin was drained and the eluate collected. The resin was taken up in fresh CH2C12 and shaken for 30 min. The resin was drained and the eluate collected and combined with the first fraction. The solvent was removed under vacuum and the residue was recrystallized from ethyl acetate-hexane, yielding 73 mg 191. Example 184
Figure imgf000363_0001
1 gram of Tentagel PHB resin (loading 0.29 mmol/gm) was taken up in DMF 25 mL and
Fmoc-(4-carboxymethy)-piperidine (318 mg, 0.87 mmol) was added. The resin was shaken for 5 min then DIC (220 mg, 0.27 mL, 1.74 mmol) and DMAP (106 mg, 0.87 mmol) were added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in 25 mL of DMF and Fmoc-L- proline (294 mg, 0.87 mmol) was added. The resin was shaken for 5 min. then PyBroP (406 mg, 0.87 mmol) and DIEA (123 mg, 0.15 mL, 0.87 mmol) were added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in 25 mL of DMF and Fmoc-3-amino-2-oxo-l- pyrrolidineacetate (331 mg, 0.87 mmol) was added and the resin was shaken for 5 min. PyBroP (406 mg, 0.87 mmol) and DIEA (123 mg, 0.15 mL, 0.87 mmol) was added and the resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test. The resin was taken up in CH2C12 and o-tolyl isocyanate (193 mg, 1.45 mmol, 0.18 mL) was added. The resin was shaken for 24 hr.
The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was then taken up in 90% TFA in CH2C12 and shaken for 4 hr. The resin was drained and the eluate collected. The resin was taken up in fresh CH2C12 and shaken for 30 min. The resin was drained and the eluate collected and combined with the first fraction. The solvent was removed under vacuum and the residue was recrystallized from ethyl acetate-hexane, yielding 69 mg 192. Example 185
Figure imgf000364_0001
In a 250 mL round-bottomed flask was placed o-tolylisothiocyanate (10.0 g, 67.1 mmol) in 150 mL of CH2C12. This solution was cooled to minus 78 °C and ammonia gas (excess) was bubbled through for 10 min. A precipitate immediately formed and was found to be the desired product o-tolylthiourea. The reaction mixture was filtered and the solid collected by washing thoroughly with cooled CH2C12. The white solid was dried under vacuum to provide 10.12 g (92% yield) of the desired o-tolylthiourea.
The o-tolylthiourea (10.12 g, 61 mmol) was then methylated by addition of methyl iodide
(9.1 g, 62 mmol) in anhydrous methanol (100 mL). The reaction was stirred at room temp for 6 hr and then concenfrated in vacuo. The residue was poured into aqueous ammonium chloride and extracted 3x with EtOAc. The combined organics were dried and concentrated in vacuo to give 8.7 g (84% yield) of 2-methyl-2-thio-o-tolylpseudourea. The pseudourea (8.7 g, 51 mmol) was dissolved in methanol (100 mL) and piperidine (8.7 g, 102 mmol) at room temp. The mixture was stirred overnight and then concentrated in vacuo to afford 9.2 g of the product ester as a pale yellow solid. This solid was saponified with LiOH to give 9.0 g of the desired final carboxylic acid 193. Example 186
Figure imgf000365_0001
Methyl-4-aminophenylacetate (4.0 g, 25 mmol) was dissolved in CH2C12 (100 mL) and to this solution was added o-tolylisothiocyante (3.7 g, 25 mmol). The reaction mixture was heated to reflux for 4 hr and then cooled to room temp. The solution was poured in to IN HCl and then exfracted 3x with EtOAc, dried over MgS04, and concentrated in vacuo to afford 5.2 g (67% yield) of thiourea methyl ester. The ester was saponified using LiOH to give 5.0 g of the desired 4-(o- tolylthioureido)phenylacetic acid 194.
Example 187
Figure imgf000365_0002
A solution of ethyl 4-[l-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylace1yl]-(25, 3R, 4Λ)-3,4-isopropylidenedioxy-2-pyrrolidinylcarbonyl]-l-piperazinylacetate (1.27 g, 1.99 mmol) in sat. HCl (gas)- MeOH (20 mL) was stirred at room temp, for 2 hr, and MeOH was evaporated off. The residue was taken up with sat. NaHC03 solution, and exfracted with CHC13 - MeOH (4 : 1, v/v). The exfracts were washed with brine, dried over MgS04, and concentrated to dryness. Chromatography of the residue with CHC13 - MeOH (5 : 1, v/v) as eluent gave ethyl 4-[l-[3- methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(25, 3R, 4R)-3,4-dihydroxy-2 -pyrrolidinyl carbonyl]- 1-piperazinylacetate (990 mg, 83 %) as a yellow amoφhous solid. IR (KBr) 3338, 2937, 2830, 1743, 1625, 1600, 1532, 1454 cm '; 'H-NMR (CDC13) d 1.25 (t, 7= 7.1 Hz, 3H), 2.20 (s, 3H), 2.46 - 2.56 (m, 4H), 3.15 (s, 2H), 3.40 - 3.72 (m, 9H), 3.62 (s, 3H), 4.01 - 4.08 (m, 2H), 4.16 (q, 7= 7.1 Hz, 2H), 4.22 (m, IH), 4. 72 (d, 7= 2.9 Hz, IH), 6.68 (d, 7= 7.6 Hz, IH), 6.72 (s, IH), 7.06 (t, 7= 7.6 Hz, IH), 7.15 - 7.18 (m, 3H), 7.52 - 7.56 (m, 2H), 7.90 (d, 7= 8.3 Hz, IH); MS (FAB) m/z 598 (M++l).
To a solution of ethyl 4-[l-[3-methoxy-4-[ΛP-(2-methylphenyl)ureido]phenylacetyl]-(25, 3R, 4Λ)-3,4-dihydroxy-2-pyιτolidinylcarbonyl]-l-piperazinylacetate (870 mg, 1.46 mmol) in THF (15 mL) was added 0.25N NaOH (7.00 mL, 1.75 mmol). After being stirred at room temp, for 3.5 hr, the reaction mixture was concenfrated. The residue was diluted with water and neufralized with IN HCl at 0 °C The mixture was concenfrated and purified by ion-exchanged resin (HP-20, Mitsubishi Chemical) to give 195 (645 mg, 78 %) as a colorless amoφhous solid. IR (KBr) 3330, 2937, 1627, 1535, 1454 cm '; 'H NMR (DMSO-d6) d 2.25 (s, 3H), 2.38 (m, IH), 2.42 - 2.58 (m, 2H), 2.64 (m, IH), 3.01 (s, 2H), 3.13 - 3.71 (m, 8H), 3.88 (s, 3H), 3.89 (m, IH), 4.05 (m, IH), 4. 58 (d, 7= 3.2 Hz, IH), 6.76 (dd, 7= 8.3, 1.5 Hz, IH), 6.91 - 6.95 (m, 2H), 7.10 - 7.16 (m, 2H), 7.79 (d, 7= 8.3 Hz, IH), 8.00 (d, 7= 8.3 Hz, IH), 8.49 (s, IH), 8.57 (s, IH); MS (FAB) m/z 570 (M++l); Anal Calcd for C28H35N508-2.75H20: C, 54.32; H, 6.59; N, 11.31. Found: C, 54.07; H, 6.11; N, 11.00. Example 188
Figure imgf000366_0001
To a suspension of 2-amino-4-thiazoleacetic acid (4 g, 25 mmol) in 1:1 CH2Cl:acetone (100 mL) was added o-tolylisocyanate (3.5 g, 26 mmol). The mixture was heated to reflux for 8 hr at which time a yellow precipitate had formed, the precipitate was filtered and the solid washed generously with 1:1 CH2C12: acetone. The solid was recrystallized with hot methanol and dried under vaccum to yield 4.8 g (66% yield) of the desired 2-(o-tolylureido)-4-fhiazoleacetic acid 196. Example 189
Figure imgf000366_0002
dioxane-water (1:1) and solid Na2C03 was added till the pH was 8-9. Boc20 (3.87g, 17.74mmole) was added and the reaction was stirred for 12 hr at room temp. The reaction mixture was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined orgamc layers were then washed with water, brine then dried over anhydrous MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was purified by flash chromatography. (4:1 hexane-ethyl acetate) Yield 4.39g 197.
Figure imgf000366_0003
The Boc-protected benzyl amine (2.00g, 6.99mmole) was dissolved in diy THF under argon. The reaction was cooled to minus 78° C. Lithium bis(trimethylsilyl)amide (13.98 mL, 13.98mmole) was added over 10 min. The reaction was stirred for one hr at minus 78° C then iodomethane (1.98g, 13.98mmole, 0.87 mL) was added rapidly. The reaction was allowed to slowly warm to room temp and stir overnight. The reaction was poured into IN HCl and the aqueous layer was extracted 3x with ethyl acetate. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (7:1 hexane- ethyl acetate) Yield 1.68g 198.
Figure imgf000367_0001
In a pressure tube was placed the Boc-protected 3-bromobenzyl methylamine (1.68g,
5.60mmole). The tube was then charged with DMF, sodium acetate (0.5 lg 6. lόmmole), P(o- tolyl)3(0.51g, 6.16mmole), and Pd(OAc)2(0.25g, 1.12mmole) The tube was flushed with argon for 10 min then methyl acrylate (0.53g, 0.53mmole, 0.55mL) was added. The tube was sealed and heated to 135° C for 24 hr. The reaction was cooled to 0°C and the tube was slowly opened. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined orgamc layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (6:1 hexane-ethyl acetate) Yield 1.60g l99.
Figure imgf000367_0002
In a pressure tube was placed the Boc-protected 3-bromobenzyl methylamine (l.OOg,
3.33mmole). The tube was then charged with DMF, sodium acetate (0.30g, 3.36mmole), P(o- tolyl)3 (0.20, 0.66mmole), and Pd(OAc)2 (0.15g, 0.66mmole). The tube was flushed with argon for 10 min then methyl methacrylate ( 37g, 3.66mmole, 0.39mL) was added. The tube was sealed and heated to 135° C for 24 hr. The reaction was cooled to 0° C and the tube was slowly opened. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined orgamc layers were washed with water, brine then dried over MgS0 . The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (6:1 hexane-ethyl acetate) Yield l.Olg 200.
Figure imgf000367_0003
The α, β-unsaturated ester (1.60g, 5.49mmole) was placed in a Paar vessel and dissolved in ethyl acetate. Pd/C (0.3g) was added and the vessel was pressured to 50 psi with H2. The vessel was agitated for 12 hr. The Paar vessel was flushed with argon and the catalyst was removed by filtration through celite. The solvent was removed under reduced pressure. Yield 1.60g 201.
Figure imgf000367_0004
The α-methyl-, β-unsaturated ester (l.Olg, 3.16mmole) was placed in a Paar vessel and dissolved in ethyl acetate. Pd/C was added and the vessel was pressured to 50 psi with H2. The vessel was agitated for 12 hr. The Paar vessel was flushed with argon and the catalyst was removed by filtration through celite. The solvent was removed under reduced pressure. Yield 996.4 lmg 202.
Figure imgf000368_0001
The Boc ester (304mg, 1.04mmole) was taken up in CH2C12 and excess trifluoroacetic acid was added. The reaction was then stirred for 2 hr. The solvent was removed and the residue was taken up in ethyl acetate and washed with sat. NaHC03 solution. The organic layer was washed with water, brine then dried over Na2S04. The solution was filtered and the solvent was removed under reduced pressure. The residue was taken up in CH2C12-DMF and HOBt
(154.30mg, 1.14mmole), 4-[N'-(o-tolylurea)-phenylacetic acid (324.11mg, 1.14mmole) and EDCI (218.53mg, 1.14mmole) were added. The reaction was stirred for 24 hr. The solution was poured into IN HCl and the aqueous layer was extracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (ethyl acetate) Yield 380.32mg 203.
Figure imgf000368_0002
The ester (380.32mg, 0.80mmole) was taken up in ethanol-water (4:1) and NaOH was added. The reaction was then heated to 50° C for 2 hr. The TLC (ethyl acetate) showed no starting material present. The reaction was cooled to room temp. The solution was poured into IN HCl and the aqueous layer was exfracted 3x ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The residue was recrystallizied from ethyl acetate-hexane. Yield 319.40mg 204. Example 190
Figure imgf000368_0003
The Boc ester (209.60, 0.65mmole) was taken up in CH2C12 and excess trifluoroacetic acid was added. The reaction was then stirred for 2 hr. The solvent was removed and the residue was taken up in ethyl acetate and washed with sat. NaHC03 solution. The organic layer was washed with water, brine then dried over Na2S04. The solution was filtered and the solvent was removed under reduced pressure. The residue was taken up in CH2C12-DMF and HOBt (97.45mg, 0.72mmole), 4 -[N'-(o-tolylurea) -phenylacetic acid (204.70mg, 0.72mmole) and EDCI (138.03mg, 0.72mmole) were added. The reaction was stirred for 24 hr. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined orgamc layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (ethyl acetate) Yield 237.8mg 205.
Figure imgf000369_0001
The ester (237.8mg, 0.49mmole) was taken up in ethanol-water (4: 1) and NaOH added.
The reaction was heated to 50° C for 2 hr. The TLC (ethyl acetate) showed no starting material present. The reaction was cooled to room temp. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The residue was recrystalized from ethyl acetate-hexane. Yield 207.8mg 206. Example 191
0!Nl ^X^^r 207
Thel,2,3,4- tetrahydroisoquinoline (12.20g, 91.60mmole) was taken up in H2SO4(40mL) and cooled to minus 10° C Concentrated HN03 (9.0mL) was slowly added to the solution while maintaining the internal temp at minus 10° C. On completion of the addition the reaction was allowed to stand and slowly warm to room temp over 12 hr. The reaction mixture was slowly added to ice and the aqueous solution was basified with NH4OH. The aqueous layer was extracted 4 times with CHC13. The combined organic layers were washed with water then dried over Na2S04. The solution was filtered and the solvent was removed under reduced pressure. The resulting brown oil was taken up in ethanol and concenfrated HCl was added. The resulting white solid was collected by filtration and dried under vacuum. Yield 8.0g 207.
Figure imgf000369_0002
The 6- nitro-l,2,3,4-tefrahydroisoquinoline (l.OOg, 5.61mmole) was taken up in ethanol. Methyl bromoacetate (0.86g, 5.61mmole, 0.53 mL) and triethylamine (1.17g, 11.59mmole, 1.62 mL) were then added and the mixture was heated to reflux for 5 hr. The solution was cooled to room temp and the solution was concentrated under vacuum. The solution was added to water and the aqueous layer was extracted 3x with ethyl acetate. The combined organic layers were dried over Na2S04, filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography (3 : 1 hexane-ethyl acetate). Yield 702mg 208.
Figure imgf000370_0001
The above ester (702mg, 2.81mmole)was placed in a Paar vessel and dissolved in ethanol. Pd/C (lOOmg) was added and the vessel was pressured to 50 psi with H2. The vessel was agitated for 24 hr. The Paar vessel was flushed with argon and the catalyst was removed by filfration through celite. The solvent was removed under reduced pressure. IH-NMR showed only desired product. Yield 587mg 209.
Figure imgf000370_0002
The aniline (587. Omg, 2.66mmole) was taken up in dry CH2C12 and pyridine under argon.
The reaction was cooled to 0°C A CH2C12 solution of 3-methoxy-4-(N'phenylureido) phenylacetyl chloride (837.70mg, 2.66mmole) was added over 5 min. The reaction was then allowed to warm to room temp and stir overnight. The reaction mixture was then poured into IN HCl and the aqueous layer was extracted 3x with ethyl acetate. The combined organic layers were then washed with sat. NaHC03, water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography (ethyl acetate). Yield 618.36mg 210.
Figure imgf000370_0003
The methyl ester (618.36mg, 1.20mmole) above was taken up in THF-H20 and LiOH (558.07mg, 13.30mmole) was added. The reaction mixture was stirred at room temp for 24 hr. The reaction was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were then washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was purified by recrystallization. (hexane-ethyl acetate). Yield 600mg 211. Example 192
°*X °"
The 3-nitro-phenyl propionic acid (l.OOg, 5.12mmole) was taken up in dry THF under argon. The reaction was cooled to 0° C and BH3-THF (1.0M, 15.37mmoIe, 15.37 mL) was added over 10 min. The reaction was stirred at 0° C for 1 hr then slowly quenched with water. The solution was slowly warmed to room temp then poured into IN HCl. The aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were then washed with sat. NaHC03, water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography (1:1 hexane-ethyl acetate) Yield 909.0mg 212.
The 3-nitro-phenyl propanol (909 X. Omg, 5.02mmole) was taken up in diy CH2C12. In a second round bottom flask (COCl)2 (700.65mg, 5.52mmole, 0.48 mL) was added to dry CH2C12 under argon. The (C0C1)2-CH2C12 solution was then cooled to minus 60° C and DMSO (862.56mg, 11.4mmole, 0.78 mL) was slowly added. The reaction was stirred at minus 60° C for 5 min then the alcohol solution was added via a cannula over 5 min. The reaction mixture was stirred at minus 60° C for 1 hr then Et3N (2.54g, 25.10mmole, 3.50 mL) was added and the reaction was allowed to slowly warm to room temp. The reaction was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were washed with sat. NaHC03, water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. HI -NMR showed no starting material present. The aldehyde 213 was used as is without further purification.
\J CH3 2M
In a round bottom flask NaH (132.48mg, 5.52mmole) was slurried in dry THF under argon. Triethyl 2-phosphonopropionate (1.31g, 5.52mmole, 1.18 mL) dissolve in diy THF was added slowly via a syringe. The reaction mixture was stirred for 30 min at room temp. The above aldehyde, dissolved in dry THF under argon, was added to the phosphonate solution via syringe over 10 min. The reaction mixture was stirred for 12 hr. The reaction was poured into IN HCl and the aqueous layer was extracted 3x with ethyl acetate. The combined organic layers were washed with sat. NaHC03, water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (1:1 ethyl acetate-hexane) Yield 992.0mg 214.
Figure imgf000372_0001
The above α, β-unsaturated ester (992.0mg, 3.77mmole) was placed in a Paar vessel and dissolved in ethanol. The vessel was flushed with argon and Pd/C (200.0mg) was added. The argon atmosphere was replaced with H2 at 50 psi. The Paar vessel was then shaken for 12 hr. The hydrogen was flushed from the vessel with argon and the catalyst was removed by filfration through celite. The solvent was removed under reduced pressure. IH-NMR showed only the desired product. Yield 851.2mg 215.
Figure imgf000372_0002
The above aniline (850.0mg, 3.61mmole) was taken up in dry CH2C12 and pyridine under argon. The reaction was cooled to 0° C. A CH2C12 solution of 3-methoxy-4-(N'phenylureido) phenylacetyl chloride (1.14g, 3.61mmole) was added over 5 min. The reaction was then allowed to warm to room temp and stir overnight. The reaction mixture was then poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were then washed with sat. NaHC03, water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography (ethyl acetate) Yield 576.0mg 216.
Figure imgf000372_0003
The above ethyl ester (576.0mg, mmole) was taken up in ethanol-water and NaOH was added. The reaction mixture was heated to 50° C for 2 hr. The reaction was cooled to room temp and then poured into IN HCl. The aqueous layer was exfracted 3x times with ethyl acetate. The combined organic layers were then washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was purified by
Sep-Pak column. Yield 534mg 217.
Example 193
Figure imgf000372_0004
One gram of Wang resin (tentagel S-PHB 0.3mmole loading) was suspended in a solution of 3-(Fmoc-amino)phenylpropionic acid (361.3 lmg, 0.90mmole), DMAP (109.95mg, 0.90mmole), HOBt 243.63mg, 0.90mmole), and DIC (227.16mg, 1.80mmole, 0.28 mL) in a mixture of DMF and CH2C12. The mixture was shaken for 20 hr and drained. The resin 218 was washed with DMF, MeOH, CH2Cl2and dried under reduced pressure.
Figure imgf000373_0001
To the above resin (500mg, 0.15mmole) was added a solution of piperidine-DMF (50% v/v, 4 mL) and the mixtiire was shaken for 4 hr. The resin was washed with DMF, MeOH, CH2C12. To the resin was added TMOF and isobutrylaldehyde (108.17mg, 1.50mmole, 0.14 mL). The mixture was shaken for 4 hr. The resin was drained and fresh TMOF and isobutrylaldehyde was added. The mixture was then shaken for 12 hr. The resin was drained and taken up in
MeOH-1% AcOH and NaCNBH3(150.0mg, 2.39mmole) was added. The resin was shaken for 6 hr. The resin was drained and washed with MeOH, MeOH-Et3N, MeOH, DMF, CH2C12. The resin was taken up in DMF and 3-methoxy-4-(N'-phenylureido)phenylacetic acid (141.45mg,0.45mmole), PyBrop (209.78mg, 0.45mmole),and DIEA (58.16mg, 0.45mmole, 0.08 mL) were added. The resin was then shaken for 24 hr then drained. The resin was washed with DMF, MeOH, CH2C12. To the resin was added a solution of TFA in CH2C12 (30% v/v 3 mL) and the mixture was shaken for 5 hr. The mixture was filtered and the filtrate was concenfrated in vacuo. The residue was purified by Sep-Pak column. After removal of the solvent, Et20 was added to the residue and the solid was collected to afford 15mg 219 as a crystalline solid. Example 194
Figure imgf000373_0002
Tentagel PHB resin (1.0 g, loading 0.29mmole/gm) was taken up in 25 mL of DMF and
6-bromohexanoic acid (169mg, 0.87mmol) was added. The resin was shaken for 5 min then DIC
(220mg, 0.27 mL, 1.74mmoles) and DMAP (35mg, 0.29mmole) were added and the resin was shaken for 14 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. To this resin was added 2,2-dimethyl-l,3-dioxolane-4-methanamine (227mg, 1.74 mmol)and lithium iodide (232mg, 1.74 mmol) in 15 mL of DMF. The resin was shaken for 14 hr at room temp. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test.
The resin was taken up in 25 mL of DMF and 4-o-tolylureido-3-methoxyphenylacetic acid
(247mg, 0.87mmole) was added and the resin was shaken for 5 min. PyBrOP (406mg, 0.87mmole) and DIEA (123mg, 0.15 mL, 0.87mmole) was added and the resin was shaken for 14 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test.
The resin was then taken up in 90% TFA in CH2C12 and shaken for 4 hr. The resin was drained and the elutant collected. The resin was taken up in fresh CH2C12 and shaken for 30 min. The resin was drained and the elutant collected and combined with the first fraction. The solvent was removed under vacuum and the residue was recrystallized from ethyl acetate-hexane, yield 56mg 220. Example 195
Figure imgf000374_0001
1 gram of Tentagel PHB resin (loading 0.29mmole/gm) was taken up in DMF 25 mL and
Fmoc- 7-aπύnoheptanoic acid (319mg, 0.87mmole) was added. The resin was shaken for 5 min then DIC (220mg, 0.27 mL, 1.74 mmol) and DMAP (106mg, 0.87mmole) were added and the resin was shaken for 24 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test. The resin was taken up in 20% piperidine in DMF and shaken for 4 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a positive bromophenylblue test.
The resin was taken up in 25 mL of DMF and 4-o-tolylureido-3-methoxyphenylacetic acid
(247mg, 0.87mmole) was added and the resin was shaken for 5 min. PyBrOP (406mg, 0.87mmole) and DIEA (123mg, 0.15 mL, 0.87mmole) was added and the resin was shaken for 14 hr. The resin was drained and washed with DMF (3x), CH3OH (3x) and CH2C12 (3x) then dried under vacuum. The resin gave a negative bromophenylblue test.
The resin was then taken up in 90% TFA in CH2C12 and shaken for 4 hr. The resin was drained and the elutant collected. The resin was taken up in fresh CH2C12 and shaken for 30 min. The resin was drained and the elutant collected and combined with the first fraction. The solvent was removed under vacuum and the residue was recrystallized from ethyl acetate-hexane, yield 66mg 221.
Example 196
Figure imgf000375_0001
To a solution of oxalyl chloride (3.8 g, 30 mmol) in CH2C12 (100 mL) was added DMSO
(2.4 g, 31 mmol) dropwise over 30 min at minus 78° C. To this solution was added N-Boc- prolinol (5.0g, 25mmol) dropwise over 15 min. The reaction was stirred at minus 78° C for 3 hr and then quenched by the cold addition of IN HCl, exfracted 3x with EtOAc, dried, and concenfrated in vacuo to afford the crude prolinal which was chromatographed (25% EtOAc/hexanes) to yield 3.8 g of the desired product.
A solution of Methyl (triphenylphosphoranylidene)butanoate (6.9 g, 19 mmol) in THF (100 mL) was generated. LiHMDS (10 mL of a 2.0M soln, 20 mmol) was added at minus 78° C and then stirred for 1 hr. The above prolinal (3.8 g, 19 mmol) was then added in one portion and the mixture was allowed to warm to room temp over 4 hr. The reaction was quenched by the addition of IN HCl, extracted 3x with EtOAc, dried, and concenfrated in vacuo to afford the crude alkene which was chromatographed (25% EtOAc/hexanes) to yield 2.9 g of he desired product.
Hydrogenation of the alkene was performed by placing the alkene (2.9 g, 10 mmol) in ethanol (20 mL) and adding a catalytic amount of 10% Pd/C followed by Parr hydrogenation at 40 psi for 4 hr, the resulting alkane was used without purification. The Boc group was removed by the addition of 1 : 1 TFA/CH2C12 at room temp. The reaction was stirred for 2 hr and the solvent was removed in vacuo. The crude amine 1.9 g was used without further purification.
A solution of the above free amine (1.9 g, 10 mmol) in CH2C12 (100 mL) was generated. To this solution was added EDCI (2.95 g, 10 mmol), DMAP (1.2 g, 10 mmol), and 4-o- tolylureido-3-methoxyphenylacetic acid (3.15g, 10 mmol) at room temp. The reaction mixture was stirred for 4 hr and then quenched by the addition of 1 N HCl, extracted 3x with EtOAc, dried, and concentrated in vacuo. The crude amide was chromatographed (5% MeOH/ CH2C12) to yield 1.95 g of the desired product.
The ester (1.95 g, 4.2 mmol) was taken up in 1:1 THF-H20 and LiOH was added at room temp. The reaction mixture was then stirred for 3 hr. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with EtOAc. The combine organic layers were washed with water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The solid was then triturated with cold ether to give 1.65 g of the desired carboxylic acid 222. Example 197
Figure imgf000376_0001
To a solution of methyl 8-aminooctanoate (2.0 g, 12 mmol) in 1:1 dioxane:water (100 mL) was added Boc anhydride (2.8 g, 13 mmol) and K2C03 (10 g). This solution was allowed to stir at room temp for 14 hr. The reaction was then poured onto 1 N HCl, extracted 3x with EtOAc, dried, and concentrated in vacuo. The crude carbamate was chromatographed (50%
EtOAc/ exanes) to yield 2.7 g of the desired product.
The Boc-protected amine was methylated by placing it in THF (75 mL), followed by the addition of LiHMDS (25 mL of a 2.0M soln., 50 mmol) at minus 78° C, this solution was then stirred for 30 min and methyl iodide (7.2 g, 50 mmol) was added in one portion the reaction mixture was allowed to warm to room temp overnight. The reaction was quenched by the addition of 1 N HCl, exfracted 3x with EtOAc, dried, and concentrated in vacuo. The crude methylated carbamate was chromatographed (50% EtOAc/hexanes) to yield 1.9 g of the desired dimethyl product.
The Boc group was removed by the addition of 1 : 1 TFA/CH2C12 at room temp. The reaction was stirred for 2 hr and the solvent was removed in vacuo. The crude amine 900 mg was used without further purification
A solution of the above free amine (900 mg, 4 5 mmol) in CH2C12 (100 mL) was generated To this solution was added EDCI (1 33 g, 4 5 mmol), DMAP (567 mg, 4 5 mmol), and 4-o-tolylureιdo-3-mefhoxyphenylacetic acid (1 45 g, 4 6 mmol) at room temp The reaction mixture was stirred for 4 hr and then quenched by the addition of 1 N HCl, exfracted 3x with EtOAc, dned, and concenfrated in vacuo The crude amide was chromatographed (5% MeOH CH2C12) to yield 1 2 g of the desired product
The ester (1 2 g, 2 4 mmol) was taken up in 1 1 THF-H20 and LiOH was added at room temp The reaction mixture was then stirred for 3 hr The solution was poured into IN HCl and the aqueous layer was exfracted 3x with EtOAc The combine orgamc layers were washed with water, bnne and dned over anhydrous magnesium sulfate The solution was filtered and the solvent removed under reduced pressure The solid was then tnturated with cold ether to give 1 01 g of the desired carboxylic acid 223 Example 198
Figure imgf000377_0001
To a suspension of 4-amιnophenylacetic acid (10 g, 66 mmol) in 1 1 CH2C12 acetone (100 mL) was added o-tolyisocyanate (8 8 g, 66 mmol) The mixture was heated to reflux for 4 hr at which time a white precipitate had formed The precipitate was filtered and the solid washed generously with 1 1 CH2C12 acetone The solid was recrystallized with hot methanol and dned under vacuum to yield 14 1 g (75% yield) of the desired 4-(o-tolylureιdo)phenylacetic acid 224
Example 199
Figure imgf000377_0002
To a suspension of 2-amιno-4-thιazoleacetic acid (4 g, 25 mmol) in 1 1 CH2C1 acetone
(100 mL) was added o-tolylisocyanate (3 5 g, 26 mmol) The mixture was heated to reflux for 8 hr at which time a yellow precipitate had formed the precipitate was filtered and the solid washed generously with 1 1 CH2C12 acetone The solid was recrystallized with hot methanol and dned under vacuum to yield 4 8 g (66% yield) of the desired 2-(o-tolylureιdo)-4-thιazoleacetic acid 225 Example 200
Figure imgf000378_0001
3-Bromo-4-hydroxybenzonitrile (5.00g, 25.25mmol) was taken up in DMF. Benzyl bromide (4.75g, 27.78mmol, 3.30mL) and Cs2C03(16.45g, 50.50mmol) were added and the reaction was heated to 50° C for 2 hr. The solution was cooled to room temperature and poured into lNHCl. The aqueous layer was extracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (hexane to 8: 1 hexane-ethyl acetate) Yield 8.90g 226.
Figure imgf000378_0002
3-Bromo-4-benzyloxybenzonitrile (1.50g, 5.21mmol) was taken up in dry THF under argon and the solution was cooled to 0° C. BH3-THF (10.41mL, 10.41mmol) was added via syringe over 5 min. The reaction mixture was then warmed to room temp then heated to reflux for
12 hr. The solution was cooled to 0° C and methanol was slowly added. When no more gas evolution was observed the solution was warmed to room temp and excess IN NaOH solution was added. Boc20 (1 25g, 5.73mmol) was added and the reaction mixture was stirred at room temp for 12 hr. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS0 . The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (7: 1 ethyl acetate-hexane) Yield 1.80g 227
Figure imgf000378_0003
The Boc-protected benzyl amine (1.80g, 4.59mmol) was dissolved in dry THF under argon. The reaction was cooled to minus 78° C. Lithium bis(trimethylsilyl)amide (13.77mL, 13.77mmol) was added over 10 min. The reaction was stirred for 1 hr at minus 78° C, then iodomethane (1.95mL, 13.77mmol, 0.86mL) was added rapidly. The reaction was allowed to slowly warm to room temp and stir overnight. The reaction was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (7:1 hexane- ethyl acetate) Yield 1.70g 228.
Figure imgf000379_0001
In a pressure tube was placed the 4-(N-methyl-Boc-aminomethyl)-2-bromobenzyloxy phenol (1.70g, 4.18mmol). The tube was then charged with DMF, sodium acetate (0.38g, 4.60mmol), dppp (0.35g, 0.84mmol), and Pd(OAc)2(0.19g, 0.84mmol) The tube was flushed with argon for 10 min and then methyl acrylate (0.40g, 4.60mmol, 0.4 lmL) was added. The tube was sealed and heated to 135 °C for 24 hr. The reaction was cooled to 0° C and the tube was slowly opened. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined orgamc layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (6:1 hexane-ethyl acetate) Yield 1.12g 229
Figure imgf000379_0002
The unsaturated ester (307.40mg, 0.75 mmol) was taken up in CH2C12 and excess TFA was added. The reaction was stirred for 4 hr at room temp. The solvent was removed under reduced pressure and the residue was dried under high vacuum. The solvent was removed and the residue was taken up in ethyl acetate and washed with sat. NaHC03 solution. The organic layer was washed with water, brine then dried over Na2S04. The solution was filtered and the solvent was removed under reduced pressure. The residue was taken up in CH2C12-DMF and HOBt ( 110.99 mg, 0.82 mmol), 3-methoxy-4-(N'-phenylureido) phenylacetic acid (258.3 lmg, 0.82 mmol) and EDCI (157.20mg, 0.82 mmol) were added. The reaction was stirred for 24 hr. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (ethyl acetate) Yield 296.30mg 230
Figure imgf000380_0001
The unsaturated ester (296.30mg, 0.49 mmol) was taken up in EtOAc and Pd/C (75mg) was added under argon. The argon atmosphere was replaced with hydrogen at 1 atmosphere and stirred for 24 hr. The hydrogen atmosphere was removed and replaced with argon. The catalyst was removed by filtration through celite and the celite pad was washed with ethyl acetate 3x. The solvent was removed under reduced pressure. H'-NMR showed only the desired product. No further purification was needed. Yield 233. OOmg 231
Figure imgf000380_0002
The ester (233.00mg, 0.45mmol) was taken up in THF-H20 (4:1) and LiOH (94.41mg, 2.25mmol) was added. The reaction mixture was stirred at room temp for 24 hr. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was washed with ether-hexane (1:1) and dried under high vacuum. Yield 211.58mg 232 Example 201
Figure imgf000380_0003
The carboxylic acid (65. OOmg, 0.13 mmol) was taken up in benzene and para- toluenesulfonic acid (lO.OOmg, 0.06 mmol) was added. A Dean-Stark trap was added and the solution was heated to reflux for 24 hr. The reaction was cooled to room temp and poured into sat. NaHC03. The organic layer was seperated and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were washed with water, brine and dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography (4:1 hexane-ethyl acetate to ethyl acetate) Yield 29.00mg 233 Example 202
Br\^ v 02Et 234 5-Bromonicotinic acid (5.15g, 25.49 mmol ) was taken up in EtOH and H2S04 (lmL) was added and the solution heated to reflux for 24 hr. The solution was cooled to rt and concentrated.
The solution was then added to sat. NaHC03 and the aqueous layer were exfracted 3 with Et20.
The combined orgamc layers were dried over Na2S0 , filtered and the solvent was removed under reduced pressure. The product was sufficiently pure for the next step. Yield 5.42g 234
N 235
The ethyl 5-Bromomcotinate (5.40g, 23.47 mmol) was taken up in 95% EtOH and NaBH4
(8.3 lg, 225.69 mmol) was added slowly at room temp. After addition the solution was stirred for
24 hr at room temp. Water was slowly added to the solution, then the mixture was stirred for 4 hr.
The EtOH was removed under reduced pressure and the aqueous layer was exfracted 3x with CH2C12. The combined orgamc layers were dried over Na2S04, filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (2:1 ethyl acetate-hexane) Yield 2.12g 235
B"QXI CI 236 The benzyl alcohol (2.12g, 11.28 mmol) was taken up Et20 and HC ^ was bubbled through the solution for 10 min. The solution was stirred at room temp for 1 hr and then the solid was collected by filfration. The solid was washed with Et 0 and the then dried. The HCl salt was added to S0C12 and the mixture was heated to reflux for 1.5 hr. The solution was cooled to room temp and Et20 was added to precipitate the product. The solid was collected by filtration, washed with Et20 and dried under vacuum. Yield 2.42g 236
Figure imgf000381_0001
The benzyl chloride (2.42g, 9.96 mmol) was added over 1 hr to CH3NH2 (75.9mL, 2.5M in EtOH) at room temp. The reaction was stirred at room temp for 48 hr. The solution was concentrated and added to sat. NaHC03. The aqueous layer was exfracted 3x with ethyl acetate.
The combined organic layers were dried over Na2S04, filtered and the solvent was removed under reduced pressure. Yield 1.19g 237
Figure imgf000382_0001
The 3-bromo-5-(N-methyl -aminomethyl)-pyridine(1.19g, 5.01 mmol) was taken up in
DMF and triethylamine (0.90g, 1.24mL, 8.89 mmol ) was added. Boc20 (1.55g, 7.10 mmol) was added and the reaction mixture was stirred at room temp for 48 hr. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography (2% methanol-CH2Cl2) Yield 1.6g 238
Figure imgf000382_0002
The sodium salt of a-methyl acrylic acid (5.00g, 46.27 mmol) was dissolved in DMF and benzyl bromide (8.70g, 50.89 mmol) was added at room temp. Potassium carbonate (7.03g, 50.89 mmol) was then added and the solution was heated to 50° C for 24 hr. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with diethyl ether. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed carefully under reduced pressure. The product was isolated by flash chromatography (2% ether-pentane) Yield 6.93g 239
Figure imgf000382_0003
In a pressure tube was placed the 3-bromo-5-(N-methyl-Boc-aminomethyl)-pyridine
(700.00mg, 2.33 mmol). The tube was then charged with DMF, triethylamine (260.05mg, 2.57mmol, 0.36mL), dppp (193.85mg, 0.47 mmol), and Pd(OAc)2 (105.52mg, 0.47 mmol) The tube was flushed with argon for 10 min then benzyl methacrylate (452.86mg, 2.57 mmol) was added. The tube was sealed and heated to 135° C for 24 hr. The reaction was cooled to 0° C and the tube was slowly opened. The solution was poured into IN HCl and the aqueous layer was extracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS0 . The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (6: 1 hexane-ethyl acetate) Yield 785.23mg 240
Figure imgf000383_0001
The unsaturated ester (392.61mg, 0.99 mmol ) was taken up in CH2C12 and excess TFA was added. The reaction was stirred for 4 hr at room temp. The solvent was removed under reduced pressure and the residue was dried under high vacuum. The solvent was removed and the residue was taken up in ethyl acetate and washed with sat. NaHC03 solution. The organic layer was washed with water, brine then dried over Na2S04. The solution was filtered and the solvent was removed under reduced pressure. The residue was taken up in CH2C12-DMF and HOBt ( 147.53mg, 1.09 mmol), 3-methoxy-4-(N'-phenylureido)phenylacetic acid ( 342.64mg, 1.09 mmol) and EDCI ( 208.96mg, 1.09 mmol) were added. The reaction was stirred for 24 hr. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (ethyl acetate) 363.79mg 241
Figure imgf000383_0002
The unsaturated ester (363. OOmg, 0.61 mmol) was taken up in CH3OH and Pd/C (100. OOmg) was added under argon. The argon atmosphere was replaced with hydrogen at 1 atmosphere and stirred for 24 hr. The hydrogen atmosphere was removed and replaced with argon. The catalyst was removed by filfration through celite and the celite pad was washed with ethyl acetate 3x. The solvent was removed under reduced pressure. H'-NMR showed only the desired product. The solid was washed with ether and then dried under high vacuum. Yield 254.79mg 242 Example 203
Figure imgf000384_0001
3-Cyanobenzaldehyde (9.41g, 71.76 mmol) was taken up in ethanol and cooled to 0° C.
The NaBH4 (2.7 lg, 71.76 mmol) was added in small portions. The solutions was stirred for 30 min at 0° C then allowed to warm to room temp and stirred for 1 hr. The reaction was slowly poured into lNHCl and the aqueous layer was extracted 3x with ethyl acetate. The combined orgamc layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The residue was taken up in DMF and imidazole (2.08g, 30.50 mmol) was added. TBDPSC1 (4.61g, 16.78 mmol, 4.36mL) was then added and the reaction was stirred at room temp for 12 hr. The solution was poured into IN HCl and the aqueous layer was extracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (7: 1 hexane-ethyl acetate to 4:1 hexane-ethyl acetate) Yield 16.23g 243
Figure imgf000384_0002
The silyl protected 3-cyanobenzyl alcohol (8.50g, 34.36 mmol) was taken up in ethyl acetate and Boc20 (8.25g, 37.79 mmol) was added. Pd/C (l.Og) was added and the Parr vessel was pressurized with hydrogen at 50 psi. The vessel was shaken for 24 hr then the hydrogen was flushed with argon and the catalyst was removed by filtration through a celite pad. The celite was washed 3x with ethyl acetate. The solvent was removed under reduced pressure and the product was isolated by flash chromatography (10:1 hexane-ethyl acetate) Yield ll.lOg 244
Figure imgf000384_0003
The 0-silyl-N-Boc-protected benzyl alcohol (5.00g, 14.22 mmol) was dissolved in dry THF under argon. The reaction was cooled to minus 78° C. Lithium bis(trimethylsilyl)amide (42.67mL, 42.67 mmol) was added over 10 min. The reaction was stirred for 1 hr at minus 78° C then iodomethane (6.06g, 42.67 mmol, 2.66mL) was added rapidly. The reaction was allowed to slowly warm to room temp and stir overnight. The reaction was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (2% ethyl acetate-hexane) Yield 4.7g 245
Figure imgf000385_0001
The O-silyl-Boc-N-methyl protected benzyl alcohol (4.7g, 9.60 mmol) was taken up in THF and TBAF (14.39mL, 1.0M in THF) at room temp. The solution was stirred for 4 hr. TLC showed no starting material present. The reaction was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (4:1 hexane-ethyl acetate to 1:1 hexane-ethyl acetate) Yield 2.39g 246
Figure imgf000385_0002
The N-methyl Boc protected benzyl alcohol (l.OOg, 3.98 mmol) was taken up in dry
CH2C12 under argon. Triphenylphosphine (1.46g, 5.57 mmol) was added and the solution was cooled to 0° C. Carbon tefrabromide (1.85g, 5.57 mmol) dissolved in dry CH2C12 was added over
10 min. The solution was stirred for 1 h at 0° C then the solvent was removed under reduced pressure. The residue was taken up in Et20 and the resulting solid was removed by filtration and the filtrate was collected and the solvent was removed under reduced pressure. The product was isolated by flash chromatography (2%ether-pentane) Yield 1.15g 247
Figure imgf000385_0003
LHMDS (3.23mL, 3.23 mmol) was added to dry DME under argon at minus 78° C. Methyl butyrate (300mg, 2.94 mmol, 0.33mL) dissolved in dry DME was added to the LHMDS over 15 min and the solution was stirred for lhr at minus 78° C. 3-N-methyl-N-Boc protected benzyl bromide (1.02g, 3.23 mmol) dissolved in dry DME was added to the enolate solution over 15 min then the solution was allowed to slowly warm to minus 20° C and stined for 4 hr. The reaction was poured into IN HCl and the aqueous layer was extracted 3x with ethyl acetate. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (3%ethyl acetate-hexane) Yield 414mg 248.
Figure imgf000386_0001
The Boc ester (121.60mg, 0.36 mmol) was taken up in CH2C12 and excess trifluoroacetic acid was added. The reaction was then stirred for 2 hr. The solvent was removed and the residue was taken up in ethyl acetate and washed with sat. NaHC03 solution. The organic layer was washed with water, brine then dried over Na2S04. The solution was filtered and the solvent was removed under reduced pressure. The residue was taken up in CH2C12-DMF and HOBt (54. lOmg, 0.40 mmol) 3-mefhoxy-4-(N'-phenylureido)phenylacetic acid (125.74mg, 0.40 mmol) and EDCI (77.0mg, 0.40 mmol) were added. The reaction was stirred for 24 hr. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (ethyl acetate) Yield 165.20mg 249
Figure imgf000386_0002
The ester (165.20, 0.31 mmol) was taken up in ethanol-water (4: 1) and NaOH was added. The reaction was then heated to 50° C for 2 hr. The TLC (ethyl acetate) showed no starting material present. The reaction was cooled to room temp. The solution was poured into IN HCl and the aqueous layer was extracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The residue was recrystallized from ethyl acetate-hexane. Yield 120.00mg 250 Example 204
Figure imgf000386_0003
Butyrolactone (250mg, 2.90 mmol, 223.20mL) was added to LHMDS (2.90mL, 1.0M in hexane) in THF at minus 78° C under argon over lOmin. The solution was stirred at minus 78°C for lhr. 3-N-methyl-N-Boc protected benzyl bromide (991.24mg, 2.90 mmol) dissolved in dry DME was added to the enolate solution over 15 min then the solution was allowed to slowly warm to room temp and stirred for 12 hr. The reaction was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (4: 1 hexane-ethyl acetate to 1:1 ethyl acetate-hexane) Yield 501.18mg 251
Figure imgf000387_0001
The Boc ester (250. OOmg, 0.78 mmol) was taken up in CH2C12 and excess trifluoroacetic acid was added. The reaction was then stirred for 2 hr. The solvent was removed and the residue was taken up in ethyl acetate and washed with sat. NaHC03 solution. The organic layer was washed with water, brine then dried over Na2S04. The solution was filtered and the solvent was removed under reduced pressure. The residue was taken up in CH2C12-DMF and HOBt (116.40mg, 0.86 mmol) 3 -methoxy-4-(N' -phenylraeido) phenylacetic acid (270.33mg, 0.86 mmol) and EDCI (165.06mg, 0.86 mmol) were added. The reaction was stirred for 24 hr. The solution was poured into IN HCl and the aqueous layer was exfracted 3x with ethyl acetate. The combined organic layers were washed with water, brine then dried over MgS04. The solution was filtered and the solvent was removed under reduced pressure. The product was isolated by flash chromatography. (ethyl acetate) Yield 119.00mg 252 Example 205 3-methoxy-4-[2-[3-methoxy-4-[Λ^-(2-methylphenyl)ureido]phenylacetyl]-N-methylaminoethoxy] benzoic acid
Figure imgf000387_0002
To a stirred and cooled (0° C) solution of N-methyl ethanolamine (3.10 g, 41.27 mmol), Et3N ( 11.80 mL, 84.66 mmol) in DMF-H20 (3:1, v/v, 40 mL) was added dropwise 30% toluene solution of benzyl chloroformate (25.40 g, 49.13 mmol) for over 15 min. The resulting mixture was stirred for 1 day at room temp. The mixture was extracted with EtOAc. The exfract was washed with sat. NaHC03, brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with n-hexane:EtOAc (3:1, v/v) then CHCl3as eluent to give 4.67 g (54%) jV-methyl-N-(benzyloxy carbonyl)ethanolamine as a colorless oil. Η-NMR (CDC13) d 1.82 (bs, 1 H), 3.00 (s, 3 H), 3.46 (bs, 2 TT), 3.77 (bs, 2 H), 5,13 (s, 2 H), 7.29-7.36 (m, 5 H).
To a stirred solution of ethyl 4-hydoxy-3 -methoxybenzoate (2.01 g, 10.25 mmol), N- methyl-N-(benzyloxycarbonyl)ethanolamine (2.11 g, 10.08 mmol), PPh3 (3.26 g, 12.43 mmol) in THF was added DIAD (2.65 mL, 13.46 mmol) and the reaction mixture was heated under reflux overnight. The mixture was evaporated, and the residue was subjected to short column chromatography on silica-gel with n-hexane/EtOAc (5:1, v/v) as eluent to give ethyl 3-methoxy-4- [2-methyl-2-(benzyloxycarbonyl) aminoethoxy]benzoate as a crude product.
To a solution of the crude product (5.20 g, 13.42 πunol) in EtOH (50 mL) was added AcOH (5 mL) and the solution was hydrogenated over 5% Pd/C for 4 hr. The mixture was filtered to remove the catalyst and the filtrate was evaporated. The residue was diluted with CHC13 and washed with sat. NaHC03, brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel with CHCl3:MeOH (10: 1, v/v) as eluent to give 510 mg (2 steps 20%>) ethyl 3-methoxy-4-(2 -methylamino ethoxy) benzoate as a yellow oil. 'H-NMR (CDC13) d 1.39 (t, 3 H, J=7.3 Hz), 1.82 (bs, 1 H), 2.52 (s, 3 H), 3.04 (t, 2 H, .7=5.3 Hz), 3.91 (s, 3 H), 4.18 (t, 2 H, J=5.3 Hz), 4.36 (q, 2 H, .7=7.3 Hz), 6.90 (d, 1 H, .7=8.3 Hz), 7.55 (d, 1 H, .7=2.0 Hz), 7.65 (dd, 1 H, .7=2.0, 8.3 Hz).
To a stirred solution of ethyl 3-methoxy-4-(2-methylaminoethoxy) benzoate (510 mg, 2.01 mmol) in DMF (13 mL) was added pentafluorophenyl ester of 3-methoxy-4-[N'-(2- methylphenyl) ureido] phenylacetic acid (900 mg, 1.87 mmol) and Et3N (0.420 mL, 3.01 mmol), and the resulting mixture was stirred for 2 days. The mixture was diluted with EtOAc, washed with 1 N HCl, sat. NaHC03, brine, and dried over Na2S04. After being evaporated, the residue was purified by column chromatography on silica-gel with CHCl3:MeOH (50: 1, v/v) to give 880 mg (85%) ethyl 3-methoxy-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)raeido]phenylacetyl]-N- methylaminoethoxy] benzoate as a colorless amorphous solid. 'H-NMR (CDC13) d 1.37-1.41 (m, 3 H), 2.28 (s, 3 H), 3.03 and 3.18 (s, 3 H), 3.56 (s, 2 H), 3.65 (s, 2 H), 3.75-3.87 (m, 6 TT), 4.06-4.24 (2 H, m), 4.33-4.39 (m, 2 H), 6.68-8.08 (series of m, 12 TT).
To a solution of ethyl 3-methoxy-4-[2-[3-methoxy-4-[iV-(2-methylphenyl)ureido] phenylacetyl]-N-methlaminoethoxy]benzoate (880 mg, 1.601 mmol) in THF (15 mL) was added 0.25 N NaOH (15 mL). Then the reaction mixture was heated under reflux overnight. The mixture was poured into 1 N HCl (100 mL), and the solid was collected. The crude solid was recrystallized from MeOH-CHCl3 to give 253 as a white powder. IR (KBr) 1700 cm"1; 'H-NMR (DMSO-cL.) d 2.25 (s,3 H), 2.50 (s, 2 H), 2.91 and 3.12 (s, 3 H) 3.53-3.76 (m, 2 H), 3.80 (s, 3 H), 3.84 (s, 3 H), 4.16-4.21 (m, 2 TT), 6.72-8.56 (series of m, 12 H), 12.68 (bs, 1 H); MS (FAB) m/z 522 (M++l); Anal. Calcd. for C28H31N307- 1H20: C, 62.33; H, 6.16; N, 6.63. Found: C, 62.17; H, 6.05; N, 7.57. Example 206
4-[[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]methylamino]ethoxy]isophthalic acid
Figure imgf000389_0001
To a stirred solution of N-methyl-N-benzyloxycarbonylethanolamine (1.05 g, 5.02 mmol), dimethyl 4-hydroxy isophthalate (1.05 g, 5.00 mmol), Ph3P (1.59 g, 6.06 mmol) in THF (20 mL) was added DIAD (1.28 mL, 6.50 mmol) at room temp. The resulting mixture was then heated under reflux overnight. After cooling to room temp, the mixture was evaporated. The residue was dissolved in EtOH and added 5% Pd/C(200mg). The stirred resulting mixture was hydrogenated for 2 hr at latin. The mixture was filtered to remove the catalyst, and the filtrate was evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (30:1, v/v) as eluent to give 480 mg (36% for 2 steps) dimethyl 4-(2-methylaminoethoxy) isophthalate as an oil. 'H-NMR (CDC13) d 1.68 (s, 1 H), 2.53 (s, 3 H), 3.01-3.04 (m, 2 H), 3.89 (s, 3 H), 3.90 (s, 3 H), 4.21-4.23 (m, 2 H), 7.00 (d, 1 H, J=8.8 Hz), 8.14 (dd, 1 H, =2.4, 8.8 Hz), 8.50 (d, 1 H, J=2.4 Hz); MS (FAB), m/z 268 (M++l).
To a stirred solution of dimethyl 4-(2-methylaminoethoxy)isophthalate (410 mg, 1.53 mmol) in DMF (13 mL) was added pentafluorophenyl ester of 3-methoxy-4-[N'-(2- methylphenyl)ureido] phenylaceic acid (700 mg, 1.46 mmol) and Et3N (340 μl, 2.44 mmol), and the resulting mixture was stirred overnight. The mixture was diluted with EtOAc, washed with 1 N HCl, sat. NaHC03, and brine. The solution was dried over Na2S04 and evaporated to give 780 mg (95%) dimethyl 4- [2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]methylamino ethoxyjisophthalate as a crystalline powder. 'H-NMR (CDC13) d 2.29 (s, 3 H), 3.24 (s, 3 H), 3.59 (s, 3 H), 3.67-3.68 (m, 2 H), 3.84 (s, 3 H), 3.91 (s, 3 H), 3.81-3.86 (m, 2 H), 4.25-4.28 (m, 2 H), 6.51-8.48 (series of m, 12 H); MS (FAB) m/z 564 (M++1). To a solution of dimethyl 4- [2-[3-methoxy-4-[Λr'-(2-methylphenyl)ureido]phenylacetyl] methylaminoethoxy] isophthalate (780 mg, 1.384 mmol) in THF (30 mL) was added 0.25 N NaOH (30 mL). The resulting mixture was then heated under reflux overnight. The mixture was poured into ice-1 N HCl (200 mL) and the solid was collected. The crude solid was reciystallized from MeOH-CHCl3 to give 420 mg (57%) 4-[[2-[3-methoxy-4-[ΛT-(2-methylphenyl)raeido]phenyl acetyl]methylamino]ethoxy] isophthalic acid 254 as a white crystalline powder, mp 139-141 °C IR (KBr) 1700 cm '; Η-NMR (DMSO-cL.) d 2.94 (s, 3 H), 3.18 (s, 3 H) 3.62-3.86 (m, total 8 H), 4.24- 4.28 (m, 2 H), 6.74-8.58 (series of m, total 12 H), 12.91 (bs, 1 TT); MS (FAB) m/z 536 (M++l); Anal. Calcd. for C28H29N308 2.5HC1: C, 53.66; H, 5.07; N, 6.70. Found: C, 53.80; H, 4.64; N, 6.70. Example 207
3-methoxy-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]aminoethoxy]benzoic acid
Figure imgf000390_0001
To a solution of 2-ethanolamine (5.16 g, 84.48 mmol), Et3N (23.50 mL, 168.60 mL) in dioxane-H20 (1/1, 160 mL) was added dropwise (Boc)20 (23.40 mL, 101.86 mmol) at room temp. The reaction mixture was stirred for 2 days at room temp. The resulting mixture was diluted with CHC13, washed with 0.5 N HCl, sat. NaHC03, and brine. The separated organic layer was dried over Na2S04 and evaporated to give 11.86 g (87%) N-Boc-2-ethanolamine as an oil. 'H-NMR (CDC13) d 1.45 (s, 9 TT), 3.29-3.31 (m, 2 TT), 3.71-3.72 (m, 2 H).
To a stirred solution of ethyl 4-hydroxy-3 -methoxybenzoate (1.46 g, 7.44 mmol), N-Boc ethanolamine (1.19 g, 7.38 mmol), PPh3 (2.53 g, 9.65 mmol) in THF (30 mL) was added DIAD (1.90 mL, 9.65 mmol), and the resulting mixture was then heated under reflux overnight. The mixture was evaporated to give a crude gum. The crude product was dissolved in CH2C12 (20 mL) and TFA (20 mL). The resulting mixture was stirred for 2.5 hr at room temp. The mixture was concentrated in vacuo and the residue was made basic with sat. NaHC03 and exfracted with CHC13. The exfract was washed with brine, dried over Na2S04, and evaporated to give the 1.61 g (90% for 2 steps ) ethyl 3-methoxy-4-(2-aminoethoxy) benzoate as a yellow oil. 'H-NMR (CDC13) d 1.39 (t, 3 H, J=7.3 Hz), 3.14-3.17 (m, 2 TT), 3.92 (s, 3 TT), 4.09-4.11 (m, 2 H), 4.36 (q, 2 H, .7=7.3 Hz), 6.89 (d, 1 H, J=8.3 Hz), 7.56 (d, 1 H, .7=2.0 Hz), 7.66 (dd, 1 H, .7=2.0, 8.3 Hz). To a stirred solution of ethyl 3-methoxy-4-(2-aminoethoxy)benzoate (250mg, 1.04 mmol) and pentafluorophenyl ester of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (500 mg, 1.04 mmol) was added Et3N (210 μl, 3.01 mmol), and the resulting mixture was stirred for 2 days. 0.25 N NaOH (20 mL) and THF (20 mL) was added to the mixtrae and the resulting mixture was heated under reflux overnight. After cooling, the mixture was evaporated and the residue was acidified by the addition of 1 N HCl. The mixture was extracted with CHC13, and the exfract was washed with brine, dried over Na2S04, and evaporated. The obtained crude solid was recrystallized from CHC13 to give 110 mg (20% for 2 steps ) 3-methoxy-4-[2-[3-methoxy-4-[N' -(2-methylphenyl) ureido]phenylacetyl]aminoethoxy] benzoic acid 255 as a white ciystalline powder, mp 180-181 °C; IR (KBr) 1687 cm '; 'H-NMR (DMSO-cL.) d 2.24 (s, 3 H), 3.37 (s, 2 H), 3.38 (s, 2 H), 3.41- 3.50 (m, 2 H), 3.81 (s, 3 H), 3.83 (s, 3 H), 4.06-4.08 (m, 2 H), 6.76-8.55 (series of m, total 12 H); MS (FAB) m/z 508 (M++l); Anal. Calcd for C27H29N307-1/2H20: C, 62.78; H, 5.85; N, 8.13. Found: C, 62.46; H, 5.69; N, 8.03. Example 208 3-methoxy-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]ethylaminoethoxy] benzoic acid
Figure imgf000391_0001
To a cooled (0° C) solution of ethyl 3-methoxy-4-(2-aminoethoxy)benzoate (1.93 g, 8.07 mmol) and Et3N (2.00 mL, 14.35 mmol) was added TFAA (1.35 mL, 9.56 mmol) and the resulting mixture was stirred overnight at room temp. The resulting mixture was diluted with Et20 and washed successively with sat. NaHC03, 1 N HCl, H20, and brine. The exfract was dried over Na2S04 and evaporated to give 1.22 g (45%) ethyl 3-methoxy-4-(2-N-trifluoroacetamidoethoxy) benzoate as an oil. 'H-NMR (CDC13) d 1.39 (t, 3 H, .7=7.3 Hz), 3.77-3.81 (m, 2 H), 3.92 (s, 3 H), 4.18-4.20 (m, 2 H), 4.37 (q, 2 H, .7=7.3 Hz), 6.92 (d, 1 H, .7=8.7 Hz), 7.59 (d, 1 H, .7=2.0 Hz), 7.67 (dd, 1 H, .7=2.0, 8.7 Hz); MS (FAB) m/z 335 (M+), 290 (M÷-OEf).
To a stirred solution of ethyl 3-methoxy-4-(2-Λ rifluoroacetamidoethoxy)benzoate (1.20 g, 3.58 mmol) in DMF (15 mL) was added K2C03 (0.98 g, 7.09 mmol) and Etl (0.43 mL, 5.38 mmol) at room temp. The resulting mixture was stirred for 2 days at 60° C. The mixture was diluted with EtOAc, washed successively with 1 N HCl, brine, and dried over Na2S04. The solvent was evaporated and the residue was purified by column chromatography on silica-gel with n- hexane-EtOAc (2:1, v/v) as eluent to give 990 mg (76%) ethyl 3-methoxy-4-[2-(N-ethyl-N- frifluoroacetamido)ethoxybenzoate as a yellow crystalline solid. 'H-NMR (CDC13) d 1.28-1.31 (m, 3 H), 1.37-1.40 (m, 3 TT), 3.64-3.69 (m, 2 H), 3.81-3.84 (m, 2 H), 3.92 (s, 3 H), 4.27-4.30 (m, 2 H), 4.34-4.39 (m, 2 H), 6.89 (d, 1 H, .7=8.3 Hz), 7.55 (d, 1 H, J=2.0 Hz), 7.66 (dd, 1 H, J=2.0, 8.3 Hz); MS (FAB) m/z 364 (M++l).
To a stirred solution of ethyl 3-methoxy-4-[2-(N-ethyl-N-frifluoroacetamido) ethoxybenzoate (990 mg, 2.73 mmol) in THF-MeOH-H20 (2: 1: 1, v/v, 20 mL) was added K2C03 (560 mg, 4.05 mmol), and the resulting mixture was stirred overmght. The resulting mixture was diluted with H20 and extracted with EtOAc The extract was washed successively with sat. NaHC03, brine, dried over Na2S04, and evaporated to give 800 mg (q.y.) ethyl 3-methoxy-4-(2- ethylaminoethoxy)benzoate as an oil. Η-NMR (CDC13) d 1.15 (t, 3 H, .7=7.3 Hz), 1.39 (t, 3 H, =7.3 Hz), 1.76 (bs, 1 H), 2.74 (q, 2 H, =7.3 Hz), 3.08 (t, 2 H, .7=5.4 Hz), 3.91 (s, 3 H), 4.18 (t, 2 H, .7=5.4 Hz), 4.36 (q, 2 H, .7=7.3 Hz), 6.90 (d, 1 H, J=8.3 Hz), 7.55 (d, 1 H, .7=2.0 Hz), 7.66 (dd, 1 H, .7=2.0, 8.3 Hz); MS (FAB) m/z 268 (M++l).
To a stirred solution of ethyl 3-methoxy-4-(2-ethylaminoethoxy)benzoate (290 mg, 1.08 mmol) and pentafluorophenyl ester of 3-methoxy-4-[Λ -(2-methylphenyl)ureido]phenylacetic acid (502 mg, 1.05 mmol) in DMF (7 mL) was added Et3N (250 μl, 1.79 mmol), and the resulting mixture was stirred overmght. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, and dried over Na2S04. The solvent was evaporated and the residue was purified by column chromatography on silica-gel with CHCl3-MeOH (40: 1, v/v) as an eluent to give 550 mg (93%) ethyl 3-methoxy-4-[2-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido] phenylacetyl]ethylaminoethoxy] benzoate as an amorphous solid. 'H-NMR (CDC13) d 1.11-1.18 (m, 3 H), 1.37-1.41 (m, 3 TT), 2.30 (s, 3 TT), 3.47-3.53 (m, 2 H), 3.61-3.75 (m, 7 TT), 3.84 (s, 3 H), 4.03-4.27 (m, 2 H), 4.33-4.39 (m, 2 H), 6.34-8.07 (series of m, total 12 H).
To a solution of ethyl 3-methoxy-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl acetyl]ethylaminoethoxy]benzoate (550 mg, 0.98 mmol) in THF (15 mL) was added 0.25 N NaOH (15 mL). The resulting mixture was then heated under reflux for 2 days. The mixtiire was poured into 1 N HCl and the solid was collected. The crude solid was recrystallized from EtOH-CHCl3 to give 182 mg (35%) 3-methoxy-4-[2-[3-methoxy-4-[Λ^-(2-methylphenyl)ureido]phenylacetyl] ethylaminoethoxy]benzoic acid 256 as a white crystalline powder, mp 115-118 °C; IR (KBr) 1707 cm'1; 'H-NMR (DMSO-cL.) d 1.02-1.12 (m, 3 H), 2.25 (s, 3 H), 2.50 (s, 2 H), 3.35-3.89 (m, 10 H), 4.11-4.16 (m, 2H), 6.71-8.56 (series of m, total 12H), 12.65 (br s, IH); MS (FAB) m/z 536 (M++l); Anal. Calcd for C29H33N307-3/4H20: C, 63.43; H,6.33; N, 7.65. Found: 63.34; H, 6.28; N, 7.28. Example 209 3-mtro-4-[2-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenylacetyl]aminoethoxy]benzoic acid
Figure imgf000393_0001
To a stirred solution of 4-hydroxy-3-nifrobenzoic acid (5.18 g, 28.29 mmol) in benzene- MeOH (4: 1, v/v, 140 mL) was added TMSCHN2 (14.10 mL, 28.20 mmol, 2 M solution in hexane) at room temp, and the resulting mixture was stirred overnight. The mixture was evaporated and the residue was purified by column chromatography on silica-gel with CHC13 as eluent to give 4.18 g (75%) methyl 3-nitro-4-hydroxybenzoate as a yellow crystalline solid. 'H-NMR (CDC13) d 3.95 (s, 3H), 7.22 (d, IH, .7=8.8 Hz), 8.24 (dd, 1 , J=2.0, 8.8 Hz), 8.83 (d, IH, .7=2.0 Hz), 10.89 (s, IH).
To a stirred solution of methyl 3-nifro-4-hydroxybenzoate (1.98 g, 10.04 mmol), N-Boc ethanolamine (1.63 g, 10.11 mmol) and PPh3 (3.43 g, 13.08 mmol) in THF (40 mL) was added DIAD (2.57 mL, 13.05 mmol), and the reaction mixture was then heated under reflux overnight. The resulting mixture was evaporated to give a gum. The residual crude gum was dissolved in CH2C12 (30 mL) and TFA (30 mL), and the mixture was stirred for 1 hr at room temp. The mixture was concenfrated in vacuo and made basic with sat. NaHC03. The mixture was exfracted with CHC13, washed with brine, and dried over Na2S04. The solvent was evaporated in vacuo to give the oily residue, which was purified by column chromatography on silica -gel with CHC13 then CHCl3-MeOH (20:1, v/v) as eluent to give 930 mg (27% for 2 steps ) methyl 3-nitro-4-(2- aminoethoxy) benzoate as gum. 'H-NMR (CDC13) d 3.16-3.19 (m, 1 H), 3.53-3.57 (m, 1 H), 3.90 and 3.94 (s, 3 H), 3.95-3.98 (m, 1 TT), 4.21-4.24 (m, 1 H), 6.89-6.91 and 7.11-7.13 (m, 1 H), 8.03- 8.19 and 8.21 (m, 1 H), 8.52 and 8.86 (m, 1 H).
To a stirred solution of pentafluorophenyl ester of 3-methoxy-4-[N' -(2-methylphenyl) ureido] phenylacetic acid (1.86 g, 3.87 mmol) and methyl 3-mtro-4-(2-aminoethoxy)benzoic acid (0.93 g, 3.87 mmol) in DMF (27 mL) was added Et3N (0.90 mL, 6.46 mmol), and the resulting mixture was stirred overnight. The mixture was poured into 0.5 N HCl and the resulting solid was collected. The crude solid was dissolved in THF-0.25 N NaOH (1/1, 20 mL) and the resulting mixture was heated under reflux overnight. The mixture was exfracted with EtOAc, washed with brine, dried over Na2S04, and evaporated. The crude solid was recrystallized from CHCl3-EtOH to give 60 mg (3% for 2 steps) 3-nifro-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl] aminoethoxy]benzoic acid 257 as a yellow ciystalline solid, mp 112-115 °C; 'H-NMR (DMSO-cL,) d 2.24 (s, 3 H), 3.37-3.66 (m, 7 H), 3.84 (s, 3 TT), 4.27-4.30 (m, 1 H), 6.74-8.56 (series of m, total 12 H); MS (FAB) m/z 523 (M++l); Anal Calcd for C26H26N408-3/2H20: C, 56.83; H, 5.32; N, 10.20. Found: C, 56.66; H, 4.90; N, 9.33. Example 210
3-methoxy-4-[2-[3-methoxy-4-[Λr'-(2-fluorophenyl)ureido]phenylacetyl]ethylaminoethoxy] benzoic acid
Figure imgf000394_0001
To a stirred solution of pentafluorophenyl ester of 3-methoxy-4-[N' -(2 -fluorophenyl) ureido] phenylacetic acid (135 mg, 0.28 mmol) and ethyl 3-methoxy-4-(2-ethylaminoethoxy) benzoate (78 mg, 0.29 mmol) was added Et3N (O.lmL, 0.72 mmol), and the resulting mixture was stirred overnight. The mixture was diluted with EtOAc, washed successively with 0.5N HCl, brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica- gel with CHCl3-MeOH (50: 1, v/v) as eluent to give 160 mg(qy.) ethyl 3-methoxy-4-[2-[3-methoxy -4-[W-(2-fluorophenyl) ureido]phenylacetyl]ethylaminoethoxy]benzoate as an oil. 'H-NMR (CDC13) d 1.13-1.23 (m, 3 TT), 1.37-1.40 (m, 3 H), 2.90-3.89 (m, 12 H), 4.09-4.28 (m, 2 H), 4.33- 4.39 (m, 2 H), 6.70-8.21 (series of m, total 12 TT).
To a stirred solution of ethyl 3-methoxy-4-[2-[3-methoxy-4-[N'-(2-fluorophenyl)ureido] phenylacetyl]ethylaminoethoxy]benzoate (160 mg, 0.28 mmol) in THF (5 mL) was added 0.25 N NaOH (5 mL) and the resulting mixture was the heated under reflux overmght. The mixture was poured into 1 N HCl and the solid was collected. The crude solid was recrystallized from EtOH- CHCl3-n-hexane to give 70 mg (46%) 3-methoxy-4-[2-[3-methoxy-4-[N'-(2-fluorophenyl)ureido] phenylacetyl]ethylaminoethoxy] benzoic acid 258 as a yellow crystalline powder, mp 105-110 °C; IR (KBr) 1687 cm '; 'H-NMR (DMSO-cL.) d 1.00-1.10 (m, 3 H), 2.48 (s, 2 TT), 3.35-3.81 (m, 10 H), 4.13-4.14 (m, 2 TT), 6.70-9.15 (series of m, 12 H); MS (FAB) m/z 540 (M++l); Anal. Calcd for C28H30FN3O7 l/2H2O: C, 61.31; H, 5.82; N, 7.47. Found: C, 61.05; H, 5.82; N, 7.47. Example 211
4-[4-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]acetyl-l-piperazinylbenzoic acid
Figure imgf000395_0001
A stirred mixture of ter/-butyl 1-piperazinecarboxylate (1.00 g, 5.37 mmol), ethyl 4- fluorobenzoate (903 mg, 5.37 mmol), and K2C03 (1.11 g, 8.06 mmol) in DMF (10 mL) was heated at 120° C overnight. After cooling, the mixture was diluted with EtOAc (300 mL), followed by washing with brine (2 x 200 mL), drying over MgS04, and evaporation. The residue was chromatographed on silica-gel with CHCl3-EtOAc (20: 1 to 4: 1, v/v) as eluent to give 257 mg (14%) ethyl 4-[4-(tert-butyloxycarbonyl)-l-piperazinyl]benzoate as a pale yellow amorphous solid. IR (KBr) 1701, 1612 cm '; 'H-NMR (CDC13) d 1.37 (3 H, t, = 7.3 Hz), 1.49 (9 H, s), 3.30 (4 H, t, J = 5.4 Hz), 3.58 (4 H, t, J= 5.4 Hz), 4.33 (2 H, q, J= 7.3 Hz), 6.87 (2 H, d, J= 8.8 Hz), 7.94 (2 H, dt, .7= 8.8, 2.4 Hz); MS (FAB) m/z 335 (M++l); Anal Calcd for C18H26N204: C, 64.54; H, 7.84; N, 8.38. Found: C, 64.39; H, 7.89; N, 8.38.
To a stirred solution of ethyl 4-[4-(ter/-butyloxycarbonyι)-l-piperazinyl]benzoate (240 mg, 0.718 mmol) in CH2C1 (5 mL) was added TFA (5 mL), and the resulting mixtiire was stirred for 3 hr. The mixture was concentrated in vacuo and the residue was made basic by the addition of sat. NaHC03, followed by extraction with CHC13 (2 x 100 mL). The combined extracts were dried over Na2C03 and evaporated to give 168 mg ethyl 4-(l-piperazinyl)benzoate (100%) as a yellow oil. 'H-NMR (CDC13) d 1.37 (3 H, t, J= 7.3 Hz), 3.03 (4 H, t, J = 4.9 Hz), 3.29 (4 H, t, J = 4.9 Hz), 4.33 (2 H, q, J = 7.3 Hz), 6.87 (2 H, dt, J = 8.8, 2.4 Hz), 7.91-7.94 (2 H, m).
To a stirred solution of ethyl 4-(l-piperazinyl)benzoate (170 mg, 0.730 mmol) and 3- methoxy-4-[Λ^-(2-methylphenyl)ureido]phenylacetic acid (229 mg, 0.730 mmol) in DMF (10 mL) was added EDCHCl (210 mg, 1.10 mmol), DMAP (catalytic amount), and HOBt (catalytic amount), and the mixture was stirred overnight. The mixture was poured into H20 (100 mL) and the solid was collected with suction. The residue was reciystallized from CHCl3-n-hexane to give 290 mg (75%) ethyl 4-[4-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]acetyl-l-piperazinyl benzoate as a colorless crystalline powder, mp 208-210 °C; IR (KBr) 1711, 1695 cm '; Η-NMR (CDC13) d 1.37 (3 H, t, J= 7.3 Hz), 2.29 (3 H, s), 3.14 (2 H, t, J = 4.9 Hz), 3.28 (2 H, t, = 4.9 Hz), 3.62 (2 H, t, J = 4.9 Hz), 3.71 (3 H, s), 3.72 (2 H, s), 3.79 (2 H, t, J = 4.9Hz), 4.33 (2 H, q, J = 7.3 Hz), 6.38 (1 H, s), 6.78-6.99 (4 H, m), 7.13-7.24 (4 H, m), 7.50 (1 H, d, J = 7.8 Hz), 7.92 (2 H, d, J = 8.8 Hz), 8.12 (1 H, d, J= 7.8 Hz); MS (FAB) m/z 531 (M +l); Anal. Calcd for C30H34N4O5 0.5H2O: C, 66.77; H, 6.54; N, 10.38. Found: C, 66.89; H, 6.39; N, 10.45.
To a stirred solution of ethyl 4-[4-[3-methoxy-4-[Λr'-(2-methylρhenyι)ureido]phenyl]- acetyl-1-piperazinylbenzoate (290 mg, 0.547 mmol) in MeOH-THF (2: 1, v/v, 15 mL) was added 0.25 N NaOH (5 mL, 1.25 mmol) and the mixture was heated under reflux for 3 hr. The mixture was poured into ice-lN HCl (100 mL) and the solid was collected with suction. The residue was recrystallized from CHCl3-MeOH to give 190 mg (69%) 4-[4-[3-methoxy-4-[N' -(2-methylphenyl) ureido]phenyl]acetyl-l-piperazinylbenzoic acid 259 as a yellow crystalline powder, mp 240-245 °C; 'H-NMR (DMSO) d 2.24 (3 H, s), 3.17-3.50 (8 H, m), 3.72 (2 H, s), 3.86 (3 H, s), 6.77 (1 H, d, J= 8.3 Hz), 6.90 (1 H, s), 6.91-6.96 (3 H, m), 7.11-7.17 (2 H, m), 1.16-1. SO (3 H, m), 8.03 (1 H, d, J= 8.3 Hz), 8.47 (1 H, s), 8.58 (1 H, s), 12.30 (1 H, s); Λnα/.Calcd for C28H30N4O5 H2O: C, 64.60; H, 6.20; N, 10.76. Found: C, 64.64; H, 5.85; N, 10.51.
Example 212
(R)-3 -methoxy-4-[2-[3 -methoxy-4- [N '-(2-methylphenyl)ureido]phenylacetylamino] - 1 -propoxy] benzoic acid
Figure imgf000396_0001
To a cooled (0°C) solution of (Λ)-2-amino-l-propanol (3.01 g, 0.04 mmol) and Et3N (6.70 mL, 0.05 mmol) in DMF-H20 (1: 1, v/v)(40 mL) was added (Boc)20 (10.0 mL, 0.04 mmol), and the resulting mixture was stirred at room temp for 2 days. The mixture was diluted with EtOAc, washed with H20, brine, dried over Na2S04 and evaporated to give 6.91 g (98%) (R)-2-N- fert-butoxycarbonylamino-1-propanol as a colorless oil. 'H-NMR (CDC13) δl.15 (d, 3 H, .7=6.8 Hz), 1.45 (s, 9 H), 3.48-3.53 (m, 1 H), 3.62-3.66 (m, 1 H), 3.76-3.77 (m, 1 H); MS (FAB) m/z 176 (M++l), 120 (M+-*Bu).
To a stirred solution of ethyl 4-hydroxy-3 -methoxybenzoate (7.74 g, 0.04 mmol), (R)-2-N- te -butoxycarbonylamino-1-propanol (6.91 g, 0.04 mmol) and Ph3P (13.44 g, 0.05 mmol) in THF (70 mL) was added diisopropyl azodicarboxylate(DIAD)(10.0 mL, 0.05 mmol), and the resulting mixture was heated under reflux overnight. After cooling to room temp, the solvent was evaporated. The mixture was dissolved in CH2C12 (50 mL) and TFA (30 mL) and the solution was stirred at room temp for 1 hr. After concentration in vacuo, the residue was poured into sat. NaHC03 and exfracted with CHC13. The exfract was washed with brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with 5% MeOH in CHC13 as eluent to give 7.93g (2 steps 79%) ethyl (Λ)-3-methoxy-4-(2-amino-l-propoxy)benzoate as a yellow oil. 'H-NMR (CDC13) δ 1.90 (d, 3 H, .7=6.8 Hz), 1.39 (t, 3 H, J=7.3 Hz), 1.72 (bs, 2 H), 3.42-3.47 (m, 1 H), 3.74-3.89 (m, 1 H), 3.91 (s, 3 TT), 3.96-4.00 (m, 1 H), 4.35 (q, 2 H, J=7.3 Hz), 6.88 (d, 1 H, J=8.3 Hz), 7.55 (d, 1 H, =2.0 Hz), 7.65 (dd, 1 H, .7=2.0, 8.3 Hz); MS (FAB) m/z 254 (M++l).
To a stirred solution of pentafluorophenyl 3-methoxy-4-[N'-(2-methylphenyl)raeido] phenylacetate (459 mg, 0.96 mmol) and ethyl (R)-3-methoxy-4-(2-aminopropoxy)benzoate (242 mg, 0.96 mmol) in DMF (5 mL) was added Et3N (200 μl, I A3 mmol), and the resulting mixture was stirred for 2 hr. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50: 1, v/v) as eluent to give 360 mg (69%) ethyl (Λ)-3-methoxy-4-[2-[3- methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetylamino]-l-propoxy]benzoate as a colorless crystalline solid. 'H-NMR (CDC13) δ 1.23-1.28 (m, 3 H), 1.38-1.41 (t, 3 H, .7=7.3 Hz), 2.32 (s, 3 H), 3.50-4.13 (m, total 11 H), 4.36 (q, 2 H, .7=7.3 Hz), 6.65-8.13 (series of m, total 12 H).
To a stirred solution of ethyl (Λ)-3-methoxy-4-[2-[3-methoxy-4-[N'-(2 -methylphenyl) ureido] phenylacetylamino]-l-propoxy]benzoate (360 mg, 0.66 mmol) in THF-MeOH (20 mL, 9: 1, v/v) was added 0.25 N NaOH (10 mL), and the resulting mixtrae was heated under reflux overnight. The mixture was poured into ice-1 N HCl, and precipitate was collected. The crude solid was recrystallized from CHCl3-n-hexane to give 172 mg(50%) 260 as a white crystalline powder, mp 168-169 °C; IR (KBr) 1687 cm '; 'H-NMR (DMSO-cL.) δ 1.18 (d, 3 H, .7=6.8 Hz), 2.24 (s, 3 H), 2.50-2.51 (m, 2 H), 3.80 (s, 3 H), 3.84 (s, 3 H), 3.87-4.06 (m, 2 H), 4.07-4.14 (m, 1 H), 6.76-8.57 (series of m, total 12 TT), 12.66 (bs, 1 H); MS (FAB) m/z 522 (M++T); Anal Calcd for C28H31N307-3/4 H20: C, 62.85; H, 6.12; N, 7.85. Found: C, 62.77; H, 5.95 N, 7.79. Example 213 4-[[2-[3-methoxy-4-[Λ''-(2-methylphenyl)ureido]phenylacetyl]allylamino]ethoxy]benzoic acid
Figure imgf000397_0001
To a stirred mixture of ethyl 4-(2-N-trifluoroacetylaminoethoxy)-3-methoxy benzoate (3.5g, 10.4mmol)and K2C03(2.3g, 16.4mmol) in DMF (20mL) was added allyl bromide (14.2mL, 16.5mmol), and the resulting mixture was stirred for 45 min at 65° C. After cooling, water was added to the mixture and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated in vacuo. The residue was dissolved in THF-MeOH-H20 (1 : 1 : l,v/v/v) (30 mL) and added K2C03 (2.3 g, 16.4 mmol). The resulting mixture was stirred for 16 hr at room temp. The mixture was diluted with EtOAc, washed with brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel with CHCl3:MeOH (95:5 to 95:5, v/v) as eluent to give 2.9 g (100%) ethyl 4-(2-allylaminoethoxy)-3-methoxybenzoate as a pale-yellow oil. 'H-NMR(CDC13, 400MHz) δ 1.39 (t, 3H, J=7.3Hz), 3.07 (t, 2H, J=5.3Hz), 3.34 (d, 2H, J=5.9Hz), 3.91 (s, 3H), 4.18 (t, 2H, J=5.4Hz), 4.35 (dd, 2H, J=7.3Hz, 14.1Hz), 5.12 (d, IH, =10.3Hz), 5.22 (dd, IH, =1.5Hz, 17.1Hz), 5.92 (m, 2H), 6.90 (d, IH, =8.3Hz), 7.55 (d, IH, J=1.5Hz), 7.65 (dd, IH, =2.0Hz, 8.3Hz); MS(FAB) m/z 278, 280(M+H)+.
To a stirred mixture of ethyl 4-(2-allylaminoethoxy)-3 -methoxy benzoate (578mg, 2. lmmol), 3-methoxy-4-[Λ/'-(2-methylphenyl)ureido]phenylaceticacid (650mg,2. lmmol), HOBt (420mg, 3.1 lmmol), and DMAP (catalytic amount) in DMF (4 mL) was added EDC (596mg,3.1 lmmol) at room temp. The resulting mixture was stirred for a further 18 hr at room temp. The mixture was poured into IN HCl and exfracted with EtOAc. The exfract was washed with brine, dried over Na2S04, and evaporated in vacuo. The residue was chromatographed on silica-gel with CHCl3:EtOAc (95:5 to 1: 1, v/v) as eluent to give lg (84%) 3-methoxy-4-[[2-[3- methoxy-4-[ V-(2-methylphenyl)ureido] phenylacetyl]allylamino]ethoxy] benzoic acid as a pale- yellow gum. 'H-NMR(CDC13, 400MHZ) δ 1.39 (t, 3H, J=7.3Hz), 2.29 (s, 3H), 3.58 and 3.63 (s, total 3H), 3.70-3.77 (m, 2H), 3.83 and 3.87 (s, 3H), 4.05-4.13 (m, 2H), 4.25 (m, IH), 4.36 (q, IH, J=7.0Hz), 5.04-5.22 (m, 2H), 5.73 (m, IH), 6.32 and 6.47 (s, IH), 6.69-6.85 (m, 2H), 7.12 (m, 2H), 7.23 (m, 2H), 7.50-7.65 (m, 2H), 8.05 (d, IH, J=7.8Hz); MS (FAB) m/z 576(M+H)+.
A mixture of 3-mefhoxy-4-[[2-[3-methoxy-4-[Λ/'-(2-methylphenyl)ureido]phenylacetyl] allylamino]ethoxy]benzoic acid (50mg, 0.09mmol) in THF-MeOH (1: 1, v/v) (2mL) and IN NaOH (0.135mL, 0.135mmol was stirred for 15 hr at room temp and 3 hr at 50°C The mixture was poured into ice- IN HCl. Solid was collected, washed with water, and air-dried. The crude solid was recrystallized from CHCl3-n-hexane to give 38mg (77%) 261 as a white ciystalline material, mp 125-130 °C; IR(KBr), 3319, 2939, 1687, 1647, 1601, 1535, 1456, 1417, 1269, 1223, 1034, 760cm '; 'H-NMR(DMSO-cL, 400MHz) δ 2.29 (s, 3H), 3.68 (s, 2H), 3.75-3.85 (m, 8H), 4.05 (br, IH), 4.19 (m, 3H), 5.10-5.25 (m, 2H), 5.65-5.90 (m, IH), 6.75 (m, IH), 6.85 (s, IH), 6.92 (m, IH), 7.02-7.20 (m, 3H), 7.48 (d, lH, =10.2Hz), 7.56 (m, IH), 7.79 (d, IH, =6.8Hz), 8.01 (m, IH), 8.46 (s, IH), 8.56 (d, IH, J=4.4Hz), 12.7 (br, IH); MS (FAB) m z 548(M+H)+; Anal, calcd. for C30H33N3O7 0.5H2O, C, 64.74; H, 6.16; N, 7.55. Found, C, 64.72; H, 6.07; N, 7.55. Example 214
3-methoxy-4-[[2-[3-methoxy-4-[Λ''-(2-methylphenyl)ureido]phenylacetyl]-(2-morpholino) ethylamino]ethoxy]benzoic acid
Figure imgf000399_0001
To a stirred solution of 3-methoxy-4-[[2-[3-methoxy-4-[7V-(2-methylphenyl)ureido] phenylacetyl]allylamino]ethoxy]benzoic acid (950mg, 1.65mmol) in THF:H20 (7mL) was added 7V-methylmoιpholine-N-oxide (579mg,4.95mmol) and osmium tefroxide (0.2M solution in water) (0.413mL, 0.08mmol). The resulting mixture was stirred for 3 hr at room temp. Sat. NaHS03 was added to the mixture, and the mixture was filtered through Celite. The filtrate was extracted with EtOAc. The exfract was washed with brine, dried over MgS0 , and evaporated in vacuo. The residue was dissolved in MeOH-THF-H20 (1: 1:1, v/v) (12mL) and added sodium periodate
(318mg,1.5mmol). The resulting mixture was stirred at an ambient temp for 1 hr. The mixture was diluted with EtOAc, washed with brine, and dried over MgS04. Solvent was evaporated in vacuo to afford 862mg (90%) ethyl 3-methoxy-4-[[2-[3-methoxy-4-[Λ^-(2-methylphenyι)ureido] phenylacetyl]-N-formylmethylamino] ethoxy] benzoate as a pale-yellow gum. 'H-NMR (CDC13, 400MHz) δ 1.39 (t, 3H, J=7.3Hz), 2.29 (s, 3H), 3.31-3.95 (m, 11H), 4.10-4.42 (m, 5H), 6.51-6.82 (m, 3H), 7.10-7.25 (m, 3H), 7.50 (m, 2H), 7.60 (m, IH), 8.10 (m, IH), 9.50 (m, IH); MS (FAB) m/z 578 (M+H)+.
To a stirred mixture of ethyl 3-methoxy-4-[[2-[3-methoxy-4-[N-(2-methylphenyl)ureido] phenylacetyl]-Λf-formylmethylamino]ethoxy]benzoate (265mg, 0.46mmol), morpholine (0.40mL, 4.59mmol), and AcOH (0.263mL, 4.6mmol) in EtOH (3mL) was added NaBH3CN (288mg, 4.6mmol) at room temp. The resulting mixture was stirred for 15 hr at room temp and the mixture was diluted with EtOAc and added sat. NaHC03 at 0° C. The resulting mixture was stirred for 0.5 hr at 0° C. The mixture was extracted with EtOAc. The exfract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was chromatographed on silica- gel with CHCl3:MeOH (95:5, v/v) as eluent to give 213mg (71%) ethyl 3-methoxy-4-[[2-[3- methoxy-4-[/V-(2-methylphenyl)ureido] phenylacetyl]-(2-moιpholino)ethylamino]ethoxy]benzoate as an oil. 'H-NMR (CDC13, 400MHz) δ 1.28 (t, 3H, J=7.0Hz), 2.31(s, 3H), 2.48 (brs, 4H), 2.52 (m, 2H), 3.60-3.91 (m, 16H), 4.11 and 4.28 (m , total 2H), 4.39 (q, 2H, J=7.0Hz), 6.70-6.85 (m, 4H), 7.15 (m, 2H), 7.50-7.63 (m, 3H), 8.08 (d, IH, J=8.0Hz); MS (FAB) m/z 649(M+H)+.
A mixture of ethyl 3-methoxy-4-[[2-[3-methoxy-4-[Λ^-(2-methylphenyl)ureido]phenyl acetyl]-(2-morpholino)ethylamino]ethoxy]benzoate (265mg, 0.46mmol) in THF (4mL) and IN NaOH (0.984mL) was stirred at 50° C for 15 hr. The pH of the mixture was adjusted to 7.4 by the addition of IN HCl, and extracted with CHCl3:MeOH(9: 1, v/v). The extract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was crystallized with Et20 to give 160 mg(78%) 262 as a white crystalline material, mp 125-130 °C; IR (KBr), 3346, 2956, 2937, 1705, 1622, 1599, 1537, 1456, 1417, 1299, 1114, 1032, 752cm '; 'H-NMR (CD3OD, 400MHz) δ 2.29 (s, 3H), 2.49-2.64 (m, 6H), 3.65-3.85 (m, 16H), 4.13 (m, IH), 4.26 (m, IH), 6.78-7.04 (m, 4H), 7.18 (m, 2H), 7.55-7.64 (m, 3H), 7.99 (m, 2H); MS (FAB) m/z 621(M+H)+; Anal. Calcd. for C^H^N ^.SHA C, 59.54; H, 6.81; N, 8.42. Found, C, 59.71; H, 6.35; N, 7.98. Example 215
3-methoxy-4-[[2-[3-methoxy-4-[Λ/'-(2-methylphenyl)ureido]phenylacetyl]-[2-[4-methyl-l- piperazinyl]ethylamino]ethoxy]benzoic acid
Figure imgf000400_0001
To a stirred mixture of ethyl 3-methoxy-4-[[2-[3-methoxy-4-[7V'-(2-methylphenyi)ureido] phenylacetyl]-N-formylmethylamino]ethoxy]benzoate (242mg, 0.42mmol), N-methylpiperazine (0.465mL, 4.2mmol), and AcOH (0.240mL, 4.2mmol) in EtOH (3mL) was added NaBH3CN (263mg, 4.2mmol) at room temp. The resulting mixture was stirred for 15 hr at room temp. The mixture was diluted with EtOAc and added sat. NaHC03 at 0° C. The resulting mixture was stirred for 0.5 hr at 0° C. The mixture was exfracted with EtOAc. The extract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was chromatographed on silica- gel with CHCl3:MeOH (95:5, v/v) as eluent to give 195mg (70%) ethyl 3-methoxy-4-[[2-[3- methoxy-4-[ V-(2-methylphenyl)ureido] phenylacetyl]-[2-(4-methyl-l-piperazinyl]ethylamino] ethoxyjbenzoate as an oil. 'H-NMR (CDC13, 400MHz) δ 1.23 (t, 3H, J=7.0Hz), 2.25 (s, 3H), 2.29 (s, 3H), 2.50 (br m, 12H), 3.44-3.85 (m, 12H), 4.10 (br, IH), 4.22 (br, IH), 4.35 (m, 2H), 6.70- 6.85 (m, 3H), 6.98 (s, IH), 7.10 (m, IH), 7.20 (m, 2H), 7.40 (m, IH), 7.60-7.70 (m, 3H), 8.05( d, IH, J=7.8Hz); MS (FAB) m/z 662(M+H)+.
A mixture of ethyl 3-methoxy-4-[[2-[3-methoxy-4-[Λ/'-(2-methylphenyl)ureido] phenylacetyl]-[2-(4-methyl-l-piperazinyl]ethylamino]ethoxy]benzoate (195mg, 0.30mmol) in THF:MeOH(4: 1, v/v) (5mL) and IN NaOH (0.885mL) was stirred at 50° C for 15 hr. The pH of the mixture was adjusted to 7.4 by the addition of IN HCl, and exfracted with CHCl3:MeOH(9:l, v/v). The exfract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was crystallized with Et20 to give 141 mg(75%) 263 as a white ciystalline material, mp
155-160 °C; IR (KBr), 2937, 1537, 783cm '; 'H-NMR (CD3OD, 400MHz) δ 2.29 (s, 3H), 2.49-2.80 (m, 15H), 3.60-3.85 (m, 9H), 3.92 (s, IH), 4.12 (m, IH), 4.25 (m, IH), 6.78-7.20 (m, 6H), 7.61 (m, 3H), 8.00 (m, IH); MS (FAB) m/z 632(M)+; Anal. Calcd. for C34H43N507'2-5H20, C, 60.16; H, 7.13; N, 10.32. Found, C, 59.72; H, 6.86; N, 9.97. Example 216
3-methoxy-4-[[2-[3-methoxy-4-[iV-(2-methylphenyl)ureido]phenylacetyl]-[2-cyclopropylanιino] ethylamino]ethoxy]benzoic acid
Figure imgf000401_0001
To a stirred mixture of ethyl 3-methoxy-4-[[2-[3-methoxy-4-[ V-(2-methylphenyl)ureido] phenylacetyl]-N-formylmethylamino]ethoxy]benzoate (267mg, 0.46mmol), cyclopropylamine (0.32mL, 4.6mmol), and AcOH (0.264mL, 4.6mmol) in EtOH (3mL) was added NaBH3CN (290mg, 4.6mmol) at room temp. The resulting mixture was stirred for 15 hr at room temp. The mixture was diluted with EtOAc and added sat. NaHC03 at 0° C. The resulting mixture was stirred for 0.5 hr at 0°C The mixture was exfracted with EtOAc. The exfract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was chromatographed on silica- gel with CHCl3:MeOH (95:5, v/v) as eluent to give 156mg (55%) ethyl 3-methoxy-4-[[2-[3- methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]-[2-cyclopropylamino]ethylamino] ethoxy]benzoate as an oil. 'H-NMR (CDC13, 400MHz) δ 0.35 (m, 4H), 1.22 (br s, 3H), 2.10 (m, IH), 2.20 (s, 3H), 2.42 (br, 2H), 2.90 (br s, 2H), 3.60-3.80 (m, lOH), 4.10 (br, IH), 4.22 (br, IH), 4.33 (br, 2H), 6.72 (m, 3H), 7.05-7.30 (m, 4H), 7.55 (m, 4H), 8.06 (br s, IH); MS (FAB) m/z 619(M+H)+.
A mixture of ethyl 3-methoxy-4-[[2-[3-methoxy-4-[iV-(2-methylphenyl)ureido] phenylacetyl]-N-[2-cyclopropylamino]ethylamino]ethoxy]benzoate (195mg, 0.30mmol)) in THF:MeOH(4: 1, v/v) (5mL) and IN NaOH (0.756mL) was stirred at 50° C for 15 hr. The pH of the mixture was adjusted to 7.4 by the addition of IN HCl, and extracted with CHCl3:MeOH(9: 1, v/v). The extract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was crystallized with Et20 to give 57 mg (38%) 3-methoxy-4-[[2-[3-methoxy-4-[7V-(2- methyl phenyl)ureido]phenylacetyl]-[2-cyclopropylamino] ethylamino]ethoxy]benzoic acid 264 as a white crystalline material, mp 135-140 °C; IR (KBr), 3324, 2937, 1535, 1032, 754cm '; 'H-
NMR (CD3OD, 400MHz) δ 0.50-0.73 (m, 4H), 2.29 (s, 3H), 2.53 (m, IH), 2.98 (m, IH), 3.21 (m, IH), 3.58-3.88 (m, 11H), 3.91 (s, IH), 4.09 (m, IH), 4.25 (m, IH), 6.76-6.92 (m, 3H), 7.01 (m, IH), 7.18 (m, 2H), 7.60 (m, 3H), 8.00 (d, =8.3Hz, IH); MS (FAB) m/z 591(M+H)+; Anal. Calcd. for C32H38N4O7-3.0H2O, C, 59.62; H, 6.88; N, 8.69. Found, C, 59.25; H, 6.29; N, 8.29. Example 217
4-[[2-[3-methoxy-4-[Λ^'-(2-fluorophenyl)ureido]phenylacetyl]-N-methylamino]ethoxy]benzoic acid
Figure imgf000402_0001
3-chloro-4-[[2-[3-methoxy-4-[N'-(2-fluorophenyl)ureido]phenylacetyl]-Λ-methylaminoethoxy] benzoic acid
Figure imgf000402_0002
To a stirred cold (0°C) solution of 2-(N-benzyloxycarbonyl-N-methyl)ethanolamine (3.01 g, 14.4 mmol), methyl 3-chloro-4-hydroxybenzoate (2.68 g, 14.4 mmol), Ph3P (5.65 g, 21.5 mmol) in THF (30 mL) was added diisopropyl azodicarboxylate (DIAD) (4.25 mL, 21.6 mmol), and the resulting mixture was heated under reflux overnight. The solution was evaporated off and the residue was purified by column chromatography on silica-gel with CHC13 as eluent to give 3.90g (72%) methyl 3-chloro-4-[2-(7V-benzyloxycarbonyl-N-methylamino)ethoxy]benzoate as a pale yellow solid. 'H-NMR (CDC13) δ 3.15 (s, 3 H), 3.74-3.76 (m, 2 TT), 3.89 (s, 3 TT), 4.17-4.27 (m, 2 H), 5.14 (s, 2 H), 6.81-6.94 (m, 1 H), 7.33-7.36 (m, 5 T), 7.85-7.92 (m, 1 TT), 8.05 (bs, 1 H). A solution of methyl 3-chloro-4-[2-(N-benzyloxycarbonyl-N-methylamino)ethoxy] benzoate (3.90 g, 10.3 mmol) in EtOAc- AcOH (40 mL, 1 : 1 , v/v) was hydrogenated over 5% Pd-C (1.95 g, 50 wt%) at 3 atm for 2 hr. The mixture was filtered and the filtrate was washed with sat. NaHC03 and the basic aqueous layer was exfracted with CHC13, washed with brine and evaporate to give unseparable mixture of methyl 3-cMoro-4-(N-methylaminoethoxy)benzoate and methyl 4- [2-(/V-methylamino) ethoxy]benzoate the title compound (1.61 g) as a pale yellow oil. 'H-NMR (CDC13) δ 2.52-2.52 and 2.53-2.54 (each m, 3 H), 2.98-3.00 and 3.03-3.05 (each m, each 2 H), 3.88 and 3.99 (each s, each 3 H), 4.11-4.14 and 4.18-4.20 (each m, each 2 H), 6.91-6.96 and 7.90- 8.05 (series of m, total 7 H).
A mixture of 3-methoxy-4-[Λ -(2-fluorophenyl)ureido]phenylacetic acid (392 mg), a mixture of methyl 3-chloro-4-[2-(N-methylamino)ethoxy]benzoate and methyl 4-[2-(Λ- methylamino)ethoxy] benzoate (305 mg), EDC(hydrochloride) (354 mg), HOBt (250 mg), and DMAP (250 mg) in DMF (8 mL) was stirred at room temp for 6 hr. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with 1% MeOH in CHC13 as eluent to give a mixture of methyl 3-chloro-4-[[2-[3-methoxy-4-[N'-(2-fluorophenyl) ureido]phenylacetyl]-N- methylaminoethoxy]benzoate and methyl 4-[[2-[3-methoxy-4-[N'-(2-fluorophenyl)ureido] phenylacetyl]-Λf-methylaminoethoxy]benzoate (550 mg) as a brown amoφhous solid.
To a stirred solution of this mixture (550 mg) of methyl 3-chloro-4-[[2-[3-methoxy-4-[N'-
(2-fluorophenyl)ureido]phenylacetyl]-N-methylaminoethoxy]benzoate and methyl 4-[[2-[3- methoxy-4- V '-(2-fluorophenyl)ureido]phenylacetyl]-Λf-methylaminoethoxy]benzoate in THF- MeOH (20 mL, 1:1, v/v) was added 0.5 N NaOH (10 mL), and the resulting mixture was heated under reflux for 6 hr. The mixture was poured into ice-1 N HCl, and the solid was collected. The crude solid was purified by preparative TLC with 10% MeOH in CHC13 as eluent to give 265 (56 mg, as a white amoφhous solid) and 266 (88 mg, as a brown amoφhous solid) . Example 218
4-[[2-[3-methoxy-4-[Λ^-(2-methylphenyl)ureido]phenylacetyl]methylamino]ethoxy]benzoic acid
Figure imgf000403_0001
3-chloro-4-[[2-[3-methoxy-4-[Λ/'-(2-methylphenyl)ureido]phenylacetyl]methylamino]ethoxy] benzoic acid
Figure imgf000404_0001
A mixture of methyl 4-[2-(7V-methyl-2-amino)ethoxy]-3-chlorobenzoate (292mg,
1.2mmol), 3-methoxy-4-[Λ/,-(2-methylphenyl)ureido]phenylaceticacid (377mg,1.2mmol), EDC (345mg, 1.8mmol), HOBt(243mg, 1.8mmol), and DMAP(29mg, 0.24mmol) in DMF(2.7mL) was stirred for 6 hr at room temp. The mixture was poured into ice- IN HCl and exfracted with EtOAc.
The exfract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was chromatographed on silica-gel with CHCl3:EtOAc (95:5 to 0: 100, v/v) as eluent to give unseparable mixture (489mg) of methyl 3-chloro-4-[[2-[3-methoxy-4-[,/V-(2- methylphenyl)ureido]phenylacetyl] methylamino]ethoxy]benzoate and methyl 4-[[2-[3-methoxy-4-
[N'-(2-methylphenyl)ureido]phenyl acetyl]methylamino]ethoxy]benzoate as pale-yellow oil.
A mixture (480mg as mixture) of methyl 3-chloro-4-[[2-[3-methoxy-4-[W-(2 -methyl phenyl)ureido] phenylacetyl]methylamino]ethoxy]benzoate and methyl 4-[[2-[3-methoxy-4-[W-(2- methylphenyl)ureido] phenylacetyl]methylamino]ethoxy]benzoate in THF-MeOH(4mL, 1:1, v/v) was stirred at 50° C for 15 hr. The mixture was poured into ice-lN HCl. The solid was collected, washed with water, and air-dried. The crude solid was purified by preparative TLC CHCl3:MeOH (93:7, v/v) as eluent to afford 267 (180mg, 2steps 31% as a crystalline material) and 268 (280mg, 2steps 44% as a crystalline material). 267 : mp 145-150 °C; 'H-NMR (DMSO-cL,, 400MHz) δ 2.31 (s, 3H), 3.05 and 3.19 (s, 3H), 3.35 and 3.38 (s, 3H), 3.72-3.85 (m, IK), 4.09 and 4.23 (m, total 2H), 6.79-7.20 (m, I ), 7.60 (m, IH), 7.86-8.09(m, 3H); MS (FAB) m/z 493(M+H)+; Anal, calcd. for C27H29N306 1.75H20, C, 62.00; H, 6.26; N, 8.03. Found, C, 62.16; H, 5.88; N, 7.82. 268: mp 145-150 °C; 'H-NMR (DMSO-α 400MHz) δ 2.29 (s, 3H), 3.06 and 3.26 (s, 3H), 3.31 and 3.35 (s, 3H), 3.85-3.94 (m, 4H), 4.18 and 4.32 (m, total 2H), 6.75-6.85 (m, 2H), 6.99-7.20 (m, 4H), 7.59 (m, IH), 7.90-8.02 (m, 3H); MS (FAB) m/z 526 M+K)+; Anal, calcd. for C27H28ClN3O6-2.0H2O, C, 57.70; H, 5.74; N, 7.48. Found, C, 57.99; H, 5.53; N, 7.07. Example 219
4- [3 -[3 -methoxy-4-[N' -(2-methylphenyl)ureido]phenylacetyl] -JV-methylamino] - 1 -propyl]benzoic acid
Figure imgf000405_0001
To a stirred cold (minus 78° C) solution of triethyl 4-phosphonomethylbenzoate (1.22 g, 4.05 mmol) in THF (10 mL) was added NaHMDS (1.0 M in THF) (4.0 mL, 4.0 mmol), and the resulting mixture was stirred for 1 hr at the same temp. A solution of 2-(N-benzyloxycarbonyl-N- methylamino) acetaldehyde (700 mg, 3.38 mmol) in THF (5 mL) was slowly added to this solution at that temp, and the mixtrae was allowed to warm to room temp for over 2 hr with stirring. The solution was quenched by the addition of sat. NH4C1 (100 mL), and exfracted with EtOAc. The exfract was washed with brine (200 mL), dried over MgS04, and evaporated. The residue was chromatographed on silica gel with CHCl3-EtOAc (20: 1, v/v) as eluent to give 810 mg (68%) ethyl (£ -4-[3-(Λf-benzyloxycarbonyl-Λf-methylamino)-l-propenylbenzoate as a yellow oil. Η-NMR
(CDC13) δ 1.40 (t, J = 7.3 Hz, 3 TT), 2.95 (m, 2 H), 4.09 (m, 2 H), 4.35-4.40 (m, 2 TT), 5.17 (s, 2 H), 6.26-6.64 (series of m, 2 H), 7.36 (m, 7 H), 7.99 (d, J = 8.3 Hz, 2 H).
A stirred solution of ethyl (£ -4-[3-(Λf-benzyloxycarbonyl-Λ^-methylamino)-l-propenyl benzoate (810 mg, 2.29 mmol) in EtOH-AcOH (10: 1, v/v, 22 mL) was hydrogenated over 5% Pd- C (1 g) for 3 days. The mixture was filtered and the filtrate was evaporated. The residue was made basic with sat. NaHC03 and exfracted with CHC13. The exfract was dried over Na2C03 and evaporated to give 438 mg (86%) ethyl 4-(3 -methylamino- l-propyl)benzoate as a yellow oil. 'H- NMR (CDC13) δ 1.39 (t, J =7.3 Hz, 3 H), 1.82 (m, 2 H), 2.43 (s, 3 H), 2.61 (t, J = 7.3 Hz, 2 H), 2.72 (t, /= 7.3 Hz, 2 TT), 3.33 (br s, 1 H), 4.36 (q, J= 7.3 Hz, 2 H), 7.25 (d, = 8.3 Hz, 2 H), 7.96 (d, J = 8.3 Hz, 2 H).
To a stirred solution of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (456 mg, 1.45 mmol) and ethyl 4-(3 -methylamino- l-propyl)benzoate (220 mg, 1.45 mmol) were added EDCHCl (417 mg, 2.16 mmol), HOBt (cat ), and DMAP (catalytic amount) in DMF (10 mL), and the resulting mixture was stined overnight. The mixture was diluted with EtOAc (300 mL), washed with brine, dried over MgS04, and evaporated. The residue was chromatographed on silica-gel with CHCl3-EtOH (10:1) to give 503 mg (71%) ethyl 4-[3-[3-methoxy-4-[N'-(2- methylphenyl) ureido]phenylacetyl-N-methylamino]-l-propyl] benzoate as a yellow oil. MS (FAB)
Figure imgf000405_0002
To a stirred solution of ethyl 4-[3-[3-methoxy-4-[Λr'-(2-methylphenyl)ureido]phenyl acetyl-N-methylamino]-l-propyl]benzoate (500 mg, 0.966 mmol) in THF (8 mL) was added 0.25 N NaOH (8 mL), and the mixture was heated under reflux overmght The resulting solution was poured into ice-1 N HCl (100 mL) and the solid was collected with suction The solid was dissolved in CHC13 (100 mL) and dried over MgS04 After removal of the solvent, the residue was chromatographed on silica gel with CHCl3-MeOH (10 1 to 5 1, v/v) to give 131 mg (28%) 4-[3-[3- methoxy-4-[N'-(2-methylphenyl)ureιdo] phenylacetyl-N-methylamιno]-l-propyl]benzoιc acid 269 as a pale yellow amoφhous solid 'H-NMR (DMSO-c .) δ 1 68-1 80 (m, 2 TT), 2 24 (s, 3 TT), 2 57 (m, 2 TT), 2 81 and 2 97 (s, each, total 3 H), 3 33 (m, 2 H), 3 57-3 61 (m, 2 H), 3 84 (s, 3 TT), 6 71 (dd, J= 29 8, 8 3 Hz, 1 H), 6 87 (d, J= 11 2 Hz, 1 H), 6 93 (t, J= 1 3 Hz, 1 H), 7 15 (m, 2 H), 7 28 (m, 2 H), 7 79 (d, J= 8 3 Hz, 1 H), 7 84-7 87 (m, 2 H), 8 02 (d, J= 8 3 Hz, 1 H), 8 49 (d, J = 7 3 Hz, 1 H), 8 58 (d, J = 4 9 Hz, 1 H), MS (FAB) n/z 490 (M++l), Λnα/ Calcd for C28H31N305-1/2H20 C, 67 45, H, 6 47, N, 8 43 Found C, 67 27, H, 6 51, N, 8 02 Example 220 4-[[2-[4-[N'-(2-methylphenyl)ureιdo]phenylacetyl]-Λr-methylamιno]ethoxy]benzoιc acιd
Figure imgf000406_0001
3-chloro-4-[[2-[4-[N'-(2-methylphenyl)ureido]phenylacetyl]-N-methylamino]ethoxy]benzoic acid
Figure imgf000406_0002
A solution of pentafluorophenyl 4-[N'-(2-methylphenyl)ureιdo]phenylacetate (562 mg, 1 29mmol), a mixture (304 mg ) of methyl 3-chloro-4-[2-(N-methylamιno)ethoxy]benzoate and methyl 4-[2-(N-methyl amιno)ethoxy]benzoate and Et3N (260 mL) in DMF (8 mL) was stirred at room temp for 4 hr The mixture was diluted with EtOAc, washed with 0 5 N HCl, bnne, dned over Na2S04 and evaporated The residue was punfied by column chromatography on silica-gel with CHCl3-MeOH (50 1, v/v) as eluent to give a mixture (670 mg) of methyl 3-chloro-4-[[2-[4- [N'-(2-methylphenyl)ureιdo)
Figure imgf000406_0003
ethoxy]benzoate and methyl 4-[[2-[4- [N '-(2-methylphenyl)ureιdo] phenylacetyl]-iV-methylamιno)ethoxy] benzoate as an oil
To a stirred suspension of this mixture (670 mg) in THF-MeOH (20 mL, 1 1, v/v) was added 0 5 N NaOH (10 mL) and the resulting mixture was heated under reflux for 6 hr The solution was poured into ice-1 N HCl and the solid was collected The crude solid was punfied by preparative thin layer chromatography (TLC) with 10% MeOH in CHC13 as eluent to give 73mg 270 as an amoφhous solid and 110 mg 271 as a white amoφhous solid 270 MS (FAB) m/z 462 (M -1) 271 MS (FAB) m/z 496 (M++l) Example 221 (5)-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)ureιdo]phenylacetylamιno]-l-propoxy]benzoιc acιd
Figure imgf000407_0001
To a cooled (0° C) solution of (S)-2-amιno-l-propanol (2 08 g, 27 7 mmol) and Et3N (4 63 mL, 33 2 mmol) in DMF-H20 (40 mL, 1 1, v/v) was added (Boc)20 (6 36 mL, 27 7 mmol), and the resulting solution was stirred at room temp for 2 days H20 was added to the mixture and extracted with EtOAc The exfract was washed with bnne and dned over Na2S04 The solvent was evaporated to give 4 24 g (87%) (S)-2- (N-terNbutoxycarbonylamιno)-l-propanol as a colorless oil 'H-NMR (CDC13) δ 1 14 (d, 3 H, J=6 8 Hz), 1 45 (s, 9 H), 3 51-3 52 (m, 1 H), 3 63- 3 66 (m, 1 H), 3 77 (m, 1 T), 4 62 (m, 1 H)
To a cooled (0° C) solution of (S)-2-(N-/er )utoxycarbonylamιno)-l-propanol (1 02 g, 5 82 mmol), methyl 4-hydroxybenzoate (0 89 g, 5 85 mmol), and Ph^ (1 98 g, 7 55 mmol) in THF (20 mL) was added diisopropyl azodicarboxylate (DIAD) (1 49 mL, 7 57 mmol), and the resulting mixture was heated under reflux overnight The solution was evaporated and the residue was dissolved in CH2C12 (20 mL) and TFA (10 mL) The mixture was stirred at room temp for 1 5 hr The solution was concenfrated in vacuo and the residue was treated with sat NaHC03 The mixture was extracted with CHC13, washed with bnne, dried over Na2S04 and evaporated The residue was punfied by column chromatography on silica-gel with CHC3 MeOH (50 1, v/v) to give 480 mg (2 steps 39%) methyl (S -4-(2-amιno-l -propoxy) benzoate as a pale yellow oil 'H-NMR (CDC13) δ 1 19 (d, 3 H, =6 4 Hz), 3 35-3 39 (m, 1 H), 3 72-3 76 (m, 1 H), 3 89 (s, 3 H), 3 90-3 94 (m, 1 H), 6 92 (d, 2 H, .7=8 8 Hz), 7 99 (d, 2 H, J=8 8 Hz)
A mixture of pentafluorophenyl 3-methoxy-4-[N'-(2-methylphenyl)raeido]phenylacetate
(505 mg, 1 05 mmol), methyl (S)-4-(2-amιno-l-propoxy)benzoate (220 mg, 1 05 mmol), and Et3N (0 220mL, 1 58 mmol) in DMF (8 mL) was stirred at room temp for 3 hr The mixture was diluted with EtOAc, washed with 0 5 N HCl, bnne, and dned over Na2S04 After removal of the solvent, the residue was recrystallized from MeOH-CHCl3-n-hexane to give 290 mg (55%) methyl (S)-4-[2-[3-methoxy-4-[N '-(2-methylphenyl) ureido]phenylacetylamino]-l-propoxy]benzoate as a white crystalline powder. 'H-NMR (DMSO-cL.) δ 1.18 (d, 3 H, J=6.8 Hz), 2,24 (s, 3 H), 3.36 (s, 2H), 3.80 (s, 3H), 3.82 (s, 3H), 3.93-4.03 (m, 2H), 4.09-4.14 (m, IH), 6.75-8.57 (series of m, total 13 H).
To a stirred solution of methyl (5)-4-[2-[3-methoxy-4-[Λf '-(2-methylphenyl)ureido]phenyl acetylamino]-l-propoxy]benzoate (290 mg, 0.57 mmol) in THF-MeOH (20 mL, 1:1, v/v) was added 0.5 N NaOH (20 mL) and the solution was heated under reflux for 2 hr. The mixture was poured into ice-1 N HCl and exfracted with CHCl3-MeOH (10 :1, v/v). The exfract was washed with brine, dried over Na2S04 and evaporated. The residue was recrystallized from MeOH-CHCl3- n-hexane to give 158 mg (56%) 272 as a white crystalline powder, mp 198-201 °C; Η-NMR
(DMSO-c ,) δ 1.18 (d, 3 H, .7=6.3 Hz), 2.24 (s, 3 H), 3.36 (s, 2 H), 3.82 (s, 3 TT), 3.87-4.10 (m, 2 H), 4.10-4.16 (m, 1 H), 6.75-6.78 (m, 1 H), 6.92-7.02 (m, 4 H), 7.11-7.18 (m, 2 H), 7.78-7.80 (m, 1 H), 7.86-7.89 (m, 2 H), 7.98-8.00 (m, 1 TT), 8.12-8.14 (m, 1 TT), 8.46 (s, 1 H), 8.55 (s, 1 H), 12.62 (bs, 1 H); MS (FAB) m/z 492 (M++l); Anal. Calcd for C27H29N306- 1/2H20: C, 64.79; H, 6.04; N, 8.21. Found: C, 64.36; H, 5.85; N, 8.21. Example 222 (S)-4-[2-[4-[N'-(2-methylphenyl)ureido]phenylacetylamino]-l-propoxy]benzoic acid
Figure imgf000408_0001
A mixture of pentafluorophenyl 4-[N'-(2-methylphenyl)ureido]phenylacetate (560 mg, 1.24 mmol), methyl (S -4-(2-amino-l-propoxy)benzoate (260 mg, 1.24 mmol), Et3N (0.260mL, 1.87 mmol) in DMF (8 mL) was stirred at room temp for 3 hr. The mixture was diluted with EtOAc and the solution was washed with 0.5 N HCl, brine, and dried over Na2S04. After removal of the solvent, the residue was purified by recrystallization from MeOH-CHCl3-n-hexane to give 210 mg (36%) (5)-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetylamino]-l- propoxyjbenzoic acid as a white crystalline powder. 'H-NMR (DMSO-cL.) δ 1.17 (d, 3 H, J=6.8 Hz), 2.24 (s, 3 H), 3.32 (s, 2 TT), 3.81 (s, 3 H), 3.92-4.03 (m, 2 H), 4.08-4.15 (m, 1 TT), 6.92-6.95 (m, 1 H), 7.04-7.06 (m, 2 H), 7.12-7.18 (m, 4 TT), 7.35-7.39 (m, 2 H), 7.83-7.85 (m, 1 H), 7.89- 7.92 (m, 3 TT), 8.12-8.14 (m, 1 H), 8.97 (s, 1 H).
To a stirred solution of methyl (5 -4-[2-[4-[N'-(2-methylphenyl)ureido]phenylacetyl amino]-l- propoxy]benzoate (200 mg, 0.42 mmol) in THF-MeOH (10 mL, 1:1, v/v) was added 0.5 N NaOH (10 mL), and the mixture was heated under reflux for 2 hr. The mixture was poured into ice-1 N HCl, and the solid was collected. The crude solid was recrystallized from MeOH-CHCl3-n- hexane to give 68 mg (34%) 273 as a white crystalline powder, mp 262-265 °C; Η-NMR (DMSO-c .) δ 1.17 (d, 3 H, .7=6.8 Hz), 2.24 (s, 3 TT), 3.32 (s, 2 H), 3.91-4.02 (m, 2 H), 4.09-4.15 (m, 1 H), 6.92-6.96 (m, 1 TT), 7.01-7.03 (m, 2 H), 7.12-7.20 (m, 4 TT), 7.36-7.40 (m, 2 H), 7.83- 7.95 (m, 4 H), 8.12-8.14 (m, 1 TT), 8.99 (s, 1 TT), 12.63 (bs, 1 H); MS (FAB) m/z 462 (M++l); Anal. Calcd for C26H27N305- 1/4H20: C, 67.01; H, 5.95; N, 9.02. Found: C, 67.13; H, 5.90; N, 9.02. Example 223 (5)-3-chloro-4-[2-[4-[N'-(2-methylphenyl)ureido]phenylacetylamino]-l-propoxy]benzoic acid
Figure imgf000409_0001
To a cooled (0° C) solution of (S)-2-(N-ter/-butoxycarbonylamino)-l-propanol (1.05 g, 5.99 mmol), methyl 3-chloro-4-hydroxybenzoate (1.12 g, 6.00 mmol), and Ph3P (2.36 g, 9.00 mmol) in THF (20 mL) was added diisopropyl azodicarboxylate (DIAD) (1.77 mL, 8.99 mmol), and the resulting mixture was heated under reflux for 2 days. The solution was evaporated off and the residue was dissolved in CH2C12 (20 mL) and TFA (10 mL). The resulting mixture was stirred at room temp for 1.5 hr. The solution was concenfrated in vacuo, and the residue was dissolved in CHC13. The mixture was exfracted with H20, and the aqueous layer was made basic by the addition of sat. NaHC03. This basic aqueous layer was exfracted with CHC13. The exfract was washed with brine, dried over Na2S04 and evaporated to give 660 mg (2 steps, 32%) methyl (S)-3- chloro-4-(2-amino-l-propoxy)benzoate as a colorless oil. 'H-NMR (CDC13) δ 1.21 (d, 3 H, .7=6.4 Hz), 3.41-3.48 (m, 1 H), 3.77-3.81 (m, 1 H), 3.89 (s, 3 H), 3.98-4.01 (m, 1 H), 6.91-6.94 (m, 1 H), 7.90-7.93 (m, 1 H), 8.05-8.06 (m, 1 H).
A mixture of pentafluorophenyl 4-[/V'-(2-methylphenyl)ureido]phenylacetate (508 mg, 1.13 mmol), methyl (5 3-chloro-4-(2-amino-l-propoxy)benzoate (275 mg, 1.13 mmol) and Et3N (0.240 mL, 1.72 mmol) in DMF (10 mL) was stirred at room temp overnight. The mixture was diluted with EtOAc, and the solution was washed with 0.5 N HCl, sat. NaHC03, brine, , dried over Na2S04, and evaporated. The residue was recrystallized from MeOH-CHCl3-n-hexane to give 240 mg (42%) methyl (S)-3-chloro-4-[2-[4-[Λ^'-(2-methylphenyl)ureido]phenylacetylamino]-l- propoxyjbenzoate as a white crystalline powder. 'H-NMR (DMSO-c .) δ 1.21 (d, 3 H, .7=6.4 Hz),
2.25 (s, 3 TT), 3.33 (s, 2 H), 3.82 (s, 3H), 4.04-4.14 (m, 3H), 6.90-6.94 (m, IH), 7.11-7.16 (m, 4H), 7.29-7.38 (m, 3H), 7.83-7.94 (m, 3H), 8.13-8.17 (m, 2H), 9.34 (s, 1 H); MS(FAB) m/z 510 (M+). To a stirred solution of methyl (S 3-chloro-4-[2-[4-[N'-(2-methylphenyl)ureido] phenylacetylamino]-l-propoxy]benzoate (240 mg, 0.47 mmol) in THF-MeOH (10 mL, 1 : 1, v/v) was added 0.5 N NaOH (10 mL), and the resulting mixture was heated under reflux overnight. The mixture was poured into ice-1 N HCl and the solid was collected. The crude solid was recrystallized from MeOH-CHCl3-n-hexane to give 98 mg (42%) 274 as a white ciystalline powder, mp 228-231 °C; 'H-NMR (DMSO-c .) δ 1.20 (d, 3 H, .7=6.3 Hz), 2.24 (s, 3 H), 3.34 (s, 2 H), 4.02-4.18 (m, 3 H), 6.92-6.95 (m, 1 H), 7.12-7.42 (series of m, total 7 H), 7.82-8.18 (series of m, total 5 H), 9.12 (s, 1 H); MS (FAB) m/z 496 (M+), 497 (M++l); Anal. Calcd for C26H26C1N305- 1/2H20: C, 61.84; H, 5.39; Cl,7.02; N,8.32. Found: C.61.76; H,5.25; Cl.7.09; N.8.25. Example 224
(S)-3-chloro-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetylamino]-l-propoxy] benzoic acid
Figure imgf000410_0001
A mixture of pentafluorophenyl 3-methoxy-4-[JV'-(2-methylphenyl)ureido]phenylacetate (513 mg, 1.07 mmol), methyl (S)-3-chloro-4-(2-amino-l-propoxy)benzoate (260 mg, 1.07 mmol) and Et3N (220 μl, 1.58 mmol) in DMF (10 mL) was stirred at room temp overnight. The mixture was diluted with EtOAc and the solution was washed with sat. NaHC03, dried over Na2S04, and evaporated. The residue was recrystallized from MeOH-CHCl3-EtOAc-n-hexane to give 400 mg (69%) methyl (S -3-chloro-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetylamino]-l- propoxy]benzoate as pale brown crystalline powder. 'H-NMR (DMSO-dβ) δ 1.21 (d, 3 H, J=6.4 Hz), 2.24 (s, 3 H), 3.37 (s, 2 H), 3.82 (s, 3 H), 3.83 (s, 3 H), 4.04-4.12 (m, 3 H), 6.75-6.77 (m, 1 H), 6.91-6.95 (m, 2 H), 7.11-7.17 (m, 2 H), 7.29-7.31 (m, 1 H), 7.78-7.99 (m, 4 H), 8.12-8.13 (m, 1 H), 8.46 (s, 1 TT), 8.55 (s, 1 H).
To a stirred solution of methyl (5)-3-chloro-4-[2-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenylacetylamino]-l-propoxy]benzoate (400 mg, 0.74 mmol) in THF-MeOH (20 mL, 1:1, v/v) was added 0.5 N NaOH (20 mL), and the resulting mixture was heated under reflux overnight. The mixture was poured into ice-1 N HCl and the solid was collected. The crude solid was recrystallized from MeOH-CHCl3-Et20 to give 200 mg (51%) 275 as a pale brown crystalline powder, mp 198-201 °C; 'H-NMR (DMSO-cL,) δ 1.21 (d, 3 H, J=6.8 Hz), 2.24 (s, 3 H), 3.37 (s, 2 TT), 3.84 (s, 3 H), 4.00-4.15 (m, 3 H), 6.76-7.28 (series of m, total 6 H), 7.77-8.14 (series of m, total 5 H), 8.46 (s, 1 H), 8.56 (s, 1 H); MS (FAB) m/z 526 (M+), 528 (M++2); Anal. Calcd for C27H28C1N306 1/4H20: C,61.13;H,5.42;C1,6.68;N, 7.92. Found: C, 60.97; H.5.48; Cl.6.86; N, 7.89. Example 225
3-dimethylamino-4-[[2-[3-methoxy-4-[Λ/'-(2-methylphenyl)raeido]phenylacetyl] methylamino] ethoxy]benzoic acid
Figure imgf000411_0001
To a stirred and cooled (0° C) solution of 2-(Λ/-Boc-N-mefhylamino)ethanol (3g, 17mmol), methyl 4-hydroxy-3-nitro benzoate (3.38g, 17mmol), and Ph^ (5.4g, 21mmol) in THF (20 mL) was added diisopropyl azodicarboxylate (DIAD) (4mL, 2 lmmol), and the resulting mixture was heated under reflux for 15 hr. The solution was evaporated off. The residue was chromatographed on silica-gel with CHCl3:MeOH (100:0 to 4: 1, v/v) as eluent to give 2.5g (39%) methyl 4-[2-(N-methyl-2-amino)ethoxy]-3-nifro benzoate as a pale yellow oil. 'H-NMR (CDC13, 400MHz) δ 2.82 (s, 3H), 3.50 (t, 2H, =4.5Hz), 3.95 (s, 3H), 4.54 (t, 2H, J=4.5Hz), 7.26 (d, IH, =8.8Hz), 8.25 (d, IH, J=8.8Hz), 8.56 (s, IH); MS (FAB) m/z 255 (M++l).
A mixture of 3-methoxy-4-[ V-(2-methylphenyl)ureido]phenylacetic acid (992mg, 3.1 lmmol), methyl 4-(N-methyl-2-aminoethoxy)-3-nitro benzoate (800mg, 3.1 lmmol) and 4- DMAP (77mg, 0.63mmol), HOBt (640mg,4.7mmol), and EDC (904mg,4.7mmol) in DMF (20 mL) was stirred at room temp overnight. The mixture was diluted with EtOAc, and the solution was washed with 0.5 N HCl, sat. NaHC03, brine, , dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel with CHCl3:EtOAc (95:5 to 0:100, v/v) as eluent to give 587mg (34%) methyl 3-nitro-4-[[2-[3-methoxy-4-[ V-(2-methylphenyl)ureido]phenylacetyl] methylamino]ethoxy]benzoate as a pale yellow oil. 'H-NMR (CDC13, 400MHz) δ 2.31 (s, 3H), 3.05 (s, IH), 3.23 (s, 2H), 3.71 (s, 2H), 3.83 (s, 3H), 3.85 (m, 3H), 3.94 (s, 3H), 4.19 and 4.39 (m, total 2H), 6.80 (m, 2H), 7.05 (m, IH), 7.22 (m, 3H), 7.62 (d, IH, =8.2Hz), 8.02 (d, IH, J=8.2Hz), 8.21 (dd, IH, J=2.1Hz, 8.8Hz, 8.55 (d, IH, =2.1Hz); MS (FAB) m/z 551(M++1).
A mixture of methyl 3-nitro-4-[[2-[3-methoxy-4-[/V-(2-methylphenyl)ureido]phenyl acetyl]methylamino]ethoxy]benzoate (587mg, 1. lmmol) and 5%-Pd-C (600mg) in THF-MeOH- AcOH (1:1: 1, v/v, 150mL) was hydrogenated at 45psi for 18hr. Insoluble catalyst was removed with suction, and the filtrate was evaporated in vacuo to afford 555mg (100%) methyl 3-amino-4- [[2-[3-methoxy-4-[N-(2-methylphenyl)ureido]phenylacetyl]methylamino]ethoxy]benzoate as a pale yellow gum. 'H-NMR (CDC13, 400MHz) δ 2.29 (s, 3H), 3.08 (m, IH), 3.19 (s, 2H), 3.65 (s, IH), 3.73-3.80 (m, 3H), 3.84 (s, 3H), 3.87(s, 3H), 4.19 and 4.40 (m, total 2H), 6.70-6.82 (m, 2H), 7.02-7.29 (m, 6H), 7.60 (d, IH, =7.8Hz), 7.92-7.99 (m, 3H); MS (FAB) /ra/z 521 (M++l).
To a stined solution of methyl 3-anuno-4-[[2-[3-methoxy-4-[Λ -(2-methylphenyl)ureido] phenylacetyl]methylamino]ethoxy]benzoate (555mg, 1. lmmol), formaldehyde (lOmL), and AcOH (0.58mL, lOmmol) in MeCN (lOmL) was added NaBH3CN (0.67g, lOmmol) at room temp, and the resulting mixture was stirred for 15 hr at the same temp. Sat. NaHC03 was added to the mixture and exfracted with CHC13. The exfract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was chromatographed on silica-gel with toluene:acetone (7:3 to 1: 1, v/v) as eluent to give 123mg (21%) methyl 3-dimethylamino-4-[[2-[3-methoxy-4-[N'-(2- methylphenyl) ureido]phenylacetyl] methylamino] ethoxy]benzoate as an oil. 'H-NMR (CDC13,
400MHz) δ 2.30 (s, 3H), 2.70 (s, 3H), 2.75 (s, 3H), 3.05 (s, IH), 3.18 (s, 2H), 3.61 (s, 3H), 3.70 (s, IH), 3.80 (m, 3H), 3.86 (s, 3H), 4.07 and 4.22 (m, total 2H), 6.28 (m, IH), 6.70-6.80 (m, 3H), 7.03 (m, IH), 7.15-7.25 (m, 4H), 7.46-7.65 (m, 2H), 8.02 (m, IH); MS (FAB) m/z 548 (M+ + 1).
A stirred mixture of methyl 3-dimethylamino-4-[[2-[3-methoxy-4-[/V-(2 -methylphenyl) ureido] phenylacetyl]methylamino]ethoxy]benzoate (123mg, 0.22mmol) in THF (15mL) and IN
NaOH (0.885mL, 0.885mmol) was heated under reflux for 15 hr. The pH of the mixture was adjusted to 5.0 by the addition of IN HCl, and exfracted with CHCl3-MeOH(9: 1, v/v). The exfract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was crystallized with Et20-n:hexane to give 118 mg(100%) 276 as a white ciystalline material, mp 125-130 °C; IR (KBr) 3346, 2940, 1620, 1597, 1535, 1456, 1417, 1227, 1039, 754cm '; 'H-NMR (CD3OD,
400MHz) δ 2.29 (s, 3H), 2.70 (s, 3H), 2.79 (s, 2H), 3.05 (s, IH), 3.22 (s, 2H), 3.75 (s, 3H), 3.85
(m, 4H), 4.15 and 4.28 (m, 2H), 6.78-7.05 (m, 4H), 7.18 (m, 2H), 7.55-7.70 (m, 3H), 7.98 (m,
IH); MS (FAB) m/z 535(M+ + 1); Anal, calcd. for C29H34N4O6-2.0H2O: C, 61.04; H, 6.71; N, 9.82.
Found: C, 61.15; H, 6.43; N, 8.94. Example 226
3-dimethylamino-4-[[2-[3-methoxy-4-[A?'-(2-fluorophenyl)ureido]phenylacetyl]methylamino] ethoxy]benzoic acid
Figure imgf000412_0001
A mixture of 3-methoxy-4-[W-(2-fIuorophenyl)ureido]phenylacetic acid(lg,3.1 lmmol), methyl 4-[2-(V-methyl-2-amino)ethoxy]-3-nifrobenzoate (800mg, 3.1 lmmol) and 4-DMAP (77mg, 0.63mmol), HOBt(640mg,4.7mmol), and EDC (904mg,4.7mmol) in DMF (20 mL) was stirred at room temp overnight. The mixture was diluted with EtOAc, and the solution was washed with 0.5 N HCl, sat. NaHC03, brine, , dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel with CHCI3-EtOAc (95:5 to 0: 100, v/v) as eluent to give 420mg (19%) methyl 3-nitro-4-[[2-[3-fluoro-4-[ -(2-fluorophenyl)ureido]phenylacetyl] methylamino] ethoxy]benzoate as a pale yellow oil. 'H-NMR (CDC13, 400MHz) δ 3.04 (s, IH), 3.24 (s, 2H), 3.72 (s, IH), 3.85 (s, 3H), 3.90 (m, 3H), 3.93 (s, 3H), 4.16 and 4.39 (2m, 3H), 6.80 (m, 2H), 6.99 (m, IH), 7.05 (m, 2H), 7.22 (d, IH, =8.8Hz), 7.51 (s, 2H), 8.00 (m, IH), 8.08 (m, IH), 8.21 (d, IH, J=8.6Hz), 8.51 (s, IH); MS (FAB) m/z 555 (M+ + 1).
A mixture of methyl 3-nifro-4-[[2-[3-methoxy-4-[Λ/'-(2-fluorophenyl)ureido]phenylacetyl] methylamino]ethoxy]benzoate (420mg, 0.76mmol) and 5%-Pd-C (lg) in THF-MeOH-AcOH (1: 1:1, v/v, 150mL) was hydrogenated at 45psi for 18 hr. Insoluble catalyst was removed with suction, and the filtrate was evaporated in vacuo to afford 397mg (100%) methyl 3-amino-4-[[2- [3-methoxy-4-[Λ/'-(2-fluorophenyl)ureido]phenylacetyl]meιhylamino]ethoxy]benzoate as a pale yellow gum. 'H-NMRv (CDC13, 400MHz) δ 3.05 and 3.13 (s, total 3H), 3.66 (s, 3H), 3.70 (s, 2H), 3.65-3.90 (m, 4H), 3.86 (s, 3H), 4.10 and 4.23 (m, 2H), 6.70-6.83 (m, 3H), 6.98-7.15 (m, 6H), 7.25-7.43 (m, 2H), 7.99 (m, IH), 8.13 (m, IH); MS (FAB) m/z 525 (MXl).
To a stirred solution of methyl 3-aimno-4-[[2-[3-methoxy-4-[JV-(2-fluorophenyl)ureido] phenylacetyl]methylamino]ethoxy]benzoate (397mg, 0.76mmol), formaldehyde (lOmL), and AcOH (0.43mL, 7.6mmol) in MeCN (lOmL) was added NaBH3CN (0.48g, 7.6mmol) at room temp, and the resulting mixture was stirred for 15 hr at the same temp. Sat. NaHC03 was added to the mixture and extracted with CHC13. The exfract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was chromatographed on silica-gel with toluene:acetone (7:3 to 1 : 1, v/v) as eluent to give 123mg (21%) methyl 3-dimethylamino-4-[[2-[3-methoxy-4-[iV-(2- methylphenyl)ureido]phenylacetyl] methylamino]ethoxy]benzoate as an oil. 'H-NMR (CDC13,
400MHz) δ 2.74 (s, 3H), 2.77 (s, 3H), 3.08 (s, IH), 3.22 (s, 2H), 3.52 (s, 3H), 3.61 (s, IH), 3.83 (m, 3H), 3.88 (s, 3H), 4.12 and 4.23 (m, total 2H), 6.68 (s, IH), 6.78 (m, 2H), 6.98 (m, 2H), 7.10 (m, IH), 7.55-7.68 (m, 4H), 7.99 (m, IH), 8.16 (t, IH, =8.3Hz); MS (FAB) m/z 553 (M++l).
A stirred mixture of methyl 3-dimethylamino-4-[[2-[3-methoxy-4-[Nl -(2 -fluorophenyl) ureido] phenylacetyl]methylamino]ethoxy]benzoate (61mg, O. llmmol) in THF (15mL) and IN NaOH (0.22mL, 0.22mmol) was heated under reflux for 15 hr. The pH of the mixture was adjusted to 5.0 by the addition of IN HCl, and exfracted with CHCl3:MeOH(9:l, v/v). The extract was washed with brine, MeOH:acetone (93:7, v/v) as eluent to give 37 mg (63%) 277 as a white crystalline material, mp 120-125 °C; 'H-NMR (CD3OD, 400MHz) δ 2.60 (s, 4H), 2.78 (s, 2H), 3.06 (s, IH), 3.22 (s, 2H), 3.75 (s, 3H), 3.85-3.92 (m, 4H), 4.17 and 4.29 (m, total 2H), 6.80-7.12 (m, 6H), 7.61-7.70 (m, 2H), 8.00 (m, IH), 8.08 (m, IH); MS (FAB) 539 (M++l); Anal, calcd. for C28H31FN406-2.75H20: C, 57.18; H, 6.26; N, 9.53. Found, C, 57.20; H, 5.62; N, 9.06. Example 227
3-dimethylamino-4-[[2-[4-[Λ/'-(2-methylphenyl)ureido]phenylacetyl]methylamino]ethoxy] benzoic acid
Figure imgf000414_0001
A mixture of pentafluorophenyl [4-[iV-(2-methylphenyl)ureido]phenyl]acetate (1.42g,
3.15mmol), methyl 4-[2-(N-methyl-2-amino)ethoxy]-3-nifro benzoate (800mg, 3.15mmol) and triethylamine (0.66mL,4.73mmol) in DMF (8 mL) was stirred at 50° C for 15 hr. The mixture was poured into ice- IN HCl and exfracted with CHC13. The extract was brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel with CHCl3:EtOAc (95:5 to 0: 100, v/v) as eluent to give 1.04g (63%) methyl 3-mtro-4-[[2-[4-[/V-(2-methylphenyl)ureido] phenylacetyl]methylamino]ethoxy]benzoate as a pale yellow oil. 'H-NMR (CDC13, 400MHz) δ 2.30 (s, 3H), 2.90, 3.02 and 3.05 (s, total IH), 3.22 (s, 2H), 3.71 (s, IH), 3.85 ( 3H), 3.93 (s,3H), 4.19 and 4.39 (m, 2H), 7.02 (m, IH), 7.19 (m, 4H), 7.35 (d, IH, J=8.3Hz), 7.40 (d, IH, =8.0Hz), 7.55 (s, 2H), 7.70 (m, IH), 8.22 (d, IH, J=6.1Kz), 8.51 (s, IH); MS (FAB) m/z 521(M++1).
A mixture of methyl 3-nitro-4-[[2-[4-[Λ7,-(2-methylphenyl)ureido]phenylacetyι] methylamino]ethoxy]benzoate (1.04g, 2mmol) and 5%-Pd-C (1.2g) in THF-MeOH-AcOH (1:1:1, v/v, 150mL) was hydrogenated at 45 psi for 18 hr. Insoluble catalyst was removed with suction, and the filtrate was evaporated in vacuo to afford methyl 3-amino-4-[[2-[4-[Λ^-(2-methylphenyl) ureido]phenylacetyl]methylamino]ethoxy]benzoate as a pale yellow gum.
To a stirred solution of 3-amino-4-[[2-[4-[Λ/'-(2-methylphenyl)ureido]phenylacetyl] methylamino]ethoxy]benzoate, formaldehyde (5mL), and AcOH (1.14mL, 20mmol) in MeCN (5mL) was added NaBH3CN (1.26g, 20mmol) at room temp, and the resulting mixture was stirred for 15 hr at the same temp. Sat. NaHC03 was added to the mixture and exfracted with CHC13. The extract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was chromatographed on silica-gel with toluene:acetone (7:3 to 1:1, v/v) as eluent to give 85mg (2 steps, 8%) methyl 3-dimethylamino-4-[[2-[4-[N'-(2-methylphenyl)ureido]phenylacetyl]methyl amino]ethoxy]benzoate as an oil. Η-NMR (CDC13, 400MHz) δ 2.12 (s, 3H), 2.73 (s, 3H), 2.75 (s, 3H), 3.05 (s, IH), 3.20 (s, 2H), 3.60 (s, IH), 3.80 (m, 3H), 3.88 (s, 3H), 4.17 (m, 2H), 6.95-7.28 (m, 8H), 7.55-7.75 (m, 3H); MS (FAB) m/z 518 (MXl).
A stirred mixture of methyl 3-dimethylamino-4-[[2-[4-[N'-(2-methylphenyl)ureido] phenylacetyl] methylamino]ethoxy]benzoate(ap315201)(85mg, 0.16mmol) in THF (15mL) and IN
NaOH (0.32mL, 0.32mmol) was heated under reflux for 15 hr. The pH of the mixture was adjusted to 5.0 by the addition of IN HCl, and exfracted with CHCl3:MeOH(9: 1, v/v). The exfract was washed with brine, dried over MgS04, and evaporated in vacuo. The residue was crystallized from Et20 to give 53 mg(65%) 278 as a white ciystalline material, mp 110-115 °C; 'H-NMR
(CD3OD, 400MHz) δ 2.29 (s, 3H), 2.75 (s, 3H), 2.76 (s, 3H), 3.02 (s, IH), 3.20 (s, 2H), 3.72 (s,
IH), 3.85 (m, 3H), 4.18 and 4.28 (m, total 2H), 6.95-7.03 (m, 2H), 7.18 (m, 4H), 7.34 (d, IH, =8.3Hz), 7.38 (d, IH, J=8.8Hz), 7.62 (d, IH, =8.3Hz), 7.66 (s, IH), 7.80 (m, IH); MS (FAB) m/z 505 (M++l). Example 228
3-isopropylamino-4-[[2-[3-methoxy-4-[iV-(2-fluorophenyl)ureido]phenylacetyl]methylamino] ethoxy]benzoic acid
Figure imgf000415_0001
To a stirred cold (0° C) solution of methyl 3-amino-4-[[2-[3-methoxy-4-[/V'-(2-fluoro phenyl)ureido]phenylacetyl]methylamino]ethoxy]benzoate (lOOmg, 0.19mmol) in acetone /
AcOH/DMF (13 mL, 6:6: 1, v/v/v) was added NaBH3CN (300 mg), and the resulting mixture was stirred for 60 hr at room temp. The mixture was pored into sat. NaHC03 and the solid was collected with suction. The precipitate was dissolved in CHC13 (20mL), and the solution was washed with brine, dried over MgS04, and evaporated under a reduced pressure. The residue was chromatographed on silica-gel plate with toluene:acetone (2: 1, v/v) as eluent to give 108 mg
(100%) methyl 3-isopropylamino-4-[[2-[3-methoxy-4-[iV-(2-fluorophenyl)ureido]phenylacetyl] methylamino]ethoxy]benzoate as a colorless oil. 'H-NMR (CDC13, 400MHz) δ 1.20 (m, IH), 2.88 (s, 6H), 3.02 and 3.12 (s, total 3H), 3.53 (s, 2H), 3.60-3.80 (m, IK), 3.85 (s, 3H), 4.10 and 4.20 (m, 2H), 6.65-675 (m, 2H), 6.90-7.08 (m, 2H), 7.22-7.35 (m, 2H), 8.02 (s, 2H), 8.10 (m, 2H), 8.21 (br, IH), 8.33 (br, IH); MS (FAB) m/z 566 (M++l). A stirred mixture of methyl 3-isopropylamino-4-[[2-[3-methoxy-4-[Λ''-(2 -fluorophenyl) ureido]phenylacetyl]methylamino]ethoxy]benzoate (116mg, 0.2mmol), 0.25 N NaOH (6 mL), and THF (6 mL) was heated under reflux for 8 hr. The mixture was poured into water (200 mL) , acidified by IN HCl and the solid was collected with suction. The solid was recrystallized from CHCl3-n-hexane-diisopropylether to give 56mg (50%) 279 as a colorless crystalline powder, mp 195-200 °C; Η-NMR (CD3OD, 400MHz) δ 1.15-1.20 (m, 6H), 3.01 (s, IH), 3.12 (s, 2H), 3.48- 3.60 (m, IH), 3.68 (s, 3H), 3.75 (s, 2H), 3.82 (s, IH), 3.86 (m, 3H), 4.15-4.23 (m, 2H), 6.80 (m, 3H), 4.15-4.23 (m, 2H), 6.80 (m, 3H), 6.98 (m, IH), 7.10 (m, 2H), 7.20 and 7.25 (s, total IH), 7.32 (m, IH), 7.98 (m, IH), 8.05 (m, IH); MS (FAB) m/z 552 (M+H)+; Anal, calcd. for C29H33FN4O6-1.0H2O: C, 61.04; H, 6.18; N, 9.82. Found, C, 61.36; H, 6.25; N, 9.45. Example 229
4-[[l-[4-[N,-(2-fluorophenyl)ureido]-3-methoxyphenylacetyl]-2-methylamino]-2-methyl-2- propoxy]benzoic acid
Figure imgf000416_0001
To a stirred solution of 2-amino-2-methyl-l-propanol (8.4g, 93.89mmol) and triethylamine (11.4g, 0.113mol) in DMF-water (1:1, v/v, lOOmL) was added di-tert-bυtyl dicarbonate (25g, 0.115mol) at 5 to 10° C. The resulting solution was stirred for 2 hr at room temp. The mixture was diluted with water(lOOmL) and extracted with EtOAc. The exfract was washed with brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel with CH2C12 as eluent to give 12g (68%) 2-terr-butoxycarbonylaιnino-2-methyl-l- propanol as a syrup. 'H-NMR (CDC13) δ 1.25 (s, 6H), 1.43 (s, 9H), 3.59 (d, J=8.3Hz, 2H), 4.68 (br, IH).
To a stirred suspension of 2-fer/-butoxycarbonylamino-2-methyl-l-propanol (5.7g, 30.11mmol) and powdered NaOH(6.7g, 0.151mol) in Et2O(200mL) was added -toluenesulfonyl chloride (6.9g, 36.14mmol) at room temp. The stirred resulting mixture was heated under reflux for 8 hr. After cooling, ice-water(lOOmL) was added to the solution. Separated Et20 layer was washed with brine, dried over Na2S04, and evaporated. To the residue was added n-hexane and fritraated. The solid was collected to afford 8.5g (82.2%) 2-terf-butoxycarbonylamino-2-methyl-l- propylp-toluenesulfonate as a crystalline material. 'H-NMR (CDC13) δ 1.26 (s, 6H), 1.38 (s, 9H), 2.37 (s, 3H), 4.05 (s, 2H), 4.49 (br, IH), 7.34 (d, J=7.8Hz, 2H), 7.78 (d, =7.8Hz, 2H).
A stirred mixture of 2- err-butoxycarbonylamino-2-methyl-l-propylp-toluenesulfonate (8.2g, 23.88mmol) and powdered NaOH (6.7g, 0.151mol) in Et20 (200mL) was heated under reflux for 10 hr. After cooling, the mixture was filtered. And the filtrate was washed with water, brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel with n- hexane:EtOAc (6: 1, v/v) as eluent to give 2.7g (66.2%) l-te ^butoxycarbonyl-2-methylpropylene imine as an oil. 'H-NMR (CDC13) δ 1.29 (s, 6H), 1.47 (s, 9H), 2.05(s, 2H).
To a stirred solution of l-terf-butoxycarbony-2-methylpropyleneimine (1.03g, 6. Olmmol) and methyl 4-hydroxybenzoate (800mg, 6.26mmol) in CH2Cl2(10mL) was added boron trifluoride diethyl ether (0.127mL, lmmol) at ambient temp. The resulting solution was stirred for a further 3 hr at the same temp. The mixture was washed with water, brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel with n-hexane:EtOAc (6:1, v/v) as eluent to give 550mg (33%) methyl 4-(l-/e^-butoxycarbonylamino-2-methyl-2-propoxy)benzoate as a gum. 'H-NMR (CDC13) δ 1.33 (s, 6H), 1.47 (s, 9H), 3.36 (d, =6.3Hz, 2H), 3.90 (s, 3H), 5.05 (br, IH), 6.99 (d, J=8.8Hz, 2H), 7.97 (d, =8.8Hz, 2H).
A mixture of methyl 4-(l-te )utoxycarbonylamino-2-methyl-2-propoxy)benzoate (460mg, 1.42mmol) and anisole (0.155mL, 1.42mmol) in CH2Cl2(15mL) and TFA (3mL) was stirred for 3 hr at room temp. The mixture was evaporated off. The residue was dissolved in CH2Cl2(30mL) and made basic by the addition of 0.5N NaOH. The CH2C12 layer was separated, dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel with CH2C12 as eluent to give 370mg (100%) methyl 4-(l-amino-2-methyl-2-propoxy)benzoate as a gum. 'H- NMR (CDC13) δ 1.34 (s, 6H), 2.87(s,2H),3.90 (s,3H),7.10 (d, J=8.8Hz,2H), 7.97 (d, J=8.8Hz, 2H).
To a stirred solution of methyl 4-(l-amino-2-methyl-2-propoxy)benzoate (370mg, 1.66πunol) and triethylamine (0.35mL, 2.49mmol) in CH2Cl2 (15mL) was added trifluoroacetic anhydride (0.316mL, 2.24mmol) at 0° C. After stirred for 1 hr at the same temp, water was added to the solution. CH2C12 layer was separated, washed with water, dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel(20mL) with CH2C12 as eluent to give 530mg (100%) methyl 4-(l-trifluoroacetamido-2-methyl-2-propoxy)benzoate as a gum. This compound was used to the subsequent reaction without further purification.
To a stirred mixture of methyl 4-(l-trifluoroacetamido-2-methyl-2-propoxy)benzoate (530mg, 1.66mmol) and K2C03 (345mg, 2.49mmol) in DMF (lOmL) was added Mel (0.14mL, 2.37mmol) at room temp. The resulting mixture was stirred for 18 hr at room temp. The mixture was poured into water, and extracted with EtOAc. The extract was washed with washed with brine, dried over Na2S04, and evaporated. The residual gum was used to the subsequent reaction without further purification.
The above crude residue was dissolved in MeOH(lOmL). To the stirred solution was added water (5mL) and Na2C03(352mg, 3.32mmol), and the resulting mixture was stirred for 5 hr at room temp. The mixture was poured into water and exfracted with CHC13. The exfract was washed with water, dried over Na2S04, and evaporated. The residue was chromatographed on silica-gel with CHC13 as eluent to give 390mg (100%) methyl 4-(l-methylamino-2-methyl-2- propoxy)benzoate as a gum. 'H-NMR (CDC13) δ 1.37 (s, 6H), 2.51 (s, 3H), 3.89 (s, 3H), 6.92 (d, =8.8Hz, 2H), 7.97 (d, J=8.8Hz, 2H).
To a stirred mixture of methyl 4-(l-methylamino-2-methyl-2-propoxy)benzoate (200mg,
0.84mmol), 4-[ V-(2-fluorophenyl)ureido]-3-methoxyphenylacetic acid (268mg, 0.84mmol), 4- DMAP(125mg, LOmmol) in DMF(5mL) was added EDC(220mg, 1.14mmol) at ambient temp. The resulting mixture was stirred for a further 10 hr at ambient temp. The mixture was poured into water, and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residual gum was triturated with CH2C12 and Et20 to give 200mg (44.1%) methyl 4-[[l-[4-[ -(2-fluorophenyl)ureido]-3-methoxyphenylacetyl]methylamino]-2-methyl-2- propoxyjbenzoate as a crystalline material. 'H-NMR (CDC13) δ 1.36 and 1.31 (each s, 6H), 3.24- 3.88 (series of s, 13 H), 6.65-8.20 (seris of m, 14H).
A mixture of methyl 4-[[l-[4-[Λ/,-(2-fluorophenyl)ureido]-3-methoxyphenylacetyl] methylamino]-2-methyl-2-propoxy]benzoate(180mg, 0.335mmol) in THF(3mL) and 0.25N
NaOH(4mL) was stirred for 5 hr at room temp. The mixture was poured into ice- IN HCl(5mL). The solid was collected, washed with water, and air-dried. The crude solid was recrystallized from EtOH-CHCl3-n-hexane to give 70 mg (40%)280 as fine needles, mp 200-207 °C; 'H-NMR (DMSO-c/6) δ 1.26 and 1.33 (each s, 6H), 3.70-3.81 (series of s, IK), 3.83 (s, 3H), 6.75-8.20 (series of m, 10H), 8.71 (s, IH), 9.17 (br s, IH), 12.72 (s, IH). Example 230
(S)-3-chloro-4-[2-[3-methoxy-4-[N'-(2-fluorophenyl)ureido]phenylacetylamino]-l-propoxy] benzoic acid
Figure imgf000418_0001
A mixture of 3-methoxy-4-[N'-(2-fluorophenyl)ureido]phenylacetic acid (327 mg, 1.03 mmol), methyl (5 -3-chloro-4-(2-amino-l-propoxy)benzoate (250 mg, 1.03 mmol), EDC(hydrochloride) (295 mg, 1.54 mmol), HOBt (208 mg, 1.54 mmol), and DMAP (25 mg, 0.20 mmol) in DMF (8 mL) was stirred at room temp overnight. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04 and evaporated. The residue was recrystallized from CHCl3-EtOAc to give 308 mg (55%) as a white crystalline powder. 'H-NMR (CDC13) δ 1.29 (d, 3 H, .7=6.8 Hz), 3.51 (s, 2 H), 3.84 (s, 3 H), 3.88 (s, 3 TT), 4.01-4.08 (m, 2 H), 4.38-4.39 (m, 1 H), 6.25 (d, 1 H, .7=8.3 Hz), 6.78-6.83 (m, 2 H), 6.90-6.95 (m, 2 TT), 7.02-7.11 (m, 2 T), 7.89 (dd, 1 H, J=2.0, 8.8 Hz), 8.02 (d, 1 H, .7=2.4 Hz), 8.20 (d, 1 H, J=8.3 Hz), 8.27-8.31 (m, 1 H), 8.53 (s, 1 TT), 8.84 (s, 1 H).
To a stirred solution of methyl (5 -3-chloro-4-[2-[3-methoxy-4-[N'-(2-fluorophenyl) ureido]phenylacetylamino]-l-propoxy]benzoate (308 mg, 0.57 mmol) in THF-MeOH (10 mL, 1: 1, v/v) was added 0.5 N NaOH (10 mL), and the reaction mixture was heated under reflux for 1 hr. The mixture was poured into ice-1 N HCl and the solid was collected. The crude solid was purified by recrystallization from MeOH-CHCl3-n-hexane to give 196 mg (65%) 281 as a white crystalline powder, mp 188-191 °C; 'H-NMR (DMSO-cL.) δ 1.21 (d, 3 H, .7=6.4 Hz), 3.38 (s, 2 H), 3.83 (s, 3 H), 4.02-4.18 (m, 3 H), 6.78-7.29 (series of m, total 6 H), 7.85-8.00 (m, 3 H), 8.12-8.19 (m, 2 H), 8.70 (s, 1 H), 9.17 (s, 1 H), 12.98 (bs, 1 TT); MS (FAB) m/z 530 (M+), 531 (M++l), 532 (M++2); Anal. Calcd for C26H25C1FN306-1/4H20: C, 58.43; H, 4.81; Cl, 6.63; F, 3.55; N, 7.86. Found: C, 58.45; H, 4.83; Cl, 6.68; F, 3.38; N, 7.79. Example 231
4-[[2-[3-methoxy-4-[Λ/'-(2-methylphenyl)ureido]phenylacetyl]methylamino]ethylamino]benzoic acid
Figure imgf000419_0001
A stirred solution of Λ?-benzyloxycarbonyl-N-methylaminoacetaldehyde (1.77g, 1. lmmol) in toluene (3mL) was added methyl-4-aminobenzoate (1.29g, 8.5mmol), and the mixture was stirred for 1 hr at room temp. The reaction mixture was evaporated under a reduced pressure and the residue was dissolved into MeCN(15 mL). To the solution was added AcOH (2.44mL, 43mmol) and NaBH3CN (2.67g, 43mmol), and the resulting mixture was stirred for 15 hr at room temp. The reaction was quenched by the addition of sat. NaHC03. The mixture was extracted with EtOAc, washed with brine, dried over MgS04, and evaporated. The residue was chromatographed on silica-gel with n-hexane: EtOAc (7:3, v/v) as eluent to give 1.26g (43%) methyl 4-[2-(N-benzyloxy carbonyl-N-methylamino)-ethylamino] benzoate as a colorless oil. 'H- NMR (CDC13, 400MHz) δ 2.96 (s, 3H), 3.32 (br m, 2H), 3.50-3.60 (m, 2H), 3.82 (s, 3H), 5.15 (each d, 2H, J=14.6Hz), 6.35 and 6.58 (m, total 2H), 7.36 (s, 5H), 7.76 and 7.84 (m, total 2H); MS (FAB) m/z 342 (M++l).
To a stirred solution of methyl 4-[2-(N-benzyloxycarbonyl-N-methylamino)ethylamino] benzoate (L26g, 3.68mmol) in MeOH(20 mL) was added 5 wt. Pd -C (700mg), and the mixture was hydrogenated (3 aim) for 4 hr at room temp. The mixture was filtered, and the filtrate was evaporated under a reduced pressure to give 600mg (78%) methyl 4-[2-(N-methylamino) ethylamino]benzoate as a colorless oil. 'H-NMR (CDC13, 400MHz) δ 2.46 (s, 3H), 2.88 (t, 2H, J=5.5Hz), 3.27 (br s, 2H), 3.85 (s, 3H), 6.57 (d, 2H, J=8.8Hz), 7.85 (d, 2H, =8.8Hz); MS (FAB) m/z 209 (M++l).
To a stined solution of methyl 4-[2-(N-methylamino)ethylamino]benzoate (590mg, 2.83mmol)3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (891mg,2.83mmol) in DMF(14mL) was added EDC (815mg,4.25mmol), HOBt (574mg,4.25mmol),and 4-DMAP (519mg, 4.25mmol), and the resulting mixture was stirred overnight at room temp. The mixture was poured into IN HCl and the solid was collected with suction. The crude solid was purified by chromatography on silica-gel (middle pressure) with CHCl3-EtOAc (10:0 to 7:3, v/v) as eluent to give 1.25g (87%) methyl 4-[[2-[3-methoxy-4-[Λ^-(2-methylphenyl)ureido]phenylacetyl] methylamino]ethylamino]benzoate as a light yellow oil. 'H-NMR (CDC13, 400MHz) δ 3.18 (s, 2H), 3.05 and 3.32 (s, total 2H), 3.72-3.85 (m, 9H), 4.12 and 4.23 (m, total 2H), 6.78 (m, 3H), 7.05 (t, IH, =7.5Hz), 7.20 (m, 2H), 7.43-7.50 (m, 3H), 7.62 (d, IH, J=8.8Hz), 8.05 (d, IH, J=8.8Hz); MS (FAB) m/z 505 (M++l ).
A stirred mixtrae of methyl 4-[[2-[3-methoxy-4-[Λ/'-(2-methylphenyl)ureido]phenylacetyl] methylamino]ethylamino]benzoate (300mg, O.όmmol) in 0.25 N NaOH (6 mL) and THF (6 mL) was heated under reflux for 8 hr. The mixture was poured into water, and acidified with IN HCl. The solid was collected with suction. The crude solid was recrystallized from n-hexane- diisopropylether to give 202mg (69%) 282 as a pale yellow crystalline powder, mp 115-120 °C; IR(KBr) 3346, 2935, 1603, 1531, 1454, 1417, 1257, 1174, 1036, 754cm '; 'H-NMR (CD3OD, 400MHz) δ 2.28 (s, 3H), 2.98 (s, IH), 3.10 (s, 2H), 3.35-3.42 (m, 2H), 3.53-3.65 (m, 3H), 3.70 (s, IH), 3.80 and 3.82 (s, 3H), 6.60-6.85 (m, 4H), 7.02 (m, IH), 7.18 (m, 2H), 7.58 (m, IH), 7.82 (m, 2H), 7.96 (m, IH); MS (FAB) m/z 491 (M++l). Example 232
(5)-3-chloro-4-[2-[N-methyl-N-[3-methoxy-4-[Λf'-(2-fluorophenyl)ureido]phenylacetyl] amino] -l-propoxy]benzoic acid
Figure imgf000421_0001
To a cooled (0° C) solution of methyl (S)-3-chloro-4-(2-amino-l-propoxy)benzoate (1.74 g, 7.14 mmol) in CH2C12 (20 mL) was added Et3N (1.19 mL, 8.54 mmol) and trifluoroacetic anhydride (TFAA) (1.11 mL, 7.86 mmol), and the reaction mixture was stirred at room temp overnight. The mixture was diluted with CHC13, washed with 0.5 N HCl, brine, dried over Na2S04 and evaporated. The residue was recrystallized from CHCl3-n-hexane to give 1.59 g (66%) (S)-3- chloro-4-(2-trifluoroacetamido-l-propoxy)benzoate as a white crystalline material, mp 122-125 °C; 'H-NMR (CDC13) δ 1.48 (d, 3 H, .7=6.8 Hz), 3.91 (s, 3 H), 4.10-4.19 (m, 2 H), 4.47-4.52 (m, 1 H), 6.68 (bs, 1 TT), 6.92-6.94 (m, 1 H), 7.93-7.95 (m, 1 H), 8.07-8.08 (m, 1 H); MS (FAB) m/z 340 (M++l); Anal. Calcd for C13H13C1F3N04: C, 45.96; H, 3.86; Cl, 10.44; F, 16.78; N, 4.12. Found: C, 45.88; H, 3.97; Cl, 10.24, F, 16.72; N, 4.18.
To a stirred solution of methyl (S)-3-chloro-4-(2-trifluoroacetamido-l-propoxy)benzoate
(800 mg, 2.36 mmol) in DMF (5 mL) was added K2C03 (651 mmol, 4.71 mmol) and Mel (0.22 mL, 3.53 mmol), and the reaction mixture was stirred at 60° C overmght. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with 5% EtOAc in CHC13 as eluent to give 850 mg (100%) methyl (5)-3-chloro-4-[2-(Λ^-methyl-N-trifluoroacetamido)-l-propoxy] benzoate as a colorless oil. 'H-NMR (CDC13) δ 1.43-1.46 (m, 3 H), 3.03 and 3.21 (s, 3 H), 3.90 (s, 3 H), 4.04-4.22 (m, 2 H), 4.81-4.87 (m, 1 H), 6.91 (d, 1 H, .7=8.3 Hz), 7.93 (dd, 1 H, .7=2.0, 8.3 TT), 8.06 (d, 1 H, .7=2.0 Hz).
To a stirred solution of methyl (5)-3-chloro-4-[2-(N-methyl-N-trifluoroacetamido)-l- propoxy] benzoate (880 mg, 2.49 mmol) in MeOH-H20 (10 mL, 1: 1, v/v) was added K2C03 (516 mg, 3.73 mmol), and the resulting mixture was stirred at room temp overnight. The mixture was diluted with EtOAc, washed with H20, brine, dried over Na2S04 and evaporated to give 460 mg (72%) (S)-3-chloro-4-(2-methylamino-l-propoxy)benzoate as a colorless oil. Η-NMR (CDC13) δ 1.20(d, 3 H, .7=6.4 Hz), 2.51 (s, 3 H), 3.07-3.12 (m, 1 TT), 3.89 (s, 3 TT), 3.92-4.04 (m, 2 H), 6.93- 6.95 (m, 1 H), 7.90-7.93 (m, 1 H), 8.05-8.06 (m, 1 H). A mixture of 3-methoxy-4-[N'-(2-fluorophenyl)ureido]phenylacetic acid (296 mg, 0.93 mmol), methyl (S)-3-chloro-4-(2-methylamino-l-propoxy)benzoate (240 mg, 0.93 mmol), EDC(hydrochloride) (268 mg, 1.40 mmol), HOBt (189 mg, 1.40 mmol), and DMAP (23 mg, 0.19 mmol) in DMF (8 mL) was stirred at room temp for 1.5 hr. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with 5% MeOH in CHC13 as eluent to give 520 mg (100%) methyl (5 -3-chloro-4-[2-[N-methyl-N-[3-methoxy-4-[N'-(2-fluorophenyl)ureido]phenylacetyl] amino] -l-propoxy]benzoate as a red-brown amoφhous solid.
To a stirred solution of this product (520 mg, 0.93 mmol) in THF (10 mL) was added 0.5 N NaOH (10 mL), and the resulting mixture was heated under reflux for 3 hr. The mixture was poured into ice-1 N HCl and the solid was collected. The crude solid was recrystallized from CHC13-Et20 to give 170 mg (2 steps, 37%) 283 as a white crystalline powder, mp 142-147 °C; Η- NMR (DMSO-cL.) δ 1.13-1.20 (m, 3 H), 2.74 and 2.94 (s, 3 H), 3.65 (s, 2 H), 3.82 and 3.84 (s, 3 H), 4.13-4.22 (m, 2 H), 4.53 and 4.91-4.92 (m, 1 H), 6.71-7.29 (series of m, total 6 T), 7.86-8.02 (m, 3 TT), 8.15-8.19 (m, 1 H), 8.71 (s, 1 H), 9.17 (s, 1 H), 13.00 (bs, 1 H); MS (FAB) m/z 544 (M+), 545 MX ); Anal. Calcd for C27H27C1FN306 1/4H20: C, 59.13; H, 5.05; Cl, 6.46; F, 3.46; N, 7.66. Found: C, 59.19; H, 4.99; Cl, 6.64; F, 3.23; N, 7.55. Example 233
(5)-3-chloro-4-[2-[N-methyl-N-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl] amino- l-propoxy]benzoic acid
Figure imgf000422_0001
A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (261 mg, 0.83 mmol), methyl (5 -3-chloro-4-(2-methylamino-l-propoxy)benzoate (214 mg, 0.83 mmol), EDC(hydrochloride) (239 mg, 1.25 mmol), HOBt (168 mg, 1.24 mmol), and DMAP (20 mg, 0.16 mmol) in DMF (8 mL) was stined at room temp for 2 hr. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (50:1, v/v) as eluent to give 470 mg (100%) methyl (5 -3-chloro-4-[2-[N-methyl-N-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]amino]-l-propoxy]benzoate as a pale yellow amoφhous solid.
To a stirred solution of the above product (470 mg, 0.95 mmol) in THF (10 mL) was added 0.5 N NaOH (10 mL) and the reaction mixture was heated under reflux for 3 hr. The mixture was poured into ice-1 N HCl and the solid was collected. The crude solid was recrystallized from CHC13-Et20 to give 168 mg (2 steps, 33%) 284 as a pale yellow crystalline powder, mp 125-130 °C; 'H-NMR (DMSO-cL.) δ 1.13-1.19 (m, 3 H), 2.24 (s, 3 H), 2.74 and 2.94 (s, 3 H), 3.65 (s, 2 TT), 3.83 and 3.85 (s, 3 H), 4.14-4.22 (m, 2 H), 4.91-4.93 (m, 1 T), 6.70-6.74 (m, 1 TT), 6.84 (m, 1 TT), 6.92-6.95 (m, 1 H), 7.11-7.17 (m, 2 H), 7.25-7.29 (m, 1 TT), 7.78-7.80 (m, 1 H), 7.85-7.93 (m, 2 H), 7.99-8.02 (m ,1 H), 8.46 (s, 1 H), 8.56 (s, 1 H), 12.99 (bs, 1 TT); MS (FAB) m/z 540 (M+), 541 (M++l); Anal. Calcd for C28H30ClN3O6- 1/2H20: C, 61.26; H, 5.69; N, 7.65. Found: C, 61.15; H, 5.58; N, 7.51. Example 234
3-isopropylamino-4-[[2-[3-methoxy-4-[ V-(2-methylphenyl)ureido]phenylacetyl]methylamino] ethoxyjbenzoic acid
Figure imgf000423_0001
To a cold (0° C), stirred solution of methyl 3-aimno-4-[[2-[3-methoxy-4-[JV-(2-methyl phenyl) ureido]phenylacetyl]methylamino]ethoxy]benzoate (300mg, 0.58mmol) in acetone-AcOH- DMF (13 mL, 6:6:1, v/v/v) was added NaBH3CN (300 mg) and the resulting mixture was stirred for 60 hr at room temp. The mixture was poured into sat. NaHC03 and exfracted with CHC13. The exfract was washed with brine, dried over MgS04, and evaporated to give 280 mg (86%) methyl 3-isopropylamino-4-[[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl] methylamino]ethoxy]benzoate as a colorless oil. 'H-NMR (CDC13, 400MHz) δ 1.21 (m, 6H), 2.30 (s, 3H), 3.05 and 3.10 (s, total 2H), 3.59 (s, 3H), 3.62-3.81 (m, 6H), 3.89 (s, 3H), 4.10 and 4.21 (m, 2H), 6.65-6.80 (m, 4H), 7.10 (m, IH), 7.20 (s, 3H), 7.32 (m, 2H), 7.54 (d, IH, J=8.3Hz), 8.00 (s, IH), 8.07 (d, IH, J=8.3Hz); MS (FAB) m/z 563 (M++l).
A stirred mixture of methyl 3-isopropylamino-4-[[2-[3-mefhoxy-4-[Λ^-(2-methylphenyl) ureido]phenylacetyl]methylamino]ethoxy]benzoate (280mg, 0.5mmol), 0.25 N NaOH (6 mL), and THF (6 mL) was heated under reflux for 8 hr. The mixtrae was poured into water (200 mL) , acidified with IN HCl and the solid was collected with suction. The solid was recrystallized from CHCl3-n-hexane-diisopropylether to give 202mg (74%) 285 as a light yellow ciystalline powder, mp 130-135 °C; 'H-NMR (CD3OD, 400MHz) δ 1.18 and 1.22 (d, total 6H, J=6.3Hz), 2.29 and 2.32 (s, total 3H), 3.04 and 3.14 (s, total 2H), 3.60-3.90 (m, 9H), 4.16 and 4.25 (m, total 2H), 6.80 (m, 3H), 7.02 (m, IH), 7.12-7.24 (m, 3H), 7.29-7.38 (m, IH), 7.59 (m, IH), 8.02 (m, IH); MS (FAB) m/z 548 (M+K)+; Anal. calcd. for C30H36N4O6: C, 65.68; H, 6.61. Found: C, 65.80; H, 6.83. Example 235
4-[[2-[3-methoxy-4-[Λ^-(2-methylphenyl)ureido]phenylacetyl]methylamino]ethyl]methylamino benzoic acid
Figure imgf000424_0001
To a stirred cold (0° C) solution of methyl 4-[[2-[3-methoxy-4-[JV-(2-methylphenyl) ureido]phenylacetyl]methylamino]ethyl]aminobenzoate (300mg, O.όmmol) in MeCN- formaldehyde-AcOH (11 mL, 8:2: 1, v/v/v) was added NaBH3CN (187 mg, 2.40 mmol), and the resulting mixture was stirred for 18 hr at room temp. The mixtiire was poured into sat. NaHC03 and extracted with CHC13. The exfract was washed with brine, dried over MgS04, and evaporated to give 309 mg (100%) methyl 4-[[2-[3-me oxy-4-[ -(2-methylphenyl)ureido]phenylacetyl]-2-/V'- methylamino]ethyl]N-methylaminobenzoate as a colorless oil. 'H-NMR (CDC13, 400MHz) δ 2.30 (m, 3H), 2.98 (m, IK), 3.46-3.72 (m, 9H), 3.82 (m, 3H), 6.32 (m, IH), 6.55-6.75 (m, 4H), 7.05- 7.50 (m, 2H), 7.82-8.02 (m, 4H); MS (FAB) m/z 518 (M++l).
A stirred mixture of methyl 4-[[2-[3-methoxy-4-[Λ^-(2-methylphenyl)ureido]phenylacetyl]
-2-Λ^-methylamino]ethyl]methylaminobenzoate (309mg, O.όmmol) in 1 N NaOH (2.4 mL), and THF (10 mL) was heated under reflux for 8 hr. The mixture was poured into water (200 mL) , acidified by the addition of IN HCl. The solid was collected with suction. The crude solid was recrystallized from CHCl3-n-hexane-diisopropylether to give 21 lmg (70%) 286 as a light yellow crystalline powder, mp 125-130 °C; IR(KBr) 3338, 2933, 1601, 1529, 1182, 1036, 752cm '; 'H- NMR (CD3OD, 400MHz) δ 2.28 and 2.29 (s, 3H), 2.95-3.02 (m, 6H), 3.60 (br, 6H), 3.80 (s, IH), 3.86 (s, 2H), 6.60-6.82 (m, 4H), 7.01-7.18 (m, 3H), 7.58 (m, IH), 7.82-7.99 (m, 3H); MS (FAB) m/z 504 (M++1). Example 236 (5)-3 -chloro-4- [2- [N-benzyl-N-[3 -methoxy-4-[N '-(2-fluorophenyl)ureido]phenylacetyl]amino] - 1 - propoxyjbenzoic acid
Figure imgf000424_0002
To a stirred solution of NaBH3CN (985 mg, 15.68 mmol) in MeOH (5 mL) was added a solution of methyl (5)-3-chloro-4-(2-amino-l-propoxy)benzoate (382 mg, 1.57 mmol) and benzaldehyde (0.19 mL) in MeOH (5 mL), and the resulting mixture was stirred at room temp overnight. The mixture was quenched by H20 and exfracted with CHC13. The exfract was washed with brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3:MeOH (30: 1, v/v) as eluent to give 336 mg (64 %) (S)-3- chloro-4-(2-N-benzylamino-l-propoxy)benzoate as a colorless oil. 'H-NMR (CDC13) δ 1.22 (d, 3 H, .7=6.4 Hz), 3.21-3.25 (m, 1 H), 3.84-4.03 (m, total 7 H), 6.89-6.91 (m, 1 H), 7.23-7.37 (m, 5 H), 7.89-7.91 (m, 1 T), 8.05 (m, 1 H).
A mixture of 3-methoxy-4-[N'-(2-fluorophenyl)ureido]phenylacetic acid (320 mg, 1.01 mmol), methyl (S)-3-chloro-4-(2-N-benzylamino-l-propoxy)benzoate (336 mg, 1.01 mmol), EDC (hydrochloride) (289 mg, 1.51 mmol), HOBt (204 mg, 1.51 mmol) and DMAP (25 mg, 0.20 mmol) in DMF (7 mL) was stirred at room temp for 2 days. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S0 and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3:MeOH (50: 1, v/v) as eluent to give 607 mg (95%) methyl (S)-3-chloro-4-[2-[Λf-benzyl-N-[3-methoxy-4-[N'-(2-fluorophenyl)ureido]phenyl acetyl]amino]-l-propoxy]benzoate as a pale yellow amoφhous solid. 'H-NMR (CDC13) δ 1.20- 1.27 (m, 3 H), 3.62 (s, 2 H), 3.73-4.16 (series of m, total 9 H), 4.71 (bs, 2 H), 6.67-7.38 (series of m, total 12 H), 7.77-8.17 (series of m, total 5 H).
To a stirred solution of methyl (S)-3-chloro-4-[2-[N-benzyl-N-[3-methoxy-4-[N'-(2- fluorophenyl) ureido]phenylacetyl]amino]-l-propoxy]benzoate (607 mg, 0.96 mmol) in THF (6 mL) was added 0.5 N NaOH (6 mL), and the resulting mixture was heated under reflux overnight. The mixture was poured into ice-1 N HCl and the solid was collected. The crude solid was recrystallized to give 192 mg (32%) 287 as a white crystalline powder, mp 125-130 °C; Η-NMR (DMSO-cL,) δ 1.07-1.23 (m, 3 H), 3.76 (s, 2 H), 3.85 (s, 3 H), 3.90-4.26 (m, 3 H), 4.56 (s, 2 H), 6.66-7.38 (series of m, total 10 H), 7.82-8.20 (series of m, total 5 H), 8.70-8.74 (m, 1 H), 9.18-9.20 (m, 1 H), 13.02 (bs, 1 H); MS (FAB) m/z 621 Qtf+l); Anal. Calcd for C33H31C1FN306 1/4H20: C, 63.46; H, 5.08; Cl, 5.68; F, 3.04; N, 6.73. Found: C, 63.67; H, 5.16; Cl, 5.75; F, 2.95; N, 6.55. Example 237
3-(N-isopropyl-N-methylamino)-4-[[2-[3-methoxy-4-[Λ',-(2-methylphenyl)ureido]phenylacetyl] methylamino] ethoxyjbenzoic acid
Figure imgf000426_0001
To a stirred cold (0° C) solution of methyl 3-isopropylamino-4-[[2-[3-methoxy-4-[JV-(2- methylphenyl)ureido]phenylacetyl]methylamino]ethoxy]benzoate (324mg, 0.58mmol) in CH3CN- foπnaldehyde-AcOH (11 mL, 8:2: 1, v/v/v) was added NaBH3CN (145 mg, 2.30 mmol), and the resulting mixture was stirred for 18 hr at room temp. The mixtrae was poured sat. NaHC03 and the solid was collected with suction. The crude solid was dissolved in CHC13 (20mL), and the solution was washed with brine, dried over MgS04, and evaporated to give 317 mg (95%) methyl
3-(Λf-isopropyl-N-methylamino)-4-[[2-[3-methoxy-4-[Λπ-(2-methylphenyl)ureido]phenylacetyl] methylamino]ethoxy] benzoate as a colorless oil. Η-NMR (CDC13) δ 1.02 (m, 6H), 2.29 (s, 3H), 2.63 (m, 3H), 3.02-3.20 (m, 3H), 3.49-3.80 (m, 8H), 3.88 (s, 3H), 4.06 and 4.21 (m, total 2H),
6.59 (m, IH), 6.76 (m, 2H), 7.11-7.23 (m, 3H), 7.50-7.62 (m, 3H), 8.05 (d, lH, J=8.3Hz); MS
(FAB) m/z 576 (M++l).
A stirred mixture of methyl 3-(N-isopropyl-N-methylamino)-4-[[2-[3-methoxy-4-[N'-(2- methylphenyl)ureido]phenylacetyl]methylamino]ethoxy]benzoate(317mg, 0.55mmol) in 0.25 N NaOH (8.2 mL) and THF (8 mL) was heated under reflux for 8 hr. The mixture was poured into water (200 mL) , acidified by the addition of IN HCl and the solid was collected with suction. The crude solid was recrystallized from CHCl3-n-hexane-diisopropylether to give 288 as a light yellow crystalline powder, mp 130-135 °C; IR (KBr) 2970, 1537, 1038, 754 cm 1; 'H-NMR (CD3OD) δ 1.12(m, 6H), 2.29 (s, 3H), 2.76 (m, IH), 2.89 (s, 2H), 3.02 (s, IH), 3.21 (s, 2H), 3.72 (s, 2H), 3.80 (s, 3H), 3.84 (m, 3H), 4.13 and 4.40 (m, total 2H), 6.76 (d, IH, =7.8Hz), 6.86 (s, IH), 7.00 (m, 2H), 7.18 (m, 3H), 7.57 (d, IH, /=7.8Hz), 7.95 (m, 2H); MS (FAB) m/z 562 (M++l); Anal. Calcd for C31H38N4O6 2.0H2O: C, 62.19; H, 7.07; N, 9.36. Found: C, 62.54; H, 6.85; N, 8.90. Example 238 3-(l-piperidinyl)-4-[[2-[3-methoxy-4-[Λ''-(2-fluorophenyl)ureido]phenylacetyl]methylamino] ethoxy]benzoic acid
Figure imgf000426_0002
To a stirred solution of methyl 3-amino-4-[[2-[3-methoxy-4-[iV-(2-fluorophenyl)ureido] phenylacetyl]methylamino]ethoxy]benzoate (300mg, 0.57mmol) in THF (2 mL) was added a solution of glutaraldehyde (50% aqueous solution) (0.13mL, 0.69mmol) in MeOH (1.4 mL), THF (0.993mL), and 3N H2S04 ( 0.952 mL) at 0° C. To the solution was added NaBH3CN (150 mg) , DMF (5 mL), and MeOH (2 mL) at room temp, and the resulting mixture was stirred for 15 hr. The mixtiire was poured into sat. NaHC03 and extracted with CHC13 . The exfract was washed with brine, dried over MgS04, and evaporated under a reduced pressure. The residue was chromatographed on silica gel with toluene:acetone (7:3, v/v) as eluent to give 145 mg (43%) methyl 3-(l-piperidinyl)-4-[[2-[3-methoxy-4-[Λ/'-(2-fluorophenyl)ureido]phenylacetyl]methyl amino]ethoxy]benzoate as a colorless oil. 'H-NMR (CDC13, 400MHz) δ 1.58-1.72 (m, 6H), 2.80- 2.92 (m, 4H), 3.26 (s, 2H), 3.58 (s, 2H), 3.69 (s, 2H), 3.80-3.89 (m, IK), 4.22 (m, 2H), 6.72 (s, IH), 6.78 (m, 2H), 6.95-7.18 (m, 2H), 7.32 (s, IH), 7.60 (s, IH), 7.63 (d, IH, J=7.8Hz), 7.98 (d, IH, =7.8Hz), 8.18 (m, IH); MS (FAB) m/z 593 (M++l).
A stirred mixture of methyl 3-(l-piperidinyl)-4-[[2-[3-methoxy-4-[V-(2 -fluorophenyl) ureido]phenylacetyl]methyIamino]ethoxy]benzoate (290mg, 0.49mmol), IN NaOH (1.95 mL) in MeOH(5mL) and THF (10 mL) was heated under reflux for 4 hr. The mixture was poured into water (200 mL) , acidified with IN HCl (pH=4.0), and exfracted with CHCl3-MeOH(9: 1, v/v). The combined extract was dried over MgS04, and evaporated. The residue was crystallized from diisopropylether-hexane to give 201mg (71%)289 as a light yellow crystalline powder, mp 125- 130°C; IR (KBr) 3338, 2935, 1599, 1537, 1041, 752 cm '; 'H-NMR (CD3OD) δ 1.52-1.73 (m, 6H), 2.88 (s, 3H), 2.98 (br, IH), 3.09 (s, IH), 3.23 (s, 2H), 3.66 (s, 2H), 3.75 (s, IH), 3.82 (s, 4H), 4.13 and 4.29 (m, total 2H), 6.78 (m, 2H), 6.99 (m, 2H), 7.10 (m, 2H), 7.60-7.70 (m, 2H), 7..96-8.07 (m, 2H); MS (FAB) m/z 578 (M++l); Anal. Calcd for C31H35FN4O6 0.5H2O: C, 63.36; H, 6.17; N, 9.53. Found: C, 63.22; H, 6.15; N, 9.16. Example 239
3-amino-4-[[2-[3-methoxy-4-[Λ'-(2-methylphenyl)raeido]phenylacetyl]methylamino]ethoxy] benzoic acid
Figure imgf000427_0001
To a stirred solution of methyl 3-aimno-4-[[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl]methylamino]ethoxy]benzoate (300 mg, 0.58 mmol) in MeOH-THF (2: 1, v/v, 12 mL) was added 0.25 N NaOH (9 mL), and the resulting mixture was heated under reflux for 16 hr. The mixture was poured into water (100 mL) and acidified by the addition of IN HCl. The solid was collected with suction. The residue was recrystallized from diisopropylether to give 243 mg (83%) 290 as a yellow crystalline powder, mp 125-130 °C; IR (KBr) 3346, 2935, 1533, 1211, 1034, 756, 637cm '; 'H-NMR (DMSO-cL.) δ 2.29 (s, 3H), 3.05 (s, IH), 3.72-3.85 (m, IK), 4.12 and 4.25 (m, total 2H), 6.76-6.89 (m, 3H), 7.00 (m, IH), 7.18 (m, 2H), 7.39 (m, 2H), 7.60 (d, IH, J=7.8Hz), 7.96 (m, IK); Anal. Calcd for C27H30N4O6 0.5H2O: C, 62.90; H, 6.06; N, 10.87. Found: C, 63.03; H, 6.14; N, 10.56. Example 240
3-(l-piperidinyl)-4-[[2-[3-methoxy-4-[Λ/'-(2-methylphenyl)ureido]phenylacetyl]methylamino] ethoxyjbenzoic acid
Figure imgf000428_0001
To a cooled and stirred solution of methyl 3-amino-4-[[2-[3-methoxy-4-[N'-(2- methylphenyl) ureido]phenylacetyl]methylamino]ethoxy]benzoate (573mg, 1. lmmol) in THF- MeOH (2: 1, v/v, 6mL) was added glutaraldehyde (0.423mL, 2.2mmol), 3N H2S04(1.83mL, 5.5mmol), and NaBH3CN (276mg, 4.4mmol). The resulting mixture was stirred for 18 hr at room temp. The mixture was poured into sat. NaHCO3(100mL) and the solid was collected with suction. The crude solid was purified by column chromatography on silica-gel with toluene-acetone (10:0 to 4: 1, v/v) to give 240mg (37%) methyl 3-(l-piperidinyl)-4-[[2-[3-methoxy-4-[ΛT-(2-methyl phenyl)ureido]phenylacetyl]methylamino]ethoxy] benzoate as a gum. 'H-NMR (CD3OD) δ 1.52- 1.72 (m, 6H), 2.30 (s, 3H), 2.36 (s, 2H), 2.89 (br s, 3H), 2.98 (m, IH), 3.05 (s, IH), 3.20 (s, 2H), 3.68 (s, 2H), 3.69 (m, 2H), 3.79 (m, 2H), 3.88 (s, 2H), 4.08 and 4.21 (m, 2H), 6.35 and 6.42 (s, total IH), 6.70 (s, IH), 6.70 (s, IH), 6.79 (m, 2H), 7.09-7.24 (m, 4H), 7.50-7.65 (m, 3H), 8.05 (d, IH, =8.3Hz); MS (FAB) m/z 588 (M++l).
A stirred mixture of methyl 3-(l-piperidinyl)-4-[[2-[3-mefhoxy-4-[W-(2 -methylphenyl) ureido]phenylacetyl]methylamino]ethoxy]benzoate (240 mg, 0.41 mmol), 1 N NaOH (1.63 mL) in MeOH (6.5 mL), H20 (5 mL), and THF (6.5 mL) was heated under reflux for 11 hr. The mixture was poured into water (200 mL), acidified by the addition of IN HCl until pH=4.0, and the solid was collected with suction. The aqueous layer was exfracted with CHCl3-MeOH (9:1, v/v, 30mL x 3). The precipitate was dissolved in the combined organic exfract. The orgamc layer was dried over MgS04 and evaporated. The residue was crystallized from diisopropylether to give 151 mg (65 %) 291 as a light yellow crystalline powder, mp 120-125°C; IR (KBr) 3354, 2935, 1535, 1252, 1217, 1034, 754, 638 cm 1; 'H-NMR (CD3OD) δ 1.55-1.72 (m, 6H), 2.30 (s, 3H), 2.89 (br, 2H), 2.98 (br, IH), 3.09 (s, IH), 3.22 (s, 2H), 3.69 (s, 3H), 3.74 (s, IH), 3.83 (m, 4H), 4.12 and
4.28 (m, total 2H), 6.75 (m, 2H), 6.88-7.02 (m, IH), 7.17 (m, 2H), 7.58-7.73 (m, 4H), 7.99 (d, IH, J=8.3Hz); MS (FAB) m/z 574 (M++l); Anal. Calcd for C32H38N4O6 0.5H2O: C, 65.85; H, 6.73; N,
9.60. Found: C, 65.94; H, 6.88; N, 9.03.
Example 241
3-amino-4-[[2-[3-methoxy-4-[Λ'-(2-fluorophenyl)ureido]phenylacetyl]methylamino]ethoxy] benzoic acid
Figure imgf000429_0001
A stirred mixture of methyl 3-aιmno-4-[[2-[3-methoxy-4-[Λ -(2-fluorophenyι)ureido] phenylacetyl]methylamino]ethoxy]benzoate (250 mg, 0.48 mmol) in IN NaOH (1.91 mL), MeOH (8 mL), H20 (6 mL), and THF (8 mL) was heated under reflux for 10 hr. The mixtiire was poured into water (200 mL), acidified by the addition of IN HCl (pH=4.8), and the solid was collected with suction. The crude solid was recrystallized from diisopropylether to give 209 mg (86 %) 292 as a pale yellow crystalline powder, mp 125-130°C; IR (KBr) 3325, 2935, 1537, 1209, 1032, 752, 449 cm 1; 'H-NMR (CD3OD) δ 3.05 (s, IH), 3.31 (s, 2H), 3.77 (m, 3H), 3.80 (s, IH), 3.84 (m, 3H), 4.14-4.26 (m, 2H), 6.80-6.87 (m, 3H), 7.01 (m, IH), 7.10 (m, 2H), 7.39 (m, 2H), 7.80 (m, IH), 8.07 (m, IH); MS (FAB) m/z 510 (M++l); Anal. Calcd for C26H27FN4O6 0.5H2O: C, 60.11; H, 5.43; F, 3.66; N, 10.78. Found: C, 60.29; H, 5.40; F, 3.60; N, 10.59. Example 242
(S)-3 -amino-4- [2-[3 -methoxy-4- [N '-(2-methylphenyl)ureido]phenylacetylamino] - 1 -propoxy] benzoic acid
Figure imgf000429_0002
To a stirred solution of (S)-2-(#-terr-butoxycarbonylamino)-l-propanol (0.90 g, 5.13 mmol), methyl 4-hydroxy-3-nifrobenzoate (1.01 g, 5.12 mmol), and Ph3P (1.75 g, 6.67 mmol) in
THF (15 mL) was added diisopropyl azodicarboxylate (DIAD) (1.31 mL, 6.65 mmol) at room temp, and the resulting mixture was heated under reflux overmght. The solution was evaporated and the residue was dissolved in CH2C12 (20 mL) and TFA (10 mL). The mixture was stirred at room temp for 3 hr. The mixture was concentrated in vacuo. The residue was dissolved in CHC13, washed with sat. NaHC03, brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with 5% MeOH in CHC13 as eluent to give 313 mg (24%) methyl(S)-3-nitro-4-(2-amino-l-propoxy)benzoate as a pale yellow oil. 'H-NMR (CDC13) δ 1.22 (d, 3 H, .7=6.8 Hz), 3.43-3.48 (m, 1 H), 3.69-3.87 (m, 2 H), 3.89 (s, 3 TT), 6.93-6.95 (m, 1 H), 7.99-8.02 (m, 1 H), 8.18-8.21 (m, 1 H). A mixture of pentafluorophenyl 3-methoxy-4-[Λf'-(2-methylphenyl)ureido]phenylacetate (591 mg, 1.23 πunol), methyl (S)-3-nitro-4-(2-amino-l-propoxy)benzoate (313 mg, 1.23 mmol), and Et3N (257 mL, 1.84 mmol) in DMF (5 mL) was stirred at room temp for 2 days. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with 5% MeOH in CHC13 as eluent to give 310 mg (46%) methyl (S)-3-nifro-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl acetylamino]-l-propoxy]benzoate as a gum. Η-NMR (CDC13) δ 1.28 (d, 3 H, J=6.8 Hz), 2.31 (s, 3 H), 3.49 (s, 2 H), 3.71 (s, 3 H), 3.92 (s, 3 TT), 4.14-4.16 (m, 2 TT), 4.38-4.41 (m, 1 H), 5.88-5.90 (m, 1 TT), 6.49 (s, 1 H), 6.70-6.71 (m, 1 H), 6.77-6.79 (m, 1 H), 7.05-7.30 (m, 4 H), 7.55-7.57 (m, 1 H), 8.02-8.06 (m, 2 H), 8.16-8.19 (m, 1 H), 8.51-8.52 (m, 1 H); MS (FAB) m/z 551 (M++l).
A stirred solution of methyl (S)-3-nitro-4-[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetylamino]-l-propoxy]benzoate (310 mg, 0.56 mmol) in MeOH-THF (10 mL, 1:1, v/v) was hydrogenated over 5% Pd-C (50 mg, 16 wt%) overnight. The mixture was filtered to remove the catalyst and the filtrate was evaporated to give methyl (S)-3-amino-4-[2-[3-methoxy-4-[N'-(2- methylphenyl) ureido]phenylacetylamino]-l-propoxy]benzoate (240 mg) as a gum.
To a stirred solution of the above crude product (220 mg) in THF-MeOH (10 mL, 1:1, v/v) was added 0.5 N NaOH (10 mL), and the resulting mixture was heated under reflux for 2 hr. The mixture was poured into ice-H20, and the aqueous layer was made acidic (pH 4.8) by the addition of 1 N HCl. The solid was collected and the crude solid was recrystallized from MeOH- CHCl3-n-hexane to give 116 mg (2 steps, 44%) 293 as a pale yellow crystalline powder, mp 200- 204 °C; 'H-NMR (DMSO-cL.) δ 1.21 (d, 3 H, .7=6.8 Hz), 2.24 (s, 3 TT), 3.37 (s, 2 H), 3.80 (s, 3 H), 3.83-3.99 (m, 2 H), 4.10-4.19 (m, 1 H), 4.99 (bs, 2 H), 6.75-7.23 (series of m, total 8 H), 7.79 (d, 1 H, .7=7.8 Hz), 7.98 (d, 1 H, .7=7.8 Hz), 8.17 (d, 1 H, .7=8.3 Hz), 8.46 (s, 1 H), 8.55 (s, 1 H); MS (FAB) m/z 507 (M++l); Anal. Calcd for C27H30N4O6- 1/2H20: C, 62.90; H, 6.06; N, 10.87. Found: C, 62.85; H, 6.10; N, 10.51. Example 243 (5 -4-[2-[3-methoxy-4-[Λ/'-(2-bromophenyl)ureido]phenylacetylamino]-l-propoxy]benzoic acid
Figure imgf000430_0001
To a stirred and cooled (0° C) solution of (.S)-2-(Λ-ter )utoxycarbonylamino)-l-propanol (6.74 g, 0.04 mol), benzyl 4-hydroxybenzoate (8.78 g, 0.04 mol), and Ph3P (15.13 g, 0.06 mol) in THF (100 mL) was added diisopropyl azodicarboxylate (DIAD) (11.4 mL, 0.06 mol), and the resulting mixture was heated under reflux overnight. The solution was evaporated and the residue was dissolved in CH2C12 (30 mL) and TFA (30 mL). The resulting solution was stined at room temp for 30 min., and the solution was evaporated in vacuo. The residue was dissolved in CHC13, washed with sat. NaHC03, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with CHC13 to CHCl3:MeOH (9: 1, v/v) as eluent to give 6.63 g (2 steps, 60%) benzyl (S)-4-(2-amino-l-propoxy) benzoate as a yellow oil. 'H-NMR (CDC13) δ 1.18 (d, = 6.3 Hz, 3 TT), 3.35-3.39 (m, 1 H), 3.71-3.75 (m, 1 TT), 3.90-3.93 (m, 1 TT), 5.34 (s, 2 H), 6.90-6.93 (m, 2 H), 7.32-7.46 (m, 5 TT), 8.01-8.04 (m, 2 H).
A mixture of 3-mefhoxy-4-[# '-(2-bromophenyl)ureido]phenylacetic acid (480 mg, 1.27 mmol), benzyl (5)-4-(2-amino-l-propoxy)benzoate (361 mg, 1.27 mmol), EDC(hydrochloride) (364 mg, 1.90 mmol), HOBt (256 mg, 1.89 mmol), and 4-DMAP (31 mg, 0.25 mmol) in DMF (8 mL) was stirred at room temp, overnight. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHC13 to 5% MeOH in CHC13 as eluent to give 476 mg (58%) benzyl (S)-4-[2-[3-methoxy-4-[Λf'-(2-bromophenyl)ureido]phenylacetylamino]-l-propoxy]benzoate as a brown solid. 'H-NMR (CDC13) δ 1.25-1.28 (m, 3 H), 3.51 (s, 2 H), 3.74 (s, 3 H), 3.95-3.97 (m, 2 TT), 4.36-4.39 (m, 1 T), 5.33 (s, 2 H), 6.75-6.94 (m, 5 H), 7.26-7.70 (m, 8 H), 7.99-8.26 (m, 5 H).
To a stirred solution of benzyl (S)-4-[2-[3-methoxy-4-[N'-(2-bromophenyl)ureido] phenylacetylamino]-l-propoxy]benzoate (476 mg, 1.39 mmol) in THF (10 mL) was added 0.5 N NaOH (10 mL), and the resulting mixture was heated under reflux for 2 hr. The mixture was poured into ice-1 N HCl, and the solid was collected. The crude solid was recrystallized from MeOH-CHCl3-n-hexane to give 240 mg (59%) 294 as a white crystalline powder, mp 202-205 °C; Η-NMR (DMSO-cL.) δ 1.18 (d, J = 6.8 Hz, 3 H), 3.37 (s, 2 H), 3.82 (s, 3 H), 3.92-4.00 (m, 2 T), 4.03-4.15 (m, 1 H), 6.77-6.79 (m, 1 TT), 6.93-7.03 (m, 4 H), 7.30-7.34 (m, 1 TT), 7.59-7.61 (m, 1 H), 7.87-7.97 (m, 4 H), 8.13-8.15 (m, 1 H), 8.73 (s, 1 H), 8.91 (s, 1 H), 12.63 (bs, 1 TT); MS (FAB) m/z 557 (M++l); Anal. Calcd for C26H26BrN306: C, 56.12; H, 4.71; Br, 14.36; N, 7.55. Found: C, 56.11; H, 4.74; Br, 14.56; N, 7.49. Example 244
(S)-4-[[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(2-aminobenzyl)amino]-l- propoxy] benzoic acid
Figure imgf000432_0001
To a stirred cooled (0° C) solution of benzyl (5)-4-(2-amino-l-propoxy)benzoate (1.50 g, 5.26 mmol) and 2-nitrobenzaldehyde (0.87 g, 5.76 mmol) in MeOH-AcOH (16 mL, 15:1, v/v) was added NaBH3CN (1.65 g, 26.3 mmol), and the resulting mixture was stirred at room temp overnight. The mixture was quenched by sat. NaHC03 and exfracted with EtOAc. The exfract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHC13 to 5% MeOH in CHC13 as eluent to give 931 mg (42%) benzyl (S)-4-[2-(2-mtrobenzylamino) -l-propoxy]benzoate as a yellow oil. 'H-NMR (CDC13) δ 1.21 (d, .7 = 6.4 Hz, 3 H), 3.13-3.18 (m, 1 H), 3.88-3.97 (m, 2 H), 4.06-4.20 (m, 2 H), 5.34 (s, 2 H), 6.89-6.94 (m, 2 H), 7.29-7.65 (m, 8 H), 7.94-8.03 (m, 3 TT); MS (FAB) m/z 421 (M++l).
A mixture of pentafluorophenyl 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetate (460 mg, 0.96 mmol), benzyl (S -4-[2-(2-nitrobenzylamino)-l-propoxy]benzoate (403 mg, 0.96 mmol), and Et3N (200 mL, 1.43 mmol) in DMF (8 mL) was stirred at room temp overnight. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with 1% MeOH in CHC13 as eluent to give 504 mg (73%) benzyl (S)-4-[[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetyl] -(2-nittobenzyl)amino]-l-propoxy]benzoate as a brown amoφhous solid. MS (FAB) m/z 111 (M++l).
A stirred solution of benzyl (5)-4-[[2-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl acetyl]-(2-nitrobenzyl)amino]-l-propoxy]benzoate (504 mg, 0.70 mmol) in MeOH-THF (11 mL, 10:1, v/v) was hydrogenated over 5% Pd-C (100 mg, 20 wt%) at 3 atm overmght. The mixture was filtered to remove the catalyst and the filtrate was evaporated. The residue was purified by preparative TLC with 5% MeOH in CHC13 as eluent to give 115 mg (27%) 295 as a white powder. MS (FAB) m/z 597 (M++l). Example 245
(S)-4-[[2-[3-methoxy-4-[N'-(2-bromophenyl)ureido]phenylacetyl]-(2-nitrobenzyl)amino]-l- propoxy]benzoic acid
Figure imgf000433_0001
To a stined and cooled (0° C) solution of benzyl (5)-4-(2-anuno-l-propoxy)benzoate (1 50 g, 5 26 mmol) and 2-mfrobenzaldehyde (0 87 g, 5 76 mmol) in MeOH-AcOH (16 mL, 15 1, v/v) was added NaBH3CN (1 65 g, 26 3 mmol), and the resulting mixture was stirred at room temp overnight The mixture was quenched by sat NaHC03 and exfracted with EtOAc The extract was washed with brine, dned over Na2S04 and evaporated The residue was punfied by column chromatography on silica-gel with CHC13 to 5% MeOH in CHC13 as eluent to give 931 mg (42%) benzyl (S)-4-[2-(2-nιfrobenzylamιno) -l-propoxy]benzoate as a yellow oil 'H-NMR (CDC13) δ 1 21 (d, 3 H, J=6 4 Hz), 3 13-3 18 (m, 1 TT), 3 88-3 97 (m, 2 TT), 4 06-4 20 (m, 2 H), 5 34 (s, 2 H), 6 89-6 94 (m, 2 H), 7 29-7 65 (m, 8 H), 7 94-8 03 (m, 3 H), MS (FAB) m/z 421 (M++l)
A mixture of 3-methoxy-4-[N'-(2-bromophenyl)ureιdo]phenylacetic acid (476 mg, 1 26 mmol), benzyl (5)-4-[2-(2-nιtrobenzylamιno)-l-propoxy]benzoate (528 mg, 1 26 mmol), EDC(hydrochlonde) (361 mg, 1 88 mmol), HOBt (255 mg, 1 89 mmol), and DMAP (30 mg, 0 25 mmol) in DMF (10 mL) was stirred at room temp overmght and at 60° C for 1 day The mixture was diluted with EtOAc, washed with 0 5 N HCl, bnne, dned over Na2S04 and evaporated The residue was punfied by column chromatography on silica-gel with CHC13 to 2% MeOH m CHC13 as eluent to give benzyl (S)-4-[[2-[3-methoxy-4-[N'-(2-bromophenyl)ureιdo]phenylacetyl]-(2- nitrobenzyl)amino]-l-propoxy]benzoic acid as an oil, which is used to the subsequent reaction without further purification
To a stirred solution of the above crude in THF-MeOH (10 mL, 1 1, v/v) was added 0 5 N
NaOH (10 mL), and the resulting mixture was heated under reflux for 3 hr The mixture was poured into ιce-H20, and the basic aqueous layer was made acidic (pH 4 3) with 1 N HCl The solid was collected, and the crude solid was purified by preparative TLC with 5% MeOH in CHC13 as eluent to give 162 mg (2 steps, 19%) 296 as a white amoφhous solid MS (FAB) m/z 692 (M++l), Anal Calcd for C33H31BrN408-7/4H20 C, 54 82, H, 4 81, N, 7 75 Found C, 54 80, H, 4 61, N, 7 24 Example 246 4-[2-7V-[3-methoxy-4-[N'-(2-methylphenyl)ureιdo]phenylacetamιdo]ethoxy]benzoιc acιd
Figure imgf000434_0001
To a cooled (0°C) solution of 2-(Λf-tert-butoxycarbonylamino)ethanol (3.20 g, 19.9 mmol), methyl 4-hydroxybenzoate (3.02 g, 19.9 mmol) and PhjP (6.25 g, 23.8 mmol) in THF (50 ml) was added dropwise DIAD (4.69 ml, 23.8 mmol) over for 5 min. The reaction mixture was heated under reflux for 3 hr. The mixture was evaporated and the residue was dissolved in CH2C12 (30 ml) and TFA (30 ml). The reaction mixture was stirred at room temperature overmght. The mixture was concentrated in vacuo and the residue was dissolved in CHC13 and H20. The solution was made basic by sat. NaHC03 and exfracted with CHC13. The extract was washed with brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica- gel with CHCl3-MeOH (30: 1, v/v) as eluent to give methyl 4-(2-aminoethoxy)benzoate (1.03 g,
34% for 2 steps) as a colorless oil. 'H-NMR (CDC13) δ 3.10-3.13 (m, 2 H), 3.89 (s, 3 H), 4.03-
4.06 (m, 2 H), 6.92-6.94 (m, 2 H), 7.98-8.00 (m, 2 TT).
A mixture of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (557 mg, 1.77 mmol), methyl 4-(2-aminoethoxy)benzoate (346 mg, 1.77 mmol), EDCHCl (408 mg, 2.13 mmol), HOBt (287 mg, 2.12 mmol) and DMAP (52 mg, 0.43 mmol) in DMF (10 ml) was stirred at room temperature for 2 days. The mixture was diluted with EtOAc and H20. The resulting precipitate was collected to give methyl 4-[2-N-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetamido] ethoxy]benzoate (598 mg, 69%) as a white crystalline powder. 'H-NMR (DMSO-cL.) δ 2.23 (s, 3 TT), 3.36 (s, 2 H), 3.42-3.45 (m, 2 H), 3.79 (s, 3 H), 3.81 (s, 3 H), 4.02-4.09 (m, 2 H), 6.73-6.75 (m, 1 H), 6.90-6.94 (m, 2 H), 7.02-7.04 (m, 2 H), 7.09-7.15 (m, 2 H), 7.77-7.79 (m, 1 H), 7.88-
7.90 (m, 2 TT), 7.95-7.98 (m, 1 H), 8.23-8.24 (m, 1 H), 8.44 (s, 1 H), 8.53 (s, 1 H); MS (FAB), m/z 492 (M++l); Anal. Calcd for C27H29N306 1/4H20: C, 65.38; H, 5.99; N, 8.47. Found: C, 65.26; H, 5.99; N, 8.49.
To a stirred solution of methyl 4-[2-N-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenylacetamido]ethoxy]benzoate (280 mg, 0.57 mmol) in THF-MeOH (10 ml, 1 : 1, v/v) was added 0.5 N NaOH (10 ml) and the reaction mixture was heated under reflux for 5 hr. The mixture was cooled to room temperature and poured into ice-1 N HCl. The resulting precipitate was collected and recrystallized from Et20-CHCl3-MeOH to give 297 (135 mg, 50%) as a white crystalline powder. MW 477.51 'H-NMR (DMSO-d6) δ 2.24 (s, 3 TT), 3.38 (s, 2 H), 3.43-3.47 (m, 2 H), 3.82 (s, 3 H), 4.06-4.09 (m, 2 H), 6.76-6.78 (m, 1 H), 6.92-7.17 (m, 6 TT), 7.79 (d, J = 8.1 Hz, 1 H), 7.88-7.89 (m, 2 H), 7.98 (d, J = 8.1 Hz, 1 H), 8.24-8.27 (m, 1 TT), 8.45 (s, 1 H), 8.55 (s, 1 H); MS (FAB) m/z 478 (M++1); Anal. Calcd for C26H27N3061/4H20: C, 64.79; H, 5.75; N, 8.72. Found: C, 64.67; H, 5.63; N, 8.60. Example 247
(S)-4-[2-Λr-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetamido]-l-propoxy]benzoic acid
Figure imgf000435_0001
To a cooled (0°C), stirred solution of (S)-2-(N-ter?-butoxycarbonylamino)-l-propanol
(6.74 g, 0.04 mol), benzyl 4-hydroxybenzoate (8.78 g, 0.04 mol), and Ph3P (15.13 g, 0.06 mol) in THF (100 ml) was added DIAD (11.4 ml, 0.06 mol), and the reaction mixture was heated under reflux overnight. The solution was evaporated and the residue was dissolved in CH2C12 (30 ml) and TFA (30 ml). The solution was stirred at room temperature for 30 min. and the solution was concenfrated in vacuo. The residue was dissolved in CHC13, washed with sat. NaHC03, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica-gel with CHC13 to CHCl3-MeOH (9: 1, v/v) as eluent to give benzyl (5)-4-(2-amino-l-propoxy)benzoate (6.63 g, 2 steps, 60%) as a yellow oil. 'H-NMR (CDC13) δ 1.18 (d, J = 6.3 Hz, 3 H), 3.35-3.39 (m, 1 TT), 3.71-3.75 (m, 1 H), 3.90-3.93 (m, 1 H), 5.34 (s, 2 H), 6.90-6.93 (m, 2H), 7.32-7.46 (m, 5H), 8.01-8.04 (m, 2H).
A mixture of 4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (480 mg, 1.27 mmol), benzyl (S)-4-(2-amino-l-propoxy)benzoate (361 mg, 1.27 mmol), EDCHCl (364 mg, 1.90 mmol), HOBt (256 mg, 1.89 mmol) and DMAP (31 mg, 0.25 mmol) in DMF (8 ml) was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04and evaporated. The residue was purified by column chromatography on silica- gel with CHC13 to 5% MeOH in CHC13 as eluent to give benzyl (S)-4-[2-[4-[N '-(2-bromophenyl) ureido] -3 -methoxyphenylacetamido] -l-propoxy]benzoate (476 mg, 58%) as a brown solid. Η-NMR (CDC13) δ 1.25-1.28 (m, 3 H), 3.51 (s, 2 H), 3.74 (s, 3 TT), 3.95-3.97 (m, 2 H), 4.36-4.39 (m, 1 H), 5.33 (s, 2 TT), 6.75-6.94 (m, 5 H), 7.26-7.70 (m, 8 TT), 7.99-8.26 (m, 5 TT).
The a stirred solution of benzyl (S)-4-[2-[4-[N '-(2-bromophenyl)ureido]-3-methoxyphenyl acetamido]-l-propoxy]benzoate (476 mg, 1.39 mmol) in THF (10 ml) was added 0.5 N NaOH (10 ml), and the reaction mixture was heated under reflux for 2 hr. The mixture was poured into ice-1 N HCl, and the resulting precipitate was collected. The crude solid was purified by recrystallization from MeOH-CHCl3-n-hexane to give 298 (240 mg, 59%) as a white crystalline powder. MW 556.41 'H-NMR (DMSO-cL.) δ 1.18 (d, J = 6.8 Hz, 3 TT), 3.37 (s, 2 H), 3.82 (s, 3 H), 3.92-4.00 (m, 2 TT), 4.03-4.15 (m, 1 H), 6.77-6.79 (m, 1 H), 6.93-7.03 (m, 4 H), 7.30-7.34 (m, 1 H), 7.59-7.61 (m, 1 H), 7.87-7.97 (m, 4 H), 8.13-8.15 (m, 1 H), 8.73 (s, 1 H), 8.91 (s, 1 H), 12.63 (bs, 1 H); MS (FAB) m/z 557 (M++l); nα/. Calcd for C26H26BrN306: C, 56.12; H, 4.71; Br, 14.36; N, 7.55. Found: C, 56.11; H, 4.74; Br, 14.56; N, 7.49. Example 248
(5)-4-[2-Λ^-[[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]-N-methylacetamido]-l-propoxy] benzoic acid
Figure imgf000436_0001
To a cooled (0°C) solution of (S)-2-[(N-/er -butoxycarbonyl)amino]-l-propanol (3.08 g, 17.6 mmol), methyl 4-hydroxybenzoate (2.67 g, 17.6 mmol) and Ph^ (5.53 g, 21.1 mmol) in THF (35 ml) was added dropwise DIAD (4.15 ml, 21.1 mmol). The reaction mixture was heated under reflux overnight. The mixtiire was evaporated and the residue was purified by column chromatography on silica-gel with n-hexane-EtOAc (5: 1, v/v) as eluent to give methyl (S)-4-[2- [(N-tert-butoxycarbonyl)amino]-l-propoxy]benzoate (1.24 g, 23%) as a white solid. 'H-NMR (CDC13) δ 1.30 (d, J = 6.8 Hz, 3 H), 1.45 (s, 9 H), 3.89 (s, 3 H), 3.98-3.99 (m, 2 H), 4.07 (m, 1 H), 4.76 (m, 1 TT), 6.91-6.93 (m, 2 H), 7.98-8.00 (m, 2 TT); MS (FAB) m/z 310 (M++l).
To a stirred solution of methyl (S)-4-[2-[(N-terNbutoxycarbonyl)amino]-l-propoxy] benzoate (1.24 g, 4.01 mmol) in CH2C12 (10 ml) was added TFA (10 ml) and the reaction mixture was stirred at room temperature overnight. The mixture was concenfrated in vacuo, and made basic by sat. NaHC03. The mixture was extracted with CHC13, washed with brine, dried over K2C03 and evaporated to give methyl (S)-4-(2-amino-l -propoxy) benzoate (790 mg, 94%) as a yellow oil. 'H-NMR (CDC13) δ 1.19 (d, J = 6.7 Hz, 3 TT), 3.34-3.42 (m, 1 H), 3.70-3.77 (m, 1 TT), 3.86-3.94 (series of s and m, total 4 H), 6.92 (d, J = 9.0 Hz, 2 H), 7.98 (d, J = 9.0 Hz, 2 TT).
To a cooled (0°C) solution of methyl (5 -4-(2-amino-l-propoxy)benzoate (790 mg, 3.78 mmol) and Et3N (630 ml, 4.52 mmol) in THF (10 ml) was added TFAA (640 ml, 4.53 mmol) and the reaction mixture was stirred at room temperature for 4 days. The mixture was diluted with 0.5 N HCl and extracted with CHC13. The exfract was washed with brine, dried over K2C03, and evaporated. The residue was purified by recrystallization from n-hexane-CHCl3 to give methyl (S)- 4-[2-(trifluoroacetamido)-l-propoxy]benzoate (790 mg, 69%) as a white crystalline material. 'H- NMR (CDC13) δ 1.42 (d, J = 6.8 Hz, 3 H), 3.89 (s, 3 TT), 4.01-4.13 (m, 2 H), 4.44-4.50 (m, 1 H), 6.57-6.61 (m, 1 TT), 6.92 (d, J = 9.0 Hz, 2 H), 8.00 (d, J = 9.0 Hz, 2 H); MS (FAB) m/z 306 (M++l); Anal. Calcd for C13H14F3N04: C, 51.15; H, 4.62; F, 18.67; N, 4.59. Found: C, 51.14; H, 4.60; F, 18.50; N, 4.54.
To a stirred solution of methyl (5)-4-[2-(trifluoroacetamido)-l-propoxy]benzoate (695 mg, 2.28 mmol) and K2C03 (630 mg, 4.56 mmol) in DMF (10 ml) was added Mel (210 ml, 3.37 mmol) and the reaction mixture was stirred at room temperature for 2 days. The mixture was diluted with H20 and exfracted with EtOAc. The exfract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with EtOAc-CHCl3 (1: 19, v/v) as eluent to give methyl (5 -4-[2-[(N-methyl)trifluoroacetamido]-l- propoxy]benzoate (720 mg, 99%) as a white solid, mp 73-75°C; 'H-NMR (CDCl3)δ 1.36-1.39 (m, 3 H), 2.96 and 3.10 (each s, total 3 H), 3.89 (s, 3 H), 3.99-4.14 (m, 2 H), 4.84-4.92 (m, 1 H), 6.88- 6.92 (m, 2 H), 7.98-8.00 (m, 2 TT); MS (FAB) m/z 320 (M++l); Anal. Calcd for C14H16F3N04: C, 52.67; H, 5.05; F, 17.85; N, 4.39. Found: C, 52.76; H, 5.09; F, 17.53; N, 4.32.
To a stirred solution of methyl (S)-4-[2-[(N-methyl)trifluoroacetamido]-l-propoxy] benzoate (710 mg, 2.22 mmol) in MeOH-H20 (10 ml, 1: 1, v/v) was added K2C03 (460 mg, 3.33 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was diluted with H20 and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated to give methyl (5 -4-[2-(N-methylamino)-l-propoxy]benzoate (430 mg, 87%) as a colorless oil. 'H-NMR (CDC13) δ 1.17 (d, J = 6.6 Hz, 3 H), 2.48 (s, 3 H), 2.98-3.06 (m, 1 H), 3.86-3.96 (series of s and m, total 5 H), 6.92 (d, J = 9.0 Hz, 2 TT), 7.98 (d, J = 9.0 Hz, 2 TT).
A mixture of 3-methoxy-4-[Λ '-(2-methylphenyl)ureido]phenylacetic acid (605 mg, 1.93 mmol), methyl (5 -4-[2-(N-methylamino)-l-propoxy]benzoate (430 mg, 1.93 mmol), EDCHCl (444 mg, 2.32 mmol), HOBt (313 mg, 2.32 mmol), Et3N (320 ml, 2.30 mmol) in THF (13 ml) was stirred at room temperature overnight. The mixture was diluted with H20 and extracted with EtOAc. The extract was washed with brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with CHCl3-MeOH (100: 1 to 75: 1, v/v) as eluent to give methyl (S)-4-[2-N-[[3-methoxy-4-[A;'-(2-methylphenyl)ureido]phenyl]-N-methylacetamido] -l-propoxy]benzoate (953 mg, 95%) as a white foam. 'H-NMR (CDC13) δ 1.12-1.13 and 1.25-1.27 (each m, total 3 H), 2.27 (s, 3 H), 2.84 and 2.92 (each s, total 3 TT), 3.63 (s, 3 H), 3.67 (s, 2 H), 3.71-4.05 (series of s and m, total 5 TT), 4.39-4.44 and 4.96-5.01 (each m, total 1 H), 6.66-6.85 (m, 5 H), 7.09-7.27 (m, 4 H), 7.53-7.55 (m, 1 TT), 7.92-7.98 (m, 2 H), 8.04-8.08 (m, 1 H); MS (FAB) m/z 520 (M++l); Anal. Calcd for C29H33NAT 1/4H20: C, 61.20; H, 6.82; N, 7.38. Found: C, 61.14; H, 5.86; N, 7.16. To a stirred solution of methyl (S)-4-[2-N-[[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenyl] -N-methylacetamido]-l-propoxy]benzoate (663 mg, 1.28 mmol) in THF (5 ml) was added 0.5 N NaOH (5 ml) and the reaction mixture was heated under reflux for 5 hr. After cooled to room temperature, the mixture was poured into ice-1 N HCl and the resulting precipitate was collected under a reduced pressure. The crude solid was dissolved in CHC13 and evaporated. The residue was washed with Et20 to give 299 (465 mg, 72%) as a white amoφhous solid. MW 505.56 'H-NMR (DMSO-cL.) δ 1.11-1.15 (m, 3 H), 2.25 (s, 3 H), 2.73 and 2.88 (each s, total 3 H), 3.60-3.76 (m, 2 H), 3.83 (s, 3 H), 4.03-4.12 (m, 2 TT), 4.41-4.50 and 4.48-4.94 (each m, total 1 H), 6.71-6.76 (m, 1 H), 6.84-6.86 (m, 1 H), 6.91-7.01 (m, 3 H), 7.11-7.12 (m, 2 H), 7.78-7.80 (m, 1 H), 7.86-7.90 (m, 2 H), 8.01-8.03 (m, 1 H), 8.45 (s, 1 H), 8.54 (s, IH); MS (FAB) m/z 520 (M++l); Anal. Calcd for d8H31NA 3/2H20: C, 63.15; H, 6.43; N, 7.89. Found: C, 63.09; H, 5.99; N, 7.64. Example 249
4-[2-N-[3-methoxy-4-[Λ''-(2-methylphenyl)ureido]phenylacetamido]-2-methyl-l-propoxy]benzoic acid
Figure imgf000438_0001
A stirred mixture of methyl 4-hydroxybenzoate (3 g, 19.72 mmol), K2C03 (6.8 g, 49.3 mmol), 3-chloropivalic acid (2.9 g, 21.69 mmol) and catalytic amount of KI (200 mg) in DMF (70 ml) was heated at 100 °C for 14days under a current of nitrogen. The mixture was poured into ice- water, and extracted with EtOAc. The exfracts were washed with brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica gel (50ml) with CHCl3-EtOH (10: 1, v/v) as eluent to give the title compound (1 g, 23%) as an amoφhous solid. 'H-NMR (CDC13) δ 1.37 (s, 6 H), 3.89 (s, 3 H), 4.03 (s, 2 H), 6.92 (d, =9 Hz, 2 H), 7.98 (d, J = 9Hz, 2 H).
To a stirred mixture of 2,2-dimethyl-3-(4-methoxycarbonyl)phenoxypropionic acid (720 mg, 2.85 mmol) and triethylamine (0.46 ml, 3.28 mmol) in tert-BuOK (10 ml) and benzene (10 ml) was added a solution of diphenyl phosphoryl azide (870 mg, 3.14 mmol) in benzene (3 ml) at room temperature. The resulting mixture was heated at reflux for 20 hr. After cooling, ice and IN HCl (5ml) was added to the mixture and exfracted with toluene. The exfracts were washed with brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica gel (50ml) with toluene-EtOAc (10:1, v/v) as eluent to give methyl 4-[l-(2-amino-2-methyl)pφoxy]benzoate as a gum (520 mg), which was used to the subsequent reaction without further purification. "H-
NMR (CDC13) δ 1.41 (s, 9 TT), 3.89 (s, 3 TT), 4.04 (s, 2 H), 4.69 (br s, IH), 6.94 (dd, .7=2 and 7 Hz, 2 H), 7.98 (dd, J =2 and 7 Hz). A solution of methyl 4-[l-(2-methyl-2-/erf-butoxycarbonylamino-)pφoxy]benzoate (520 mg) and anisole (0.175 ml, 1.61 mmol) in CH2C12 (5 ml) and TFA (3 ml) was stirred at room temperature for 18 hr. The mixture was evaporated off. The residue was dissolved in CH2C12, and the mixture was made basic by the addition of sat. NaHC03. Separated CH2C12 layer was dried over Na2S04 and Na2C03, and evaporated. The residue was chromatographed on silica gel with CHCl3-EtOH (10: 1, v/v) as eluent to give methyl 4-[l-(2-amino-2-methyl)pφoxy]benzoate (250 mg, 39% in two steps) as a gum. 'H-NMR (CDC13) δ 3.75 (s, 2 H), 3.89 (s, 3 TT), 6.93 (d, J =8.8 Hz, 2 H), 7.98 (d, .7 =8.8 Hz, 2 H).
To a stirred mixture of methyl 4-[l-(2-amino-2-methyl)pφoxy]benzoate (250 mg, 1.12 mmol), 3-methoxy-4-[iV-(2-methylphenyl)ureido]phenylacetic acid (352 mg, 1.12 mmol), 4-
DMAP (165 mg, 1.34 mmol) in DMF (10 ml) was added EDC HCl (290 mg, 1.51 mmol) at room temperature. The resulting mixtrae was stirred at room temperature for 18 hr. The mixture was pored into ice-water. The solid was collected, washed with water and air-dried. The crude solid was purified by silica gel column chromatography with CHCl3-EtOH (4: 1, v/v) as eluent to give methyl 4-[2-N-[3-methoxy-4-[Λ^-(2-methylphenyl)ureido]phenylacetamido]-2-methyl-l- propoxy]benzoate (580mg, q.y.) as a ciystalline material. IR (KBr) 3350, 3286, 1712, 1687, 1637, 1606cm '; Η-NMR (CDC13) δ 1.39 (s, 6 H), 2.33 (s, 3 H), 3.41 (s, 2 H), 3.63 (s, 3 H), 3.88 (s, 3H), 4.05 (s, 2 H), 5.44 (br s, 1 H), 6.33 (br s, 1 H), 6.79 (d, J= 8.3 Hz, 2 H), 7.12 (s, 1 H), 7.18 (t, J = 7.5 Hz, 1 H), 7.53 (d, J= 7.8 Hz, 1 TT), 7.94 (d, J = 7.8 Hz, 2 H), 8.14 (d, = 8.3 Hz, 1 H); MS (FAB) m/z 520 (M+ +1); Anal Calcd for C29H33N306: C, 67.04; H, 6.40; N, 8.09. Found: C, 66.86; H, 6.36; N, 8.22.
To a stirred solution of methyl 4-[2-[3-methoxy-4-[./V'-(2-methylphenyl)ureido]phenyl acetamido]-2-methyl-2-propoxy]benzoate (510 mg, 0.98 mmol) was added 0.25N NaOH (8 ml, 2 mmol) at room temperature. The resulting mixture was stirred at an ambient temperature for 18 hr. The mixture was pored into ice-lN HCl (5 ml), the solid was collected, washed with water and air-dried. The crude solid was recrystallized from CHCl3-EtOH-Et20 to give 300 (480 mg, 97%) as fine needles. MW 505.56 IR (KBr) n 3346, 3294, 1687, 1637, 1604 cm '; 'H-NMR (DMSO-d6) δ 1.35 (s, 6 H), 2.24 (s, 3 H), 3.33 (s, 2 H), 3.80 (s, 3 H), 4.15 (s, 2 H), 6.75 (d, J = 8.3 Hz, 1 TT), 6.88 (s, 1 H), 6.95-6.99 (m, 3 H), 7.11-7.17 (m, 3 H), 7.80 (d, J= 8.3 Hz, 1 H), 7.82 (s, 1 H), 7.87 (d, J= 8.8 Hz, 2 H), 7.98 (d, J= 7.8 Hz, 1 H), 8.45 (s, 1 H), 8.54 (s, 1 H), 12.62 (br s, 1 H); MS (FAB) m/z 506 (M+ +1); Anal. Calcd for C28H31N306: C, 66.52; H, 6.18; N, 8.31. Found: C, 66.22; H, 6.28; N, 8.11. Example 250
3-amino-4-[2-N-[4-[Λ''-(2-chlorophenyl)ureido]-3-methoxyphenylacetamido]-2-methyl-l- propoxy]benzoic acid
Figure imgf000440_0001
To a stirred solution of 4-amino-2-nitrophenol (10 g, 64.88 mmol) in AcOH (70 ml) and
DMSO (20 ml) was added c. H2S04 at 0-5 °C To a stirred this solution was added dropwise a solution of NaN02 (5.4 g, 77.9 mmol) in water (5 ml) below 20 °C for over 10 min. The resulting mixture was further stirred for 0.5 hr at 5 °C This mixture was poured into a stirred solution of
KI (30 g, 0.182 mol) and catalytic amount of Cu powder (200 mg) in ice-water (200 ml) for over 10 min. The resulting mixture was for a further 1 hr at an ambient temperature. The mixture was extracted with CH2C1 . The extracts were washed successively with sat. Na2S203 and brine. The organic layer was dried over Na2S04, and evaporated. The residue was chromatographed on silica- gel (50ml) with CHCl3-EtOAc (3: 1, v/v) as eluent to give 4-iodo-2-nifrophenol (2.5 g, 15%) as a yellow crystalline material. 'H-NMR (CDC13) δ 6.94 (d, J = 8.8 Hz, 1 H), 7.82 (dd, J = 2 and 8.8Hz, 1 H), 8.42 (d, J = 2 Hz, IH), 10.49 (s, 1 H).
To a stirred solution of 4-iodo-2-nitrophenol (2 g, 7.75 mmol), hydroxypivalic acid methyl ester (1.05 g, 7.92 mmol) and PPh3 (2.3 g, 8.68 mmol) in THF (10 ml) was added dropwise a solution of DIAD (1.77 g, 8.30 mmol) in THF (2 ml) under ice-water bath cooling. The resulting mixture was then heated under reflux for 18hr. After cooling, the mixture was evaporated off. The residue was chromatographed on silica gel (100 ml) with with toluene-EtOAc (4: 1, v/v) as eluent to give methyl 3-(4-iodo-2-nitro)phenoxy-2,2-dimethylpropionate (2.9 g, q.y.) as a ciystalline material. 'H-NMR (CDC13) δ 1.34 (s, 6 H), 3.71 (s, 3 H), 4.08 (s, 2 H), 6.86 (d, J = 8.8 Hz, 1 TT), 7.78 (dd, .7 = 2 and 8.8Hz, 1 TT), 8.12 (d, J= 2 Hz, IH).
A mixture of methyl 3-(4-iodo-2-nitro)phenoxy-2,2-dimethylpropionate (2.8 g, 7.38 mmol) in THF (15 ml) and 0.25 N NaOH (60 ml, 15 mol) at an ambient temperature for 18 hr.
The mixture was poured into ice-lN HCl (20 ml). The solid was collected, washed with water and air-dried. The crude solid was recrystallized from CHCl3-EtOH-IPE to afford 3-(4-iodo-2- nitro)phenoxy-2,2-dimethylpropionic acid (2.0 g, 74%) as a crystalline material. Mp 165-182°C; IR (KBr) n 1716, 1525, 1344 cm 1; 'H-NMR (CDC13) δ 1.38 (s, 6 H), 4.10 (s, 2 H), 6.86 (d, J = 8.8 Hz, 1 H), 7.79 (dd, J = 2.2 and 8.8Hz, 1 H), 8.12 (d, J = 2 Hz, IH); MS (FAB) m/z 366 (M+ +1); Anal Calcd for C29H33N306: C, 36.18; H,3.18; N, 3.84. Found: C, 36.85; H, 3.35; N, 3.79. To a stirred mixture of 3-(4-iodo-2-nitro)phenoxy-2,2-dimethylpropionic acid (1.93 g, 5.29 mmol) and triethylamine (590 mg, 5.81 mmol) in fer/-BuOH (15 ml) and toluene (15 ml) was added a solution of diphenyl phosphoryl azide (1.53 g, 5.55 mmol) in toluene (3 ml) at room temperature. The resulting mixture was then heated at reflux for 20 hr. After cooling, ice and IN HCl (5ml) was added to the mixture and extracted with toluene. The extracts were washed with brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica gel (50ml) with toluene-EtOAc (10:1, v/v) as eluent to give 3-nitro-4-(2-/er/-butoxycarbonylamino-2-methyl- l-propoxy)iodobenzene (1.91 g, 83%) as a gum. 'H-NMR (CDC13) δ 1.38 (s, 9 H), 1.39 (s, 6 TT), 4.19 (s, 2 H), 4.67 (br s, 1 H), 6.88 (d, J = 8.8 Hz, 1 H), 7.77 (dd, J= 2.0 and 8.8Hz, 1 H), 8.12 (d, .7 = 2.0 Hz, I H).
A mixture of 3-nitro-4-(2-/er -butoxycarbonylamino-2-methyl-l-propoxy)iodobenzene (1.9 g, 4.36 mmol), Pd(OAc)2 and l,3-bis(diphenylphosphino)propane (dppp) (90 mg, 0.22 mmol) in triethylamine-MeOH-DMSO (1:2:5, v/v, 48 ml) was stirred under a current of CO (gas) at 70 °C for 6 hr. After cooling, the mixture was poured into water and exfracted with EtOAc. The extracts were washed with brine, dried over Na2S04, and evaporated. The residue was chromatographed on silica gel (50ml) with toluene-EtOAc (6: 1, v/v) as eluent to give methyl 4-(2- fer/-butoxycarbonyl amino-2-methyl-l-propoxy)-3-mtrobenzoate (820 mg, 51%) as a gum. 'H- NMR (CDC13) δ 1.38 (s, 9 H), 1.42 (s, 6 TT), 3.93 (s, 3 H), 4.29 (s, 2 H), 4.67 (br s, 1 TT), 7.15 (d, J = 8.8 Hz, I H), 8.18 (dd, .7 = 1.7 and 8.8Hz, 1 H), 8.52 (d, J = 1.7 Hz, IH).
A stirred mixture of methyl 4-(2-ferr-butoxycarbonylamino-2-methyl-l-propoxy)-3- nifrobenzoate (350 mg, 0.95 mmol) and 5% Pd-C (70 mg) in EtOH (30 ml) was hydrogenated in an atmospheric hydrogen pressure at room temperature for 20 hr. Insoluble Pd-catalyst was removed with suction and washed with EtOH. The filtrate was evaporated off to afford methyl 4- (2- er/-butoxycarbonyl amino-2-methyl)-l-propoxy-3-aminobenzoate as a gum, which was used to the subsequent reaction without further purification. 'H-NMR (CDC13) δ 1.41 (s, 9 H), 1.43 (s, 6 H), 3.86 (s, 3 H), 4.07 (s, 2 H), 4.67 (br s, 1 H), 6.80 (d, J= 8.5 Hz, 1 H), 7.39 (d, J = 2.2 Hz, IH), 7.44 (dd, .7 = 2.2 and 8.5Hz, 1 H).
To a stirred mixture of the above methyl 4-(2-fer/-butoxycarbonylamino-2-methyl)-l- propoxy-3-aminobenzoate and triethylamine (0.20 ml, 1.43 mmol) in CH2C12 (10 ml) was added a solution of trifluoroacetic anhydride (0.182 ml, 1.28 mmol) in CH2C12 (3 ml) at 0-5 °C. The resulting mixture was stirred at room temperature for 1 hr. Ice-sat. NaHC03 was added to the mixture, and extracted with CH2C12. The extracts were washed with brine, dried over Na2S04, and evaporated. The residue was dissolved in CH2C12 (5 ml) and added anisole (0.105 ml, 0.95 mmol) and TFA (2 ml). The resulting mixture was stirred at room temperature for 18 hr. The mixture was evaporated in vacuo, and the residue was diluted with CH2C12 and made basic by the addition of sat. NaHC03. The separated CH2C12 layer was dried over Na2S04, and evaporated. The residue was chromatographed on silica gel (50ml) with CHCl3-EtOH (99: 1, v/v) as eluent to give methyl 4- (2-amino-2-methyl-l-propoxy)-3-trfluoroacetamidobenzoate (631 mg, 63% in 3-steps) as a gum. 'H-NMR (CDC13) δ 1.29 (s, 9 H, tert-Bu), 3.86 (s, 2 H, CH2), 3.91 (s, 3 H, ), 6.99 (d, J = 8.5 Hz, 1 H), 7.91 (dd, J = 2.0 and 8.5 Hz, IH), 8.83 (d, J= 8.5Hz, 1 H).
To a stirred mixture of methyl 4-(2-amino-2-methyl)-l-propoxy-3-tιfluoroacetamido benzoate (200 mg, 0.598 mmol), 4-[Λ/'-(2-chlorophenyl)ureido]-3-methoxyphenylacetic acid (210 mg, 0.598 mmol), 4-DMAP (90 mg, 0.72 mmol) in DMF (7 ml) was added EDC HCl (160 mg, 0.81 mmol) at room temperature. The resulting mixture was stirred at room temperature for 20 hr. The mixture was pored into ice-water. The solid was collected, washed with water and air-dried. The crude solid was purified by silica gel column chromatography with CHC13- EtOH (98:2, v/v) as eluent to give methyl 4-[2-Λf-[4-[Λ/'-(2-chlorophenyl)ureido]-3-methoxyphenylacetamido]-2- methyl-1 -propoxy] -3 -trfluoroacetamidobenzoate (580mg, q.y.) as a ciystalline material. 'H-NMR (CDC13) δ 1.42 (s, 6 H), 3.42 (s, 2 H), 3.69 (s, 3 H), 3.89 (s, 3 H), 4.23 (s, 2 TT), 5.33 (br s, 1 H), 6.66 (s, 1 TT), 6.71 (m, 1 H), 6.92 (d, J = 8.5 Hz, 1 H), 7.02 (m, 1 TT), 7.09 (m, 2 H), 7.29 (m, 1 TT), 7.37 (d, J = 8.0 Hz, IH), 7.87 (dd, = 2 and 8.5Hz, 1 H), 7.97 (d, J= 8.0 Hz, 1 H), 8.19 (d, J = 8.2 Hz, 1 H), 8.59 (br s, 1 H), 8.74 (d, J = 2.0 Hz, 1 H).
To a stirred solution of methyl 4-[2-N-[4-[ V-(2-chlorophenyl)ureido]-3-methoxyphenyl acetamido]-2-methyl-l-propoxy]-3-trfluoroacetamidobenzoate (320 mg, 0.492 mmol) in THF (2 ml) was added 0.25N NaOH (6 ml, 1.5 mmol) at an ambient temperature. And the resulting mixture was stirred for 20 hr. The mixtiire was poured into ice-lN HCl (2 ml). The solid was collected, washed with water and air-dried. The crude solid was recrystallized from CHC13- EtOH- Et20 to give 301 (240mg, 89%) as fine needles. MW 541.00 IR (KBr) n 3338, 3296, 1691, 1641 cm '; 'H-NMR (CDC13) δ 'H-NMR (DMSO cL.) δ 1.37 (s, 6 H), 3.35 (s, 2 TT), 3.77 (s, 3 H), 4.05 (s, 2 H), 4.96 (br s, 1 H), 6.75 (br d, J = 8.3 Hz, 1 H), 6.78 (d, = 8.3 Hz, 1 H), 6.87 (d, = 1.7 Hz, 1 H), 7.01 (m, 1 TT), 7.15 (dd, J= 2 and 8.5 Hz, IH), 7.24 (d, J = 2 Hz, 1 H), 7.27 (dt, = 2.0 and 8.5 Hz, 1 H), 7.43 (dd, .7= 2 and 8.0 Hz, 1 H), 7.78 (br s, 1 H), 7.90 (d, J = 8.0 Hz, 1 H), 8.08 (dd, J = 2 and 8.3 Hz, 1 H), 8.85 (s, 1 TT), 8.89 (s, 1 H), 12.23 (br s, 1 H); MS (FAB) m/z 541 (M+ +1); Anal. Calcd for C27H29C1NA: C, 58.00; H, 5.59; N, 10.02. Found: C, 57.97; H, 5.39; N, 10.01. Example 251
2-acetylamino-4-[2-N-[3-methoxy-4-[Λ''-(2-methylphenyl)ureido]phenyl]-Λ^-methylacetamido] ethylaminobenzoateic acid
Figure imgf000443_0001
To a stirred solution of 2-acetylamino-4-nifrobenzoic acid (1.28 g, 5.71 mmol) in benzene-MeOH (4: 1, v/v, 25 mL), was added trimethylsilyldiazomethane (2.0 M solution in n- hexane, 4.28 ml, 8.56 mmol) at 0 °C. The stirring was continued for 18 hours at rt. The reaction was poured into hexane, and the resulting precipitate was collected by filtration to give methyl 2- acetylamino-4-nifrobenzoate (1.32 g, 97%) as a white solid; mp no data; 'H-NMR (400 MHz, CDC13) δ 2.30 (s, 3 H), 4.00 (s, 3 TT), 7.88 (m, 1 H), 8.18 (dd, J = 2.0 Hz, 8.8 Hz, 1 H), 9.60 (t, J =
2.2 Hz, 1 H), 11.10 (s, 1 H); MS (ESI) m/z 238 (M+).
To a solution of methyl 2-acetylamino-4-nitrobenzoate (1.31 g, 5.50 mmol) in MeOH (30 mL) was added 5% Pd on carbon (195 mg), and the stirring under H2 gas (3 atm) was continued for 18 hours at it. The catalyst was filtered off and the mixture was evaporated. The resulting crude solid was recrystallized with CHCl3-MeOH-hexane to give methyl 2-acetylamino-4- aminobenzoate (1.03 g, 90%) as a white solid. 'H-NMR (400 MHz, CDC13) δ 2.23 (s, 3 TT), 3.82 (s, 3 H), 4.20 (s, 2 H), 6.30 (dd, J = 2.5 Hz, 8.8 Hz, 1 H), 7.80 (d, J = 8.8 Hz, 1 H), 8.06 (s, 1 H), 11.26 (s, 1 TT); MS (FAB), m/z 208 (M+).
To a cooled solution of methyl 2-acetylamino-4-aminobenzoate (300 mg, 1.44 mmol) and Λ -ferf-butoxycarbonyl-N-methylglycinal (499 mg, 2.88 mmol) in 1,2-dichloroethane (30 ml), was added NaBH(OAc)3 (964 mg, 4.32 mmol) and the stirring was continued for 64 h at 0 °C The mixture was poured into sat. NaHC03 and was exfracted with CHC13 (50 ml x 3), washed with brine, and dried over MgS04. After removal of the solvent in vacuo, the residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC- 5404-FC, linear gradient of hexane-EtOAc from 9: 1 to 2: 1) to give methyl 2-acetylamino-4-[2-(N- ter -butoxycarbonyl-N-methylamino)ethylamino]benzoate (451 mg, 86%) as a colorless oil. 'H- NMR (CDC13, 400 MHz) δ 1.48 (s, 9 TT), 2.22 (s, 3 H), 2.90 (s, 3 H), 3.32 (m, 2 H), 3.50 (m, 2 TT), 3.80 (s, 3 H), 6.20 (dd, .7 = 2.2 Hz, 8.8 Hz, 1 H), 7.80 (m, 1 H), 7.95 (m, I H), 11.30 (brs, I H); MS (FAB) m/z 366 (M++l).
To a stirred solution of methyl methyl 2-acetylamino-4-[2-(N-ter -butoxycarbonyl-N- methylamino)ethylamino]benzoate (450 mg, 1.23 mmol) in dichloromethane (5 mL), was added TFA (5 mL) and the stirring was continued for 18 h at rt. After removal of the solvent in vacuo, the residue was dissolved in CHC13 (200 mL), washed with brine, sat. NaHC03, and dried over MgS04. The solvent was removed to give methyl 2-acetylamino-4-[2-(N-methylamino) ethylamino] benzoate (298 mg, 88%) as a colorless oil. 'H-NMR (CDC13, 400 MHz) δ 2.21 (s, 3 H), 2.46 (s, 3 H), 2.88 (m, 2 H), 3.31 (m, 2 H), 3.83 (s, 3 H), 4.85 (br, 1 H), 6.24 (dd, J = 2.5 Hz, 8.8 Hz, 1 H), 7.80 (d, J = 8.8 Hz, 1 H), 7.99 (d, J = 2.5 Hz, 1 H); MS (FAB), m/z 266 (M++l).
A mixture of methyl 2-acetylamino-4-[2-(N-methylamino)ethylamino]benzoate (145 mg, 0.55 mmol), 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (172 mg, 0.55 mmol), EDC HCl (158 mg, 0.83 mmol), HOBt (141 mg, 1.05 mmol), and DMAP (13 mg, 0.11 mmol) in DMF (10 ml) was stirred for 18 hours. The mixture was diluted with EtOAc (300 ml), washed with brine, and dried over MgS04. After removal of the solvent, residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient of CHCl3-MeOH from 100:0 to 70:30) to give methyl 2-acetylamino-4-[2-N-[3-methoxy-4-[N'-(2- methylphenyl)ureido]phenyl]-N-methylacetamido]ethylaminobenzoate (309 mg, 100%) as an amoφhous foam. 'H-NMR (CDCl3)δ 2.22 (s, 3 TT), 2.30 (s, 3 TT), 3.02 (s, 3 H), 3.35 (m, 2 TT), 3.58 (s, 3 H), 3.50-3.74 (m, 4 H), 3.85 (s, 3 TT), 6.20 (m, 1 H), 6.58 (s, 1 H), 6.65-6.75 (m, 3 H), 7.13 (m, 2 H), 7.40-7.50 (m, 2 H), 7.75 (m, 2 H), 7.90 (m, 1 H), 8.00 (m, 1 H), 11.32 (s, 1 H); MS (FAB) m/z 562 (M++l).
To a solution of methyl 2-acetylamino-4-[2-N-[3-methoxy-4-[N'-(2-methylphenyl)ureido] phenyl]-N-methylacetamido]ethylaminobenzoate (309 mg, 0.55 mmol) in THF-MeOH (1: 1, v/ v, 9 ml), was added 0.25 N NaOH (4.4 ml, 1.1 mmol) at rt, and heated to reflux. The stirring was continued for 18 hours at reflux. The reaction mixture was poured into water, and acidified to pH 5.0 with I O N HCl. The resulting precipitate was recrystallized with hexane-diethylether to give 302 (175 mg, 58%) as a pale red powder. MW 547.60 'H-NMR (CD3OD) δ 2.16 (d, J = 4.8 Hz, 3 H), 2.28 (d, J = 4.2 Hz, 3 TT), 2.98 and 3.10 (2 s, total 3 TT), 3.35 (m, 2 TT), 3.68 (m, 4 H), 3.81 and 3.84 (2 s, total 3 H), 6.30 (m, 1 H), 6.60-6.82 (m, 2 TT), 7.00 (m, 1 TT), 7.15 (m, 2 H), 7.53 (m, 1 H), 7.77-7.96 (m, 3 H); MS (FAB) m/z 548 (M++l); Anal. Calcd for C29H33N506 -0.5 H20: C, 62.58; H, 6.16; N, 12.58. Found: C, 62.55; H, 6.31; N, 12.15. Example 252
2-acetylamino-4-[2-N-[4-[Λ''-(2-bromophenyl)ureido]-3-methoxyphenyl]-N-methylacetamido] ethylaminobenzoic acid
Figure imgf000445_0001
A mixture of methyl 2-acetylamino-4-(2-N-methylamino-l-ethylamino)benzoate (145 mg,
0.55 mmol), 3-methoxy-4-[N'-(2-bromophenyl)ureido]phenylacetic acid (209 mg, 0.55 mmol),
EDC HCl (158 mg, 0.83 mmol), HOBt (141 mg, 1.05 mmol), and DMAP (13 mg, 0.11 mmol) in DMF (10 ml) was stirred for 18 hours. The mixture was diluted with EtOAc (300 ml), washed with brine, and dried over MgS04. After removal of the solvent, residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient of CHCl3-MeOH from 100:0 to 70:30) to give methyl 2-acetylamino-4-[2-N-[4-[N'-(2-bromo phenyl)ureido]-3-methoxyphenyl]-N-methylacetamido]ethylaminobenzoate (294 mg, 85%) as an amoφhous foam. 'H-NMR (CDC13) δ 2.21 (s, 3 H), 3.05 (s, 3 H), 3.40 (m, 2 H), 3.65-3.70 (m, 4 T), 3.78 (s, 3 H), 3.86 (s, 3 TT), 6.21 (m, 1 H), 6.79 (m, 2 H), 6.93 (m, 1 H), 7.10 (d, J = 10.3 Hz, 1
H), 7.30 (m, 1 h), 7.42 (m, 1 H), 7.61 (m, 1 TT), 7.78-7.85 (m, 2 TT), 7.93 (m, 2 H), 8.13 (m, 1 H);
MS (FAB), m/z 627 (M+).
To a solution of methyl 2-acetylamino-4-[3-methoxy-4-[N'-(2-bromophenyl)ureido] phenylacetamido]-2-N-methylamino-l-ethylaminobenzoate (294 mg, 0.47 mmol) in THF-MeOH (1 : 1, v/ v, 8 ml), was added 0.25 N NaOH (3.8 ml, 0.94 mmol) at rt, and heated to reflux. The stirring was continued for 18 hours at reflux. The reaction mixture was poured into water, and acidified to pH 5.0 with 1.0 N HCl. The resulting precipitate was recrystallized with hexane- diethylether to give 303 as a white powder (210 mg, 73%). MW 612.47 mp 155-160 ° C; 'H- NMR (CD3OD) δ 22.18 (d, J = 5.5 Hz, 3 TT), 3.00 and 3.12 (2 s, total 3 TT), 3.39 (m, 1 H), 3.60 (m, 4 H), 3.70 (s, 1 TT), 3.85 and 3.86 (2 s, total 3 TT), 6.31 (m, 1 H), 6.68 (m, 1 TT), 6.78 (m, 1 H), 6.78 and 6.85 (2 m, total 1 H), 6.97 (m, 1 H), 7.30 (m, 1 H), 7.56 (m, 1 TT), 7.80-7.95 (m, 4 H); MS (ESI) m/z 613 (M+); Anal. Calcd for C28H3ιBr,N5O6 0.75 H20: C, 53.64; H, 5.22; N, 11.17. Found: C, 53.89; H, 5.23; N, 10.69. Example 253
4-[2-Λf-[[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenyl]-N-phenylacetamido]ethoxy]benzoic acid
Figure imgf000445_0002
To a solution of methyl 4-[2-(methanesulfonyloxy)ethoxy]benzoate (2.74 g, 10 mmol) in
MeCN (50 ml), was added aniline (9.1 ml, 100 mmol) at rt. The reaction was stirred for 64 hours at reflux. The mixture was poured into H20 (200 mL), exfracted with EtOAc (100 mL x 2), dried over MgS04. After removal of the solvent in vacuo, the unreacted aniline was removed in vacuo by co-evaporation with toluene (10 mL x 3) at 80 °C. The residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, f50 mm x 150 mm, CHC13) to give methyl 4-[2-(N-phenylamino)ethoxy]benzoate (2.23 g, 82%) as a colorless oil. Η- NMR (CDC13) δ 3.56 (t, = 5.1 Hz, 2 H), 3.90 (s, 3 H), 4.21 (t, J = 5.1 Hz, 2 H), 6.68 (dd, J = 1.0 Hz, 8.6 Hz, 2 H), 6.75 (t, J = 7.3 Hz, 1 H), 7.20 (AB type d, J = 7.3 Hz, 2 H), 8.00 (d, J = 9.1 Hz, 2 TT); MS (ESI) m/z 272 (M++l).
A mixture of methyl 4-[2-(N-phenylamino)ethoxy]benzoate (136 mg, 0.5 mmol), 3- methoxy-4-[N'-(2-chlorophenyl)ureido]phenylacetic acid (167 mg, 0.5 mmol) and PyBOP (781 mg, 0.75 mmol), -PrNEt2 (261 ml, 0.96 mmol) in DMF (10 ml) was stirred for 18 hours. The mixture was diluted with EtOAc (100 mL) , washed with 1 N HCl, brine and dried over MgS04. The residue was co-evaporated with toluene (10 ml x 3) to remove DMF. The residue was chromatographed on TLC (MERCK, silicagel 60, 2 mm, 2 plates, CHCl3-MeOH, 20: 1) to give methyl 4-[2-N-[[4-[Λr'-(2-chlorophenyl)ureido]-3-methoxyphenyl]-/V-phenylacetamido]ethoxy] benzoate (129 mg, 44%) as a white amoφhous foam. Η-NMR (CDC13) δ 3.42 (s, 1 TT), 3.69 (d, J = 8.3 Hz, 1 H), 3.74 (s, 3 H), 3.87 (s, 3 H), 4.10 (m, 2 H), 4.23 (m, 2 H), 6.48-7.44 (m, 13 H), 7.93 (d, J = 9.3 Hz, 2 TT), 8.18 (dd, J= 1.5 Hz, 8.3 Hz, 1 H); MS (ESI) m/z 588 (M+).
To a solution of methyl 4-[2-N-[[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenyl]-N- phenyl acetamido]ethoxy]benzoate (124 mg, 0.19 mmol) in THF-MeOH (6: 1, v/ v, 3 ml), was added 0.5 N NaOH (2 ml, 1 mmol) at rt, and heated to reflux in a sealed bottle. The stirring was continued for 15 hours at reflux. The reaction mixture was poured into water, acidified with 1.0 N HCl, extracted with CHCl3-MeOH (2: 1, 20 mL x 3), and dried over MgS04. After removal of the solvent, the residue was crystallized with CHCl3-hexane-diethylether to give 304 (77 mg, 64%) as a white powder. MW 574.02 'H-NMR (CD3OD) δ 3.45 (s, 2 H), 3.79 (s, 3 TT), 4.12 (m, 2 TT), 4.22 (m, 2 H), 6.48 (dd, = 2.0 Hz, 8.3 Hz, 1 H), 6.61 (d, J= 2.0 Hz, 1 TT), 6.87 (d, J= 8.8 Hz, 2 H), 7.00 (m, 1 TT), 7.22 (m, 3 H), 7.36 (m, 1 H), 7.43 (m, 3 H), 7.90 (d, J = 8.3 Hz, 1 H), 7.95 (d, J = 8.8 Hz, 2 H), 8.02 (dd, J = 1.5 Hz, 8.3 Hz, 1 TT); MS (ESI) m/z 574 (M+); Anal. Calcd for C31H28C1NA 0.5 H20: C, 63.86; H, 5.01; N, 7.21. Found: C, 63.67; H, 4.91; N, 6.99. Example 254
(S)-4-[2-N-[[3-methoxy-4-[Λ^'-(2-methylphenyl)raeido]phenyl]-N-(2-aminobenzyl)acetamido]-l- propoxy]benzoic acid
Figure imgf000447_0001
To a cooled (0°C) solution of benzyl (S)-4-(2-amino-l-propoxy)benzoate (1.50 g, 5.26 mmol) and 2-nitrobenzaldehyde (0.87 g, 5.76 mmol) in MeOH-AcOH (16 ml, 15: 1, v/v) was added NaBH3CN (1.65 g, 26.3 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was quenched by sat. NaHC03 and exfracted with EtOAc. The exfract was washed with brine, dried over Na2S04 and evaporated. The residue was purified by column chromatography on silica gel with CHC13 to 5% MeOH in CHC13 as eluent to give benzyl (5 -4-[2-
(2-nitrobenzylamino) -l-propoxy]benzoate (931 mg, 42%) as a yellow oil. 'H-NMR (CDC13) δ
1.21 (d, = 6.4 Hz, 3 H), 3.13-3.18 (m, 1 H), 3.88-3.97 (m, 2 H), 4.06-4.20 (m, 2 H), 5.34 (s, 2 H), 6.89-6.94 (m, 2 H), 7.29-7.65 (m, 8 H), 7.94-8.03 (m, 3 H); MS (FAB) m/z 421 (M++l).
A mixture of pentafluorophenyl 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetate (460 mg, 0.96 mmol), benzyl (5)-4-[2-(2-nitrobenzylamino)-l-propoxy]benzoate (403 mg, 0.96 mmol) and Et3N (200 ml, 1.43 mmol) in DMF (8 ml) was stirred at room temperature overmght. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04, and evaporated. The residue was purified by column chromatography on silica-gel with 1% MeOH in CHC13 as eluent to give benzyl (S)-4-[2-N-[[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]-Λ'- (2-nitrobenzyl) acetamido]-l-propoxy]benzoate (504 mg, 73%) as a brown amoφhous solid. MS (FAB), rø/z 717 (M++l).
A stined solution of benzyl (5 -4-[2-N-[[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido] phenyl]-Λ -(2-nifrobenzyl)acetamido]-l-propoxy]benzoate (504 mg, 0.70 mmol) in MeOH-THF (11 ml, 10: 1, v/v) was hydrogenated over 5% Pd-C (100 mg, 20 wt%) at 3 atm overnight. The mixture was filtered to remove the catalyst and the filtrate was evaporated. The residue was purified by preparative thin layer chromatography with 5% MeOH in CHC13 as eluent to give 305 (115 mg, 27%) as a white powder. MW 596.67 MS (FAB), m/z 597 (M++l). Example 255
(S -4-[2-N-[[4-[Λf'-(2-bromophenyl)ureido]-3-methoxyphenyl]-Λf-(2-nitrobenzyl) acetamido]-l- propoxy]benzoic acid
Figure imgf000448_0001
To a cooled (0) solution of benzyl (S)-4-(2-amino-l-propoxy)benzoate (1.50 g, 5.26 mmol) and 2-nitrobenzaldehyde (0.87 g, 5.76 mmol) in MeOH-AcOH (16 ml, 15:1, v/v) was added NaBH3CN (1.65 g, 26.3 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was quenched by sat. NaHC03 and exfracted with EtOAc. The exfract was washed with brine, dried over Na S04 and evaporated. The residue was purified by column chromatography on silica gel with CHC13 to 5% MeOH in CHC13 as eluent to give benzyl (5)-4-[2- (2-nitrobenzylamino) -l-propoxy]benzoate (931 mg, 42%) as a yellow oil. 'H-NMR (CDC13) δ 1.21 (d, J= 6.4 Hz, 3 H), 3.13-3.18 (m, 1 H), 3.88-3.97 (m, 2 H), 4.06-4.20 (m, 2 TT), 5.34 (s, 2 H), 6.89-6.94 (m, 2 H), 7.29-7.65 (m, 8 H), 7.94-8.03 (m, 3 H); FAB-MAS, m/z 421 (M++l).
A mixture of 4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (476 mg, 1.26 πunol), benzyl (5 -4-[2-(2-nifrobenzylamino)-l-propoxy]benzoate (528 mg, 1.26 mmol), EDCHCl (361 mg, 1.88 mmol), HOBt (255 mg, 1.89 mmol) and DMAP (30 mg, 0.25 mmol) in DMF (10 ml) was stirred at room temperature overnight. And the reaction could not be completed, so the reaction mixture was stirred at 60°C for 1 day. The mixture was diluted with EtOAc, washed with 0.5 N HCl, brine, dried over Na2S04and evaporated. The residue was purified by column chromatography on silica-gel with CHC13 to 2% MeOH in CHC13 as eluent to give the title compound as a crude oil. To a stirred solution of the crude product in THF-MeOH (10 ml, 1:1, v/v) was added 0.5 N NaOH (10 ml) and the reaction mixture was heated under reflux for 3 hr. The mixture was poured into ice-H20 and the basic aqueous layer was acidified (pH 4.3) with 1 N HCl. The resulting precipitate was collected and the crude solid was purified by preparative thin layer chromatography with 5% MeOH in CHC13 as eluent to give 306 (162 mg, 2 steps, 19%) as a white amoφhous solid. MW 691.53 MS (FAB), m/z 692 (M++l); Anal. Calcd for C33H31BrN4087/4H20: C, 54.82; H, 4.81; N, 7.75. Found: C, 54.80; H, 4.61; N, 7.24. Example 256
4-[2-N-cyclopropyl-N-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenyl]acetamido] ethoxybenzoic acid
Figure imgf000448_0002
A mixture of methyl 4-(2-cyclopropylaminoethoxy)benzoate (290 mg, 1.23 mmol), 4-[ΛT-(2- chlorophenyl)ureido]-3-methoxyphenylacetic acid (412 mg, 1.23 mmol), EDC HCl (354 mg, 1.85 mmol), HOBt (cat), and DMAP (cat.) in DMF (10 ml) was stirred overmght. The mixture was partitioned between EtOAc (300 ml) and H20 (100 ml). The orgamc phase was separated, washed with brine (2 x 100 ml), dried over MgS04, and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (20: 1) as eluent to give methyl 4-[2-N-cyclopropyl-N-[4-[N'-(2- chlorophenyl)ureido]-3-methoxyphenyl]acetamido]ethoxybenzoate (506 mg, 75%) as a yellow viscous oil. 'H-NMR (CDC13) δ 0.90-0.97 (m, 4 H), 2.75 (m, 1 H), 3.61 (s, 3 TT), 3.79 (t, J= 5.4 Hz, 2 H), 3.87 (s, 3 H), 3.88 (s, 2 H), 4.16 (t, = 5.4 Hz, 2 H), 6.76-6.80 (m, 4 H), 6.95 (dt, J = 7.8, 1.5 Hz, 1 H), 7.21-7.31 (m, 2 H), 7.53 (s, 1 H), 7.56 (s, 1 TT), 7.93 (d, = 8.3 Hz, 3 H), 8.19 (dd, = 8.3, 1.5 Hz, I H).
To a stirred solution of methyl 4-[2-N-cyclopropyl-N-[4-[N'-(2-chlorophenyl)ureido]-3- methoxyphenyl]acetamido]ethoxybenzoate (506 mg, 0.917 mmol) in THF (7 ml) was added 0.25 N NaOH (7.3 ml, 1.83 mmol). After stirring overnight, the mixture was poured into 1 N HCl (50 ml) and exfracted with CHCl3-MeOH (4:1, 2 x 200 ml). The combined exfracts were dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (20: 1 to 10: 1) as eluent to give 307 (403 mg, 82%) as a colorless amoφhous solid. MW 537.99 'H- NMR (DMSO) δ 0.86-0.91 (m, 4 TT), 2.75 (m, 1 H), 3.69 (t, J = 5.5 Hz, 2 H), 3.81 (s, 3 H), 3.84 (s, 2 H), 4.16 (t, J= 5.5 Hz, 2 H), 6.76 (d, = 8.3 Hz, 1 TT), 6.88 (s, 1 H), 6.97-7.04 (m, 3 H), 7.28 (t, = 7.8 Hz, I H), 7.44 (d, .7 = 7.8 Hz, 1 H), 7.88 (d, J= 8.8 Hz, 2 H), 7.96 (d, 7 = 8.1 Hz, I K), 8.10 (d, J =8.3 Hz, 1 H), 8.89 (s, 1 H), 8.93 (s, 1 H), 12.65 (s, br s); MS (FAB), m/z 538 (M++l); Anal. Calcd for C28H28C1N306: C, 62.51; H, 5.25; N, 7.81. Found: C, 61.85; H, 5.42; N, 7.41. Example 257
4-[2-Λr-cyclohexyl-N-[3-methoxy-4-[Λ '-(2-methylphenyl)ureido]phenyl] acetamido]ethoxybenzoic acid
Figure imgf000449_0001
To a solution of methyl 4-[(2-methanesulfonyloxy)-l-ethoxy]benzoate (2.74 g, 10 mmol) in MeCN (50 ml), was added cyclohexylamine (5.72 ml, 50 mmol) at rt. The reaction was stirred for 18 hours at reflux. The mixture was poured into H20 (200 mL), exfracted with EtOAc (100 mL x 2), dried over MgS04. After removal of the solvent, residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, f50 mm x 150 mm, linear gradient of CHCl3-EtOAc from 10:0 to 1: 1) to give methyl 4-(2-N-cyclohexylamino)ethoxy benzoate (2.43 g, 88%) as a colorless oil. 'H-NMR (CDC13) δ 1.10 (m, 2 H), 1.25 (m, 2 H), 1.60 (br, 2 H), 1.73 (m, 2 H), 1.90 (br, 2 H), 2.49 (m, 1 H), 3.02 (t, = 5.2 Hz, 2 H), 3.88 (s, 3 H), 4.12 (t, J = 5.2 Hz, 2 H), 6.90 (d, J = 6.90 Hz, 2 H), 7.99 (d, J= 7.99 Hz, 2 H); MS (ESI) m/z 278 (M++l).
A mixture of methyl 4-(2-N-cyclohexylamino)ethoxybenzoate (139 mg, 0.5 mmol), 3- methoxy-4-[Λf'-(2-methylphenyl)ureido]phenylacetic acid (157 mg, 0.5 mmol), EDCHCl (144 mg, 0.75 mmol), HOBt (128 mg, 0.95 mmol), and DMAP (12 mg, 0.1 mmol) in DMF (2.5 ml) was stirred for 18 hours. The mixture was diluted with EtOAc (200 ml), washed with IN HCl and brine, and dried over MgS04. After removal of the solvent, residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient CHC13- EtOAc 10:0 to 1:4) to give methyl 4-[2-N-cyclohexyl-N-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenyl] acetamido] ethoxybenzoate (247 mg, 86%) as an amoφhous foam. 'H-NMR (CDC13) δ 1.08-1.80 (m, 10 TT), 2.30 (s, 3 TT), 3.60-3.79 (m, 8 H), 3.88 (s, 3 H), 4.16 (m, 2 H), 6.30 (s, 1 H), 6.70-6.83 (m, 2 TT), 6.88 (d, 2 H, J= 9.0 Hz), 7.12 (m, 2 H), 7.23 (m, 1 H), 7.60 (d, 1 H, J = 8.3 Hz), 7.92 (d, 2 H, J = 9.0 Hz), 8.10 (d, 1 H, J = 8.0 Hz); MS (ESI) m/z 574 (M++l).
To a solution of methyl 4-[2-N-cyclohexyl-N-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido] phenyl] acetamido]ethoxybenzoate (247 mg, 0.43 mmol) in THF-MeOH (6: 1, v/ v, 7 ml), was added 0.5 N NaOH (3.4 ml, 0.84 mmol) at rt, and heated to reflux in a sealed bottle. The stirring was continued for 18 hours at reflux. The reaction mixture was poured into water, acidified with I O N HCl, exfracted with CHCl3-MeOH (2: 1, 20 mL x 3), and dried over MgS04. After removal of the solvent, the residue was crystallized with CHCl3-hexane-diethylether to give 308 (196 mg, 81%) as a white powder. MW 559.62 'H-NMR (CD3OD) δ 0.90-1.82 (m, 10 TT), 2.29 (s, 3 H), 3.62 (m, 2 H), 3.78 (s, 3 TT), 3.80 (m, 3 H), 4.12 (m, 2 H), 6.82 (m, 2 H), 6.96 (m, 3 TT), 7.16 (m, 2 H), 7.58 (d, J = 7.7 Hz, 1 H), 7.92 (m, 3 H); MS (ESI) m/z 560 (M++1); Anal. Calcd for C32H37N3O6-0.5 H20: C, 67.59; H, 6.74; N, 7.39. Found: C, 67.83; H, 6.80; N, 7.13. Example 258
4-[2-N-[4-[jV'-(2-chlorophenyl)ureido]-3-methoxyphenyl]-N-propargylacetamido] ethoxybenzoic acid
Figure imgf000450_0001
To a solution of methyl 4-[(2-methanesulfonyloxy)-l-ethoxy]benzoate (2.74 g, 10 mmol) in MeCN (50 ml), was added propargylamine (3.43 ml, 50 mmol) at rt. The reaction was stirred for 18 hours at reflux. The mixture was poured into H20 (200 mL), exfracted with EtOAc (100 mL x 2), dried over MgS04. After removal of the solvent in vacuo, the residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC- 5404-FC, f50 mm x 150 mm, linear gradient of CHCl3-EtOAc from 10:0 to 9: 1) to give methyl 4- (2-Λf-propargylamino) ethoxybenzoate (2.33 g, 100%) as a colorless oil. 'H-NMR (CDC13) δ 2.28 (d, J= 2.4 Hz, 1 H), 3.11 (t, J= 5.1 Hz, 2 TT), 3.52 (d, J= 2.4 Hz, 2 H), 3.88 (s, 3 H), 4.15 (t, J = 5.1 Hz, 2 H), 6.90 (d, J = 8.8 Hz, 2 TT), 7.98 (d, = 8.8 Hz, 2 TT); MS (ESI) m/z 234 (M++l).
A mixture of methyl 4-(2-N-propargylamino)ethoxybenzoate (117 mg, 0.5 mmol), 3- methoxy-4-[Λ/'-(2-chlorophenyl)ureido]phenylacetic acid (167 mg, 0.5 mmol), EDCΗCI (144 mg, 0.75 mmol), HOBt (128 mg, 0.96 mmol), and DMAP (12 mg, 0.1 mmol) in DMF (10 ml) was stirred for 18 hours. The mixture was diluted with EtOAc (100 mL) , washed with 1 N HCl, brine and dried over MgS04. The residue was co-evaporated with toluene (10 ml x 3) to remove DMF. The residue was chromatographed on TLC (MERCK, silicagel 60, 2 mm, 2 plates, CHCl3-MeOH, 20: 1) to give methyl 4-[2-N-[4-[Λ^'-(2-chlorophenyl)ureido]-3-methoxyphenyl]-N-propargyl acetamido] ethoxybenzoate (244 mg, 89%) as a white amoφhous foam. 'H-NMR (CDC13) δ 2.20 and 2.32 (2 m, total 1 H), 3.72 (s, 2 H), 3.83 (m, 5 H), 3.88 (s, 3 H), 4.09-4.35 (m, 4 TT), 6.77-6.86 (m, 4 H), 6.99 (m, 1 H), 7.11 (m, 2 H), 7.24 (m, 1 H), 7.34 (d, J= 7.9 Hz, 1 H), 7.96 (m, 3 H), 8.18 (dd, .7 = 1.5 Hz, 8.3 Hz, 1 H); MS (ESI) m/z 550 (M+).
To a solution of methyl 4-[2-N-[4-[N'-(2-chlorophenyl)raeido]-3-methoxyphenyl]-N- propargyl acetamido]ethoxybenzoate (240 mg, 0.44 mmol) in THF-MeOH-H20 (2:2:1, v/v, 10 ml), was added NaOH (500 mg, 12.5 mmol) at rt. The stirring was continued for 2 hours at rt. The reaction mixture was poured into water, acidified with 1.0 N HCl, exfracted with CHCl3-MeOH (2: 1, 20 mL x 3), and dried over MgS04. The residue was chromatographed on TLC (Whatman, 1 mm, 3 plates, CHCl3-MeOH, 92:8) to give 309 (202 mg, 86%) as a white solid. MW 535.98 'H- NMR (CD3OD) δ 2.60 and 2.81 (2d, .7 = 2.5 Hz, total 1 H), 3.79-3.94 (m, 4 H), 3.85 (s, 3 TT), 4.15 (m, 1 H), 4.24 (m, 1 TT), 4.32 (m, 2 H), 6.80 (d, J= 8.3 Hz, 1 H), 6.85 (d, J= 4.3 Hz, 1 H), 6.94 (m, 2 H), 7.02 (m, 1 H), 7.25 (m, 1 H), 7.38 (m, 1 H), 7.87-8.02 (m, 4 H); MS (ESI) m/z 536 (M++l); Anal. Calcd for C28 H26C1N306'2.25 H20: C,58.33; H,5.33; N,7.29. Found: C,58.23; H,4.77; N,6.91.
Examples 259 and 260 4-[2-N-allyl-N-[4-[Λr'-(2-chlorophenyl)ureido]-3-methoxyphenyl]acetamido]ethoxybenzoic acid
Figure imgf000452_0001
A mixture of methyl 4-(2-N-allylamino)ethoxybenzoate (118 mg, 0.5 mmol), 3-methoxy-
4-[JV'-(2-chlorophenyl)ureido]phenylacetic acid (167 mg, 0.5 mmol), EDCΗCI (144 g, 0.75 mmol), HOBt (128 mg, 0.95 mmol), and DMAP (12 mg, 0.1 mmol) in DMF (2.5 ml) was stirred for 18 hours. The mixture was diluted with EtOAc (300 ml), washed with IN HCl and brine, and dried over MgS04. After removal of the solvent, residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient CHC13- EtOAc 100:0 to 85: 15) to give methyl 4-[2-N-allyl-N-[4-[iV-(2-chlorophenyl)ureido]-3- methoxyphenyl]acetamido] ethoxybenzoate (253 mg, 92%) as an amoφhous foam. 'H-NMR (CDC13) δ 3.65-3.85 (m, 4 H), 3.73 (s, 3 H), 3.88 (s, 3 H), 5.08 (m, 2 H), 4.22 (m, 2 H), 5.10-5.24 (m, 2 H), 5.76 (m, 1 H), 6.77 (m, 2 H), 6.85 (m, 2 H), 6.99 (m, 1 H), 7.06 (m, 2 H), 7.26 (m, 1 TT), 7.34 (d, 1 H, J = 8.1 Hz), 7.94 (d, 2 H, J = 8.8 Hz), 7.98 (m, 1 H), 8.18 (d, 1 H, J = 6.9 Hz); MS (FAB) m/z 552 (M+).
To a solution of methyl 4-[2-N-allyl-N-[4-[Λr-(2-chlorophenyl)ureido]-3-methoxyphenyl] acetamido]ethoxybenzoate (250 mg, 0.45 mmol) in THF-MeOH (1: 1, v/ v, 8 ml), was added 0.25 N NaOH (3.6 ml, 0.91 mmol) at rt, and heated to reflux. The stirring was continued for 18 hours at reflux. The reaction mixture was poured into water, and acidified with 1.0 N HCl. The resulting precipitate was collected by filtration. The precipitate was recrystallized with hexane- diethylether to give 310 as a white powder (195 mg, 80%). MW 537.99 'H-NMR (CD3OD)δ 3.61 (s, 1 H), 3.76 (s, 3 H), 3.82 (m, 1 H), 3.85 (s, 1 H), 3.88 (m, 1 H), 4.11-4.25 (m, 4 H), 5.12-5.25 (m, 2 H), 5.81 (m, 1 H), 6.78 (d, 1 H, J = 8.3 Hz), 6.82 (m, 1 TT), 6.92 (m, 2 H), 7.01 (m, 1 H), 7.26 (m, 1 H), 7.37 (m, 1 H), 7.96 (m, 3 H), 8.02 (m, 1 H); MS (FAB) m/z 537 (M+); Anal. Calcd for C28H28C1N3061 4 H20: C, 61.99; H, 5.30; N, 7.75. Found: C, 62.00; H, 5.56; N, 7.76. Example 261 4-[2-/V-allyl-Λf-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl]acetamido]ethoxybenzoic acid
Figure imgf000452_0002
A mixture of methyl 4-(2-N-allylamino)ethoxybenzoate (118 mg, 0.5 mmol), 4-[ T-{2- bromophenyl)ureido]-3-methoxyphenylacetic acid (190 mg, 0.5 mmol), EDCΗCI (144 mg, 0.75 mmol), HOBt (128 mg, 0.95 mmol), and DMAP (12 mg, 0.1 mmol) in DMF (2.5 ml) was stirred for 18 hours. The mixture was diluted with EtOAc (300 ml), washed with IN HCl and brine, and dried over MgS04. After removal of the solvent, residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient CHC13- EtOAc 100:0 to 70:30) to give methyl 4-[2-N-allyl-N-[4-[N'-(2-bromophenyl)ureido]-3- methoxyphenyl] acetamido]ethoxybenzoate (251 mg, 84%) as an amoφhous foam. Η-NMR
(CDCl3)δ 3.65-3.85 (m, 4 TT), 3.73 (s, 3 TT), 3.88 (s, 3 H), 4.08 (m, 2 H), 4.22 (m, 2 H), 5.10-5.25 (m, 2 TT), 5.78 (m, 1 H), 6.79 (m, 1 H), 6.85 (m, 3 H), 6.93 (m, 1 H), 7.02 (m, 2 H), 7.30 (m, 1 H), 7.51 (m, 1 H), 7.94 (d, 2 H, J = 8.8 Hz), 7.97 (m, 1 H), 8.14 (m, 1 H); MS (FAB) m/z 596 (M+).
To a solution of methyl 4-[2-N-allyl-N-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl] acetamido]ethoxybenzoate (251 mg, 0.42 mmol) in THF-MeOH (1: 1, v/ v, 8 ml), was added 0.25 N NaOH (3.4 ml, 0.84 mmol) at rt, and heated to reflux. The stirring was continued for 18 hours at reflux. The reaction mixture was poured into water, and acidified with 1.0 N HCl. The resulting precipitate was collected by filtration. The precipitate was recrystallized with Hexane- diethylether to give 311 (192 mg, 78%) as a white powder. MW 582.44 'H-NMR (CD3OD) δ 3.61 (s, 3 H), 3.77 (s, 3 H), 3.80 (m, 1 H), 3.85 (s, 1 H), 3.88 (s, 1 H), 4.12-4.25 (m, 4 H), 5.12-5.23 (m, 2 H), 5.81 (m, 1 H), 6.76 (m, 1 TT), 6.82 (m, 1 TT), 6.93 (m, 3 H), 7.29 (m, 1 H), 7.56 (m, 1 H), 7.94 (m, 4 H); MS (FAB), m/z 582 (M+); Anal. Calcd for Cj8H28BrN306: C, 57.74; H, 4.85; N, 7.21. Found: C, 57.40; H, 5.07; N, 7.04. For HCl salt of 311 : Anal. Calcd for C28H27BrN3O6-0.25 H20: C, 55.23; H, 4.55; N, 6.90. Found: C, 54.98; H, 4.71; N, 6.53. Example 262
4-[2-N-allyl-N-[3-methyl-4-[N'-(2-methylphenyl)ureido]phenyl]acetamido]ethoxybenzoic acid
Figure imgf000453_0001
A mixture of methyl 4-(2-N-allylamino-l-ethyl)ethoxybenzoate (87 mg, 0.37 mmol), 3- methyl-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (100 mg, 0.37 mmol), EDC HCl (105 mg, 0.56 mmol), HOBt (95 mg, 0.70 mmol), and DMAP (9 mg, 0.07 mmol) in DMF (7.4 ml) was stirred for 18 hours. The mixture was diluted with EtOAc (100 ml), washed with IN HCl and brine, and dried over MgS04. The residue was co-evaporated with toluene (10 ml x 3) to remove DMF. The residue was chromatographed on TLC (Whatman, PLK-5F, 2 plates, CHCl3-MeOH, 97:3) to give methyl 4-[2-N-allyl-N-[3-methyl-4-[N'-(2-methylphenyl)ureido]phenyl]acetamido] ethoxybenzoate (190 mg, 100%) as a white amoφhous foam. Η-NMR (CDCl3)δ 2.05 and 2.09 (2s, total 3 TT), 2.20 and 2.21 (s, total 3 TT), 3.62 (s, 2 TT), 3.76 (m, 2 H), 3.90 (s, 3 H), 3.88 (m, 1 H), 4.08 (m, 2 H), 4.11 (m, 1 H), 6.28 (m, 2 TT), 5.78 (m, 1 H), 6.88 (d, J = 8.8 Hz, 2 H), 7.05 (m, 1 H), 7.12 (m, 1 H), 7.21 (m, 1 H), 7.58 (m, 2 H), 7.95 (d, J = 8.8 Hz, 2 H), 8.02 (m, 1 H); MS (FAB), /z 516 (M++l).
To a solution of methyl 4-[2-N-allyl-Λr-[3-methyl-4-[N'-(2-methylphenyl)ureido]phenyl] acetamido]ethoxybenzoate (217 mg, 0.43 mmol) in THF-MeOH (6: 1, v/ v, 7 ml), was added 0.5 N NaOH (1.9 ml, 0.86 mmol) at rt, and heated to reflux. The stirring was continued for 2 hours at reflux in a sealed bottle. The reaction mixture was poured into water, acidified with 1.0 N HCl, exfracted with CHCl3-MeOH (2: 1, 20 mL x 3), and dried over MgS04. After removal of the solvent, the residue was crystallized with CHCl3-hexane-diethylether to give 312 (84 mg, 38%) as a white powder. MW 501.57 'H-NMR (CD3OD)δ 2.18 and 2.24 (s, total 3 H), 2.30 (d, J = 4.9 Hz, 3 H), 3.70 (s, 1 H), 3.78 (m, 2 H), 3.88 (s, 1 H), 4.12 (m, 4 H), 5.20 (m, 2 H), 5.81 (m, 1 H), 6.92- 7.20 (m, 7 H), 7.58 (m, 2 H), 7.96 (m, 2 H); MS (ESI) m/z 502 (M+); Anal Calcd for C29H3,N305: C, 69.44; H, 6.23; N, 8.38. Found: C, 68.99; H, 6.39; N, 8.03. Example 263 4-[2-N-allyl-N-[3-chloro-4-[N'-(2-methylphenyl)ureido]phenyl]acetamido]ethoxybenzoic acid
Figure imgf000454_0001
To a stirred solution of methyl 4-(2-N-allylaminoethoxy)benzoate (141 mg, 0.60 mmol) and 3-chloro-4-[Λf'-(2-methylphenyl)ureido]phenylacetic acid (191 mg, 0.60 mmol) in DMF (5 mL) were added EDC-HC1 (172.5 mg, 0.90 mmol), HOBt (154 mg, 1.14 mmol), and DMAP (15 mg, 0.12 mmol), and the stirring was continued overnight at rt. The mixture was diluted with EtOAc (50 mL) and washed with IM HCl (x 3), IM NaOH (x 1), and brine. The mixture was dried over anhydrous MgS04 and concenfrated under a reduced pressure to give methyl 4-[2-N- allyl-N-[3-chloro-4-[N'-(2-methylphenyl)ureido] phenyl]acetamido]ethoxybenzoate (350 mg, 109%) as a white powder. 'H-NMR (CDC13) δ 2.35 (s, 3 TT), 3.60 (s, 1 H), 3.75 (m, 2 H), 3.90 (s, 3 H), 4.10 (m, 4 H), 4.21 (m, 1 H), 5.20 (m, 2 H), 5.80 (m, 1 H), 6.50 (s, 1 H) , 6.85 (m, 2 H), 7.08 (m, 2 H), 7.20 (m, 4 TT), 7.50 (d, J= 8.1 Hz, 1 TT), 7.95 (d, J= 8.1 Hz, 2 H), 8.12 (d, J= 8.1 Hz, 1 H); MS (ESI) m/z: 536 (M++H).
To a stirred solution of methyl 4-[2-N-allyl-Λ-[3-cMoro-4-[Λ/ -(2-methylphenyl)ureido] phenyl]acetamido]ethoxybenzoate (321 mg, 0.6 mmol) in THF-MeOH-H20 (2:2: 1, v/v, 30 ml), was added NaOH (500 mg, 12.5 mmol) at rt. The stirring was continued for 18 hours at rt. The reaction mixture was poured into water, washed with diethyl ether, acidified with IM HCl, extracted with CHCl3-MeOH (2: 1, 20 mL x 3), dried over anhydrous MgS04, and concentrated under a reduced pressure. The residue was solidified with CHCL/n-hexane to give 313 (283 mg, 83%) as a white solid. IR (KBr): 3345, 1581, 1529, 1243, 1167 cm '; 'H-NMR (CD3OD)δ 2.30 (s, 3 H), 3.71 (s, 1 H), 3.78 (m, 1 H), 3.82 (m, 1 H), 3.89 (s, 1 H), 4.10 (m, 1 TT), 4.19 (m, 2 H), 4.21 (t, J= 5.4 Hz, 1 H), 5.20 (m, 2 H), 5.82 (m, 1 H), 6.95 (m, 2 H), 7.03 (m, 1 H), 7.18 (m, 3 H), 7.28 (s, 1 H), 7.60 (d, J= 8.1 Hz, 1 TT), 7.99 (m, 3 H); MS (ESI) m/z 522 (M++l); Anal. Calcd for C28H28C1NA-1.75 H20: C, 60.76; H, 5.74; N, 7.59. Found: C, 60.43; H, 5.34; N, 7.17. Example 264 methyl 4-[2-N-[2-(4-moφholinyl)ethyl]-N-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl] acetamido]ethoxybenzoate
Figure imgf000455_0001
To a stirred solution of methyl 4-[2-N-(2,3-dihydroxy-l-propyl)-[3-methoxy-4-[N'-(2- methylphenyl) ureido]phenylacetamido]ethoxy]benzoate (1.83 g, 3.24 mmol) in THF-MeOH-H20 (1: 1: 1, v / v / v, 15 mL) was added sodium periodate (2.08 g, 9.71 mmol), and stirred for 18 hours at rt. A saturated Na2S203 (50 ml) was added to the reaction mixture and the mixture was stirred for 1 hour. The mixture was exfracted with EtOAc (100 ml x 3), washed with brine, dried over MgS04. The solvent was removed to give the title compound (1.73 g, 100%) as an amoφhous foam. 'H-NMR (CDC13) δ 2.32 (t, 3 H, J= 2.8 Hz), 3.33-4.30 (m, 8 H), 3.72 (s, 3 TT), 3.86 (s, 3 H), 6.20 (m, 1 H), 6.70 (m, 1 H), 6.80 (m, 4 H), 7.06 (m, 1 TT), 7.18 (m, 1 H), 7.26 (m, 1 H), 7.49 (d, 1 H, 7= 7.4 Hz), 7.96 (m, 2 H), 8.10 (m, 1 TT), 9.57 and 9.63 (2 s, total 1 H); MS (FAB), m/z 534 (M++ 1).
To a stined solution of methyl 4-[2-N-formylmethyl-N-[3-methoxy-4-[N'-(2 -methyl phenyl)ureido]phenylacetamido]ethoxy]benzoate (400 mg, 0.75 mmol) in EtOH (7.5 ml), were added moφholine (654 ml, 7.5 mmol) and acetic acid (429 ml , 7.5 mmol) at rt. The reaction was stirred for 5 min. at rt, then cooled to 0 °C To the cooled solutionl, was added NaBH3CN (471 mg, 7.5 mmol) and the stirring was continued for 1 h at rt. The mixture was poured into sat. NaHC03 and was exfracted with EtOAc (50 ml x 3), washed with brine, and dried over MgS04. After removal of the solvent in vacuo, the residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient toluene-acetone 100:0 to 1: 1) to give 314 (346 mg, 76%) as a white amoφhous foam. 'H-NMR (CDC13, 400 MHz) δ 2.31 (s, 3H), 2.46 (m, 4 H), 3.52-3.79 (m, 12 TT), 3.70 (d, 3 H, 7 = 2.7 Hz), 4.05 and 4.22 (m, total 2 H), 6.24 and 6.29 (s, total 1 H), 6.73 (m, 2 H), 6.85 (m, 2 H), 7.07 (s, 1 TT), 7.17 (m, 1 TT), 7.25 (m, 2 H), 7.50 (t, 1 H, J= 7.3 Hz), 7.96 (m, 2 H), 8.08 (m, 1 H); MS (FAB), m^r 605 (M++ I); Anal. Calcd for C33H40N4O71/2 H20: C, 64.58; H, 6.73; N, 9.13. Found: C, 64.95; H, 6.88; N, 8.82. HCl salt of 314 : Anal. Calcd for C33H41ClN407-2.5 H20: C, 57.76; H, 6.76; N, 8.16; Cl, 5.17; Found: C, 58.29; H, 6.81; N, 7.42; Cl, 5.05. Example 265
4-[2-N-[2-(4-moφholinyl)ethyl]-N-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]aceιamido] ethoxybenzoic acid
Figure imgf000456_0001
To a solution of methyl 4-[2-N-[2-(4-moφholinyl)ethyl]-Λf-[3-methoxy-4-[N'-(2-methylphenyl) ureido]phenyl]acetamido]ethoxybenzoate (146 mg, 0.24 mmol) in THF-MeOH (1: 1, v/ v, 6 ml), was added 0.25 N NaOH (1.9 ml, 0.48 mmol) at rt, and heated to reflux. The stirring was continued for 18 hours at reflux. The reaction mixture was poured into water, and acidified with 1.0 N HCl. The mixture was exfracted with CHCl3-MeOH (3: 1, v/ v, 30 mi x 5). The combined organic solvent was dried over MgS04. After removal of solvent, the residue was crystallized with diethylether to give 315 (102 mg, 71%) as a white powder. 'H-NMR (CD3OD) δ 2.28 (d, J = 3.0 Hz, 3 T), 2.46 (m, 1 H), 2.40 (m, 1 TT), 2.56 (m, 1 H), 2.63 (m, 1 H), 3.62-3.80 (m, 12 H), 3.85 (s, 3 H), 4.12 (m, 1 H), 4.26 (m, 1 H), 6.82 (m, 2 H), 6.96 (m, 2 H), 7.01 (m, 1 H), 7.17 (m, 2 H), 7.58 (d, J= 7.8 Hz, 1 TT), 7.93 (m, 3 H); MS (FAB) m/z 591 (M+); Anal. Calcd for C32H38N4071.0 H20: C, 63.14; H, 6.62; N, 9.20. Found: C, 63.48; H, 6.66; N, 8.79. Example 266
4-[2-N-cyclopropyl-N-[3-methoxy-4-[Λ^'-(2-methylphenyl)ureido]phenyl]acetamido] ethoxybenzoic acid
Figure imgf000456_0002
To a stirred solution of methyl 4-(2-hydroxyethyloxy)benzoate (5.00 g, 25.5 mmol),
DMSO (18.1 ml, 255 mmol), Et3N (17.7 ml, 127.5 mmol) in CH2C12 (200 ml) was added S03 Py
(12.2 g, 76.5 mmol). After stirring for 5 h, the mixture was concentrated in vacuo and the residue was diluted with H20 (100 ml). The mixture was exfracted with EtOAc (2 x 200 ml). The combined exfracts were washed with brine (100 ml), dried over (MgS04), and evaporated. The residue was chromatographed on silica gel with hexane-EtOAc (4: 1) to give 4: 1 mixture of methyl 4-formyl methyloxybenzoate and methyl 4-hydroxybenzoate (2.00 g) as a white solid. 'H-NMR (CDCl3)δ 3.90 (s, 3 H), 4.64 (d, J= 1.0 Hz, 2 TT), 6.92 (d, J= 9.0 Hz, 2 H), 8.02 (d, J = 9.0 Hz, 2 H), 9.86 (d, J = 1.0 Hz, I H).
To a stirred solution of 4: 1 mixture of methyl 4-formylmethyloxybenzoate and methyl 4- hydroxybenzoate (1.00 g) and cyclopropylamine (425 ml, 6.18 mmol) in MeOH-AcOH (10: 1, 11 ml) was added NaBH3CN (681 mg, 10.3 mmol). After stirring overnight, the mixture was quenched by addition of sat. NaHC03 (50 ml) and exfracted with CHC13 (2 x 200 ml). The combined extracts were dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (20: 1) to give methyl 4-(2-cyclopropyl aminoethoxy)benzoate (595 mg, 49%) as a colorless oil. 'H-NMR (CDCl3)δ 0.37-0.49 (m, 4 TT), 1.91 (m, 1 H), 2.18-2.23 (m, 1 H), 3.11 (t, J = 5.2 Hz, 2 H), 3.88 (s, 3 TT), 4.12 (t, J = 5.2 Hz, 2 H), 6.92 (d, J = 8.8 Hz, 2 TT), 7.98 (d, .7= 8.8 Hz, 2 H).
A mixture of methyl 4-(2-cyclopropylaminoethoxy)benzoate (290 mg, 1.23 mmol), 3- methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (387 mg, 1.23 mmol), EDC HCl (354 mg, 1.85 πunol), HOBt (cat.), and DMAP (cat.) in DMF (10 ml) was stirred overnight. The mixture was partitioned between EtOAc (300 ml) and H20 (100 ml). The orgamc phase was separated, washed with brine (2 x 100 ml), dried over MgS04, and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (50:1) to give the title compound (426 mg, 65%) as a yellow viscous oil. 'H-NMR (CDCl3)δ 0.90-0.97 (m, 4 H), 2.28 (s, 3 H), 3.60 (s, 3 H), 3.77 (t, J = 5.4 Hz, 2 TT), 3.85 (s, 2 TT), 3.87 (s, 3 H), 4.15 (t, J = 5.4 Hz, 2 H), 6.60-6.81 (m, 5 H), 7.09-7.23 (m, 4 H), 7.57 (d, J= 8.3 Hz, 1 H), 7.92-7.95 (m, 2 TT), 8.04 (d, J= 8.3 Hz, 1 TT).
To a stirred solution of methyl 4-[2-[Λ^-cyclopropyl-[3-methoxy-4-[Λr -(2-methylphenyl) ureido]phenyl]acetamido]ethoxy]benzoate (426 mg, 0.801 mmol) in THF (7 ml) was added 0.25 N NaOH (6.4 ml, 1.60 mmol). After stirring overnight, the mixture was poured into 1 N HCl (50 ml) and exfracted with CHCl3-MeOH (4: 1, 2 x 200 ml). The combined extracts were dried over MgS04 and evaporated. The residue was chromatographed on silica gel with CHCl3-MeOH (20:1 to 10:1) as eluent to give 316 (333 mg, 80%) as a colorless amoφhous solid. 'H-NMR (DMSO) δ 0.86-0.91 (m, 4 H), 2.25 (s, 3 H), 2.74 (m, 1 H), 3.69 (t, J= 5.5 Hz, 2 H), 3.81 (s, 3 TT), 3.83 (s, 2 H), 4.15 (t, J = 5.5 Hz, 2 TT), 6.75 (d, J = 8.3 Hz, 1 TT), 6.87 (s, 1 H), 6.92-6.99 (m, 3 H), 7.11-7.17 (m, 2 H), 7.81 (d, = 8.1 Hz, 1 H), 7.88 (d, J= 8.5 Hz, 2 H), 8.01 (d, J =8.1 Hz, 1 H), 8.47 (s, 1 H), 8.55 (s, 1 H), 12.96 (s, br s); MS (FAB), m/z 518 (M++l); Anal. Calcd for C^NA: C, 67.30; H, 6.04; N, 8.12. Found: C, 66.71; H, 6.26; N, 7.82. Example 267
4-[2-N-[2-(N\ N'-dimethylamino)-l-ethyl)-N-[-4-[N"-(2-chlorophenyl)ureido]-3-methoxphenyl] acetamido]ethoxybenzoic acid
Figure imgf000458_0001
To a solution of methyl 4-[2-N-[2-(N\ N'-dimethylamino)-l-ethyl)-N-[-4-[Λ'"-(2- chlorophenyl) ureido]-3-methoxphenyl]acetamido]ethoxybenzoate (100 mg, 0.17 mmol) in THF- MeOH (1 : 1, v/ v, 3 ml), was added 0.25 N NaOH (2.0 ml, 0.5 mmol) at rt, and heated to reflux. The stirring was continued for 3 hours at reflux. The reaction mixture was poured into water, and acidified to pH 5.0 with 1.0 N HCl. After removal of the orgamc solvent in vacuo, the resulting mixture was chromatographed with HP-20 (H20-MeOH 100:0 to 0:100) to give 317 (63 mg, 64%) as a white powder. 'H-NMR (CD3OD) δ 2.41 (s, 2 H), 2.65 (s, 3 H), 2.69 (s, 3 TT), 3.02 (m, 2 H), 3.62-3.85 (m, 4 H), 3.84 (s, 3 H), 4.05 and 4.22 (m, total 2 H), 6.82-6.88 (m, 4 H), 7.02 (m, 1 H), 7.25 (m, 1 H), 7.38 (m, 1 H), 7.92 (m, 2 H), 8.01 (m, 2H); MS (FAB), m/z 569 (M+);Anal. Calcd for C29H33C1NA3.0 H20: C, 55.90; H, 6.31; N, 8.99. Found: C, 56.40; H, 6.50; N, 8.08. Example 268 isopropyl 4-[2-N-[2-(4-moφholinyl)ethyl]-Λ^-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl] acetamido] ethoxybenzoate
Figure imgf000458_0002
To a stirred solution of 4-[2-N-[2-(4-moφholinyl)ethyl]-N-[3-methoxy-4-[N'-(2- methylphenyl) ureido]phenyl]acetamido]ethoxybenzoic acid (250 mg, 0.42 mmol) in DMF (2 mL), were added isopropyl iodide (264 ml, 2.53 mmol) and K2C03 (88 mg, 0.64 mmol) at rt. The reaction was stirred for 2 hours at 50 °C The mixture was poured into brine and was exfracted with CHC13 (50 ml x 3), washed with brine, and dried over MgS04. After removal of the solvent in vacuo, the residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient toluene-acetone 100:0 to 40: 60) to give 318 (261 mg, 97%) as a white amoφhous foam. 'H-NMR (CDC13, 400 MHz) δ 1.35 (s, 3 H), 1.36 (s, 3 H), 2.31 (s, 3 H), 2.45 (m, 4 H), 2.50 (m, 2 H), 3.55-3.78 (m, 10 H), 3.70 (s, 3 H), 4.05 and 4.20 (t, J = 5.2 Hz, total 2 H), 5.22 (m, 1 T), 6.24 and 6.33 (2 s, total 1 H), 6.70-6.83 (m, 4 TT), 7.08 (s, 1 H), 7.15 (m, 1 TT), 7.22 (m, 1 H), 7.40 (t, J = 9.0 Hz, 1 H), 7.93 (d, J = 8.8 Hz, 1 H), 7.97 (d, J = 8.8 Hz, 1 H), 8.07 (t, J = 7.8 Hz, 1 H); MS (FAB), m/z 633 (M++ 1); Anal. Calcd for QjH^N -O S H20: C, 65.05; H, 7.10; N, 8.67. Found: C, 65.19; H, 7.09; N, 8.50. Example 269
4-[2-N-[2-(3,3-difluoro-l-pyrrolidinyl)ethyl]-N-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl] acetamido] ethoxybenzoic acid sodium salt
Figure imgf000459_0001
To a stirred solution of methyl 4-[2-N-formylmethyl-N-[3-methoxy-4-[N'-(2- bromophenyl)ureido] phenyl]acetamido]ethoxybenzoate (300 mg, 0.5 mmol) in 1,2-dichloroethane (3.6 ml), was added 3,3-difluoropyrrolidine AcOH salt (420 mg, 2.5 mmol) at rt. The reaction was stirred for 5 min. at rt, then cooled to 0 °C To the cooled solution, was added NaBH(OAc)3 (530 mg, 2.5 mmol), and the stirring was continued for 4 h at rt. The mixture was poured into sat. NaHC03, was exfracted with CHC13 (50 mL x 3), washed with brine, and dried over MgS04. After removal of the solvent in vacuo, the residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient CHCl3-MeOH 10:0 to 97:3) to give methyl 4-[2-N-[2-(3,3-difluoro-l-pyrrolidinyl)ethyl]-N-[4-[N'-(2-bromophenyl) ureido] -3 -methoxyphenyl] acetamido]ethoxybenzoate (345 mg, 100%) as a white amoφhous foam. 'H-NMR (CDC13, 400 MHz) δ 2.20-2.80 (m, 6 H), 3.48 (m, 2 H), 3.70-3.80 (m, 9 TT), 3.89 (s, 3 H), 4.09 (m, 1 H), 4.21 (m, 1 H), 6.79-6.85 (m, 4 TT), 6.93 (m, 1 H), 7.08 (m, 2 H), 7.30 (m, 1 H), 7.50 (m, 1 TT), 7.96 (m, 3 H), 8.13 (dd, J = 1.5 Hz, 8.3 Hz, 1 H); MS (ESI) m/z 689 (M+).
To a solution of methyl 4-[2-N-[2-(3,3-difluoro-l-pyrrolidinyl)ethyl]-N-[4-[N'-(2- bromophenyl) ureido]-3-methoxyphenyl]acetamido]ethoxybenzoate (345 mg, 0.5 mmol) in THF- MeOH (1: 1, v/ v, 8 ml), was added 0.25 N NaOH (4 ml, 1.0 mmol) at rt, and heated to reflux. The stirring was continued for 6 hours at reflux. The solvent was removed, and the residue was chromatographed on HP-20 (H20-MeOH, 0: 100 to 100: 0) to give 319 (306 mg, 91%) as a pale red powder. 'H-NMR (CD3OD, 400 MHz) δ 2.20-2.90 (m, 6 H), 3.60 (m, 2 TT), 3.70-3.92 (m, 9 H), 4.10 (m, 1 H), 4.22 (m, 1 H), 6.84 (m, 4 H), 6.96 (m, 1 H), 7.30 (m, IH), 7.55 (m, IH), 7.93 (m, 3H), 7.97 (m, 1 H); MS (ESI) m/z 676 (M++l); Anal. Calcd for C31H32BrF2N406-2.5 H20: C, 52.85; H, 5.29; N, 7.95. Found: C, 52.67; H, 5.20; N, 8.11. Example 270 4-[2-N-(Λ''-methoxy-N'-methylamino)ethyl-Λf-[3-methoxy-4-[N"-(2-methylphenyl)ureido] phenyl]acetamido]ethoxybenzoic acid sodium salt
Figure imgf000460_0001
To a stirred solution of methyl 4-[2-Λ-formylmethyl-[3-methoxy-4-[Λ '-(2-methylphenyl) ureido] phenylacetamido]ethoxy]benzoate (350 mg, 0.66 mmol) in EtOH (13 ml), was added N- methoxy-N-methylamine hydrochloride (637 mg, 6.6 mmol) at rt. The reaction was sonicated for 5 min. at rt, then cooled to 0 °C To the cooled solution, was added NaBH3CN (105 mg, 1.65 mmol) and the stirring was continued for 18 h at rt. The mixture was poured into sat. NaHC03 and was extracted with CHC13 (50 ml x 3), washed with brine, and dried over MgS04. After removal of the solvent in vacuo, the residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient toluene-acetone 9: 1 to 2: 3) to give the title compound (344 mg, 91%) as a white amoφhous foam. 'H-NMR (CDC13, 400 MHz) δ 2.29 (s, 3 TT), 2.52 and 2.58 (s, total 3 H), 2.79 (m, 2 TT), 3.49-3.76 (m, 9 H), 3.88 (s, 3 TT), 4.05 and 4.20 (m, total 2 H), 6.69-6.86 (m, 5 H), 7.10 (m, 1 H), 7.20 (m, 2 h), 7.29 (m, 1 H), 7.44 (m, 1 H), 7.94 and 7.99 (d, J = 8.6 Hz, total 2 H), 8.06 (m, 1 H); MS (FAB), m/z 579 (M++ 1); Anal. Calcd for C3,H38N407 -2.5H20: C, 59.70; H, 6.95; N, 8.98. Found: C, 59.58; H.6.65; N, 8.90.
To a solution of methyl 4-[2-N-(N'-methoxy-N'-methylamino)ethyl-N-[3-methoxy-4-[N"- (2-methylphenyl)ureido]phenyl]acetamido]ethoxybenzoate (138 mg, 0.24 mmol) in THF-MeOH (1: 1, v/ v, 4 ml), was added 0.25 N NaOH (1.9 ml, 0.48 mmol) at rt, and heated to reflux. The stirring was continued for 18 hours at reflux. The solvent was removed, and the residue was chromatographed on HP-20 (H20-MeOH, 100: 0 to 0: 100) to give 320 (140 mg, 100%) as a white powder. 'H-NMR (CD3OD) δ 2.29 (s, 3 H), 2.54 and 2.56 (2 s, total 3 H), 2.82 (m, 2 H), 3.48 (m, 2 H), 3.65-5.80 (m, 9 H), 4.09 and 4.21 (2 m, total 2 TT), 6.80 (m, 4 TT), 7.00 (t, J = 7.5 Hz, 1 H), 7.18 (m, 2 H), 7.57 (d, J = 7.8 Hz, 1 H), 7.88 (m, 2 H), 7.99 (m, 1 H); MS (FAB), m/z 565 (M++l); Anal. Calcd for C30H35N4O7Na-1.0 H20: C, 59.59; H, 6.17; N, 9.27. Found: C, 59.10; H, 6.28; N, 8.86.
Example 271
4-[2-Λ^-(N'-methoxy-N'-methylamino)ethyl-Λr-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl acetamido]ethoxy]benzoic acid
Figure imgf000461_0001
To a stirred solution of methyl 4-[2-N-formylmethyl-N-[3-methoxy-4-[N'-(2- bromophenyl)ureido] phenyl]acetamido]ethoxybenzoate (209 mg, 0.35 mmol) in EtOH (7 ml), was added N-methoxy-N-methylamine HCl salt (341 mg, 3.5 mmol) at rt. The reaction was sonicated for 5 min. at rt, then cooled to 0 ° C. To the cooled solution, was added NaBH(OAc)3 (370 mg, 1.75 mmol) and the stirring was continued for 18 h at rt. The mixture was poured into sat. NaHC03 , exfracted with CHC13 (50 ml x 3), and dried over MgS04. After removal of the solvent, the residue was chromatographed on TLC (Whatman, PLK-5F, 2 plates, CHCl3-MeOH, 98:2) to give methyl 4-[2-N-(W -methoxy-N'-methylamino)ethyl-N-[4-[N'-(2-bromophenyi)ureido]-3- methoxyphenyl acetamido]ethoxy]benzoate (89 mg, 40%) as a white amoφhous foam. 'H-NMR (CDC13, 400 MHz) δ 2.52 and 2.60 (2 s, 3 H), 2.80 (m, 2 H), 3.48 and 3.50 (2 s, total 3 TT), 3.65 (m, 2 H), 3.72 (s, 3 H), 3.77 (m, 4 H), 3.90 (s, 3 H), 4.08 (m, 1 H), 4.22 (m, 1 H), 6.82 (m, 5 H), 7.12 (s, 2 H), 7.30 (m, 1 H), 7.52 (d, /= 8.1 Hz, 1 H), 7.94 (m, 3 H), 8.15 (d, J= 8.3 Hz, 1 H); MS (ESI) m/z 643 (M+).
To a solution of methyl 4-[2-N-(N,-methoxy-N'-methylamino)ethyl-N-[4-[N'-(2- bromophenyl)ureido]-3-methoxyphenylacetamido]ethoxy]benzoate (89 mg, 0.14 mmol) in THF- MeOH (5: 1, v/ v, 6 ml), was added 0.5 N NaOH (1.4 ml, 0.7 mmol) at rt, and heated to reflux in a glass sealed bottle. The stirring was continued for 3 hours at reflux. The reaction was poured into water, and was acidified with 1 N HCl to pH 5, extracted with CHCl3-MeOH (2: 1, v/ v, 30 mL x 3), dried over MgS04. The solvent was removed in vacuo to give 321 (53 mg, 60%) as a white powder. 'H-NMR (CD3OD, 400 MHz)δ 2.62 and 2.64 (2 s, total 3 TT), 2.80 (m, 2 TT), 3.50 (d, J = 7.3 Hz, 3 H), 3.63-3.88 (m, 6 T), 4.12 (m, 1 H), 4.25 (m, 1 H), 6.82-7.00 (m, 5 TT), 7.30 (m, 1 H), 7.58 (m, IH), 7.95 (m, 4 H); MS (FAB), m/z 629 (M+); Anal. Calcd for C29H33BrN4O7-0.25 H20: C, 54.94; H, 5.33; N, 8.84. Found: C, 55.39; H, 5.53; N, 8.23. Example 272
4-[2-N-(N\ Λ^'-diallyl)ethyl-N-[3-methoxy-4-[Λ^"-(2-methylphenyl)ureido]phenyl]acetamido] ethoxybenzoic acid sodium salt
Figure imgf000461_0002
To a stirred solution of methyl 4-[2-N-formylmethyl-N-[3-methoxy-4-[N'-(2- methylphenyl)ureido] phenyl] acetamido] ethoxybenzoate (400 mg, 0.75 mmol) in EtOH (15 ml), were added diallylamine (926 ml, 7.5 mmol) and acetic acid (429 ml, 7.5 mmol) at rt. The reaction was stirred for 5 min. at rt, then cooled to 0 "C To the cooled solution, was added NaBH3CN (118 mg, 1.9 mmol) and the stirring was continued for 1 h at rt. The mixture was poured into sat. NaHC03 and was extracted with EtOAc (50 ml x 3), washed with brine, and dried over MgS0 . After removal of the solvent in vacuo, the residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient toluene-acetone 9: 1 to 1: 1) to give methyl 4-[2-N-(N ΛP-diallyl)ethyl-N-[3-methoxy-4-[ΛT'-(2- methylphenyl)ureido] phenyl] acetamido] ethoxybenzoate (385 mg, 84%) as a white amoφhous foam. Η-NMR (CDC13, 400 MHz) δ 2.30 (s, 3 H), 2.60 (m, 2 H), 3.09 (m, 4 H), 3.49 (m, 2 H), 3.60 (s, 2 H), 3.70 (m, 5 H), 3.89 (s, 3 H), 4.02 and 4.19 (2 m, total 2 TT), 5.01-5.20 (m, 4 TT), 4.79 (m, 2 H), 6.30 and 6.32 (2 s, total 1 T), 6.70-6.84 (m, 5 H), 7.08 (m, 1 TT), 7.14 (m, 1 H), 7.25 (m, 1 H), 7.60 (m, 1 H), 7.93 and 7.98 (2 d, J = 8.8 Hz, 2.H), 8.03 and 8.06 (2 d, J = 8.3 Hz, 1 H); MS (FAB), m/z 615 (M++ 1).
To a stirred solution of methyl 4-[2-N-(N', N'-diallyl)ethyl-N-[3-methoxy-4-[Λ^"-(2- methylphenyl) ureido]phenyl]acetamido]ethoxybenzoate (385 mg, 0.63 mmol) in MeOH (3 ml), was added IN HCl (756 ml, 0.76 mmol) at rt. The reaction was stirred for 5 min. at rt, then evaporated to give methyl 4-[2-ΛHN, Λr-diallyl)ethyl-N-[3-methoxy-4-[N"-(2-methylphenyl) ureido]phenyl] acetamido]ethoxybenzoate HCl salt (385 mg, 99%) as an amoφhous foam. Anal. Calcd for C35H43C1NA 0.5 H20: C, 63.67; H, 6.72; N, 8.49. Found: C, 63.67; H, 6.69; N, 8.43.
To a solution of 4-[2-N-(ΛT, N'-diallyl)ethyl-N-[3-methoxy-4-[N"-(2-methylphenyl) ureido]phenyι]acetamido]ethoxybenzoate (175 mg, 0.29 mmol) in THF-MeOH (1: 1, v/ v, 20 ml), was added 0.25 N, NaOH (2.5 ml, 0.63 mmol) at rt, and heated to reflux. The stirring was continued for 1 hours at reflux. The solvent was removed, and the residue was chromatographed on HP-20 (H20-MeOH, 100: 0 to 0: 100) to give 322 (160 mg, 94%) as a white powder. 'H-NMR (CD3OD) δ 2.29 (s, 3 H), 2.60 (t, J = 6.9 Hz, 1 H), 2.67 (t, J = 7.0 Hz, 1 H), 3.10 (d, = 6.6 Hz, 2 H), 3.14 (d, J = 6.6 Hz, 2 TT), 3.59 (m, 2 H), 3.69-3.80 (m, 4 H), 3.80 (s, 3 H), 4.06 (t, = 5.2 Hz, 4.21 (t, J = 5.1 Hz, 1 TT), 5.15 (m, 4 H), 5.80 (m, 2 H), 6.79 (m, 2 TT), 6.84 (d, J= 8.8 Hz, 2 H), 7.00 (t, J= 7.5 Hz, 1 TT), 7.14 (m, 2 h), 7.48 (m, 1 H), 7.91 (dd, J= 6.1 Hz, 8.8 Hz, 2 H), 8.00 (m, 1 H); MS (FAB), m/z 601 (M+); Anal. Calcd for C34H39N406Na -0.5 H20: C, 64.65; H, 6.38; N, 8.87. Found: C, 64.53; H, 6.58; N, 8.78. Example 273
4-[2-N-(N', N'-diallyl)ethyl-/V-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenylacetamido]ethoxy] benzoic acid sodium salt
Figure imgf000463_0001
To a stirred solution of methyl 4-[2-N-formylmethyl-N-[4-[Λf'-(2-chlorophenyl)ureido]-3- methoxy phenylacetamido]ethoxy]benzoate (100 mg, 0.18 mmol) in EtOH (3.6 ml), was added diallylamine (223 ml, 1.81 mmol) at rt. The reaction was stirred for 5 min. at rt, then cooled to 0 °C. To the cooled solution, were added AcOH (104 ml, 1.81 mmol) and NaBH3CN (28 mg, 0.45 mmol), and the stirring was continued for 18 h at rt. The mixture was poured into sat. NaHC03, was extracted with CHC13 (30 mL x 3), washed with brine, and dried over MgS0 . After removal of the solvent in vacuo, the residue was chromatographed on silica gel (middle pressure chromatography system: YAMAZEN YFLC-5404-FC, linear gradient CHCl3-MeOH 10:0 to 20: 1) to give methyl 4-[2-N-(N N'-diallyl)ethyl-N-[4-[N'-(2-chlorophenyl)ureido]-3-methoxyphenyl acetamido] ethoxy] benzoate (96 mg, 83%) as a white amoφhous foam. 'H-NMR (CDC13, 400 MHz) δ 2.60 (m, 2 H), 3.09 (d, J = 6.4 Hz, 1 TT), 3.11 (d, J = 6.4 Hz, 3 H), 3.52 (m, 2 TT), 3.61 (s, 2 H), 3.70-3.80 (m, 5 H), 3.86 (s, 3 H), 4.05 and 4.20 (2 m, total 2 H), 5.06-5.21 (m, 4 H), 5.80 (m, 2 H), 6.71-6.85 (m, 4 H), 6.98 (m, 1 H), 7.22 (m, 1 H), 7.32 (m, 3 TT), 7.93 (d, J = 7.8 Hz, 2 H), 7.98 (m, 1 H), 8.18 (dd, J = 1.5 Hz, 8.2 Hz, 1 H); MS (ESI) m/z 635 (M+).
To a solution of methyl 4-[2-N-(ΛP, N'-diallyl)ethyl-N-[4-[N'-(2-chlorophenyl)ureido]-3- methoxy phenylacetamido]ethoxy]benzoate (96 mg, 0.15 mmol) in THF-MeOH (1 : 1, v/ v, 8 ml), was added 0.25 N NaOH (3.91 ml, 0.98 mmol) at rt, and heated to 50 °C The stirring was continued for 6 hours at reflux. The solvent was removed, and the residue was chromatographed on HP-20 (H20-MeOH, 0: 100 to 100: 0) to give 323 (88 mg, 94%) as a white powder. 'H-NMR (CD3OD, 400 MHz) δ 2.61 (m, 2 H), 3.10 (s, 2 H), 3.12 (s, 2 TT), 3.59 (m, 2 H), 3.70 (s, 2 H), 3.78 (m, 2 H), 3.82 (s, 3 H), 4.10 (m, 1 H), 4.21 (m, 1 H), 5.18 (m, 4 H), 5.81 (m, 2 H), 6.82 (m, 4 H), 7.01 (t, J = 7.8 Hz, 1 H), 7.25 (m, 1 H), 7.39 (d, J = 7.8 Hz, 1 H), 7.90 (m, 2 H), 8.02 (m, 2 TT); MS (ESI) m/z 621 (M+); Anal Calcd for C33H36ClN406Na-1.25 H20: C, 59.55; H, 5.83; N, 8.42. Found: C, 59.90; H, 5.74; N, 7.96. Example 274 4-[2-N-[3-methoxy-4-[7V'-(2-methylphenyl)ureido]phenyl]-N-methylacetoamido]ethyl-l- piperazinylacetic acid
Figure imgf000464_0001
To a stirred suspension of l-(2-hydroxyethyl)piperazine (5.21g, 40.0mmol) and K2C03
(8.76g, 63.4mmol) in CH3CN (100ml) was added ethyl bromoacetate (5.60ml, 50.5mmol) at 0°C.
The reaction mixture was heated under reflux for 5h, diluted with EtOAc, and washed with water and brine. The extract dried over Na2S04, concentrated to dryness and afforded ethyl 4-(2- hydroxyethyl)-l-piperazinylacetate (9.65g, 100%) as a yellow oil. 'H-NMR (CDC13) δ 1.23 (t, 3H, =7.3Hz), 2.51-2.61(m, 11H), 3.22(s, 2H), 3.61(t, 2H, =5.4Hz), 4.19(q, 2H, J=7.3Hz).
To a solution of 2,4-dinitrobenzenesulfonyl chloride (l.Og, 3.75mmol) and pyridine (0.34ml, 4.20mmol) in THF (19ml) was added dropwise methylamine (2.0M THF solution, 2.3ml, 4.60mmol) at 0°C The reaction mixture was stirred for lhr, quenched by the addition of IN HCl solution, and extracted with EtOAc. The exfract was washed with sat. NaHC03 solution and brine, dried over Na2S04 , and concenfrated to dryness. The residue was recrystallized from EtOAc-Et20 to give methyl 2,4-dinifrobenzenesulfonamide (546mg, 56%) as a colorless solid. 'H-NMR (DMSO) δ 2.60 (d, 3H, J=4.9Hz), 8.22 (d, IH, =8.8Hz), 8.31 (q, IH, =4.9Hz), 8.66 (dd, IH, .7=8.8, 2.0Hz), 8.90 (d, IH, J=2.0Hz).
To a solution of ethyl 4-(2-hydroxyethyl)- 1-piperazinylacetate (452mg, 2.09mmol), methyl 2,4-dinifrobenzenesulfon-amide (546mg, 2.09mmol) and PPh3 (658mg, 2.5 lmmol) in THF was added DIAD (0.50ml, 251mmol) at 0°C After stirring 17h at room temperature, the reaction mixture was concentrated to dryness. Chromatography of the residue with EtOAc-MeOH (10:1) to afford ethyl 4-[2-[N-(2,4-dimtrobenzensulfonyl)-N-methylamino]ethyl]-l-piperazinylacetate
(864mg, 90%) as a reddish oil. 'H-NMR (CDC13) δ 1.27 (t, 3H, =6.8Hz), 2.35-2.63 (m, 10H), 2.98 (s, 3H), 3.20 (s, 2H), 3.41 (t, 2H, J=6.8Hz), 4.17 (q, 2H, =6.8Hz), 8.33 (d, IH, =8.3Hz), 8.46 (d, IH, J=2.0Hz), 8.50 (dd, IH, .7=8.3, 2.0Hz).
A solution of ethyl 4-[2-[N-(2,4-dinifrobenzensulfonyl)-N-methylamino]ethyl]-l- piperazinylacetate (864mg, 1.88 mmol) .mercaptoacetic acid (0.17ml, 2.44mmol) and Et3N
(0.53ml, 3.76mmol) in CH2C12 (25ml) was stirred at rt for 3hr. The reaction mixture ethyl 4-(2- methylaminoethyl)-l-piperazinylacetate (388mg, 90%) as reddish oil. 'H-NMR (CDC13) δ 1.27 (t, 3H, =6.8Hz), 2.50 (s, 3H), 2.53-2.60 (m, 8H), 2.75 (t, 2H, J=5.9Hz), 3.20 (s, 2H), 4.18 (q, 2H, y=6.8Hz). To a solution of ethyl 4-(2-methylaminoethyl)-l-piperazinylacetate (388mg, 1.69mmol), Et3N (0.32ml, 2.25mmol) and DMAP (46mg, 0.38mmol) in DMF (15ml) was stirred for 15min at room temperature, then (532mg, 1.69mmol), HOBt (103mg, 0.76mmol) and EDC HCl (486mg, 2.53mmol) was added to the reaction mixture which was stirred for 15h at rom temperature The reaction mixture was diluted with EtOAc, which was washed with brine, dried over Na2S04, and concentrated to dryness. Chromatography of the residue with CHCl3-MeOH (10:1, v/v) to afford ethyl 4-[2-N-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]-A^-methylacetoamido]ethyl-l- piperazinylacetate (889mg, mixture of DMF) as a reddish oil. 'H-NMR (CDC13) δ 1.25-1.29 (m, 3H), 2.29 (s, 3H), 2.42-2.63 (m, 10H), 3.20, 3.18 (each s, total 3H), 3.55, 3.40 (each t, total 2H, J=6.8Hz), 3.65, 3.69 (each s, total 2H), 3.72 (s, 3H), 4.15-4.21 (m, 2H), 6.50 (m, IH), 6.77-6.81 (m, 8H), 7.11-7.24 (m, 3H), 7.53 (d, IH, J=8.3Hz), 8.02 (s, IH), 8.06 (d, IH, J=7.8Hz).
To a stirred solution of ethyl 44-[2-N-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]- N-methylacetoamido] ethyl- 1-piperazinylacetate (889mg, 1.69mmol) in THF-EtOH (5:1, v/v, 18 ml) was added 4N NaOH (0.84ml, 3.38mmol). The reaction mixture was stirred at rt for 4h, adjusted to pH 7.5 with IN HCl and exfracted with CHCl3-MeOH (4: 1, v/v). The combined extracts were dried over MgS04 and concenfrated to afforded 324 (218mg, 26% 2steps) as a brown amoφhous foam. IR(KBr) n 3299, 3004, 1700, 1627, 1598, 1536cm '; 'H-NMR (DMSO) δ 2.25 (s, 3H), 2.36-2.62 (m, lOH), 2.84, 2.99 (each s, total 3H), 3.13, 3.14 (each s, total 2H), 3.38-3.45 (m, 2H), 3.61, 3.65 (each s, total 2H), 3.86 (s, 3H), 6.74 (t, IH, J=7.8Hz), 6.87 (s, IH), 6.93 (t, IH, J=7.8Hz), 7.11-7.17 (m, 2H), 7.79 (d, IH, J=7.8Hz), 8.01 (d, IH, =7.8Hz), 8.47 (s, IH), 8.57 (s, IH); MS (FAB) m/z 498 (M++l); Anal. Calcd for C26H35NA'2HC1 H20: C, 53.06; H, 6.67; N, 11.89. Found: C, 53.04; H, 6.15; N, 11.09. Example 275 l-[2-[Λ/-methyl-N-[3-methoxy-4-[Λ^-(2-methylphenyl)ureido]phenyl]acetamido]ethyl]-4- piperidinylacetic acid
Figure imgf000465_0001
To a stirred solution of 2-(Λr-benzyloxycarbonyl-N-methylamino)acetaldehyde (2.07 g,
10.0 mmol) and ethyl 4-piperidinylideneacetate (1.69 g, 10.0 mmol) in MeOH-AcOH (10: 1, v/v,
22 ml) was added NaBH3CN (1.32 g, 20 mmol) and the stirring was continued overnight. The mixture was quenched by addtion of sat. NaHC03 (200 ml) and extracted with CHC13 (3 x 150 ml).
The combined extracts were dried over MgS04 and evaporated. The residue was crhomatographed on silica-gel with CHCl3-EtOH (40:1, v/v) to give ethyl l-[2-(N-benzyloxycarbonyl-N- methylamino) ethyl]-4-piperidinylideneacetate (1.71 g, 47%) as a colorless oil. 'H-NMR (CDC13) δ 1.25 (t, J = 7.3 Hz, 3 H), 2.16 (m, 2 H), 2.57 (m, 4 H), 2.95 (m, 7 H), 3.44 (m,2 TT), 4.13 (q, J = 7.3 Hz, 2 H), 5.12 (s, 2 H), 5.49-5.53 (m, 1 H), 7.35 (m, 5 H).
A solution of ethyl l-[2-(Λ^-benzyloxycarbonyl-Λf-methylamino)ethyl]-4-piperidinylidene acetate (1.70 g, 4.72 mmol) in EtOH-AcOH (20: 1, v/v, 21 ml) was hydrogenated over 5% Pd/C (2 g) for 3 days with stirring. The mixture was filtered and the filtrate was concenfrated in vacuo. The residue was made basic with sat. NaHC03and exfracted with CHC13 (300 ml). The exfract was dried over Na2C03 and evaporated to give ethyl l-(2-methylaminoethyl)-4-piperidinylacetate (813 mg, 75%) as a yellow oil. Η-NMR (CDC13) δ 1.25 (t, J = 7.3 Hz, 3 H), 1.68-1.81 (m, 5 H), 1.97 (t, J = 11.2 Hz, 2 H), 2.22 (d, J= 7.3 Hz, 2 H), 2.43-2.47 (m, 5 H), 2.66 (t, J= 6.4 Hz, 2 H), 2.85-2.90 (m, 2 H), 4.13 (q, J = 7.3 Hz, 2 TT).
To a stirred solution of 3-methoxy-4-[N'-(2-methylphenyl)ureido]phenylacetic acid (550 mg, 1.75 mmol) and ethyl l-(2-methylaminoethyl)-4-piperidinylacetate (400 mg, 1.75 mmol) in DMF (10 ml) were added EDC HCl (503 mg, 2.63 mmol), HOBt (cat.), and DMAP (cat.) and the stirring was continued overnight. The mixture was diluted with EtOAc (300 ml), washed with brine (200 ml), dried over MgS04, and evaporated. The residue was crhomatographed on silica gel with CHCl3-EtOH (10: 1, v/v) to give ethyl l-[2-[N-methyl-N-[3-methoxy-4-[N'-(2- methylphenyl) ureido]phenyl]acetamido]ethyl]-4-piperidinylacetate (697 mg, 76%) as a yellow gum. 'H-NMR (CDC13) δ 1.19-2.06 (series of m, 12 H), 2.21 (t, = 7.8 Hz, 2 H), 2.28 (s, 3 H), 2.41 (t, J= 7.3 Hz, 1 H), 2.46 (t, J= 7.3 Hz, 1 H), 2.80-2.89 (m, 2 H), 2.95 and 3.01 (s, each, total 3 H), 3.40 and 3.50 (t, = 6.8 Hz, each, total 2 H), 3.64-3.75 (m, 5 H), 4.09-4.16 (m, 2 H), 6.59 (s, 1 H), 6.77-6.79 (m, 2 H), 7.12 (t, J = 7.3 Hz, 1 TT), 7.21-7.27 (m, 3 H), 7.54 (d, J = 8.3 Hz, 1 TT), 8.06 (dd, .7 = 8.3, 2.4 Hz, 1 H).
To a stirred solution of ethyl l-[2-[ V-methyl-N-[3-methoxy-4-[Λ -(2 -methylphenyl) ureido]phenyl]acetamido]ethyl]-4-piperidinylacetate (690 mg, 1.32 mmol) in THF (11 ml) was added 0.25 N aq. NaOH (11 ml, 2.75 mmol) and the stirring was continued overnight. The mixture was diluted with H20 (50 ml), neufralized with 1 N HCl, and exfracted with CHCl3-MeOH (2: 1, v/v, 3 x 100 ml). The combined extracts were dried over MgS04 and evaporated. The residue was dissolved in MeOH (50 ml) and activated carbon (2 g) was added to this solution. The suspension was refluxed for 30 min with stirring and filtered through Celite. The filtrate was evaporated and the residue was triturated by taking up CHC13 and adding hexane until a precipitate fomed. This precipitate was collected and dried in vacuo to give 325 (75 mg, 11%) as a white amoφhous solid. 'H-NMR (DMSO) δ 1.19-2.99 (series of m, total 17 H), 3.32-3.43 (m, 4 H), 3.62-3.65 (m, 2H), 3.86 (s, 3 H), 6.73 (t, = 8.3 Hz, 1 H), 6.87 (s, 1 H), 6.93 (t, J = 7.8 Hz, 1 H), 7.11-7.17 (m, 2 TT), 7.79 (d, J = 8.3 Hz, 1 TT), 8.01 (d, J= 8.3 Hz, 1 H), 8.47 (s, 1 H), 8.57 (s, 1 TT); MS-FAB m/z 497 (M++l); Anal. Calcd for C27H36N405'HC1: C, 60.84; H, 7.00; N, 10.51. Found: C, 60.97; H, 7.14; N, 10.17. Example 276 l-[2-[N-methyl-Λ^-[4-[Λ^-(2-methylphenyl)ureido]phenyl]acetamido]ethyl]-4-piperidinylacetic acid
Figure imgf000467_0001
To a stirred solution of ethyl l-(2-methylaminoethyl)-4-piperidinylacetate (400 mg, 1.75 mmol) and Et3N (366 ul, 2.63 mmol) in DMF (10 ml) was added pentafluorophenyl 4-(N'-(2- methylphenyl)ureido)phenylacetate (788 mg, 1.75 mmol) and the stirring was continued overnight. The mixture was diluted with EtOAc (300 ml), washed with brine (200 ml), dried over MgS04, and evaporated. The residue was crhomatographed on silica-gel with CHCl3-EtOH (10: 1, v/v) to give ethyl l-[2-[N-methyl-N-[4-[N'-(2-methylphenyl)ureido]phenyl]acetamido]ethyl]-4-piperidinyl acetate (630 mg, 73%) as a colorless oil.
To a stirred solution of ethyl l-[2-[N-methyl-N-[4-[Ar-(2-methylphenyl)ureido]phenyl] acetamido] ethyl] -4-piperidinylacetate (630 mg, 1.27 πunol) in THF (10 ml) was added 0.25 N aq. NaOH (10 ml) and the stirring was continued overnight. The reaction mixture was diluted with H20 (100 ml), neufralized with 1 N HCl, and exfracted with CHCl3-MeOH (2:1, v/v, 3 x 100 ml). The combined extracts were dried over MgS04 and evaporated. The residue was triturated by taking up CHC13 and adding hexane until precipitate formed. This precipitate was collected and dried in vacuo to give 326 (20 mg, 3%) as a white amoφhous solid. 'H-NMR (DMSO)δ 1.69 (m, 5 TT), 2.15 (m, 4 H), 2.24 (s, 2 H), 2.50 (m, 2 H), 2.83 and 2.99 (s, each, total 3 H), 3.32-3.49 (m, 4 TT), 3.63 (d, J = 6.8 Hz, 2 H), 6.91-6.95 (m, 1 H), 7.13 (m, 4 H), 7.39 (d, J = 8.3 Hz, 2 T), 7.83 (d, J= 7.3 Hz, 1 H), 7.97 (m, 1 H), 9.12 (m, 1 H); MS (FAB): m/z 467 (M++l). Example 277 4-[2-N-[4-[N'-(2-methylphenyl)ureido]phenyl]-N-methylacetamido]ethyl-l-piperazinylacetic acid
Figure imgf000467_0002
To a solution of ethyl 4-(2-methylaminoethyl)-l-piperazinylacetate (700mg, 3.05mmol), Et3N (0.64ml, 4.58mmol) and DMAP (75mg, O.όlmmol) in THF (15ml) was stirred for 30min at rt, then 4-[N'-(2-methylphenyl)ureido]phenylacetic acid (917mg, 3.05mmol), HOBt (82mg, O.όlmmol) and EDC HCl (879mg, 4.58mmol) was added to the reaction mixture which was stirred for 12h at rt. The reaction mixture was diluted with EtOAc, which was washed with brine, dried over Na2S04, and concentrated to dryness. Chromatography of the residue with CHCl3-MeOH (10: 1, v/v) afforded ethyl 4-[2-N-[4-[N'-(2-methylphenyl)ureido]phenyl]-N-methylacetaιnido]ethyl- 1 -piperazinylacetate (996mg, 66%) as a yellow amoφhous foam. 'H-NMR (CDC13) δ 1.25-1.29 (m, 3H), 2.20 (s, 3H), 2.47-2.58 (m, 10H), 2.97, 3.05 (each s, total 3H), 3.17, 3.20 (each s, total 2H), 3.45, 3.52 (each d, total 2H, J=6.8Hz), 3.64, 3.68 (each s, 2H), 4.15-4.21 (m, 2H), 7.01-7.19 (m, 8H), 7.48 (m, IH), 7.64 (m, IH); MS (FAB) m/z 496 (M++l).
To a stirred solution of ethyl 4-[2-Λ^-[4-[N'-(2-methylphenyl)ureido]phenyl]-N-methyl acetamido] ethyl- 1-piperazinylacetate (996mg, 2.0 lmmol) in THF-EtOH (5:1, 12 ml) was added 4N NaOH (1.0ml, 4.00mmol). The reaction mixture was stirred at rt for 4h, adjusted to pH 7.5 with IN HCl and extracted with CHCl3-MeOH (4:1, v/v). The combined extracts were dried over MgS04 and concentrated to afforded 327 (73mg, 8%) as a yellow amoφhous foam. IR(KBr) n 3338, 2925, 2850, 2821, 1704, 1627, 1540cm '; 'H-NMR (DMSO) δ 2.24 (s, 3H), 2.33-2.61 (m, 10H), 2.82, 2.95 (each s, total 3H), 3.00, 3.02 (each s, total 2H), 3.39 (t, 2H, J=6.8Hz), 3.60, 3.62 (each s, total 2H), 6.92 (t, IH, J=7.8Hz), 7.09-7.16 (m, 4H), 7.41-7.44 (m, 2H), 7.76, 7.77 (each d, 2H, J=7.8Hz), 8.46, 8.53 (each s, IH), 9.54, 9.59 (each s, IH); MS (FAB) m/z 468 (M++l); Anal. Calcd for C25H33N505-2HC1: C, 55.56; H, 6.53; N, 12.96. Found: C, 54.99; H, 6.45; N, 11.58. Example 278
4-[2-N-[4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenyl]-N-methylacetamido]ethyl-l- piperazinylacetic acid
Figure imgf000468_0001
To a solution of ethyl 4-(2-methylaminoethyl)-l-piperazinylacetate (695mg, 3.03mmol), Et3N (0.64ml, 4.58mmol) and DMAP (75mg, O.όlmmol) in DMF (15ml) was stirred for 15min at rt, then 4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenylacetic acid (965mg, 3.03mmol), HOBt (82mg, 0.61mmol) and EDC HCl (872mg, 4.54mmol) was added to the reaction mixture which was stirred for 12h at rt. The reaction mixture was diluted with EtOAc, which was washed with brine, dried over Na2S0 , and concenfrated to dryness. Chromatography of the residue with CHC13- MeOH (10:1, v/v) afforded ethyl 4-[2-N-[4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenyl]-N- methyl acetamido]ethyl- 1-piperazinylacetate (1.21g, mixture of DMF) as a black oil. Η-NMR (CDC13) δ 1.24-1.29 (m, 3H), 2.45-2.59 (m, 10H), 2.98, 3.05 (each s, total 3H), 3.17, 3.20 (each s, total 2H), 3.44, 3.52 (each t, total 2H, J=6.8Hz), 3.66 (s,2H), 4.15-4.21 (m, 2H), 6.77-6.78 (m, 2H), 6.79-7.11 (m, 3H), 7.68-7.95 (m, 2H), 7.64 (broad s, IH), 8.20 (t, IH, J=7.8Hz); MS (FAB) m/z 530 (M++l).
To a stirred solution of ethyl 4-[2-N-[4-[N'-(2-fluorophenyl)ureido]-3-methoxyphenyl]-N- methyl acetamido] ethyl- 1 -piperazinylacetate ( 1.21 g, mixture of DMF) in THF-EtOH (5:1, v/v, 12 ml) was added 4N NaOH (1.0ml, 4.00mmol). The reaction mixture was stirred at rt for 4h, adjusted to pH 7.5 with IN HCl and extracted with CHCl3-MeOH (4:1, v/v). The combined extracts were dried over MgS04 and concenfrated to afforded 328 (78mg, 5% 2steps) as a brown amoφhous foam. IR(KBr) n 3299, 2940, 2830, 1704, 1627, 1598, 1536cm '; 'H-NMR (DMSO) δ 2.36-2.61 (m, 10H), 2.83, 2.98 (each s, total 3H), 3.11 (s, 2H), 3.37-3.43 (m, 2H), 3.62, 3.65 (each s, total 2H), 3.85 (s, 3H), 6.75 (m, IH), 6.87 (s, IH), 6.98 (s, IH), 7.12 (t, IH, J=7.8Hz), 7.20, 7.23 (each d, 2H, J=7.8Hz), 8.01 (d, IH, J=7.8Hz), 8.17 (t, IH, J=7.8Hz), 8.72 (s, IH), 9.19 (s, IH); MS (FAB) m/z 502 (M++l); Anal. Calcd for C25H32FN5O5-2HCl-0.5H2O: C, 51.46; H, 6.05; N, 12.00. Found: C, 51.08; H, 5.69; N, 11.27. Example 279
3-fluoro-l-[2-N-methyl-N-[3-methoxy-4-[Λr'-(2-methylphenyl)ureido]phenyl]acetamido]ethyl-4- piperidinylacetic acid
Figure imgf000469_0001
To a stirred solution of l-ferr-butoxycarbonyl-4-piperidone (14.9 g, 74.8 mmol) in DMF (35 mL) was added TMSC1 (11.4 mL, 89.7 mmol) and then Et3N (25.0 mL, 179 mmol) dropwise at room temperature, and the reaction mixture was heated at 80 °C for 18 hr. Hexane was added to the reaction mixture, and the resulting mixture was washed with sat. NaHC03 and brine, dried over Na2S04, and concenfrated to dryness. Chromatography of the residue with hexane - EtOAc (5 : 1, v/v) as eluent gave l-/e /-butoxycarbonyl-l,2,3,6-tefrahydro-4-(trimethylsilyloxy)pyridine (20.4 g, 99 %) as a yellow oil. 'H-NMR (CDC13) δ 0.19 (s, 9H), 1.46 (s, 9H), 2.05 - 2.15 (m, 2H), 3.48 - 3.56 (m, 2H), 3.83 - 3.91 (m, 2H), 4.79 (broad s, IH).
To a solution of l-/eλ- butoxycarbonyl-l,2,3,6-tetrahydro-4-(trimethylsilyloxy)pyricϋne (20. 4 g, 75.0 mmol) in CH3CN (500 mL) was added Selectfluor™ (29.2 g, 82.5 mmol) at room temperature, and the reaction mixture was stirred for 2 hr. EtOAc was added to the reaction mixture, and the mixture was washed with brine, dried over Na2S04, and concentrated to dryness. Chromatography of the residue with CHC13 - MeOH (6 : 1, v/v) as eluent gave l-tert- butoxycarbonyl-3-fluoro-4-piperidone (14.5 g, 89 %) as a colorless oil. 'H-NMR (CDC13) δ 1.50 (s, 9H), 2.44 (t, J = 6.9 Hz, IH), 2.48 - 2.63 (m, 2H), 3.26 (ddd, J= 13.5, 10.5, 3.9 Hz, IH), 3.72 (t, J = 6.9 Hz, IH), 4.16 (m, IH), 4.42 (m, IH), 4.83 (dt, 49.2, 6.9 Hz, IH).
To a solution of triethyl phosphonoacetate (3.72 g, 16.6 mmol) in THF (70 mL) was added lithium bis(trimethylsilyl)amide (l.OM THF solution, 15.5 mL, 15.5 mmol) at -78 °C After being stirred at the same temperature for 1 hr, l-terf-butoxycarbonyl-3-fluoro-4-piperidone (3.02 g, 13.9 mmol) was added to the reaction mixture. The mixture was stirred for 30 min at the same temperature, quenched by the addition of sat. NH4C1 solution and exfracted with EtOAc. The extracts were washed with brine, dried over Na2S04, and concenfrated to dryness. Chromatography of the residue with hexane - EtOAc (8 : 1, v/v) as eluent gave ethyl (1- butoxycarbonyl-3-fluoropiperidin-4-yliden)acetate (3.23 g, 81 %) as a colorless solid. 'H-NMR δ 1.30 (t, = 7.1 Hz, 3H), 1.48 (s, 9H), 2.10 (m, IH), 2.56 (m, IH), 2.77 (m, IH), 3.13 - 3.54 (m, 2H), 3.70 (m, IH), 4.17 4.18 (each q, = 7.1 Hz, total 2H), 5.82 5.98 (each s, total IH), 6.41 (each d, = 46.9 Hz, total IH); MS (FAB) m/z 288 (M++l).
A solution of ethyl (l-butoxycarbonyl-3-fluoropiperidin-4-yliden)acetate (1.32 g, 4.59 mmol) in THF (30 mL) was hydrogenated over Pd-C (TMEDA complex, 66.0 mg) at room temperature for 2 hr under hydrogen atmosphere. The catalyst was filtered off and the filtrate was concenfrated to dryness. Chromatography of the residue with hexane - EtOAc (9 : 1, v/v) as eluent gave ethyl l-/e^-butoxycarbonyl-3-fluoro-4-piperidinylacetate (653 mg, 73 %) as a colorless oil. 'H-NMR (CDC13) δ 1.26 (t, = 7.1 Hz, 3H), 1.45 (s, 9H), 1.53 - 1.79 (m, 2H), 1.92 - 2.09 (m,
2H), 2.31 (dd, J= 16.4, 6.9 Hz, IH), 2.52 (dd, J = 16.4, 7.3 Hz, IH), 2.61 - 3.06 (m, 2H) , 4.14 (q, J = 7.1 Hz, 2H), 4.28 - 4.77 (m, 2H); 13C NMR (CDC13) 14.29, 25.80, 28.42, 35.99, 36.20, 60.55, 79.78, 86.72. 88.48, 154.94, 171.93; FAB-MS m/z 290 (M++l).
To a solution of ethyl l-/e /-butoxycarbonyl-3-fluoro-4-piperidinylacetate (653 mg, 2.26 mmol) in CH2C12 (10 mL) was added TFA (5 mL) at 0 °C After being stirred at room temperature for 4 hr, the reaction mixture was concenfrated. The residue was taken up with sat. NaHC03 solution and exfracted with THF - EtOAc (1 : 1, v/v). The exfracts were dried over MgS04 and concenfrated to afford ethyl 3-fluoro-4-piperidinylacetate (420 mg, 98 %) as a yellow oil. 'H-NMR (CDCLj) δ 1.26 (t, = 7.4 Hz, 3H), 1.68 - 1.80 (m. 2H), 2.18 (m, IH), 2.32 (dd, J = 16.6, 6.8 Hz, IH), 2.54 (dd, .7= 16.6, 7.5 Hz, IH), 2.82 (m, IH), 2.90, 3.00 (each d, J= 14.4 Hz, total IH), 3.31 (m, IH), 3.51 (m, IH), 4.15 (q, = 7.4 Hz, 2H), 4.82, 4.71 (each broad s, total IH). To a solution of ethyl 3-fluoro-4-piperidinylacetate (230 mg, 1.22 mmol) and 2-(N-tert- butoxy carbonyl-/V-methylamino)acetaldehyde (211 mg, 1.22 mmol) in THF (5 mL) was added NaBH(OAc)3 (386 mg, 1.82 mmol) and acetic acid (70.0 mL, 1.22 mmol) at room temperature After being stirred for 24 hr, the reaction mixture was quenched by the addition of sat. NaHC03 solution and exfracted with EtOAc. The exfracts were washed with brine, dried over Na2C03, and concentrated to dryness. Chromatography of the residue with CHC13 - MeOH (6 : 1, v/v) as eluent gave ethyl 3-fluoro-l-[2-(/V-ter -butoxycarbonyl-N-methylamino)ethyl]-4-piperidinylacetate (236 mg, 56 %) as a reddish oil. 'H-NMR (CDC13) δ 1.25 (t, = 7.1 Hz, 3H), 1.45 (s, 9H), 1.53 1.79 (m, 2H), 1.90 - 2.09 (m, 2H), 2.15 (dd, J = 16.4, 7.1 Hz, IH), 2.45 - 2.58 (m, 2H), 2.87 (s, 3H), 2.90 - 2.99 (m, 2H), 3.20 (m,lH), 3.24 - 3.45 (m, 2H), 4.14 (q, J= 7.1 Hz, 2H), 4.61, 4.73 (each broad s, IH); ESI-MS m/z 347.
To a solution of ethyl 3-fluoro-l-[2-(N-terr-butoxycarbonyl-N-methylaιnino)ethyl]-4- piperidinylacetate (236 mg, 0.68 mmol) in CH2C12 (10 mL) was added TFA (5 mL) at 0 °C After being stirred at room temperature for 4 hr, the reaction mixture was concenfrated. The residue was taken up with sat. NaHC03 solution and extracted with CHC13. The exfracts were dried over MgS04 and concentrated to afford ethyl 3-fluoro-l-[2-(N-methylamino)ethyl]-4-piperidinylacetate (117 mg, 70 %) as a reddish oil. Η-NMR (CDCl3)δ 1.26 (t, J = 7.1 Hz, 3H), 1.58 (m ,1H), 1.70 (m, IH), 1.99 (m, IH), 2.14 (m,lH), 2.27 - 2.33 (m, IH), 2.47 (s, 3H), 2.48 - 2.56 (m, 4H), 2.72 (t, J = 6.3 Hz, 2H), 2.90 (m, IH), 3.16 (m, IH), 4.14 (q, J = 7.1 Hz, 2H), 4.67 (d, = 48.3 Hz, IH); ESI-MS m/z 247 (M÷+l).
To a solution of 3-methoxy-4-[Λr'-(2-methylphenyl)ureido]phenylacetic acid (164 mg, 0.52 mmol), ethyl 3-fluoro-l-[2-(N-methylamino)ethyl]-4-piperidinylacetate (117 mg, 0.47 mmol), Et3N (0.10 mL, 0.71 mmol), and HOBt (13.0 mg, 0.09 mmol) in THF (5 mL) was added EDC-HCl (137 mg, 0.71 mmol). After being stirred at room temperature for 8 hr, the reaction mixture was diluted with water and exfracted with EtOAc. The exfracts were washed with brine, dried over Na2S04, and concentrated to dryness. Chromatography of the residue with toluene - acetone (1 : 2, v/v) as eluent gave ethyl 3-fluoro-l-[2-N-methyl-N-[3-methoxy-4-[Λf'-(2-methylphenyl)ureido] phenyl]acetamido]ethyl-4-piperidinylacetate (160 mg, 62 %) as a yellow amoφhous solid. 1H- NMR (CDC13) δ 1.24 - 1.28 (m, 3H), 1.51 - 2.23 (m IK), 2.26 (s, 3H), 2.35 (s, 2H), 2.39 - 2.56 (m, 3H), 2.88 (m, IH), 2.95, 3.03 (each s, total 3H), 3.11 (m, IH), 3.44 (m, IH), 3.56 (m, IH),
3.64 (s, 2H), 3.68 (s, 3H), 4.11 - 4.17 (m, 2H), 4.57, 4.69 (each s, total IH), 6.72 - 6.82 (m, 2H), 7.10 - 7.33 (m, 5H), 7.54 (d, J = 8.1 Hz, IH), 8.06 (d, = 8.1 Hz, IH); ESI-MS m/z 543 (M++l). To a solution of ethyl 3-fluoro-l-[2-N-methyl-Λr-[3-methoxy-4-[N' -(2-methylphenyl) ureido]phenyl]acetamido]ethyl-4-piperidinylacetate (160 mg, 0.29 mmol) in THF (3 mL) was added 0.25N NaOH (1.30 mL, 0.32 mmol). After being stirred at room temperature for 1 hr, the reaction mixture was concentrated. The residue was diluted with water and neufralized with IN HCl at 0 °C. The mixture was concentrated and purified by ion-exchanged resin (HP-20,
Mitsubishi Chemical) to give 329 (110 mg, 74 %) as a yellow amoφhous solid. IR (KBr) 3343, 2937, 1700, 1617, 1589, 1535, 1486, 1455, 1417 cm 1; Η-NMR (CD3OD) δ 1.57 - 1.72 (m ,2H), 1.98 (m, IH), 2.26 (m, IH), 2.28 (s, 3H), 2.37 - 2.59 (m, 3H), 2.66 - 2.89 (m, 2H), 2.95, 3.09 (each s, total 3H), 3.14 (m, IH), 3.40 (m, IH), 3.51 (m, IH), 3.59 (m, IH), 3.71 (s, 2H), 3.78 (m, IH), 3.89 (s, 3H), 4.69, 4.81 (each s, total IH), 6.79 (dd, .7 = 8.1, 1.5 Hz, IH), 6.90 (broad s, IH), 7.01 (t, J= 7.8 Hz, IH), 7.13 -7.19 (m, 2H), 7.58(d, = 7.8Hz, 1H),8.00 (d,J = 8.1 Hz, IH); ESI-MS m/z 515 (M++l); Anal. Calcd for C27H35FN403-H20: C, 60.89; H, 7.00; N, 10.52. Found: C, 61.09; H, 6.80; N, 9.87. Example 280 4-[2-N-[2-(4-fluorophenoxy)ethyl]-Λ^-[3-methoxy-4-[Λp-(2-methylphenyl)ureido]phenyl] acetamido]ethylpiperazinyl-l-acetic acid
Figure imgf000472_0001
To a solution of 2-(N-benzyl-Λ -ferf-butoxycarbonylamino)ethanol (6.85 g, 27.3 mmol), 4- fluorophenol (3.07 g, 27.3 mmol) and PPh3 (7.83 g, 30.0 mmol) in THF (100 mL) was added DIAD (6.00 mL, 30.0 mmol) at room temperature After being stirred for 3 hr, the reaction mixtiire was concenfrated. Chromatography of the residue with hexane - EtOAc (8 : 1, v/v) as eluent gave l-[2-(N-benzyl-N-/er/-butoxycarbonylamino)ethoxy]-4-fluorobenzene (8.19 g, 64 %) as a yellow oil. 'H-NMR (CDCl3)δ 1.42 - 1.50 (m, 9H), 3.41 - 3.67 (m, 2H), 3.92 - 4.11 (m, 2H),
4.51 - 4.63 (m, 2H), 6.73 - 6.85 (m, 2H), 6.89 - 6.98 (m, 2H), 7.24 (m 5H); FAB-MS m/z 346 (M++l).
To a solution of l-[2-(Λ^-benzyl-Λf-fer^-butoxycarbonylamino)ethoxy]-4-fluorobenzene (8.19 g, 23.7 mmol) in CH2C12 (50 mL) was added TFA (40 mL) at 0 °C After being stirred at room temperature for 1 hr, the reaction mixture was concenfrated. The residue was taken up with sat. NaHC03 solution and extracted with CHC13. The extracts were washed with brine, dried over Na2S04, and concentrated to give l-(2-N-benzylaminoethoxy)-4-fluorobenzene (4.38 g, 75 %) as a reddish oil. 'H-NMR (CDCl3)δ 3.00 (t, = 5.2 Hz, 2H), 3.87 (s, 2H), 4.04 (t, J= 5.2 Hz, 2H), 6.80 - 6.85 (m, 2H), 6.92 - 6.98 (m, 2H), 7.23 - 7.36 (m, 5H); FAB-MS m/z 246 (M++l).
A mixture of l-(2-Λ^-benzylaminoethoxy)-4-fluorobenzene (1.08 g, 4.40 mmol), ethyl 4- (2-bromoethyl)piperazinyl-l-acetate (1.23 g, 4.40 mmol), and K2C03 (0.61 g, 17.9 mmol) in CH3CN (50 mL) was heated under reflux for 8 hr. The resulting mixtrae was filtered and the filtrate was concentrated to dryness. Chromatography of the residue with toluene - acetone (3 : 1, v/v) as eluent gave ethyl 4-[2-N-benzyl-JV-[2-(4-fluorophenoxy)ethyl]amino]ethylpiperazinyl-l- acetate (1.51 g, 77 %) as a reddish oil. 'H-NMR (CDCl3)δ 1.27 (t, J= 7.1 Hz, 3H), 2.31 - 2.66 (m, 10H), 2.75 (t, = 6.6 Hz, 2H), 2.90 (t, J= 6.1 Hz, 2H), 3.18 (s, 2H), 3.72 (s, 2H), 3.97 (t, J = 6.1 Hz, 2H), 4.17 (q, J = 7.1 Hz, 2H), 6.75 - 6.79 (m, 2H), 6.91 - 6.96 (m, 2H), 7.21 - 7.35 (m, 5H); FAB-MS m/z 444 (M++l).
A solution of ethyl 4-[2-N-benzyl-N-[2-(4-fluorophenoxy)ethyl]amino]ethylpiperazinyl-l- acetate (1.50 g, 3.38 mmol) in EtOH (30 mL) was hydrogenated over 5 % Pd-C (53.1 % wet, 0.73 g) under hydrogen atmosphere for 4 hr. The catalyst was filtered off and the filtrate was concenfrated. The residue was taken up with sat. NaHC03 solution and exfracted with CHC13. The exfracts were washed with brine, dried over Na2S04, and concenfrated to afford ethyl 4-[2-N- [2-(4-fluorophenoxy)ethyl]amino]ethylpiperazinyl-l-acetate (1.12 g, 94%) as a reddish oil. 'H- NMR (CDC13) δ 1.27 (t, J= 7.1 Hz, 3H), 1.81 (broad s, IH), 2.47 - 2.66 (m, 12H), 3.00 (t, J = 5.4 Hz, 2H), 3.20 (s, 2H), 4.03 (t, J = 5.4 Hz, 2H), 4.18 (q, = 7.1 Hz, 2H), 6.81 - 6.85 (m, 2H), 6.90
- 6.99 (m, 2H); FAB-MS m/z 354 (M++l).
To a solution of 3-methoxy-4-[Λf'-(2-methylphenyl)ureido]phenylacetic acid (485 mg,
1.54 mmol), ethyl 4-[2-N-[2-(4-fluorophenoxy)ethyl]amino]ethylpiperazinyl-l-acetate (545 mg, 1.54 mmol), Et3N (0.32 mL, 2.32 mmol), and HOBt (41.5 mg, 0.31 mmol) in THF (15 mL) was added EDC HCl (883 mg, 2.32 mmol) at room temperature After stirring for 24 hr, the reaction mixture was diluted with water and exfracted with CHC13 - MeOH (10 : 1, v/v). The extracts were washed with brine, dried over Na2S04, and concentrated to dryness. Chromatography of the residue with CHC13 - MeOH (4 : 1, v/v) as eluent to give ethyl 4-[2-N-[2-(4-fluorophenoxy)ethyl]- Λr-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]acetamido]ethylpiperazinyl-l-acetate (532 mg, 53 %) as a yellow amoφhous solid. 'H-NMR (CDCl3)δ 1.26, 1.27 (each t, J= 7.1 Hz, total 3H), 2.27 (s, 3H), 2.51 - 2.63 (m, 10H), 3.16, 3.19 (each s, total 2H), 3.51 - 3.56 (m, 2H), 3.63, 3.67 (each s, total 2H), 3.69 - 3.81 (m, 5H), 3.95, 4.10 (each t, J= 5.2 Hz, total 2H), 4.16, 4.18 (each q, J = 7.1 Hz, total 2H), 6.56 (d, J = 8.1 Hz, IH), 6.72 - 6.78 (m, 4H), 6.89 - 6.98 (m, 2H), 7.12 (t, J = 1.6 Hz, IH), 7.20 - 7.23 (m, 3H), 7.51 (d, = 7.6 Hz, IH), 8.04 (d, J = 8.1 Hz, IH); FAB-MS m/z 650 (M++l).
To a solution of ethyl 4-[2-N-[2-(4-fluorophenoxy)ethyl]-N-[3-methoxy-4-[N'-(2- methylphenyl) ureido]phenyl]acetamido]ethylpiperazinyl-l-acetate (532 mg, 0.82 mmol) in dioxane (8 mL) was added dropwise 0.25N NaOH (5.00 mL, 1.25 mmol) at room temperature, and the reaction mixture was stirred for 1 hr. The resulting mixture was concenfrated, diluted with water, and neufralized with IN HCl at 0 °C. The mixtrae was exfracted with CHC13 - MeOH (4 : 1, v/v). The extracts were washed with brine, dried over Na2S04, and concenfrated to dryness. Chromatography of the residue with CHC13 - MeOH (3 : 1, v/v) as eluent gave 330 (168 mg, 33 %) as a pale yellow amoφhous solid. IR (KBr) 3338, 2938, 2829, 1635, 1533, 1506, 1454, 1415 cm 1; 'H-NMR (DMSO-eQδ 2.25 (s, 3H), 2.37 - 2.48 (m, 6H), 2.53 - 2.67 (m, 6H), 3.09 (m, 2H), 3.44 - 3.49 (m, 2H), 3.64 - 3.69 (m, 2H), 3.72 (s, 2H), 3.80, 3.84 (each s, total 3H), 4.06 - 4.09 (m, 2H), 6.73 (m, IH), 6.85 (s, IH), 6.91 - 6.97 (m ,3H), 7.07 - 7.18 (m, 4H), 7.78 (d, J = 8.1 Hz, IH), 8.00 (dd, .7= 8.1, 2.7 Hz, IH), 8.53 (m, IH), 8.59 (m, IH); FAB-MS m/z 622 (M++l); Anal. Calcd for C33H40FNA-2HC1: C, 57.06; H, 6.09; N, 10.08. Found: C, 56.83; H, 6.05; N, 9.90. Example 281
4-[2-Λ^-[2-(4-acetylphenoxy)ethyl]-N-[3-methoxy-4-[Λ -(2-methylphenyl)ureido]phenyl] acetamido] ethylpiperazinyl- 1 -acetic acid
Figure imgf000474_0001
To a solution of 2-(JV-benzyl-jV-/er butoxycarbonylamino)ethanol (5.90 g, 23.5 mmol), 4- hydroxyacetophenone (3.18 g, 23.5 mmol) and PPh3 (6.74 g, 25.8 mmol) in THF (100 mL) was added DIAD (5.20 mL, 25.8 mmol) at room temperature The reaction mixture was heated under reflux for 4 hr and concentrated. Chromatography of the residue with hexane - EtOAc (5 : 1, v/v) as eluent gave 4-[2-(N-benzyl-N-teλ-f-butoxycarbonylamino)ethoxy]acetophenone (3.64 g, 42 %) as a yellow oil. 'H-NMR (CDC13) δ 1.43 - 1.65 (m, 9H), 2.55 (s, 3H), 3.41 - 3.69 (m, 2H), 4.02 - 4.24 (m, 2H), 4.49 - 4.66 (m, 2H), 6.81 - 6.93 (m, 2H), 7.19 - 7.37 (m, 5H), 7.91 (d, J = 8.8 Hz, 2H); FAB-MS m/z 370 (M++l).
To a solution of 4-[2-(N-benzyl-Λ/-/er/-butoxycarbonylamino)ethoxy]acetophenone (3.05 g, 8.26 mmol) in CH2C12 (30 mL) was added TFA (20 mL) at 0 °C After being stirred at room temperature for 2 hr, the reaction mixture was concenfrated. The residue was taken up with sat. NaHC03 solution and exfracted with CHC13. The exfracts were washed with brine, dried over Na2S04, and concenfrated to give 4-(2-N-benzylaminoethoxy)acetophenone (2.21 g, 99 %) as a reddish oil. 'H-NMR (CDC13) δ 2.04 (broad s, IH), 2.55 (s, 3H), 3.05 (t, J = 5.4 Hz, 2H), 3.88 (s, 2H), 4.15 (t, J = 5.4 Hz, 2H), 6.92 (d, J= 8.9 Hz, 2H), 7.24 - 7.36 (m, 5H), 7.91 (d, J = 8.9 Hz, 2H); FAB-MS m/z 270 (M++l).
To a solution of ethyl 4-(2-hydroxyethyl)piperazinyl-l-acetate (11.3 g, 52.1 mmol) and
CBr4 (20.7 g, 62.5 mmol) in CH2C12 (200 mL) was added PPh3 (19.2 g, 73.0 mmol) portionwise at 0 °C and the reaction mixture was stirred for 30 min. Hexane was added to the mixture, the precipitates were filtered off, and the filtrate was concenfrated to afford ethyl 4-(2-bromoethyl) piperazinyl- 1 -acetate (13.7 g, 94 %) as a yellow oil. 'H-NMR (CDCl3)δ 1.27 (t, J = 7.1 Hz, 3H), 2.61 - 2.78 (m, 8H), 2.81 (t, J= 7.6 Hz, 2H), 3.20 (s, 2H), 3.42 (t, J= 7.6Hz, 3H), 4.18 (q, = 7.1 Hz, 2H).
A mixture of 4-(2-N-benzylaminoethoxy)acetophenone (681 mg, 2.52 mmol), ethyl 4-(2- bromoethyl)piperazinyl-l -acetate (705 mg, 2.52 mmol), and K2C03 (349 g, 2.52 mmol) in CH3CN (10 mL) was heated under reflux for 22 hr. The resulting mixture was filtered and the filtrate was concentrated to dryness. Chromatography of the residue with toluene - acetone (1 : 1, v/v) as eluent gave ethyl 4-[2-[N-benzyl-N-[2-(4-acetylphenoxy)ethyl]amino]ethylpiperazinyl-l-acetate (920 mg, 78 %) as a reddish oil. 'H-NMR (CDC13) δ 1.27 (t, J = 7.1 Hz, 3H), 2.45 - 2.53 (m, 10H), 2.55 (s, 3H), 2.76 (t, J= 6.8 Hz, 2H), 2.94 (t, J= 6.1 Hz, 2H), 3.18 (s, 2H), 3.73 (s, 2H), 4.06 (t, J = 6.1 Hz, 2H), 4.17 (q, J = 1.1 Hz, 2H), 6.85 (d, J = 1.1 Hz, 2H), 7.22 - 7.35 (m, 5H), 7.90 (d, J = 7.1 Hz, 2H); FAB-MS m/z 468 (M++l).
A solution of ethyl 4-[2-[N-benzyl-N-[2-(4-acetylphenoxy)ethyl]amino]ethylpiperazinyl-l- acetate (920 mg, 1.97 mmol) in EtOH (30 mL) was hydrogenated over 5 % Pd-C (53.1 % wet, 510 mg) under hydrogen atmosphere for 4 hr. The catalyst was filtered off and the filtrate was concentrated. The residue was taken up with sat. NaHC03 solution and exfracted with CHC13. The extracts were washed with brine, dried over Na S04, and concenfrated to afford ethyl 4-[2-Λr- [2-(4-acetyl phenoxy)ethyl]amino]ethylpiperazinyl-l-acetate (690 mg, 93%) as a reddish oil. 'H- NMR (CDC13) δ 1.27 (t, J= 7.1 Hz, 3H), 2.55 (s, 3H), 2.46 - 2.54 (m, 10H), 2.78 (t, J = 6.2 Hz, 2H), 3.04 (t, J = 5.2 Hz, 2H), 3.20 (s, 2H), 4.13 (t, J = 5.2 Hz, 2H), 4.18 (q, J= 7.1 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 7.92 (d, = 8.8 Hz, 2H); FAB-MS m/z 378 (M++l).
To a solution of 3-methoxy-4-[Λf -(2-methylphenyl)ureido]phenylacetic acid (558 mg,
1.77 mmol), ethyl 4-[2-N-[2-(4-acetylphenoxy)ethyl]amino]ethylpiperazinyl-l-acetate (670 mg, 1.77 mmol), Et3N (0.38 mL, 2.66 mmol), and HOBt (50.0 mg, 0.35 mmol) in THF (10 mL) was added EDC HCl (883 mg, 2.32 mmol) at room temperature After stirring for 15 hr, the reaction mixture was diluted with water and exfracted with CHC13 - MeOH (10 : 1, v/v). The exfracts were washed with brine, dried over Na2S04, and concenfrated to dryness. Chromatography of the residue with CHC13 - MeOH (4 : 1, v/v) as eluent to give ethyl 4-[2-Λ^-[2-(4-acetylphenoxy)ethyl]- jV-[3-methoxy-4-[N'-(2-methylphenyl)ureido]phenyl]acetamido]ethylpiperazinyl-l-acetate (724 mg, 61 %) as a yellow amoφhous solid. 'H-NMR (CDC13) δ 1.25, 1.27 (each t, = 7.1 Hz, total 3H), 2.29 (s, 3H), 2.45 - 2.51 (m, 8H), 2.54 (s, 3H), 2.55 - 2.63 (m, 2H), 3.17, 3.19 (each s, total 2H), 3.51 - 3.55 (m, 2H), 3.60 (s, 2H), 3.69 (s, 3H), 3.71 - 3.78 (m, 2H), 4.04 - 4.23 (m, 4H), 6.47 (m, IH, J= 8.1 Hz), 6.72 - 6.76 (m, 2H), 6.85 (d, = 8.8 Hz, 2H), 7.12 - 7.19 (m, 2H), 7.20 - 7.24 (m, 2H), 7.51 (d, 8.1 Hz, IH), 7.88 (d, J= 8.8 Hz, 2H), 8.04 (d, J = 8.1 Hz, IH); FAB-MS m/z 674 (M++l).
To a solution of ethyl 4-[2-N-[2-(4-acetylphenoxy)ethyl]-N-[3-methoxy-4-[N'-(2- methylphenyl) ureido]phenyl]acetamido]ethylpiperazinyl-l-acetate (724 mg, 1.07 mmol) in THF (10 mL) was added dropwise 0.25N NaOH (6.50 mL, 1.61 mmol) at room temperature, and the reaction mixture was stirred for 1 hr. The resulting mixture was concentrated, diluted with water, and neufralized with IN HCl at 0 °C. The mixture was extracted with CHC13 - MeOH (4 : 1, v/v). The extracts were washed with brine, dried over Na2S04, and concenfrated to dryness. Chromatography of the residue with CHC13 - MeOH (3 : 1, v/v) as eluent gave 331 (450 mg, 65 %) as a pale yellow amoφhous solid. IR (KBr) 3345, 2938, 2821, 1673, 1631, 1598, 1533, 1455, 1417 cm 1; 'H-NMR (DMSO-tf6) δ 2.25 (s, 3H), 2.35 - 2.47 (m, 8H), 2.51 (s, 3H), 2.53 - 2.58 (m, 2H), 2.96 (s, 2H), 3.46 - 3.50 (m, 2H), 3.69 (s, 2H), 3.73 - 3.77 (m, 2H), 3.80, 3.83 (each s, total 3H), 4.19 - 4.22 (m, 2H), 6.73 (m, IH), 6.85 (s, IH), 6.92 (t, J= 7.3 Hz, IH), 7.30 (d, J = 7.3 Hz, 2H), 7.10 - 7.16 (m, 2H), 7.79 (d, J = 8.3 Hz, IH), 7.90 - 7.95 (m, 2H), 8.00 (t, J = 8.3 Hz, IH), 8.55 (m, IH), 8.61 (m, IH); FAB-MS m/z 646 (M++l); Anal Calcd for C35H43N507-2HC1- 1H20: C, 57.06; H, 6.43; N, 9.51. Found: C, 59.17; H, 6.32; N, 9.61. Example 282
4-[2-N-[4-[N'-(2-bromophenyl)ureido]3-methoxyphenyl]-Λr-benzylacetamido] ethyl-1- piperidinylacetic acid
Figure imgf000476_0001
methyl 4-[2-N-[4-[N'-(2-bromophenyl)ureido]-3-methoxyphenyl]-N-benzylacetamido]ethyl-l- piperidinylaceate
Figure imgf000477_0001
A mixture of piperidine ethanol (10.0 g, 77.4 mmol), benzyl 2-bromoacetate (17.8 g,
77.6 mmol) and K2C03 (21.4 g, 155 mmol) in CH3CN (200 ml) was heated under reflux with stirring for 2 h. The insoluble solid was removed by filtration, and the filfrate was concenfrated in vacuo. The residue was poured into ice cooled 1N-HC1 and exfracted with CHC13. The organic layer was washed with water, drying over anhydrous Na2S04, and concentrated in vacuo. The residue was chromatographed on silica gel with EtOAc as eluent to give benzyl 4-(2- hydroxyethyl)-l-piperidinylacetate (16.3 g, 76%) as a colorless oil. 'H-NMR (CDCl3)δ 1.31-1.40 (m, 3 H), 1.52 (dd, J = 12.8, 6.3 Hz, 2H), 1.68 (brd, = 10.0 Hz, 3 H), 2.16 (t, J = 11.6 Hz, 2 T),
2.92 (brd, J= 11.6 Hz, 2 TT), 3.24 (s, 2 H), 3.69 (t, J= 6.8 Hz, 2 TT), 5.16 (s, 2 H), 7.35 (m, 5 TT).
To a stirred solution of benzyl 4-(2-hydroxyethyl)-l-piperidinylacetate (14.9 g, 53.8 mmol) in CH2C12 (150 ml) was added Et3N (37.5 ml, 269 mmol) and DMSO (41.6 ml, 538 mmol). The reaction mixture was cooled to 0 °C and S03Py (25.7 g, 161 mmol) was added portion wise, and the resulting mixture was stirred at rt overnight. The mixture was concenfrated in vacuo, and the residue was diluted with water, followed by exfracted with Et 0. The organic layer was washed with water, dried over anhydrous Na2C03 and concenfrated in vacuo. The residue was chromatographed on silica gel with EtOAc-hexane (2 : 1) as eluent to give (4-N-carbobenzyloxy methylpiperidinyl)acetaldehyde (4.63 g, 31%) as a colorless oil. Η-NMR (CDC13) δ 1.36-1.46 (m, 2 H), 1.69 (br s, 2 H), 1.72 (br s, 1 H), 1.90 (m, 1 H), 2.21 (dt, J= 11.6, 2.4 Hz, 2 H), 2.37 (dd, = 6.8, 1.6 Hz, 2 H), 2.92 (d, J = 11.6 Hz, 2 H), 3.25 (s, 2 H), 5.16 (s, 2 H), 7.35 (m, 5 TT), 9.77 (t, = 2.0 Hz, 1 H).
To a stirred solution of N-benzylamine (1.06 ml, 9.75 mmol) in MeOH (20 ml) was added AcOH (560 ml, 9.75 mmol) and (4-N-carbobenzyloxymethylpiperidinyl)acetaldehyde (1.79 g, 6.50 mmol) in MeOH (5 ml) and cooled to 0 °C NaBH3CN (645 mg, 9.75 mmol) was added in one portion, and the resulting mixture was stirred overnight at rt. The mixture was concenfrated in vacuo, and the residue was poured into aq.NaHC03, then exfracted with CHC13. The organic layer was washed with water, dried over anhydrous Na2S04 and concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH-EtOAc (10 : 1 : 1) as eluent to give N- benzyl-2-[4-(#-carbobenzyloxymethylpiperidinyl)]ethylamine (872 mg, 37%) as a colorless oil. Η-NMR (CDC13) δ 1.36-1.46 (m, 2 H), 1.69 (brs, 2 TT), 1.72 (brs, 1 H), 1.90 (m, 1 H), 2.21 (dt, = 11.6, 2.4 Hz, 2 H), 2.37 (dd, J= 6.8, 1.6 Hz, 2 H), 2.92 (d, = 11.6 Hz, 2 H), 3.25 (s, 2 H), 5.16 (s, 2 H), 7.35 (m, 5 H), 9.77 (t, J= 2.0 Hz, 1 H).
To a stirred solution of N-benzyl-2-[4-(N-carbobenzyloxymethylpiperidinyl)]ethylamine (356 mg, 0.972 mmol), 4-[N'-(2-bromophenyl)ureido]-3-methoxyphenylacetic acid (369 mg, 0.972 mmol) and N,N-dimethylaminopyridine (119 mg, 0.972 mmol) in DMF (15 ml) was added EDCHCl (372 mg, 1.94 mmol) at rt, and the resulting mixture was stirred overnight. The reaction mixture was poured into water and exfracted with EtOAc. The organic layer was washed with brine and dried over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give benzyl 4-[2-N-[4-[N'- (2-bromophenyl )ureido]3-methoxyphenyl]-N-benzylacetamido]ethyl-l-piperidinylacetate (611 mg, 86%) as a colorless oil. 'H-NMR (CDC13) mixture of rotamars δ 1.15-2.09 (series of m, 7 H), 2.06- 2.14 (m, 2 TT), 2.84-2.96 (m, 2 TT), 3.17-3.23 (s, total 2 TT), 3.21 and 3.23(s, total 2 H), 3.38-3.42 (m, 1 H), 3.65 and 3.73 (s, total 2 H), 3.83 and 3.84 (s, total 3 H),4.49 (s, 1 H), 4.60 (s, 1 TT), 5.15 (d, J= 2.8 Hz, 2 H), 6.74-7.83 (series of m, 16 H), 7.51-7.53 (m, 1 H), 7.94-8.02 (m, 1 H), 8.18 (d, J= 8.4 Hz, 2 H); MS (FAB) m/z 727 (M+), 729 (M++2).
To a stirred solution of benzyl 4-[2-N-[4-[N'-(2-bromophenyl)ureido]3-methoxyphenyl]- Λf-benzylacetamido]ethyl-l-piperidinylacetate (347 mg, 0.477 mmol) in MeOH-H20 (5 : 1, 6 ml) was added LiOH (13.6 mg, 0.57 mmol) at rt, and the resulting mixture was stirred for overnight. The reaction mixture was poured into water and the solution was neutralized with aq. W-HC1, then extracted with CHC13. The organic layer was washed with brine and dried over anhydrous Na2S04, then concenfrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give 332 (97.3 mg, 32%) as a colorless amoφhous solid, and 333 (168 mg, 54%) as a colorless amoφhous solid, respectively. 332 'H-NMR (CD3OD), mixture of rotamars δ 1.29-1.90 (series of m, 7 TT), 2.75-2.86 (m, 2 TT), 3.28-3.51 (series of m, 6 TT), 3.74 and 3.78 (s, total 2 H), 3.87 and 3.89 (s, total 3 H), 4.66 (s, 1 TT), 4.85 (s, 1 TT), 6.79-7.00 (series of m, 3 H), 7.16 (d, = 7.2 Hz, 1 H), 7.23-7.37 (m, 5 H), 7.57 (dd, .7= 8.4, 1.2 Hz, 1 H), 7.88-8.00 (series of m, 2 TT); MS (FAB) m/z 637 (M+), 639 (M++2). 333 Η-NMR (CDC13), mixture of rotamars δ 1.15-2.11 (series of m, 7 TT), 2.89-2.97 (m, 2 H), 3.17-3.49 (series of m, 6 TT), 3.17 and 3.18 (s, total 3 TT), 3.70 and 3.71 (s, total 3 H), 3.83 and 3.84 (s, total 2 TT), 4.49, 4.60 and 4.71 (s, total 2 H), 6.75-8.16 (series of m, 14 H); MS (FAB) m/z 651 (M+), 653 (M++2). Example 283 4-[2-N-[4-[N'-(2-chlorophenyl)-3-methoxyureido]phenyl]-N-benzylacetamido]ethyl-l-piperidinyl acetic acid
Figure imgf000479_0001
To a stirred solution of N-benzyl-2-[4-(N-carbobenzyloxymethylpiperidinyl)]ethylamine (372 mg, 1.11 mmol), 4-[Λp-(2-chlorophenyl)ureido]-3-methoxyphenyl]acetic acid (758 mg, 1.11 mmol) and N,N-dimethylaminopyridine (136 mg, 1.11 mmol) in DMF (15ml) was added EDCHCl (426 mg, 2.22 mmol) at rt, and the resulting mixture was stirred for 12 h. The reaction mixture was poured into water and extracted with EtOAc. The organic layer was washed with brine and dried over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (10 : 1) as eluent to give benzyl 4-[2-N-[4-[N'-(2-chlorophenyl)-3- methoxyureido]phenyl]-N-benzylacetamido]ethyl-l-piperidinylacetate (668 mg, 88%) as a pale yellowish oil. 'H-NMR (CDC13) mixture of rotamars δ 1.15-1.83 (series of m, 7 H), 2.04-2.13 (m, 2 H), 2.83-2.95 (m, 2 H), 2.88 and 2.99 (s, total 2 H), 3.20 and 3.23 (s, total 2 H), 3.20-3.23 (overlap, 1 H), 3.38-3.42 (m, 1 H), 3.65-3.74 (m, 3 TT), 4.50 (s, 1 H), 4.61 (s, 1 H), 5.14 (d, J= 4.4 Hz, 2 H), 6.72-6.82 (series of m, 2 H), 6.94-6.99 (m, 1 H), 7.13-7.50 (series of m, 14 H), 7.94-8.02 (m, 1 H), 8.18 (d, J = 8.0 Hz, 2 H); MS (FAB) m/z 683 (M++H).
To a stirred solution of benzyl 4-[2-N-[4-[Λ -(2-chlorophenyl)-3-methoxyureido]phenyl]- N-benzylacetamido]ethyl-l-piperidinylacetate (633 mg, 0.93 mmol) in MeOH-H20 (10 : 1, 10 ml) was added LiOH (24.4 mg, 1.02 mmol) at rt, and the resulting mixture was stirred overnight. The reaction mixture was poured into water and the solution was neufrallized with aq.1N-HC1, then exfracted with CHC13. The organic layer was washed with brine and dried over anhydrous Na2S04, then concentrated in vacuo. The residue was chromatographed on silica gel with CHCl3-MeOH (20 : 1) as eluent to give methyl 4-[2-N-[4-[N-(2-chlorophenyl)-3-methoxyureido]phenyl]-N- benzylacetamido] ethyl- 1-piperidinylacetate (504 mg, 89%) as a colorless amoφhous solid. 'H- NMR (CDC13), mixture of rotamars δ 1.26-1.64 (series of m, 7 TT), 2.02-2.10 (m, 2 H), 2.86 (t, J = 10.4 Hz, 2 H), 3.17 (d, J= 8.0 Hz, 2 H), 3.16-3.22 (m, overlap, 1 TT), 3.40 (t, J= 7.6 Hz, 1 TT),
3.48 (s, 1 H), 3.65 and 3.73 (s, total 2 H), 3.70 and 3.71 (s, total 3 H), 3.79 and 3.80 (s, total 3 H), 4.50, 4.60 and 4.70 (s, total 2 H), 6.73-6.85 (series of m, 2 H), 6.98 (t, J = 7.6 Hz, 1 H), 7.13-7.37 (series of m, 9 ), 7.96 (m, 1 H), 8.18 (d, J= 8.0 Hz, 2 H); MS (FAB) m/z 607 (M++H).
To a stirred solution of methyl 4-[2-Λ^-[4-[7^'-(2-chlorophenyl)-3-methoxyraeido]phenyl]- iV-benzylacetamido] ethyl- 1-piperidinylacetate (177 mg, 0.292 mmol) in MeOH-H20 (5 : 1, 6 ml) was added LiOH (21.6 mg, 0.90 mmol), and the resulting mixture was stirred for 4 h at rt. The mixture was poured into water, and the solution was neutrallized with aq.1N-HC1, then exfracted with CHC13. The organic layer was washed with brine and dried over anhydrous Na2S04, then concentrated to yield 334 (155 mg, 92%) as a colorless amoφhous solid. 'H-NMR (CD3OD) mixture of rotamars δ 1.28-1.90 (series of m, 7 H), 2.84 (brs, 2 H), 3.30-3.52 (series of m, 6 TT), 3.74 and 3.82 (s, total 2 H), 3.87 and 3.88 (s, total 3 TT), 4.63 (s, 1 H), 4.66 (s, 1 H), 6.79-7.05 (series of m, 3 H), 7.16 (d, J= 7.2 Hz, 1 TT), 7.24-7.40 (m, 5 H), 7.88 (s, 1 H), 7.98-8.04 (series of m, 2 H); MS (ESI) m/z 593 (M+), 615 (M++Na+).
It should be understood that while this invention has been described herein in terms of specific embodiments set forth in detail, such embodiments are presented by way of illustration of general principles, and the invention is not necessarily limited thereto. Modifications and variations in any given material or process step will be readily apparent to those skilled in the art without departing from the true spirit and scope of the following claims, and all such modifications are included within the scope of the present invention.

Claims

CLAIMS We claim:
1. A compound represented by Formula I, or a salt thereof,
Figure imgf000481_0001
wherein
W is chosen from aryl group, substituted aryl group, heteroaryl group and substituted heteroaryl group;
W' is chosen from arylene group, substituted arylene group, heteroarylene group and substituted heteroarylene group; A is chosen from =0, =S and =NH;
R is chosen from a direct bond, alkyenylene group and -(CH2)n-, wherein n is chosen from 1 and 2;
X is chosen from -C(O)-, -CH2- and S(0)2; M is chosen from
Figure imgf000481_0002
wherein
(X Q- — -N N ' is a divalent 4-, 5-, 6- or 7-membered heterocychc moiety,
wherein the nitrogen atom is the point of attachment to X; R1, R2 and R3 are independently chosen from -H, -OH,-NH2, halogen atom, alkyl group, substituted alkyl group, aryl group, substituted aryl group, alkoxy group, substituted alkoxy group, monoalkylamino group, substituted monoalkylamino group, dialkylamino group, substituted dialkylamino group, cycloalkylamino group, substituted cycloalkylamino group, alkylsulfonylamino group, substituted alkylsulfonylamino group, arylsulfonylamino group, substituted arylsulfonylamino group, aryloxy group, substituted aryloxy group, heteroaryloxy group, substituted heteroaryloxy group, benzyloxy group and substituted benzyloxy group, or two of R1, R2 and R3 taken together may form a 3-, 4-, 5-, 6-, or 7-membered carbocyclic or heterocychc residues optionally substituted with from 1 to 3 substituents chosen independently from -OH, halogen atom, -NH2, alkyl group, alkoxy group, aryl group, aryloxy group, alkylamino group, benzyloxy group and heteroaryl group; R4 is chosen from -H and lower alkyl group;
Y is a direct bond or a divalent radical chosen from -C(O)-, -C(0)NH-, alkenylene group, alkynylene group and -(CH2)kY2, wherein k is chosen from 1, 2 and 3; and Y2 is a direct bond or a divalent radical chosen from -0-, -S-,
-S(O), -S(0)2- and -NY3-, wherein Y is chosen from -H and lower alkyl group;
Z is chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group and substituted cycloalkylene group; A1 is a direct bond or a divalent radical chosen from alkenylene group, alkynylene group, -(CH2)t- and ACH^y, wherein t is chosen from 1, 2 and 3; and v is chosen from 0, 1, 2, and 3; and
R is chosen from -OH, lower alkoxy group, -N(H)OH, N^ KI and
Figure imgf000482_0001
Figure imgf000483_0001
wherein
Figure imgf000483_0002
is a divalent 4-, 5-, 6- or 7—membered heterocychc moiety, wherein
the nitrogen atom is the point of attachment to X; R6 and R7 are independently chosen from -H, -OH, halogen atom, alkyl group and alkoxy group; Y1 is a divalent radical chosen from -0-, -S-, -S(O)-, -S(0)2- and -NY4-, wherein Y4 is chosen from -H and lower alkyl group; Z1 is a divalent radical chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group and substituted cycloalkylene group; A2 is a direct bond or a divalent radical chosen from alkenylene group, alkynylene group and -(CH2)e wherein e is chosen from 1, 2 and 3; and
R is chosen from -OH, lower alkoxy group, -N(H)OH, ^ N_r^ and
H
A NH
Figure imgf000483_0003
wherein
Figure imgf000484_0001
wherein
N f is a divalent 4-, 5-, 6- or 7-membered heterocychc
moiety, optionally substituted with from 1 to 3 substitutents chosen independently from alkyl group, alkoxy group, hydroxyalkyl group, -OH, benzyloxy group, -NH2, halogen atom, aryl group and heteroaryl group, said moiety may be fused to 1 or 2 additional carbocyclic or heterocychc residues optionally substituted with from 1 to 3 substitutents chosen independently from alkyl group, aryloxy group, alkoxy group, hydroxyalkyl group, -OH, benzyloxy group, -NH2, , halogen atom, aryl group and heteroaryl group; m and q are independently chosen from 0, 1, 2 and 3; X1 is chosen from -CH= and -N=; R9 is chosen from -H and lower alkyl group;
R10 is chosen from -COOH, lower alkoxycarbonyl group,
Figure imgf000484_0002
H
N- a anndd f Nirft N ; and
Z2 is chosen from -H, COOH and lower alkoxycarbonyl group; and
Figure imgf000484_0003
wherein
R11 is chosen from -0-, -N-S */
Figure imgf000484_0004
and -NR 1 1 2 2
wherein R12 is chosen from -H, alkyl group, substituted alkyl group, cycloalkyl group, substituted cycloalkyl group, aryl group, substituted aryl group, benzyl group, substituted benzyl group, lower alkenyl group, substituted lower alkenyl group and lower alkynyl group the left hand bond is the point of attachment to -X- and the right hand bond is the point of attachment to -Z3; Z3 is chosen from a direct bond, a divalent aliphatic hydrocarbon moiety having 1 to 12 carbon atoms, 10 wherein one or more carbon atoms may be replaced with -O- or -NR13-
wherein R13 is chosen from -H and lower alkyl group, and
15 one or more hydrogen atoms attached to an aliphatic carbon atom may be replaced with lower alkyl group; and
Figure imgf000485_0001
wherein x is chosen from 0 and 1;
20 y is chosen from 1, 2, and 3; and
R14 is chosen from -H, -OH and halogen atom,
Figure imgf000485_0002
R11 is -NR12, wherein
,14a
R '
25 Z 4 i :s chosen f ^rom. X -CH
wherein R14a is chosen from -H, -OH, lower alkyl group and halogen atom;
v~~ OH a an„rtd X ^ — , wherein the left hand bond is the point of attachment to R11 and the right hand bond is the point of attachment to Q2;
Q is a divalent radical chosen from arylene group, substituted arylene group, heterocyclylene group, substituted heterocyclylene group, cycloalkylene group, substituted cycloalkylene group,
Figure imgf000486_0001
wherein R 15 and R 16 are independently chosen
from -H, halogen atom and lower alkyl group; and
A A
R R> wherein R17 and R18 are independently chosen
from -H, lower alkyl group, substituted lower alkyl group and lower alkenyl group; and
L1 is chosen from -COOH and -COOR19 wherein
R19 is a lower alkyl group.
2. A compound according to claim 1, or a salt thereof, wherein M is
Figure imgf000486_0002
3. A compound according to claim 1, or a salt thereof, wherein M is
Figure imgf000486_0003
4. A compound according to claim 1, or a salt thereof, wherein M is
Figure imgf000487_0001
5. A compound according to claim 1, or a salt thererof, wherein M is
^R11_Z3_Q2_L1
6. A compound according to claim 2, or a salt thereof, wherein at least one radical of R1,
R2 and R3 is -OH or halogen atom.
7. A compound according to claim 6, or a salt thereof, wherein A is =0, R is -(CH2)n- and X is -C(O)-.
8. A compound according to claim 7, or a salt thereof, wherein Y is chosen from alkenylene group, alkynylene group and -(CH2)kY2; Y2 is chosen from a direct bond, -0-, -S(O) and -NY3-; and Y3 is -H .
9. A compound according to claim 8, or a salt thereof, wherein Y is chosen from -O- and
-NY"1
10. A compound according to claim 2, or a salt thereof, wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof.
11. A compound according to claim 10, or a salt thereof, wherein W1 is unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to the -NH- thereof.
12. A compound according to claim 2, or a salt thereof, wherein W1 is phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to the -NH- thereof and having 1 to 3 substituents chosen from lower alkyl group and halogen atom.
13. A compound according to claim 2, or a salt thereof, wherein A1 is a direct bond or -(CH2)t- .
14. A compound according to claim 13, or a salt thereof, wherein A1 is a direct bond.
15. A compound according to claim 14, or a salt thereof, wherein R5 is -OH.
16. A compound according to claim 2, or a salt thereof, wherein W is unsubstituted phenyl group or phenyl group having one or two substituents chosen from lower alkyl group and halogen atom at the ortho positions thereof; W1 is unsubstituted phenylene group or phenylene group having a substituent chosen from methoxy group, lower alkyl group and halogen atom at the ortho position to the -NH- thereof; R is -CH2-; X is -C(O)- and R5 is -OH.
17. A compound according to claim 16, or a salt thereof, chosen from the group consisting of
Figure imgf000488_0001
Figure imgf000489_0001
Figure imgf000490_0001
Figure imgf000491_0001
Cxl Hx H Hx OMneX*x ™
Figure imgf000491_0003
Figure imgf000491_0002
Figure imgf000492_0001
Figure imgf000493_0001
Mae H π H π n OiMwioe
Figure imgf000494_0001
Figure imgf000495_0001
Figure imgf000496_0001
Ht H OMreY x>»»
ClX H Hς OMre *
Figure imgf000496_0002
Figure imgf000496_0003
Figure imgf000497_0001
Figure imgf000498_0001
18. A compound according to claim 17, or a salt thereof, chosen from the group consisting of
Figure imgf000499_0001
Figure imgf000500_0001
Figure imgf000501_0001
■ MMae H π H π n OuM«e
Figure imgf000501_0002
Figure imgf000501_0003
Figure imgf000502_0001
Figure imgf000502_0002
i Mwiαe H H OMM-e
Figure imgf000502_0004
Figure imgf000502_0003
Figure imgf000503_0001
Figure imgf000504_0001
Figure imgf000505_0001
Figure imgf000506_0001
Figure imgf000507_0001
19. A compound according to claim 2, or a salt thereof, wherein R5 is lower alkoxy group. AMENDED CLAIMS
[received by the International Bureau on 24 November 2000 (24.11.00); new claims 20-30 added; other claims unchanged (1 page)]
20. A method of inhibiting cell adhesion in a mammal, said method comprising administering to said mammal an effective amount of a compound according to any of claims 1 to 19.
21. A method of treating a condition associated with VLA-4 mediated cell adhesion in a mammal, aid method comprising administering to said mammal an effective amount of a compound according to any of claims 1 to 19.
22. A method according to claim 21, wherein the condition associated with VLA-4 mediated cell adhesion is chosen from inflammatory responses, autoimmune responses and tumor metastasis.
23. A method according to claim 21, wherein the condition associated with VLA-4 mediated cell adhesion is chosen from asthma, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and transplantation rejection.
24. Use of a compound according to any of claims 1-19 for therapy.
25. Use of a compound according to any of claims 1-19 in the manufacture of a medicament for the treatment of a condition associated with VLA-4 mediated cell adhesion.
26. A pharmaceutical composition comprising as a therapeutic agent, a compound according to any of claims 1 to 19 and a pharmaceutically acceptable carrier or excipient.
27. A pharmaceutical composition according to claim 26, further comprising one or more additional therapeutic agents.
28. A pharmaceutical composition according to claim 27, wherein said one or more additional therapeutic agents are chosen from the group consisting of antiinflammatory, antirheumatic, corticosteroid, immunosuppressive, antipsoriatic, bronchodilator, antiasthmatic and antidiabetic agents.
29. A pharmaceutical composition according to claim 28, wherein one of said one or more additional therapeutic agents is an antiinflammatory agent.
30. A pharmaceutical composition according to claim 29, wherein said antiinflammatory agent is chosen from a steroid and an NSATD.
PCT/US2000/018079 1999-06-30 2000-06-30 Vla-4 inhibitor compounds WO2001000206A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU59031/00A AU781438B2 (en) 1999-06-30 2000-06-30 VLA-4 inhibitor compounds
IL14628800A IL146288A0 (en) 1999-06-30 2000-06-30 Vla-4 inhibitor compounds
JP2001505915A JP2003503350A (en) 1999-06-30 2000-06-30 VLA-4 inhibitor compounds
BR0012068-5A BR0012068A (en) 1999-06-30 2000-06-30 Vla-4 inhibitory compounds
MXPA01013406A MXPA01013406A (en) 1999-06-30 2000-06-30 Vla-4 inhibitor compounds.
EP00945035A EP1189612A4 (en) 1999-06-30 2000-06-30 Vla-4 inhibitor compounds
CA002369308A CA2369308A1 (en) 1999-06-30 2000-06-30 Vla-4 inhibitor compounds
NO20016319A NO324892B1 (en) 1999-06-30 2001-12-21 VLA-4 inhibitor compounds, their use as well as pharmaceutical preparation
US10/034,585 US6756378B2 (en) 1999-06-30 2001-12-28 VLA-4 inhibitor compounds
HK02105102.2A HK1043318A1 (en) 1999-06-30 2002-07-09 Vla-4 inhibitor compounds
US10/787,905 US7179819B2 (en) 1999-06-30 2004-02-26 VLA-4 inhibitor compounds
US11/594,432 US20070054909A1 (en) 1999-06-30 2006-11-08 VLA-4 inhibitor compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14160299P 1999-06-30 1999-06-30
US14169299P 1999-06-30 1999-06-30
US14160199P 1999-06-30 1999-06-30
US60/141,602 1999-06-30
US60/141,692 1999-06-30
US60/141,601 1999-06-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/034,585 Continuation US6756378B2 (en) 1999-06-30 2001-12-28 VLA-4 inhibitor compounds

Publications (1)

Publication Number Publication Date
WO2001000206A1 true WO2001000206A1 (en) 2001-01-04

Family

ID=27385682

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/018079 WO2001000206A1 (en) 1999-06-30 2000-06-30 Vla-4 inhibitor compounds

Country Status (13)

Country Link
EP (1) EP1189612A4 (en)
JP (1) JP2003503350A (en)
CN (1) CN1391473A (en)
AR (1) AR035011A1 (en)
AU (1) AU781438B2 (en)
BR (1) BR0012068A (en)
CA (1) CA2369308A1 (en)
HK (1) HK1043318A1 (en)
IL (1) IL146288A0 (en)
MX (1) MXPA01013406A (en)
NO (1) NO324892B1 (en)
TW (1) TWI283240B (en)
WO (1) WO2001000206A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053275A2 (en) * 2000-01-17 2001-07-26 Bayer Aktiengesellschaft Substituted aryl ketones
WO2001058871A1 (en) * 2000-02-14 2001-08-16 Bayer Aktiengesellschaft Piperidyl carboxylic acids as integrin antagonists
WO2003030889A1 (en) * 2001-10-03 2003-04-17 Bayer Healthcare Ag Para-amino benzoic acids as integrin antagonists
WO2004031118A1 (en) * 2002-10-03 2004-04-15 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
WO2004041791A1 (en) * 2002-11-06 2004-05-21 Glaxo Group Limited N-aryl acetyl cyclic amine derivatives as orexin antagonists
EP1501791A1 (en) * 2002-05-09 2005-02-02 Mimotopes Pty Ltd Amino acid analogues
JP2005537333A (en) * 2002-06-27 2005-12-08 ノボ・ノルデイスク・エー/エス Arylcarbonyl derivatives as therapeutic agents
US6984651B2 (en) 2000-06-21 2006-01-10 Bristol-Myers Squibb Pharma, Company Piperidine amides as modulators of chemokine receptor activity
US7132443B2 (en) 2001-06-27 2006-11-07 Smithklinebeecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
WO2007069635A1 (en) 2005-12-13 2007-06-21 Daiichi Sankyo Company, Limited Vla-4 inhibitory drug
US7345179B2 (en) 2003-05-09 2008-03-18 Daiichi Pharmaceutical Co., Ltd. Process for producing pyrrolidine derivative
US7541373B2 (en) 2002-06-27 2009-06-02 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US7786155B2 (en) 2007-10-16 2010-08-31 Novartis Ag Organic compounds
WO2011061751A1 (en) * 2009-11-18 2011-05-26 Suven Life Sciences Limited BICYCLIC COMPOUNDS AS α4β2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
WO2012137982A3 (en) * 2011-04-05 2013-04-04 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
USRE45183E1 (en) 2004-01-06 2014-10-07 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
WO2020173861A1 (en) 2019-02-26 2020-09-03 Bayer Aktiengesellschaft Condensed bicyclic heterocyclic derivatives as pest control agents
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
US11833136B2 (en) 2018-06-12 2023-12-05 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432281B2 (en) * 2003-10-07 2008-10-07 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
JP2005350417A (en) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd Method for producing pyrrolidine derivative using reductive etherification method
US7776891B2 (en) * 2004-08-16 2010-08-17 Merck Sharp & Dohme Corp. VLA-4 antagonists
AU2009228778B2 (en) * 2008-03-26 2012-04-19 Novartis Ag Hydroxamate-based inhibitors of deacetylases B

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022966A1 (en) * 1995-01-23 1996-08-01 Biogen, Inc. Cell adhesion inhibitors
WO1997003094A1 (en) * 1995-07-11 1997-01-30 Biogen, Inc. Cell adhesion inhibitors
WO1998053814A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
WO1999054321A1 (en) * 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020272A1 (en) * 1997-10-21 1999-04-29 Merck & Co., Inc. Azapeptide acids as cell adhesion inhibitors
ATE337298T1 (en) * 1997-10-31 2006-09-15 Aventis Pharma Ltd SUBSTITUTED ANILIDES
ATE311371T1 (en) * 1998-06-30 2005-12-15 Pfizer Prod Inc NON-PEPTIDE INHIBITORS OF VLA-4 DEPENDENT CELL BINDING FOR THE TREATMENT OF INFLAMMATION, AUTOIMMUNE DISEASES AND RESPIRATORY DISORDERS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022966A1 (en) * 1995-01-23 1996-08-01 Biogen, Inc. Cell adhesion inhibitors
WO1997003094A1 (en) * 1995-07-11 1997-01-30 Biogen, Inc. Cell adhesion inhibitors
WO1998053814A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
WO1999054321A1 (en) * 1998-04-21 1999-10-28 Aventis Pharma Limited Substituted diamines and their use as cell adhesion inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1189612A4 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053275A3 (en) * 2000-01-17 2003-04-17 Bayer Ag Substituted aryl ketones
WO2001053275A2 (en) * 2000-01-17 2001-07-26 Bayer Aktiengesellschaft Substituted aryl ketones
US6864219B2 (en) 2000-01-17 2005-03-08 Bayer Aktiengesellschaft Substituted aryl ketones
WO2001058871A1 (en) * 2000-02-14 2001-08-16 Bayer Aktiengesellschaft Piperidyl carboxylic acids as integrin antagonists
US6984651B2 (en) 2000-06-21 2006-01-10 Bristol-Myers Squibb Pharma, Company Piperidine amides as modulators of chemokine receptor activity
US7157487B2 (en) 2000-12-28 2007-01-02 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
US7132443B2 (en) 2001-06-27 2006-11-07 Smithklinebeecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003030889A1 (en) * 2001-10-03 2003-04-17 Bayer Healthcare Ag Para-amino benzoic acids as integrin antagonists
JP2005508941A (en) * 2001-10-03 2005-04-07 バイエル・ヘルスケア・アクチェンゲゼルシャフト Para-aminobenzoic acid as an integrin antagonist
EP1501791A4 (en) * 2002-05-09 2006-08-30 Mimotopes Pty Ltd Amino acid analogues
AU2003221636B2 (en) * 2002-05-09 2009-11-12 Baker Idi Heart And Diabetes Institute Holdings Limited Amino acid analogues
EP1501791A1 (en) * 2002-05-09 2005-02-02 Mimotopes Pty Ltd Amino acid analogues
US7541373B2 (en) 2002-06-27 2009-06-02 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
USRE45670E1 (en) 2002-06-27 2015-09-15 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US7384967B2 (en) 2002-06-27 2008-06-10 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
JP2005537333A (en) * 2002-06-27 2005-12-08 ノボ・ノルデイスク・エー/エス Arylcarbonyl derivatives as therapeutic agents
JP4881559B2 (en) * 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー/エス Arylcarbonyl derivatives as therapeutic agents
US8063081B2 (en) 2002-06-27 2011-11-22 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
JPWO2004031118A1 (en) * 2002-10-03 2006-02-09 小野薬品工業株式会社 LPA receptor antagonist
JP4691988B2 (en) * 2002-10-03 2011-06-01 小野薬品工業株式会社 LPA receptor antagonist
WO2004031118A1 (en) * 2002-10-03 2004-04-15 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
US8124645B2 (en) 2002-10-03 2012-02-28 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
US7820682B2 (en) 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
WO2004041791A1 (en) * 2002-11-06 2004-05-21 Glaxo Group Limited N-aryl acetyl cyclic amine derivatives as orexin antagonists
US7345179B2 (en) 2003-05-09 2008-03-18 Daiichi Pharmaceutical Co., Ltd. Process for producing pyrrolidine derivative
US7691894B2 (en) 2003-07-24 2010-04-06 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
US7893279B2 (en) 2003-07-24 2011-02-22 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
USRE45183E1 (en) 2004-01-06 2014-10-07 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
WO2007069635A1 (en) 2005-12-13 2007-06-21 Daiichi Sankyo Company, Limited Vla-4 inhibitory drug
US8129366B2 (en) 2005-12-13 2012-03-06 Daiichi Sankyo Company, Limited VLA-4 inhibitory drug
US7786155B2 (en) 2007-10-16 2010-08-31 Novartis Ag Organic compounds
WO2011061751A1 (en) * 2009-11-18 2011-05-26 Suven Life Sciences Limited BICYCLIC COMPOUNDS AS α4β2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
US8735423B2 (en) 2009-11-18 2014-05-27 Suven Life Sciences Limited Bicyclic compounds as α4β2 nicotinic acetylcholine receptor ligands
EA020506B1 (en) * 2009-11-18 2014-11-28 Сувен Лайф Сайенсиз Лимитед BICYCLIC COMPOUNDS AS αβNICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
WO2012137982A3 (en) * 2011-04-05 2013-04-04 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
US9527807B2 (en) 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
US11833136B2 (en) 2018-06-12 2023-12-05 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2020173861A1 (en) 2019-02-26 2020-09-03 Bayer Aktiengesellschaft Condensed bicyclic heterocyclic derivatives as pest control agents
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Also Published As

Publication number Publication date
NO20016319D0 (en) 2001-12-21
CN1391473A (en) 2003-01-15
EP1189612A1 (en) 2002-03-27
CA2369308A1 (en) 2001-01-04
IL146288A0 (en) 2002-07-25
NO20016319L (en) 2002-02-28
TWI283240B (en) 2007-07-01
NO324892B1 (en) 2007-12-27
AU5903100A (en) 2001-01-31
AU781438B2 (en) 2005-05-26
MXPA01013406A (en) 2003-09-04
BR0012068A (en) 2002-05-14
AR035011A1 (en) 2004-04-14
HK1043318A1 (en) 2002-09-13
EP1189612A4 (en) 2005-02-16
JP2003503350A (en) 2003-01-28

Similar Documents

Publication Publication Date Title
WO2001000206A1 (en) Vla-4 inhibitor compounds
US20070054909A1 (en) VLA-4 inhibitor compounds
KR100554815B1 (en) N-aroylphenylalanine derivatives
JP5248783B2 (en) HCVNS-3 serine protease inhibitor
ES2228869T3 (en) SERINE PROTEASE DERIVATIVES.
US8183239B2 (en) Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
EP1465861A1 (en) Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
IE910778A1 (en) Acetic acid derivatives
AU2003256069A1 (en) Process for preparing quinolin antibiotic intermediates
HRP20040075A2 (en) Novel cyclohexyl sulphones
KR100793095B1 (en) Novel Sulfone Amide Derivatives Capable Of Inhibiting BACE
KR20070050475A (en) Novel cyclic aminobenzoic acid derivative
US6514997B2 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
AU759488B2 (en) Amino acid derivatives and drugs containing the same as the active ingredient
US20030225059A1 (en) Cyclohexyl derivatives and their use as therapeutic agents
NZ551974A (en) Alpha-helical minetics
EP1149843A1 (en) Substituted phenethylamine derivatives
EP3101005A1 (en) Ror gamma (rory) modulators
JPH05155847A (en) Amino acid derivative and use thereof as medicine
US6812237B2 (en) N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
CA2407463C (en) N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
KR20020095418A (en) VLA-4 Inhibitor compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00809510.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2369308

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 59031/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000945035

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/013406

Country of ref document: MX

Ref document number: IN/PCT/2001/1784/CHE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2001 505915

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10034585

Country of ref document: US

Ref document number: 1020017016881

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000945035

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017016881

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 59031/00

Country of ref document: AU